<SEC-DOCUMENT>0001193125-16-485683.txt : 20160229
<SEC-HEADER>0001193125-16-485683.hdr.sgml : 20160229
<ACCEPTANCE-DATETIME>20160229171036
ACCESSION NUMBER:		0001193125-16-485683
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160229
DATE AS OF CHANGE:		20160229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sage Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001597553
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36544
		FILM NUMBER:		161469396

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-299-8380

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d111598d10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML><HEAD>
<TITLE>10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2015 </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 001-36544 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Sage
Therapeutics, Inc. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>27-4486580</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>215 First Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02142</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) 299-8380 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:60.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:148.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.0001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>NASDAQ Global Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp; <FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form
10-K.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange
Act. (Check one): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">The aggregate market value of the registrant&#146;s voting and non-voting common stock held by non-affiliates of the registrant (without
admitting that any person whose shares are not included in such calculation is an affiliate) as of June&nbsp;30, 2015 was approximately $903,465,958, computed by reference to the closing price of the registrant&#146;s common stock on the NASDAQ
Global Market reported for such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">As of February&nbsp;16, 2016, there were 32,022,187 shares of common stock, $0.0001 par value per
share, outstanding. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part I.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_1">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_3">Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_4">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_5">Mine Safety Disclosures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part II.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_6">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_7">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_8">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_9">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_10">Financial Statements and Supplementary Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_11">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_12">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_13">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part III.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_14">Directors, Executive Officers and Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_15">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_16">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_17">Certain Relationships and Related Transactions, and Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_18">Principal Accounting Fees and Services</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part IV.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_19">Exhibits and Financial Statement Schedules</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc111598_20">Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involve risks and uncertainties. We make such
forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report are
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;expects&#148;, &#147;intends&#148;, &#147;plans&#148;,
&#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;predicts&#148;, &#147;potential&#148;, &#147;continue&#148; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are
not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates in the central nervous system, or CNS, disorders we discuss in this Annual Report, and potentially in other indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability, within the expected timeframes, to complete our ongoing non-clinical studies and clinical trials; to announce the results of such studies and trials; to advance our product candidates into additional
clinical trials, including pivotal clinical trials; and to successfully complete such clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans with respect to filing for regulatory approval for our product candidates, if clinical trial development is successful, and the potential to obtain such approval and to commercialize any product, if approved
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, the potential for future revenues and capital requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations with respect to the availability of supplies of our product candidates, and the expected performance of our third-party manufacturers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations with respect to the performance of our contract research organization and other third parties whose activities are important to our development and future commercialization efforts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain intellectual property protection for our proprietary assets and other forms of exclusivity relevant to our business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the estimated number of patients in indications of interest to us, and the size of the potential markets for our product candidates and our ability to serve those markets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated rate and degree of market acceptance of our product candidates for any indication once approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of costs we may incur in connection with our activities, and our ability to obtain additional financing when needed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for success of competing products that are or become available for the indications that we are pursuing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential risk of loss of key scientific or management personnel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other risks and uncertainties, including those listed under Part II, Item&nbsp;1A. Risk Factors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this Annual Report reflect our current views with respect to future events and with respect to our future
financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or
implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item&nbsp;1A. Risk Factors and elsewhere in this Annual
Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new
information becomes available in the future. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual Report contains estimates, projections and other information concerning our industry,
the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on
estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the
information reflected in this Annual Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by
market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, not prove to have been accurate. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise,
references in this report to &#147;Sage&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Sage Therapeutics, Inc. and its subsidiaries. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_1"></A>Item&nbsp;1. Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening central nervous system, or CNS, disorders, where there are inadequate or no approved existing therapies. We are targeting
CNS indications where patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate is SAGE-547, a proprietary intravenous formulation of allopregnanolone, a naturally occurring neurosteroid that
acts as a synaptic and extrasynaptic modulator of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor. GABA is the major inhibitory neurotransmitter in the CNS, and mediates downstream neurologic and bodily function via
activation of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. We believe that allosteric modulation of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor has the potential to be well-suited for the
treatment of seizures and certain other CNS disorders because it allows for the fine-tuning of neuronal signals rather than complete activation or complete inhibition. SAGE-547 is in Phase 3 clinical development as an adjunctive therapy for the
treatment of super-refractory status epilepticus, or SRSE. SRSE is a rare and life-threatening condition where a patient is in a state of continuous seizure called status epilepticus, or SE, and all of the standard treatment regimens normally
sufficient to stop the seizure activity have failed. We expect to report top-line results from the global, randomized, double-blind, placebo-controlled Phase 3 trial of SAGE-547 in SRSE in the second half of 2016. If successful, we believe the
results of the Phase 3 clinical trial, together with other clinical data obtained from the SAGE-547 clinical program, and results of ongoing non-clinical studies, could form the basis of a New Drug Application, or NDA submission, in the U.S. for
SAGE-547. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also used SAGE-547 in proof-of-concept clinical trials to explore potential uses of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators to treat post-partum depression, or PPD, a distinct and readily identified major depressive disorder, and essential tremor, a debilitating neurological disorder that causes
involuntary, rhythmic shaking with no known cause. We are currently conducting an additional Phase 2 exploratory trial of SAGE-547 in the treatment of severe PPD. We expect the data from these exploratory trials to guide the development of
second-generation GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators for the applicable diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
next-generation product candidates, SAGE-217 and SAGE-689, also target the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor system. These compounds have been designed to have pharmaceutical properties that optimize both their
non-clinical profiles and potential clinical profiles for the treatment of certain seizure and non-seizure CNS disorders. We are currently conducting a Phase 1 clinical trial of SAGE-217, which we expect to complete in the first half of 2016. If the
Phase 1 clinical trial of SAGE-217 supports further development, we plan to commence Phase 2 clinical trials of SAGE-217, initially in essential tremor and orphan epilepsies. SAGE-689 is in non-clinical development. Our Phase 1 clinical trial of
SAGE-689 has been delayed to respond to a request from the United States Food and Drug Administration, or FDA, for additional non-clinical study data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also studying novel compounds that target the NMDA receptor, a critical excitatory receptor system in the brain implicated in a broad
range of CNS disorders. The first product candidate selected for development from this program is SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors. We have begun non-clinical studies of SAGE-718, with an initial
development focus on two rare conditions, Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor Encephalitis. Beyond these conditions, we believe measuring levels of anti-NMDA antibodies or decreased levels of cerebrosterol, a naturally occurring
oxysterol, may represent biomarkers to identify for future study broader patient populations characterized by cognitive dysfunction and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
neuropsychiatric symptoms resulting from NMDA receptor dysfunction or hypofunction. Examples of these potential areas for future evaluation include certain types, aspects or subpopulations of a
number of diseases such as depression, Alzheimer&#146;s disease, attention deficit hyperactivity disorder, schizophrenia, Huntington&#146;s disease, and neuropathic pain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue our focus on allosteric modulation of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA
receptor systems in the brain. The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA receptor systems are broadly accepted as impacting many psychiatric and neurological disorders, spanning disorders of mood, seizure, cognition,
anxiety, sleep, pain, epilepsy, and movement disorders among others. We believe that we will have the opportunity to develop molecules from our internal portfolio to address a number of these disorders in the future. Our ability to identify and
develop such novel CNS therapies is enabled by our proprietary chemistry platform that is centered on a scaffold of chemically modified endogenous neuroactive steroid compounds. We believe our know-how around the chemistry and activity of allosteric
modulators allows us to efficiently design molecules with different characteristics by enabling us to control important properties such as half-life, brain penetration and the types of receptors with which our compounds interact with the goal of
developing product candidates that have the potential to bind with targets in the brain with more precision, increased tolerability, and fewer off-target side effects than either current CNS therapies or previous therapies which have failed in
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE was founded in 2010, based on leading research in the areas of brain function and neuroactive steroids, to explore
novel approaches to CNS therapeutics. Since our inception, we have continued to expand our know-how related to CNS therapeutics through our research and development programs, and to pursue intellectual property protection with respect to our
proprietary chemistry platform. In addition, we have assembled a world-class management team that together has been a part of the successful discovery, development and commercialization of more than 20 marketed CNS therapies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
January 2016, we completed a follow-on public offering of 3,157,894 shares of our common stock at a price to the public of $47.50 per share, for net proceeds, after deducting underwriters&#146; discounts and commissions and estimated offering
expenses, of approximately $140.4 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading biopharmaceutical company focused on development and commercialization of novel proprietary therapies for the
treatment of life-threatening CNS disorders. Key elements of our strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Rapidly advance SAGE-547 as a treatment for SRSE. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Utilize SAGE-547 in exploratory trials in certain diseases of interest to help guide the development of second-generation GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators for those
diseases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Develop our next generation product candidates, SAGE-217, SAGE-689 and SAGE-718, in parallel with SAGE-547. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Enhance the probability of success in treating CNS disorders by developing unique assets with differentiated features, and focus our internal development activities on CNS indications where we can make well- informed,
rapid go/no-go decisions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Grow our pipeline more broadly utilizing the strengths of our proprietary chemistry platform and scientific know-how, to lessen our long-term reliance on a single franchise and to facilitate long-term growth.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Build a commercial capability to bring our CNS therapeutics, if and when approved, to physicians and patients for the target indications. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Understanding the Foundations of Our Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neurotransmission </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CNS is composed of
a vast and complex network of different structures and cell types, most of which serve directly or indirectly, to provide a means for the nervous system to signal or communicate with other nerve cells in order to regulate and control all brain
function. The cell type responsible for this signaling is called a neuron. Chemical or electrical signals can exert their effects on neurons by traveling across a physical gap located between two neurons, called a synapse. Presynaptic neurons
transmit signals whereas postsynaptic neurons react to the signals. The human brain contains approximately 86 billion neurons, each having hundreds to tens of thousands of synapses to allow for this communication. This process is essential to all
things, from organ function, to movement, to memory and all behavioral processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neurotransmission is the process by which signaling
molecules, called neurotransmitters, are released by a presynaptic neuron, travel over the synaptic space and bind to and interact with receptors on a postsynaptic neuron. Depending on the nature of the neurotransmitter and receptor, this
interaction results in excitation, inhibition or modulation of the receiving neuron&#146;s behavior. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Synaptic receptors are primarily
located inside the synaptic cleft, or the space where the neurons communicate, and have been historically considered to be the most important part of the neuron. However, recent understanding of neurotransmission and brain function has shown there
are many extrasynaptic receptors that also respond to neurotransmitters to exert their effects. For example, it is becoming increasingly understood that extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor-mediated
neurotransmission is critical to generalized neurological function and has demonstrated influence over general physiological states such as sleep, hunger, anxiety and seizure, among other things. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allosteric Modulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on
developing drugs based on selective allosteric modulation of key CNS synaptic and extrasynaptic receptors. Molecules that function directly on synaptic or extrasynaptic receptors at the site where the native, or natural, molecule binds to inhibit or
activate them are known as orthosteric molecules. Alternatively, allosteric modulators are a class of small molecules very different from classical orthosteric drugs, as allosteric modulators interact at a site different from the native site and
allow the potential for fine-tuning of neuronal signals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orthosteric drugs aimed at key synaptic receptors typically have a targeted
effect of complete activation or complete inhibition of the neuron, with little subtlety in how they exert their effect. As a result, neurons may be unable to respond to normal stimuli, and can become over-stimulated by a neurotransmitter or be
unable to respond to normal neurotransmission, thus potentially negatively impacting both the efficacy and safety profile of an orthosteric CNS drug development candidate. We believe that nowhere in the body is it more important to maintain normal
rhythms than in the brain, and accordingly we believe that allosteric modulation approaches are well-suited for the treatment of seizure and other CNS diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize our proprietary chemistry capabilities to design and identify drugs that are
allosteric modulators that bind to either or both synaptic and extrasynaptic receptors, and that have properties targeted to the indications of interest. Our current focus is on developing compounds that are positive allosteric modulators of both
synaptic and extrasynaptic sites of either the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor or the NMDA receptor system. Our goal is to select for development compounds that we believe are capable of varying degrees of
desired activity rather than complete activation or inhibition of the receptor as is typically observed with orthosteric drugs. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g42i94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allosteric Modulation of Extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> Receptors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors are the major inhibitory neurotransmitter receptors in the human brain,
playing a key role in reducing neuron excitability. Our initial focus is on the development of positive allosteric modulators of both synaptic and extrasynaptic sites of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor.
Benzodiazepines, or BDZs, are allosteric modulators that primarily act at a particular receptor, the synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor, with little or no activity at extrasynaptic sites. We believe we
can enhance the potential utility of modulating the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor for certain indications, and effectively avoid some of the limitations of BDZs, by developing compounds that bind to both
synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptors. The extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor is structurally distinct from the synaptic receptor,
possesses unique pharmacology and is located in a different place than the synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor. In addition, the extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>
receptor remains intact during prolonged periods of seizure with no down-regulation while synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors are down-regulated, or diminished in their activity causing some SE patients
to be resistant to the action, or pharmacology, of drugs that only target the synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, such as BDZs. Published non-clinical testing utilizing well-validated animal models of SE
and sophisticated instruments for identifying the expression of both synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors on the surface of neurons support this hypothesis. These studies, performed in
rats, showed a reduced number and activity of synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors during SE, in contrast to the preserved number and activity of extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors under the same conditions. These studies were done by measuring the amount of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> synaptic and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> extrasynaptic receptors that are present on the surface of the neurons. The analysis of protein present for each of the respective
receptors in animals in the SE-state, versus normal animals, shows the difference in GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor expression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below shows the results of a rodent study where the subject animals were placed into an SE-like condition of prolonged seizure
resulting in continuous spontaneous seizures. SAGE-547 was then administered to certain animals while the others received a BDZ. In this animal model, BDZs were unable to adequately control the seizure condition which we believe is due to
down-regulation of synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. In contrast, SAGE-547, working at both synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, appears
to have treated the seizures in these animals and resolved their SE. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g74x61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allosteric Modulation of NMDA Receptors to Address Certain CNS Conditions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NMDA is a major excitatory receptor system in the brain. NMDA receptors serve a critical role in CNS-related activities. Orthosteric drug
candidate approaches to modulating the NMDA receptor have also been fraught with difficulties. NMDA receptor antagonists have been explored for treating Alzheimer&#146;s disease and neuropathic pain and for inducing anesthesia. Drugs that antagonize
NMDA receptors have generally been limited by adverse effects, such as neurotoxicity, deteriorating mental status and psychotomimetic, or the onset of psychotic symptoms, following the administration of the drug. NMDA receptor agonists have been
tested in schizophrenia, and many believe that they may have a role in enhancing cognition and mood. However, their ability to be used at effective doses in humans has generally been limited by non-clinical findings indicating these agents may
induce cell death through excess excitation of nerve cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have identified, and continue to evaluate, a number of positive and
negative allosteric modulators of the NMDA receptor that we believe have the potential to overcome the difficulties associated with orthosteric approaches. Like our GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> allosteric modulators,
our NMDA receptor allosteric modulators work at sites located in the synaptic and extrasynaptic spaces of the neuron and enhance, or modulate, the activity of the native molecule without directly activating the NMDA receptor. Initial animal testing
of our NMDA receptor allosteric modulators has shown evidence that targeting the synaptic and extrasynaptic spaces may help avoid the excitotoxicity and psychotomimesis observed with directly activating, orthosteric compounds. This in turn may
eventually allow us to discover and develop, alone or with partners, compounds to treat certain conditions where NMDA receptor dysfunction may play a role in cognitive dysfunction and neuropsychiatric symptoms such as certain types, aspects or
subpopulations of depression, Alzheimer&#146;s disease, attention deficit hyperactivity disorder, schizophrenia, Huntington&#146;s disease, and neuropathic pain. The first product candidate selected for development from this program is SAGE-718. We
have begun non-clinical studies of SAGE-718, with an initial development focus on two rare conditions, Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor Encephalitis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our proprietary chemistry platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary chemistry platform is centered on novel chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid
compounds that are allosteric modulators of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> or NMDA receptors. We have leveraged this platform to assemble a chemistry portfolio of greater than 2,000 compounds. We believe our
proprietary chemistry platform allows us to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">optimize the properties of neuroactive steroid compounds to develop proprietary, new chemical entities, with the potential to be used as oral, intravenous, or IV, or intramuscular therapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">control important properties such as half-life, brain penetration and the types of receptors our drugs act upon, thereby modulating either inhibition or excitation either acutely or chronically; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create drugs that are designed to exert control over the intensity of receptor activation or deactivation, with the potential to hit targets in the brain with more precision, with the goal of increased tolerability and
fewer off-target side effects than current CNS therapies. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the status of our development programs as of the date of this Annual Report: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g32j29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE-547 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE-547 is a proprietary
IV formulation of allopregnanolone, a naturally occurring neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor. SAGE-547 is being developed as an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjunctive therapy in conjunction with underlying anesthesia, as a treatment for SRSE. In the third quarter of 2015, we initiated the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy
Utilized in Status Epilepticus), a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate SAGE-547 as a treatment for patients with SRSE. We expect to announce top-line results for the Phase 3 clinical trial in the
second half of 2016. If successful, we believe the results from this Phase 3 clinical trial, together with other clinical data obtained from the SAGE-547 development program and results of completed and ongoing non-clinical studies, could form the
basis of an NDA submission for SAGE-547 in the U.S. The FDA granted us orphan drug designation for SAGE-547 in the treatment of SE including SRSE, and Fast Track designation for our investigational new drug application for SAGE-547 as a treatment
for SRSE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Super-refractory Status Epilepticus (SRSE) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SRSE is rare, life-threatening condition where a patient is in a state of SE and all standard treatment regimens normally sufficient in
stopping seizure activity have failed. The Neurocritical Care Society defines SE as one continuous unremitting seizure lasting longer than five minutes, or recurrent seizures without regaining consciousness between seizures for greater than five
minutes. Seizures are episodes of abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from rapid uncoordinated movement of the trunk and extremities, known as tonic-clonic seizure, to a brief loss of
awareness, known as an absence seizure. An electroencephalogram, or EEG, is a measurement of electrical activity within neurons of the brain. Each line of an EEG represents a different region of the brain and becomes aberrant during a state of
seizure. In cases of recurring or frequent seizures, or with persistent and long seizures, uncontrolled neurotransmission results in remodeling or changes to brain synaptic function. These physiological and anatomical changes to the brain include
changes to the receptor systems of neurons, and shape of the neuron thereby impacting its ability to function, resulting in disorganization of brain proteins and potentially neuronal death. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g84s67.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common causes of SE in adults include preexisting epilepsy, cerebrovascular disease, metabolic
and electrolyte disturbances, encephalopathies, head trauma and drug or substance intoxication. SE is more common in children, often as a result of high fever during the first year of life. It is the most common neurologic emergency in pediatric
practice. An SE patient is first treated with BDZs, and if no response, is then treated with other, second-line, anti-seizure drugs. If the seizure persists after second-line therapy, the patient is diagnosed as having refractory SE, or RSE,
admitted to the intensive care unit, or ICU, and placed into a medically induced coma. Currently, there are no therapies that have been specifically approved to treat refractory SE, or RSE; however, physicians typically use anesthetic agents to
induce the coma and stop the seizure immediately. The primary drugs used to induce coma are continuously infused IV agents such as propofol, midazolam or pentobarbital. The RSE patient is continually monitored through EEG to ensure burst suppression
is achieved. Burst suppression is a pattern of brain waves seen on an EEG characterized by periods of activity alternating with periods of little or no activity in the brain, informing medical personnel of the effectiveness of the medically induced
coma. The goal of burst suppression is to allow the brain and corresponding neuronal tissue to restore function and reset to normal pre-seizure levels. After a short period of burst suppression, typically 24 hours, physicians attempt to wean the
patient from the medically induced coma to evaluate EEG activity to assess if the neuronal activity has returned to normal levels. If unsuccessful, the patient is placed back into the medically induced coma in order to protect underlying
neurological activity and brain function. At this point, patients are considered to be in a state of SRSE. The current standard of care for SRSE is empiric, and there are no therapies at present that have been specifically approved for this
indication. We estimate that there are approximately 150,000 cases of SE each year in the United States, of which approximately 25,000 progress to SRSE. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g63h32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently conducting the STATUS trial, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial, to evaluate
SAGE-547 as a treatment for patients with SRSE. We expect to enroll up to 140 patients, ages two and above, in the STATUS trial in order to obtain an estimated 126 evaluable patients. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anticipate that we will qualify approximately 150 sites in the United States, Canada and Europe. The trial design, endpoints and statistical analysis approach are based on an agreement we reached
with the FDA under a Special Protocol Assessment. Subjects will be randomized in a 1:1 ratio to receive either SAGE-547 or placebo in addition to standard-of-care third-line anti-seizure agents for six days. The primary efficacy endpoint of the
trial is continued resolution of SE for 24 hours following wean of all third-line agents and the blinded study drug (SAGE-547 or placebo). Patients who do not respond during the initial treatment period will be eligible for open-labeled treatment
with SAGE-547. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g83r49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;17, 2015, we reported we had treated the first patient enrolled in the Phase 3 clinical
trial. We expect to report top-line results from this trial in the second half of 2016. If successful, we believe the results from this Phase 3 clinical trial, together with other clinical data obtained from the SAGE-547 development program and
results of completed and ongoing non-clinical studies, could form the basis of an NDA submission for SAGE-547 in the U.S. The FDA has granted us orphan drug designation for SAGE-547 in the treatment of SE including SRSE, and Fast Track designation
for our investigational new drug application for SAGE-547 as a treatment for SRSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2015, we reported final results from
our open-label Phase 1/2 clinical trial of SAGE-547 in SRSE. In the Phase 1/2 clinical trial, 77% of 22 evaluable patients met the key efficacy endpoint of being successfully weaned off their anesthetic agents while SAGE-547 was being administered
at the maintenance dose. Subsequent post-hoc analysis involving duration of the weaning period (five days versus six days) showed that 16 of 22 (73%)&nbsp;evaluable subjects were successfully weaned off both anesthetic agents and SAGE-547 within
five days of starting the SAGE-547 infusion without the need to reinstate anesthetic agents in the following 24-hour period, while 18 of 22 (82%)&nbsp;evaluable subjects were weaned off both anesthetic agents and SAGE-547 within six days of starting
the SAGE-547 infusion without the need to reinstate anesthetic agents in the following 24-hour period which is the key efficacy endpoint of the Phase 3 clinical trial. SAGE-547 also showed favorable tolerability and a benefit-risk profile supporting
further development for this acutely ill patient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
population. Overall, 64% of 25 patients enrolled in the trial experienced at least one serious adverse event, though none were drug-related as determined by the Safety Review Committee.
Independent of treatment response, six patient deaths occurred within the study period, all driven by underlying medical conditions. Safety and tolerability were assessed by monitoring adverse events, EEG, physical examinations, neurological
examinations, vital signs, clinical laboratory measures, electrocardiograms and concomitant medication usage. In order to allow full assessment of pharmacologic activity, the trial employed broad inclusion criteria, primarily excluding patients only
if there is major damage to the brain, such as anoxic injury, devastating stroke or the presence of a large lesion. Other secondary objectives used to measure efficacy included scores on global and specific scales relating to cognition, agitation
and depth of coma and survival. We can provide no assurance that the positive results observed in the Phase 1/2 trial will be replicated in the Phase 3 clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emergency-use experience with SAGE-547 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have compiled evidence of activity with SAGE-547 in a small number of SRSE patients, on an emergency-use basis, in situations where
administration of SAGE-547 was permitted outside of clinical trials. The data generated from these emergency-use cases supported further clinical development of SAGE-547 in the treatment of SRSE. We expect that there may be additional emergency-use
cases, and also expect to continue enrollment in a Phase 3 open-label expanded access trial, designated Study 302, which was initiated in April 2015. Study 302 is designed to make SAGE-547 available to patients in the U.S. who are affected by SRSE,
but who have not been admitted to, nor can be transferred to, a STATUS trial site. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE-547 Proof-of-Concept Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also used SAGE-547 in proof-of-concept clinical trials to explore potential uses of
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators to treat post-partum depression, or PPD, a distinct and readily identified depressive disorder that affects certain women following childbirth, and essential tremor, a
debilitating neurological disorder that causes involuntary, rhythmic shaking with no known cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;9, 2015, we reported
top-line data from our proof-of-concept open-label clinical trial of SAGE-547 in PPD that indicated a statistically significant improvement from baseline in depression in four women within 24 hours after administration of intravenous SAGE-547.
During the SAGE-547 treatment period, all four patients rapidly achieved remission, as measured by the Hamilton Rating Scale for Depression, or HAM-D, and improved from a mean HAM-D score of 26.5 at baseline to a mean HAM-D score of 1.8 at the end
of the 60-hour treatment period. All four patients also demonstrated consistent improvement as measured by the Clinical Global Impression-Improvement, or CGI-I scale. SAGE-547 was well-tolerated in all patients treated with no serious adverse events
observed on therapy or during the 30-day follow-up period, and no discontinuations due to adverse events. A total of 14 adverse events were reported in four patients. The only adverse event reported in more than one patient was sedation (sleepiness)
observed in two patients, which led to a decrease in dose. In November 2015, we initiated a multi-center, placebo-controlled, proof-of-concept trial of SAGE-547 in severe PPD patients. We plan to enroll up to 32 patients diagnosed with severe PPD in
the trial which is intended to validate the activity signal observed in the earlier open-label study of SAGE-547 in the treatment for PPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2015, we announced results from a proof-of-concept clinical trial of SAGE-547 to evaluate the GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> mechanism of action as a treatment for essential tremor. In a randomized, double-blind, placebo-controlled, crossover trial of 25 patients affected by essential tremor, where patients were exposed
to the target steady state dose of SAGE-547 for only two hours, several clinician-rated and accelerometer-rated measures showed significant reductions in tremor. These changes included a statistically significant reduction in accelerometer-measured
upper limb kinetic tremor (p=0.046) which is one of the major manifestations of tremor impacting morbidity. Likewise, clinician ratings of large tremor motions, as well as smaller movements such as writing and spiral drawing, also showed improvement
approaching statistical significance (p=0.056). In addition, SAGE-547 demonstrated a clinically meaningful reduction of tremor amplitude as measured by accelerometer (at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
least a 30% reduction from baseline) in 33% of patients, compared with 16% of patients in the placebo arm. In this phase of the trial, anti-tremor activity of SAGE-547 was observed at
non-sedating doses, and peak anti-tremor activity correlated with steady state SAGE-547 levels. The time points showing the greatest reductions in tremor corresponded to peak plasma measurements. Seventeen of these patients were exposed to higher
doses of SAGE-547 in an open-label extension with 44% demonstrating at least a 30% reduction in tremor amplitude from baseline. The most common adverse events at higher doses were fatigue and dizziness. Hypotension led to discontinuation of one
patient. No serious adverse events were observed on therapy or during the 30-day follow-up period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE-217 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE-217 is a novel neuroactive steroid that is a positive allosteric modulator of
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. Like SAGE-547, SAGE-217 targets synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. We are currently conducting a Phase 1
clinical trial of SAGE-217, which we expect to complete in the first half of 2016. While SAGE-547 is an IV infusion intended for acute administration, SAGE-217 is currently being studied as an oral solution. We are in the process of developing a
solid dosage formulation of SAGE-217 intended for chronic use. In the event the results of the Phase 1 clinical trial of SAGE-217 support further development, we plan to commence Phase 2 clinical trials of SAGE-217 in the treatment of orphan
epilepsies and essential tremor, and potentially PPD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Epilepsies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE-217 has shown dose-related anticonvulsant activity in multiple acute seizure and chronic epilepsy models. If the results of the Phase 1
clinical trial of SAGE-217 support further development, we plan to develop the compound as an oral therapy for rare neurologic conditions associated with high frequencies of seizures, such as Tuberous Sclerosis and Dravet, Rett, PCDH-19, Dup15q and
Lennox-Gastaut syndromes, all of which have small patient populations and an unmet medical need for additional treatment options to treat the seizures. Dravet syndrome, also called severe myoclonic epilepsy of infancy, is a severe form of epilepsy.
It typically appears during the first year of life with frequent fever-related seizures. Later, other types of seizures typically arise in patients with this disease. SE may also occur. Children with Dravet syndrome typically experience poor
development of language and motor skills, hyperactivity and difficulty relating to others. Rett syndrome is a neurodevelopmental disorder that affects girls almost exclusively. It is characterized by normal early growth and development followed by a
slowing of development, loss of focused use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures and intellectual disability. Lennox-Gastaut Syndrome, or LGS, typically manifests in children between
the ages of three and five, and is widely considered as a catastrophic childhood epilepsy in which multiple seizure types, including tonic and atonic, are common. LGS is typically associated with cognitive impairment and behavioral abnormalities
such as hyperactivity. PCDH-19 is a pediatric epilepsy disorder linked to the X-chromosome and characterized by clustered seizures in girls with typical onset between ages one and three. Seizures may become infrequent or cease completely as the
child ages. The long term prognosis for PCDH-19 patients is variable though most patients suffer from cognitive impairment. Tuberous Sclerosis, or TSC, is caused by abnormalities in the TSC1 and TSC2 gene. Seizures are common in TSC, affecting
approximately 90% of patients. Approximately 50% of patients are cognitively affected. Dup15q Syndrome is an identifiable syndrome which results from duplications of a specific chromosome. Babies with Dup15q Syndrome typically have poor muscle tone,
also known as hypotonia. Motor milestone such as rolling over, sitting up or walking are usually significantly delayed. Over half of patients with the Dup15q Syndrome will have at least one seizure. The majority of those patients will experience
their first seizure before the age of five. Seizures are common in dup 15q syndrome patients with the idic(15) variant, and typically difficult to control, often presenting with infantile spasms and progressing to a Lennox-Gastaut-type syndrome.
Despite being associated with different genetics and neuropathology these conditions both share growing evidence on the role of the GABA system in ameliorating seizures and other behavioral features of these disorders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Essential Tremor </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Essential tremor, or ET, is one of the most common neurological disorders. It is a non-life threatening, chronic, progressive disorder
associated with involuntary, rhythmic shaking in the upper limbs and head that can cause substantial disability. Some cases of ET are inherited, and for others there is no known cause. We estimate that ET affects approximately 10&nbsp;million people
in the United States, a significant portion of whom are thought to be undiagnosed and untreated. We estimate that approximately 1.5&nbsp;million of those ET patients have moderate to severe symptoms. Common treatments for ET include primidone,
propranolol, gabapentin and benzodiazepines. Current treatments are only moderately effective, reducing, but not resolving, tremor amplitudes in approximately 50% of patients. Data suggest that ET is associated with brain neurodegeneration, and GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor dysfunction, thus providing a rationale for studying compounds that are allosteric modulators of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor and show
anti-convulsant activity as potential treatments for ET. As described above, in a randomized, double-blind, placebo-controlled, crossover trial of 25 patients affected by ET, where patients were exposed to the target steady state dose of SAGE-547
for only two hours, several clinician-rated and accelerometer-rated measures showed significant reductions in tremor. Given its similar mechanism of action, we believe that SAGE-217 also has potential as a treatment for ET, but with a
bioavailability and pharmacodynamic/pharmacokinetic profile intended for once-daily oral dosing. If the Phase 1 clinical trial results support further development, we plan to commence a Phase 2 clinical trial of SAGE-217 in the treatment of ET. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-partum Depression </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PPD is a
depressive disorder affecting a small portion of women after childbirth, and is characterized by sadness and depressed mood, loss of interest in daily activities, changes in eating and sleeping habits, fatigue and decreased energy, inability to
concentrate, and feelings of worthlessness, shame or guilt, leading to significant functional impairment. Without sufficient treatment, PPD has devastating consequences for the mother and for her family. PPD inhibits the mother&#146;s ability to
perform daily activities and to bond with the baby and other members of the family. PPD also carries an increased risk for suicide in some women. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that PPD affects 10%-15% of mothers with onset at or before 6 months postpartum. Onset of moderate-severe symptoms is typically
2-4 weeks after birth. Initial treatment can extend for a minimum of 6 months. Current standard of care for severe PPD comprises the cautious use of pharmacological therapies. Women with severe PPD may be hospitalized to provide a safe and stable
environment for recovery if they have suicidal ideation or attempt, are unable to function and care for themselves, or require monitoring during a change in or trial of a new medication. There are no current approved therapies specifically for PPD.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Naturally occurring allopregnanolone is found at its highest levels in women during the third trimester of pregnancy, returning to normal
level generally within 24 hours of giving birth. Data suggest that women with PPD may be unusually sensitive to this rapid decline in allopregnanolone, potentially causing GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>-system mediated
mood disruption. Given this data, we believe that allosteric modulators of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor may have potential in the treatment of PPD. As noted above, we have initiated a multi-center,
placebo-controlled proof-of-concept clinical trial of SAGE-547 in patients with severe PPD. We plan to enroll up to 32 patients diagnosed with severe PPD in the trial which is intended to validate the activity signal observed in the earlier
open-label study of SAGE-547 in the treatment of PPD. If the ongoing proof-of-concept clinical trial of SAGE-547 in severe PPD generates compelling data that confirms the potential of allosteric
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulation in the treatment of severe PPD, we plan to commence development of SAGE-217 in the treatment of PPD. SAGE-217 shares important GABA receptor pharmacology with
SAGE-547. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE-689 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE-689 is a
novel positive allosteric modulator of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. SAGE-689 has shown anticonvulsant, anxiolytic and sedative properties in animal models. We believe SAGE-689 has potential as an acute
adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sedation are desirable prior to the introduction of general anesthesia, including, for example, for the treatment of SE patients whose seizures have not resolved after treatment with BDZs.
Patients with SE at this stage have been transported by ambulance to the hospital, and frequently have received treatment in the emergency room with anti-seizure drugs. If their seizure does not resolve rapidly the patient must be transferred to the
ICU and immediately placed into a medically induced coma to minimize the risk of brain damage. We believe the profile of SAGE-689 supports development as a second-line therapy for the treatment of SE patients whose seizures have not resolved after
treatment with BDZs prior to a patient being placed into a medically induced coma. These characteristics include a wide therapeutic window to allow for modulation of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor without
inducing deep anesthesia, and a short half-life to permit rapid onset and loss of activity. The latter property is intended to facilitate rapid discharge or transfer to the ICU without residual drug on board. SAGE-689 is being formulated for IV or
intramuscular administration to optimize these characteristics in a clinical setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we filed an investigational new drug
application, or IND, for SAGE-689, however, commencement of our Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from the FDA for additional non-clinical study data. There is no guarantee that we will be able to generate
data that will satisfy the FDA, and enable us to commence the Phase 1 clinical trial. If we are able to successfully address the FDA&#146;s questions, we plan to commence a Phase 1 clinical development program for SAGE-689 which will be designed to
rapidly assess relevant product characteristics for this compound, such as quality of sedation, impact on EEG in normal patients and possibly in patients with epilepsy, pharmacokinetics and general safety. If early Phase 1 clinical trials are
successful we plan to use our Phase 1 clinical trials to evaluate SAGE-689&#146;s ability to induce EEG-confirmed effects on brain activity, including EEG burst-suppression. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE-718 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE-718 is the first product
candidate selected for development from our NMDA receptor program. SAGE-718 is a novel oxysterol-based positive allosteric modulator of NMDA receptors. In 2013, our scientists and collaborators published an article in The Journal of Neuroscience
describing data from animal studies demonstrating that 24(S)-Hydroxycholesterol (cerebrosterol), a naturally occurring oxysterol, shows potent and selective activity in animal models as a positive allosteric modulator of NMDA receptors acting at a
novel oxysterol modulatory site. SAGE-718 has been designed to be a highly potent and selective modulator of NMDA receptors with an optimized pharmacokinetic profile intended to support oral dosing. SAGE-718 has demonstrated robust activity in
preclinical models of NMDA receptor hypofunction. We have begun non-clinical studies of SAGE-718, with an initial development focus on two rare conditions, Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor Encephalitis for which there are currently
no approved treatments. Smith-Lemli-Opitz Syndrome, or SLOS is a rare metabolic disorder caused by a mutation in the DHCR7 (7-dehydrocholesterol reductase) gene which codes for an enzyme that is involved in the production of cholesterol in the
brain. SLOS is associated with significantly decreased plasma levels of cerebrosterol, suggesting that normal oxysterol-based modulation of NMDA receptors is disrupted in these patients. People affected by SLOS are unable to make enough of the
necessary cholesterol in the brain to support normal growth and development, and are affected by a broad range of neuropsychiatric and neurodevelopmental symptoms. Anti-NMDA Receptor Encephalitis, or ANRE, is a rare autoimmune disorder in which
antibodies attack NMDA receptors. Symptoms of ANRE include a highly characteristic set of neuropsychiatric deficits, including cognitive and behavioral disturbances, movement disorders and loss of consciousness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond SLOS and ANRE, we believe measuring levels of anti-NMDA antibodies or decreased cerebrosterol levels may represent biomarkers to
identify for future study broader patient populations characterized by cognitive dysfunction and neuropsychiatric symptoms resulting from NMDA receptor dysfunction or hypofunction. Examples of these potential areas for future evaluation include
certain types, aspects or subpopulations of a number of diseases such as depression, Alzheimer&#146;s disease, attention deficit hyperactivity disorder, schizophrenia, Huntington&#146;s disease, and neuropathic pain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Further Exploitation of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA Receptors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue our focus on allosteric modulation of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA
receptor systems in the brain. The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA receptor systems are broadly accepted as impacting many psychiatric and neurological disorders, spanning disorders of mood, seizure, cognition,
anxiety, sleep, pain, epilepsy, and movement disorders among others. We believe that we will have the opportunity to develop molecules from our internal portfolio to address a number of these disorders in the future. Our ability to identify and
develop such novel CNS therapies is enabled by our proprietary chemistry platform that is centered on a scaffold of chemically modified endogenous neuroactive steroid compounds. We believe our know-how around the chemistry and activity of allosteric
modulators allows us to efficiently design molecules with different characteristics by enabling us to control important properties such as half-life, brain penetration and the types of receptors with which our drugs interact with the goal of
developing product candidates that have the potential to bind with targets in the brain with more precision, increased tolerability, and fewer off-target side effects than either current CNS therapies or previous therapies which have failed in
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current focus will remain on those indications where we can independently develop and commercialize our products, if
approved. We believe our broad potential pipeline lessens our reliance on the success of any one program. We believe our ability to design and develop novel molecules with distinct profiles and receptor subtype selectivity will also provide us, in
the future, with an opportunity to create value by potentially partnering these assets with third parties who possess the development and commercialization capabilities to pursue these programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own nor operate, and currently have no plans to own or operate, any manufacturing facilities. We currently resource all of our
non-clinical and clinical material supply through third party contract manufacturing organizations, or CMOs, and intend to buy all of our future commercial supplies from CMOs if our product candidates are approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established relationships with several CMOs under which the CMOs have manufactured non-clinical and clinical supplies of SAGE-547,
SAGE-217, SAGE-689 and SAGE-718 active pharmaceutical ingredient, or API, as well as drug product. All clinical supplies are manufactured under current Good Manufacturing Practices, or cGMP. Starting materials and key intermediates to support the
production of these candidates are manufactured by other CMOs on a purchase order basis. We do not currently have arrangements in place for either long-term supply or redundant supply of bulk drug substance or drug product for any of our product
candidates. It is our intent to put long-term supply agreements in place for commercial manufacturing at the appropriate time, and to mitigate potential commercial supply risks for any products that are approved in the future through inventory
management and through exploring additional manufacturers to provide API and/or drug product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have sufficient SAGE-547 drug
product on hand for our Phase 3 clinical trial in SRSE, and Phase 2a clinical trial in severe PPD and ongoing non-clinical studies, and are working with our CMOs to prepare for validation and commercial manufacturing of SAGE-547. We currently have
sufficient SAGE-217 drug substance on hand for our ongoing Phase 1 clinical trials using an oral solution as the dosage form. We are developing a solid dosage form of SAGE-217 for future clinical trials. We currently have sufficient SAGE-689 drug
substance on hand to support the planned Phase 1 clinical trial if we are able to satisfy the FDA&#146;s request for additional information sufficiently for the FDA to allow us to commence the Phase 1 trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE-547, SAGE-217, SAGE-689 and SAGE-718 are small molecules isolated as stable crystalline solids. We believe the syntheses of SAGE-547,
SAGE-217, SAGE-689 and SAGE-718 are reliable and reproducible from readily available starting materials, and the synthetic routes are amenable to large-scale manufacturing and do not require unusual equipment or special handling in the manufacturing
process. The enantiomeric purity of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SAGE-547, SAGE-217, SAGE-689 and SAGE-718 is derived from starting materials that are obtained from natural sources. We expect to continue to identify and develop drug candidates that are
amenable to cost-effective manufacturing at contract manufacturing facilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&nbsp;31, 2015, 2014 and 2013 were, $69.4 million, $24.1 million and $14.4
million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our stage of development, we have not yet established a commercial organization or distribution capabilities, nor have we entered into
any partnership or co-promotion arrangements with an established pharmaceutical company. We are concentrating our internal efforts on CNS disorders where we believe we can efficiently commercialize our products, if approved, on our own. For example,
in the United States we believe that SRSE patients are easily identifiable in tertiary care centers where there are ICUs and staff trained in treating refractory or SRSE patients. In a recent secondary analysis of Premier Network Hospitals&#146;
2012 billing data, we found approximately 70% of SRSE discharges, as determined by business rules we and our consultants established, occurred in 925 U.S. hospitals of 300 beds or more. As a result, we believe we can successfully launch and
commercialize SAGE-547 in SRSE, if approved, on our own, using a small and highly specialized sales force similar to those of other rare-disease companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we are focused on CNS disorders where we believe we can efficiently commercialize our product candidates on our own, we may decide to
establish agreements or alliances with one or more distributors or pharmaceutical company collaborators to develop and commercialize our products, if approved, in certain territories outside the United States where we do not believe it makes
commercial sense for us to proceed on our own. We may also consider partnering opportunities for assets geared toward treating CNS disorders such as depression and cognition that impact large patient populations, depending on, among other things,
the applicable indications, the expected development pathway and related costs, and our available resources. In order to effectively and efficiently develop product candidates for these larger markets or more difficult indications or regions, we
intend to partner at an appropriate stage with companies who have clinical expertise and pre-existing commercial infrastructure in these areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered
into several license agreements to support our various programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Washington University </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, we entered into a license agreement with Washington University, or WU. Under this agreement, and subject to certain rights of
the U.S. government and rights retained by WU, WU granted to us an exclusive, worldwide license under certain patent rights to make, have made, sell, and offer for sale, use and import products covered by certain of its patent rights. WU&#146;s
rights in a patent application disclosing and claiming SAGE-689 are included in this license agreement. Under this agreement, WU also granted us non-exclusive license under certain technical information and tangible research information to use such
technical information and/or tangible research information to make, have made, sell, offer for sale, use and import products that embody or were made using a method or process covered in the technical information and/or tangible research
information. The WU license also grants us a right to sublicense our licensed rights to third parties, provided each sublicensee enters into a written agreement with us with terms consistent with our agreement with WU. We must pay to WU a percentage
of the revenue we receive from sublicensing our rights under this agreement, initially in the mid-teens and decreasing to the mid-single digits over time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the WU license, we are required to use commercially reasonable efforts to continue
active, diligent development of licensed products and to use commercially reasonable efforts to manufacture, promote and sell licensed products throughout the territory and in the field during the term of the agreement. We must deliver written
reports to WU describing our progress no later than January&nbsp;31 and July&nbsp;31 of the first two calendar years of the agreement, and no later than January&nbsp;31 of each calendar year thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must pay to WU an annual maintenance fee until and including the year in which our first Phase 2 clinical trial is initiated, and we must
make up to $0.7 million and $0.5 million in clinical development and regulatory milestones, respectively, to WU, for each licensed product, upon reaching certain milestones relating to the clinical development of our product candidates. The license
agreement also requires us to make low single-digit royalty payments to WU in connection with the sales of licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WU
agreement will expire on a licensed product-by-licensed product basis upon the later of (i)&nbsp;the last day that at least one valid patent claim covering the licensed product exists, or (ii)&nbsp;the tenth anniversary of the day of the first
commercial sale of the licensed product. We may terminate the WU Agreement early for convenience upon providing WU with 90 days&#146; written notice. WU may terminate this agreement early in the event of our failure to cure a material breach within
the applicable cure period or our bankruptcy. In the event of early termination of this agreement before the expiration of the last to expire of the patent rights, we must immediately discontinue manufacture, sale and distribution of any licensed
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CyDex Pharmaceuticals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, we amended and restated our existing commercial license agreement with CyDex Pharmaceuticals, Inc., or CyDex. Under the
terms of the commercial license agreement, as amended and restated, CyDex has granted us an exclusive license to CyDex&#146;s Captisol drug formulation technology and related intellectual property for the manufacture of pharmaceutical products
incorporating SAGE-547 or SAGE-689, and the development and commercialization of the resulting products in the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i)&nbsp;the ocular treatment of any disease
or condition with a formulation, including a hormone; (ii)&nbsp;topical ocular treatment of inflammatory conditions; (iii)&nbsp;treatment and prophylaxis of fungal infections in humans; and (iv)&nbsp;any ocular treatment for retinal degeneration.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the CyDex license, we are required during the term of the agreement to use commercially reasonable efforts to continue
active, diligent development of the licensed product, to seek regulatory approval of the licensed product and to commercialize the licensed product following regulatory approval. We must deliver periodic progress reports to CyDex. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to make milestone payments under the amended and restated license agreement with CyDex based on the achievement of clinical
development and regulatory milestones in the amount of $0.8 million in clinical milestones and $3.8 million in regulatory milestones for each of the first two fields with respect to SAGE-547; $1.3 million in clinical milestones and $8.5 million in
regulatory milestones for each of the third and fourth fields with respect to SAGE-547; and $0.8 million in clinical milestones and $1.8 million in regulatory milestones for one field with respect to SAGE-689. The CyDex license is perpetual until
terminated. We may terminate the CyDex agreement for convenience upon providing 180 days&#146; prior written notice to CyDex. Either party has the right to terminate the agreement for failure to cure a material breach in the applicable cure period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also be required to pay royalties to CyDex on sales of SAGE-547 and SAGE-689, if successfully developed, in the low single digits
based on levels of net sales. We are also party to a supply agreement with CyDex which was amended in September 2015 to cover the supply of CyDex&#146;s Captisol for use in the manufacture of products incorporating SAGE-689. Under the amended supply
agreement with CyDex, we are also required to purchase all of our requirements for Captisol with respect to SAGE-547 and SAGE-689 from CyDex, and CyDex is required to supply us with Captisol for such purposes, subject to certain limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>University of California </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we entered into a license agreement with The Regents of the University of California, or the Regents, which was amended in May
2014. Pursuant to this agreement, and subject to certain rights of the U.S. government and rights retained by the Regents, the Regents granted us a non-exclusive, non-transferable license under all personal property rights of the Regents covering
the tangible personal property in an IND application package owned by the Regents, or the Data, and a specified quantity of cGMP grade allopregnanolone, or the Material, to (i)&nbsp;use the Data for reference or incorporation in an IND for the use
of the Material as a treatment of SE, essential tremor and/or severe PPD and (ii)&nbsp;use the Material or modifications of the Material to develop a pharmaceutical formulation for clinical trials for SE, essential tremor and/or postpartum
depression. The rights licensed to us are not sublicenseable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we are required to use commercially reasonable
efforts to proceed with the development, manufacture and sale of one or more products containing allopregnanolone, a derived product under the agreement, for the treatment of SE, essential tremor and/or severe PPD. As of January&nbsp;1, 2014, we
must deliver written reports to the Regents describing our progress no later than 60 days subsequent to June&nbsp;30 and December&nbsp;31 of each fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement requires us to make up to $0.1 million in milestone payments in connection with the first derived product that meets the
relevant milestones, and we must also pay royalties of less than 1% to the Regents for each derived product for a period of 15 years following the first commercial sale of such derived product. This agreement will terminate on the earlier to occur
of (i)&nbsp;27 years after the effective date or (ii)&nbsp;15 years after the last-derived product is first commercially sold. We may terminate this agreement early for convenience upon providing 60 days&#146; prior written notice to the Regents.
The Regents may terminate this agreement early in the event of material default, including failure to provide timely progress reports, after the applicable cure period, or in the event of our bankruptcy. In the event of early termination of this
agreement, we have the right to sell any partially made derived products for a period of 120 days from the date of termination, but would not otherwise have rights after termination under the licensed rights to make, have made, use, sell, have sold,
offer for sale or import products containing allopregnanolone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2015, we entered into an exclusive license agreement with the
Regents whereby we were granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In exchange for such license, we paid an upfront payment of $50,000, and will make annual maintenance
fees of $15,000 until the calendar year following the first sale, if any, of a licensed product. We are obligated to make milestone payments following the achievement of specified regulatory and sales milestones of up to $0.7 million and $2.0
million in the aggregate, respectively. Following the first sale, if any, of a licensed product, we are obligated to pay royalties at a low single digit percentage of net sales, if any, subject to specified minimum annual royalty amounts. Unless
terminated by operation of law or by acts of the parties under the terms of the agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire, whichever is later. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture,
and any other aspects of inventions that are commercially important to the development of our business. We may also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent
protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to expand our intellectual property estate by filing patent applications directed to compositions,
methods of use, treatment and patient selection and formulations and manufacturing processes created or identified from our ongoing development of our product candidates. Our success will depend on our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents;
preserve the confidentiality of our trade secrets; and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities
to develop and maintain our proprietary position. We seek to obtain domestic and international patent protection, and endeavor to promptly file patent applications for new commercially valuable inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual
questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after issuance. Moreover, many jurisdictions, including the United
States, permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing, or may
in the future pursue, will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even
longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by our pending patent applications or of patent applications we may
file in the future. Moreover, we may have to participate in interference proceedings or derivation proceedings declared by the United States Patent and Trademark Office, or U.S. PTO, to determine priority of invention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio includes
patent applications in the early stages of prosecution and no patents have, as of yet, issued from our patent application estate. These patent applications fall into three categories: (1)&nbsp;SAGE-547-related; (2)&nbsp;GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators; including genus and species claims to SAGE-217 and SAGE-689; and (3)&nbsp;NMDA receptor modulators, including SAGE-718. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own five patent families generally related to SAGE-547. One of these patent families includes a patent application having claims to
compositions containing allopregnanolone and a cyclodextrin. The compositions can be used for the treatment of CNS disorders such as traumatic brain injury and SE. The second patent family includes patent applications having claims directed to
methods of treating seizure disorders, such as SE, by administering allopregnanolone using particular dosing regimens or multiple dosage phases. Any U.S. patents that may issue from these families of patent applications would have a statutory
expiration date in January and August of 2033, respectively. The applications are also pending in foreign countries, including Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Indian, Japan, Mexico, New Zealand, Russia, Singapore, and
South Africa. A third family of patent applications includes methods of treating essential tremor and depression such as severe PPD. A fourth family of patent applications includes claims to deuterated neuroactive steroid compounds and compositions.
A fifth family of patent applications includes claims to formulation and manufacturing of SAGE-547. Any U.S. patents that may issue from these families of patent applications would have a statutory expiration date in September 2035,&nbsp;April 2036,
and June 2036, respectively. The time period for electing to pursue foreign patent protection for the inventions disclosed in these patent applications by filing national stage patent applications in individual jurisdictions has not yet expired, and
we will need to decide whether and where to pursue ex-U.S. protection before expiration of the applicable deadlines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the
patent applications licensed from WU, we own 23 families of patent applications, resulting from work done exclusively by us and our contract research organizations, directed to additional GABA receptor modulating compounds and methods of using these
compounds, for example in anesthesia or treatment of GABA-related disorders. Any U.S. patents that may issue from these patent applications would have a statutory expiration ranging from October 2032 to November 2036. Other than SAGE-547 and
SAGE-689, we have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pending within these families of patent applications genus and species claims to the majority of the compounds in our GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor
modulating compound collection, including SAGE-217. These families of patent applications are in the early stages of patent prosecution and include families for which only provisional applications have been filed. The time period for electing to
pursue foreign patent protection by filing national stage patent applications in individual jurisdictions has not yet expired for some of these patent families, and we will need to decide whether and where to pursue ex-U.S. protection before
expiration of the applicable deadlines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed a portfolio of patent applications owned by WU, which are directed
to certain GABA receptor modulating compounds and methods of using these compounds, for example in anesthesia or treatment of GABA-related disorders. This portfolio includes seven families of patent applications. One of these seven families of
patent applications is co-owned by us, and this co-owned family includes pending patent applications in the United States, Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Philippines, Russia, Singapore,
and South Africa. This co-owned application discloses and claims SAGE-689 and its use in anesthesia or treatment of GABA-related disorders. Any U.S. patents that may issue from the SAGE-689 patent family would have a statutory expiration date of
December 2033. In addition, U.S. 7,781,421, solely owned by WU, expires in September 2027. Any patents that may issue, if any, from the remaining five families solely owned by WU would have statutory expiration dates that range from 2032 to 2034.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also own nine families of applications directed to modulators of NMDA receptors. Four of these families of patent applications are
directed to compounds that modulate NMDA receptors, including SAGE-718, which can be used to treat NMDA receptor-related disorders such as CNS related conditions. One of these families of patent applications is directed to using a naturally
occurring compound as a biomarker for a subject who would benefit from treatment with a modulator of NMDA receptors. One of these families of patent applications is directed to using a modulator of NMDA receptors to treat a rare NMDA loss of
function disorder. Any patents that may issue, if any, from these families of applications directed to modulators of NMDA receptors would have statutory expiration dates in September 2032 and July 2036. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent term </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base term of a
U.S. patent is 20 years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the
patent for administrative delays at the U.S. PTO. In some cases, the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of a U.S. patent may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984,
referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of the
active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of an FDA-approved drug, an FDA-approved method of treatment using the drug, and/or a
method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign jurisdictions,
including Europe and Japan, also have patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. In the future, if and when our pharmaceutical products
receive FDA approval, we expect to apply for patent term extension on patents covering those products, their methods of use, and/or methods of manufacture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trade secrets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we
may rely on trade secrets and know-how to develop and maintain our competitive position. Companies typically rely on trade secrets to protect aspects of their business that are not amenable to, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that they do not consider appropriate for, patent protection. We protect trade secrets, if any, and know-how by establishing confidentiality agreements and invention assignment agreements with
our employees, consultants, scientific advisors, contractors and partners. These agreements provide that all confidential information developed or made known during the course of an individual or entity&#146;s relationship with us must be kept
confidential during and after the relationship. These agreements also generally provide that all relevant inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or
assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
biopharmaceuticals industry is highly competitive. There are many public and private companies, universities, governmental agencies and other research organizations actively engaged in the research and development of products that may be similar to
our product candidates or address similar markets. It is probable that the number of companies seeking to develop products and therapies similar to our products will increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there are no therapies that have been specifically approved for treatment of SRSE. However, many products approved for other
indications, for example, general anesthetics and anti-seizure drugs, are used off-label for various stages of SE therapy. Additionally, though not indicated, acupuncture, hypothermia, and electroconvulsive therapy are sometimes used prior to
withdrawal of care for patients with SRSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the field of neuroactive steroids focused on modulation of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> or NMDA receptors, our principal competitor is Marinus Pharmaceuticals, Inc., which we believe is developing a reformulated form of ganaxolone, a known GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> positive allosteric modulator neuroactive steroid, for the potential treatment of drug-resistant partial complex seizures and fragile X syndrome. In addition, Marinus has announced initiation of
the clinical phase of its intravenous Ganaxolone program in SE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our potential competitors, alone or with their strategic
partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the
commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be
reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also
may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug
products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the
regulatory authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. drug development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. Drugs
are also subject to other federal, state and local statutes and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time
and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject a company to administrative or judicial sanctions. These sanctions
could include, among other actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of
production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates must be approved by the FDA through the NDA process before they may be legally marketed in the United States. The
process required by the FDA before a drug may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of extensive non-clinical studies and testing, sometimes referred to as non-clinical laboratory tests, non-clinical animal studies and formulation studies, in accordance with applicable regulations, including
the FDA&#146;s current Good Laboratory Practice, or GLP, regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the FDA of an IND application, which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each trial may be initiated; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish
the safety and efficacy of the proposed drug for each proposed indication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the FDA of an NDA, for a new drug; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A determination by the FDA within 60 days of its receipt of an NDA to accept the NDA filing for review; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and
controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential FDA audit of the non-clinical and/or clinical trial sites that generated the data in support of the NDA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The non-clinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain
that any approvals for our product candidates will be granted on a timely basis, if at all. Non-clinical tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as well as animal studies to assess the
characteristics and potential safety and efficacy of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data required to support an NDA are generated in two distinct
development stages: non-clinical and clinical. For new chemical entities, the non-clinical development stage generally involves synthesizing the active component, developing the formulation and determining the manufacturing process, as well as
carrying out non-human toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. Non-clinical tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as
well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the non-clinical tests must comply with federal regulations, including GLPs. The sponsor must submit the results of the
non-clinical tests, together with manufacturing information, analytical data, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug
product to humans. Some non-clinical testing may continue even after the IND is submitted, but an IND must become effective before human clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the
protocols for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials, including whether subjects will be exposed to unreasonable
health risks, and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug
candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not
arise that could cause the trial to be suspended or terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the drug
candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCPs, which include the requirement that all research
subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols describing, among other details, the objectives of the clinical trial, dosing procedures, subject selection and
exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be
reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants, and considers
such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial
subject or his or her legal representative and must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical
trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA so long as the clinical trial is conducted in compliance with an international
guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the
participants in the clinical trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical trials </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is
to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical trials typically involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic
information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3 clinical trials generally involve large numbers of patients at multiple sites (typically from several hundred to several thousand subjects), and are designed to provide the data necessary to demonstrate the
effectiveness of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with
placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after
initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase 4 clinical trials as a condition of
approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and
written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies, or any findings from animal or in vitro testing that suggests a significant risk for
human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. Success in one phase does not mean that the results will be observed in subsequent phases. Each phase may involve
multiple studies. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an
IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients.
Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial
may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and
physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of
the drug candidate and, among other things, we must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be
conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NDA and FDA review process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of non-clinical studies and of the clinical trials, together with other detailed information, including extensive manufacturing
information and information on the composition of the drug and proposed labeling, are submitted to the FDA in the form of an NDA requesting approval to market the drug for one or more specified indications. The FDA reviews an NDA to determine, among
other things, whether a drug is safe and effective for its intended use and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength, quality and purity. FDA approval of an NDA
must be obtained before a drug may be offered for sale in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act, or
PREA, an NDA or supplement to an NDA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for
which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#146;s fee schedule, effective through December&nbsp;31, 2016, the
user fee for an application requiring clinical data, such as an NDA, is $2.4 million. PDUFA also imposes an annual product fee for human drugs of $0.1 million and an annual establishment fee of $0.6 million on facilities used to manufacture
prescription drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products
designated as orphan drugs, unless the product also includes a non-orphan indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all NDAs submitted before it
accepts them for filing, and may request additional information rather than accepting an NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA
begins an in-depth review of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the filing date in which to complete its initial review of a standard NDA and respond to the
applicant, and six months from the filing date for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often significantly extended by FDA requests for additional information or
clarification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the
proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA
will generally conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and
facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure
compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and
other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. The review and evaluation of an NDA by the FDA is
extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial
marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter
usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or one or more additional pivotal Phase 3 clinical trials, and/or other significant and
time-consuming requirements related to clinical trials, non-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or
withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret
data differently than we interpret the same data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that the FDA will ultimately approve a drug product for marketing
in the United States, and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific diseases and dosages or the indications for use
may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA typically requires that certain contraindications, warnings or precautions be included in the product labeling, and may condition the approval of
the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-marketing testing or clinical trials and surveillance to monitor the effects of approved products. For example,
the FDA may require Phase 4 testing which involves clinical trials designed to further assess a drug&#146;s safety and efficacy and may require testing and surveillance programs to monitor the safety of approved products that have been
commercialized. The FDA may also place other conditions on approvals including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA
must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for
non-compliance with regulatory requirements or if problems occur following initial marketing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orphan drug designation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is
generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing and making a drug
product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting an NDA. After the FDA grants orphan product designation, the
identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a
different indication than that for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same product as defined by the FDA
or if our product candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug designated as an orphan product receives marketing approval for an indication broader than what is
designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union, or EU, has similar, but not identical, benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expedited development and review programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria.
Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to
the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug as a Fast Track product at any time during the clinical development of the
product. Unique to a Fast Track product, the FDA may review sections of the marketing application on a rolling basis before the complete NDA is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the
FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a Fast Track program, may be
eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where
no satisfactory alternative therapy exists or offers a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an
application for a new drug designated for priority review in an effort to facilitate the review. A product may also be eligible for accelerated approval. Drugs studied for their safety and efficacy in treating serious or life-threatening illnesses
and that provide meaningful therapeutic benefit over existing treatments, may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an
effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor
of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it will require such
post-marketing restrictions, as it deems necessary to assure safe use of the drug, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distribution restricted to certain facilities or physicians with special training or experience; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distribution conditioned on the performance of specified medical procedures. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitations
imposed would be commensurate with the specific safety concerns presented by the drug. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of
the commercial launch of the product. Additionally, a drug may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or
condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more indications. The benefits of breakthrough therapy designation includes the same benefits as fast track
designation, plus intensive guidance from FDA to ensure an efficient drug development program. Fast Track designation, priority review, accelerated approval and breakthrough designation do not change the standards for approval, but may expedite the
development or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pediatric trials </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act, or FDASIA, which was signed into law on July&nbsp;9, 2012, amended the FDCA to
require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or
PSP, within sixty days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design,
age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from
pediatric studies along with supporting information. FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data
collected from non-clinical studies, early phase clinical trials, and/or other clinical development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-marketing requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA,
including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information,
product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#146;s approved labeling (known as
&#147;off-label use&#148;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the Internet. Although physicians may prescribe legally available drugs for off-label uses,
manufacturers may not market or promote such off-label uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug, including changes in
indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the applicant to develop additional data or conduct additional
non-clinical studies and clinical trials. As with new NDAs, the review process is often significantly extended by FDA requests for additional information or clarification. Any distribution of prescription drug products and pharmaceutical samples
must comply with the U.S. Prescription Drug Marketing Act, or the PDMA, a part of the FDCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, once a product is
approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. We rely, and expect to continue to
rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring
of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These manufacturers must comply with cGMP regulations that require among other things, quality control and quality assurance as well as the corresponding
maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their
establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time,
money, and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such
facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA, including, among
other things, recall or withdrawal of the product from the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discovery of previously unknown problems with a product or the failure
to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil
or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings and contraindications, and also may require the
implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could delay or prevent regulatory approval of our
products under development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other regulatory matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory
authorities in addition to the FDA, including, in the United States, the Centers for Medicare&nbsp;&amp; Medicaid Services; other divisions of the Department of Health and Human Services; the United States Department of Justice; the Drug Enforcement
Administration; the Consumer Product Safety Commission; the Federal Trade Commission; the Occupational Safety&nbsp;&amp; Health Administration; the Environmental Protection Agency; and state and local governments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws. These
laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a company marketing a prescription drug (or a party acting on its behalf) to knowingly and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
willfully solicit, receive, offer, or pay any remuneration that is intended to induce or reward the referral of business, including the purchase, order, or prescription of a particular drug, for
which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation
in federal healthcare programs. In addition, the Patient Protection and Affordable Health Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, among other things, amends the intent requirement of
the federal Anti-Kickback Statute and criminal healthcare fraud statutes created by the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA. A person or entity no longer needs to have actual knowledge of the statute or
specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of
the False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we would not submit claims directly to payors, drug manufacturers can be held liable under the federal
False Claims Act, which prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for
items or services not provided as claimed, or claims for medically unnecessary items or services. The government may deem companies to have &#147;caused&#148; the submission of false or fraudulent claims by, for example, providing inaccurate billing
or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate
information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. Penalties for a False Claims Act violation include three
times the actual damages sustained by the government, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the
federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims
laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the
federal False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget
Reconciliation Act of 1990 and more recent requirements in ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet
applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive
record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory
action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or
withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for
example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely
affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. patent term restoration and marketing exclusivity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for
limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The
patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable
to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term
extension or restoration. In the future, we intend to apply for restoration of patent term for one of our then owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials
and other factors involved in the filing of the relevant NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing exclusivity provisions under the FDCA can also delay the
submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is
a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator
drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity
or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than
bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity
covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of
use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the non-clinical studies and
adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is
another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity
protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Union drug development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
European Union, our future products may also be subject to extensive regulatory requirements. As in the United States, medicinal products can only be marketed if a marketing authorization from the competent regulatory agencies has been obtained.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of non-clinical and clinical research in the
European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of
clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be
initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all suspected
unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical trials legislation is currently undergoing a revision process mainly aimed at harmonizing and streamlining the clinical trials
authorization process, simplifying adverse event reporting procedures, improving the supervision of clinical trials, and increasing their transparency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pediatric data or an approved Pediatric Investigation Plan, or PIP, or waiver, is required to have been approved by the European
Medicines Agency, or EMA, prior to submission of a marketing authorization application to the EMA. In most EU countries, we are also required to have an approved PIP before we can begin enrolling pediatric patients in a clinical trial. We have not
yet submitted a PIP to the EMA for any of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Union drug review and approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA, (which is comprised of 27 Member States of the EU (excludes Croatia) plus Norway, Iceland and
Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal
Products for Human Use, or CHMP, of the EMA and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and
medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active
substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are
available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through
the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized
Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS
prepares a draft assessment report, a draft summary of the product characteristics, or SPC, and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval.
If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States
(i.e., in the RMS and the Member States Concerned). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, before granting the MA, the EMA or the
competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Union new chemical entity exclusivity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, new chemical entities, sometimes referred to as new active substances, qualify for eight years of data exclusivity upon
marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic application for eight
years, after which a generic marketing authorization application can be submitted, and the innovator&#146;s data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of 11 years if, during the
first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant
clinical benefit in comparison with existing therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Union orphan designation and exclusivity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of
products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union Community and for which no satisfactory method of
diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening,
seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years
of market exclusivity is granted following medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to
justify maintenance of market exclusivity. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review
and approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rest of the world regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the
requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable
foreign regulatory requirements applicable to a given country, we may not be able to obtain regulatory approval for our product candidates in such country if we choose to seek such approval, or we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reimbursement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are
successful in developing and gaining regulatory approval for our product candidates, sales of our products will be dependent on the availability and extent of coverage and reimbursement from third-party payers. In the United States, healthcare
providers are reimbursed for covered services and products they use through Medicare, Medicaid, and other government healthcare programs as well as through commercial insurance and managed healthcare organizations. In the United States no uniform
policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, the
coverage determination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly reducing reimbursements for medical products
and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. Changes in government legislation or regulation and changes in private
third-party payers&#146; policies toward reimbursement for our products may reduce reimbursement of our products&#146; costs to physicians, pharmacies, and distributors. The U.S. government, state legislatures and foreign governments have shown
significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of
more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results for any products we commercialize in the future. Decreases in third-party reimbursement for our products or a decision by
a third-party payor not to cover a product for which we received marketing approval could reduce physician usage of our products and have a material adverse effect on our sales, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pricing and reimbursement environment for our products may change in the future and become more challenging due to, among other reasons,
policies advanced by a new presidential administration, federal agencies, new healthcare legislation passed by Congress or fiscal challenges faced by all levels of government health administration authorities. The American Recovery and Reinvestment
Act of 2009, or ARRA, for example, allocated new federal funding to compare the effectiveness of different treatments for the same condition. The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency
for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although ARRA does not mandate the use of the results of comparative
effectiveness studies for reimbursement purposes, it is not clear what effect, if any, the research will have on the sales of any products for which we receive marketing approval or on the reimbursement policies of public and private payors. It is
possible that comparative effectiveness research demonstrating benefits in a competitor&#146;s product could adversely affect the sales of any product for which we receive marketing approval. For example, if third-party payors find our products not
to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the goals of the federal Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2010, collectively referred to herein as ACA, was to expand coverage for the uninsured while at the same time containing overall healthcare costs. With regard to pharmaceutical products, among other things, the ACA expands and
increases industry rebates for drugs covered under Medicaid. The ACA also imposed new reporting requirements on drug manufacturers for payments made to physicians and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of $1,000 to $10,000 for each payment or ownership interest that is not timely, accurately, or completely reported (annual
maximum of $150,000), and $10,000 to $100,000 for each knowing failure to report (annual maximum of $1 million). The reporting requirements apply only to manufacturers of products for which reimbursement is available under a federal healthcare
program. Other health regulatory laws, such as the federal anti-kickback statute and the federal civil False Claims Act, have been applied to marketing and other activities engaged in by pharmaceutical companies whose products are reimbursed by
federal healthcare programs, and, in many cases, government investigations or private lawsuits under these laws have led such companies to enter settlements that include significant monetary and other penalties, We cannot predict the full impact of
the ACA or the other laws described above on our business until we have a marketed product. Many states have adopted laws similar to the federal laws discussed above. Some of these state laws apply to the referral of patients for healthcare services
reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. There has also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been a recent trend of increased federal and state regulation of payments made to physicians. Certain states mandate implementation of compliance programs, impose restrictions on drug
manufacturers&#146; marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians. In addition, other legislative changes have been proposed and adopted in the United States since the ACA
was enacted. Beginning April&nbsp;1, 2013, Medicare payments for all items and services under Part A and B, including drugs and biologicals, and most payments to plans under Medicare Part D were reduced by 2% under the sequestration (i.e., automatic
spending reductions) required by the Budget Control Act of 2011, or BCA, as amended by the American Taxpayer Relief Act of 2012. The BCA requires sequestration for most federal programs, excluding Medicaid, Social Security, and certain other
programs. The BCA caps the cuts to Medicare payments for items and services and payments to Part D plans at 2%. Subsequent legislation extended the 2% reduction, on average, to 2025. As long as these cuts remain in effect, they could adversely
impact payment for any products we may commercialize in the future. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for
healthcare products and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in many foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.
Historically, products launched in the European Union do not follow price structures of the United States, and generally prices tend to be significantly lower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Employees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;15, 2016, we employed 62 full-time employees, including 39 in research and development and 23 in general and
administrative and no part-time employees. 21 of our employees hold M.D. or Ph.D. degrees. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective-bargaining arrangements. We
consider our employee relations to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Cambridge, Massachusetts, and consist of 22,067 square feet in a multi-tenant building. Our lease
expires on February&nbsp;28, 2022. We expect to lease additional space prior to the expiration of our lease to meet the needs of the business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
the date of this Annual Report on Form 10-K, we were not party to any legal matters or claims. In the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate
would have a material adverse impact on our financial position, results of operations or cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of Delaware on April&nbsp;16, 2010 and commenced operations on January&nbsp;19, 2011 as
Sterogen Biopharma, Inc. On September&nbsp;13, 2011, we changed our name to Sage Therapeutics, Inc. under our Second Amended and Restated Certificate of Incorporation. Our mailing address and executive offices are located at 215 First Street,
Cambridge, Massachusetts and our telephone number at that address is (617)&nbsp;299-8380. We maintain an Internet website at the following address: www.sagerx.com. The information on our website is not incorporated by reference in this annual report
on Form 10-K or in any other filings we make with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available on or through our website
certain reports and amendments to those reports that we file with or furnish to the Securities and Exchange Commission in accordance with the Securities Exchange Act of 1934, as amended. These include our annual reports on Form 10-K, our quarterly
reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as
soon as reasonably practicable after we electronically file the information with, or furnish it to, the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may read and copy any materials we file with the SEC at the SEC&#146;s Public Reference Room at 100&nbsp;F&nbsp;Street, NE, Washington, DC
20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other information regarding
us and other issuers that file electronically with the SEC. The SEC&#146;s Internet website address is http://www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_2"></A>Item&nbsp;1A. Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together
with all other information in this Annual Report on Form 10-K, or Annual Report, including our financial statements and related notes, before investing in our common stock. Any of the risk factors we describe below could adversely affect our
business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of the money you paid to buy our common stock.
Additional risks that we currently do not know about, or that we currently believe to be immaterial, may also impair our business. Certain statements below are forward-looking statements. See &#147;Cautionary Note Regarding Forward-Looking
Statements&#148; in this Annual Report. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Product Development, Regulatory Approval and Commercialization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on the success of our current product candidates, of which SAGE-547 is in Phase 3 clinical development for super-refractory status
epilepticus; SAGE 217 is in Phase 1 clinical development; and SAGE-689 and SAGE-718 are in non-clinical development; and other product candidates are at earlier stages. We cannot be certain that we will be able to complete, within the expected
time-frames, our non-clinical studies or clinical trials, or to announce results on the time-lines we expect. We cannot be certain that we will be able to advance our product candidates into additional trials, or to successfully develop, or obtain
regulatory approval for, or successfully commercialize, any of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no drug products for
sale, and may never be able to successfully develop marketable drug products. Our business depends heavily on our ability to successfully complete non-clinical and clinical development of our current product candidates, and to obtain regulatory
approval and successfully commercialize those product candidates. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through non-clinical studies and clinical trials that the product candidate
is safe and effective for use in each target indication. Our lead product candidate, SAGE-547, is currently in Phase 3 clinical development for the treatment of super-refractory status epilepticus, or SRSE. SAGE 217 is in Phase 1 clinical
development, and SAGE-689 and SAGE-718 are in non-clinical development and other product candidates are at earlier stages. Drug development involves a high degree of risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to complete our clinical trials or announce results from our clinical trials on the time-lines we expect. For instance, we
may experience slower than expected clinical site initiation, or slower than expected identification and enrollment of evaluable patients. There is also the potential for delays or problems in analyzing data, or the potential need for additional
analysis or data or the need to enroll additional patients. We may also encounter delays arising from unexpected adverse events in a trial or other unexpected hurdles or issues in the conduct of any trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to demonstrate the efficacy and safety of our current product candidates or any other product candidate at each stage of
clinical development. We may change formulations of our product candidates which could delay development or require us to conduct additional clinical trials or non-clinical studies. The results of clinical trials or non-clinical testing of our
product candidates at any stage may not support further development or may not be sufficient to obtain regulatory approval. Clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject
to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Drug development is a long, expensive and
uncertain process, and delay or failure can occur at any stage of our clinical trials. Success in non-clinical studies or in earlier stage clinical trials may not be repeated or observed in ongoing or future studies involving the same compound or
other product candidates. The drug development process can take many years, and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the
United States, only a small percentage will successfully complete the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Food and Drug Administration, or FDA, regulatory approval process and will be commercialized. Accordingly, even if we are able to obtain the requisite financing, when needed, to continue to fund
our development efforts, we cannot assure you that any of our product candidates will be successfully developed or commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
not permitted to market our product candidates in the United States until we receive approval of a New Drug Application, or an NDA, from the FDA, or in any foreign countries until we receive the requisite marketing approval from such countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining approval of an NDA in the U.S. or marketing approval in any country outside the U.S. is a complex, lengthy, expensive and uncertain
process, and the FDA and regulatory authorities outside the U.S. may delay, limit or deny approval of any of our product candidates for many reasons, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to demonstrate, to the satisfaction of the FDA or other regulatory authorities that our product candidates are safe and effective in any indication; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our non-clinical studies and clinical trials may be negative, or may not meet the level of statistical or clinical significance required by the FDA or regulatory authorities outside the U.S. for marketing
approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or regulatory authorities outside the U.S. may disagree with the number, design, size, conduct, or implementation of our non-clinical studies or clinical trials or changes in drug formulation used in our
non-clinical studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or regulatory authorities outside the U.S. may require that we conduct additional non-clinical studies and clinical trials prior to approval or post-approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or the applicable foreign regulatory agency may not approve the formulation, labeling or specifications of any of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the contract research organizations, or CROs, that we retain to conduct our non-clinical studies and clinical trials may take actions outside of our control that materially adversely impact our non-clinical studies and
clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or regulatory authorities outside the U.S. may find the data from non-clinical studies and clinical trials insufficient to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its
safety risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or regulatory authorities outside the U.S. may disagree with our interpretation of data from our non-clinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or regulatory authorities outside the U.S. may not accept data generated at our non-clinical studies and clinical trial sites; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval
of our application or may recommend that the FDA require, as a condition of approval, additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or the applicable foreign regulatory agency may determine that the manufacturing processes or facilities of third-party contract manufacturers with which we contract do not conform to applicable requirements,
including current Good Manufacturing Practices, or cGMPs; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or applicable foreign regulatory agency may change its approval policies or adopt new regulations. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive marketing approval for our product candidates, regulatory or other
governmental authorities may still impose significant restrictions on our products, including restrictions on indicated uses or marketing, or may impose ongoing requirements for potentially costly post-approval studies. For example, we expect that,
prior to product launch, the U.S. Drug Enforcement Agency, or DEA, will need to determine the controlled substance schedule of SAGE-547, taking into account the recommendation of the FDA. The process may be more time consuming than we expect, and
may delay our ability to market SAGE-547 if it is approved. Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market our product candidates. Any such setback
would have a material adverse effect on our business and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot be certain that the results of our ongoing Phase 3 clinical trial of
SAGE-547 will be sufficient to support the submission of an NDA for this product candidate, and in any event we must obtain additional clinical and non-clinical data before an NDA may be submitted. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the FDA requires two pivotal trials to support approval of an NDA, but in certain circumstances, will approve an NDA based on only
one pivotal trial. If successful, we believe the results from our ongoing Phase 3 clinical trial of SAGE-547, together with other safety and efficacy data from the SAGE-547 development program, could form the basis of an NDA submission for SAGE-547.
However, depending upon the outcome of the Phase 3 clinical trial and the other development activities under the current program, the FDA may require that we conduct additional pivotal trials before we can submit an NDA for SAGE-547. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we will need to complete several other clinical and non-clinical studies prior to submitting an NDA to the FDA, including studies
to evaluate the pharmacokinetics and/or pharmacodynamics of SAGE-547 in special populations. If the results of these additional clinical and non-clinical studies are delayed or yield unanticipated results, it may delay or prevent the submission or
approval of an NDA for SAGE-547. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval
process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received Fast Track designation for our investigational new drug application, or IND, for SAGE-547 for the
treatment of SRSE, and in the future we may seek Fast Track designation for other product candidates as well. If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address
unmet medical needs for this condition, the sponsor may apply for the FDA Fast Track designation. Fast Track designation does not necessarily lead to a faster development pathway or regulatory review process, and does not increase the likelihood of
regulatory approval. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The number of patients with SRSE and the other diseases and disorders for which we are developing product candidates has not been established with
precision. The number of patients suffering from SRSE is small. If the actual number of patients with SRSE or any other diseases or disorders we elect to pursue with our product candidates is smaller than we anticipate, we may encounter difficulties
in enrolling patients in our clinical trials, thereby delaying or preventing development of our product candidates, and even if such product candidates are approved, our revenue and ability to achieve profitability may be materially adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, SAGE-547, is currently being studied in a Phase 3 clinical trial for the treatment of patients with
SRSE. There is no precise method of establishing the actual number of patients with SRSE in any geography over any time period. Moreover, SRSE is an acute episodic condition. If we are not able to identify patients at the time of SRSE onset, we will
have difficulty completing our Phase 3 clinical trial. We estimate that the annual incidence of SRSE in the United States is approximately 25,000 patients per year, and it may be that only a subset of those patients would be potential candidates for
treatment with SAGE-547. We plan to develop our product candidates in certain other indications, including potentially status epilepticus, refractory status </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
epilepticus, orphan epilepsies, post-partum depression, essential tremor, Smith-Lemli-Opitz Syndrome and anti-NMDA receptor encephalitis. We may not be able to accurately estimate the prevalence
or size of the addressable patient population for some or all of those indications or any other indication that we elect to pursue. In estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our
estimates as to the prevalence of SRSE, we apply assumptions to available information that may not prove to be accurate. In each case, there is a range of estimates in the published literature which include estimates within the range that are lower
than our estimates. The actual number of patients with SRSE or any other indication in which we elect to pursue development of our product candidates may be significantly lower than we believe. If the actual number of patients with SRSE or any other
indication in which we elect to pursue development of our product candidates is lower than our estimates, we may experience difficulty in enrolling patients in our clinical trials, thereby delaying development of our product candidates. A prevalence
calculation is an estimate of the total number of patients with a disease or the rate of occurrence of a disease in a population. Even if our prevalence estimates are correct, our products, if approved, may be indicated for only a subset of patients
with a particular disease or condition. If any of our product candidates are approved and our prevalence estimates with respect to any indication or our market assumptions are not accurate, the markets for our product candidates for these
indications may be smaller than we anticipate, which could limit our revenues and our ability to achieve profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If serious adverse events
or other undesirable side effects are identified during the use of SAGE-547 or any of our other product candidates in emergency-use cases, investigator sponsored trials, expanded access programs, or any clinical trials, it may adversely affect our
development of such product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our product candidates could cause us or regulatory
authorities to interrupt, delay or halt non-clinical studies and clinical trials, or could make it more difficult for us to enroll patients in our clinical trials. If serious adverse events or other undesirable side effects, or unexpected
characteristics of SAGE-547 or any of our other product candidates are observed in emergency-use cases, investigator sponsored clinical trials, or clinical trials, further clinical development of such product candidate may be delayed or we may not
be able to continue development of such product candidate at all, and the occurrence of these events could have a material adverse effect on our business. Undesirable side effects caused by our product candidates could also result in the delay or
denial of regulatory approval by the FDA or other regulatory authorities or in a more restrictive label than we expect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Positive results from early
non-clinical studies and clinical trials of our product candidates are not necessarily predictive of the results of later non-clinical studies and clinical trials of our product candidates. If we cannot replicate the positive results from our
earlier non-clinical studies and clinical trials of our product candidates in our later non-clinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Positive results from non-clinical studies and clinical trials, including proof-of-concept trials, of our product candidates may
not necessarily be predictive of the results we may obtain from subsequent non-clinical studies or clinical trials using the same product candidate or other product candidates. For example, the positive results from our Phase 1/2 clinical trial of
SAGE-547 in SRSE and results from earlier emergency use cases, may not be replicated in our ongoing Phase 3 clinical trial. Our Phase 3 clinical trial of SAGE-547 differs in important ways from the Phase 1/2 clinical trial, which could cause the
outcome of the Phase 3 clinical trial to differ from the earlier stage clinical trial. The Phase 3 clinical trial of SAGE-547 is a placebo-controlled trial, while our Phase 1/2 clinical trial was open-label, and in our Phase 3 clinical trial an
intent-to-treat statistical analysis, which is a more rigorous statistical analysis, will be employed in evaluating the Phase 3 data. In addition, the formulation of SAGE-547 we are using in our Phase 3 trial is somewhat different than the
formulation used in the Phase 1/2 trial. We do not believe the change in formulation will negatively affect trial results, but we cannot be sure. Similarly, the results from our early-stage proof-of-concept clinical trials of SAGE-547 in essential
tremor and post-partum depression may not be replicated in subsequent clinical trials of SAGE-547 or other product candidates in those indications even if the mechanism of action of the product candidates is the same. Many
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials after achieving positive results in early-stage development, and we
cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, non-clinical findings made while clinical trials were underway or safety or efficacy observations made in non-clinical studies and
clinical trials that are different than in earlier trials, including previously unreported adverse events. For example, we may observe safety issues in clinical studies of our product candidates that we did not observe or appreciate in non-clinical
studies. The results from non-clinical animal models may not be replicated in clinical trials. Many drug candidates, including many targeting CNS disorders, with promising non-clinical profiles have failed to demonstrate similar safety, non-toxicity
and efficacy in humans. Moreover, non-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in non-clinical studies and clinical
trials nonetheless failed to obtain FDA approval. If we fail to produce positive results in our planned non-clinical studies or clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization
prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failures
or delays in the commencement or completion of our planned clinical trials of our product candidates could result in increased costs to us and could delay, prevent or limit our ability to generate revenue and continue our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful completion of clinical trials at each applicable stage of development is a prerequisite to submitting an NDA to the FDA and,
consequently, the ultimate approval and commercial marketing of SAGE-547 for SRSE and our other product candidates for the indications in which we develop them. We do not know whether any of our clinical trials will begin or be completed on
schedule, if at all, as the commencement and completion of clinical trials can be delayed or prevented for a number of reasons, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may deny permission to proceed with our planned clinical trials or any other clinical trials we may initiate, or may place a clinical trial on hold; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in filing or receiving approvals of additional INDs that may be required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative results from our ongoing non-clinical studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">challenges in identifying, recruiting and enrolling patients to participate in clinical trials, including, in the case of SAGE-547, due to the small size of the patient population and acute nature of SRSE; the proximity
of patients to trial sites; the requirement for a pediatric investigation plan to enroll pediatric patients in most EU countries; challenges in meeting regulatory requirements to commence clinical trials in countries outside the U.S.; eligibility
criteria for the clinical trial; the nature of the clinical trial protocol; the availability of approved effective treatments for the relevant disease; and competition from other clinical trial programs for similar indications; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching or failing to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different
CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical trials, for example delays in the manufacturing of sufficient supply of finished drug product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties obtaining Institutional Review Board, or IRB, approval, and equivalent approval for sites outside the U.S., to conduct a clinical trial at a prospective site or sites; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the occurrence of severe or unexpected drug-related side effects experienced by patients in a clinical trial or unexpected results in ongoing non-clinical studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in validating any endpoints utilized in a clinical trial; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to satisfy the CMC requirements of the FDA or file amendments to our IND as requested by the FDA prior to the initiation of a clinical trial; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA and applicable regulatory authorities outside the U.S. disagreeing with our clinical trial design and our interpretation of data from clinical trials, or changing the requirements for approval even after the
regulatory authority has reviewed and commented on the design for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reports from non-clinical or clinical testing of other CNS therapies that raise safety or efficacy concerns; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties retaining patients who have enrolled in a clinical trial but may be prone to withdraw due to rigors of the clinical trials, lack of efficacy, side effects, personal issues or loss of interest.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. For example,
commencement of a Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from the FDA for additional non-clinical study data. There is no guarantee that we will be able to generate data that will satisfy the FDA, and enable us
to commence the Phase 1 clinical trial. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a clinical trial, a data and safety monitoring board, or DSMB, overseeing the
clinical trial at issue or other regulatory authorities due to a number of factors, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities that reveals deficiencies or violations that require us to undertake corrective action, including the imposition of a
clinical hold; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues, including any that could be identified in our ongoing non-clinical studies, or adverse side effects or lack of effectiveness identified in ongoing clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in government regulations or administrative actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">problems with clinical supply materials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in regulatory requirements, FDA guidance
or unanticipated events during our non-clinical studies and clinical trials of our product candidates may occur, which may result in changes to non-clinical studies and clinical trial protocols or additional non-clinical studies and clinical trial
requirements, which could result in increased costs to us and could delay our development timeline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory
requirements, FDA guidance or unanticipated events during our non-clinical studies and clinical trials may force us to amend non-clinical studies and clinical trial protocols or the FDA or applicable regulatory authorities outside the U.S. may
impose additional non-clinical studies and clinical trial requirements. Amendments or changes to our clinical trial protocols would require resubmission to the FDA and IRBs for review and approval, which may adversely impact the cost, timing or
successful completion of clinical trials. Similarly, amendments to our non-clinical studies may adversely impact the cost, timing, or successful completion of those non-clinical studies. If we experience delays completing, or if we terminate, any of
our non-clinical studies or clinical trials, or if we are required to conduct additional non-clinical studies or clinical trials, the commercial prospects for our product candidates may be harmed and our ability to generate product revenue will be
delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect that we will continue to rely, on third parties to conduct any clinical trials for our
product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize products, if approved, and our business could be
substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the ability to independently conduct clinical trials. We rely on medical institutions,
clinical investigators, contract laboratories and other third parties, such as CROs, to conduct clinical trials of our product candidates. We enter into agreements with third-party CROs to provide monitors for and to manage data for our ongoing
clinical trials. We rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and completion of
these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as
well as difficulties in coordinating activities. Outside parties may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have staffing difficulties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fail to comply with contractual obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience regulatory compliance issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">undergo changes in priorities or become financially distressed; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">form relationships with other entities, some of which may be our competitors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors
may materially adversely affect the willingness or ability of third parties to conduct our clinical trials, and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we are responsible for ensuring that each of our
clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific requirements and standards, and our reliance on CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to
comply with regulations and guidelines, including current Good Clinical Practices, or cGCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and
accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and
comparable foreign regulatory authorities for any products in clinical development. The FDA enforces cGCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs or clinical
sites fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. We cannot assure you that, upon inspection, the FDA or applicable regulatory authorities outside the U.S. will determine that our clinical trials comply with cGCPs. In addition, our clinical trials must be conducted with
product candidates produced under cGMPs regulations. Our failure or the failure of our CROs or contract manufacturers to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, and
could also subject us to enforcement action up to and including civil and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these
third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality
or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, and we are unable to rely on clinical data collected, we could be required to repeat,
extend the duration of, or increase the size of our clinical trials and this could significantly delay commercialization and require significantly greater expenditures. As a result, we believe that our financial results and the commercial prospects
for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely completely on third-party suppliers to manufacture our clinical drug supplies for our product
candidates, and we intend to rely on third parties to produce non-clinical, clinical and commercial supplies of our product candidates in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture supplies of our product
candidates, or any future product candidates, for use in the conduct of our non-clinical studies and clinical trials, or for future commercial use, and we rely completely on third-party suppliers for both active drug substances and finished drug
products. For example, SAGE-547 used in the emergency-use cases was manufactured at an academic site, the active pharmaceutical ingredient for SAGE-547 for our Phase 1/2 clinical trial was manufactured at an academic site and SAGE-547 as formulated
for our Phase 1/2 clinical trial was manufactured at a third-party manufacturer&#146;s site. SAGE-547, as formulated for our Phase 3 clinical trial, is also manufactured at a third-party manufacturer&#146;s site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will rely on our contract manufacturers to manufacture registration batches of both active drug substances and finished drug products
required for regulatory approval as well as validation batches required for commercial manufacture. We expect our contract manufacturers to comply with cGMPs in the manufacture of our products. The facilities used by our contract manufacturers to
manufacture the active pharmaceutical ingredient and final drug product must typically complete a pre-approval inspection by the FDA and other comparable foreign regulatory agencies to assess compliance with applicable requirements, including cGMPs,
after we submit our NDA or equivalent foreign regulatory submission to the applicable regulatory agency. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or applicable foreign regulatory agencies, and pass regulatory inspections, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no direct control over
our contract manufacturers&#146; ability to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our third-party contract manufacturers are engaged with other companies to supply and/or manufacture
materials or products for such companies, which exposes our third-party contract manufacturers to regulatory risks for the production of such materials and products. As a result, failure to satisfy the regulatory requirements for the production of
those materials and products may affect the regulatory clearance of our contract manufacturers&#146; facilities generally. If the FDA or an applicable foreign regulatory agency determines now or in the future that these facilities for the
manufacture of our product candidates are noncompliant, we may need to find alternative manufacturing facilities, which would adversely impact our ability to develop and obtain regulatory approval for our product candidates and to market any
approved products in the future. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have long-term supply agreements in place with our contract manufacturers, and each batch of our product
candidates is individually contracted under a quality agreement and purchase order. If our existing contract manufacturers are not willing to enter into long-term supply agreements, or are not willing or are unable to supply drug substance or drug
product to us, and we engage new contract manufacturers, such contractor manufacturers must scale up the manufacturing process, complete validation batches, pass an inspection by the FDA and other applicable foreign regulatory agencies, and be
approved by regulatory authorities as our manufacturer before we are able to use drug product or drug substance they manufacture for commercial purposes which could result in significant delays or gaps in product availability. We plan to continue to
rely upon contract manufacturers and, potentially, collaboration partners, to manufacture commercial quantities of our products, if approved. If we are unable to maintain arrangements for third-party manufacturing, or are unable to do so on
commercially reasonable terms, or are unable to obtain timely regulatory approvals in connection with our contract manufacturers, we may not be able to successfully complete development of our product candidates or commercialize our products, if
approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval for our product candidates in the United States, we may never receive
regulatory approval to market our product candidates outside of the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive marketing approval for our
product candidates in the United States, we may never receive regulatory approval to market our product candidates outside of the United States. In order to market any product outside of the United States, we must establish and comply with the
numerous and varying safety, efficacy and other regulatory requirements of other countries. Approval procedures vary among countries and can involve additional product candidate testing and additional administrative review periods. The time required
to obtain approvals in other countries might differ from that required to obtain FDA approval. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may
have a negative effect on the regulatory process in others. The marketing approval processes in other countries may implicate all of the risks detailed above regarding FDA approval in the United States as well as other risks. In particular, in many
countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in bringing products to market in such countries.
Even if we are able to successfully develop our product candidates and obtain marketing approval in a country, we may not be able to obtain pricing and reimbursement approvals in such country at acceptable levels or at all, and any pricing and
reimbursement approval we may obtain may be subject to onerous restrictions such as caps or other hurdles or restrictions on reimbursement. Failure to obtain marketing and pricing approval in countries outside the U.S. or any delay or other setback
in obtaining such approval would impair our ability to market our product candidates in such foreign markets. Any such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and
sell our product candidates, we may not be able to generate any revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have an infrastructure for the sales,
marketing and distribution of pharmaceutical products. In order to market our product candidates, if approved by the FDA or any other regulatory body, we must build our sales, marketing, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable
terms, our business, results of operations, financial condition and prospects will be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing
approval for our product candidates, our approved products may not achieve broad market acceptance, which would limit the revenue that we generate from their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our product candidates, if approved by the FDA or other applicable regulatory authorities, will depend upon the
awareness and acceptance of our approved products among the medical community, including physicians, patients and healthcare payors. Market acceptance of our products, if approved, will depend on a number of factors, including, among others: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy of our products as demonstrated in clinical trials, and, if required by any applicable regulatory authority in connection with the approval for the applicable indications, to provide patients with
incremental health benefits, as compared with other available CNS therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the labeling approved for our products by the FDA or other applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which our products are approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative treatments already approved or expected to be commercially launched in the near future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of our products over current treatment options or alternative treatments, including future alternative treatments; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support and timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicity concerning our products or competing products and treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing and cost effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to increase awareness of our approved products through marketing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain sufficient third-party coverage or reimbursement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of patients to pay out-of-pocket in the absence of third-party coverage. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
our product candidates are approved, but do not achieve an adequate level of acceptance by patients, physicians and payors, we may not generate sufficient revenue from our products to become or remain profitable. Before granting reimbursement
approval, healthcare payors may require us to demonstrate that our product candidates, in addition to treating these target indications, also provide incremental health benefits to patients. Our efforts to educate the medical community and
third-party payors about the benefits of our products, if approved, may require significant resources and may never be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product
candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt non-clinical
studies and clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited
duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others
identify undesirable side effects caused by such products (or any other similar products) after such approval, a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw or limit their approval of such products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way such products are distributed or administered, conduct additional clinical trials or change the labeling of the products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to regulatory investigations and government enforcement actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide to remove such products from the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any of these events could prevent us from
achieving or maintaining market acceptance of the affected products and could substantially increase the costs of commercializing our products and significantly impact our ability to successfully commercialize our products and generate revenues.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval for our product candidates, we may still face future development and
regulatory difficulties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive marketing approval for our product candidates, regulatory authorities may still impose
significant restrictions on our products, indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. For example, we expect that, prior to product launch, the U.S. Drug Enforcement Agency, or DEA, will
need to determine the controlled substance schedule of SAGE-547, taking into account the recommendation of the FDA. The DEA process may be more time consuming than we expect. Our products, if approved, will also be subject to ongoing FDA
requirements governing the labeling, packaging, storage and promotion of the product and record keeping and submission of safety and other post-market information. The FDA has significant post-marketing authority, including, for example, the
authority to require labeling changes based on new safety information and to require post-marketing studies or clinical trials to evaluate serious safety risks related to the use of a drug. The FDA also has the authority to require, as part of an
NDA or post-approval, the submission of a REMS. Any REMS required by the FDA may lead to increased costs to assure compliance with additional post-approval regulatory requirements and potential requirements or restrictions on the sale of approved
products, all of which could lead to lower sales volume and revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers of drug products and their facilities are subject to
continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMPs and other regulations. If we or a regulatory agency discover problems with our products, if approved, such as adverse events of
unanticipated severity or frequency, or problems with the facility where our products are manufactured, a regulatory agency may impose restrictions on our products, the manufacturer or us, including requiring withdrawal of such products from the
market or suspension of manufacturing. If we, our product candidates or approved products or the manufacturing facilities for our product candidates or products fail to comply with applicable regulatory requirements, a regulatory agency may, among
other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to applications submitted by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain products, refuse to permit the import or export of products, or require that we initiate a product recall. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competing therapies could emerge adversely affecting our opportunity to generate revenue from the sale of our product candidates, if approved.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceuticals industry is highly competitive. There are many public and private companies, universities, governmental
agencies and other research organizations actively engaged in the research and development of products that may be similar to our product candidates or address similar markets. It is probable that the number of companies seeking to develop products
and therapies similar to our products will increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there are no therapies specifically approved for SRSE or RSE. However,
many products approved for other indications, including general anesthetics and anti-seizure drugs, are used off-label for various stages of SE therapy. Additionally, though not indicated, acupuncture, hypothermia, and electroconvulsive therapy are
sometimes used prior to withdrawal of care for patients with SRSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the field of neuroactive steroids focused on modulation of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> or NMDA receptors, our principal competitor is Marinus Pharmaceuticals, Inc., or Marinus, which is developing a reformulated form of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ganaxolone, a known GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> positive allosteric modulator neuroactive steroid, for potential treatment of drug-resistant partial complex
seizures and fragile X syndrome. In addition, Marinus has announced initiation of the clinical phase of its intravenous Ganaxolone program in SE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and human resources
than we do, and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the
biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products
more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our
development and commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug development programs and the potential commercialization of our product
candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those
product candidates in some or all markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation
of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate,
the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to
such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate
on and whether such collaboration could be more attractive than the one with us for our product candidate. The terms of any collaboration or other arrangements that we may establish may not be favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be restricted under existing license agreements from entering into future agreements on certain terms with potential
collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of
potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we
are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or
bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future collaborations that we enter into may not be successful. The
success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding
clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be
difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such
termination or expiration would adversely affect us financially and could harm our business reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to
identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which
there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and
commercialize products based on our proprietary chemistry platform. Although some of our product candidates are in non-clinical and clinical development, our research programs may fail to identify other potential product candidates for clinical
development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may not have a positive risk/benefit
profile or may have other characteristics that may make the product candidates unmarketable or unlikely to receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and management resources, we focus on a limited number of research programs and product candidates and are
currently focused on certain CNS disorders. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Research programs to identify new
product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our resource allocation decisions may cause
us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable drugs.
If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaboration, licensing or other royalty arrangements in cases
in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material
adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties,
contractual damages, reputational harm and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not currently have any products
on the market, once we begin commercializing our products, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our
business. Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of our product candidates, if approved. Our future arrangements with third-party payors will expose us to broadly applicable fraud
and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates, if we obtain marketing approval. Restrictions under
applicable federal and state healthcare laws and regulations include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing
remuneration, directly or indirectly, in cash or in kind, to induce </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as
Medicare and Medicaid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The federal False Claims Act imposes criminal and civil penalties, including those from civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to
the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme
to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The federal transparency requirements, sometimes referred to as the &#147;Sunshine Act,&#148; under the Patient Protection and Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies
that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership
and investment interests. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Analogous state laws and regulations, such as state anti-kickback and false claims laws and transparency laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could be costly. It
is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our
operations, including anticipated activities to be conducted by our sales team, were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines and exclusion from government funded healthcare programs, such as Medicare and Medicaid, any of which could substantially disrupt our operations. If any of the physicians or other providers or entities with
whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have
improperly promoted off-label uses, we may become subject to significant liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory agencies strictly
regulate the promotional claims that may be made about prescription products, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s
approved labeling. If we are found to have promoted off-label uses for any product, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and
has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if
approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SAGE-547
will, and our other product candidates may, contain controlled substances, the manufacture, use, sale, importation, exportation, prescribing and distribution of which are subject to regulation by the DEA. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before we can commercialize SAGE-547, and potentially our other product candidates, it is expected that the DEA will need to determine the
controlled substance schedule, taking into account the recommendation of the FDA. This could delay our marketing of a product candidate and could potentially shorten the benefit of any regulatory exclusivity periods for which we may be eligible. If
approved, SAGE-547 is expected to be, and our other product candidates may be, regulated as &#147;controlled substances&#148; as defined in the Controlled Substances Act of 1970, or CSA, and the implementing regulations of the DEA, which establish
registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to our third-party manufacturers and to
distributors, prescribers and dispensers of our product candidates. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and
packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established
medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the
lowest relative risk of abuse among such substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that SAGE-547 will, and our other product candidates may, be listed by the
DEA as Schedule IV controlled substances under the CSA. Consequently, the manufacturing, shipping, storing, selling and using of the products will be subject to an additional regulation. Distribution, prescribing and dispensing of these drugs are
also regulated. Other Schedule IV compounds include sedative hypnotics such as benzodiazepines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual registration is required for any
facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of their restrictive nature, these laws and regulations could limit commercialization of our product candidates containing controlled
substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties and state actions, among
other consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if approved, reimbursement policies could limit our ability to sell our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance and sales of our product candidates will depend on reimbursement policies and may be affected by healthcare reform measures.
Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels for those medications. Cost containment is a primary
concern in the U.S. healthcare industry and elsewhere. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that
reimbursement will be available for our product candidates and, if reimbursement is available, the level of such reimbursement. Reimbursement may impact the demand for, or the price of, our product candidates. If
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some foreign countries, particularly in Canada and European countries, the pricing of prescription pharmaceuticals is subject to strict
governmental control. In these countries, pricing negotiations with governmental authorities can take six to twelve months or longer after the receipt of regulatory approval and product launch. To obtain favorable reimbursement for the indications
sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates with other available therapies. If reimbursement for our product candidates is unavailable in
any country in which we seek reimbursement, if it is limited in scope or amount, if it is conditioned upon our completion of additional clinical trials, if it is conditioned on unreasonable caps or rebates, or if pricing is set at unsatisfactory
levels, our operating results could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even though we have obtained orphan drug designation for SAGE-547 as a
treatment for SE, including SRSE, there may be limits to the regulatory exclusivity afforded by such designation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though we
have obtained orphan drug designation for SAGE-547 for treatment of SE, including SRSE, from the FDA, there are limitations to exclusivity afforded by such designation. In the United States, the company that first obtains FDA approval for a
designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for a period of seven years. This orphan drug exclusivity prevents the FDA from approving another application, including a
full NDA to market the same drug for the same orphan indication, except in very limited circumstances, including when the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. For purposes of small
molecule drugs, the FDA defines &#147;same drug&#148; as a drug that contains the same active moiety and is intended for the same use as the drug in question. To obtain approval for a drug that shares the same active moiety as an already approved
orphan-designated drug, it must be demonstrated to the FDA that the drug is safer or more effective than the approved orphan designated drug, or that it makes a major contribution to patient care. In addition, a designated orphan drug may not
receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later
determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other
risks and uncertainties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future profitability may depend, in part, on our ability to gain approval of, and commercialize, our
product candidates in foreign markets for which we may rely on collaboration with third parties. If we are able to gain approval for, and commercialize our product candidates in foreign markets, we would be subject to additional risks and
uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our customers&#146; ability to obtain reimbursement for our product candidates in foreign markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to directly control commercial activities to the extent we are relying on third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">import or export licensing requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer accounts receivable collection times; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer lead times for shipping; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">language barriers for technical training; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection of intellectual property rights in some foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the existence of additional potentially relevant third party intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency exchange rate fluctuations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic
instability, trade restrictions and changes in tariffs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Intellectual Property Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that are sufficient to protect our product
candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended
to cover our products and compositions, their methods of use and any other inventions that are important to the development of our business. We may also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do
not consider appropriate for, patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend significantly on our ability to obtain and maintain patent and
other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, should they issue, preserve the confidentiality of our trade secrets and operate without infringing
the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the proprietary position of our product
candidates. Our owned and licensed patent applications relate to SAGE-547, GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators, including genus and species claims to SAGE-217, SAGE-689 and NMDA receptor modulators,
including SAGE-718. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no issued patents covering any of our lead product candidates, SAGE-547, SAGE-217, SAGE-689 or
SAGE-718. We cannot provide any assurances that any of our pending patent applications will mature into issued patents and, if they do, that such patents will include, claims with a scope sufficient to protect our product candidates or otherwise
provide any competitive advantage. For example, the patent applications that may provide coverage for SAGE-547, only cover particular formulations and particular methods of using such formulations to treat seizure conditions, such as SE. As a
result, if a patent issues from such patent applications, it would not prevent third-party competitors from creating, making and marketing alternative formulations, that fall outside the scope of our patent claims or practicing alternative methods.
There can be no assurance that any such alternative formulations will not be equally effective as our formulation of SAGE-547. Moreover, other parties have developed technologies that may be related or competitive to our approach, and may have filed
or may file patent applications and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent
position. Such third-party patent positions may limit or even eliminate our ability to obtain patent protection for certain inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual
questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S.
patents and patent applications may also be subject to interference proceedings, <I>ex parte</I> reexamination, or <I>inter partes</I> review proceedings, supplemental examination and challenges in district court. Patents may be subjected to
opposition, post-grant review, or comparable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or
reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents, should they issue, that we may own or exclusively license may not provide any protection against
competitors. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, though a patent, if it were to issue, is presumed valid and enforceable, its issuance is not conclusive as to
its validity or its enforceability, and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Even if a patent issues, and is held to be valid and enforceable, competitors may
be able to design around our patents, such as using pre-existing or newly developed technology. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. We may not be able to prevent the
unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors, former employees and current employees. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of
the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these developments were to occur, they could have a material adverse effect on our sales if any of our product candidates are
approved in those countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to
detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#146;s or potential competitor&#146;s product. Any litigation to
enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming, and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate
and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, proceedings to enforce
or defend our patents, if and when issued, could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of
the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents, if and when issued, covering our product candidates are invalidated or found unenforceable, our financial position and results of operations
would be materially and adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered our product candidates, our financial position and results of operations would also be materially and adversely
impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our current product candidates or any other products or product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our pending patent applications will issue as patents at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will be able to successfully commercialize our product candidates, if approved, before our relevant patents expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we were the first to make the inventions covered by each of our pending patent applications and any patents that may issue in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we were the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others will not develop similar or alternative technologies that do not infringe any patents that may be issued to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others will not use pre-existing technology to effectively compete against us; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our patents, if issued, will be found to ultimately be valid and enforceable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will develop additional proprietary technologies or product candidates that are separately patentable; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that our commercial activities or products will not infringe upon the patents or proprietary rights of others. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely upon unpatented trade secrets, and depend on unpatented know-how and continuing technological innovation to develop and maintain
our competitive position, which we seek to protect, in part, by confidentiality agreements with our employees and our collaborators and consultants. It is possible that technology relevant to our business will be independently developed by a person
that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we
could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise become known or be independently discovered by our competitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing
or increase the costs of commercializing our product candidates, if approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our ability to
operate without infringing the intellectual property and proprietary rights of third parties. We cannot assure you that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third
parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights.
Other parties may allege that our product candidates or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. As we
continue to develop and, if approved, commercialize our current product candidates and future products, competitors may claim that our technology infringes their intellectual property rights as part of business strategies designed to impede our
successful commercialization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent
applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that our product candidates may infringe, or which such third parties claim are infringed by our
technologies. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always
uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be
able to do this. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material
adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent and
other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. Patent litigation is costly and time-consuming. Any claim relating to intellectual property infringement that is
successfully asserted against us may require us to pay substantial damages, including treble damages and attorney&#146;s fees if we are found to be willfully infringing another party&#146;s patents, for past use of the asserted intellectual property
and royalties and other consideration going forward if we are forced to take a license. In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing,
manufacturing, selling or otherwise commercializing our product candidates. In the case of trademark claims, if we are found to be infringing, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be required to redesign, or rename, some or all of our product candidates to avoid infringing the intellectual property rights of third parties, which may not be possible and, even if
possible, could be costly and time-consuming. Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored
and may not effectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign to us any inventions developed in
connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Patent and Trademark Office, or U.S. PTO, and various foreign governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the patent applications we own or license are issued, competitors may infringe these patents. To counter
infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is
unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could
put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to
our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the
prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual
property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could
also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent, if and when issued, covering one
of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions include
allegations that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the
United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <I>ex parte</I> reexamination, or <I>inter partes</I> review and equivalent proceedings in foreign jurisdictions, e.g.,
opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and
unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal
assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our
intellectual property rights even in the jurisdictions where we seek protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on
product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States,
assuming that rights are obtained in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able
to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. The statutory deadlines for
pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and
further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to
prevent third parties from so competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some foreign countries do not protect intellectual property rights to the same extent
as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries,
do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology. For example, an April 2014 report from the Office of the United States Trade Representative identified a number of
countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989. This could make it
difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant
licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent
protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the
benefit of patent protection in such countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, proceedings to enforce our patent rights in foreign jurisdictions could
result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue
developing or commercializing our product candidates, if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties or, in certain
cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
party to a number of license agreements under which we are granted rights to intellectual property that are important to our business and we expect that we may need to enter into additional license agreements in the future. Our existing license
agreements impose, and we expect that future license agreements will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our
obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Our business could suffer, for example,
if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on
acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we have done previously, we may need to obtain licenses from third parties to advance our research or allow
commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products in the absence of such a license. We may fail to
obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be
required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the
third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is of critical importance to our business and involves complex
legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right to sublicense patent and other rights to third parties under collaborative development relationships; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into
several licenses to support our various programs. We completed an exclusive license agreement with Washington University, or WU, under certain patent families that comprise a variety of small molecule allosteric modulators of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors and for which we have the worldwide right to develop and commercialize. A patent family that discloses and claims SAGE-689 is licensed to us under this agreement. We are obligated to pay
WU certain clinical/regulatory milestones and single-digit royalties on products developed from this technology. Termination of our license agreement with WU would have a material adverse impact on our ability to develop and commercialize SAGE-689.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into an exclusive license agreement with CyDex Pharmaceuticals, Inc., or CyDex, a wholly owned subsidiary of Ligand
Pharmaceuticals, Inc., to use its Captisol technology to develop SAGE-547 and SAGE-689 for the field of use, which includes all fields for the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i)&nbsp;the
ocular treatment of any disease or condition with a formulation, including a hormone; (ii)&nbsp;topical ocular treatment of inflammatory conditions; (iii)&nbsp;treatment and prophylaxis of fungal infections in humans; and (iv)&nbsp;any ocular
treatment for retinal degeneration. We are obligated to pay CyDex certain clinical/regulatory milestones and, if approved and marketed, single-digit royalties on SAGE-547 and SAGE-689. In addition, we have entered into a supply agreement with CyDex,
pursuant to which CyDex supplies us with Captisol to formulate both products. Absent an alternative agreement by the parties, our rights under our exclusive license agreement terminate in the event that the supply agreement terminates. Currently,
our SAGE-547 and SAGE-689 product candidates are formulated in Captisol. Termination of our license agreement with CyDex would have a material adverse impact on our ability to develop and commercialize SAGE-547 and SAGE-689 in their current
formulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also entered into a non-exclusive license with The Regents of the University of California, or the Regents. Pursuant to
this agreement the Regents granted us a non-exclusive, non-transferable license under all personal property rights of the Regents covering the tangible personal property in an IND application package owned by the Regents, or the Data, and a
specified quantity of cGMP grade allopregnanolone, or the Material, to (i)&nbsp;use the Data for reference or incorporation in an IND for use of the Material as a treatment of SE, essential tremor and/or postpartum depression and (ii)&nbsp;use the
Material or modifications of the Material to develop a pharmaceutical formulation for clinical trials for SE, essential tremor and/or postpartum depression. This agreement requires us to pay milestone payments in connection with the first derived
product, which would include SAGE-547, that meets the relevant milestones and we must also pay single-digit royalties for each derived product for a period of 15 years following the first commercial sale of such derived product. Termination of our
license agreement with the Regents would have a material adverse impact on our ability to develop and commercialize derived products, which would include SAGE-547. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2015, we entered into an exclusive license agreement with the Regents under which we were
granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In exchange for such license, we paid an upfront payment and will pay annual maintenance fees until the calendar year following
the first sale, if any, of a licensed product. We are obligated to make milestone payments following the achievement of specified regulatory and sales milestones. Following the first sale, if any, of a licensed product, we are obligated to pay
royalties at a low single digit percentage of net sales, if any, of licensed products, subject to specified minimum annual royalty amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into additional licenses to third-party intellectual property that are necessary or useful to our business. Our current licenses
and any future licenses that we may enter into impose various royalty payment, milestone, and other obligations on us. For example, as is the case for the Washington University license, the licensor may retain control over patent prosecution and
maintenance under a license agreement, in which case, we may not be able to adequately influence patent prosecution or prevent inadvertent lapses of coverage due to failure to pay maintenance fees. If we fail to comply with any of our obligations
under a current or future license agreement, the licensor may allege that we have breached our license agreement, and may accordingly seek to terminate our license. In addition, future licensors may decide to terminate their licenses with us at
will. Termination of any of our current or future licenses could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop and commercialize a product candidate or
product, if approved, as well as harm our competitive business position and our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if our licensors fail to
abide by the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable
terms, our business could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some intellectual property which we have licensed may have been discovered through government funded programs and
thus may be subject to federal regulations such as &#147;march-in&#148; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of
resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the
intellectual property rights we have licensed may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the intellectual property rights licensed to us under
the license agreements with WU and the Regents may have been generated using U.S. government funds. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to
the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any
governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not
been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to
as &#147;march-in rights&#148;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor fails, to disclose the invention to the government and fail to file an application to register the
intellectual property within specified time limits. In addition, the U.S. government may acquire title to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated under
a government funded program is also subject to certain reporting requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources. In addition, the U.S. government requires that any products embodying
the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable
but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into future arrangements involving government funding, and we discover compounds or drug candidates as a result of such funding,
intellectual property rights to such discoveries may be subject to the applicable provisions of the Bayh-Dole Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain additional
protection under the Hatch-Waxman Amendments and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of the future U.S. patents
we own or license may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term
of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to
apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. For example, we may not be granted an extension if the active ingredient of SAGE-547, allopregnanolone, is used in another drug company&#146;s
product candidate and that product candidate is the first to obtain FDA approval. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or
restoration or the term of any such extension is less than we request, and we do not have any other exclusivity, our competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues could be
materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect
our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property,
particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has recently
enacted and is currently implementing wide-ranging patent reform legislation: the Leahy-Smith America Invents Act, referred to as the America Invents Act. The America Invents Act includes a number of significant changes to U.S. patent law. These
include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. It is not yet clear what, if any, impact the America Invents Act will have on the operation of our business. However, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents that may issue from our patent applications, all of which could have a
material adverse effect on our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, recent U.S. Supreme Court rulings have narrowed the scope
of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. The full impact of these decisions is not yet known. For example, on March&nbsp;20, 2012 in <I>Mayo Collaborative Services, DBA
Mayo Medical Laboratories, et al. v. Prometheus Laboratories, Inc.</I>, the Court held that several claims drawn to measuring drug metabolite levels from patient samples and correlating them to drug doses were not patentable subject matter. The
decision appears to impact diagnostics patents that merely apply a law of nature via a series of routine steps and it has created uncertainty around the ability to obtain patent protection for certain inventions. Additionally, on June&nbsp;13, 2013
in <I>Association for Molecular Pathology v. Myriad Genetics, Inc.</I>, the Court held that claims to isolated genomic DNA are not patentable, but claims to complementary DNA molecules are patent eligible because they are not a natural product. The
effect of the decision on patents for other isolated natural products is uncertain. On June 19, 2014 in <I>Alice Corporation Pty. Ltd. v. CLS Bank International, et al.</I>, a case involving patent claims directed to a method for mitigating
settlement risk, the Court held that the patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligibility of claims directed to abstract ideas, products of nature, and laws of nature should be determined using the same framework set forth in Prometheus. The U.S. PTO recently issued a set
of guidelines setting forth procedures for determining subject matter eligibility of claims directed to abstract ideas, products of nature, and laws of nature in line with the Prometheus, Myriad, and Alice decisions. The guidance does not limit the
application of Myriad to DNA but, rather, applies the decision to other natural products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to increasing uncertainty with
regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by the U.S. Congress, the federal courts and the U.S. PTO,
the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade
secrets of their former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our employees have been previously employed at other biotechnology or pharmaceutical
companies, including our competitors or potential competitors. We also engage advisors and consultants who are concurrently employed at universities or who perform services for other entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not aware of any claims currently pending against us, we may be subject to claims that we or our employees, advisors or
consultants have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third party. We have and may in the future also be subject to claims that an
employee, advisor or consultant performed work for us that conflicts with that person&#146;s obligations to a third party, such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out of work
performed for us. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such
claims, in addition to paying monetary claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to develop and commercialize our product candidates,
which would materially adversely affect our efforts and results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Numerous factors may limit any potential competitive advantage provided by our
intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because
intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party
has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by the claims of patents, should such patents issue from our patent
applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to make the inventions covered by a pending patent application that we own; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to file patent applications covering an invention; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may independently develop similar or alternative technologies without infringing our intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pending patent applications that we own or license may not lead to issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents, if issued, that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop or in-license additional proprietary technologies that are patentable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of others may have an adverse effect on our business. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events
occur, they could significantly harm our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Company-Related Risks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As our product candidates reach later stage clinical development, we will need to develop and expand our company, and we may encounter difficulties in
managing this development and expansion, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As our product candidates reach later stage clinical
development and, as we plan for a potential commercial launch of products, if approved, we expect to increase our number of employees and the scope of our operations. To successfully execute our activities, and to manage our anticipated expansion,
we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. In addition, our management may need to divert a disproportionate
amount of its attention away from its day-to-day activities, and devote a substantial amount of time to managing these expansion activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or
recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes or delays, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
The physical expansion of our operations may lead to significant costs, and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected
expansion, our expenses may increase more than expected, and our ability to successfully develop and gain regulatory approval of our product candidates and generate or increase our revenue, if such product candidates are approved, could be reduced
and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the
future expansion of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our President and Chief Executive Officer and to attract,
retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on Dr.&nbsp;Jeffrey&nbsp;M. Jonas, our Chief Executive Officer,
President, and Director. We have entered into an employment agreement with Dr.&nbsp;Jonas, but he may terminate his employment with us at any time. Although we do not have any reason to believe that we will lose the services of Dr.&nbsp;Jonas in the
foreseeable future, the loss of his services might impede the achievement of our research, development and commercialization objectives. We also do not have any key-man life insurance on Dr.&nbsp;Jonas. We rely on consultants and advisors, including
scientific, clinical and regulatory advisors, to assist us in formulating and implementing our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under
consulting or advisory contracts with other entities that may limit their availability to us and may not be subject to our standard non-compete agreements. Recruiting and retaining qualified personnel will also be critical to our success. We may not
be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific personnel from
universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities, including violating applicable
regulatory standards and requirements or engaging in insider trading, which could significantly harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed
to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to: comply with the regulations of the FDA and applicable non-U.S. regulators; provide accurate information to the FDA and applicable
non-U.S. regulators; comply with healthcare fraud and abuse and anti-kick-back laws and regulations, in the United States and abroad; comply with anti-bribery and anti-corruption laws and regulations in the United States and abroad; report financial
information or data accurately; or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials or other material information, which could result in regulatory sanctions and serious harm to our reputation. We
have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of our product candidates in clinical trials and the sale of our products, if approved, expose us to the risk of product liability
claims. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with our product candidates. For example, we may be sued if any product we develop allegedly causes
injury or is found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we become subject to product liability
claims and cannot successfully defend ourselves against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of patients from our clinical trials, or difficulty in enrolling clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our products following marketing approval, if obtained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">damage to our reputation and exposure to adverse publicity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased FDA warnings on product labels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to successfully gain approval and commercialize our product candidates or any future product candidates, if approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain product liability insurance coverage for our clinical trials with a $10 million annual aggregate coverage limit. Nevertheless, our
insurance coverage may be insufficient to reimburse us for any expenses or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
losses we may suffer. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including if insurance
coverage becomes increasingly expensive. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may not be able to obtain this product
liability insurance on commercially reasonable terms. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved
in our favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in
defending such a claim or claims and the resulting judgments exceed our insurance coverage, our financial condition, business and prospects could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will continue to incur significant costs as a result of operating as a public company, and our management team will be required to devote substantial
time to compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we incur significant legal, accounting and other expenses that we did not
incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the Securities and Exchange Commission and The NASDAQ Stock Market have imposed various requirements on public companies, including
establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and
regulations cause us to incur significant legal and financial compliance costs, and make some activities more time-consuming and costly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we are required to furnish a report by our management on
our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the
prescribed period, we conduct a process each year to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we dedicate internal resources, engage outside consultants and adopt a
detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude that our internal control
over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As we continue to grow, we will need to hire additional qualified accounting and financial personnel with appropriate public company experience.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to grow our organization, we will need to establish and maintain effective disclosure and financial controls, and
make changes in our corporate governance practices. We will need to hire additional accounting and financial personnel with appropriate public company experience and technical accounting knowledge, and it may be difficult to recruit and maintain
such personnel. Even if we are able to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment and the indirect consequences related to the diversion of management resources
from product development efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to
limitation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, we had federal and state net operating loss carryforwards of $131.5&nbsp;million and
$130.7&nbsp;million, respectively, which begin to expire in 2031. As of December&nbsp;31, 2015, we also had federal and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state research and development tax credit carryforwards of $1.6 million and $0.7 million, respectively, which begin to expire in 2031 and 2027, respectively. As of December&nbsp;31, 2015, we had
federal orphan drug tax credit carryforwards of $16.4 million, which begin to expire in 2034. Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, changes in our ownership may limit the amount of our net operating
loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50%
within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and research and development tax credit carryforwards before they expire. The completion of follow-on public
offerings in April 2015 and January 2016 and our initial public offering, or IPO, together with private placements and other transactions that have occurred since our inception, may have triggered such an ownership change pursuant to
Section&nbsp;382. Any such limitation, whether as the result of our IPO, follow-on offerings, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material
adverse effect on our results of operations in future years. We have not completed a study to assess whether an ownership change for purposes of Section&nbsp;382 has occurred, or whether there have been multiple ownership changes since our
inception, due to the significant costs and complexities associated with such study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect
our business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general
conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise
additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products if we receive
marketing approval. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may
not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Natural disasters could severely disrupt our operations, and have a material
adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged
critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial
period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster
recovery and business continuity plans, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our
third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our development programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our third-party CROs and other contractors and
consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident, or security breach to
date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating
to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be
delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such
acquisitions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third
parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully
integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from
realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Financial Position and Need for Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a biopharmaceutical company with a limited operating history, and have not generated any revenue from product sales. We have incurred significant
operating losses since our inception, and anticipate that we will incur continued losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
biopharmaceutical company with a limited operating history on which investors can base an investment decision. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We were incorporated
in April 2010. Our operations to date have been limited primarily to organizing and staffing our company, raising capital and conducting research and development activities for our product candidates. We have never generated any revenue from product
sales. We have not obtained regulatory approvals for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations to date through
proceeds from sales of common stock, redeemable convertible preferred stock and, to a lesser extent, the issuance of convertible notes. On July&nbsp;23, 2014, we completed the sale of 5,750,000 shares of our common stock in our IPO, at a price to
the public of $18.00 per share, resulting in net proceeds of $94.0 million after deducting underwriting discounts and commissions and offering expenses paid by us. On April&nbsp;20, 2015, we completed the sale of 2,628,571 shares of our common stock
in a public offering, at a price to the public of $52.50 per share, resulting in net proceeds of $129.1 million after deducting underwriting discounts and commissions and offering expenses paid by us. On January&nbsp;12, 2016, we completed the sale
of 3,157,894 shares of our common stock in a public offering, at a price to the public of $47.50 per share, resulting in net proceeds of $140.4 million after deducting underwriting discounts and commissions and estimated offering expenses paid by
us. From our inception through December&nbsp;31, 2015, we had received net proceeds of $313.7 million from such transactions. As of December&nbsp;31, 2015, our cash and cash equivalents were $186.8 million. We have incurred significant net losses in
each year since our inception, including net losses of $94.5 million, $33.8 million, and $18.3 million for the years ended December&nbsp;31, 2015, 2014, and 2013 respectively. Substantially all of our operating losses have resulted from costs
incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable
future. Our prior losses, combined with expected future losses, have had, and will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. We expect our research and development expenses to significantly increase
in connection with our clinical trials of our product candidates. In addition, if we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced-manufacturing expenses. As a public company, we
incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with
developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our product
candidates, and we do not know when, or if, we will generate any revenue. We do not expect to generate significant revenue unless and until we obtain marketing approval of, and begin to sell a product. Our ability to generate revenue depends on a
number of factors, including, but not limited to, our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate and successfully complete all efficacy and safety clinical trials and non-clinical studies required to file for, and obtain, U.S. and foreign marketing approval for our product candidates </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commercialize our product candidates, if approved, by developing a sales force or entering into collaborations with third parties; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve market acceptance of our product candidates in the medical community and with third-party payors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Absent our entering into a collaboration or partnership agreement, we expect to incur significant sales and marketing costs as we prepare to
commercialize our product candidates, if and when approved. Even if we successfully complete clinical development of our product candidates, and our product candidates are approved for commercial sale, and despite expending these costs, our product
candidates may not be commercially successful. We may not achieve profitability soon after generating product sales, if ever. If we are unable to generate product revenue, we will not become profitable, and may be unable to continue operations
without continued funding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain
this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently advancing our product candidates through non-clinical and clinical development. Developing small molecule products is
expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue to advance our product candidate in clinical trials. Depending on the status of
regulatory approval or, if approved, commercialization of our product candidates, as well as the progress we make in selling our products, if approved, we may also require additional capital to fund operating needs even after approval. We may also
need to raise additional funds if we choose to pursue additional indications and/or geographies for our product candidates, identify new potential opportunities or otherwise expand our activities more rapidly than we presently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, our cash and cash equivalents were $186.8 million. Based on our current operating plan, we expect that our
existing cash and cash equivalents, including cash generated in the follow-on offering in January 2016, will be sufficient to fund our current operations into the beginning of 2018. Our current operating plan does not contemplate that all of the
planned activities will proceed at the same pace, or that all of the activities will be fully initiated or completed during that time. We may use available capital resources sooner than we expect under our current operating plan. In addition, our
operating plan may change as a result of many factors currently unknown to us. We may need or choose to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding,
marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. In any event, we expect to require additional capital to obtain regulatory approval for, and to
commercialize, our product candidates. Raising funds in the current economic environment may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if
market conditions are favorable or if we have specific strategic considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their day-to-day activities,
which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms
of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline.
The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such
as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could
also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or
otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the commercialization of any product, if approved, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require
us to relinquish rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek additional capital through a combination of private and public equity offerings, debt
financings, collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our
stockholders in our company will be diluted. In addition, the terms of any such securities may include liquidation or other preferences that materially adversely affect the rights of our stockholders. Debt financing, if available, would increase our
fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional
funds through collaboration, strategic partnerships and licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, our intellectual property, future revenue streams or grant licenses on terms that
are not favorable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market volatility may affect our stock price and the value of an investment in our stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price for our common stock, similar to that of other biopharmaceutical companies, is volatile. The market price of our common stock
may fluctuate significantly in response to a number of factors, most of which we cannot control, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">plans for, progress of, timing of, changes to, delays in or results from, non-clinical studies and clinical trials of our product candidates, including any adverse events or announcements related to such studies or
trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay in filing for regulatory approval of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure or delay of the FDA or any other regulatory authority to approve our product candidates, or any unexpected limitation on the approved indication or onerous condition of approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of new products, technologies, commercial relationships, acquisitions or other events by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success or failure of our CNS therapies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse developments with respect to our intellectual property portfolio </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our product candidates, if approved, to achieve commercial success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in stock market prices and trading volumes of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions and overall fluctuations in U.S. equity markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our quarterly operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our financial guidance or securities analysts&#146; estimates of our financial performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to raise additional capital and the terms on which we can raise it; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussion of us or our stock price by the press and by online investor communities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other risks and uncertainties described in these risk factors. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a significant stockholder, which
will limit a stockholder&#146;s ability to influence corporate matters and may give rise to conflicts of interest. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A fund
affiliated with Third Rock Ventures LLC, or TRV, is our largest stockholder. As of December&nbsp;31, 2015, TRV beneficially owned approximately 16.4% of our common stock. Accordingly, TRV exerts and will continue to exert significant influence over
us and any action requiring the approval of the holders of our common stock, including the election of directors and amendments to our organizational documents, such as increases in our authorized shares of common stock and approval of significant
corporate transactions. Furthermore, the interests of TRV may not always coincide with the interests of other stockholders and TRV may act in a manner that advances its best interests and not necessarily those of other stockholders, including
seeking a premium value for its common stock, which might affect the prevailing market price for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers,
directors, principal stockholders and their affiliates will continue to exercise significant control over our company, which will limit the ability of our stockholders to influence corporate matters and could delay or prevent a change in corporate
control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, existing holdings of our executive officers, directors, principal stockholders and their
affiliates, including investment funds affiliated with ARCH Venture Fund VII, L.P., or ARCH, TRV, and entities affiliated with Fidelity Investment, or Fidelity, represent beneficial ownership, in the aggregate, of approximately 35% of our
outstanding common stock. As a result, these stockholders, if they act together, will be able to influence significantly our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of
directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These stockholders acquired some or all of their shares of common stock for substantially less than the price of the shares of common stock acquired in
the our IPO or any follow-on offering, and these stockholders may have interests, with respect to their common stock, that are different from those of investors in our IPO or any follow-on offering and the concentration of voting power among these
stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying, deferring or preventing a change of control of us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impeding a merger, consolidation, takeover or other business combination involving us; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock may cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could
significantly reduce the market price of our common stock, and impair our ability to raise adequate capital through the sale of additional equity securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in how we use the proceeds from our IPO and follow-on public offerings, and may not use these proceeds effectively, which could
affect our results of operations and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have considerable discretion in the application of the
net proceeds from our follow-on public offerings and our IPO. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds
from the follow-on offerings or from the IPO in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter
documents and under Delaware law could make an acquisition of us, even one that may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us
or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval.
In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to
merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an
offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for
stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to
pay dividends on our common stock and, consequently, the ability of our stockholders to achieve a return on their investment will depend on appreciation in the price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our common stock, and do not currently intend to do so in the foreseeable future. We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business, and do not anticipate declaring or paying any cash dividends in the foreseeable future. Therefore, the success of an investment in
shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchased them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts stop publishing research or reports about our business or if they issue unfavorable commentary or downgrade our common
stock, the price of our common stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock relies in part on the research and
reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline if one or more equity research analysts downgrade our common stock or if analysts issue other
unfavorable commentary or cease publishing reports about us or our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1B. Unresolved Staff Comments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_3"></A>Item&nbsp;2. Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Cambridge, Massachusetts, and consist of 22,067 square feet in a multi-tenant building. Our lease
expires on February&nbsp;
28, 2022. We expect to lease additional space prior to expiration of our existing lease to meet the needs of the business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_4"></A>Item&nbsp;3.
 Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not a party to any legal proceedings, and we are not aware of any claims or actions pending or threatened
against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial
position, results of operations or cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_5"></A>Item&nbsp;4. Mine Safety Disclosures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_6"></A>Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;18, 2014, our common stock began trading on the NASDAQ Global Market under the symbol &#147;SAGE&#148;. Prior to that time, there was no public market for our common stock. Shares sold in our initial public offering on July&nbsp;17, 2014
were priced at $18.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2016, the closing price for our common stock as reported on the NASDAQ Global
Market was $32.69. The following table sets forth the high and low sales prices per share of our common stock as reported on the NASDAQ Global Market for the period indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;16, 2016, there were 20 stockholders of record of our common stock. The actual number of holders of our common stock is
greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose
shares may be held in trust by other entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Graph </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph illustrates a comparison of the total cumulative stockholder return for our common stock since July&nbsp;18, 2014, which is
the date our shares began trading, through December 31, 2015, to two indices: the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes an initial investment of $100 on July&nbsp;18, 2014, in our common stock, the stocks
comprising the NASDAQ Composite Index, and the stocks comprising the NASDAQ Biotechnology Index. Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Comparison of Cumulative Total Return* </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Among Sage Therapeutics, Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g35y17.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">$100 invested on July&nbsp;18, 2014 in stock or index. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance graph shall not be
deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically
incorporate such information by reference, and shall not otherwise be deemed filed under such acts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock
in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will
depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information required by Item&nbsp;5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item&nbsp;12. of Part III of this Annual Report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuer Purchases of Equity Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not purchase any of our registered equity securities during the period covered by this Annual Report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds from Registered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2014, we closed the sale of 5,750,000 shares of common stock to the public at an initial public offering price of $18.00 per
share, including the exercise in full by the underwriters of their over-allotment option, pursuant to which we sold an additional 750,000 shares of common stock at a price of $18.00 per share. The offer and sale of the shares in the IPO were
registered under the Securities Act pursuant to registration statements on Form S-1 (File No.&nbsp;333-196849), which was filed with the SEC on June&nbsp;17, 2014 and amended subsequently and declared effective on July&nbsp;17, 2014. Following the
sale of the shares in connection with the closing of our IPO, the offering terminated. The offering did not terminate before all the securities registered in the registration statements were sold. The underwriters of the offering were JP Morgan and
Goldman Sachs&nbsp;&amp; Co. acting as joint book-running managers for the offering and as representatives of the underwriters. Leerink Partners and Canaccord Genuity acted as co-managers for the offering. We raised approximately $94.0 million in
net proceeds in the IPO after deducting underwriting discounts and commissions of approximately $7.3 million and other offering expenses of approximately $2.3 million. No offering expenses were paid directly or indirectly to any of our directors or
officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2015, we have used the majority of the net offering proceeds from our IPO, primarily to fund clinical development of SAGE-547, IND-enabling activities and initiation of clinical development for SAGE-217, IND-enabling activities
for SAGE-689, research and development activities to find additional product candidates and general corporate purposes. We invested the funds received in cash equivalents in accordance with our investment policy. None of such payments were direct or
indirect payments to any of our directors or officers (or their associates), to persons owning ten percent or more of our common stock or to any other affiliates. As described in our final prospectus filed with the SEC on July&nbsp;17, 2014 pursuant
to Rule 424(b) under the Securities Act, we expect to use the remaining net proceeds from our IPO to continue to fund the costs of our clinical development of SAGE-547 and SAGE-217, to fund Phase 1 clinical development of SAGE-689, if we are able to
satisfy the FDA&#146;s request for additional data, and for other development activities, as well as for working capital and general corporate purposes, including funding the costs of operating as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_7"></A>Item&nbsp;6. Selected Consolidated Financial Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected consolidated financial data set forth below are derived from our audited consolidated financial statements and may not be
indicative of future operating results. The following selected consolidated financial data should be read in conjunction with Item&nbsp;7, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the
consolidated financial statements and the notes thereto included elsewhere in this Annual Report. The consolidated selected financial data in this section are not intended to replace our consolidated financial statements and the related notes
included elsewhere in this Annual Report. Our historical results are not necessarily indicative of our future results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for per share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated statements of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares used in net loss per share attributable to common stockholders&#151;basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,778,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,574,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,118,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated balance sheet data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock and additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 8 to our consolidated financial statements appearing elsewhere in this Annual Report for further details on the calculation of basic and diluted net loss per share attributable to common stockholders.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">On January&nbsp;12, 2016, we completed the sale of 3,157,894 shares of common stock in an underwritten public offering at a price to the public of $47.50 per share, resulting in net proceeds of $140.4 million after
deducting underwriting discounts and commissions and estimated offering costs paid by us. This amount is not included in the amounts shown. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_8"></A>Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to
treat life-threatening central nervous system, or CNS, disorders, where there are inadequate or no approved existing therapies. We are targeting CNS indications where patient populations are easily identified, clinical endpoints are well-defined,
and development pathways are feasible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the status of our development programs as of the date of this
Annual Report. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g111598g86y30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate is SAGE-547, a proprietary intravenous formulation of allopregnanolone, a
naturally occurring neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor. GABA is the major inhibitory neurotransmitter in the CNS, and mediates downstream
neurologic and bodily function via activation of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. We believe that allosteric modulation of the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor has the
potential to be well-suited for the treatment of seizures and certain other CNS disorders because it allows for the fine-tuning of neuronal signals rather than complete activation or complete inhibition. SAGE-547 is in Phase 3 clinical development
as an adjunctive therapy for the treatment of super-refractory status epilepticus, or SRSE. SRSE is a rare and life-threatening condition where a patient is in a state of continuous seizure called status epilepticus, or SE, and all of the standard
treatment regimens normally sufficient to stop the seizure activity have failed. We expect to report top-line results from the global, randomized, double-blind, placebo-controlled Phase 3 trial of SAGE-547 in SRSE in the second half of 2016. If
successful, we believe the results of the Phase 3 clinical trial, together with other clinical data obtained from the SAGE-547 clinical program, and results of ongoing non-clinical studies, could form the basis of a New Drug Application, or NDA
submission, for SAGE-547. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also used SAGE-547 in proof-of-concept clinical trials to explore potential uses of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators to treat post-partum depression, or PPD, a distinct and readily identified major depressive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disorder, and essential tremor, a debilitating neurological disorder that causes involuntary, rhythmic shaking with no known cause. We are currently conducting an additional Phase 2 exploratory
trial of SAGE-547 in the treatment of severe PPD. We expect the data from these exploratory trials to guide the development of second-generation GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators for the applicable
diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next-generation product candidates, SAGE-217 and SAGE-689, also target the GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor system. These compounds have been designed to have pharmaceutical properties that optimize both their non-clinical profiles and potential clinical profiles for the treatment of certain
seizure and non-seizure CNS disorders. We are currently conducting a Phase 1 clinical trial of SAGE-217, which we expect to complete in the first half of 2016. If the Phase 1 clinical trial of SAGE-217 supports further development, we plan to
commence Phase 2 clinical trials of SAGE-217, initially in essential tremor and orphan epilepsies. SAGE-689 is in non-clinical development. Our Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from the United States Food
and Drug Administration, or FDA, for additional non-clinical study data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also studying novel compounds that target the NMDA
receptor, a critical excitatory receptor system in the brain implicated in a broad range of CNS disorders. The first product candidate selected for development from this program is SAGE-718, an oxysterol-based NMDA positive allosteric modulator. We
have begun non-clinical studies of SAGE-718, with an initial development focus on two rare conditions, Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor Encephalitis. Beyond these conditions, we believe measuring levels of anti-NMDA antibodies or
decreased levels of cerebrosterol, a naturally occurring oxysterol, may represent biomarkers to identify for future study broader patient populations characterized by cognitive dysfunction and neuropsychiatric symptoms resulting from NMDA receptor
dysfunction or hypofunction. Examples of these potential areas for future evaluation include certain types, aspects or subpopulations of a number of diseases such as depression, Alzheimer&#146;s disease, attention deficit hyperactivity disorder,
schizophrenia, Huntington&#146;s disease, and neuropathic pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue our focus on allosteric modulation of the GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA receptor systems in the brain. The GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> and NMDA receptor systems are broadly accepted as impacting many psychiatric and
neurological disorders, spanning disorders of mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and movement disorders among others. We believe that we will have the opportunity to develop molecules from our internal portfolio to address a
number of these disorders in the future. Our ability to identify and develop such novel CNS therapies is enabled by our proprietary chemistry platform that is centered on a scaffold of chemically modified endogenous neuroactive steroid compounds. We
believe our know-how around the chemistry and activity of allosteric modulators allows us to efficiently design molecules with different characteristics by enabling us to control important properties such as half-life, brain penetration and the
types of receptors with which our compounds interact with the goal of developing product candidates that have the potential to bind with targets in the brain with more precision, increased tolerability, and fewer off-target side effects than either
current CNS therapies or previous therapies which have failed in development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAGE was founded in 2010, based on leading research in the
areas of brain function and neuroactive steroids, to explore novel approaches to CNS therapeutics. Since our inception, we have continued to expand our know-how related to CNS therapeutics through our research and development programs, and to pursue
intellectual property protection with respect to our proprietary chemistry platform. In addition, we have assembled a strong management team that together has been a part of the successful discovery, development and commercialization of more than 20
marketed CNS therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue to date. We have incurred net losses in each year since our inception, and we
have an accumulated deficit of $161.3 million as of December&nbsp;31, 2015. Our net losses were $94.5 million, $33.8 million and $18.3 million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. These losses have resulted
principally from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to incur significant expenses and increasing operating losses for the foreseeable
future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our expenses will increase substantially in connection with our ongoing
activities, as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance clinical development of SAGE-547, our lead product candidate in our SE program, including completing the Phase 3 clinical trial for SAGE-547 in SRSE and additional clinical and non-clinical studies of SAGE-547
required for a NDA, advancing regulatory activities focused on potential filing of the NDA, and initial preparations for a potential commercial launch; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to advance our efforts to establish proof of principle of the potential for use of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators in PPD; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete the Phase 1 clinical trial of SAGE-217 in healthy volunteers, and if successful, advance development of SAGE-217 as an oral therapy for orphan epilepsies such as Dravet syndrome and Rett syndrome, and in
certain non-seizure indications such as essential tremor; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance development of SAGE-689 as an adjunctive second-line therapy for the treatment of SE, including conducting additional non-clinical studies, and potential clinical trials, if we are able to successfully address
the data request from the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance our early-stage novel allosteric modulator for NMDA into non-clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and development efforts for other drug candidates in the treatment of CNS disorders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek regulatory approvals for our product candidates that successfully complete clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add personnel, including personnel to support our product development and future commercialization efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems, and; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, leverage and expand our intellectual property portfolio. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we will need
additional financing to support our continuing operations. Until such time that we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings
or other sources, which may include collaborations with third parties. Arrangements with collaborators or others may require us to relinquish rights to certain of our technologies or product candidates. In addition, we may never successfully
complete development of any of our product candidates, obtain adequate patent protection for our technology, obtain necessary regulatory approval for our product candidates or achieve commercial viability for any approved product. Adequate
additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and on our ability to pursue our business strategy. We will
need to generate significant revenue to achieve profitability, and we may never do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our existing cash and cash
equivalents as of December&nbsp;31, 2015, in addition to the funds raised by our public offering of common stock in January 2016, will enable us to fund our operating expenses and capital expenditure requirements, based on our current operating
plan, into the beginning of 2018. See &#147;&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any
revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. If our developmental efforts result in clinical success and regulatory approval or collaboration agreements with
third parties for our product candidates, we may generate revenue from those product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating expenses since inception have consisted primarily of research and development activities and general and administrative costs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses, which consist primarily of costs associated with our product research and development efforts, are expensed
as incurred. Research and development expenses consist primarily of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">personnel costs, including salaries, benefits, stock-based compensation and travel expenses for employees engaged in scientific research and development functions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with contract research organizations, or CROs, and investigative sites that conduct our non-clinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses associated with manufacturing clinical trial materials and developing external manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of outside consultants engaged in scientific research and development activities, including their fees, stock-based compensation and travel expenses; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other expenses related to our non-clinical studies and clinical trials and expenses related to our regulatory activities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payments made under our third-party licensing agreements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs for certain development
activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been developing our product candidates and focusing on other research and development programs, including exploratory efforts to
identify new compounds, target validation for identified compounds and lead optimization for our earlier-validated programs. Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of external
costs, such as fees paid to investigators, central laboratories, CROs and contract manufacturing organizations, or CMOs, in connection with our non-clinical studies and clinical trials; third-party license fees related to our product candidates; and
fees paid to outside consultants who perform work on our programs. We do not allocate employee-related costs and other indirect costs to specific research and development programs because these costs are deployed across multiple product programs
under research and development and, as such, are separately classified as unallocated research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes our research and development expenses by program: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-547</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-217</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-689</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business. Product candidates in later stages of
clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses
will continue to increase in the foreseeable future as we continue or initiate clinical trials and non-clinical studies for certain product candidates and pursue later stages of clinical development of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot determine with certainty the duration and completion costs of the current or future
clinical trials of our product candidates or if, when, or to what extent we will generate revenue from the commercialization and sale of any of our product candidates if approved for marketing and sale. The duration, costs, and timing of clinical
trials and development of our product candidates will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, size, rate of progress, and expense of our ongoing as well as any additional non-clinical studies, clinical trials and other research and development activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future clinical trial and non-clinical study results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decisions by regulatory authorities related to our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties in clinical trial enrollment rate or design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant and changing government regulation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt and timing of any regulatory approvals, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of
these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to
require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials,
we could be required to expend significant additional financial resources and time on the completion of clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and
Administrative Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel costs, consisting of salaries, benefits,
stock-based compensation and travel expenses of our executive, finance, business and corporate development and other administrative functions. General and administrative expenses also include expenses incurred under agreements with third parties
relating to evaluation, planning and preparation for a potential commercial launch, facilities and other expenses, including rent, depreciation, maintenance of facilities, insurance and supplies; and professional fees for audit, tax and legal
services, including legal expenses to pursue patent protection of our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and
administrative expenses will increase in the future as we increase our headcount to support the expected growth in our business and the potential commercialization of our product candidates. We also anticipate increased expenses associated with
general operations, including costs related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations
costs. Additionally, we anticipate an increase in payroll and related expenses as we continue to build our organizational capabilities and as a result of our preparation for commercial operations, especially as it relates to the sales and marketing
of our product candidates, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The
preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. We believe that
the estimates and assumptions involved in the accounting policies described below may have the greatest potential impact on our consolidated financial statements and, therefore, consider these to be our critical accounting policies. We evaluate our
estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. While our significant accounting policies are described in more detail in the notes to our consolidated
financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs
incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones
are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated
accrued research and development expenses include fees paid to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CROs in connection with performing research and development services on our behalf; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investigative sites or other providers in connection with clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors in connection with non-clinical development activities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors related to product manufacturing, development and distribution of clinical supplies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with
multiple CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments
made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical
trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and level of effort to be expended in each period. If the actual timing of the
performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status
and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material
adjustments to our prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize compensation expense for all stock-based awards made to employees and nonemployee directors, including grants of stock options and
restricted stock, based on estimated fair value on date of grant, over the requisite service period. For awards that vest upon achievement of a performance condition, we recognize compensation expense when achievement of the performance condition is
deemed probable over the implicit service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically granted stock options with exercise prices equivalent to the fair
value of our common stock as of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure stock-based awards granted to nonemployee consultants at the fair value of
the award on each date on which the awards vest. Compensation expense is recognized over the period during which services are rendered by such nonemployee consultants until completed. At the end of each financial reporting period prior to the
completion of the service, the fair value of these awards is re-measured using, for options, the then-current fair value of our common stock and updated assumptions in the Black-Scholes option-pricing model and using, for restricted stock, the
then-current fair value of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option grant is estimated using the Black-Scholes
option-pricing model. Until July&nbsp;18, 2014, we were a private company and we lacked company-specific historical and implied volatility information. Considering this and the short history of being a public company, we estimate our expected
volatility based on the historical volatility of our publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded stock price. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected term of our options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options, while the expected term of our options
granted to consultants and nonemployees has been determined based on the contractual term of the options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time
periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions we used to determine the fair value of stock options granted to employees and nonemployee directors are as follows, presented
on a weighted average basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2015&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.89</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.03&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.38&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.04&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These assumptions represented our best estimates, but the estimates involve inherent uncertainties and the
application of our judgment. As a result, if factors change and we use significantly different assumptions or estimates when valuing our stock options, our stock-based compensation expense could be materially different. We recognize compensation
expense for only the portion of awards that are expected to vest. In developing a forfeiture rate estimate for pre-vesting forfeitures, we have considered our historical experience of actual forfeitures. If our future actual forfeiture rate is
materially different from our estimate, our stock-based compensation expense could be significantly different from what we have recorded in the current period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense recognized during the years ended December&nbsp;31, 2015, 2014, and 2013 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stock-based compensation expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2015, we had unrecognized stock-based compensation expense related to our unvested
service-based stock option awards of $31.5&nbsp;million, which is expected to be recognized over the remaining weighted average vesting period of 3.01 years. In addition, we have 358,976 shares of outstanding unvested stock options that vest upon
the achievement of certain performance criteria. Total unrecognized compensation related to those awards was $7.8&nbsp;million at December 31, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from
contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue
and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The guidance
becomes effective for us in the year ending December&nbsp;31, 2018, and we could early adopt the standard for the year ending December&nbsp;31, 2017. We are currently assessing the method of adoption and the impact that this new accounting guidance
will have on our consolidated financial statements and footnote disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, Presentation of
Financial Statements&#151;Going Concern (Subtopic 205-40). The new guidance addresses management&#146;s responsibility to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide
related footnote disclosures. Management&#146;s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first
interim period within annual reporting periods beginning after December&nbsp;15, 2016. Early adoption is permitted. We are evaluating the effect that this guidance will have on our consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the classification of deferred
tax assets and liabilities. The new standard requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The standard is effective for interim and annual
periods beginning after December&nbsp;15, 2016 and allows for early adoption using a full retrospective method or a prospective method. We have elected to early adopt the provisions of this new standard using a prospective method. As a result, all
deferred taxes as of December&nbsp;31, 2015 are classified as noncurrent on a net basis in our consolidated balance sheet, while prior periods remain as previously reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02&#151;<I>Leases</I> (ASC&nbsp;842), which sets out the
principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or
operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line
basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months
or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 <I>Leases. </I>The standard is effective on January&nbsp;1, 2019, with early adoption permitted. We are
in the process of evaluating the impact of this new guidance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2015 and 2014 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2015 and 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-547</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-217</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-689</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the fiscal year ended December&nbsp;31, 2015 were $69.4 million,
compared to $24.1 million for the year ended December&nbsp;31, 2014. The increase of $45.3 million year over year was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $29.0 million in expenses of our SAGE-547 program, due to the advancement of the program into clinical development, including the completion of the Phase 1/2 clinical trial, commencement of activities for
our Phase 3 clinical trial, an increase in work related to CMC and toxicology. For the years ended December&nbsp;31, 2015 and 2014, payments made to consultants and licensors in connection with the achievement of development milestones met by
consultants and licensors were $2.7 million and $0.4 million, respectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $3.6 million in expenses of our SAGE-217 program with advancement of the lead optimization program through IND-enabling non-clinical development activities (e.g., toxicology studies, process development,
and drug substance manufacturing), filing of the IND and initiation of the Phase 1 clinical trial in October 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $4.7 million in expenses of our other research and development programs and discovery efforts for our next clinical candidates and back-up programs; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $7.9 million in unallocated expenses, including an increase of $4.8 million of non-cash stock-based compensation expense, due to the hiring of additional full-time employees to support the growth in our
activities. The amount of non-cash stock-based compensation expense recorded to research and development expense related to the achievement of performance-based vesting criteria was $2.0 million for the year ended December&nbsp;31, 2015. No
stock-based compensation expense related to the achievement of performance-based vesting criteria was recorded to research and development expense for the year ended December&nbsp;31, 2014. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial planning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the years ended December&nbsp;31, 2015 and 2014 were $25.3 million and
$9.7 million, respectively. The increase of $15.6 million in general and administrative expenses year over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
year was primarily due to a $10.6 million increase in personnel-related costs due to the effects of hiring additional full-time employees to support operations, finance, human resources, legal
and early commercial planning activities, including an increase of $7.9 million in non-cash stock-based compensation expense. The amount of non-cash stock-based compensation includes amounts related to the achievement of the performance-based
vesting criteria of $2.7 million for the year ended December&nbsp;31, 2015. No stock-based compensation expense related to the achievement of performance-based vesting criteria was recorded to general and administrative expenses for the year ended
December&nbsp;31, 2014. The increase of $1.5 million in professional fees was primarily due to increased costs associated with being a public company, including costs related to audit, legal, regulatory and tax-related services, as well as investor
relations costs. The increase of $2.2 million in commercial planning was associated preparations for a potential commercial launch. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest income, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income, net, for the years ended December&nbsp;31, 2015 and 2014 was $0.2 million and $8,000, respectively. The increase in interest
income was primarily due to increased cash and cash equivalent balances due to our July 2014 and April 2015 public offerings of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other expense, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense, net was insignificant for the years ended December&nbsp;31, 2015 and 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2014 and 2013 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2014 and 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase</B><br><B>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and development expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase</B><br><B>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-547</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-689</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SAGE-217</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the fiscal year ended December&nbsp;31, 2014 were $24.1 million,
compared to $14.4 million for the year ended December&nbsp;31, 2013. The increase of $9.7 million year over year was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $5.2 million in expenses of our SAGE-547 program. We initiated the Phase 1/2 clinical trial of SAGE-547 in SRSE in early 2014; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $0.3 million in expenses of our SAGE-689 program with advancement of the lead optimization program into IND-enabling non-clinical development (e.g. toxicology studies, process development, and drug
substance manufacturing); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $1.6 million in expenses of our SAGE-217 program with advancement of the lead optimization program into IND-enabling non-clinical development (e.g. toxicology studies, process development, and drug
substance manufacturing); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a net decrease of $0.3 million in expenses of our other research and development programs reflecting a focus on advancing SAGE-689 and SAGE-217 into IND-enabling non-clinical development, portfolio priorities, and
timing of investment in certain research programs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of $2.9 million in employee related spending to support the growth in our research and development activities, reflecting the effects of hiring additional, full-time employees during 2014. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the years ended December&nbsp;31, 2014 and 2013 were $9.7 million and
$3.9 million, respectively. The increase of $5.8 million in general and administrative expenses year over year was primarily due to the $2.6 million increase in personnel related costs due to the effects of hiring additional, full-time employees
during 2014 to support operations, finance, human resources, and early commercial planning activities as well as an increase in stock-based compensation expense costs and $2.5 million increase in professional fees associated with being a public
company, including costs related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, and investor relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other income, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income, net and other expense, net were insignificant for the years ended December&nbsp;31, 2014 and 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
our inception in April 2010, we have not generated any revenue and have incurred recurring net losses. As of December&nbsp;31, 2015, we had an accumulated deficit of $161.3 million. From our inception through December&nbsp;31, 2015, we have received
net proceeds of $313.7 million from the sales of redeemable convertible preferred stock, the issuance of convertible notes and the proceeds from our IPO and April 2015 follow-on offering. On January&nbsp;12, 2016, we completed the sale of 3,157,894
shares of common stock in an underwritten public offering at a price to the public of $47.50 per share, resulting in net proceeds of $140.4 million after deducting underwriting discounts and commissions and estimated offering costs paid by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, our primary sources of liquidity were our cash and cash equivalents, which totaled $186.8 million. We invest our
cash equivalents and investments in highly liquid, interest-bearing investment-grade and government securities to preserve principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the primary sources and uses of cash for the periods presented
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(70,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the fiscal year ended December 31, 2015 was $70.7&nbsp;million, compared to $27.0 million for the fiscal
year ended December 31, 2014. The increase of $43.7 million year over year was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An increase of $60.7 million in cash used related to our net loss, primarily due to increased research and development activities related to our lead programs in development and increased general and administrative
expenses due to increased headcount to support our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An increase of $13.9 million in non-cash charges, primarily due to an increase in stock-based compensation expense due to increased hiring during the year, including $4.8 million of stock-based compensation expense
recognized upon the achievement of a performance-based vesting criteria; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An increase of $3.1 million in cash provided by changes in our operating assets and liabilities, primarily due to the growth of the business and the timing of vendor invoicing and payments. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the fiscal year ended December 31, 2014 was $27.0&nbsp;million, compared to $17.5&nbsp;million for the
fiscal year ended December 31, 2013. The increase of $9.5 million year over year was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An increase of $15.5 million in cash used related to our net loss, primarily due to increased research and development activities related to our lead programs in development and increased general and administrative
expenses due to increased headcount to support our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An increase of $2.5 million in non-cash charges, primarily due to an increase in stock-based compensation expense due to increased hiring during the year; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An increase of $3.5 million in cash provided by changes in our operating assets and liabilities, primarily due to the growth of the business and the timing of vendor invoicing and payments. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2015 and 2014, we used $0.2 million and $0.1 million, respectively, of cash for purchases of property
and equipment. During the year ended December&nbsp;31, 2013, cash used by investing activities was insignificant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing
Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2015, 2014 and 2013, net cash provided by financing activities was $129.9
million, $146.9 million and $22.8 million, respectively. Net cash provided by financing activities in the year ended December&nbsp;31, 2015 primarily consisted of $129.1 million of net proceeds from a follow-on underwritten public offering of our
common stock after deducting commissions and underwriting discounts and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering costs. Net cash provided by financing activities in the year ended December&nbsp;31, 2014 consisted primarily of $94.0 million in net proceeds from our IPO on July&nbsp;23, 2014 and
$52.9 million from the issuance of Series B and Series C redeemable convertible preferred stock. Net cash provided by financing activities in the year ended December&nbsp;31, 2013 consisted of $22.8 million from the issuance of Series A redeemable
convertible preferred stock and from the exercise of stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We
do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the
foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, continue preparations for potential future commercialization, and begin to commercialize any
products, if approved. We expect to incur additional costs associated with general operations. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization expenses for
product sales, marketing and manufacturing. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash and cash equivalents as of December&nbsp;31, 2015, in addition to the
funds raised by our public offering of common stock in January 2016, will enable us to fund our operating expenses and capital expenditure requirements into the beginning of 2018. During that time, we expect that our expenses will increase
substantially as we continue clinical development of SAGE-547, including completing our Phase 3 clinical trial; complete Phase 1 clinical development for SAGE-217 and advance the product candidate into Phase 2 clinical trials, if the Phase 1
clinical trial is successful; advance SAGE-689 into Phase 1 clinical development, if permitted by the FDA; conduct additional proof-of-concept studies of SAGE-547 in PPD; continue non-clinical studies of SAGE-718, our early-stage novel allosteric
modulator for NMDA; fund new and ongoing research and development activities and working capital, and fund other general corporate purposes. Our current operating plan does not contemplate that all of these activities will proceed at the same pace,
or that all of these activities will be fully initiated or completed during that time. We have based our estimates on assumptions that could change, and we may use our available capital resources sooner than we currently expect. Because of the
numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and
commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our product candidates to progress through clinical development successfully; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timings, costs, and results of non-clinical studies and clinical trials for our existing and future product candidates, and the costs of preparing regulatory filings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing, and outcome of regulatory reviews and approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of the product candidates we pursue and the nature and scope of the development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or in-license other products and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish any future collaboration arrangements on favorable terms, if at all; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level and timing of costs associated with preparations for a potential commercial launch, including manufacturing-related costs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance
our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or in light of specific strategic considerations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute the ownership interest of our stockholders. If we
raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms
that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant
rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations
and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations at December&nbsp;31, 2015 and the effect such obligations
are expected to have on our liquidity and cash flow in future periods: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than</B><br><B>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;Than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total(2)(3)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts related to contingent milestone payments are not considered contractual obligations as they are
contingent on the successful achievement of certain milestones. These contingent milestones may not be achieved. We have not included any of these amounts in the table as we cannot estimate or predict when, or if, these amounts will become due. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We lease office space in Cambridge, Massachusetts under operating lease agreements that initially expire in February 2022. The minimum lease payments in the table do not include related common area maintenance charges
or real estate taxes, which costs are variable. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">We have acquired exclusive and non-exclusive rights to use, research, develop and offer for sale certain products and patents under licensing agreements, including amendments entered into in April and May 2014, and
September 2015, with Washington University, CyDex Pharmaceuticals, Inc. and two with The Regents of the University of California. The license agreements obligate us to make payments to the licensors for license fees, milestones, license maintenance
fees and royalties. We are obligated to make future remaining milestone payments under these agreements of up to $34.1 million upon achieving certain pre-commercialization milestones, such as clinical trials and regulatory approvals.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the year ended December&nbsp;31, 2015, clinical development and regulatory milestones were met for some of the programs.
We recorded research and development expense related to these milestones for the year ended December&nbsp;31, 2015 of $1.1 million. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">We enter into contracts in the normal course of business with CROs for clinical trials, non-clinical research studies and testing, manufacturing and other services and products as part of general operations. These
contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Under a January 2014 consulting agreement, we are obligated to make remaining milestone payments of up to $1.5 million and to issue up to 87,303 shares of our common stock to a nonemployee consultant upon achieving
certain clinical trial milestones and regulatory approval milestones. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the year ended December&nbsp;31, 2015, the second
and third clinical development milestones for one of the programs included in the consulting agreement were met. We recorded research and development expense for the year ended December&nbsp;31, 2015 of $1.7 million, comprised of $0.5 million in
cash and $1.2 million related to the issuance of 23,809 shares of our common stock, related to the achievement of these milestones. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet
Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have, nor did we have during the periods presented, any off-balance sheet arrangements as defined by
SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_9"></A>Item&nbsp;7A. Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had cash and cash equivalents of approximately $186.8 million at December&nbsp;31, 2015. The primary objectives of our investment activities
are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk relates to fluctuations in interest rates, which are affected by changes in the general level of U.S.
interest rates. Given the short-term nature of our cash and cash equivalents, we believe that a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operation. We do not
have any foreign currency or other derivatives financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that our cash and cash equivalents have
significant risk of default or illiquidity. While we believe our cash and cash equivalents do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value.
In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material
effect on our results of operations during the year ended December&nbsp;31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_10"></A>Item&nbsp;8. Financial Statements and
Supplementary Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements required to be filed pursuant to this Item&nbsp;8 are appended to this Annual Report. An
index of those financial statements is found in Item&nbsp;15. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_11"></A>Item&nbsp;9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_12"></A>Item&nbsp;9A. Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we
file or submit under the Securities and Exchange Act of 1934 is (1)&nbsp;recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules and forms and (2)&nbsp;accumulated and communicated to our management,
including our President and Chief Executive Officer, who is our principal executive officer and Chief Financial Officer, who is also our principal financial and accounting officer, as appropriate, to allow timely decisions regarding required
disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, our management, with the participation of our principal executive
officer and principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Our principal executive officer and principal financial and accounting officer have concluded based upon the evaluation described above that, as of December&nbsp;31, 2015, our disclosure controls and procedures were
effective at the reasonable assurance level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Report on Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule
13a&#151;15(f) under the Exchange Act). Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with generally accepted accounting principles. Management evaluated the effectiveness of our internal control over financial
reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in <I>Internal Control&#151;Integrated Framework</I> (the 2013 Framework). Management, under the supervision and with the
participation of the principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015 and concluded that it was effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015 has been audited by PricewaterhouseCoopers
LLP, an independent registered public accounting firm, as stated in their report, which is included herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial
Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes to our internal control over financial reporting that occurred during the period covered by this
Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_13">
</A>Item&nbsp;9B. Other Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_14"></A>Item&nbsp;10. Directors, Executive Officers and Corporate Governance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2016 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_15"></A>Item&nbsp;11. Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2016 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_16"></A>Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2016 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_17"></A>Item&nbsp;13. Certain Relationships and Related Transactions, and Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2016 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_18"></A>Item&nbsp;14. Principal Accounting Fees and Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement
related to the 2016 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc111598_19"></A>Item&nbsp;15. Exhibits, Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The following documents are filed as part of this report: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Financial Statements: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx111598_a1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx111598_a2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx111598_a3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx111598_a4">Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#146; Equity (Deficit)
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx111598_a5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx111598_a6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Financial Statement Schedules: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the
financial statements or the notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Exhibits. The exhibits filed as part of this Annual Report on Form 10-K are set forth on
the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc111598_20"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Form
10-K to be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE THERAPEUTICS, INC. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;29, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">/s/ Jeffrey M. Jonas</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey M. Jonas, M.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, President and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been
signed by the following persons in the capacities indicated below and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jeffrey M. Jonas</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jeffrey M. Jonas, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kimi Iguchi</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kimi Iguchi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer (Principal Financial and Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Robert T. Nelsen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert T. Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Steven Paul</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Steven Paul, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kevin P. Starr</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kevin P. Starr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Howard Pien</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Howard Pien</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ James Frates</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James Frates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Michael F. Cola</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Michael F. Cola</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;29, 2016</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx111598_a1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sage
Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations and comprehensive
loss, of changes in redeemable convertible preferred stock and stockholders&#146; equity (deficit) and of cash flows present fairly, in all material respects, the financial position of Sage Therapeutics, Inc. and its subsidiaries at
December&nbsp;31, 2015 and 2014, and the results of their operations and their cash flows for each of the three years in the period ended December&nbsp;31, 2015 in conformity with accounting principles generally accepted in the United States of
America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2015, based on criteria established in <I>Internal Control&#151;Integrated Framework
</I>(2013)&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company&#146;s management is responsible for these financial statements, for maintaining effective internal control over financial reporting
and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#146;s Report on Internal Control over Financial Reporting appearing under Item&nbsp;9A. Our responsibility is to express opinions on
these financial statements and on the Company&#146;s internal control over financial reporting based on our audits which was an integrated audit in 2015. We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over
financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered
necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2 to the consolidated
financial statements, the Company changed the manner in which it classifies deferred income taxes in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company&#146;s internal control over financial reporting includes those policies and procedures that (i)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of the company; (ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of
the company&#146;s assets that could have a material effect on the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers&nbsp;LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;29, 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sage Therapeutics, Inc. and Subsidiaries </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx111598_a2"></A>Consolidated Balance Sheets </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">189,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December&nbsp;31, 2015 and 2014; no shares issued or outstanding at
December&nbsp;31, 2015 and 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 120,000,000 shares authorized at December&nbsp;31, 2015 and 2014; 28,823,549 and 25,621,791 shares
issued and outstanding at December&nbsp;31, 2015 and 2014, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">189,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sage Therapeutics, Inc. and Subsidiaries </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx111598_a3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares used in net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,778,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,574,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sage Therapeutics, Inc. and Subsidiaries </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx111598_a4"></A>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and
Stockholders&#146; Equity (Deficit) </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A,&nbsp;B&nbsp;and&nbsp;C&nbsp;Redeemable<BR>Convertible&nbsp;Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,970</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,395,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of Series A Preferred Stock, net of issuance costs of $18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,732</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock in payment of licensing fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,709</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,622,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of Series B Preferred Stock, net of issuance costs of $30</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,970</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of Series C Preferred Stock, net of issuance costs of $110</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,973,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,890</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock in payment of consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,294</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of redeemable convertible preferred stock to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,723,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,863</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,007,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Initial public offering of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,621,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock under employee stock purchase plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock in payment of consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Public offering of common stock, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,628,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,823,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(161,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sage Therapeutics, Inc. and Subsidiaries </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx111598_a5"></A>Consolidated Statements of Cash Flows </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash licensing and consulting fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,516</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series A preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series B preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the issuance of Series C preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercise and employee stock purchase plan issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from public offering of common stock, net of commissions and underwriting discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of non-cash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred stock to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering costs included in accounts payable or accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SAGE THERAPEUTICS, INC. AND SUBSIDIARIES </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx111598_a6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Nature of the Business </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sage Therapeutics, Inc. (&#147;Sage&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company
committed to developing and commercializing novel medicines to treat life-altering central nervous system (&#147;CNS&#148;) disorders, where there are inadequate or no approved existing therapies. The Company is targeting CNS indications where
patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was
incorporated under the laws of the state of Delaware on April&nbsp;16, 2010 and commenced operations on January&nbsp;19, 2011 as Sterogen Biopharma, Inc. On September&nbsp;13, 2011, the Company changed its name to Sage Therapeutics, Inc. under its
Second Amended and Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to companies in the
biotech industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates;
the risks associated with commercializing pharmaceutical products, if we are able to obtain regulatory approval; the potential for development by third parties of new technological innovations that may compete with the Company&#146;s products; the
dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; and the uncertainty of being able to secure additional capital when needed to fund
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and negative cash flows from operations since its inception. As of December&nbsp;31, 2015,
the Company had an accumulated deficit of $161.3 million. From its inception through December&nbsp;31, 2015, the Company has raised aggregate net proceeds of $90.6 million from the issuance of Series A, Series B and Series C redeemable convertible
preferred stock. In July 2014, the Company raised net proceeds of $94.0 million from the sale of common stock in its initial public offering, (&#147;IPO&#148;). In April 2015, the Company raised net proceeds of $129.1 million from the sale of common
stock in a follow-on underwritten public offering. In January 2016, the Company raised net proceeds of $140.4 million from the sale of common stock in a follow-on underwritten public offering. Based on its current operating plans, the Company
believes its cash and cash equivalents balance of $186.8 million as of December&nbsp;31, 2015, in addition to the funds raised from the public offering of common stock in January 2016, will be sufficient to fund its anticipated level of operations
into the beginning of 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of Significant Accounting Policies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of significant accounting policies followed in the preparation of these financial statements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements have been prepared in conformity
with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and the disclosure of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ
from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash
equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A deposit of $39 thousand was restricted from withdrawal as of December&nbsp;31, 2015 and 2014. The restriction is related to securing the
Company&#146;s facility lease and expires in 2022 in accordance with the operating lease agreement. This balance is included in restricted cash on the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property
and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and
any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived
Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability
whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset
for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted
future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash
flows. To date, the Company has not recorded any impairment losses on long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and
benefits, overhead costs, depreciation, contract services and other related costs. Research and development costs are expensed to operations as the related obligation is incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Contract Costs and Accruals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside
of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of
the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the
end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates have not been materially different from the actual costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements
of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation expense for all stock-based awards made to employees and nonemployee directors, including grants of stock
options and restricted stock, based on estimated fair value on date of grant, over the requisite service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For stock options and
restricted stock issued to nonemployee consultants, the Company recognizes the fair value of such instruments as an expense over the period in which the related services are received. The fair value of the awards and measurement of related
stock-based compensation is subject to periodic adjustments as the underlying equity instruments vest. For awards that vest upon achievement of a performance condition, the Company recognizes compensation expense when achievement of the performance
condition is deemed probable over the implicit service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option grant is estimated using the Black-Scholes
option-pricing model. Through July 2014, the Company was a private company and lacks sufficient Company-specific historical and implied volatility information. Therefore, the Company estimates expected volatility based on the historical volatility
of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its traded stock price. The expected term of the Company&#146;s options has been determined utilizing
the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options, while the expected term of its options granted to consultants and nonemployees has been determined based on the contractual term of the options. The
risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that
the Company never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also applies a
forfeiture rate in order to calculate stock-based compensation expense. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised. The Company
recognizes compensation expense for only the portion of awards that are expected to vest. Expected forfeitures are based on the Company&#146;s historical experience and management&#146;s expectations of future forfeitures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basic and Diluted Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Company&#146;s IPO in July 2014, all of the Company&#146;s outstanding shares of redeemable convertible preferred stock
were converted into shares of common stock. Prior to this conversion, the Company followed the two-class method when computing net loss per share as the Company had issued shares that meet the definition of participating securities. The two-class
method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common
stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#146;s redeemable convertible preferred
shares contractually entitled the holders of such shares to participate in dividends, but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did not apply for periods
in which the Company reported a net loss or a net loss attributable to common stockholders resulting from dividends or accretion related to its redeemable convertible preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the
weighted average number of common shares outstanding for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common
shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted common shares, as determined using the treasury stock method. For periods in which the
Company has reported net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common shares are not assumed to have been
issued if their effect is antidilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reported a net loss attributable to common stockholders for the years ended
December&nbsp;31, 2015, 2014 and 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The product candidates developed by the Company require approvals from the U.S. Food and Drug Administration or foreign regulatory agencies
prior to commercial sales. There can be no assurance that the Company&#146;s current and future product candidates will receive the necessary approvals. If the Company fails to successfully complete clinical development and generate results
sufficient to file for regulatory approval or is denied approval or approval is delayed, it may have a material adverse impact on the Company&#146;s business and its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical success
of its product candidates, ability to obtain regulatory approval of its product candidates, the commercial success of its product, if approved, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its
approved products, if any, by physicians and consumers, significant competition and untested manufacturing capabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit
Risk and of Significant Suppliers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk
consist primarily of cash and cash equivalents. The Company has all cash and cash equivalents balances at two accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to
unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on
third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the
active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts
for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of
existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation
allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of
Deferred Taxes, which simplifies the presentation of deferred income taxes. The Company early adopted ASU 2015-17 effective December&nbsp;31, 2015 on a prospective basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quoted market prices in active markets for identical assets or liabilities. At December&nbsp;31, 2015 and 2014, the Company&#146;s Level 1 assets consisted of money market funds totaling $186.8 million and $127.8 million,
respectively.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market
data for substantially the full term of the assets or liabilities. At December 31, 2015 and 2014, the Company had no Level 2 assets or liabilities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. At December 31, 2015 and 2014, the Company had no Level 3 assets or
liabilities.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments generally consist of cash equivalents, accounts payable and accrued
expenses. The carrying amounts for the applicable financial instruments reported in the balance sheets approximate their fair values at December&nbsp;31, 2015 and 2014, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as other assets until such financings are consummated. After consummation of the IPO in July 2014, $2.3 million
of these costs were recorded in stockholders&#146; equity as a reduction of additional paid-in capital generated as a result of the IPO. After consummation of the follow-on public offering of common stock in April 2015, $0.5 million of these costs
were recorded in stockholders&#146; equity as a reduction of additional paid-in capital generated as a result of the offering. As of December&nbsp;31, 2015, the Company had recorded deferred offering costs of $0.2 million which are shown as a
non-current asset. They are for the follow-on public offering that was consummated in January 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The
Company&#146;s singular focus is on advancing medicines to treat central nervous system disorders, where there are inadequate or no approved existing therapies. All tangible assets are held within the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive
loss includes net loss as well as other changes in stockholders&#146; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&nbsp;31, 2015, 2014 and 2013, there was no
difference between net loss and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Offerings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2014, the Company completed the sale of 5,750,000 shares of its common stock in its IPO (the &#147;IPO&#148;), at a price to
the public of $18.00 per share, resulting in net proceeds to the Company of $94.0 million after deducting underwriting discounts and commissions and offering costs paid by the Company. The shares began trading on Nasdaq Global Market on
July&nbsp;18, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with preparing for the IPO, the Company&#146;s board of directors and stockholders
approved a 1-for-3.15 reverse stock split of the Company&#146;s common stock effective July&nbsp;2, 2014. All share and per share amounts in the financial statements contained herein and notes thereto have been retroactively adjusted, where
necessary, to give effect to this reverse stock split. In connection with the closing of the IPO, all of the Company&#146;s outstanding redeemable convertible preferred stock automatically converted into shares of common stock as of July&nbsp;23,
2014, resulting in the issuance by the Company of an additional 18,007,575 shares of common stock. The significant increase in common stock outstanding in July 2014 will impact the year-over-year comparability of the Company&#146;s net loss per
share calculations over the next year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;20, 2015, the Company completed the sale of 2,628,571 shares of common stock in an
underwritten public offering of its common stock at a price to the public of $52.50 per share, resulting in net proceeds to the Company of $129.1 million after deducting underwriting discounts and commissions and offering costs paid by the Company.
A description of the sale of shares of common stock held in January 2016 is included in Note 13. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue
arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or
services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty
of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a
modified retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in the year ending December&nbsp;31, 2018, and the Company could early adopt the standard for the year ending December&nbsp;31,
2017. The Company is currently assessing the method of adoption and the impact that this new accounting guidance will have on its consolidated financial statements and footnote disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements&#151;Going Concern (Subtopic 205-40). The new guidance
addresses management&#146;s responsibility to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide related footnote disclosures. Management&#146;s evaluation should be based on
relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December&nbsp;15,
2016. Early adoption is permitted. The Company is evaluating the effect that this guidance will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the classification of deferred
tax assets and liabilities. The new standard requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The standard is effective for interim and annual
periods beginning after December&nbsp;15, 2016 and allows for early adoption using a full retrospective method or a prospective method. The Company has elected to early adopt the provisions of this new standard using a prospective method. As a
result, all deferred taxes as of December&nbsp;31, 2015 are classified as noncurrent on a net basis in the Company&#146;s consolidated balance sheet, while prior periods remain as previously reported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU&nbsp;2016-02&#151;<I>Leases</I> (ASC&nbsp;842), which sets out
the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or
operating leases based on the principle of whether or not the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis
over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12&nbsp;months regardless of their classification. Leases with a term of
12&nbsp;months or less will be accounted for similar to existing guidance for operating leases today. ASC&nbsp;842 supersedes the previous leases standard, ASC&nbsp;840 <I>Leases. </I>The standard is effective on January&nbsp;1, 2019, with early
adoption permitted. The Company is in the process of evaluating the impact of this new guidance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Balance Sheet Components </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful&nbsp;Life<BR>(Years)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2015, 2014 and 2013 was $0.1 million, $0.1 million
and $47 thousand, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company rents its 22,067 square foot office space under an operating lease that was expires in 2022. In March 2013, the Company signed a
sublease agreement to sublet 1,900 square feet. Rental income from this sublease was $4 thousand per month. In September, 2015, this sublease was terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rent expense, net of sublease income, for the years ended December&nbsp;31, 2015, 2014, and 2013, was $0.4 million, $0.3 million, and $0.3
million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under non-cancelable operating leases are as follows at
December&nbsp;31, 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:95.55pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CyDex License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
September 2015, the Company and CyDex Pharmaceuticals, Inc. (&#147;CyDex&#148;) amended and restated their existing commercial license agreement. Under the terms of the commercial license agreement as amended and restated, CyDex has granted to the
Company an exclusive license to CyDex&#146;s Captisol drug formulation technology and related intellectual property for the manufacture of pharmaceutical products incorporating the Company&#146;s compounds known as SAGE-547 and SAGE-689, and the
development and commercialization of the resulting products in the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i)&nbsp;the ocular treatment of any disease or condition with a formulation, including a
hormone; (ii)&nbsp;topical ocular treatment of inflammatory conditions; (iii)&nbsp;treatment and prophylaxis of fungal infections in humans; and (iv)&nbsp;any ocular treatment for retinal degeneration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the inclusion of SAGE-689 in the license granted by CyDex, the Company paid to CyDex $0.1 million, which was recorded as
research and development expense in 2015 in connection with execution of the amended and restated license agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is
obligated to make milestone payments under the amended and restated license agreement with CyDex based on the achievement of clinical development and regulatory milestones in the amount of $0.8 million in clinical milestones and $3.8 million in
regulatory milestones for each of the first two fields with respect to SAGE-547; $1.3 million in clinical milestones and $8.5 million in regulatory milestones for each of the third and fourth fields with respect to SAGE-547; and $0.8 million in
clinical milestones and $1.8 million in regulatory milestones for one field with respect to SAGE-689. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2015, the Company recorded research and development expense and made payments of cash of $0.8 million related to clinical development milestones that were met for this agreement. For the years ended December&nbsp;31, 2014 and 2013,
the Company did not record any expense or make any milestone or royalty payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Washington University License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, the Company entered into a license agreement with Washington University whereby the Company was granted exclusive, worldwide
rights to develop and commercialize a novel set of neuroactive steroids developed by Washington University. In exchange for development and commercialization rights, the Company paid an upfront, non-refundable payment of $50 thousand and is required
to pay an annual license maintenance fee of $15 thousand on each subsequent anniversary date, until the first Phase 2 clinical trial for a licensed product is initiated. The Company is obligated to make milestone payments to Washington University
based on achievement of clinical development and regulatory milestones of up to $0.7 million and $0.5 million, respectively. Additionally, the Company fulfilled its obligation to issue to Washington University 47,619 shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of common stock on December&nbsp;13, 2013. The fair value of these shares totaling $0.1 million was recorded as research and development expense in 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is obligated to pay royalties to Washington University at rates in the low single digits on net sales of licensed products covered
under patent rights and royalties at rates in the low single digits on net sales of licensed products not covered under patent rights. Additionally, the Company has the right to sublicense and is required to make payments at varying percentages of
sublicensing revenue received, initially in the mid-teens and descending to the mid-single digits over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2014, the Company did not record any expense or make any milestone or royalty payments. In September 2015, a regulatory milestone was met for one of the programs. Accordingly, the Company recorded research and development expenses
and made a cash payment of $50 thousand in 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>University of California License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, the Company entered into a non-exclusive license agreement with The Regents of the University of California whereby the
Company was granted a non-exclusive license to certain clinical data and clinical material for use in the development and commercialization of biopharmaceutical products in the licensed field, including status epilepticus and post-partum depression.
In May 2014, the license agreement was amended to add the treatment of essential tremor to the licensed field of use, materials and milestone fee provisions of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will be required to pay to The Regents of the University of California clinical development milestones of up to $0.1 million and
pay royalties of less than 1% on net sales for a period of fifteen years following the sale of the first commercial product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The license
will terminate on the earlier to occur of (i)&nbsp;27 years after the effective date or (ii)&nbsp;15 years after the last-derived product is first commercially sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December 31, 2014 and 2013, the Company did not record any expense or make any milestone or royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2015, three clinical development milestones were met. Accordingly, the Company recorded research and development expenses and made cash
payments totaling $0.1 million. In June 2015, the Company entered into an exclusive license agreement with The Regents of the University of California whereby the Company was granted an exclusive license to certain patent rights related to the use
of allopregnanolone to treat various diseases. In exchange for such license, the Company paid an upfront payment of $50 thousand and will make annual maintenance fees of $15 thousand until the calendar year following the first sale, if any, of a
licensed product. The Company is obligated to make milestone payments following the achievement of specified regulatory and sales milestones of up to $0.7 million and $2.0 million in the aggregate, respectively. Following the first sale, if any, of
a licensed product, the Company is obligated to pay royalties at a low single digit percentage of net sales, if any, of licensed products, subject to specified minimum annual royalty amounts. Unless terminated by operation of law or by acts of the
parties under the terms of the agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire, whichever is later. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consulting Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January
2014, the Company entered into a consulting agreement with a nonemployee advisor whereby the Company is obligated to make cash payments of up to $2.0 million and to issue up to 126,984 shares of common stock upon attainment of certain clinical
development and regulatory milestones. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January and March 2014, the first clinical development milestones for each of two programs
included in the consulting agreement were met. Accordingly, the Company recorded research and development expense for the year ended December&nbsp;31, 2014 of $0.2 million, comprised of $50 thousand in cash and $0.1 million related to the issuance
of 15,872 shares of the Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, the second and third clinical
development milestones for one of the programs included in the consulting agreement was met. Accordingly, the Company recorded research and development expense for the year ended December&nbsp;31, 2015 of $1.7 million, comprised of $0.5 million in
cash and $1.2 million related to the issuance of 23,809 shares of the Company&#146;s common stock, related to the achievement of these milestones. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Redeemable Convertible Preferred Stock </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has newly authorized preferred stock amounting to 5,000,000 shares as of December&nbsp;31, 2015 and 2014. The
newly authorized preferred stock was classified under stockholders&#146; equity (deficit) as of December&nbsp;31, 2015 and 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2014 and 2013, the Company&#146;s Certificate of Incorporation, as amended and restated, authorized the Company to issue no shares and 37,750,000, respectively, shares of $0.0001 par value preferred stock. In July 2014, all issued
and outstanding redeemable convertible preferred stock was converted to common stock, see Note 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had issued Series A, Series
B and Series C redeemable convertible preferred stock (collectively, the &#147;Redeemable Preferred Stock&#148;). The Redeemable Preferred Stock was classified outside of stockholders&#146; equity (deficit) as of December&nbsp;31, 2013 because the
shares contained redemption features that are not solely within the control of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2013, the Company issued an
additional 5,000,000 shares in the second funding of the second tranche of Series A Preferred Stock at $1.00 per share, resulting in net proceeds of $5.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2013, the Company issued an additional 5,000,000 shares in the third funding of the second tranche of Series A Preferred Stock
at $1.00 per share, resulting in net proceeds of $5.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2013, the Company issued an additional 12,500,000
shares in the third tranche of Series A Preferred Stock at $1.00 per share, resulting in net proceeds of $12.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;18, 2013, the Company issued 250,000 shares of Series A Preferred Stock at $1.00 per share, resulting in net proceeds of $0.3 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2013, the Company entered into a Stock Purchase Agreement whereby the Company would issue up to $20.0 million of Series B
redeemable convertible preferred stock (&#147;Series B Preferred Stock&#148;) at $1.50 per share. The initial purchase and sale in the amount of $10.0 million could have occurred once certain development milestones had been successfully achieved.
The second tranche of $10.0 million could be issued after the initial closing and at the discretion of the Board of Directors. In November 2013, the Company met the development milestones to issue the first tranche of the Series B Preferred Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;7, 2014, the Company issued 6,666,666 shares of Series B Preferred Stock at $1.50 per share, resulting in net proceeds of
$10.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2014, the Company issued 3,333,333 shares of Series B Preferred Stock at $1.50 in a second closing,
resulting in net proceeds of $5.0 million. At that time, the Company decided not to draw on the remaining $5.0 million of the second tranche of the Series B Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred issuance costs of $30 thousand in 2014 with the issuance of the Series B
Preferred Stock which were recorded as a reduction of the proceeds received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, the Company entered into a Stock
Purchase Agreement whereby the Company issued 8,973,905 shares of Series C redeemable convertible preferred stock (&#147;Series C Preferred Stock&#148;) at $4.2345 per share for net proceeds of $38.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred issuance costs of $0.1 million in 2014 with the issuance of the Series C Preferred Stock which were recorded as a
reduction of the proceeds received. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Common Stock </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015 and 2014, the Company has authorized 120,000,000 shares of common stock with a par value of
$0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s
stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. As of December&nbsp;31, 2015 and 2014, no dividends have been declared. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock-Based Compensation </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2014 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2014, the Company&#146;s stockholders approved the 2014 Stock Option and Incentive Plan (the &#147;2014 Stock Option
Plan&#148;), which became effective upon the completion of the IPO. The 2014 Stock Option Plan provides for the grant of restricted stock awards, incentive stock options and non-statutory stock options. The 2014 Stock Option Plan replaced the
Company&#146;s 2011 Stock Option and Grant Plan (the &#147;2011 Stock Option Plan&#148;). The Company will no longer grant stock options or other awards under the 2011 Stock Option Plan. Any options or awards outstanding under the 2011 Stock Option
Plan remained outstanding and effective. As of December&nbsp;31, 2015, the total number of shares reserved under all equity plans is 3,862,172, and the Company had 859,363 shares available for future issuance under such plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2014 Stock Option Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the
Company&#146;s issued and outstanding shares of common stock on the immediately preceding December&nbsp;31. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terms of restricted stock
awards and stock option agreements, including vesting requirements, are determined by the Board of Directors or the Compensation Committee of the Board of Directors, subject to the provisions of the applicable stock option plan. Options and
restricted stock awards granted by the Company generally vest based on the grantee&#146;s continued service with the Company during a specified period following grant. Awards granted to employees generally vest ratably over four years, with a 25%
cliff vesting at the one year anniversary for new employee awards. During 2013, the Company also granted a pool of option awards which vest ratably over one year. All awards are exercisable from the date of grant for a period of ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2015, the Company granted 497,100 options to employees to purchase shares of common stock that contain performance-based vesting
criteria, primarily related to achievement of certain clinical and regulatory development milestones related to the Company&#146;s product candidates. Recognition of stock-based compensation expense associated with these performance-based stock
options commences when the performance condition is considered probable of achievement, using management&#146;s best estimates. During the quarter ended June&nbsp;30, 2015, the achievement of one milestone was considered probable and that milestone
was achieved during the quarter ended September&nbsp;30, 2015. The related expense was recognized over the estimated service period. This milestone represents 35% of the performance-based grants that were made during 2015. The achievement of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remaining milestones was deemed to be not probable as of December&nbsp;31, 2015 and therefore no expense has been recognized related to these awards. During the year ended December&nbsp;31, 2015,
the Company recognized stock-based compensation expense of $4.8 million related to stock options with performance-based vesting criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense recognized during the years ended December&nbsp;31, 2015, 2014, and 2013 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stock-based compensation expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For stock option awards, the fair value of the options is estimated at the grant date using the Black-Scholes
option-pricing model, taking into account the terms and conditions upon which options are granted. The fair value of the options is amortized on a straight-line basis for awards to employees and on a graded basis for awards to non-employees over the
requisite service period of the awards for awards to employees and graded vesting is used for non-employees. The weighted average grant date fair value per share relating to outstanding stock options granted under the Company&#146;s stock option
plans during the years ended December&nbsp;31, 2015, 2014 and 2013 was $34.08, $14.33 and $0.38, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each
option granted to employees and nonemployee directors during the years ended December&nbsp;31, 2015, 2014 and 2013 under the Company&#146;s stock option plans has been calculated on the date of grant using the following weighted average assumptions:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99.89</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.03&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.38&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.04&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected dividend yield: </I>The Company has not paid and does not anticipate paying any dividends in the
foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate: </I>The Company determined the risk-free interest rate by using a weighted average
equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected volatility: </I>As
the Company has only been a public company since July 2014, there is not sufficient historical volatility for the expected term of the options. Therefore, the Company used an average historical share price volatility based on an analysis of reported
data for a peer group of comparable companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected term (in years): </I>Expected term represents the period that the
Company&#146;s stock option grants are expected to be outstanding. As the Company has only been a public company since July 2014, there is not sufficient historical term data to calculate the expected term of the options. Therefore, the Company
elected to utilize the &#147;simplified&#148; method to estimate the expected term of option grants issued to employees. Under this approach, the weighted average expected life is presumed to be the average of the vesting term and the contractual
term of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods
if actual forfeitures differ from estimates. The Company estimates forfeitures based on historical termination behavior. For the years ended December&nbsp;31, 2015, 2014, and 2013, a forfeiture rate of 10% was applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For options granted to nonemployees, the expected life of the option used is ten years, which is the contractual term of each such option. All
other assumptions used to calculate the grant date fair value are generally consistent with the assumptions used for options granted to employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes activity related to stock options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Remaining&nbsp;Life&nbsp;(in</B><br><B>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,996,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,516,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(417,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,002,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested or expected to vest as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">723,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, the Company had unrecognized stock-based compensation expense related to its
unvested service-based stock option awards of $31.5 million, which is expected to be recognized over the remaining weighted average vesting period of 3.01 years. The total fair value of shares vested for the years ended December&nbsp;31, 2015, 2014
and 2013 was $9.2 million, $1.0 million, and $9 thousand, respectively. In addition, the Company has 358,976 shares of outstanding unvested stock options that vest upon the achievement of certain performance criteria. Total unrecognized compensation
related to those awards was $7.8 million at December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intrinsic value of stock options exercised during the years ended
December&nbsp;31, 2015 and 2014 was $28.4 million and $2.4 million, respectively, and the intrinsic value of stock options exercised during the year ended December&nbsp;31, 2013 was zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
the year ended December&nbsp;31, 2013, the Company granted restricted stock awards to certain officers, employees, directors, and consultants of the Company. During the years ended December&nbsp;31, 2015, 2014 and 2013, the Company recorded $0.3
million, $0.2 million and $11 thousand, respectively, of stock-based compensation expense related to its restricted stock. The table below summarizes activity relating to restricted stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December 31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December 31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, the Company had unrecognized stock-based compensation expense
related to its unvested restricted stock awards of $34 thousand, which is expected to be recognized over the remaining weighted average vesting period of 0.56 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2015 and 2014, no shares of restricted stock were issued. During the year ended December&nbsp;31,
2013, current and former employees of the Company purchased a total of 130,158 shares of restricted stock, resulting in proceeds of $50 thousand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unvested shares are subject to repurchase by the Company, at the issuance price, upon the employee&#146;s termination at the Company&#146;s
sole discretion. In the year ended December&nbsp;31, 2014, the Company repurchased 6,778 shares of restricted common stock issued to employees at their $0.04 original purchase price per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2014 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2014, the Company&#146;s stockholders approved the 2014 Employee Stock Purchase Plan. A total of 282,000 shares of common stock
were initially authorized for issuance under this plan. The 2014 Employee Stock Purchase Plan became effective upon the completion of the IPO. As of December&nbsp;31, 2015, 3,852 shares have been issued under this plan. Included in accrued
liabilities at December&nbsp;31, 2015 is $64 thousand of stock compensation expense related to an enrollment period for which the related shares had not been issued as of December&nbsp;31, 2015. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Net Loss Per Share </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows for the years
ended December&nbsp;31, 2015, 2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders (in&nbsp;thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of common stock outstanding&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,778,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,574,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of shares of common stock equivalents resulting from common stock options and preferred common stock (as
converted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common stock outstanding&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,778,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,574,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents outstanding as of December&nbsp;31, 2015 and 2014, were
excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,643,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,689,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,791,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no provision for income taxes because the Company has historically incurred operating losses and maintains a full
valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the years differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses primarily because of
changes in valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of U.S. statutory rate to the Company&#146;s effective tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax due at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s net deferred tax asset at December&nbsp;31, 2015 and 2014 are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized start-up costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting method change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net deferred tax asset before valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, the Company had federal and state net operating loss carryforwards
of $131.5&nbsp;million and $130.7 million, respectively, which begin to expire in 2031. As of December&nbsp;31, 2015, the Company had federal and state research and development tax credits carryforwards of $1.6 million and $0.7 million,
respectively, which begin to expire in 2031 and 2027, respectively. As of December&nbsp;31, 2015, the Company had federal orphan drug tax credit carry forwards of $16.4 million, which begin to expire in 2034. At December 31, 2015, the Company has
excess equity based compensation tax deductions related to net operating losses for federal and state purposes of $18.9&nbsp;million and $18.9 million respectively. The Company has excess equity based compensation related to credits for federal and
state purposes of $1.3 million and $0.2 million, respectively. These excess tax benefits have not been included in the net deferred tax assets before valuation allowance since these benefits would be credited directly to additional paid in capital
if subsequently recognized through a reduction in taxes payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, net deferred tax assets increased
approximately $40.8&nbsp;million primarily due to the operating loss and tax credits incurred during the year. This increase in net deferred tax assets was offset by a corresponding increase in the valuation allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which
are comprised principally of net operating loss carryforwards and capitalized start-up costs. Under the applicable accounting standards, management has considered the Company&#146;s history of losses and concluded that it is more likely than not
that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance of $69.1 million and $28.3 million has been established at December&nbsp;31, 2015 and 2014, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;382 of the Internal Revenue Code, certain substantial changes in the Company&#146;s ownership may result in a
limitation on the amount of net operating loss carryforwards and tax carryforwards that may be used in future years. Utilization of the net operating loss (&#147;NOL&#148;) and tax credit carryforwards may be subject to a substantial annual
limitation under Section&nbsp;382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and tax credit
carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since
its formation, due to significant complexity and related costs associated with such a study. There could also be additional ownership changes in the future which may result in additional limitations on the utilization of NOL carryforwards and
credits. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company to
determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting
the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing
authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a rollforward of the Company&#146;s unrecognized tax benefits: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits&#151;as of the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross increases&#151;current period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross decreases&#151;tax positions of prior periods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,880</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefits&#151;as of the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2014, the Company filed an application for change in accounting method with the IRS to
capitalize start-up costs that were historically deducted and included as part of the NOL carryforward through December&nbsp;31, 2013. As a result, the Company&#146;s unrecognized tax benefits, which historically related to start-up costs, are zero
at December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will recognize interest and penalties related to uncertain tax positions in income tax expense
when in a taxable income position. As of December&nbsp;31, 2015 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#146;s statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the
Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations, and the Company&#146;s tax returns are open under statute from 2012 to the present. The tax attributes prior to
2012 may still be adjusted upon examination. The Company&#146;s policy is to record interest and penalties related to income taxes as part of the tax provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which simplifies the presentation of
deferred income taxes. This ASU requires that deferred tax assets and liabilities be classified as non-current in a statement of financial position. The standard is effective for public companies for fiscal years beginning after December&nbsp;31,
2016, including interim periods within that reporting period. Early adoption is permitted for any interim and annual financial statements that have not yet been issued. The Company early adopted ASU 2015-17 effective December&nbsp;31, 2015 on a
prospective basis. Adoption of this ASU resulted in a reclassification of the current deferred tax liability to a non-current deferred tax liability, which is netted with the long-term deferred tax asset in its consolidated balance sheet as of
December&nbsp;31, 2015. No prior periods were retrospectively adjusted. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Employee Benefit Plan </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a 401(k) profit sharing plan (the &#147;Plan&#148;) for its employees. Each participant in the Plan
may elect to contribute a portion of his or her annual compensation to the Plan subject to annual limits established by the Internal Revenue Service. Effective November&nbsp;1, 2014, the Company instituted an employer match of 50% of eligible
contributions up to 6% of employee contributions. For the years ended December&nbsp;31, 2015 and 2014, the Company contributed $0.2 million and $15 thousand, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related Party Transactions </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has received consulting and management services from Third Rock Ventures LLC, which through its
affiliates, owned 16.4% of the Company&#146;s common stock at December&nbsp;31, 2015. The Company recorded expenses of $21 thousand, $0.2 million, and $0.6 million for these services for the years ended December&nbsp;31, 2015, 2014, and 2013,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Selected Quarterly Financial Data (Unaudited) </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table contains quarterly financial information for 2015 and 2014. The Company believes that the following
information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>First</B><br><B>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Second<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Third<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fourth<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,897</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>First<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Second<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Third<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fourth<BR>Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,471</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Event </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;12, 2016, the Company completed the sale of 3,157,894 shares of its common stock at a price to the public of
$47.50 per share, resulting in net proceeds to the Company of $140.4 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit List </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant&#146;s Current Report on Form 8-K (File&nbsp;No.&nbsp;000-36544) filed on
July 25, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By-laws of the Registrant and the amendments thereto, as currently in effect (incorporated by reference to Exhibit 3.4 of the Registrant&#146;s Current Report on Form 8-K (File No. 000-36544) filed on July 25, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Investors&#146; Rights Agreement by and among the Registrant and certain of its stockholders dated March 11, 2014 (incorporated by reference to Exhibit 4.2 of the Registrant&#146;s Registration Statement
on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#146;s Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-196849)</FONT> filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement by and between the Registrant and Washington University, dated November 11, 2013 (incorporated by reference to Exhibit 10.3 of the Registrant&#146;s Registration Statement on Form S-1 (File No.
333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Commercial License by and between the Registrant and CyDex Pharmaceuticals, Inc., dated September 25, 2015 (incorporated by reference to Exhibit 10.1 of the Registrant&#146;s Quarterly Report on Form 10-Q (File
No. 001-36544) filed on November 6, 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Exclusive License Agreement by and between the Registrant and the Regents of University of California, dated October 23, 2013, as amended May 14, 2014 (incorporated by reference to Exhibit 10.5 of the Registrant&#146;s
Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement, by and between the Registrant and ARE-MA Region No. 38, LLC, dated December 11, 2011, as amended by First Amendment to Lease, by and between ARE-MA Region No. 38, LLC, dated October 26, 2012, and Second Amendment to
Lease, by and between ARE-MA Region No. 38, LLC, dated May 9, 2013 (incorporated by reference to Exhibit 10.6 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.6+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer letter by and between the Registrant and Jeffrey M. Jonas, dated July 18, 2013 (incorporated by reference to Exhibit 10.7 of the Registrant&#146;s Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-196849)</FONT> filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.7+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer letter by and between the Registrant and Albert J. Robichaud, dated September 25, 2011 (incorporated by reference to Exhibit 10.8 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July
8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer letter by and between the Registrant and Stephen J. Kanes, dated May 21, 2013 (incorporated by reference to Exhibit 10.9 of the Registrant&#146;s Registration Statement on Form S-1
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-196849)</FONT> filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer letter by and between the Registrant and Kimi Iguchi, dated February 7, 2013 (incorporated by reference to Exhibit 10.10 of the Registrant&#146;s Registration Statement on Form S-1 (File&nbsp;No.&nbsp;333-196849) filed on July
8, 2014)</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.10+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and Jeffrey M. Jonas, dated August 19, 2013 (incorporated by reference to Exhibit 10.11 of the Registrant&#146;s Registration Statement on Form
S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.11+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and Albert J. Robichaud, dated November 7, 2011 (incorporated by reference to Exhibit 10.12 of the Registrant&#146;s Registration Statement on
Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.12+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and Stephen J. Kanes, dated July 17, 2013 (incorporated by reference to Exhibit 10.13 of the Registrant&#146;s Registration Statement on Form
S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.13+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and Kimi Iguchi, dated March 8, 2013 (incorporated by reference to Exhibit 10.14 of the Registrant&#146;s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.14+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.15 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement to be entered into between the Registrant and its directors (incorporated by reference to Exhibit 10.16 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on
July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement to be entered into between the Registrant and its officers (incorporated by reference to Exhibit 10.17 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July
8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Supply Agreement by and between the Registrant and CyDex Pharmaceuticals, Inc., dated December 13, 2012, as amended August 21, 2013 and April 30, 2014 (incorporated by reference to Exhibit 10.18 of the Registrant&#146;s Registration
Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.18+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.19 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.19+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter by and between the Registrant and Thomas D. Anderson, dated April 15, 2014 (incorporated by reference to Exhibit 10.20 of the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8,
2014)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.20+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severance and Change In Control Agreement between the Registrant and Jeffrey M. Jonas, dated September 25, 2014 (incorporated by reference to Exhibit 10.20 of the Registrant&#146;s Annual Report on Form 10-K (File No. 001-36544)
filed on March 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.21+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severance and Change In Control Agreement between the Registrant and Kimi Iguchi, dated September 30, 2014 (incorporated by reference to Exhibit 10.21 of the Registrant&#146;s Annual Report on Form 10-K (File No. 001-36544) filed on
March 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.22+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severance and Change In Control Agreement between the Registrant and Stephen J. Kanes, dated September 30, 2014 (incorporated by reference to Exhibit 10.22 of the Registrant&#146;s Annual Report on Form 10-K (File No. 001-36544)
filed on March 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.23+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severance and Change In Control Agreement between the Registrant and Albert J. Robichaud, dated September 25, 2014 (incorporated by reference to Exhibit 10.23 of the Registrant&#146;s Annual Report on Form 10-K (File No. 001-36544)
filed on March 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.24+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Severance and Change In Control Agreement between the Registrant and Thomas D. Anderson, dated September 26, 2014 (incorporated by reference to Exhibit 10.24 of the Registrant&#146;s Annual Report on Form 10-K (File No. 001-36544)
filed on March 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.25*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement by and between the Registrant and the Regents of the University of California, dated June 6, 2015 (incorporated by reference to Exhibit 10.1 of the Registrant&#146;s Quarterly Report on Form 10-Q/A (File
No. 001-36544) filed on October 31, 2015)</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amendment to Lease, by and between Registrant and ARE-MA Region No. 38, LLC, dated as of September 9, 2015 (incorporated by reference to Exhibit 10.3 of the Registrant&#146;s Quarterly Report on Form 10-Q (File No. 001-36544)
filed on November 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment to Lease, by and between the Registrant and ARE-MA Region No. 38, LLC, dated as of October 27, 2015 (incorporated by reference to Exhibit 10.4 of the Registrant&#146;s Quarterly Report on Form 10-Q (File No.
001-36544) filed on November 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 3 to Supply Agreement, by and between the Registrant and CyDex Pharmaceuticals, Inc., dated September 25, 2015 (incorporated by reference to Exhibit 10.2 of the Registrant&#146;s Quarterly Report on Form 10-Q (File No.
001-36544) filed on November 6, 2015)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.29</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment to Lease, by and between the Registrant and ARE-MA Region No. 38, LLC, dated as of December 9, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Labels Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Link Document</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(+)</TD>
<TD ALIGN="left" VALIGN="top">Management contract or compensatory plan or arrangement. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(**)</TD>
<TD ALIGN="left" VALIGN="top">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form&nbsp;10-K and will not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of
1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant
specifically incorporates it by reference. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>2
<FILENAME>d111598dex1029.htm
<DESCRIPTION>EX-10.29
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.29</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.29 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIFTH AMENDMENT TO LEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FIFTH AMENDMENT TO LEASE (this <B>&#147;Fifth Amendment&#148;) </B>is made as of December&nbsp;9, 2015, by and between <B><FONT
STYLE="white-space:nowrap">ARE-MA</FONT> REGION NO. 38, LLC, </B>a Delaware limited liability company <B>(&#147;Landlord&#148;), </B>and <B>SAGE THERAPEUTICS, INC., </B>a Delaware corporation <B>(&#147;Tenant&#148;).</B> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.
</B>Landlord and Tenant are now parties to that certain Lease Agreement dated as of December&nbsp;21, 2011, as amended by that certain First Amendment to Lease dated as of October&nbsp;26, 2012, as further amended by that certain Second Amendment to
Lease dated as of May&nbsp;9, 2013, as further amended by that certain Third Amendment to Lease dated as of September&nbsp;9, 2015 (the <B>&#147;Third Amendment&#148;), </B>and as further amended by that certain Fourth Amendment to Lease dated as of
October&nbsp;27, 2015 (as amended, the <B>&#147;Lease&#148;). </B>Pursuant to the Lease, Tenant leases certain premises consisting of approximately 22,067 rentable square feet of space <B>(&#147;Premises&#148;) </B>in a building located at 215 First
Street, Cambridge, Massachusetts <B>(&#147;Building&#148;). </B>The Premises are more particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. </B>Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, amend the terms of
<U>Section&nbsp;4</U> of the Third Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the foregoing Recitals, which are incorporated
herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Third Expansion Premises Base Rent</U>. </B>Effective as of the date of the Third Amendment, <U>Section&nbsp;4</U> of the Third Amendment is deleted in its entirety and replaced with the following:
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;4. <B>Base Rent</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>a. Current Premises. </B>Tenant shall continue to pay Base Rent for the Current Premises as provided for in the Lease through
December&nbsp;31, 2015. For the period commencing on January&nbsp;1, 2016, through February&nbsp;28, 2016, Tenant shall pay Base Rent for the Current Premises in the amount of $47.50 per rentable square foot of the Current Premises per year. For the
period commencing March&nbsp;1, 2016, through February&nbsp;28, 2017, Tenant shall pay Base Rent for the Current Premises in the amount of $48.50 per rentable square foot of the Current Premises per year. Commencing on March&nbsp;1, 2017, Tenant
shall commence paying Base Rent for the Current Premises at the same Base Rent per rentable square foot that Tenant is then paying for the Third Expansion Premises, as adjusted pursuant to <U>Section&nbsp;4(b)</U> below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>b. Third Expansion Premises. </B>Commencing on the <B>&#147;Third Expansion Premises Rent Commencement Date&#148;, </B>which shall be the
earlier to occur of (i)&nbsp;the Third Expansion Premises Commencement Date, or (ii)&nbsp;March&nbsp;1, 2016, Tenant shall pay Base Rent for the Third Expansion Premises in the amount of $50.00 per rentable square foot of the Third Expansion
Premises per year. Base Rent for the Third Expansion Premises shall be increased on each annual anniversary of Third Expansion Premises Rent Commencement Date by $1.00 per rentable square foot of the Third Expansion Premises per year. Base Rent for
the Third Expansion Premises, as so adjusted, shall thereafter be due as provided herein.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g111598001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Brokers</U>. </B>Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, <B>&#147;Broker&#148;) </B>in connection with the transaction reflected
in this Fifth Amendment and that no Broker brought about this transaction, other than Transwestern RBJ and Cushman&nbsp;&amp; Wakefield. Landlord and Tenant each hereby agrees to indemnify and hold the other harmless from and against any claims by
any Broker claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>OFAC</U>. </B>Tenant and Landlord are currently (a)&nbsp;in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control
<B>(&#147;OFAC&#148;) </B>of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the <B>&#147;OFAC Rules&#148;), </B>(b)&nbsp;not listed on, and shall not during the term of the Lease be
listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other
governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c)&nbsp;not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Miscellaneous</U></B>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>a. </B>This Fifth Amendment is the entire agreement between
the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Fifth Amendment may be amended only by an agreement in writing, signed by the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>b. </B>This Fifth Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective successors and assigns.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>c. </B>This Fifth Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which
when taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other
counterpart identical thereto except having additional signature pages executed by other parties to this Fifth Amendment attached thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>d. </B>Except as amended and/or modified by this Fifth Amendment, the Lease is hereby ratified and confirmed and all other terms of the
Lease shall remain in full force and effect, unaltered and unchanged by this Fifth Amendment. In the event of any conflict between the provisions of this Fifth Amendment and the provisions of the Lease, the provisions of this Fifth Amendment shall
prevail. Whether or not specifically amended by this Fifth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Fifth Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signatures are on the next page] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g111598001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties hereto have executed this Fifth Amendment as of the day
and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAGE THERAPEUTICS, INC.,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anne Marie Cook</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">SVP, General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARE-MA REGION NO. 38, LLC,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware limited liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">ALEXANDRIA&nbsp;REAL&nbsp;ESTATE<BR>EQUITIES,&nbsp;L.P.,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">a Delaware limited partnership, managing member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ARE-QRS CORP.,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Maryland corporation,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">general
partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">


<IMG SRC="g111598037.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Eric S. Johnson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">RE Legal Affairs</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g111598001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d111598dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SUBSIDIARIES </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:34.15pt; font-size:8pt; font-family:Times New Roman">Subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:45.85pt; font-size:8pt; font-family:Times New Roman">Jurisdiction of<BR>Incorporation</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sage Securities Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Massachusetts</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sage (Bermuda) Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Bermuda</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d111598dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No. 333-208870) and S-8 (Nos. 333-197498 and 333-204549) of
Sage Therapeutics, Inc. of our report dated February&nbsp;29, 2016 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;29, 2016 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d111598dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Jeffrey M.
Jonas, M.D., certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this annual report on Form 10-K of Sage Therapeutics, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;29, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey M. Jonas</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey M. Jonas, M.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, President and Director (Principal Executive Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d111598dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS UNDER SECTION 302 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Kimi
Iguchi, certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this annual report on Form 10-K of Sage Therapeutics, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;29, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kimi Iguchi</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kimi Iguchi</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer (Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d111598dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATIONS PURSUANT TO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18
U.S.C. SECTION 1350, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AS ADOPTED PURSUANT TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this Annual Report on Form 10-K of Sage Therapeutics, Inc. (the &#147;Company&#148;) for the fiscal year ended
December&nbsp;31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to
(section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey M. Jonas</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey M. Jonas, M.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, President and Director (Principal Executive Officer)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February 29, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kimi Iguchi</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kimi Iguchi</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer (Principal Financial and Accounting Officer)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February 29, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>sage-20151231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 7 -->
<!-- Creation date: 2016-02-29T16:27:37Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:sage="http://www.SageTherapeutics.com/20151231" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sage-20151231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20131031_0_1632078x1815931_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_C9AD99F7-4888-4E9C-950E-B80F3D2097C3_2002_0">100000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20131130_0_1632078x1930456_1634968x1702458" unitRef="iso4217_USD" decimals="-5" id="id_9807917_7665D46B-1E1A-46FD-8B6F-0F3D3D927D93_2003_2">500000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20131130_0_1632078x1930456_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_7665D46B-1E1A-46FD-8B6F-0F3D3D927D93_2002_2">700000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE925099--1510-K0012_STD_0_20131130_0_1637024x1733189_1641810x1633314" unitRef="iso4217_USD" decimals="-5" id="id_9807917_6FC6C455-BE6C-453A-A716-9286D813F6F9_1003_2">10000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <sage:UndrawnAmount contextRef="eol_PE925099--1510-K0012_STD_0_20140212_0_1637024x1666381_1641810x1633314" unitRef="iso4217_USD" decimals="-5" id="id_9807917_64715BCF-C385-435F-9DB5-31692FF27F21_2001_3">5000000</sage:UndrawnAmount>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20140212_0_1641810x1633314" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_64715BCF-C385-435F-9DB5-31692FF27F21_1001_1">1.50</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20140212_0_1641810x1633314" unitRef="shares" decimals="INF" id="id_9807917_64715BCF-C385-435F-9DB5-31692FF27F21_1001_0">3333333</us-gaap:TemporaryEquitySharesIssued>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_0_20160216_0" unitRef="shares" decimals="INF" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_2_8">32022187</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20130318_0_1637024x1666381_1641810x1641034" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_A591513B-683C-45D2-BAAE-1379CC883F75_2001_1">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20130318_0_1637024x1666381_1641810x1641034" unitRef="shares" decimals="INF" id="id_9807917_A591513B-683C-45D2-BAAE-1379CC883F75_2001_0">5000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20140311_0_1641810x1637021" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_AEBEB7C8-98C9-46CF-805D-A84B0FBB37FD_1001_1">4.2345</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20140311_0_1641810x1637021" unitRef="shares" decimals="INF" id="id_9807917_AEBEB7C8-98C9-46CF-805D-A84B0FBB37FD_1001_0">8973905</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20150420_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_B28010D9-58E6-404C-AA6B-FEFF5F6262AE_1001_1">52.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20130701_0_1637024x1666381_1641810x1641034" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_9D3C4D9D-92A2-4DA7-A3E8-50ACDE9FC6ED_2001_1">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20130701_0_1637024x1666381_1641810x1641034" unitRef="shares" decimals="INF" id="id_9807917_9D3C4D9D-92A2-4DA7-A3E8-50ACDE9FC6ED_2001_0">5000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20140702_0_1639657x1738299" unitRef="shares" decimals="INF" id="id_9807917_8FD642A9-0953-438E-A9A0-9A2F76C1693E_1001_0">282000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20140723_0_1637033x1634411" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_9B5BF914-E9FD-46EC-ABF0-2D00AFFDEE76_2001_1">18.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20130912_0_1637024x1765361_1641810x1641034" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_2E066A98-4743-47BD-9B8C-97C47C986EE2_2001_1">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20130912_0_1637024x1765361_1641810x1641034" unitRef="shares" decimals="INF" id="id_9807917_2E066A98-4743-47BD-9B8C-97C47C986EE2_2001_0">12500000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20131015_0_1641810x1633314" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_6FC6C455-BE6C-453A-A716-9286D813F6F9_1001_1">1.50</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20131015_0_1641810x1633314" unitRef="shares" decimals="INF" id="id_9807917_6FC6C455-BE6C-453A-A716-9286D813F6F9_1001_0">20000000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE925099--1510-K0012_STD_0_20131015_0_1641810x1633314" unitRef="iso4217_USD" decimals="-5" id="id_9807917_6FC6C455-BE6C-453A-A716-9286D813F6F9_1001_2">10000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20131018_0_1641810x1641034" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_B0861C68-BF23-459C-8A3B-E23854923890_2001_1">1.00</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20131018_0_1641810x1641034" unitRef="shares" decimals="INF" id="id_9807917_B0861C68-BF23-459C-8A3B-E23854923890_2001_0">250000</us-gaap:TemporaryEquitySharesIssued>
  <dei:EntityPublicFloat contextRef="eol_PE925099--1510-K0012_STD_0_20150630_0" unitRef="iso4217_USD" decimals="0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_3_9">903465958</dei:EntityPublicFloat>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20150630_0_1632078x1815931_1634968x1702458" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FBB1BCC7-8364-4F4F-965A-7190F88DFE21_2002_2">700000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20150630_0_1632078x1815931_1634968x1813302" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FBB1BCC7-8364-4F4F-965A-7190F88DFE21_2003_2">2000000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_1005_800001">-13394000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_BBFDE3B6-B22D-43EC-9785-4974FA60FF53_2001_0">1477000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_5001_24">2802000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0_1641810x1641034_1643450x1671852" unitRef="shares" decimals="INF" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_2001_400002">15000000</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_1001_400002">1395273</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_1004_700001">-13394000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20121231_0_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_1001_500001">14970000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_E05F9014-1952-4538-AAF1-68CA5B827A6E_1002_1">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_9807917_E05F9014-1952-4538-AAF1-68CA5B827A6E_1002_0">37750000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_3005_800012">-31536000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_BBFDE3B6-B22D-43EC-9785-4974FA60FF53_1003_0">2880000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_4003_24">8066000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0_1642755x1632468" unitRef="shares" decimals="0" id="id_9807917_1C0DE13D-4C03-418F-8221-5920FD0B0432_1001_1">170832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:SharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_3001_400013">1622761</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_3004_700012">-31675000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_3003_600012">139000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1671852" unitRef="shares" decimals="INF" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_5001_400008">37750000</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_5001_500007">37709000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20140107_0_1641810x1633314" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_0854DA5D-972E-430B-8B89-7DE3FF8BA2E5_2001_1">1.50</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20140107_0_1641810x1633314" unitRef="shares" decimals="INF" id="id_9807917_0854DA5D-972E-430B-8B89-7DE3FF8BA2E5_2001_0">6666666</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_E05F9014-1952-4538-AAF1-68CA5B827A6E_1001_1">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_27">120000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_24">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_29">25621791</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_26">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_22">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_23">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_E05F9014-1952-4538-AAF1-68CA5B827A6E_1001_0">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_28">25621791</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_21">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_30">188727000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_2_3">46000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_2_1">1279000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_32">121885000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_16">23000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_2_2">574000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_12">2429000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_13">4687000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_31">-66845000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_17">7780000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_33">129665000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_71652546-7B41-4D0C-AE44-0A9CB9E1D9A5_1002_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:CommonStockValue contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_25">3000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_18" />
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_14">641000</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_2_3">146000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_15">7757000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_A210F481-9677-4B0C-A9AF-4BBA03E0CD05_1002_1">28303000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:PreferredStockValue contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_20" />
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_4">494000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_0">21907000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_5">332000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_8">28303000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:Assets contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_9">129665000</us-gaap:Assets>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_5">163000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_6">39000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_10">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:AssetsCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_4">128822000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_7">20000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_3">1056000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_2">127766000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_2_8">641000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_2_2">309000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_3">4433000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <sage:DeferredTaxAssetsStockOptions contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_6">623000</sage:DeferredTaxAssetsStockOptions>
  <sage:DeferredTaxAssetsChangeInAccountingMethod contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_2">2020000</sage:DeferredTaxAssetsChangeInAccountingMethod>
  <sage:AccruedDevelopmentExpensesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_2_0">2788000</sage:AccruedDevelopmentExpensesCurrent>
  <sage:DeferredTaxAssetsCapitalizedStartUpCosts contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1002_1">2514000</sage:DeferredTaxAssetsCapitalizedStartUpCosts>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634505x1641629" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_1002_1">103000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634505x1935408" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_2002_0">206000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1634767" unitRef="iso4217_USD" decimals="INF" id="id_9807917_D0F6718A-04FF-4C42-B134-89D83B01805F_1002_1">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1634767" unitRef="iso4217_USD" decimals="INF" id="id_9807917_D0F6718A-04FF-4C42-B134-89D83B01805F_1002_0">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1637150" unitRef="iso4217_USD" decimals="INF" id="id_9807917_8839B7C9-134B-4B47-9DC3-F73AEEFCE378_1002_1">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1637150" unitRef="iso4217_USD" decimals="INF" id="id_9807917_8839B7C9-134B-4B47-9DC3-F73AEEFCE378_1002_0">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1643241_1637541x1637231" unitRef="iso4217_USD" decimals="-5" id="id_9807917_CA11B835-53ED-4261-9CD5-FEE04A5B8533_1002_0">127800000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_1001_1">1996615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_1001_1">7.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-3" id="id_9807917_CB670FC1-3C25-42EA-BCBC-231905970377_1001_1">59362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_5001_400028">25621791</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1632657" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_5001_500027">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_5004_700027">-66845000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_5003_600027">188727000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_27">120000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_24">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_29">28823549</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_26">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_22">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_23">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_28">28823549</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_21">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_1">1088000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_0">978000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_30">335032000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_1_3">29000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_6">6926000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_1_1">2718000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_32">173695000</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_4">1176000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_16">14000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_1_2">935000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_519F8A8B-B350-461C-BC38-20A430B3FE0D_1_0">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_12">5159000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_13">10148000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_31">-161340000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_17">15321000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_33">189016000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_71652546-7B41-4D0C-AE44-0A9CB9E1D9A5_1001_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:CommonStockValue contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_25">3000</us-gaap:CommonStockValue>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_71652546-7B41-4D0C-AE44-0A9CB9E1D9A5_1001_1">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_18" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_3">1154000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_1_3">261000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_5">1398000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_15">15307000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_A210F481-9677-4B0C-A9AF-4BBA03E0CD05_1001_0">69069000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:PreferredStockValue contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_20" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_51A07D7E-BF75-42D7-B52A-88601BDFDA59_1001_2">1132000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_4">1062000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_3001_7">16400000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_0">44172000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_5">716000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_8">69069000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_4_6">7800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:Assets contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_9">189016000</us-gaap:Assets>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_3001_1">130700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_5">286000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_6">39000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_10">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:AssetsCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_4">188491000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredOfferingCosts contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_7">200000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_7">21000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_3001_0">131500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_3">1738000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B262B9BC-0246-46FC-914C-4961965E2886_1_2">186753000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_1_2">547000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_3">17013000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <sage:DeferredTaxAssetsStockOptions contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_6">5097000</sage:DeferredTaxAssetsStockOptions>
  <sage:DeferredTaxAssetsChangeInAccountingMethod contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_2">1347000</sage:DeferredTaxAssetsChangeInAccountingMethod>
  <sage:AccruedDevelopmentExpensesCurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_4942D532-44A1-45BE-9655-1D3A2E1D4D1D_1_0">6466000</sage:AccruedDevelopmentExpensesCurrent>
  <sage:DeferredTaxAssetsCapitalizedStartUpCosts contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7D0F4039-04FA-4EE0-9AF1-9A7E3820D01C_1001_1">2335000</sage:DeferredTaxAssetsCapitalizedStartUpCosts>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x1702458" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FEEB4454-2387-424A-962C-613CF8A8C89A_6_0">1800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FEEB4454-2387-424A-962C-613CF8A8C89A_5_0">800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000444" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FEEB4454-2387-424A-962C-613CF8A8C89A_1_0">800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000446" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FEEB4454-2387-424A-962C-613CF8A8C89A_2_0">3800000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000449" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FEEB4454-2387-424A-962C-613CF8A8C89A_3_0">1300000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000450" unitRef="iso4217_USD" decimals="-5" id="id_9807917_FEEB4454-2387-424A-962C-613CF8A8C89A_4_0">8500000</sage:AdditionalPaymentsBasedOnAchievementOfCertainDevelopment>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634505x1641629" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_1001_1">147000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634505x1935408" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DE2A72CC-3D8D-4367-9412-E3C6144BFE09_2001_0">400000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1634767" unitRef="iso4217_USD" decimals="INF" id="id_9807917_D0F6718A-04FF-4C42-B134-89D83B01805F_1001_1">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1634767" unitRef="iso4217_USD" decimals="INF" id="id_9807917_D0F6718A-04FF-4C42-B134-89D83B01805F_1001_0">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1637150" unitRef="iso4217_USD" decimals="INF" id="id_9807917_8839B7C9-134B-4B47-9DC3-F73AEEFCE378_1001_1">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1637150" unitRef="iso4217_USD" decimals="INF" id="id_9807917_8839B7C9-134B-4B47-9DC3-F73AEEFCE378_1001_0">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1643241_1637541x1637231" unitRef="iso4217_USD" decimals="-5" id="id_9807917_CA11B835-53ED-4261-9CD5-FEE04A5B8533_1001_0">186800000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1639657x1738299" unitRef="iso4217_USD" decimals="-3" id="id_9807917_C8013E9D-8881-435B-96A3-CA0F3FE68165_1001_0">64000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1639657x2000438" unitRef="shares" decimals="INF" id="id_9807917_9FAC1265-EAFD-4A1D-B467-5FA8C8C1441B_2001_1">859363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1639657x2000438" unitRef="shares" decimals="INF" id="id_9807917_9FAC1265-EAFD-4A1D-B467-5FA8C8C1441B_2001_0">3862172</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1641051" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_4001_4">700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <sage:DeferredTaxLiabilitiesShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1641051" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_4001_12">200000</sage:DeferredTaxLiabilitiesShareBasedCompensation>
  <sage:DeferredTaxAssetsShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1641051" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_4001_10">18900000</sage:DeferredTaxAssetsShareBasedCompensation>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1643648" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_5001_3">1600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <sage:DeferredTaxLiabilitiesShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1643648" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_5001_11">1300000</sage:DeferredTaxLiabilitiesShareBasedCompensation>
  <sage:DeferredTaxAssetsShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1643648" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_5001_9">18900000</sage:DeferredTaxAssetsShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1632468" unitRef="shares" decimals="0" id="id_9807917_1C0DE13D-4C03-418F-8221-5920FD0B0432_3001_6">42781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1632468" unitRef="iso4217_USD" decimals="-3" id="id_9807917_414C281A-A791-4875-9FB7-BC731C7C7172_2001_0">34000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_3001_5">3002809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="shares" decimals="0" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1004_5">358976</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_3001_5">26.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_3001_6">24.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_3001_7">723895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_3001_7">14.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_3001_6">2421859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-3" id="id_9807917_CB670FC1-3C25-42EA-BCBC-231905970377_3001_4">31729000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1004_0">31500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-3" id="id_9807917_CB670FC1-3C25-42EA-BCBC-231905970377_3001_3">82344000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-3" id="id_9807917_CB670FC1-3C25-42EA-BCBC-231905970377_3001_2">96479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1642993x1703828" unitRef="pure" decimals="3" id="id_9807917_11044BA5-F7D4-4FDB-BCF8-4EA868FE13E1_2001_0">0.164</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:SharesIssued contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_8001_400042">28823549</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1632657" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_8001_500041">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_8004_700041">-161340000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_8003_600041">335032000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE925099--1510-K0012_STD_0_20160112_0_1636141x1633766" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_A8EFF925-D29E-4C83-9EB1-AB3E285C8367_1001_1">47.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20140212_0_1641810x1633314" unitRef="iso4217_USD" decimals="-5" id="id_9807917_64715BCF-C385-435F-9DB5-31692FF27F21_1_2">5000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="eol_PE925099--1510-K0012_STD_1_20141101_0" unitRef="pure" decimals="INF" id="id_9807917_839EB9BD-6629-44FE-A89F-2018205A7C54_1_0">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="eol_PE925099--1510-K0012_STD_1_20141101_0" unitRef="pure" decimals="INF" id="id_9807917_839EB9BD-6629-44FE-A89F-2018205A7C54_1_1">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20130318_0_1637024x1666381_1641810x1641034" unitRef="iso4217_USD" decimals="-5" id="id_9807917_A591513B-683C-45D2-BAAE-1379CC883F75_1001_2">5000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20140311_0_1641810x1637021" unitRef="iso4217_USD" decimals="-5" id="id_9807917_AEBEB7C8-98C9-46CF-805D-A84B0FBB37FD_1_2">38000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_1_20150420_0" unitRef="shares" decimals="INF" id="id_9807917_B28010D9-58E6-404C-AA6B-FEFF5F6262AE_1_0">2628571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE925099--1510-K0012_STD_1_20150420_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B28010D9-58E6-404C-AA6B-FEFF5F6262AE_1_2">129100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20130701_0_1637024x1666381_1641810x1641034" unitRef="iso4217_USD" decimals="-5" id="id_9807917_9D3C4D9D-92A2-4DA7-A3E8-50ACDE9FC6ED_1001_2">5000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE925099--1510-K0012_STD_1_20140702_0" unitRef="pure" decimals="4" id="id_9807917_527705E3-E005-4C71-A02A-1079181CC238_2_2">0.3175</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <sage:CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption contextRef="eol_PE925099--1510-K0012_STD_1_20140702_0_1639304x1633605_1639657x1734414" unitRef="pure" decimals="INF" id="id_9807917_F6CD9E02-64AC-4F52-B803-8072A059B663_1001_0">0.04</sage:CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE925099--1510-K0012_STD_1_20140723_0" unitRef="shares" decimals="INF" id="id_9807917_527705E3-E005-4C71-A02A-1079181CC238_1_3">18007575</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_1_20140723_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_A3DF5A72-B9ED-464F-88AF-1BF3056C7BE9_1_0">2300000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE925099--1510-K0012_STD_1_20140723_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D8FBE533-ED87-4EEF-AAB5-BC9F37279AF1_3_2">94000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_1_20140723_0_1637033x1634411" unitRef="shares" decimals="INF" id="id_9807917_9B5BF914-E9FD-46EC-ABF0-2D00AFFDEE76_1001_0">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE925099--1510-K0012_STD_1_20140723_0_1637033x1634411" unitRef="iso4217_USD" decimals="-5" id="id_9807917_9B5BF914-E9FD-46EC-ABF0-2D00AFFDEE76_1001_2">94000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20130912_0_1637024x1765361_1641810x1641034" unitRef="iso4217_USD" decimals="-5" id="id_9807917_2E066A98-4743-47BD-9B8C-97C47C986EE2_1001_2">12500000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20131018_0_1641810x1641034" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B0861C68-BF23-459C-8A3B-E23854923890_1001_2">300000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_1_20140107_0_1641810x1633314" unitRef="iso4217_USD" decimals="-5" id="id_9807917_0854DA5D-972E-430B-8B89-7DE3FF8BA2E5_1001_2">10000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_1_20160112_0_1636141x1633766" unitRef="shares" decimals="INF" id="id_9807917_A8EFF925-D29E-4C83-9EB1-AB3E285C8367_1_0">3157894</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE925099--1510-K0012_STD_1_20160112_0_1636141x1633766" unitRef="iso4217_USD" decimals="-5" id="id_9807917_A8EFF925-D29E-4C83-9EB1-AB3E285C8367_1_2">140400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <sage:UpfrontNonrefundablePayment contextRef="eol_PE925099--1510-K0012_STD_30_20131130_0_1632078x1930456" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7665D46B-1E1A-46FD-8B6F-0F3D3D927D93_1001_0">50000</sage:UpfrontNonrefundablePayment>
  <sage:LicenseMaintenanceCostAnnual contextRef="eol_PE925099--1510-K0012_STD_30_20131130_0_1632078x1930456" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7665D46B-1E1A-46FD-8B6F-0F3D3D927D93_1001_1">15000</sage:LicenseMaintenanceCostAnnual>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_30_20150430_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_A3DF5A72-B9ED-464F-88AF-1BF3056C7BE9_2_0">500000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <sage:UpFrontPayment contextRef="eol_PE925099--1510-K0012_STD_30_20150630_0_1632078x1815931" unitRef="iso4217_USD" decimals="-3" id="id_9807917_FBB1BCC7-8364-4F4F-965A-7190F88DFE21_1001_0">50000</sage:UpFrontPayment>
  <sage:LicenseMaintenanceCostAnnual contextRef="eol_PE925099--1510-K0012_STD_30_20150630_0_1632078x1815931" unitRef="iso4217_USD" decimals="-3" id="id_9807917_FBB1BCC7-8364-4F4F-965A-7190F88DFE21_1001_1">15000</sage:LicenseMaintenanceCostAnnual>
  <sage:MaximumMilestonePayments contextRef="eol_PE925099--1510-K0012_STD_31_20140131_0_1632078x1773506_1634968x1767662" unitRef="iso4217_USD" decimals="INF" id="id_9807917_CADA1091-2E8E-4F9B-BB9B-B4B8C6086269_1001_0">2000000</sage:MaximumMilestonePayments>
  <sage:MaximumMilestoneShareBasedPayments contextRef="eol_PE925099--1510-K0012_STD_31_20140131_0_1632078x1773506_1634968x1767662" unitRef="shares" decimals="INF" id="id_9807917_CADA1091-2E8E-4F9B-BB9B-B4B8C6086269_1001_1">126984</sage:MaximumMilestoneShareBasedPayments>
  <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue contextRef="eol_PE925099--1510-K0012_STD_31_20130331_0_1639226x1913817" unitRef="iso4217_USD" decimals="-3" id="id_9807917_F94445FE-206D-49FF-A159-5362F6146A78_2002_3">4000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
  <sage:AreaOfLeasedProperty contextRef="eol_PE925099--1510-K0012_STD_31_20130331_0_1639226x1913817" unitRef="sqft" decimals="INF" id="id_9807917_F94445FE-206D-49FF-A159-5362F6146A78_2002_2">1900</sage:AreaOfLeasedProperty>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_11">-17516000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_3_3">P6Y15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_4">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_3_2">0.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_10">-12.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" id="id_9807917_2104B254-2DDA-4764-87A9-DFEA9F45C954_2_1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_6">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_3_5">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="INF" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_0">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_3_1">0.9989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_5">-0.405</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_1">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_3_0">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_3_6">1492288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_3_4">1492288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_94144CFB-9928-4326-89CD-761E16969B6D_3_0">0.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="shares" decimals="0" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_11">1492288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_7">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_13">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_7">-18281000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4005_800003">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_9">-18288000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_5">1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4005_800010">61000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4005_800005">20000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_7">317000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_4">-18279000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_6">-3000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4005_800007">-7000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4005_800008">64000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_BBFDE3B6-B22D-43EC-9785-4974FA60FF53_3_1">1403000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_3">61000</us-gaap:ShareBasedCompensation>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_8">7000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_98EE6CED-9C15-48A6-887F-9FA7F6AACF59_3_0">300000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_23">5264000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_3">18279000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_14">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_22">22783000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_1">14357000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_3_2">61000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_10">236000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_19">51000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_3_2">3922000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_9">674000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:Depreciation contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_5">47000</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_949F6B65-499F-4009-9B7E-7B088548E2B1_3_0">47000</us-gaap:DepreciationDepletionAndAmortization>
  <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_9807917_36046CCB-5A66-4499-B69D-C5CC86B83B66_3_0">0.10</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate>
  <sage:LicensingOrConsultantFeesPaidInCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3_4">64000</sage:LicensingOrConsultantFeesPaidInCommonStock>
  <sage:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_3_2">0.001</sage:EffectiveIncomeTaxRateReconciliationPermanentItems>
  <sage:MilestonePaymentsExpensedDuringPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_D377B2E0-02DF-4B4E-9912-7E448EF01F3A_3_2">0</sage:MilestonePaymentsExpensedDuringPeriod>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="INF" id="id_9807917_692DF8DC-D192-4FA1-88FC-A0ECB3BDDEBB_1003_600001">0</sage:MilestonePayments>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="INF" id="id_9807917_692DF8DC-D192-4FA1-88FC-A0ECB3BDDEBB_1003_600000">0</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1632078x1930456" unitRef="iso4217_USD" decimals="-5" id="id_9807917_7665D46B-1E1A-46FD-8B6F-0F3D3D927D93_1004_4">100000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <sage:IssueOfCommonStockObligation contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1632078x1930456" unitRef="shares" decimals="INF" id="id_9807917_7665D46B-1E1A-46FD-8B6F-0F3D3D927D93_1004_3">47619</sage:IssueOfCommonStockObligation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1634394x1639948" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_1003_1">23000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1634394x1642216" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_2003_0">38000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_7003_600004">18000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_3003_16">22732000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034_1643450x1671852" unitRef="shares" decimals="INF" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_7001_400005">22750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_7001_500003">22732000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_7001_500006">7000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1632468" unitRef="shares" decimals="0" id="id_9807917_2F578199-D12C-4441-BE1D-7FCBB251C6F7_1003_0">130158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1632468" unitRef="iso4217_USD" decimals="-3" id="id_9807917_CBCE53E7-623A-4607-8670-08FC90F1A78E_1003_1">11000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1632468" unitRef="iso4217_USD" decimals="-3" id="id_9807917_2F578199-D12C-4441-BE1D-7FCBB251C6F7_1003_1">50000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-3" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1003_3">9000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1003_4">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1642993x1703828" unitRef="iso4217_USD" decimals="-3" id="id_9807917_11044BA5-F7D4-4FDB-BCF8-4EA868FE13E1_1004_1">600000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1632657" unitRef="shares" decimals="0" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4001_400006">176695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4001_400004">3174</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4001_400009">47619</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4004_700011">-18281000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4003_600003">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4003_600010">61000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4003_600005">20000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4003_600007">-7000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_4003_600008">64000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_11">-27042000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_2_3">P6Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_2_4">-0.085</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_2_2">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_10">-1.67</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_2_3">1791973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="shares" decimals="INF" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_2_5">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="INF" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_2_0">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_2_1">0.9886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_2_5">-0.460</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_2_1">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_2_0">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_2_6">21574347</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_2_4">21574347</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_94144CFB-9928-4326-89CD-761E16969B6D_2_0">14.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="shares" decimals="0" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_11">21574347</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_2_7">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_13">128000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_7">-33811000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6005_800014">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_9">-36105000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_5">8000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6005_800020">2512000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6005_800016">14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_7">715000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_4">-33810000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_6">-9000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6005_800021">-2294000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_21">2285000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6005_800018">127000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_3">2512000</us-gaap:ShareBasedCompensation>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_8">2294000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_839EB9BD-6629-44FE-A89F-2018205A7C54_2_3">15000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_BBFDE3B6-B22D-43EC-9785-4974FA60FF53_2_2">2880000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_98EE6CED-9C15-48A6-887F-9FA7F6AACF59_2_0">300000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_23">119700000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_3">33810000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_14">-128000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_22">146870000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_1">24100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_20">96255000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_2_2">2512000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_10">4353000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_19">40000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_2_2">9710000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_28">92863000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_9">441000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:Depreciation contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_5">51000</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_949F6B65-499F-4009-9B7E-7B088548E2B1_2_0">100000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DividendsCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_40FACEA0-F8D2-4047-9C78-973ED49E63ED_2_2">0</us-gaap:DividendsCommonStock>
  <sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6005_800022">92863000</sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends>
  <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="2" id="id_9807917_36046CCB-5A66-4499-B69D-C5CC86B83B66_2_0">0.10</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate>
  <sage:LicensingOrConsultantFeesPaidInCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2_4">127000</sage:LicensingOrConsultantFeesPaidInCommonStock>
  <sage:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_2_2">0.010</sage:EffectiveIncomeTaxRateReconciliationPermanentItems>
  <sage:MilestonePaymentsExpensedDuringPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_D377B2E0-02DF-4B4E-9912-7E448EF01F3A_2_2">0</sage:MilestonePaymentsExpensedDuringPeriod>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1773506_1634968x1973966" unitRef="iso4217_USD" decimals="-3" id="id_9807917_DD06B85D-C480-4C70-805C-113C81D2724E_1001_1">50000</sage:MilestonePayments>
  <sage:MilestoneBasedShareCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1773506_1634968x1973966" unitRef="shares" decimals="INF" id="id_9807917_DD06B85D-C480-4C70-805C-113C81D2724E_1001_3">15872</sage:MilestoneBasedShareCompensation>
  <sage:MilestoneStockCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1773506_1634968x1973966" unitRef="iso4217_USD" decimals="-5" id="id_9807917_DD06B85D-C480-4C70-805C-113C81D2724E_1001_2">100000</sage:MilestoneStockCompensation>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1773506_1634968x1973966" unitRef="iso4217_USD" decimals="-5" id="id_9807917_DD06B85D-C480-4C70-805C-113C81D2724E_1001_0">200000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="INF" id="id_9807917_692DF8DC-D192-4FA1-88FC-A0ECB3BDDEBB_1002_500001">0</sage:MilestonePayments>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="INF" id="id_9807917_692DF8DC-D192-4FA1-88FC-A0ECB3BDDEBB_1002_500000">0</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1930456_1634968x1702458" unitRef="iso4217_USD" decimals="INF" id="id_9807917_0F32CDEC-4FBF-4C05-BBD7-3D34DD29D52D_1002_500001">0</sage:MilestonePayments>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1930456_1634968x1702458" unitRef="iso4217_USD" decimals="INF" id="id_9807917_0F32CDEC-4FBF-4C05-BBD7-3D34DD29D52D_1002_500000">0</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1634394x1639948" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_1002_1">1419000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1634394x1642216" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_2002_0">1093000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_7005_800024">93970000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_7001_400025">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411_1643450x1632657" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_7001_500024">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_7003_600024">93969000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1639081x1633925" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_2002_0">1621906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1639081x1944181" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_3002_1">170067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1633314" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_10003_600011">30000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1633314" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1002_17">14970000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1633314_1643450x1671852" unitRef="shares" decimals="INF" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_10001_400010">9999999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1633314_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_10001_500009">14970000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1637021" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_11003_600014">110000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1637021" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_2002_18">37890000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1637021_1643450x1671852" unitRef="shares" decimals="INF" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_11001_400013">8973905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1637021_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_11001_500012">37890000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1632468" unitRef="shares" decimals="INF" id="id_9807917_2F578199-D12C-4441-BE1D-7FCBB251C6F7_1002_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1632468" unitRef="shares" decimals="INF" id="id_9807917_67E778B5-A018-4B95-90F2-76DB10758579_1001_0">6778</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1632468" unitRef="iso4217_USD" decimals="-5" id="id_9807917_CBCE53E7-623A-4607-8670-08FC90F1A78E_1002_0">200000</us-gaap:AllocatedShareBasedCompensationExpense>
  <sage:SharesRepurchasePricePerShare contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1632468" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9807917_67E778B5-A018-4B95-90F2-76DB10758579_1001_1">0.04</sage:SharesRepurchasePricePerShare>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1633925" id="id_9807917_9D6DD309-CB13-4B08-824A-B5AC1FF796F6_1001_1">P8Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1002_2">1000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1002_4">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1642993x1703828" unitRef="iso4217_USD" decimals="-3" id="id_9807917_11044BA5-F7D4-4FDB-BCF8-4EA868FE13E1_1003_1">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1632657" unitRef="shares" decimals="0" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6001_400017">138108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6001_400015">87475</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6001_400019">15872</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1632657" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6001_500022">2000</sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends>
  <sage:StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1632657" unitRef="shares" decimals="0" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6001_400023">18007575</sage:StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6004_700026">-33811000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6004_700021">-1359000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6003_600014">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6003_600020">2512000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6003_600016">14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6003_600021">-935000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6003_600018">127000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_6003_600022">92861000</sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_9001_500015">2294000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1671852" unitRef="iso4217_USD" decimals="-3" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_9001_500016">-92863000</sage:StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends>
  <sage:StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1671852" unitRef="shares" decimals="0" id="id_9807917_809CDABE-E62F-4B62-B104-AE827FF5B1FF_9001_400017">-56723904</sage:StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E0FFFDD7-179A-4A35-BC63-2D88621D15F7_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_11">-70681000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_1_3">P6Y11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_7C5D5F0F-E402-4EF3-96BA-4537326E81E9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Significant components of the Company&amp;#x2019;s net deferred tax
 asset at December&amp;#xA0;31, 2015 and 2014 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net operating losses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Capitalized start-up costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accounting method change&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,020&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tax credit carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,062&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;494&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;716&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,097&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Others&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total net deferred tax asset before valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;69,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,303&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(69,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,303&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_3">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_4">-0.090</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E0FFFDD7-179A-4A35-BC63-2D88621D15F7_1_3">2015</dei:DocumentFiscalYearFocus>
  <dei:AmendmentFlag contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E0FFFDD7-179A-4A35-BC63-2D88621D15F7_1_1">false</dei:AmendmentFlag>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_B27E5F3A-62DD-436C-A047-D83E6E09FCD6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The table below summarizes activity relating to restricted
 stock:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December 31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170,832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Issued&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(128,051&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Repurchased&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December 31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_1_2">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:IncomeTaxExaminationDescription contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_7A91A8F9-7C01-4F04-AE45-5D95D6B11A8E_1_0">For tax positions  meeting the more likely than not threshold, the tax amount recognized in the  financial statements is reduced by the largest benefit that has a greater than  fifty percent likelihood of being realized upon the ultimate settlement with the  relevant taxing authority.</us-gaap:IncomeTaxExaminationDescription>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_77A35438-3BB6-4F82-8900-89890B274B5F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment Data&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company manages its operations as a single segment for the
 purposes of assessing performance and making operating decisions.
 The Company&amp;#x2019;s singular focus is on advancing medicines to
 treat central nervous system disorders, where there are inadequate
 or no approved existing therapies. All tangible assets are held
 within the United States.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_10">-3.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_959FA428-AE9B-4C57-B2A6-441462ADD588_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are recorded at cost and depreciated over
 their estimated useful lives using the straight-line method. Upon
 retirement or sale, the cost of assets disposed of and the related
 accumulated depreciation are removed from the accounts and any
 resulting gain or loss is credited or charged to income. Repairs
 and maintenance costs are expensed as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_A2478CAC-0691-47EC-9921-8A42CA32C31B_1_0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_1_3">2689921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_50A4A0C8-9274-4F87-8BE9-C28BD0DD9A2C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 A deposit of $39 thousand was restricted from withdrawal as of
 December&amp;#xA0;31, 2015 and 2014. The restriction is related to
 securing the Company&amp;#x2019;s facility lease and expires in 2022 in
 accordance with the operating lease agreement. This balance is
 included in restricted cash on the accompanying balance sheets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <dei:DocumentType contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E0FFFDD7-179A-4A35-BC63-2D88621D15F7_1_0">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_2">0001597553</dei:EntityCentralIndexKey>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_1502F676-9F96-4C5A-BDBE-21196CD4536A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents outstanding as of
 December&amp;#xA0;31, 2015 and 2014, were excluded from the computation
 of diluted net loss per share attributable to common stockholders
 for the periods presented because including them would have been
 anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,643,833&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,621,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee Stock Purchase Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,689,921&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,791,973&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_58B585C8-7B41-4266-8D2E-2B0136743C50_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss includes net loss as well as other changes in
 stockholders&amp;#x2019; equity (deficit) that result from transactions
 and economic events other than those with stockholders. For the
 years ended December&amp;#xA0;31, 2015, 2014 and 2013, there was no
 difference between net loss and comprehensive loss.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_6">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <dei:EntityFilerCategory contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_7">Large Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_50B677BB-34DB-48DC-8FF1-A3F595105DC1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenses are comprised of costs incurred
 in performing research and development activities, including
 salaries and benefits, overhead costs, depreciation, contract
 services and other related costs. Research and development costs
 are expensed to operations as the related obligation is
 incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_55A8CBD0-7FCD-45A3-B128-98D0ED054A62_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying consolidated financial statements include those of
 the Company and its subsidiaries after elimination of all
 intercompany accounts and transactions. The accompanying
 consolidated financial statements have been prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&amp;#x201C;GAAP&amp;#x201D;).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="shares" decimals="INF" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_1_5">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="INF" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_0">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E6021AC0-7121-4197-99AA-D1E97ED884B7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk and of Significant
 Suppliers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist primarily of cash and cash
 equivalents. The Company has all cash and cash equivalents balances
 at two accredited financial institutions, in amounts that exceed
 federally insured limits. The Company does not believe that it is
 subject to unusual credit risk beyond the normal credit risk
 associated with commercial banking relationships.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is dependent on third-party manufacturers to supply
 products for research and development activities in its programs.
 In particular, the Company relies and expects to continue to rely
 on a small number of manufacturers to supply it with its
 requirements for the active pharmaceutical ingredients and
 formulated drugs related to these programs. These programs could be
 adversely affected by a significant interruption in the supply of
 active pharmaceutical ingredients and formulated drugs.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E7BEABA6-BE3A-4DAE-9AB6-6389C726F526_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Nature of the Business&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Sage Therapeutics, Inc. (&amp;#x201C;Sage&amp;#x201D; or the
 &amp;#x201C;Company&amp;#x201D;) is a clinical-stage biopharmaceutical
 company committed to developing and commercializing novel medicines
 to treat life-altering central nervous system (&amp;#x201C;CNS&amp;#x201D;)
 disorders, where there are inadequate or no approved existing
 therapies. The Company is targeting CNS indications where patient
 populations are easily identified, clinical endpoints are
 well-defined, and development pathways are feasible.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company was incorporated under the laws of the state of
 Delaware on April&amp;#xA0;16, 2010 and commenced operations on
 January&amp;#xA0;19, 2011 as Sterogen Biopharma, Inc. On
 September&amp;#xA0;13, 2011, the Company changed its name to Sage
 Therapeutics, Inc. under its Second Amended and Restated
 Certificate of Incorporation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is subject to risks and uncertainties common to
 companies in the biotech industry, including, but not limited to,
 the risks associated with developing product candidates at each
 stage of non-clinical and clinical development; the challenges
 associated with gaining regulatory approval of such product
 candidates; the risks associated with commercializing
 pharmaceutical products, if we are able to obtain regulatory
 approval; the potential for development by third parties of new
 technological innovations that may compete with the Company&amp;#x2019;s
 products; the dependence on key personnel; the challenges of
 protecting proprietary technology; the need to comply with
 government regulations; the high costs of drug development; and the
 uncertainty of being able to secure additional capital when needed
 to fund operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has incurred losses and negative cash flows from
 operations since its inception. As of December&amp;#xA0;31, 2015, the
 Company had an accumulated deficit of $161.3 million. From its
 inception through December&amp;#xA0;31, 2015, the Company has raised
 aggregate net proceeds of $90.6 million from the issuance of Series
 A, Series B and Series C redeemable convertible preferred stock. In
 July 2014, the Company raised net proceeds of $94.0 million from
 the sale of common stock in its initial public offering,
 (&amp;#x201C;IPO&amp;#x201D;). In April 2015, the Company raised net proceeds
 of $129.1 million from the sale of common stock in a follow-on
 underwritten public offering. In January 2016, the Company raised
 net proceeds of $140.4 million from the sale of common stock in a
 follow-on underwritten public offering. Based on its current
 operating plans, the Company believes its cash and cash equivalents
 balance of $186.8 million as of December&amp;#xA0;31, 2015, in addition
 to the funds raised from the public offering of common stock in
 January 2016, will be sufficient to fund its anticipated level of
 operations into the beginning of 2018.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_1C5FF498-4A96-44F5-8B4E-15B9DDDBA441_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company capitalizes certain legal, accounting and other
 third-party fees that are directly associated with in-process
 equity financings as other assets until such financings are
 consummated. After consummation of the IPO in July 2014, $2.3
 million of these costs were recorded in stockholders&amp;#x2019; equity
 as a reduction of additional paid-in capital generated as a result
 of the IPO. After consummation of the follow-on public offering of
 common stock in April 2015, $0.5 million of these costs were
 recorded in stockholders&amp;#x2019; equity as a reduction of additional
 paid-in capital generated as a result of the offering. As of
 December&amp;#xA0;31, 2015, the Company had recorded deferred offering
 costs of $0.2 million which are shown as a non-current asset. They
 are for the follow-on public offering that was consummated in
 January 2016.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_A62B937F-7844-49EB-8A4A-53EBF52A3738_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Selected Quarterly Financial Data
 (Unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table contains quarterly financial information for
 2015 and 2014. The Company believes that the following information
 reflects all normal recurring adjustments necessary for a fair
 statement of the information for the periods presented. The
 operating results for any quarter are not necessarily indicative of
 results for any future period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;First&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Second&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Third&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fourth&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;(in thousands,
 except per share amounts)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loss from operations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss and comprehensive loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,871&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,871&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;First&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Second&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Third&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fourth&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;(in thousands,
 except per share amounts)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loss from operations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss and comprehensive loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_CA930BAD-5BBC-4665-8487-78C607602120_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,788&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee related expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Professional services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_1_1">0.9054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:CommonStockVotingRights contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_40FACEA0-F8D2-4047-9C78-973ED49E63ED_1_3">Each share of common stock entitles the holder to one vote on all matters  submitted to a vote of the Company&apos;s stockholders.</us-gaap:CommonStockVotingRights>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_5">-0.431</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_2104B254-2DDA-4764-87A9-DFEA9F45C954_1_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_527705E3-E005-4C71-A02A-1079181CC238_3_0">In connection with preparing for the IPO, the Company&apos;s board of directors and  stockholders approved a 1-for-3.15 reverse stock split of the Company&apos;s common  stock</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_1">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_48F43828-45FB-4092-9BF1-AB5A9536A694_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Property and equipment, net consists of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Life&lt;br /&gt;
 (Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer hardware and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;400&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;163&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_F34A8607-6B2F-4A87-8C1A-F4651399610E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted net income (loss) per share attributable to
 common stockholders was calculated as follows for the years ended
 December&amp;#xA0;31, 2015, 2014 and 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic net loss per share attributable to common stockholders:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders
 (in&amp;#xA0;thousands)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Weighted average shares of common stock outstanding&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,778,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,574,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,492,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Dilutive effect of shares of common stock equivalents resulting
 from common stock options and preferred common stock (as
 converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Weighted average common stock outstanding&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,778,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,574,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,492,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_CFEB254F-B562-4889-BCC7-A650DEA6597F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense recognized during the years ended
 December&amp;#xA0;31, 2015, 2014, and 2013 was as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Stock-based compensation expense:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,924&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,093&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,316&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_9807917_71D92B68-6175-44B7-85DD-4CEBDCA3209C_1_0">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_5">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityRegistrantName contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_1">Sage Therapeutics, Inc.</dei:EntityRegistrantName>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_B4FC338D-D843-4FB1-BE89-82A733A0C569_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table contains quarterly financial information for
 2015 and 2014. The Company believes that the following information
 reflects all normal recurring adjustments necessary for a fair
 statement of the information for the periods presented. The
 operating results for any quarter are not necessarily indicative of
 results for any future period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;First&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Second&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Third&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fourth&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;(in thousands,
 except per share amounts)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loss from operations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25,059&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,612&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss and comprehensive loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,871&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,871&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,035&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.84&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;First&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Second&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Third&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fourth&lt;br /&gt;
 Quarter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;(in thousands,
 except per share amounts)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loss from operations&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss and comprehensive loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,769&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_FEEB75C2-43D3-43DB-8154-89710B948B63_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following is a rollforward of the Company&amp;#x2019;s unrecognized
 tax benefits:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefits&amp;#x2014;as of the beginning of the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gross increases&amp;#x2014;current period tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gross decreases&amp;#x2014;tax positions of prior periods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefits&amp;#x2014;as of the end of the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_C88FFA51-CBAD-47A1-9AD5-F9A30FF888F4_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Employee Benefit Plan&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company maintains a 401(k) profit sharing plan (the
 &amp;#x201C;Plan&amp;#x201D;) for its employees. Each participant in the Plan
 may elect to contribute a portion of his or her annual compensation
 to the Plan subject to annual limits established by the Internal
 Revenue Service. Effective November&amp;#xA0;1, 2014, the Company
 instituted an employer match of 50% of eligible contributions up to
 6% of employee contributions. For the years ended December&amp;#xA0;31,
 2015 and 2014, the Company contributed $0.2 million and $15
 thousand, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_4">Yes</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="shares" decimals="0" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_1_6">27778288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_614D71EC-4A2F-4107-83F6-1659F3BCD8EC_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 There is no provision for income taxes because the Company has
 historically incurred operating losses and maintains a full
 valuation allowance against its net deferred tax assets. The
 reported amount of income tax expense for the years differs from
 the amount that would result from applying domestic federal
 statutory tax rates to pretax losses primarily because of changes
 in valuation allowance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A reconciliation of U.S. statutory rate to the Company&amp;#x2019;s
 effective tax rate is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tax due at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State taxes, net of federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Foreign rate differential&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Federal and state credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(40.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Significant components of the Company&amp;#x2019;s net deferred tax
 asset at December&amp;#xA0;31, 2015 and 2014 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net operating losses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,907&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Capitalized start-up costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accounting method change&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,020&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tax credit carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,062&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;494&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;716&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,097&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Others&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total net deferred tax asset before valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;69,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,303&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(69,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,303&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2015, the Company had federal and state net
 operating loss carryforwards of $131.5&amp;#xA0;million and $130.7
 million, respectively, which begin to expire in 2031. As of
 December&amp;#xA0;31, 2015, the Company had federal and state research
 and development tax credits carryforwards of $1.6 million and $0.7
 million, respectively, which begin to expire in 2031 and 2027,
 respectively. As of December&amp;#xA0;31, 2015, the Company had federal
 orphan drug tax credit carry forwards of $16.4 million, which begin
 to expire in 2034. At December 31, 2015, the Company has excess
 equity based compensation tax deductions related to net operating
 losses for federal and state purposes of $18.9&amp;#xA0;million and
 $18.9 million respectively. The Company has excess equity based
 compensation related to credits for federal and state purposes of
 $1.3 million and $0.2 million, respectively. These excess tax
 benefits have not been included in the net deferred tax assets
 before valuation allowance since these benefits would be credited
 directly to additional paid in capital if subsequently recognized
 through a reduction in taxes payable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2015, net deferred tax assets increased
 approximately $40.8&amp;#xA0;million primarily due to the operating
 loss and tax credits incurred during the year. This increase in net
 deferred tax assets was offset by a corresponding increase in the
 valuation allowance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Management of the Company has evaluated the positive and negative
 evidence bearing upon the realizability of its deferred tax assets,
 which are comprised principally of net operating loss carryforwards
 and capitalized start-up costs. Under the applicable accounting
 standards, management has considered the Company&amp;#x2019;s history of
 losses and concluded that it is more likely than not that the
 Company will not recognize the benefits of federal and state
 deferred tax assets. Accordingly, a full valuation allowance of
 $69.1 million and $28.3 million has been established at
 December&amp;#xA0;31, 2015 and 2014, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Pursuant to Section&amp;#xA0;382 of the Internal Revenue Code, certain
 substantial changes in the Company&amp;#x2019;s ownership may result in
 a limitation on the amount of net operating loss carryforwards and
 tax carryforwards that may be used in future years. Utilization of
 the net operating loss (&amp;#x201C;NOL&amp;#x201D;) and tax credit
 carryforwards may be subject to a substantial annual limitation
 under Section&amp;#xA0;382 of the Internal Revenue Code of 1986 due to
 ownership change limitations that have occurred previously or that
 could occur in the future. These ownership changes may limit the
 amount of NOL and tax credit carryforwards that can be utilized
 annually to offset future taxable income and tax, respectively. The
 Company has not completed a study to assess whether an ownership
 change has occurred, or whether there have been multiple ownership
 changes since its formation, due to significant complexity and
 related costs associated with such a study. There could also be
 additional ownership changes in the future which may result in
 additional limitations on the utilization of NOL carryforwards and
 credits. Further, until a study is completed and any limitation is
 known, no amounts are being presented as an uncertain tax
 position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company applies the authoritative guidance on accounting for
 and disclosure of uncertainty in tax positions, which requires the
 Company to determine whether a tax position of the Company is more
 likely than not to be sustained upon examination, including
 resolution of any related appeals of litigation processes, based on
 the technical merits of the position. For tax positions meeting the
 more likely than not threshold, the tax amount recognized in the
 financial statements is reduced by the largest benefit that has a
 greater than fifty percent likelihood of being realized upon the
 ultimate settlement with the relevant taxing authority.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following is a rollforward of the Company&amp;#x2019;s unrecognized
 tax benefits:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefits&amp;#x2014;as of the beginning of the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gross increases&amp;#x2014;current period tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Gross decreases&amp;#x2014;tax positions of prior periods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefits&amp;#x2014;as of the end of the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 During 2014, the Company filed an application for change in
 accounting method with the IRS to capitalize start-up costs that
 were historically deducted and included as part of the NOL
 carryforward through December&amp;#xA0;31, 2013. As a result, the
 Company&amp;#x2019;s unrecognized tax benefits, which historically
 related to start-up costs, are zero at December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company will recognize interest and penalties related to
 uncertain tax positions in income tax expense when in a taxable
 income position. As of December&amp;#xA0;31, 2015 and 2014, the Company
 had no accrued interest or penalties related to uncertain tax
 positions and no amounts have been recognized in the
 Company&amp;#x2019;s statement of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company files tax returns as prescribed by the tax laws of the
 jurisdictions in which it operates. In the normal course of
 business, the Company is subject to examination by federal and
 state jurisdictions, where applicable. There are currently no
 pending tax examinations, and the Company&amp;#x2019;s tax returns are
 open under statute from 2012 to the present. The tax attributes
 prior to 2012 may still be adjusted upon examination. The
 Company&amp;#x2019;s policy is to record interest and penalties related
 to income taxes as part of the tax provision.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During November 2015, the FASB issued ASU 2015-17, Balance Sheet
 Classification of Deferred Taxes, which simplifies the presentation
 of deferred income taxes. This ASU requires that deferred tax
 assets and liabilities be classified as non-current in a statement
 of financial position. The standard is effective for public
 companies for fiscal years beginning after December&amp;#xA0;31, 2016,
 including interim periods within that reporting period. Early
 adoption is permitted for any interim and annual financial
 statements that have not yet been issued. The Company early adopted
 ASU 2015-17 effective December&amp;#xA0;31, 2015 on a prospective
 basis. Adoption of this ASU resulted in a reclassification of the
 current deferred tax liability to a non-current deferred tax
 liability, which is netted with the long-term deferred tax asset in
 its consolidated balance sheet as of December&amp;#xA0;31, 2015. No
 prior periods were retrospectively adjusted.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_C90F4F5B-0394-478C-AB85-A73EF6251B4B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A reconciliation of U.S. statutory rate to the Company&amp;#x2019;s
 effective tax rate is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tax due at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State taxes, net of federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Permanent items&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Foreign rate differential&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Federal and state credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(40.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_4B9A1912-16E8-4EFF-B40A-CBE8023AE2E2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The table below summarizes activity related to stock options:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="47%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;br /&gt;
 Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&amp;#xA0;Life&amp;#xA0;(in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,996,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,516,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(417,475&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(92,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,002,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,479&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested or expected to vest as of December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,421,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;82,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable as of December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;723,895&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,729&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <dei:EntityVoluntaryFilers contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_6">No</dei:EntityVoluntaryFilers>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_CC931959-7C1B-4C80-A6E8-D48C802CFD66_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Long-lived assets consist of property and equipment. Long-lived
 assets to be held and used are tested for recoverability whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. Factors
 that the Company considers in deciding when to perform an
 impairment review include significant underperformance of the
 business in relation to expectations, significant negative industry
 or economic trends, and significant changes or planned changes in
 the use of the assets. If an impairment review is performed to
 evaluate a long-lived asset for recoverability, the Company
 compares forecasts of undiscounted cash flows expected to result
 from the use and eventual disposition of the long-lived asset to
 its carrying value. An impairment loss would be recognized when
 estimated undiscounted future cash flows expected to result from
 the use of an asset are less than its carrying amount. The
 impairment loss would be based on the excess of the carrying value
 of the impaired asset over its fair value, determined based on
 discounted cash flows. To date, the Company has not recorded any
 impairment losses on long-lived assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_3E457B58-5A2A-47A3-9EA0-90E572124AB2_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company rents its 22,067 square foot office space under an
 operating lease that was expires in 2022. In March 2013, the
 Company signed a sublease agreement to sublet 1,900 square feet.
 Rental income from this sublease was $4 thousand per month. In
 September, 2015, this sublease was terminated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Rent expense, net of sublease income, for the years ended
 December&amp;#xA0;31, 2015, 2014, and 2013, was $0.4 million, $0.3
 million, and $0.3 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Future minimum lease payments under non-cancelable operating leases
 are as follows at December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 95.55pt"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,088&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,398&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,926&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;CyDex License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In September 2015, the Company and CyDex Pharmaceuticals, Inc.
 (&amp;#x201C;CyDex&amp;#x201D;) amended and restated their existing
 commercial license agreement. Under the terms of the commercial
 license agreement as amended and restated, CyDex has granted to the
 Company an exclusive license to CyDex&amp;#x2019;s Captisol drug
 formulation technology and related intellectual property for the
 manufacture of pharmaceutical products incorporating the
 Company&amp;#x2019;s compounds known as SAGE-547 and SAGE-689, and the
 development and commercialization of the resulting products in the
 treatment, prevention or diagnosis of any disease or symptom in
 humans or animals other than (i)&amp;#xA0;the ocular treatment of any
 disease or condition with a formulation, including a hormone;
 (ii)&amp;#xA0;topical ocular treatment of inflammatory conditions;
 (iii)&amp;#xA0;treatment and prophylaxis of fungal infections in
 humans; and (iv)&amp;#xA0;any ocular treatment for retinal
 degeneration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As consideration for the inclusion of SAGE-689 in the license
 granted by CyDex, the Company paid to CyDex $0.1 million, which was
 recorded as research and development expense in 2015 in connection
 with execution of the amended and restated license agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company is obligated to make milestone payments under the
 amended and restated license agreement with CyDex based on the
 achievement of clinical development and regulatory milestones in
 the amount of $0.8 million in clinical milestones and $3.8 million
 in regulatory milestones for each of the first two fields with
 respect to SAGE-547; $1.3 million in clinical milestones and $8.5
 million in regulatory milestones for each of the third and fourth
 fields with respect to SAGE-547; and $0.8 million in clinical
 milestones and $1.8 million in regulatory milestones for one field
 with respect to SAGE-689.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 For the year ended December&amp;#xA0;31, 2015, the Company recorded
 research and development expense and made payments of cash of $0.8
 million related to clinical development milestones that were met
 for this agreement. For the years ended December&amp;#xA0;31, 2014 and
 2013, the Company did not record any expense or make any milestone
 or royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Washington University License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In November 2013, the Company entered into a license agreement with
 Washington University whereby the Company was granted exclusive,
 worldwide rights to develop and commercialize a novel set of
 neuroactive steroids developed by Washington University. In
 exchange for development and commercialization rights, the Company
 paid an upfront, non-refundable payment of $50 thousand and is
 required to pay an annual license maintenance fee of $15 thousand
 on each subsequent anniversary date, until the first Phase 2
 clinical trial for a licensed product is initiated. The Company is
 obligated to make milestone payments to Washington University based
 on achievement of clinical development and regulatory milestones of
 up to $0.7 million and $0.5 million, respectively. Additionally,
 the Company fulfilled its obligation to issue to Washington
 University 47,619 shares of common stock on December&amp;#xA0;13, 2013.
 The fair value of these shares totaling $0.1 million was recorded
 as research and development expense in 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company is obligated to pay royalties to Washington University
 at rates in the low single digits on net sales of licensed products
 covered under patent rights and royalties at rates in the low
 single digits on net sales of licensed products not covered under
 patent rights. Additionally, the Company has the right to
 sublicense and is required to make payments at varying percentages
 of sublicensing revenue received, initially in the mid-teens and
 descending to the mid-single digits over time.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 For the year ended December&amp;#xA0;31, 2014, the Company did not
 record any expense or make any milestone or royalty payments. In
 September 2015, a regulatory milestone was met for one of the
 programs. Accordingly, the Company recorded research and
 development expenses and made a cash payment of $50 thousand in
 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;University of California License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In October 2013, the Company entered into a non-exclusive license
 agreement with The Regents of the University of California whereby
 the Company was granted a non-exclusive license to certain clinical
 data and clinical material for use in the development and
 commercialization of biopharmaceutical products in the licensed
 field, including status epilepticus and post-partum depression. In
 May 2014, the license agreement was amended to add the treatment of
 essential tremor to the licensed field of use, materials and
 milestone fee provisions of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company will be required to pay to The Regents of the
 University of California clinical development milestones of up to
 $0.1 million and pay royalties of less than 1% on net sales for a
 period of fifteen years following the sale of the first commercial
 product.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The license will terminate on the earlier to occur of (i)&amp;#xA0;27
 years after the effective date or (ii)&amp;#xA0;15 years after the
 last-derived product is first commercially sold.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 For the years ended December 31, 2014 and 2013, the Company did not
 record any expense or make any milestone or royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During 2015, three clinical development milestones were met.
 Accordingly, the Company recorded research and development expenses
 and made cash payments totaling $0.1 million. In June 2015, the
 Company entered into an exclusive license agreement with The
 Regents of the University of California whereby the Company was
 granted an exclusive license to certain patent rights related to
 the use of allopregnanolone to treat various diseases. In exchange
 for such license, the Company paid an upfront payment of $50
 thousand and will make annual maintenance fees of $15 thousand
 until the calendar year following the first sale, if any, of a
 licensed product. The Company is obligated to make milestone
 payments following the achievement of specified regulatory and
 sales milestones of up to $0.7 million and $2.0 million in the
 aggregate, respectively. Following the first sale, if any, of a
 licensed product, the Company is obligated to pay royalties at a
 low single digit percentage of net sales, if any, of licensed
 products, subject to specified minimum annual royalty amounts.
 Unless terminated by operation of law or by acts of the parties
 under the terms of the agreement, the license agreement will
 terminate when the last-to-expire patents or last-to-be abandoned
 patent applications expire, whichever is later.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Consulting Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In January 2014, the Company entered into a consulting agreement
 with a nonemployee advisor whereby the Company is obligated to make
 cash payments of up to $2.0 million and to issue up to 126,984
 shares of common stock upon attainment of certain clinical
 development and regulatory milestones.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In January and March 2014, the first clinical development
 milestones for each of two programs included in the consulting
 agreement were met. Accordingly, the Company recorded research and
 development expense for the year ended December&amp;#xA0;31, 2014 of
 $0.2 million, comprised of $50 thousand in cash and $0.1 million
 related to the issuance of 15,872 shares of the Company&amp;#x2019;s
 common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the year ended December&amp;#xA0;31, 2015, the second and third
 clinical development milestones for one of the programs included in
 the consulting agreement was met. Accordingly, the Company recorded
 research and development expense for the year ended
 December&amp;#xA0;31, 2015 of $1.7 million, comprised of $0.5 million
 in cash and $1.2 million related to the issuance of 23,809 shares
 of the Company&amp;#x2019;s common stock, related to the achievement of
 these milestones.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="shares" decimals="0" id="id_9807917_2107F0D7-BBF1-4E69-888D-9D2301FDB3B9_1_4">27778288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_67F418CE-9369-4AF5-838C-71EC7B452049_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Fair value is the price that would be received to sell an asset or
 paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. Financial assets and
 liabilities carried at fair value are to be classified and
 disclosed in one of the following three categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="6%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="4%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Level 1&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Quoted market prices in active markets for
 identical assets or liabilities. At December&amp;#xA0;31, 2015 and
 2014, the Company&amp;#x2019;s Level 1 assets consisted of money market
 funds totaling $186.8 million and $127.8 million,
 respectively.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Level 2&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Observable inputs other than Level 1 prices,
 such as quoted prices for similar assets or liabilities; quoted
 prices in markets that are not active; or other inputs that are
 observable or can be corroborated by observable market data for
 substantially the full term of the assets or liabilities. At
 December 31, 2015 and 2014, the Company had no Level 2 assets or
 liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Level&amp;#xA0;3&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities. At December 31, 2015 and 2014,
 the Company had no Level 3 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s financial instruments generally consist of cash
 equivalents, accounts payable and accrued expenses. The carrying
 amounts for the applicable financial instruments reported in the
 balance sheets approximate their fair values at December&amp;#xA0;31,
 2015 and 2014, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_94144CFB-9928-4326-89CD-761E16969B6D_1_0">34.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <dei:DocumentPeriodEndDate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_E0FFFDD7-179A-4A35-BC63-2D88621D15F7_1_2">2015-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:UseOfEstimates contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_A5F8790E-3432-4041-BDFA-61C37BE44A48_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and the
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_BE833C19-05BA-4229-ABFE-E274813C3C0F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes compensation expense for all stock-based
 awards made to employees and nonemployee directors, including
 grants of stock options and restricted stock, based on estimated
 fair value on date of grant, over the requisite service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For stock options and restricted stock issued to nonemployee
 consultants, the Company recognizes the fair value of such
 instruments as an expense over the period in which the related
 services are received. The fair value of the awards and measurement
 of related stock-based compensation is subject to periodic
 adjustments as the underlying equity instruments vest. For awards
 that vest upon achievement of a performance condition, the Company
 recognizes compensation expense when achievement of the performance
 condition is deemed probable over the implicit service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of each option grant is estimated using the
 Black-Scholes option-pricing model. Through July 2014, the Company
 was a private company and lacks sufficient Company-specific
 historical and implied volatility information. Therefore, the
 Company estimates expected volatility based on the historical
 volatility of publicly traded peer companies and expects to
 continue to do so until such time as it has adequate historical
 data regarding the volatility of its traded stock price. The
 expected term of the Company&amp;#x2019;s options has been determined
 utilizing the &amp;#x201C;simplified&amp;#x201D; method for awards that
 qualify as &amp;#x201C;plain-vanilla&amp;#x201D; options, while the expected
 term of its options granted to consultants and nonemployees has
 been determined based on the contractual term of the options. The
 risk-free interest rate is determined by reference to the U.S.
 Treasury yield curve in effect at the time of grant of the award
 for time periods approximately equal to the expected term of the
 award. Expected dividend yield is based on the fact that the
 Company never paid cash dividends and does not expect to pay any
 cash dividends in the foreseeable future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company also applies a forfeiture rate in order to calculate
 stock-based compensation expense. To the extent actual forfeitures
 differ from the estimates, the difference will be recorded as a
 cumulative adjustment in the period the estimates are revised. The
 Company recognizes compensation expense for only the portion of
 awards that are expected to vest. Expected forfeitures are based on
 the Company&amp;#x2019;s historical experience and management&amp;#x2019;s
 expectations of future forfeitures.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_FFFF00F9-9419-413B-A381-DCDE0D10820F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all highly liquid investments with an
 original maturity of three months or less at the date of purchase
 to be cash equivalents.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_9A599EEA-FD56-41A2-A432-82E99A4DC509_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;2014 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On July&amp;#xA0;2, 2014, the Company&amp;#x2019;s stockholders approved the
 2014 Stock Option and Incentive Plan (the &amp;#x201C;2014 Stock Option
 Plan&amp;#x201D;), which became effective upon the completion of the
 IPO. The 2014 Stock Option Plan provides for the grant of
 restricted stock awards, incentive stock options and non-statutory
 stock options. The 2014 Stock Option Plan replaced the
 Company&amp;#x2019;s 2011 Stock Option and Grant Plan (the &amp;#x201C;2011
 Stock Option Plan&amp;#x201D;). The Company will no longer grant stock
 options or other awards under the 2011 Stock Option Plan. Any
 options or awards outstanding under the 2011 Stock Option Plan
 remained outstanding and effective. As of December&amp;#xA0;31, 2015,
 the total number of shares reserved under all equity plans is
 3,862,172, and the Company had 859,363 shares available for future
 issuance under such plans.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The 2014 Stock Option Plan provides for an annual increase, to be
 added on the first day of each fiscal year, by up to 4% of the
 Company&amp;#x2019;s issued and outstanding shares of common stock on
 the immediately preceding December&amp;#xA0;31.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Terms of restricted stock awards and stock option agreements,
 including vesting requirements, are determined by the Board of
 Directors or the Compensation Committee of the Board of Directors,
 subject to the provisions of the applicable stock option plan.
 Options and restricted stock awards granted by the Company
 generally vest based on the grantee&amp;#x2019;s continued service with
 the Company during a specified period following grant. Awards
 granted to employees generally vest ratably over four years, with a
 25% cliff vesting at the one year anniversary for new employee
 awards. During 2013, the Company also granted a pool of option
 awards which vest ratably over one year. All awards are exercisable
 from the date of grant for a period of ten years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During 2015, the Company granted 497,100 options to employees to
 purchase shares of common stock that contain performance-based
 vesting criteria, primarily related to achievement of certain
 clinical and regulatory development milestones related to the
 Company&amp;#x2019;s product candidates. Recognition of stock-based
 compensation expense associated with these performance-based stock
 options commences when the performance condition is considered
 probable of achievement, using management&amp;#x2019;s best estimates.
 During the quarter ended June&amp;#xA0;30, 2015, the achievement of one
 milestone was considered probable and that milestone was achieved
 during the quarter ended September&amp;#xA0;30, 2015. The related
 expense was recognized over the estimated service period. This
 milestone represents 35% of the performance-based grants that were
 made during 2015. The achievement of the remaining milestones was
 deemed to be not probable as of December&amp;#xA0;31, 2015 and
 therefore no expense has been recognized related to these awards.
 During the year ended December&amp;#xA0;31, 2015, the Company
 recognized stock-based compensation expense of $4.8 million related
 to stock options with performance-based vesting criteria.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense recognized during the years ended
 December&amp;#xA0;31, 2015, 2014, and 2013 was as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Stock-based compensation expense:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,924&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,093&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,316&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For stock option awards, the fair value of the options is estimated
 at the grant date using the Black-Scholes option-pricing model,
 taking into account the terms and conditions upon which options are
 granted. The fair value of the options is amortized on a
 straight-line basis for awards to employees and on a graded basis
 for awards to non-employees over the requisite service period of
 the awards for awards to employees and graded vesting is used for
 non-employees. The weighted average grant date fair value per share
 relating to outstanding stock options granted under the
 Company&amp;#x2019;s stock option plans during the years ended
 December&amp;#xA0;31, 2015, 2014 and 2013 was $34.08, $14.33 and $0.38,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of each option granted to employees and nonemployee
 directors during the years ended December&amp;#xA0;31, 2015, 2014 and
 2013 under the Company&amp;#x2019;s stock option plans has been
 calculated on the date of grant using the following weighted
 average assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;98.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.59&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.03&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.38&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.04&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Expected dividend yield:&lt;/i&gt; The Company has not paid and does
 not anticipate paying any dividends in the foreseeable future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Risk-free interest rate:&lt;/i&gt; The Company determined the
 risk-free interest rate by using a weighted average equivalent to
 the expected term based on the U.S. Treasury yield curve in effect
 as of the date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Expected volatility:&lt;/i&gt; As the Company has only been a public
 company since July 2014, there is not sufficient historical
 volatility for the expected term of the options. Therefore, the
 Company used an average historical share price volatility based on
 an analysis of reported data for a peer group of comparable
 companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Expected term (in years):&lt;/i&gt; Expected term represents the
 period that the Company&amp;#x2019;s stock option grants are expected to
 be outstanding. As the Company has only been a public company since
 July 2014, there is not sufficient historical term data to
 calculate the expected term of the options. Therefore, the Company
 elected to utilize the &amp;#x201C;simplified&amp;#x201D; method to estimate
 the expected term of option grants issued to employees. Under this
 approach, the weighted average expected life is presumed to be the
 average of the vesting term and the contractual term of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Forfeitures are estimated at the time of grant and revised, if
 necessary, in subsequent periods if actual forfeitures differ from
 estimates. The Company estimates forfeitures based on historical
 termination behavior. For the years ended December&amp;#xA0;31, 2015,
 2014, and 2013, a forfeiture rate of 10% was applied.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For options granted to nonemployees, the expected life of the
 option used is ten years, which is the contractual term of each
 such option. All other assumptions used to calculate the grant date
 fair value are generally consistent with the assumptions used for
 options granted to employees.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The table below summarizes activity related to stock options:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="47%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;br /&gt;
 Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Remaining&amp;#xA0;Life&amp;#xA0;(in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,996,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,362&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,516,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(417,475&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(92,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,002,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,479&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested or expected to vest as of December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,421,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;82,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable as of December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;723,895&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,729&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2015, the Company had unrecognized
 stock-based compensation expense related to its unvested
 service-based stock option awards of $31.5 million, which is
 expected to be recognized over the remaining weighted average
 vesting period of 3.01 years. The total fair value of shares vested
 for the years ended December&amp;#xA0;31, 2015, 2014 and 2013 was $9.2
 million, $1.0 million, and $9 thousand, respectively. In addition,
 the Company has 358,976 shares of outstanding unvested stock
 options that vest upon the achievement of certain performance
 criteria. Total unrecognized compensation related to those awards
 was $7.8 million at December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The intrinsic value of stock options exercised during the years
 ended December&amp;#xA0;31, 2015 and 2014 was $28.4 million and $2.4
 million, respectively, and the intrinsic value of stock options
 exercised during the year ended December&amp;#xA0;31, 2013 was
 zero.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 During the year ended December&amp;#xA0;31, 2013, the Company granted
 restricted stock awards to certain officers, employees, directors,
 and consultants of the Company. During the years ended
 December&amp;#xA0;31, 2015, 2014 and 2013, the Company recorded $0.3
 million, $0.2 million and $11 thousand, respectively, of
 stock-based compensation expense related to its restricted stock.
 The table below summarizes activity relating to restricted
 stock:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December 31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170,832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Issued&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(128,051&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Repurchased&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding as of December 31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2015, the Company had unrecognized
 stock-based compensation expense related to its unvested restricted
 stock awards of $34 thousand, which is expected to be recognized
 over the remaining weighted average vesting period of 0.56
 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the years ended December&amp;#xA0;31, 2015 and 2014, no shares
 of restricted stock were issued. During the year ended
 December&amp;#xA0;31, 2013, current and former employees of the Company
 purchased a total of 130,158 shares of restricted stock, resulting
 in proceeds of $50 thousand.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Unvested shares are subject to repurchase by the Company, at the
 issuance price, upon the employee&amp;#x2019;s termination at the
 Company&amp;#x2019;s sole discretion. In the year ended
 December&amp;#xA0;31, 2014, the Company repurchased 6,778 shares of
 restricted common stock issued to employees at their $0.04 original
 purchase price per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;2014 Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On July&amp;#xA0;2, 2014, the Company&amp;#x2019;s stockholders approved the
 2014 Employee Stock Purchase Plan. A total of 282,000 shares of
 common stock were initially authorized for issuance under this
 plan. The 2014 Employee Stock Purchase Plan became effective upon
 the completion of the IPO. As of December&amp;#xA0;31, 2015, 3,852
 shares have been issued under this plan. Included in accrued
 liabilities at December&amp;#xA0;31, 2015 is $64 thousand of stock
 compensation expense related to an enrollment period for which the
 related shares had not been issued as of December&amp;#xA0;31,
 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_220F1318-D1BC-4699-953B-DC112C31358D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basic and Diluted Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Upon the closing of the Company&amp;#x2019;s IPO in July 2014, all of
 the Company&amp;#x2019;s outstanding shares of redeemable convertible
 preferred stock were converted into shares of common stock. Prior
 to this conversion, the Company followed the two-class method when
 computing net loss per share as the Company had issued shares that
 meet the definition of participating securities. The two-class
 method determines net loss per share for each class of common and
 participating securities according to dividends declared or
 accumulated and participation rights in undistributed earnings. The
 two-class method requires income available to common stockholders
 for the period to be allocated between common and participating
 securities based upon their respective rights to receive dividends
 as if all income for the period had been distributed. The
 Company&amp;#x2019;s redeemable convertible preferred shares
 contractually entitled the holders of such shares to participate in
 dividends, but did not contractually require the holders of such
 shares to participate in losses of the Company. Accordingly, the
 two-class method did not apply for periods in which the Company
 reported a net loss or a net loss attributable to common
 stockholders resulting from dividends or accretion related to its
 redeemable convertible preferred shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share attributable to common stockholders is
 computed by dividing the net loss attributable to common
 stockholders by the weighted average number of common shares
 outstanding for the period. Diluted net loss per share attributable
 to common stockholders is computed by dividing the diluted net loss
 attributable to common stockholders by the weighted average number
 of common shares outstanding for the period, including potential
 dilutive common shares assuming the dilutive effect of outstanding
 stock options and unvested restricted common shares, as determined
 using the treasury stock method. For periods in which the Company
 has reported net losses, diluted net loss per common share
 attributable to common stockholders is the same as basic net loss
 per common share attributable to common stockholders, since
 dilutive common shares are not assumed to have been issued if their
 effect is antidilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company reported a net loss attributable to common stockholders
 for the years ended December&amp;#xA0;31, 2015, 2014 and 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_79949F05-F3F7-4465-8B26-02F6F6B94720_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued guidance that outlines a single
 comprehensive model for entities to use in accounting for revenue
 arising from contracts with customers and supersedes most current
 revenue recognition guidance, including industry specific guidance.
 The guidance is based on the principle that an entity should
 recognize revenue to depict the transfer of goods or services to
 customers in an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The guidance also requires additional disclosure about
 the nature, amount, timing and uncertainty of revenue and cash
 flows arising from customer contracts, including significant
 judgments and changes in judgments and assets recognized from costs
 incurred to fulfill a contract. Entities have the option of using
 either a full retrospective or a modified retrospective approach
 for the adoption of the new standard. The guidance becomes
 effective for the Company in the year ending December&amp;#xA0;31,
 2018, and the Company could early adopt the standard for the year
 ending December&amp;#xA0;31, 2017. The Company is currently assessing
 the method of adoption and the impact that this new accounting
 guidance will have on its consolidated financial statements and
 footnote disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In August 2014, the FASB issued ASU 2014-15, Presentation of
 Financial Statements&amp;#x2014;Going Concern (Subtopic 205-40). The new
 guidance addresses management&amp;#x2019;s responsibility to evaluate
 whether there is substantial doubt about an entity&amp;#x2019;s ability
 to continue as a going concern and to provide related footnote
 disclosures. Management&amp;#x2019;s evaluation should be based on
 relevant conditions and events that are known and reasonably
 knowable at the date that the financial statements are issued. The
 standard will be effective for the first interim period within
 annual reporting periods beginning after December&amp;#xA0;15, 2016.
 Early adoption is permitted. The Company is evaluating the effect
 that this guidance will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In November 2015, the FASB issued ASU 2015-17, Balance Sheet
 Classification of Deferred Taxes, which simplifies the
 classification of deferred tax assets and liabilities. The new
 standard requires that all deferred tax assets and liabilities,
 along with any related valuation allowance, be classified as
 noncurrent on the balance sheet. The standard is effective for
 interim and annual periods beginning after December&amp;#xA0;15, 2016
 and allows for early adoption using a full retrospective method or
 a prospective method. The Company has elected to early adopt the
 provisions of this new standard using a prospective method. As a
 result, all deferred taxes as of December&amp;#xA0;31, 2015 are
 classified as noncurrent on a net basis in the Company&amp;#x2019;s
 consolidated balance sheet, while prior periods remain as
 previously reported.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In February 2016, the Financial Accounting Standards Board (FASB)
 issued ASU&amp;#xA0;2016-02&amp;#x2014;&lt;i&gt;Leases&lt;/i&gt;&amp;#xA0;(ASC&amp;#xA0;842), which sets out
 the principles for the recognition, measurement, presentation and
 disclosure of leases for both parties to a contract (i.e. lessees
 and lessors). The new standard requires lessees to apply a dual
 approach, classifying leases as either finance or operating leases
 based on the principle of whether or not the lease is effectively a
 financed purchase by the lessee. This classification will determine
 whether lease expense is recognized based on an effective interest
 method or on a straight line basis over the term of the lease,
 respectively. A lessee is also required to record a right-of-use
 asset and a lease liability for all leases with a term of greater
 than 12&amp;#xA0;months regardless of their classification. Leases with
 a term of 12&amp;#xA0;months or less will be accounted for similar to
 existing guidance for operating leases today. ASC&amp;#xA0;842
 supersedes the previous leases standard, ASC&amp;#xA0;840&amp;#xA0;&lt;i&gt;Leases.&amp;#xA0;&lt;/i&gt;The standard is effective
 on January&amp;#xA0;1, 2019, with early adoption permitted. The Company
 is in the process of evaluating the impact of this new
 guidance.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_1EE7FAE4-8C7A-4A3E-9F09-4AF04265D13A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Future minimum lease payments under non-cancelable operating leases
 are as follows at December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 95.55pt"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,088&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,398&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,926&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_287A02FA-0403-44EC-AC4A-8BF931FF343F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Summary of Significant Accounting
 Policies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following is a summary of significant accounting policies
 followed in the preparation of these financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying consolidated financial statements include those of
 the Company and its subsidiaries after elimination of all
 intercompany accounts and transactions. The accompanying
 consolidated financial statements have been prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&amp;#x201C;GAAP&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and the
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all highly liquid investments with an
 original maturity of three months or less at the date of purchase
 to be cash equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 A deposit of $39 thousand was restricted from withdrawal as of
 December&amp;#xA0;31, 2015 and 2014. The restriction is related to
 securing the Company&amp;#x2019;s facility lease and expires in 2022 in
 accordance with the operating lease agreement. This balance is
 included in restricted cash on the accompanying balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are recorded at cost and depreciated over
 their estimated useful lives using the straight-line method. Upon
 retirement or sale, the cost of assets disposed of and the related
 accumulated depreciation are removed from the accounts and any
 resulting gain or loss is credited or charged to income. Repairs
 and maintenance costs are expensed as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Long-lived assets consist of property and equipment. Long-lived
 assets to be held and used are tested for recoverability whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. Factors
 that the Company considers in deciding when to perform an
 impairment review include significant underperformance of the
 business in relation to expectations, significant negative industry
 or economic trends, and significant changes or planned changes in
 the use of the assets. If an impairment review is performed to
 evaluate a long-lived asset for recoverability, the Company
 compares forecasts of undiscounted cash flows expected to result
 from the use and eventual disposition of the long-lived asset to
 its carrying value. An impairment loss would be recognized when
 estimated undiscounted future cash flows expected to result from
 the use of an asset are less than its carrying amount. The
 impairment loss would be based on the excess of the carrying value
 of the impaired asset over its fair value, determined based on
 discounted cash flows. To date, the Company has not recorded any
 impairment losses on long-lived assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development expenses are comprised of costs incurred
 in performing research and development activities, including
 salaries and benefits, overhead costs, depreciation, contract
 services and other related costs. Research and development costs
 are expensed to operations as the related obligation is
 incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research Contract Costs and Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has entered into various research and development
 contracts with research institutions and other companies both
 inside and outside of the United States. These agreements are
 generally cancelable, and related payments are recorded as research
 and development expenses as incurred. The Company records accruals
 for estimated ongoing research costs. When evaluating the adequacy
 of the accrued liabilities, the Company analyzes progress of the
 studies, including the phase or completion of events, invoices
 received and contracted costs. Significant judgments and estimates
 may be made in determining the accrued balances at the end of any
 reporting period. Actual results could differ from the
 Company&amp;#x2019;s estimates. The Company&amp;#x2019;s historical accrual
 estimates have not been materially different from the actual
 costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company expenses patent costs as incurred and classifies such
 costs as general and administrative expenses in the accompanying
 statements of operations and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company recognizes compensation expense for all stock-based
 awards made to employees and nonemployee directors, including
 grants of stock options and restricted stock, based on estimated
 fair value on date of grant, over the requisite service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For stock options and restricted stock issued to nonemployee
 consultants, the Company recognizes the fair value of such
 instruments as an expense over the period in which the related
 services are received. The fair value of the awards and measurement
 of related stock-based compensation is subject to periodic
 adjustments as the underlying equity instruments vest. For awards
 that vest upon achievement of a performance condition, the Company
 recognizes compensation expense when achievement of the performance
 condition is deemed probable over the implicit service period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of each option grant is estimated using the
 Black-Scholes option-pricing model. Through July 2014, the Company
 was a private company and lacks sufficient Company-specific
 historical and implied volatility information. Therefore, the
 Company estimates expected volatility based on the historical
 volatility of publicly traded peer companies and expects to
 continue to do so until such time as it has adequate historical
 data regarding the volatility of its traded stock price. The
 expected term of the Company&amp;#x2019;s options has been determined
 utilizing the &amp;#x201C;simplified&amp;#x201D; method for awards that
 qualify as &amp;#x201C;plain-vanilla&amp;#x201D; options, while the expected
 term of its options granted to consultants and nonemployees has
 been determined based on the contractual term of the options. The
 risk-free interest rate is determined by reference to the U.S.
 Treasury yield curve in effect at the time of grant of the award
 for time periods approximately equal to the expected term of the
 award. Expected dividend yield is based on the fact that the
 Company never paid cash dividends and does not expect to pay any
 cash dividends in the foreseeable future.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company also applies a forfeiture rate in order to calculate
 stock-based compensation expense. To the extent actual forfeitures
 differ from the estimates, the difference will be recorded as a
 cumulative adjustment in the period the estimates are revised. The
 Company recognizes compensation expense for only the portion of
 awards that are expected to vest. Expected forfeitures are based on
 the Company&amp;#x2019;s historical experience and management&amp;#x2019;s
 expectations of future forfeitures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basic and Diluted Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Upon the closing of the Company&amp;#x2019;s IPO in July 2014, all of
 the Company&amp;#x2019;s outstanding shares of redeemable convertible
 preferred stock were converted into shares of common stock. Prior
 to this conversion, the Company followed the two-class method when
 computing net loss per share as the Company had issued shares that
 meet the definition of participating securities. The two-class
 method determines net loss per share for each class of common and
 participating securities according to dividends declared or
 accumulated and participation rights in undistributed earnings. The
 two-class method requires income available to common stockholders
 for the period to be allocated between common and participating
 securities based upon their respective rights to receive dividends
 as if all income for the period had been distributed. The
 Company&amp;#x2019;s redeemable convertible preferred shares
 contractually entitled the holders of such shares to participate in
 dividends, but did not contractually require the holders of such
 shares to participate in losses of the Company. Accordingly, the
 two-class method did not apply for periods in which the Company
 reported a net loss or a net loss attributable to common
 stockholders resulting from dividends or accretion related to its
 redeemable convertible preferred shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share attributable to common stockholders is
 computed by dividing the net loss attributable to common
 stockholders by the weighted average number of common shares
 outstanding for the period. Diluted net loss per share attributable
 to common stockholders is computed by dividing the diluted net loss
 attributable to common stockholders by the weighted average number
 of common shares outstanding for the period, including potential
 dilutive common shares assuming the dilutive effect of outstanding
 stock options and unvested restricted common shares, as determined
 using the treasury stock method. For periods in which the Company
 has reported net losses, diluted net loss per common share
 attributable to common stockholders is the same as basic net loss
 per common share attributable to common stockholders, since
 dilutive common shares are not assumed to have been issued if their
 effect is antidilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company reported a net loss attributable to common stockholders
 for the years ended December&amp;#xA0;31, 2015, 2014 and 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The product candidates developed by the Company require approvals
 from the U.S. Food and Drug Administration or foreign regulatory
 agencies prior to commercial sales. There can be no assurance that
 the Company&amp;#x2019;s current and future product candidates will
 receive the necessary approvals. If the Company fails to
 successfully complete clinical development and generate results
 sufficient to file for regulatory approval or is denied approval or
 approval is delayed, it may have a material adverse impact on the
 Company&amp;#x2019;s business and its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is subject to risks common to companies in the
 development stage including, but not limited to, dependency on the
 clinical success of its product candidates, ability to obtain
 regulatory approval of its product candidates, the commercial
 success of its product, if approved, the need for substantial
 additional financing to achieve its goals, uncertainty of broad
 adoption of its approved products, if any, by physicians and
 consumers, significant competition and untested manufacturing
 capabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk and of Significant
 Suppliers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist primarily of cash and cash
 equivalents. The Company has all cash and cash equivalents balances
 at two accredited financial institutions, in amounts that exceed
 federally insured limits. The Company does not believe that it is
 subject to unusual credit risk beyond the normal credit risk
 associated with commercial banking relationships.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is dependent on third-party manufacturers to supply
 products for research and development activities in its programs.
 In particular, the Company relies and expects to continue to rely
 on a small number of manufacturers to supply it with its
 requirements for the active pharmaceutical ingredients and
 formulated drugs related to these programs. These programs could be
 adversely affected by a significant interruption in the supply of
 active pharmaceutical ingredients and formulated drugs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company accounts for income taxes under the asset and liability
 method. Under this method, deferred tax assets and liabilities are
 recognized for the estimated future tax consequences attributable
 to differences between financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases.
 Deferred tax assets and liabilities are measured using enacted
 rates in effect for the year in which these temporary differences
 are expected to be recovered or settled. Valuation allowances are
 provided if based on the weight of available evidence, it is more
 likely than not that some or all of the deferred tax assets will
 not be realized. During November 2015, the FASB issued ASU 2015-17,
 Balance Sheet Classification of Deferred Taxes, which simplifies
 the presentation of deferred income taxes. The Company early
 adopted ASU 2015-17 effective December&amp;#xA0;31, 2015 on a
 prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Fair value is the price that would be received to sell an asset or
 paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. Financial assets and
 liabilities carried at fair value are to be classified and
 disclosed in one of the following three categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 &lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="6%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="4%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Level 1&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Quoted market prices in active markets for
 identical assets or liabilities. At December&amp;#xA0;31, 2015 and
 2014, the Company&amp;#x2019;s Level 1 assets consisted of money market
 funds totaling $186.8 million and $127.8 million,
 respectively.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Level 2&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Observable inputs other than Level 1 prices,
 such as quoted prices for similar assets or liabilities; quoted
 prices in markets that are not active; or other inputs that are
 observable or can be corroborated by observable market data for
 substantially the full term of the assets or liabilities. At
 December 31, 2015 and 2014, the Company had no Level 2 assets or
 liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Level&amp;#xA0;3&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#x2014;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities. At December 31, 2015 and 2014,
 the Company had no Level 3 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s financial instruments generally consist of cash
 equivalents, accounts payable and accrued expenses. The carrying
 amounts for the applicable financial instruments reported in the
 balance sheets approximate their fair values at December&amp;#xA0;31,
 2015 and 2014, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company capitalizes certain legal, accounting and other
 third-party fees that are directly associated with in-process
 equity financings as other assets until such financings are
 consummated. After consummation of the IPO in July 2014, $2.3
 million of these costs were recorded in stockholders&amp;#x2019; equity
 as a reduction of additional paid-in capital generated as a result
 of the IPO. After consummation of the follow-on public offering of
 common stock in April 2015, $0.5 million of these costs were
 recorded in stockholders&amp;#x2019; equity as a reduction of additional
 paid-in capital generated as a result of the offering. As of
 December&amp;#xA0;31, 2015, the Company had recorded deferred offering
 costs of $0.2 million which are shown as a non-current asset. They
 are for the follow-on public offering that was consummated in
 January 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment Data&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company manages its operations as a single segment for the
 purposes of assessing performance and making operating decisions.
 The Company&amp;#x2019;s singular focus is on advancing medicines to
 treat central nervous system disorders, where there are inadequate
 or no approved existing therapies. All tangible assets are held
 within the United States.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss includes net loss as well as other changes in
 stockholders&amp;#x2019; equity (deficit) that result from transactions
 and economic events other than those with stockholders. For the
 years ended December&amp;#xA0;31, 2015, 2014 and 2013, there was no
 difference between net loss and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Public Offerings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On July&amp;#xA0;23, 2014, the Company completed the sale of 5,750,000
 shares of its common stock in its IPO (the &amp;#x201C;IPO&amp;#x201D;), at a
 price to the public of $18.00 per share, resulting in net proceeds
 to the Company of $94.0 million after deducting underwriting
 discounts and commissions and offering costs paid by the Company.
 The shares began trading on Nasdaq Global Market on July&amp;#xA0;18,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 In connection with preparing for the IPO, the Company&amp;#x2019;s board
 of directors and stockholders approved a 1-for-3.15 reverse stock
 split of the Company&amp;#x2019;s common stock effective July&amp;#xA0;2,
 2014. All share and per share amounts in the financial statements
 contained herein and notes thereto have been retroactively
 adjusted, where necessary, to give effect to this reverse stock
 split. In connection with the closing of the IPO, all of the
 Company&amp;#x2019;s outstanding redeemable convertible preferred stock
 automatically converted into shares of common stock as of
 July&amp;#xA0;23, 2014, resulting in the issuance by the Company of an
 additional 18,007,575 shares of common stock. The significant
 increase in common stock outstanding in July 2014 will impact the
 year-over-year comparability of the Company&amp;#x2019;s net loss per
 share calculations over the next year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On April&amp;#xA0;20, 2015, the Company completed the sale of 2,628,571
 shares of common stock in an underwritten public offering of its
 common stock at a price to the public of $52.50 per share,
 resulting in net proceeds to the Company of $129.1 million after
 deducting underwriting discounts and commissions and offering costs
 paid by the Company. A description of the sale of shares of common
 stock held in January 2016 is included in Note 13.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2014, the FASB issued guidance that outlines a single
 comprehensive model for entities to use in accounting for revenue
 arising from contracts with customers and supersedes most current
 revenue recognition guidance, including industry specific guidance.
 The guidance is based on the principle that an entity should
 recognize revenue to depict the transfer of goods or services to
 customers in an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The guidance also requires additional disclosure about
 the nature, amount, timing and uncertainty of revenue and cash
 flows arising from customer contracts, including significant
 judgments and changes in judgments and assets recognized from costs
 incurred to fulfill a contract. Entities have the option of using
 either a full retrospective or a modified retrospective approach
 for the adoption of the new standard. The guidance becomes
 effective for the Company in the year ending December&amp;#xA0;31,
 2018, and the Company could early adopt the standard for the year
 ending December&amp;#xA0;31, 2017. The Company is currently assessing
 the method of adoption and the impact that this new accounting
 guidance will have on its consolidated financial statements and
 footnote disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In August 2014, the FASB issued ASU 2014-15, Presentation of
 Financial Statements&amp;#x2014;Going Concern (Subtopic 205-40). The new
 guidance addresses management&amp;#x2019;s responsibility to evaluate
 whether there is substantial doubt about an entity&amp;#x2019;s ability
 to continue as a going concern and to provide related footnote
 disclosures. Management&amp;#x2019;s evaluation should be based on
 relevant conditions and events that are known and reasonably
 knowable at the date that the financial statements are issued. The
 standard will be effective for the first interim period within
 annual reporting periods beginning after December&amp;#xA0;15, 2016.
 Early adoption is permitted. The Company is evaluating the effect
 that this guidance will have on its consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In November 2015, the FASB issued ASU 2015-17, Balance Sheet
 Classification of Deferred Taxes, which simplifies the
 classification of deferred tax assets and liabilities. The new
 standard requires that all deferred tax assets and liabilities,
 along with any related valuation allowance, be classified as
 noncurrent on the balance sheet. The standard is effective for
 interim and annual periods beginning after December&amp;#xA0;15, 2016
 and allows for early adoption using a full retrospective method or
 a prospective method. The Company has elected to early adopt the
 provisions of this new standard using a prospective method. As a
 result, all deferred taxes as of December&amp;#xA0;31, 2015 are
 classified as noncurrent on a net basis in the Company&amp;#x2019;s
 consolidated balance sheet, while prior periods remain as
 previously reported.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In February 2016, the Financial Accounting Standards Board (FASB)
 issued ASU&amp;#xA0;2016-02&amp;#x2014;&lt;i&gt;Leases&lt;/i&gt; (ASC&amp;#xA0;842), which
 sets out the principles for the recognition, measurement,
 presentation and disclosure of leases for both parties to a
 contract (i.e. lessees and lessors). The new standard requires
 lessees to apply a dual approach, classifying leases as either
 finance or operating leases based on the principle of whether or
 not the lease is effectively a financed purchase by the lessee.
 This classification will determine whether lease expense is
 recognized based on an effective interest method or on a straight
 line basis over the term of the lease, respectively. A lessee is
 also required to record a right-of-use asset and a lease liability
 for all leases with a term of greater than 12&amp;#xA0;months
 regardless of their classification. Leases with a term of
 12&amp;#xA0;months or less will be accounted for similar to existing
 guidance for operating leases today. ASC&amp;#xA0;842 supersedes the
 previous leases standard, ASC&amp;#xA0;840 &lt;i&gt;Leases.&lt;/i&gt; The standard
 is effective on January&amp;#xA0;1, 2019, with early adoption
 permitted. The Company is in the process of evaluating the impact
 of this new guidance.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dei:TradingSymbol contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7D0211A-BD94-4DC2-B1F0-2497139F13D5_1_0">SAGE</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="shares" decimals="0" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_11">27778288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_B5EE6B6C-DC5A-4B29-964E-875C270DB90F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of each option granted to employees and nonemployee
 directors during the years ended December&amp;#xA0;31, 2015, 2014, and
 2013 under the Company&amp;#x2019;s stock option plans has been
 calculated on the date of grant using the following weighted
 average assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;98.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99.89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.59&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.03&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.38&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.04&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_B9C73C82-F54C-4861-A250-A133D07AAB83_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic and diluted net income (loss) per share attributable to
 common stockholders was calculated as follows for the years ended
 December&amp;#xA0;31, 2015, 2014 and 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic net loss per share attributable to common stockholders:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders
 (in&amp;#xA0;thousands)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,495&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(18,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Weighted average shares of common stock outstanding&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,778,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,574,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,492,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Dilutive effect of shares of common stock equivalents resulting
 from common stock options and preferred common stock (as
 converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Weighted average common stock outstanding&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,778,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,574,347&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,492,288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following common stock equivalents outstanding as of
 December&amp;#xA0;31, 2015 and 2014, were excluded from the computation
 of diluted net loss per share attributable to common stockholders
 for the periods presented because including them would have been
 anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="80%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,643,833&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,621,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,781&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee Stock Purchase Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,689,921&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,791,973&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_7">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D93C2943-974B-44B1-B135-57E0FED00F05_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company accounts for income taxes under the asset and liability
 method. Under this method, deferred tax assets and liabilities are
 recognized for the estimated future tax consequences attributable
 to differences between financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases.
 Deferred tax assets and liabilities are measured using enacted
 rates in effect for the year in which these temporary differences
 are expected to be recovered or settled. Valuation allowances are
 provided if based on the weight of available evidence, it is more
 likely than not that some or all of the deferred tax assets will
 not be realized. During November 2015, the FASB issued ASU 2015-17,
 Balance Sheet Classification of Deferred Taxes, which simplifies
 the presentation of deferred income taxes. The Company early
 adopted ASU 2015-17 effective December&amp;#xA0;31, 2015 on a
 prospective basis.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_6B157FA3-9275-46E5-9A8F-36D6F43D4466_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Related Party
 Transactions&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Since inception, the Company has received consulting and management
 services from Third Rock Ventures LLC, which through its
 affiliates, owned 16.4% of the Company&amp;#x2019;s common stock at
 December&amp;#xA0;31, 2015. The Company recorded expenses of $21
 thousand, $0.2 million, and $0.6 million for these services for the
 years ended December&amp;#xA0;31, 2015, 2014, and 2013,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D609A66A-E1E3-48AD-A8CD-04C27B9E014B_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Subsequent Event&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On January&amp;#xA0;12, 2016, the Company completed the sale of
 3,157,894 shares of its common stock at a price to the public of
 $47.50 per share, resulting in net proceeds to the Company of
 $140.4 million after deducting underwriting discounts and
 commissions and estimated offering expenses payable by the
 Company.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_13">198000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_7">-94495000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10005_800029">603000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_9">-94495000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_5">178000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_8">165000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10005_800037">15176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10005_800031">17000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_7">681000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10005_800033">127000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_4">-94650000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_6">-23000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_75F161F2-DB8F-4273-8D75-A5598CDC0913_1_0">40800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_21">584000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10005_800035">1211000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_E0BCC9EA-5A42-4336-80E4-42BB7598EA23_1_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_3">15240000</us-gaap:ShareBasedCompensation>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_839EB9BD-6629-44FE-A89F-2018205A7C54_3_2">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_9807917_98EE6CED-9C15-48A6-887F-9FA7F6AACF59_1_0">400000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_23">58987000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_3">94650000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_14">-198000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_22">129866000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_1">69357000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_20">129720000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_1_2">15240000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_10">5404000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_19">730000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7E797482-438C-48E1-B9BC-01109128778C_1_2">25293000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_9">2690000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:Depreciation contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_5">115000</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_949F6B65-499F-4009-9B7E-7B088548E2B1_1_0">100000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DividendsCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_9807917_40FACEA0-F8D2-4047-9C78-973ED49E63ED_1_2">0</us-gaap:DividendsCommonStock>
  <sage:CommonStockTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_1923992C-1695-40E8-93D5-434F692D9254_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of December&amp;#xA0;31, 2015 and 2014, the Company has authorized
 120,000,000 shares of common stock with a par value of $0.0001 per
 share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Each share of common stock entitles the holder to one vote on all
 matters submitted to a vote of the Company&amp;#x2019;s stockholders.
 Common stockholders are entitled to receive dividends, as may be
 declared by the Board of Directors, if any. As of December&amp;#xA0;31,
 2015 and 2014, no dividends have been declared.&lt;/p&gt;


 &lt;/div&gt;</sage:CommonStockTextBlock>
  <sage:InitialPublicOfferingPolicyPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_F49599D9-6A42-4F72-BF2B-36B68C2A4B83_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Public Offerings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On July&amp;#xA0;23, 2014, the Company completed the sale of 5,750,000
 shares of its common stock in its IPO (the &amp;#x201C;IPO&amp;#x201D;), at a
 price to the public of $18.00 per share, resulting in net proceeds
 to the Company of $94.0 million after deducting underwriting
 discounts and commissions and offering costs paid by the Company.
 The shares began trading on Nasdaq Global Market on July&amp;#xA0;18,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In connection with preparing for the IPO, the Company&amp;#x2019;s board
 of directors and stockholders approved a 1-for-3.15 reverse stock
 split of the Company&amp;#x2019;s common stock effective July&amp;#xA0;2,
 2014. All share and per share amounts in the financial statements
 contained herein and notes thereto have been retroactively
 adjusted, where necessary, to give effect to this reverse stock
 split. In connection with the closing of the IPO, all of the
 Company&amp;#x2019;s outstanding redeemable convertible preferred stock
 automatically converted into shares of common stock as of
 July&amp;#xA0;23, 2014, resulting in the issuance by the Company of an
 additional 18,007,575 shares of common stock. The significant
 increase in common stock outstanding in July 2014 will impact the
 year-over-year comparability of the Company&amp;#x2019;s net loss per
 share calculations over the next year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On April&amp;#xA0;20, 2015, the Company completed the sale of 2,628,571
 shares of common stock in an underwritten public offering of its
 common stock at a price to the public of $52.50 per share,
 resulting in net proceeds to the Company of $129.1 million after
 deducting underwriting discounts and commissions and offering costs
 paid by the Company. A description of the sale of shares of common
 stock held in January 2016 is included in Note 13.&lt;/p&gt;
 &lt;/div&gt;</sage:InitialPublicOfferingPolicyPolicyTextBlock>
  <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="2" id="id_9807917_36046CCB-5A66-4499-B69D-C5CC86B83B66_1_0">0.10</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate>
  <sage:ResearchContractCostsAndAccrualsPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_46BF4E62-E883-4804-8AE1-06A9BEA0802A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research Contract Costs and Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has entered into various research and development
 contracts with research institutions and other companies both
 inside and outside of the United States. These agreements are
 generally cancelable, and related payments are recorded as research
 and development expenses as incurred. The Company records accruals
 for estimated ongoing research costs. When evaluating the adequacy
 of the accrued liabilities, the Company analyzes progress of the
 studies, including the phase or completion of events, invoices
 received and contracted costs. Significant judgments and estimates
 may be made in determining the accrued balances at the end of any
 reporting period. Actual results could differ from the
 Company&amp;#x2019;s estimates. The Company&amp;#x2019;s historical accrual
 estimates have not been materially different from the actual
 costs.&lt;/p&gt;
 &lt;/div&gt;</sage:ResearchContractCostsAndAccrualsPolicyTextBlock>
  <sage:TaxCreditsExpirationStartYear contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_1_8">2034</sage:TaxCreditsExpirationStartYear>
  <sage:LicensingOrConsultantFeesPaidInCommonStock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_4">1211000</sage:LicensingOrConsultantFeesPaidInCommonStock>
  <sage:FederalAndStateNetOperatingLossCarryForwardsExpirationYear contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_1_2">2031</sage:FederalAndStateNetOperatingLossCarryForwardsExpirationYear>
  <sage:BusinessRisksAndUncertaintiesPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_4DA08CB8-4715-4AC1-BB70-B9E7B9126E55_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The product candidates developed by the Company require approvals
 from the U.S. Food and Drug Administration or foreign regulatory
 agencies prior to commercial sales. There can be no assurance that
 the Company&amp;#x2019;s current and future product candidates will
 receive the necessary approvals. If the Company fails to
 successfully complete clinical development and generate results
 sufficient to file for regulatory approval or is denied approval or
 approval is delayed, it may have a material adverse impact on the
 Company&amp;#x2019;s business and its financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is subject to risks common to companies in the
 development stage including, but not limited to, dependency on the
 clinical success of its product candidates, ability to obtain
 regulatory approval of its product candidates, the commercial
 success of its product, if approved, the need for substantial
 additional financing to achieve its goals, uncertainty of broad
 adoption of its approved products, if any, by physicians and
 consumers, significant competition and untested manufacturing
 capabilities.&lt;/p&gt;
 &lt;/div&gt;</sage:BusinessRisksAndUncertaintiesPolicyTextBlock>
  <sage:StockholdersEquityReverseStockSplitEffectiveDate contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_527705E3-E005-4C71-A02A-1079181CC238_3_1">2014-07-02</sage:StockholdersEquityReverseStockSplitEffectiveDate>
  <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_A2478CAC-0691-47EC-9921-8A42CA32C31B_1_1">P1Y</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod>
  <sage:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_9807917_FAAF2324-BFB5-4A0D-8838-77260C0DEB56_1_2">0.009</sage:EffectiveIncomeTaxRateReconciliationPermanentItems>
  <sage:BalanceSheetComponentsTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_20508499-0FE3-412F-9687-505BAD95E8A1_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Balance Sheet Components&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Property and equipment, net consists of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Life&lt;br /&gt;
 (Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Computer hardware and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;400&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Furniture and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: Accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;163&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Depreciation expense for the years ended December&amp;#xA0;31, 2015,
 2014 and 2013 was $0.1 million, $0.1 million and $47 thousand,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,788&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee related expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Professional services&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</sage:BalanceSheetComponentsTextBlock>
  <sage:PatentCostsPolicyTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" id="id_9807917_2D904598-58E1-4D20-BA2F-A72178FD351A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company expenses patent costs as incurred and classifies such
 costs as general and administrative expenses in the accompanying
 statements of operations and comprehensive loss.&lt;/p&gt;
 &lt;/div&gt;</sage:PatentCostsPolicyTextBlock>
  <sage:PublicOfferingCostsIncludedInCurrentLiabilities contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_27A9CE57-1DF9-4F37-A3C8-4D30E1A96078_1_29">165000</sage:PublicOfferingCostsIncludedInCurrentLiabilities>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1773506_1634968x2010615" unitRef="iso4217_USD" decimals="-5" id="id_9807917_22BC42E6-AC06-4A4B-9D94-AB0CC6293139_1001_1">500000</sage:MilestonePayments>
  <sage:MilestoneBasedShareCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1773506_1634968x2010615" unitRef="shares" decimals="INF" id="id_9807917_22BC42E6-AC06-4A4B-9D94-AB0CC6293139_1001_3">23809</sage:MilestoneBasedShareCompensation>
  <sage:MilestoneStockCompensation contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1773506_1634968x2010615" unitRef="iso4217_USD" decimals="-5" id="id_9807917_22BC42E6-AC06-4A4B-9D94-AB0CC6293139_1001_2">1200000</sage:MilestoneStockCompensation>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1773506_1634968x2010615" unitRef="iso4217_USD" decimals="-5" id="id_9807917_22BC42E6-AC06-4A4B-9D94-AB0CC6293139_1001_0">1700000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1778734" unitRef="iso4217_USD" decimals="-5" id="id_9807917_4E334511-E056-4A99-8E51-F5D00A112964_1_0">100000</us-gaap:ResearchAndDevelopmentExpense>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_692DF8DC-D192-4FA1-88FC-A0ECB3BDDEBB_1001_400001">800000</sage:MilestonePayments>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1778734_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_692DF8DC-D192-4FA1-88FC-A0ECB3BDDEBB_1001_400000">800000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <sage:PercentageOfNetSalesRequiredForRoyaltyEntitlement contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931" unitRef="pure" decimals="2" id="id_9807917_C9AD99F7-4888-4E9C-950E-B80F3D2097C3_1001_2">0.01</sage:PercentageOfNetSalesRequiredForRoyaltyEntitlement>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_7E07D415-C52B-44BE-BE2E-59391B4DCBE9_1001_1">100000</sage:MilestonePayments>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1634968x1904565" unitRef="iso4217_USD" decimals="-5" id="id_9807917_7E07D415-C52B-44BE-BE2E-59391B4DCBE9_1001_0">100000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <sage:LicenseAgreementMaximumTerm contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1640593x1729521" id="id_9807917_D377B2E0-02DF-4B4E-9912-7E448EF01F3A_1001_0">P27Y</sage:LicenseAgreementMaximumTerm>
  <sage:LicenseAgreementMaximumTerm contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1640593x1931239" id="id_9807917_D377B2E0-02DF-4B4E-9912-7E448EF01F3A_2001_1">P15Y</sage:LicenseAgreementMaximumTerm>
  <sage:MilestonePayments contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1930456_1634968x1702458" unitRef="iso4217_USD" decimals="-3" id="id_9807917_0F32CDEC-4FBF-4C05-BBD7-3D34DD29D52D_1001_400001">50000</sage:MilestonePayments>
  <sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1930456_1634968x1702458" unitRef="iso4217_USD" decimals="-3" id="id_9807917_0F32CDEC-4FBF-4C05-BBD7-3D34DD29D52D_1001_400000">50000</sage:ResearchAndDevelopmentExpenseRelatedToMilestonePayment>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1634394x1639948" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_1001_1">9316000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1634394x1642216" unitRef="iso4217_USD" decimals="-3" id="id_9807917_76B55248-ED35-4358-9C4A-9C6FEE327CCC_2001_0">5924000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1634505x1641629" id="id_9807917_5DE5A967-0068-44F7-8720-8B6E20D54B8E_1001_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1634505x1935408" id="id_9807917_5DE5A967-0068-44F7-8720-8B6E20D54B8E_2001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1636161x1635815" unitRef="pure" decimals="INF" id="id_9807917_A2478CAC-0691-47EC-9921-8A42CA32C31B_1001_2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1637033x1634411" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_11005_800038">129171000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1637033x1634411_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_11001_400039">2628571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1637033x1634411_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_11003_600038">129171000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639081x1632468" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_1001_2">3307</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639081x1633925" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_2001_0">2643833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639081x1944181" unitRef="shares" decimals="INF" id="id_9807917_6962191E-5075-4ED6-9780-90CC6F676BEB_3001_1">42781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <sage:OperatingLeaseExpirationPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639226x1713423" id="id_9807917_F94445FE-206D-49FF-A159-5362F6146A78_1001_1">2022</sage:OperatingLeaseExpirationPeriod>
  <sage:AreaOfOfficeSpace contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639226x1713423" unitRef="sqft" decimals="INF" id="id_9807917_F94445FE-206D-49FF-A159-5362F6146A78_1001_0">22067</sage:AreaOfOfficeSpace>
  <sage:PercentageOfPerformanceBasedGrantsThatWereAchieved contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1734414" unitRef="pure" decimals="2" id="id_9807917_E584A08A-0627-4F33-8856-6F330DB318D8_1002_1">0.35</sage:PercentageOfPerformanceBasedGrantsThatWereAchieved>
  <sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1734414_1642755x1770756" unitRef="shares" decimals="INF" id="id_9807917_924CC947-D899-4758-964C-1CA020A56B55_1001_0">497100</sage:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod>
  <sage:PerformanceBasedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1734414_1642755x1770756" unitRef="iso4217_USD" decimals="-5" id="id_9807917_E584A08A-0627-4F33-8856-6F330DB318D8_1001_0">4800000</sage:PerformanceBasedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1738299" unitRef="shares" decimals="INF" id="id_9807917_8FD642A9-0953-438E-A9A0-9A2F76C1693E_1002_1">3852</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1855330" unitRef="shares" decimals="INF" id="id_9807917_9FAC1265-EAFD-4A1D-B467-5FA8C8C1441B_1001_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <sage:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1641238x1641051" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_1001_6">2027</sage:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
  <sage:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1641238x1643648" id="id_9807917_D7B0BAF3-BCA3-4B5A-8FCC-239586E92C30_2001_5">2031</sage:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
  <us-gaap:PreferredStockTextBlock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1641810x1632459" id="id_9807917_00AE1F45-FE75-44C1-8868-36B61FB58AF8_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Redeemable Convertible Preferred
 Stock&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company has newly authorized preferred stock amounting to
 5,000,000 shares as of December&amp;#xA0;31, 2015 and 2014. The newly
 authorized preferred stock was classified under stockholders&amp;#x2019;
 equity (deficit) as of December&amp;#xA0;31, 2015 and 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of December&amp;#xA0;31, 2014 and 2013, the Company&amp;#x2019;s
 Certificate of Incorporation, as amended and restated, authorized
 the Company to issue no shares and 37,750,000, respectively, shares
 of $0.0001 par value preferred stock. In July 2014, all issued and
 outstanding redeemable convertible preferred stock was converted to
 common stock, see Note 2.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company had issued Series A, Series B and Series C redeemable
 convertible preferred stock (collectively, the &amp;#x201C;Redeemable
 Preferred Stock&amp;#x201D;). The Redeemable Preferred Stock was
 classified outside of stockholders&amp;#x2019; equity (deficit) as of
 December&amp;#xA0;31, 2013 because the shares contained redemption
 features that are not solely within the control of the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;18, 2013, the Company issued an additional 5,000,000
 shares in the second funding of the second tranche of Series A
 Preferred Stock at $1.00 per share, resulting in net proceeds of
 $5.0 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On July&amp;#xA0;1, 2013, the Company issued an additional 5,000,000
 shares in the third funding of the second tranche of Series A
 Preferred Stock at $1.00 per share, resulting in net proceeds of
 $5.0 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On September&amp;#xA0;12, 2013, the Company issued an additional
 12,500,000 shares in the third tranche of Series A Preferred Stock
 at $1.00 per share, resulting in net proceeds of $12.5 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On October&amp;#xA0;18, 2013, the Company issued 250,000 shares of
 Series A Preferred Stock at $1.00 per share, resulting in net
 proceeds of $0.3 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On October&amp;#xA0;15, 2013, the Company entered into a Stock Purchase
 Agreement whereby the Company would issue up to $20.0 million of
 Series B redeemable convertible preferred stock (&amp;#x201C;Series B
 Preferred Stock&amp;#x201D;) at $1.50 per share. The initial purchase
 and sale in the amount of $10.0 million could have occurred once
 certain development milestones had been successfully achieved. The
 second tranche of $10.0 million could be issued after the initial
 closing and at the discretion of the Board of Directors. In
 November 2013, the Company met the development milestones to issue
 the first tranche of the Series B Preferred Stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On January&amp;#xA0;7, 2014, the Company issued 6,666,666 shares of
 Series B Preferred Stock at $1.50 per share, resulting in net
 proceeds of $10.0 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On February&amp;#xA0;12, 2014, the Company issued 3,333,333 shares of
 Series B Preferred Stock at $1.50 in a second closing, resulting in
 net proceeds of $5.0 million. At that time, the Company decided not
 to draw on the remaining $5.0 million of the second tranche of the
 Series B Preferred Stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company incurred issuance costs of $30 thousand in 2014 with
 the issuance of the Series B Preferred Stock which were recorded as
 a reduction of the proceeds received.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On March&amp;#xA0;11, 2014, the Company entered into a Stock Purchase
 Agreement whereby the Company issued 8,973,905 shares of Series C
 redeemable convertible preferred stock (&amp;#x201C;Series C Preferred
 Stock&amp;#x201D;) at $4.2345 per share for net proceeds of $38.0
 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The Company incurred issuance costs of $0.1 million in 2014 with
 the issuance of the Series C Preferred Stock which were recorded as
 a reduction of the proceeds received.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1641810x1632459" unitRef="iso4217_USD" decimals="-5" id="id_9807917_D8FBE533-ED87-4EEF-AAB5-BC9F37279AF1_1002_1">90600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468" unitRef="shares" decimals="INF" id="id_9807917_2F578199-D12C-4441-BE1D-7FCBB251C6F7_1001_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468" unitRef="shares" decimals="INF" id="id_9807917_1C0DE13D-4C03-418F-8221-5920FD0B0432_5001_4">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468" unitRef="shares" decimals="0" id="id_9807917_1C0DE13D-4C03-418F-8221-5920FD0B0432_5001_3">128051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:StockRepurchasedDuringPeriodShares contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468" unitRef="shares" decimals="INF" id="id_9807917_1C0DE13D-4C03-418F-8221-5920FD0B0432_5001_5">0</us-gaap:StockRepurchasedDuringPeriodShares>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468" id="id_9807917_414C281A-A791-4875-9FB7-BC731C7C7172_1001_1">P6M22D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468" unitRef="iso4217_USD" decimals="-5" id="id_9807917_CBCE53E7-623A-4607-8670-08FC90F1A78E_1001_0">300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_5001_4">92638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" id="id_9807917_9D6DD309-CB13-4B08-824A-B5AC1FF796F6_3001_2">P8Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" id="id_9807917_9D6DD309-CB13-4B08-824A-B5AC1FF796F6_3001_4">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_5001_4">26.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_5001_2">45.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_5001_2">1516307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_9E4A3D92-E1A6-4D5E-8564-2DCC7DE27AA4_5001_3">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="shares" decimals="INF" id="id_9807917_BFA055F2-4CD5-44F4-8C50-08DAA3920F34_5001_3">417475</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1001_1">P3Y4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" id="id_9807917_9D6DD309-CB13-4B08-824A-B5AC1FF796F6_3001_3">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1001_2">9200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925" unitRef="iso4217_USD" decimals="-5" id="id_9807917_B8160A09-B2DB-4AD8-9141-7FE26BD1FC60_1001_4">28400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1642993x1703828" unitRef="iso4217_USD" decimals="-3" id="id_9807917_11044BA5-F7D4-4FDB-BCF8-4EA868FE13E1_1001_1">21000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10001_400034">3852</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1632657" unitRef="shares" decimals="0" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10001_400032">128051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10001_400030">417475</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1632657" unitRef="shares" decimals="INF" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10001_400036">23809</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1633302" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10004_700040">-94495000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10003_600029">603000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10003_600037">15176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10003_600031">17000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10003_600033">127000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1641496" unitRef="iso4217_USD" decimals="-3" id="id_9807917_7B3A8408-5FA5-4B7E-B469-440710A01B7F_10003_600035">1211000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_1_4">-3.70</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_1_2">-5790000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_1_3">-6116000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_1_1">-5790000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_1_0">5790000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_90_20150331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_1_4">-0.66</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_1_2">-16871000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_1_3">-16871000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_1_1">-16897000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_90_20150331_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_1_0">16897000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_2_4">-4.57</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_2_2">-6192000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_2_3">-7769000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_2_1">-6188000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_2_0">6188000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_91_20150630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_2_4">-0.90</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_2_2">-25027000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_2_3">-25027000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_2_1">-25059000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_91_20150630_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_2_0">25059000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_3_4">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_3_2">-9468000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_3_3">-9859000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_3_1">-9471000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_3_0">9471000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_92_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_3_4">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_3_2">-24035000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_92_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_3_3">-24035000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_3_1">-24082000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_92_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_3_0">24082000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_92_20141231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_4_4">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_4_2">-12361000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_4_3">-12361000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_4_1">-12361000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_92_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_874A66A2-C01B-47EF-B92D-974C460CCAC5_4_0">12361000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE925099--1510-K0012_STD_92_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_4_4">-0.99</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_4_2">-28562000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE925099--1510-K0012_STD_92_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_4_3">-28562000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE925099--1510-K0012_STD_92_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_4_1">-28612000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE925099--1510-K0012_STD_92_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_9807917_64DCA139-BF01-4832-ABD4-43CFE070D01E_4_0">28612000</us-gaap:OperatingExpenses>
  <context id="eol_PE925099--1510-K0012_STD_92_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_92_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_92_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_92_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_90_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1642993x1703828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sage:ThirdRockVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1642755x1632468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1641810x1632459">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1641238x1643648">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1641238x1641051">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1855330">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandElevenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1738299">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1734414_1642755x1770756">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sage:PerformanceMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639657x1734414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639226x1713423">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sage:OperatingLeaseOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639081x1944181">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639081x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1639081x1632468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1637033x1634411_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1637033x1634411_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1637033x1634411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1636161x1635815">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1634505x1935408">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sage:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1634505x1641629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1930456_1634968x1702458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:WashingtonUniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1640593x1931239">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">sage:ScenarioTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1640593x1729521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">sage:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1815931">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1778734_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1778734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0_1632078x1773506_1634968x2010615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:SecondAndThirdClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1642993x1703828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sage:ThirdRockVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1642755x1632468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1637021_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1637021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1633314_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1639081x1944181">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sage:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1639081x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1637033x1634411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1930456_1634968x1702458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:WashingtonUniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1778734_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0_1632078x1773506_1634968x1973966">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1642993x1703828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sage:ThirdRockVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1642755x1632468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1632078x1930456">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:WashingtonUniversityLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0_1632078x1778734_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_31_20130331_0_1639226x1913817">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sage:SubleaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_31_20140131_0_1632078x1773506_1634968x1767662">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_30_20150630_0_1632078x1815931">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_30_20150430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_30_20131130_0_1632078x1930456">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:WashingtonUniversityLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20160112_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-12</startDate>
      <endDate>2016-01-12</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140107_0_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-07</startDate>
      <endDate>2014-01-07</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20131018_0_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-18</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20130912_0_1637024x1765361_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:ThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-09-12</startDate>
      <endDate>2013-09-12</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140723_0_1637033x1634411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-23</startDate>
      <endDate>2014-07-23</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140723_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-07-23</startDate>
      <endDate>2014-07-23</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140702_0_1639304x1633605_1639657x1734414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-02</startDate>
      <endDate>2014-07-02</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140702_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-07-02</startDate>
      <endDate>2014-07-02</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20130701_0_1637024x1666381_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-01</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20150420_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2015-04-20</startDate>
      <endDate>2015-04-20</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140311_0_1641810x1637021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-03-11</startDate>
      <endDate>2014-03-11</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20130318_0_1637024x1666381_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-18</startDate>
      <endDate>2013-03-18</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20141101_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_1_20140212_0_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-12</startDate>
      <endDate>2014-02-12</endDate>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20160112_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-01-12</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1642993x1703828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sage:ThirdRockVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1642755x1632468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1643648">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1641238x1641051">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1639657x2000438">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1639657x1738299">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1643241_1637541x1637231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1637150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1634760x1634767">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1634505x1935408">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sage:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1634505x1641629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ThirdAndFourthRegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000449">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ThirdAndFourthClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000446">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstAndSecondRegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x2000444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:FirstAndSecondClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0_1632078x1778734_1634968x1702458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:CydexLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1643241_1637541x1637231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1637150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1634760x1634767">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1634505x1935408">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sage:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0_1634505x1641629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20140107_0_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-07</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1641496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131231_0_1642755x1632468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20121231_0_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20121231_0_1643450x1633302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20121231_0_1643450x1632657">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20121231_0_1641810x1641034_1643450x1671852">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sage:SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20150630_0_1632078x1815931_1634968x1813302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:SalesMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20150630_0_1632078x1815931_1634968x1702458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131018_0_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-18</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131015_0_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-15</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20130912_0_1637024x1765361_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:ThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-12</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20140723_0_1637033x1634411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-07-23</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20140702_0_1639657x1738299">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sage:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-07-02</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20130701_0_1637024x1666381_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-01</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20150420_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2015-04-20</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20140311_0_1641810x1637021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-11</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20130318_0_1637024x1666381_1641810x1641034">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-18</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20160216_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
    </entity>
    <period>
      <instant>2016-02-16</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20140212_0_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-12</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20140212_0_1637024x1666381_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-12</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131130_0_1637024x1733189_1641810x1633314">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">sage:FirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131130_0_1632078x1930456_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:WashingtonUniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131130_0_1632078x1930456_1634968x1702458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:WashingtonUniversityLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:RegulatoryMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="eol_PE925099--1510-K0012_STD_0_20131031_0_1632078x1815931_1634968x1904565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001597553</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sage:UniversityOfCaliforniaLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sage:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>sage-20151231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 7 -->
<!-- Creation date: 2016-02-29T16:27:37Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31"
  xmlns:us-types="http://fasb.org/us-types/2015-01-31"
  xmlns:sage="http://www.SageTherapeutics.com/20151231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.SageTherapeutics.com/20151231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>109 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock" id="Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlock">
        <link:definition>111 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock" id="Role_NotesToFinancialStatementsPreferredStockTextBlock">
        <link:definition>113 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock" id="Role_NotesToFinancialStatementsCommonStockTextBlock">
        <link:definition>114 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>115 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>116 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>117 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
        <link:definition>118 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>119 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>120 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>121 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>122 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables" id="Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables">
        <link:definition>123 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>124 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>125 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables">
        <link:definition>126 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>127 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>128 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation" id="DisclosureNatureOfTheBusinessAdditionalInformation">
        <link:definition>129 - Disclosure - Nature of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>130 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet" id="DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet">
        <link:definition>131 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation" id="DisclosureBalanceSheetComponentsAdditionalInformation">
        <link:definition>132 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses" id="DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses">
        <link:definition>133 - Disclosure - Balance Sheet Components - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation">
        <link:definition>134 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases">
        <link:definition>135 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments, Under Non-Cancelable Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation" id="DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation">
        <link:definition>136 - Disclosure - Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation" id="DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation">
        <link:definition>137 - Disclosure - Commitments and Contingencies - Washington University License Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation" id="DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation">
        <link:definition>138 - Disclosure - Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation" id="DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation">
        <link:definition>139 - Disclosure - Commitments and Contingencies - Consulting Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation" id="DisclosureRedeemableConvertiblePreferredStockAdditionalInformation">
        <link:definition>140 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation" id="DisclosureCommonStockAdditionalInformation">
        <link:definition>141 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>142 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense" id="DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense">
        <link:definition>143 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" id="DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
        <link:definition>144 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions" id="DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions">
        <link:definition>145 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock" id="DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock">
        <link:definition>146 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders" id="DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders">
        <link:definition>147 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding" id="DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding">
        <link:definition>148 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>149 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate" id="DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate">
        <link:definition>150 - Disclosure - Income Taxes - Summary of Reconciliation of U.S. Statutory Rate to Company's Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset" id="DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset">
        <link:definition>151 - Disclosure - Income Taxes - Summary of Significant Components of Company's Net Deferred Tax Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits">
        <link:definition>152 - Disclosure - Income Taxes - Summary of Rollforward of Company's Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation" id="DisclosureEmployeeBenefitPlanAdditionalInformation">
        <link:definition>153 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartyTransactionsAdditionalInformation">
        <link:definition>154 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation" id="DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation">
        <link:definition>155 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation" id="DisclosureSubsequentEventAdditionalInformation">
        <link:definition>156 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sage-20151231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sage-20151231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sage-20151231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sage-20151231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedDevelopmentExpensesCurrent" id="sage_AccruedDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" id="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AreaOfLeasedProperty" id="sage_AreaOfLeasedProperty" type="num:areaItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AreaOfOfficeSpace" id="sage_AreaOfOfficeSpace" type="num:areaItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BalanceSheetComponentsTextBlock" id="sage_BalanceSheetComponentsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessRisksAndUncertaintiesPolicyTextBlock" id="sage_BusinessRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalDevelopmentAndRegulatoryMilestoneMember" id="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalDevelopmentMilestonesMember" id="sage_ClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesLineItems" id="sage_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesTable" id="sage_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" id="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockTextBlock" id="sage_CommonStockTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComputerHardwareAndSoftwareMember" id="sage_ComputerHardwareAndSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsultingAgreementMember" id="sage_ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CydexLicenseAgreementMember" id="sage_CydexLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsCapitalizedStartUpCosts" id="sage_DeferredTaxAssetsCapitalizedStartUpCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsChangeInAccountingMethod" id="sage_DeferredTaxAssetsChangeInAccountingMethod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsShareBasedCompensation" id="sage_DeferredTaxAssetsShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsStockOptions" id="sage_DeferredTaxAssetsStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" id="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxLiabilitiesShareBasedCompensation" id="sage_DeferredTaxLiabilitiesShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="sage_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationPermanentItems" id="sage_EffectiveIncomeTaxRateReconciliationPermanentItems" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeStockPurchasePlanMember" id="sage_EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalAndStateNetOperatingLossCarryForwardsExpirationYear" id="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstAndSecondClinicalDevelopmentMilestonesMember" id="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstAndSecondRegulatoryMilestonesMember" id="sage_FirstAndSecondRegulatoryMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstClinicalDevelopmentMilestonesMember" id="sage_FirstClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstTrancheMember" id="sage_FirstTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxDisclosureLineItems" id="sage_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxDisclosureTable" id="sage_IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="InitialPublicOfferingPolicyPolicyTextBlock" id="sage_InitialPublicOfferingPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IssueOfCommonStockObligation" id="sage_IssueOfCommonStockObligation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementMaximumTerm" id="sage_LicenseAgreementMaximumTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseMaintenanceCostAnnual" id="sage_LicenseMaintenanceCostAnnual" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicensingOrConsultantFeesPaidInCommonStock" id="sage_LicensingOrConsultantFeesPaidInCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumMilestonePayments" id="sage_MaximumMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumMilestoneShareBasedPayments" id="sage_MaximumMilestoneShareBasedPayments" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneBasedShareCompensation" id="sage_MilestoneBasedShareCompensation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePayments" id="sage_MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestonePaymentsExpensedDuringPeriod" id="sage_MilestonePaymentsExpensedDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneStockCompensation" id="sage_MilestoneStockCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NatureOfBusinessLineItems" id="sage_NatureOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NatureOfBusinessTable" id="sage_NatureOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OperatingLeaseExpirationPeriod" id="sage_OperatingLeaseExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeaseOneMember" id="sage_OperatingLeaseOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentCostsPolicyTextBlock" id="sage_PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfNetSalesRequiredForRoyaltyEntitlement" id="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfPerformanceBasedGrantsThatWereAchieved" id="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformanceBasedShareBasedCompensationExpense" id="sage_PerformanceBasedShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformanceMilestoneMember" id="sage_PerformanceMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PublicOfferingCostsIncludedInCurrentLiabilities" id="sage_PublicOfferingCostsIncludedInCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryMilestonesMember" id="sage_RegulatoryMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentExpenseRelatedToMilestonePayment" id="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchContractCostsAndAccrualsPolicyTextBlock" id="sage_ResearchContractCostsAndAccrualsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesMilestonesMember" id="sage_SalesMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioOneMember" id="sage_ScenarioOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioTwoMember" id="sage_ScenarioTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondAndThirdClinicalDevelopmentMilestonesMember" id="sage_SecondAndThirdClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondTrancheMember" id="sage_SecondTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" id="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" id="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" id="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharesRepurchasePricePerShare" id="sage_SharesRepurchasePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityReverseStockSplitEffectiveDate" id="sage_StockholdersEquityReverseStockSplitEffectiveDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" id="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" id="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubleaseAgreementMember" id="sage_SubleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesLineItems" id="sage_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesTable" id="sage_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="TaxCreditsExpirationStartYear" id="sage_TaxCreditsExpirationStartYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdAndFourthClinicalDevelopmentMilestonesMember" id="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdAndFourthRegulatoryMilestonesMember" id="sage_ThirdAndFourthRegulatoryMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdRockVenturesLimitedLiabilityCompanyMember" id="sage_ThirdRockVenturesLimitedLiabilityCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ThirdTrancheMember" id="sage_ThirdTrancheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandElevenStockOptionPlanMember" id="sage_TwoThousandElevenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFourteenEmployeeStockPurchasePlanMember" id="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" id="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandFourteenStockOptionPlanMember" id="sage_TwoThousandFourteenStockOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UndrawnAmount" id="sage_UndrawnAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UniversityOfCaliforniaLicenseAgreementMember" id="sage_UniversityOfCaliforniaLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontNonrefundablePayment" id="sage_UpfrontNonrefundablePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpFrontPayment" id="sage_UpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WashingtonUniversityLicenseAgreementMember" id="sage_WashingtonUniversityLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>sage-20151231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 7 -->
<!-- Creation date: 2016-02-29T16:27:37Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DocumentandEntityInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfIncome" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNatureOfTheBusinessAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureRedeemableConvertiblePreferredStockAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommonStockTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredOfferingCosts" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicensingOrConsultantFeesPaidInCommonStock" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="sage_LicensingOrConsultantFeesPaidInCommonStock" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AccruedDevelopmentExpensesCurrent" xlink:label="sage_AccruedDevelopmentExpensesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sage_AccruedDevelopmentExpensesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="sage_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sage_EffectiveIncomeTaxRateReconciliationPermanentItems" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="sage_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsChangeInAccountingMethod" xlink:label="sage_DeferredTaxAssetsChangeInAccountingMethod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsStockOptions" xlink:label="sage_DeferredTaxAssetsStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sage_DeferredTaxAssetsCapitalizedStartUpCosts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sage_DeferredTaxAssetsChangeInAccountingMethod" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sage_DeferredTaxAssetsStockOptions" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>sage-20151231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 7 -->
<!-- Creation date: 2016-02-29T16:27:37Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DocumentandEntityInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfIncome" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNatureOfTheBusinessAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureRedeemableConvertiblePreferredStockAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommonStockTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" xlink:label="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" xlink:label="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicensingOrConsultantFeesPaidInCommonStock" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PublicOfferingCostsIncludedInCurrentLiabilities" xlink:label="sage_PublicOfferingCostsIncludedInCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sage_LicensingOrConsultantFeesPaidInCommonStock" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sage_PublicOfferingCostsIncludedInCurrentLiabilities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_NatureOfBusinessLineItems" xlink:label="sage_NatureOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_NatureOfBusinessTable" xlink:label="sage_NatureOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="sage_NatureOfBusinessTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockholdersEquityReverseStockSplitEffectiveDate" xlink:label="sage_StockholdersEquityReverseStockSplitEffectiveDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sage_SummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sage_StockholdersEquityReverseStockSplitEffectiveDate" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ComputerHardwareAndSoftwareMember" xlink:label="sage_ComputerHardwareAndSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sage_ComputerHardwareAndSoftwareMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AreaOfLeasedProperty" xlink:label="sage_AreaOfLeasedProperty"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AreaOfOfficeSpace" xlink:label="sage_AreaOfOfficeSpace"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_OperatingLeaseExpirationPeriod" xlink:label="sage_OperatingLeaseExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_OperatingLeaseOneMember" xlink:label="sage_OperatingLeaseOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SubleaseAgreementMember" xlink:label="sage_SubleaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AreaOfOfficeSpace" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_OperatingLeaseExpirationPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AreaOfLeasedProperty" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sage_OperatingLeaseOneMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sage_SubleaseAgreementMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CydexLicenseAgreementMember" xlink:label="sage_CydexLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstAndSecondRegulatoryMilestonesMember" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondRegulatoryMilestonesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthRegulatoryMilestonesMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_CydexLicenseAgreementMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IssueOfCommonStockObligation" xlink:label="sage_IssueOfCommonStockObligation"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UpfrontNonrefundablePayment" xlink:label="sage_UpfrontNonrefundablePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_WashingtonUniversityLicenseAgreementMember" xlink:label="sage_WashingtonUniversityLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_UpfrontNonrefundablePayment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseMaintenanceCostAnnual" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_IssueOfCommonStockObligation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_WashingtonUniversityLicenseAgreementMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseAgreementMaximumTerm" xlink:label="sage_LicenseAgreementMaximumTerm"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePaymentsExpensedDuringPeriod" xlink:label="sage_MilestonePaymentsExpensedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ScenarioOneMember" xlink:label="sage_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ScenarioTwoMember" xlink:label="sage_ScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UniversityOfCaliforniaLicenseAgreementMember" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_SalesMilestonesMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseAgreementMaximumTerm" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePaymentsExpensedDuringPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_UpFrontPayment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseMaintenanceCostAnnual" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_UniversityOfCaliforniaLicenseAgreementMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioOneMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioTwoMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ConsultingAgreementMember" xlink:label="sage_ConsultingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MaximumMilestonePayments" xlink:label="sage_MaximumMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MaximumMilestoneShareBasedPayments" xlink:label="sage_MaximumMilestoneShareBasedPayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestoneBasedShareCompensation" xlink:label="sage_MilestoneBasedShareCompensation"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestoneStockCompensation" xlink:label="sage_MilestoneStockCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SecondAndThirdClinicalDevelopmentMilestonesMember" xlink:label="sage_SecondAndThirdClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstClinicalDevelopmentMilestonesMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_SecondAndThirdClinicalDevelopmentMilestonesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MaximumMilestonePayments" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MaximumMilestoneShareBasedPayments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestoneStockCompensation" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestoneBasedShareCompensation" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_ConsultingAgreementMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstTrancheMember" xlink:label="sage_FirstTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SecondTrancheMember" xlink:label="sage_SecondTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdTrancheMember" xlink:label="sage_ThirdTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UndrawnAmount" xlink:label="sage_UndrawnAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="sage_SecondTrancheMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="sage_ThirdTrancheMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="sage_FirstTrancheMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ShareholdersEquityClassAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sage_UndrawnAmount" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" xlink:label="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PerformanceBasedShareBasedCompensationExpense" xlink:label="sage_PerformanceBasedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PerformanceMilestoneMember" xlink:label="sage_PerformanceMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SharesRepurchasePricePerShare" xlink:label="sage_SharesRepurchasePricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandElevenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandElevenStockOptionPlanMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenStockOptionPlanMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_PerformanceBasedShareBasedCompensationExpense" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_SharesRepurchasePricePerShare" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_PerformanceMilestoneMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.2900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sage_EmployeeStockPurchasePlanMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsShareBasedCompensation" xlink:label="sage_DeferredTaxAssetsShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:label="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxLiabilitiesShareBasedCompensation" xlink:label="sage_DeferredTaxLiabilitiesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" xlink:label="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IncomeTaxDisclosureLineItems" xlink:label="sage_IncomeTaxDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IncomeTaxDisclosureTable" xlink:label="sage_IncomeTaxDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TaxCreditsExpirationStartYear" xlink:label="sage_TaxCreditsExpirationStartYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_IncomeTaxDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_TaxCreditsExpirationStartYear" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_DeferredTaxAssetsShareBasedCompensation" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_DeferredTaxLiabilitiesShareBasedCompensation" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sage_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdRockVenturesLimitedLiabilityCompanyMember" xlink:label="sage_ThirdRockVenturesLimitedLiabilityCompanyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sage_ThirdRockVenturesLimitedLiabilityCompanyMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>sage-20151231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 7 -->
<!-- Creation date: 2016-02-29T16:27:37Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_9807917_1642737_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_9807917_1642737_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_9807917_1646304_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_9807917_1646304_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AccruedDevelopmentExpensesCurrent" xlink:label="sage_AccruedDevelopmentExpensesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_AccruedDevelopmentExpensesCurrent_lbl" xml:lang="en-US" id="id_9807917_1797973_3_1">Accrued Development Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_AccruedDevelopmentExpensesCurrent_lbl" xml:lang="en-US" id="id_9807917_1797973_1_1">Accrued Development Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_AccruedDevelopmentExpensesCurrent_lbl" xml:lang="en-US" id="id_9807917_1797973_2_1">Development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AccruedDevelopmentExpensesCurrent" xlink:to="sage_AccruedDevelopmentExpensesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1646636_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1646636_2_1">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1646636_6_1">Total accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1646637_1_1">Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1646637_2_1">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_9807917_1645521_1_1">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_9807917_1645521_2_1">Professional services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9807917_1647288_1_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9807917_1647288_14_1">Less: Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_9807917_1644587_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_9807917_1644587_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_9807917_1641496_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_9807917_1641496_2_1">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment_lbl" xml:lang="en-US" id="id_9807917_1742153_3_1">Additional payments based on achievement of certain development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment_lbl" xml:lang="en-US" id="id_9807917_1742153_1_1">Additional Payments Based On Achievement Of Certain Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment_lbl" xml:lang="en-US" id="id_9807917_1742153_2_1">Expected milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_9807917_1635471_1_1">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_9807917_1635471_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_9807917_1645027_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_9807917_1645027_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9807917_1650010_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9807917_1650010_2_1">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9807917_1650010_12_1">Total Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_9807917_1633423_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_9807917_1633423_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_9807917_1634668_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_9807917_1634668_2_1">Anti-dilutive common stock equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_9807917_1639081_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_9807917_1639081_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9807917_1636654_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_9807917_1636654_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_9807917_1642368_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_9807917_1642368_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AreaOfLeasedProperty" xlink:label="sage_AreaOfLeasedProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_AreaOfLeasedProperty_lbl" xml:lang="en-US" id="id_9807917_1824112_3_1">Area of leased property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_AreaOfLeasedProperty_lbl" xml:lang="en-US" id="id_9807917_1824112_1_1">Area Of Leased Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_AreaOfLeasedProperty_lbl" xml:lang="en-US" id="id_9807917_1824112_2_1">Area of leased property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AreaOfLeasedProperty" xlink:to="sage_AreaOfLeasedProperty_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AreaOfOfficeSpace" xlink:label="sage_AreaOfOfficeSpace"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_AreaOfOfficeSpace_lbl" xml:lang="en-US" id="id_9807917_1805306_3_1">Area Of Office Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_AreaOfOfficeSpace_lbl" xml:lang="en-US" id="id_9807917_1805306_1_1">Area Of Office Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_AreaOfOfficeSpace_lbl" xml:lang="en-US" id="id_9807917_1805306_2_1">Office space rented under operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_AreaOfOfficeSpace" xlink:to="sage_AreaOfOfficeSpace_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_9807917_1632222_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_9807917_1632222_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_9807917_1648873_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_9807917_1648873_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_9807917_1636242_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_9807917_1636242_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_9807917_1650014_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_9807917_1650014_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_9807917_1643954_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_9807917_1643954_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_9807917_1648997_1_1">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_9807917_1648997_2_1">Assets fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1642755_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1642755_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_BalanceSheetComponentsTextBlock" xlink:label="sage_BalanceSheetComponentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_BalanceSheetComponentsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1893279_3_1">Balance Sheet Components [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_BalanceSheetComponentsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1893279_1_1">Balance Sheet Components [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_BalanceSheetComponentsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1893279_2_1">Balance Sheet Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_BalanceSheetComponentsTextBlock" xlink:to="sage_BalanceSheetComponentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1635868_1_1">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1635868_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_BusinessRisksAndUncertaintiesPolicyTextBlock" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1786224_3_1">Business Risks And Uncertainties Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1786224_1_1">Business Risks And Uncertainties Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1786224_2_1">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_BusinessRisksAndUncertaintiesPolicyTextBlock" xlink:to="sage_BusinessRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9807917_1651160_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9807917_1651160_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9807917_1651160_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_9807917_1651160_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_9807917_1648882_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_9807917_1648882_6_1">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642769_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642769_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_9807917_1634691_1_1">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_9807917_1634691_2_1">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_9807917_1636285_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_9807917_1636285_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xml:lang="en-US" id="id_9807917_1767662_3_1">Clinical Development And Regulatory Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xml:lang="en-US" id="id_9807917_1767662_1_1">Clinical Development And Regulatory Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xml:lang="en-US" id="id_9807917_1767662_2_1">Clinical Development and Regulatory Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:to="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1904565_3_1">Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1904565_1_1">Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1904565_2_1">Clinical Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ClinicalDevelopmentMilestonesMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_9807917_1646952_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_9807917_1646952_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1640697_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1640697_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1641131_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1641131_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_9807917_1904563_3_1">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_9807917_1904563_1_1">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_9807917_1904563_2_1">Commitments And Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_CommitmentsAndContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_9807917_1852432_3_1">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_9807917_1852432_1_1">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" id="id_9807917_1852432_2_1">Commitments And Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_9807917_1640698_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_9807917_1640698_2_1">Total number of shares reserved under equity plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_9807917_1632657_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_9807917_1632657_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9807917_1637092_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9807917_1637092_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1633455_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1633455_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_9807917_1641977_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_9807917_1641977_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1635113_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1635113_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption_lbl" xml:lang="en-US" id="id_9807917_1996522_3_1">Common stock shares outstanding reserved for issuance increase percentage on stock option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption_lbl" xml:lang="en-US" id="id_9807917_1996522_1_1">Common Stock Shares Outstanding Reserved For Issuance Increase Percentage On Stock Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption_lbl" xml:lang="en-US" id="id_9807917_1996522_2_1">Percentage of increase to stock option on issued and outstanding shares of Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" xlink:to="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommonStockTextBlock" xlink:label="sage_CommonStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_CommonStockTextBlock_lbl" xml:lang="en-US" id="id_9807917_1663046_3_1">Common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_CommonStockTextBlock_lbl" xml:lang="en-US" id="id_9807917_1663046_1_1">Common Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_CommonStockTextBlock_lbl" xml:lang="en-US" id="id_9807917_1663046_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CommonStockTextBlock" xlink:to="sage_CommonStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_9807917_1646846_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_9807917_1646846_2_1">Common stock, $0.0001 par value; 120,000,000 shares authorized at December 31, 2015 and 2014; 28,823,549 and 25,621,791 shares issued and outstanding at December 31, 2015 and 2014, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US" id="id_9807917_1637914_1_1">Common Stock, Voting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US" id="id_9807917_1637914_2_1">Voting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639488_1_1">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639488_2_1">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642400_1_1">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642400_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1635502_1_1">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1635502_2_1">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ComputerHardwareAndSoftwareMember" xlink:label="sage_ComputerHardwareAndSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="id_9807917_1935408_3_1">Computer Hardware And Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="id_9807917_1935408_1_1">Computer Hardware And Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="id_9807917_1935408_2_1">Computer Hardware and Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ComputerHardwareAndSoftwareMember" xlink:to="sage_ComputerHardwareAndSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_9807917_1636695_1_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_9807917_1636695_2_1">Concentration of Credit Risk and of Significant Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ConsultingAgreementMember" xlink:label="sage_ConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ConsultingAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1773506_3_1">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ConsultingAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1773506_1_1">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ConsultingAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1773506_2_1">Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ConsultingAgreementMember" xlink:to="sage_ConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_9807917_1650519_1_1">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" id="id_9807917_1650519_2_1">Conversion of preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_9807917_1642408_1_1">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" id="id_9807917_1642408_2_1">Issuance of additional shares of common stock upon conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_9807917_1638733_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_9807917_1638733_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CydexLicenseAgreementMember" xlink:label="sage_CydexLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_CydexLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1778734_3_1">CyDex License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_CydexLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1778734_1_1">CyDex License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_CydexLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1778734_2_1">CyDex License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_CydexLicenseAgreementMember" xlink:to="sage_CydexLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1637486_1_1">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1637486_2_1">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" id="id_9807917_1650157_1_1">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" id="id_9807917_1650157_2_1">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="sage_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" id="id_9807917_1950261_3_1">Deferred tax assets capitalized start-up costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" id="id_9807917_1950261_1_1">Deferred Tax Assets Capitalized Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" id="id_9807917_1950261_2_1">Capitalized start-up costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="sage_DeferredTaxAssetsCapitalizedStartUpCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsChangeInAccountingMethod" xlink:label="sage_DeferredTaxAssetsChangeInAccountingMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DeferredTaxAssetsChangeInAccountingMethod_lbl" xml:lang="en-US" id="id_9807917_1795341_3_1">Deferred tax assets change in accounting method.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DeferredTaxAssetsChangeInAccountingMethod_lbl" xml:lang="en-US" id="id_9807917_1795341_1_1">Deferred Tax Assets Change In Accounting Method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sage_DeferredTaxAssetsChangeInAccountingMethod_lbl" xml:lang="en-US" id="id_9807917_1795341_14_1">Accounting method change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DeferredTaxAssetsChangeInAccountingMethod" xlink:to="sage_DeferredTaxAssetsChangeInAccountingMethod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_9807917_1648382_1_1">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_9807917_1648382_6_1">Total net deferred tax asset before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_9807917_1649882_1_1">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_9807917_1649882_6_1">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1651169_1_1">Deferred Tax Assets, Net of Valuation Allowance, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1651169_2_1">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_9807917_1648153_1_1">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_9807917_1648153_2_1">Net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_9807917_1650784_1_1">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" id="id_9807917_1650784_2_1">Federal operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_9807917_1649018_1_1">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="id_9807917_1649018_2_1">State operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_9807917_1650522_1_1">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_9807917_1650522_2_1">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9807917_1648268_1_1">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9807917_1648268_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsShareBasedCompensation" xlink:label="sage_DeferredTaxAssetsShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DeferredTaxAssetsShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_2015550_3_1">Deferred tax assets share based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DeferredTaxAssetsShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_2015550_1_1">Deferred Tax Assets Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_DeferredTaxAssetsShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_2015550_2_1">Excess equity based compensation, tax deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DeferredTaxAssetsShareBasedCompensation" xlink:to="sage_DeferredTaxAssetsShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsStockOptions" xlink:label="sage_DeferredTaxAssetsStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DeferredTaxAssetsStockOptions_lbl" xml:lang="en-US" id="id_9807917_1684268_3_1">Deferred tax assets stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DeferredTaxAssetsStockOptions_lbl" xml:lang="en-US" id="id_9807917_1684268_1_1">Deferred Tax Assets Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_DeferredTaxAssetsStockOptions_lbl" xml:lang="en-US" id="id_9807917_1684268_2_1">Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DeferredTaxAssetsStockOptions" xlink:to="sage_DeferredTaxAssetsStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" id="id_9807917_1651677_1_1">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" id="id_9807917_1651677_2_1">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_9807917_1651791_1_1">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_9807917_1651791_2_1">Research and development tax credits carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:label="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xml:lang="en-US" id="id_9807917_1774673_3_1">Deferred tax assets tax credit carryforwards research expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xml:lang="en-US" id="id_9807917_1774673_1_1">Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xml:lang="en-US" id="id_9807917_1774673_2_1">Research and development tax credits carryforwards expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:to="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="id_9807917_1648015_1_1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="id_9807917_1648015_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9807917_1647498_1_1">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9807917_1647498_2_1">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9807917_1647498_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1647065_1_1">Deferred Tax Liabilities, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1647065_2_1">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxLiabilitiesShareBasedCompensation" xlink:label="sage_DeferredTaxLiabilitiesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DeferredTaxLiabilitiesShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_1884042_3_1">Deferred Tax Liabilities Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DeferredTaxLiabilitiesShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_1884042_1_1">Deferred Tax Liabilities Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_DeferredTaxLiabilitiesShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_1884042_2_1">Excess equity based compensation, tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DeferredTaxLiabilitiesShareBasedCompensation" xlink:to="sage_DeferredTaxLiabilitiesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_9807917_1648156_1_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_9807917_1648156_2_1">Employer contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" id="id_9807917_1637114_1_1">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" id="id_9807917_1637114_2_1">Employer matching contribution, percent of match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_9807917_1642820_1_1">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_9807917_1642820_2_1">Maximum annual contributions per employee, percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_9807917_1651565_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_9807917_1651565_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_9807917_1651566_1_1">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_9807917_1651566_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_9807917_1640297_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_9807917_1640297_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642836_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642836_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" id="id_9807917_1651810_1_1">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" id="id_9807917_1651810_2_1">Dividends declared</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DocumentAndEntityInformationAbstract" xlink:label="sage_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_9807917_1666892_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_9807917_1666892_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_9807917_1666892_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="sage_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_9807917_1631516_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_9807917_1631516_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_9807917_1633130_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_9807917_1633130_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_9807917_1642039_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_9807917_1642039_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_9807917_1634742_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_9807917_1634742_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_9807917_1643648_1_1">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_9807917_1643648_2_1">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_9807917_1633917_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_9807917_1633917_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_9807917_1634329_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_9807917_1634329_2_1">Net loss per share attributable to common stockholders-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642845_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642845_2_1">Basic and Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644008_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644008_2_1">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1644010_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1644010_6_1">Total effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_9807917_1636341_1_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_9807917_1636341_2_1">Tax due at statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9807917_1637967_1_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_9807917_1637967_2_1">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" id="id_9807917_1632292_1_1">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" id="id_9807917_1632292_2_1">Foreign rate differential</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_9807917_1635549_1_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_9807917_1635549_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="sage_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US" id="id_9807917_1878207_3_1">Effective Income Tax Rate Reconciliation Permanent Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US" id="id_9807917_1878207_1_1">Effective Income Tax Rate Reconciliation Permanent Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sage_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US" id="id_9807917_1878207_14_1">Permanent items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="sage_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_9807917_1638361_1_1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_9807917_1638361_2_1">State taxes, net of federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_9807917_1632294_1_1">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_9807917_1632294_14_1">Federal and state credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1644907_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1644907_2_1">Employee related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_9807917_1648664_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_9807917_1648664_2_1">Total unrecognized stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_9807917_1644016_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_9807917_1644016_2_1">Weighted average period of unrecognized compensation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_9807917_1633925_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_9807917_1633925_2_1">Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_9807917_1944181_3_1">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_9807917_1944181_1_1">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_9807917_1944181_2_1">Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_EmployeeStockPurchasePlanMember" xlink:to="sage_EmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_9807917_1634753_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_9807917_1634753_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1635556_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1635556_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_9807917_1638773_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_9807917_1638773_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_9807917_1635557_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_9807917_1635557_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_9807917_1647157_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_9807917_1647157_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_9807917_1639155_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_9807917_1639155_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_9807917_1640748_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_9807917_1640748_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_9807917_1639522_1_1">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_9807917_1639522_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1636759_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1636759_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_9807917_1644027_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_9807917_1644027_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="id_9807917_1638776_1_1">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="id_9807917_1638776_2_1">Percentage of ownership held with related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_9807917_1637539_1_1">Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_9807917_1637539_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_9807917_1637541_1_1">Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_9807917_1637541_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_9807917_1634760_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_9807917_1634760_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_lbl" xml:lang="en-US" id="id_9807917_1637986_1_1">Fair Value by Shareholders' Equity Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_lbl" xml:lang="en-US" id="id_9807917_1637986_2_1">Fair Value by Shareholders' Equity Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_9807917_1643241_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_9807917_1643241_2_1">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_9807917_1637150_1_1">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_9807917_1637150_2_1">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_9807917_1634767_1_1">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_9807917_1634767_2_1">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1641610_1_1">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1641610_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_9807917_1637995_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_9807917_1637995_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" xlink:label="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US" id="id_9807917_1740035_3_1">Federal and state net operating loss carry forwards expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US" id="id_9807917_1740035_1_1">Federal And State Net Operating Loss Carry Forwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear_lbl" xml:lang="en-US" id="id_9807917_1740035_2_1">Federal and state net operating loss carryforwards expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" xlink:to="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000444_3_1">First And Second Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000444_1_1">First And Second Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000444_2_1">First and Second Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:to="sage_FirstAndSecondClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstAndSecondRegulatoryMilestonesMember" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000446_3_1">First And Second Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000446_1_1">First And Second Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000446_2_1">First and Second Regulatory Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstAndSecondRegulatoryMilestonesMember" xlink:to="sage_FirstAndSecondRegulatoryMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_FirstClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1973966_3_1">First Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_FirstClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1973966_1_1">First Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_FirstClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1973966_2_1">First Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstClinicalDevelopmentMilestonesMember" xlink:to="sage_FirstClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstTrancheMember" xlink:label="sage_FirstTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_FirstTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1733189_3_1">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_FirstTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1733189_1_1">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_FirstTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1733189_2_1">First Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_FirstTrancheMember" xlink:to="sage_FirstTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_9807917_1641629_1_1">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_9807917_1641629_2_1">Furniture and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9807917_1650296_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_9807917_1650296_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_9807917_1639948_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_9807917_1639948_2_1">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1640809_1_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1640809_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_9807917_1631567_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_9807917_1631567_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_9807917_1634394_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_9807917_1634394_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_9807917_1635998_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_9807917_1635998_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_9807917_1641238_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_9807917_1641238_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_9807917_1634395_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_9807917_1634395_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1638039_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1638039_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IncomeTaxDisclosureLineItems" xlink:label="sage_IncomeTaxDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="id_9807917_1954489_3_1">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="id_9807917_1954489_1_1">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="id_9807917_1954489_2_1">Income Tax Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_IncomeTaxDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IncomeTaxDisclosureTable" xlink:label="sage_IncomeTaxDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="id_9807917_1714221_3_1">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="id_9807917_1714221_1_1">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="id_9807917_1714221_2_1">Income Tax Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IncomeTaxDisclosureTable" xlink:to="sage_IncomeTaxDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639962_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639962_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US" id="id_9807917_1633988_1_1">Income Tax Examination, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US" id="id_9807917_1633988_2_1">Income tax position description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_9807917_1646705_1_1">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_9807917_1646705_2_1">Accrued interest or penalties related to uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9807917_1648041_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_9807917_1648041_2_1">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644088_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644088_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_9807917_1651075_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_9807917_1651075_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_9807917_1650059_1_1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_9807917_1650059_2_1">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US" id="id_9807917_1644979_1_1">Increase (Decrease) in Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US" id="id_9807917_1644979_14_1">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_9807917_1631969_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_9807917_1631969_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_9807917_1645210_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_9807917_1645210_14_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xml:lang="en-US" id="id_9807917_1636000_1_1">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xml:lang="en-US" id="id_9807917_1636000_2_1">Dilutive effect of shares of common stock equivalents resulting from common stock options and preferred common stock (as converted)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_InitialPublicOfferingPolicyPolicyTextBlock" xlink:label="sage_InitialPublicOfferingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_InitialPublicOfferingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1664209_3_1">Initial Public Offering Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_InitialPublicOfferingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1664209_1_1">Initial Public Offering Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_InitialPublicOfferingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1664209_2_1">Public Offerings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_InitialPublicOfferingPolicyPolicyTextBlock" xlink:to="sage_InitialPublicOfferingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" id="id_9807917_1644889_1_1">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" id="id_9807917_1644889_2_1">Interest income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_9807917_1634411_1_1">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_9807917_1634411_2_1">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IssueOfCommonStockObligation" xlink:label="sage_IssueOfCommonStockObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_IssueOfCommonStockObligation_lbl" xml:lang="en-US" id="id_9807917_2000302_3_1">Issue of common stock obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_IssueOfCommonStockObligation_lbl" xml:lang="en-US" id="id_9807917_2000302_1_1">Issue Of Common Stock Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_IssueOfCommonStockObligation_lbl" xml:lang="en-US" id="id_9807917_2000302_2_1">Issuance of common stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_IssueOfCommonStockObligation" xlink:to="sage_IssueOfCommonStockObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1639226_1_1">Lease Arrangement, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1639226_2_1">Lease Arrangement, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1640396_1_1">Lease Arrangement, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1640396_2_1">Lease Arrangement, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_9807917_1646694_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_9807917_1646694_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_9807917_1646695_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_9807917_1646695_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1636826_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1636826_2_1">Liabilities and Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1647463_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1647463_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_9807917_1639229_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_9807917_1639229_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9807917_1646137_1_1">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_9807917_1646137_2_1">Liabilities fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" id="id_9807917_1646905_1_1">Liability for Uncertain Tax Positions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US" id="id_9807917_1646905_2_1">Uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseAgreementMaximumTerm" xlink:label="sage_LicenseAgreementMaximumTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_LicenseAgreementMaximumTerm_lbl" xml:lang="en-US" id="id_9807917_1996404_3_1">License agreement maximum term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_LicenseAgreementMaximumTerm_lbl" xml:lang="en-US" id="id_9807917_1996404_1_1">License Agreement Maximum Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_LicenseAgreementMaximumTerm_lbl" xml:lang="en-US" id="id_9807917_1996404_2_1">Licenses Expiration period, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseAgreementMaximumTerm" xlink:to="sage_LicenseAgreementMaximumTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_LicenseMaintenanceCostAnnual_lbl" xml:lang="en-US" id="id_9807917_1929067_3_1">License maintenance cost annual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_LicenseMaintenanceCostAnnual_lbl" xml:lang="en-US" id="id_9807917_1929067_1_1">License Maintenance Cost Annual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_LicenseMaintenanceCostAnnual_lbl" xml:lang="en-US" id="id_9807917_1929067_2_1">Annual license maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicenseMaintenanceCostAnnual" xlink:to="sage_LicenseMaintenanceCostAnnual_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicensingOrConsultantFeesPaidInCommonStock" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock_lbl" xml:lang="en-US" id="id_9807917_1735839_3_1">Licensing or Consultant Fees Paid in Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock_lbl" xml:lang="en-US" id="id_9807917_1735839_1_1">Licensing or Consultant Fees Paid in Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock_lbl" xml:lang="en-US" id="id_9807917_1735839_2_1">Non-cash licensing and consulting fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_LicensingOrConsultantFeesPaidInCommonStock" xlink:to="sage_LicensingOrConsultantFeesPaidInCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_9807917_1633605_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_9807917_1633605_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MaximumMilestonePayments" xlink:label="sage_MaximumMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_MaximumMilestonePayments_lbl" xml:lang="en-US" id="id_9807917_1722189_3_1">Maximum milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_MaximumMilestonePayments_lbl" xml:lang="en-US" id="id_9807917_1722189_1_1">Maximum Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_MaximumMilestonePayments_lbl" xml:lang="en-US" id="id_9807917_1722189_2_1">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MaximumMilestonePayments" xlink:to="sage_MaximumMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MaximumMilestoneShareBasedPayments" xlink:label="sage_MaximumMilestoneShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_MaximumMilestoneShareBasedPayments_lbl" xml:lang="en-US" id="id_9807917_1996408_3_1">Maximum milestone share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_MaximumMilestoneShareBasedPayments_lbl" xml:lang="en-US" id="id_9807917_1996408_1_1">Maximum Milestone Share Based Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_MaximumMilestoneShareBasedPayments_lbl" xml:lang="en-US" id="id_9807917_1996408_2_1">Shares of common stock for attaining milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MaximumMilestoneShareBasedPayments" xlink:to="sage_MaximumMilestoneShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestoneBasedShareCompensation" xlink:label="sage_MilestoneBasedShareCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_MilestoneBasedShareCompensation_lbl" xml:lang="en-US" id="id_9807917_1996409_3_1">Milestone based share compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_MilestoneBasedShareCompensation_lbl" xml:lang="en-US" id="id_9807917_1996409_1_1">Milestone Based Share Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_MilestoneBasedShareCompensation_lbl" xml:lang="en-US" id="id_9807917_1996409_2_1">Milestone based share compensation, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestoneBasedShareCompensation" xlink:to="sage_MilestoneBasedShareCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_MilestonePayments_lbl" xml:lang="en-US" id="id_9807917_1679428_3_1">Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_MilestonePayments_lbl" xml:lang="en-US" id="id_9807917_1679428_1_1">Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_MilestonePayments_lbl" xml:lang="en-US" id="id_9807917_1679428_2_1">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestonePayments" xlink:to="sage_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePaymentsExpensedDuringPeriod" xlink:label="sage_MilestonePaymentsExpensedDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_MilestonePaymentsExpensedDuringPeriod_lbl" xml:lang="en-US" id="id_9807917_1956091_3_1">Milestone or royalty payments, expenses recognized during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_MilestonePaymentsExpensedDuringPeriod_lbl" xml:lang="en-US" id="id_9807917_1956091_1_1">Milestone Payments Expensed During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_MilestonePaymentsExpensedDuringPeriod_lbl" xml:lang="en-US" id="id_9807917_1956091_2_1">Milestone or royalty payments, expense recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestonePaymentsExpensedDuringPeriod" xlink:to="sage_MilestonePaymentsExpensedDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestoneStockCompensation" xlink:label="sage_MilestoneStockCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_MilestoneStockCompensation_lbl" xml:lang="en-US" id="id_9807917_1996423_3_1">Milestone stock compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_MilestoneStockCompensation_lbl" xml:lang="en-US" id="id_9807917_1996423_1_1">Milestone Stock Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_MilestoneStockCompensation_lbl" xml:lang="en-US" id="id_9807917_1996423_2_1">Payments for stock issued upon reaching a milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_MilestoneStockCompensation" xlink:to="sage_MilestoneStockCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_9807917_1637231_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_9807917_1637231_2_1">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_NatureOfBusinessLineItems" xlink:label="sage_NatureOfBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_NatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_9807917_1952602_3_1">Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_NatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_9807917_1952602_1_1">Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_NatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_9807917_1952602_2_1">Nature Of Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="sage_NatureOfBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_NatureOfBusinessTable" xlink:label="sage_NatureOfBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_NatureOfBusinessTable_lbl" xml:lang="en-US" id="id_9807917_1951143_3_1">Nature Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_NatureOfBusinessTable_lbl" xml:lang="en-US" id="id_9807917_1951143_1_1">Nature Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_NatureOfBusinessTable_lbl" xml:lang="en-US" id="id_9807917_1951143_2_1">Nature Of Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_NatureOfBusinessTable" xlink:to="sage_NatureOfBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1649336_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1649336_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9807917_1633620_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9807917_1633620_2_1">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1649062_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1649062_2_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9807917_1638471_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9807917_1638471_2_1">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1631616_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_9807917_1631616_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9807917_1639627_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_9807917_1639627_2_1">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9807917_1644530_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9807917_1644530_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9807917_1644530_6_1">Net loss and comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_9807917_1644530_12_1">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" id="id_9807917_1636452_1_1">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" id="id_9807917_1636452_2_1">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_9807917_1644761_1_1">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_9807917_1644761_2_1">Net loss attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_9807917_1644761_6_1">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" id="id_9807917_1642160_1_1">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" id="id_9807917_1642160_2_1">Basic net loss per share attributable to common stockholders:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642952_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1642952_2_1">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_9807917_1637244_1_1">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_9807917_1637244_2_1">Supplemental disclosure of non-cash investing and financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_9807917_1648944_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_9807917_1648944_2_1">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_9807917_1648944_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_9807917_1632029_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_9807917_1632029_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_9807917_1645424_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_9807917_1645424_2_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_OperatingLeaseExpirationPeriod" xlink:label="sage_OperatingLeaseExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_OperatingLeaseExpirationPeriod_lbl" xml:lang="en-US" id="id_9807917_1653891_3_1">Operating Lease Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_OperatingLeaseExpirationPeriod_lbl" xml:lang="en-US" id="id_9807917_1653891_1_1">Operating Lease Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_OperatingLeaseExpirationPeriod_lbl" xml:lang="en-US" id="id_9807917_1653891_2_1">Operating lease end year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_OperatingLeaseExpirationPeriod" xlink:to="sage_OperatingLeaseExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_OperatingLeaseOneMember" xlink:label="sage_OperatingLeaseOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_OperatingLeaseOneMember_lbl" xml:lang="en-US" id="id_9807917_1713423_3_1">Operating Lease One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_OperatingLeaseOneMember_lbl" xml:lang="en-US" id="id_9807917_1713423_1_1">Operating Lease One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_OperatingLeaseOneMember_lbl" xml:lang="en-US" id="id_9807917_1713423_2_1">Operating Lease One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_OperatingLeaseOneMember" xlink:to="sage_OperatingLeaseOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_9807917_1644876_1_1">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_9807917_1644876_6_1">Total Operating leases, future minimum payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_9807917_1644520_1_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_9807917_1644520_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_9807917_1644960_1_1">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_9807917_1644960_2_1">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_9807917_1647220_1_1">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_9807917_1647220_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_9807917_1647781_1_1">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_9807917_1647781_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_9807917_1644405_1_1">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_9807917_1644405_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_9807917_1647452_1_1">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_9807917_1647452_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_lbl" xml:lang="en-US" id="id_9807917_1647666_1_1">Operating Leases, Income Statement, Sublease Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_lbl" xml:lang="en-US" id="id_9807917_1647666_2_1">Lease income per month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:to="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_9807917_1648832_1_1">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_9807917_1648832_2_1">Rent expense, net of sublease income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_9807917_1641734_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_9807917_1641734_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1636873_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1636873_2_1">Nature of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1644757_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_9807917_1644757_2_1">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1645291_1_1">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1645291_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9807917_1645664_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_9807917_1645664_2_1">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PatentCostsPolicyTextBlock" xlink:label="sage_PatentCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1961751_3_1">Patent Costs Policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1961751_1_1">Patent Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1961751_2_1">Patent Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PatentCostsPolicyTextBlock" xlink:to="sage_PatentCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_9807917_1636887_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_9807917_1636887_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9807917_1646217_1_1">Payment of Financing and Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9807917_1646217_2_1">Payment of offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9807917_1646217_14_1">Payment of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9807917_1645412_1_1">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9807917_1645412_2_1">Preferred Stock, issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_9807917_1645412_12_1">Redeemable convertible preferred Stock, issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9807917_1644389_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_9807917_1644389_14_1">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl" xml:lang="en-US" id="id_9807917_1809343_3_1">Percentage of Net Sales Required for Royalty Entitlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl" xml:lang="en-US" id="id_9807917_1809343_1_1">Percentage of Net Sales Required for Royalty Entitlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl" xml:lang="en-US" id="id_9807917_1809343_2_1">Percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:to="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" xlink:label="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved_lbl" xml:lang="en-US" id="id_9807917_1996500_3_1">Percentage of performance based grants that were achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved_lbl" xml:lang="en-US" id="id_9807917_1996500_1_1">Percentage Of Performance Based Grants That Were Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved_lbl" xml:lang="en-US" id="id_9807917_1996500_2_1">Percentage of performance based grants that were achieved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" xlink:to="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PerformanceBasedShareBasedCompensationExpense" xlink:label="sage_PerformanceBasedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_PerformanceBasedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9807917_2014637_3_1">Performance based share based compensation expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_PerformanceBasedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9807917_2014637_1_1">Performance Based Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_PerformanceBasedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_9807917_2014637_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PerformanceBasedShareBasedCompensationExpense" xlink:to="sage_PerformanceBasedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PerformanceMilestoneMember" xlink:label="sage_PerformanceMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_PerformanceMilestoneMember_lbl" xml:lang="en-US" id="id_9807917_1770756_3_1">Performance Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_PerformanceMilestoneMember_lbl" xml:lang="en-US" id="id_9807917_1770756_1_1">Performance Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_PerformanceMilestoneMember_lbl" xml:lang="en-US" id="id_9807917_1770756_2_1">Performance Milestone [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PerformanceMilestoneMember" xlink:to="sage_PerformanceMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_9807917_1639657_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_9807917_1639657_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_9807917_1637683_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_9807917_1637683_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xml:lang="en-US" id="id_9807917_1633657_1_1">Postemployment Benefits [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xml:lang="en-US" id="id_9807917_1633657_2_1">Postemployment Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9807917_1642594_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9807917_1642594_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1639289_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1639289_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_9807917_1640465_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_9807917_1640465_2_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1634872_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1634872_2_1">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634494_1_1">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634494_2_1">Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_9807917_1647540_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_9807917_1647540_2_1">Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2015 and 2014; no shares issued or outstanding at December 31, 2015 and 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_9807917_1650984_1_1">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_9807917_1650984_2_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_9807917_1650988_1_1">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_9807917_1650988_2_1">Net proceeds from sale of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_9807917_1650988_12_1">Proceeds from initial public offering of common stock, net of commissions and underwriting discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_9807917_1649597_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_9807917_1649597_32_1">Proceeds from underwritten initial public offering of common stock, net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_9807917_1649597_2_1">Proceeds from public offering of common stock, net of commissions and underwriting discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_9807917_1649597_12_1">Proceeds from public offering of common stock, net of commissions and underwriting discounts and estimated offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1651874_1_1">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1651874_2_1">Proceeds from the issuance of preferred stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_9807917_1649221_1_1">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="id_9807917_1649221_2_1">Convertible preferred stock proceeds raised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1649980_1_1">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1649980_2_1">Proceeds from the issuance of preferred stock, net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" id="id_9807917_1650105_1_1">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" id="id_9807917_1650105_2_1">Proceeds from stock option exercise and employee stock purchase plan issuances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_9807917_1651377_1_1">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="id_9807917_1651377_2_1">Proceeds from restricted shares sold to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_9807917_1643397_1_1">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_9807917_1643397_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1634505_1_1">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1634505_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_9807917_1651381_1_1">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_9807917_1651381_2_1">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_9807917_1642195_1_1">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_9807917_1642195_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9807917_1649598_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9807917_1649598_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_9807917_1649598_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634506_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634506_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_9807917_1638511_1_1">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_9807917_1638511_2_1">Summary of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1637279_1_1">Property, Plant and Equipment, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1637279_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_9807917_1634075_1_1">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_9807917_1634075_2_1">Property and equipment, useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PublicOfferingCostsIncludedInCurrentLiabilities" xlink:label="sage_PublicOfferingCostsIncludedInCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_PublicOfferingCostsIncludedInCurrentLiabilities_lbl" xml:lang="en-US" id="id_9807917_1980374_3_1">Public offering costs included in current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_PublicOfferingCostsIncludedInCurrentLiabilities_lbl" xml:lang="en-US" id="id_9807917_1980374_1_1">Public Offering Costs Included In Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_PublicOfferingCostsIncludedInCurrentLiabilities_lbl" xml:lang="en-US" id="id_9807917_1980374_2_1">Public offering costs included in accounts payable or accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_PublicOfferingCostsIncludedInCurrentLiabilities" xlink:to="sage_PublicOfferingCostsIncludedInCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1642602_1_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1642602_2_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_9807917_1637710_1_1">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_9807917_1637710_2_1">Selected Quarterly Financial Data (Unaudited)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_9807917_1639304_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_9807917_1639304_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_9807917_1634888_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_9807917_1634888_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1632459_1_1">Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1632459_2_1">Redeemable Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_RegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1702458_3_1">Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_RegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1702458_1_1">Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_RegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1702458_2_1">Regulatory Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_RegulatoryMilestonesMember" xlink:to="sage_RegulatoryMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_9807917_1634903_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_9807917_1634903_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_9807917_1651880_1_1">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_9807917_1651880_2_1">Payment for consulting and management services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_9807917_1641778_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_9807917_1641778_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_9807917_1640485_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_9807917_1640485_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_9807917_1642993_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_9807917_1642993_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644230_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644230_2_1">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1632078_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1632078_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1644231_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1644231_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_9807917_1649370_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_9807917_1649370_2_1">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_9807917_1649370_12_1">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_9807917_1642216_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_9807917_1642216_2_1">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_9807917_1635712_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_9807917_1635712_2_1">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl" xml:lang="en-US" id="id_9807917_2000301_3_1">Research and development expense related to milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl" xml:lang="en-US" id="id_9807917_2000301_1_1">Research And Development Expense Related To Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl" xml:lang="en-US" id="id_9807917_2000301_2_1">Research and development expense related to milestone expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:label="sage_ResearchContractCostsAndAccrualsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1688088_3_1">Research Contract Costs and Accruals Policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1688088_1_1">Research Contract Costs and Accruals [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1688088_2_1">Research Contract Costs and Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:to="sage_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1649613_1_1">Restricted Cash and Cash Equivalents, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1649613_2_1">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" id="id_9807917_1649613_12_1">Restricted cash deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_9807917_1632468_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_9807917_1632468_2_1">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_9807917_1646649_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_9807917_1646649_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_9807917_1633302_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_9807917_1633302_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_9807917_1638152_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_9807917_1638152_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SalesMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1813302_3_1">Sales Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SalesMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1813302_1_1">Sales Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SalesMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_1813302_2_1">Sales Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SalesMilestonesMember" xlink:to="sage_SalesMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ScenarioOneMember" xlink:label="sage_ScenarioOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ScenarioOneMember_lbl" xml:lang="en-US" id="id_9807917_1729521_3_1">Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ScenarioOneMember_lbl" xml:lang="en-US" id="id_9807917_1729521_1_1">Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ScenarioOneMember_lbl" xml:lang="en-US" id="id_9807917_1729521_2_1">After The Effective Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ScenarioOneMember" xlink:to="sage_ScenarioOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ScenarioTwoMember" xlink:label="sage_ScenarioTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_9807917_1931239_3_1">Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_9807917_1931239_1_1">Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_9807917_1931239_2_1">After The First Sale [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ScenarioTwoMember" xlink:to="sage_ScenarioTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_9807917_1638535_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_9807917_1638535_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1637735_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1637735_2_1">Summary of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_9807917_1634103_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_9807917_1634103_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634916_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634916_2_1">Summary of Common Stock Equivalents Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1632086_1_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1632086_2_1">Summary of Significant Components of Company's Net Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1638542_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1638542_2_1">Summary of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1640501_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1640501_2_1">Summary of Reconciliation of U.S. Statutory Rate to Company's Effective Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1638543_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1638543_2_1">Summary of Recognized Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1643011_1_1">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1643011_2_1">Schedule of Future Minimum Lease Payments, Under Non-Cancelable Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_9807917_1636513_1_1">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_9807917_1636513_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639330_1_1">Schedule of Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639330_2_1">Summary of Quarterly Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_9807917_1632493_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_9807917_1632493_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_9807917_1643015_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_9807917_1643015_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1633705_1_1">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1633705_2_1">Summary of Activity Relating to Restricted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1640512_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1640512_2_1">Summary of Activity Relating to Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1643831_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1643831_2_1">Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639335_1_1">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_9807917_1639335_2_1">Summary of Rollforward of Company's Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SecondAndThirdClinicalDevelopmentMilestonesMember" xlink:label="sage_SecondAndThirdClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SecondAndThirdClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2010615_3_1">Second and Third Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SecondAndThirdClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2010615_1_1">Second And Third Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SecondAndThirdClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2010615_2_1">Second and Third Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SecondAndThirdClinicalDevelopmentMilestonesMember" xlink:to="sage_SecondAndThirdClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SecondTrancheMember" xlink:label="sage_SecondTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SecondTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1666381_3_1">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SecondTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1666381_1_1">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SecondTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1666381_2_1">Second Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SecondTrancheMember" xlink:to="sage_SecondTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634128_1_1">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_9807917_1634128_2_1">Segment Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1641034_1_1">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1641034_2_1">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1671852_3_1">Series A, Series B and Series C redeemable Convertible Preferred Stock[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1671852_1_1">Series A Series B And Series C Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1671852_2_1">Series A, B and C Redeemable Convertible Preferred Stock[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:to="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1633314_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1633314_2_1">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1637021_1_1">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_9807917_1637021_2_1">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_1648110_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_9807917_1648110_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl" xml:lang="en-US" id="id_9807917_1861591_3_1">Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl" xml:lang="en-US" id="id_9807917_1861591_1_1">Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl" xml:lang="en-US" id="id_9807917_1861591_2_1">Share based compensation, vest period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_9807917_1634556_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_9807917_1634556_2_1">Share based compensation granted under plan vest period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_9807917_1635812_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_9807917_1635812_2_1">Share based compensation, vesting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_9807917_1635421_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="id_9807917_1635421_2_1">Forfeited, Shares-Restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_9807917_1632936_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_9807917_1632936_2_1">Issued, Shares-Restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9807917_1634558_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9807917_1634558_4_1">Outstanding, Shares at ending balance-Restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_9807917_1634558_5_1">Outstanding, Shares at beginning balance-Restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_9807917_1636131_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_9807917_1636131_2_1">Vesting of restricted stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_9807917_1636131_14_1">Vested, Shares-Restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate_lbl" xml:lang="en-US" id="id_9807917_1671308_3_1">Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate_lbl" xml:lang="en-US" id="id_9807917_1671308_1_1">Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate_lbl" xml:lang="en-US" id="id_9807917_1671308_2_1">Share option, forfeiture rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_9807917_1638236_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_9807917_1638236_2_1">Share based compensation, term of plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_9807917_1638565_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_9807917_1638565_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_9807917_1631722_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_9807917_1631722_2_1">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_9807917_1637827_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_9807917_1637827_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_9807917_1633734_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_9807917_1633734_2_1">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_9807917_1637335_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_9807917_1637335_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1631723_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1631723_2_1">Options with performance-based criteria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_9807917_1635424_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_9807917_1635424_2_1">Number of shares available for future issuance under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_9807917_1648111_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_9807917_1648111_2_1">Exercisable, Aggregate Intrinsic Value-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_9807917_1637337_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_9807917_1637337_2_1">Exercisable, Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1642255_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1642255_2_1">Exercisable, Weighted Average Exercise Price-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_9807917_1635425_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_9807917_1635425_2_1">Exercisable, Weighted Average Remaining Life-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_9807917_1650874_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_9807917_1650874_2_1">Intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_9807917_1633736_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_9807917_1633736_14_1">Forfeited, Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_9807917_1640581_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_9807917_1640581_2_1">Granted, Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_9807917_1640581_12_1">Stock option grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9807917_1641797_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_9807917_1641797_2_1">Weighted average grant date fair value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" id="id_9807917_1633737_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" id="id_9807917_1633737_2_1">Number of shares outstanding unvested stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_9807917_1651525_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_9807917_1651525_2_1">Outstanding, Aggregate Intrinsic Value-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9807917_1632583_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9807917_1632583_4_1">Ending balance, Outstanding Shares-Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_9807917_1632583_5_1">Beginning balance, Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1634132_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1634132_4_1">Ending balance, Outstanding Weighted Average Exercise Price-Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1634132_5_1">Beginning balance, Weighted Average Exercise Price-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_9807917_1826654_3_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_9807917_1826654_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="id_9807917_1826654_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_9807917_1634936_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_9807917_1634936_2_1">Outstanding, Weighted Average Remaining Life-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_9807917_1648736_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_9807917_1648736_2_1">Vested or expected to vest, Aggregate Intrinsic Value-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_9807917_1643442_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_9807917_1643442_2_1">Vested or expected to vest, Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1636531_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1636531_2_1">Vested or expected to vest, Weighted Average Exercise Price-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_9807917_1644249_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_9807917_1644249_2_1">Vested or expected to vest, Weighted Average Remaining Life-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_9807917_1645267_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_9807917_1645267_2_1">Total fair value of shares vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod_lbl" xml:lang="en-US" id="id_9807917_1667085_3_1">The number of share options granted during the period for which vesting is contingent upon company corporate goals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod_lbl" xml:lang="en-US" id="id_9807917_1667085_1_1">Share Based Compensation Arrangement By Share Based Payment Award Performance Based Share Option Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod_lbl" xml:lang="en-US" id="id_9807917_1667085_2_1">Options with performance-based criteria</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_9807917_1634939_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_9807917_1634939_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1641363_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1641363_2_1">Exercised, Weighted Average Exercise Price-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1635427_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1635427_2_1">Forfeited, Weighted Average Exercise Price-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1638569_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_9807917_1638569_2_1">Granted, Weighted Average Exercise Price-Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="id_9807917_1635815_1_1">Share-based Compensation Award, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="id_9807917_1635815_2_1">Share-based Compensation Award, Tranche One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityClassAxis_lbl" xml:lang="en-US" id="id_9807917_1637024_1_1">Shareholders' Equity Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityClassAxis_lbl" xml:lang="en-US" id="id_9807917_1637024_2_1">Shareholders' Equity Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_ShareholdersEquityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_9807917_1637341_1_1">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_9807917_1637341_4_1">Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="id_9807917_1637341_5_1">Balance, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_9807917_1642714_1_1">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" id="id_9807917_1642714_2_1">Common stock price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SharesRepurchasePricePerShare" xlink:label="sage_SharesRepurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SharesRepurchasePricePerShare_lbl" xml:lang="en-US" id="id_9807917_1819489_3_1">Shares Repurchase Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SharesRepurchasePricePerShare_lbl" xml:lang="en-US" id="id_9807917_1819489_1_1">Shares Repurchase Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SharesRepurchasePricePerShare_lbl" xml:lang="en-US" id="id_9807917_1819489_2_1">Stock repurchased, purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SharesRepurchasePricePerShare" xlink:to="sage_SharesRepurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_9807917_1643028_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_9807917_1643028_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_9807917_1641051_1_1">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_9807917_1641051_2_1">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_9807917_1641810_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_9807917_1641810_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_9807917_1643450_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_9807917_1643450_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_9807917_1641812_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_9807917_1641812_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_9807917_1643038_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_9807917_1643038_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_9807917_1640591_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_9807917_1640591_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1643451_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1643451_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_9807917_1640593_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_9807917_1640593_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_9807917_1632950_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_9807917_1632950_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9807917_1644941_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9807917_1644941_4_1">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9807917_1644941_5_1">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_9807917_1644941_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1634143_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_9807917_1634143_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_9807917_1642265_1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_9807917_1642265_2_1">Reverse stock split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_9807917_1638248_1_1">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_9807917_1638248_2_1">Reverse stock split description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockholdersEquityReverseStockSplitEffectiveDate" xlink:label="sage_StockholdersEquityReverseStockSplitEffectiveDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_StockholdersEquityReverseStockSplitEffectiveDate_lbl" xml:lang="en-US" id="id_9807917_1825500_3_1">Stockholders Equity Reverse Stock Split Effective Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_StockholdersEquityReverseStockSplitEffectiveDate_lbl" xml:lang="en-US" id="id_9807917_1825500_1_1">Stockholders Equity Reverse Stock Split Effective Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_StockholdersEquityReverseStockSplitEffectiveDate_lbl" xml:lang="en-US" id="id_9807917_1825500_2_1">Reverse stock split effective date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_StockholdersEquityReverseStockSplitEffectiveDate" xlink:to="sage_StockholdersEquityReverseStockSplitEffectiveDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_9807917_1635836_1_1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_9807917_1635836_2_1">Issuance of common stock under employee stock purchase plan, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_9807917_1635836_12_1">Number of shares issued under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="id_9807917_1644258_1_1">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="id_9807917_1644258_2_1">Issuance of common stock in payment of licensing and consultant fees, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_9807917_1633033_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_9807917_1633033_2_1">Issuance of common stock, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_9807917_1633033_12_1">Shares issued during period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" xlink:label="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1701987_3_1">Stock Issued During Period Shares Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1701987_1_1">Stock Issued During Period Shares Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_9807917_1701987_2_1">Conversion of redeemable convertible preferred stock to common stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" xlink:to="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_9807917_1642361_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_9807917_1642361_2_1">Issuance of common stock from exercise of stock options, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_9807917_1642361_14_1">Exercised, Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" xlink:label="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends_lbl" xml:lang="en-US" id="id_9807917_1657011_3_1">Stock Issued During Period Value Conversion Of Redeemable Convertible Preferred Stock Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends_lbl" xml:lang="en-US" id="id_9807917_1657011_1_1">Stock Issued During Period Value Conversion Of Redeemable Convertible Preferred Stock Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends_lbl" xml:lang="en-US" id="id_9807917_1657011_2_1">Conversion of redeemable convertible preferred stock to common stock, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" xlink:to="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9807917_1645391_1_1">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_9807917_1645391_2_1">Issuance of common stock under employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" id="id_9807917_1646313_1_1">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" id="id_9807917_1646313_2_1">Issuance of common stock in payment of licensing and consultant fees, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_9807917_1645146_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_9807917_1645146_2_1">Shares issued during period, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" id="id_9807917_1645035_1_1">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" id="id_9807917_1645035_2_1">Vesting of restricted stock, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_9807917_1644722_1_1">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_9807917_1644722_2_1">Issuance of common stock from exercise of stock options, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="id_9807917_1643850_1_1">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="id_9807917_1643850_2_1">Stock repurchased, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="id_9807917_1643850_14_1">Repurchased, Shares-Restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SubleaseAgreementMember" xlink:label="sage_SubleaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SubleaseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1913817_3_1">Sublease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SubleaseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1913817_1_1">Sublease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SubleaseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1913817_2_1">Sublease Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SubleaseAgreementMember" xlink:to="sage_SubleaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_9807917_1639792_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_9807917_1639792_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_9807917_1633766_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_9807917_1633766_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_9807917_1633767_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_9807917_1633767_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644261_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_9807917_1644261_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_9807917_1631799_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_9807917_1631799_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1636141_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_9807917_1636141_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1633768_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_9807917_1633768_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_9807917_1637033_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_9807917_1637033_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_9807917_1961765_3_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_9807917_1961765_1_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_9807917_1961765_2_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sage_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_9807917_1858129_3_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_9807917_1858129_1_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_9807917_1858129_2_1">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sage_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_9807917_1648116_1_1">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_9807917_1648116_2_1">Federal orphan drug tax credit carry forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TaxCreditsExpirationStartYear" xlink:label="sage_TaxCreditsExpirationStartYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_TaxCreditsExpirationStartYear_lbl" xml:lang="en-US" id="id_9807917_1732207_3_1">The year in which tax credits will begin to expire.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_TaxCreditsExpirationStartYear_lbl" xml:lang="en-US" id="id_9807917_1732207_1_1">Tax Credits Expiration Start Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_TaxCreditsExpirationStartYear_lbl" xml:lang="en-US" id="id_9807917_1732207_2_1">Tax credit carry forwards expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TaxCreditsExpirationStartYear" xlink:to="sage_TaxCreditsExpirationStartYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" id="id_9807917_1646195_1_1">Temporary Equity, Accretion to Redemption Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" id="id_9807917_1646195_2_1">Accretion of redeemable convertible preferred stock to redemption value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_9807917_1648114_1_1">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_9807917_1648114_2_1">Accretion of redeemable convertible preferred stock to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_9807917_1648114_14_1">Accretion of redeemable convertible preferred stock to redemption value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" id="id_9807917_1632116_1_1">Temporary Equity, by Class of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" id="id_9807917_1632116_2_1">Temporary Equity, by Class of Stock [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_9807917_1645977_1_1">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_9807917_1645977_2_1">Redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1634153_1_1">Temporary Equity Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" id="id_9807917_1634153_2_1">Temporary Equity Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" id="id_9807917_1636562_1_1">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" id="id_9807917_1636562_2_1">Temporary Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9807917_1632124_1_1">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_9807917_1632124_2_1">Redeemable convertible preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1640606_1_1">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" id="id_9807917_1640606_2_1">Redeemable convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" id="id_9807917_1643527_1_1">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" id="id_9807917_1643527_2_1">Redeemable convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_9807917_1639366_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_9807917_1639366_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000449_3_1">Third And Fourth Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000449_1_1">Third And Fourth Clinical Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000449_2_1">Third and Fourth Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:to="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000450_3_1">Third And Fourth Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000450_1_1">Third And Fourth Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="id_9807917_2000450_2_1">Third and Fourth Regulatory Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:to="sage_ThirdAndFourthRegulatoryMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdRockVenturesLimitedLiabilityCompanyMember" xlink:label="sage_ThirdRockVenturesLimitedLiabilityCompanyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ThirdRockVenturesLimitedLiabilityCompanyMember_lbl" xml:lang="en-US" id="id_9807917_1703828_3_1">Third Rock Ventures Limited Liability Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ThirdRockVenturesLimitedLiabilityCompanyMember_lbl" xml:lang="en-US" id="id_9807917_1703828_1_1">Third Rock Ventures Limited Liability Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ThirdRockVenturesLimitedLiabilityCompanyMember_lbl" xml:lang="en-US" id="id_9807917_1703828_2_1">Third Rock Ventures LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ThirdRockVenturesLimitedLiabilityCompanyMember" xlink:to="sage_ThirdRockVenturesLimitedLiabilityCompanyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdTrancheMember" xlink:label="sage_ThirdTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_ThirdTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1765361_3_1">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_ThirdTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1765361_1_1">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_ThirdTrancheMember_lbl" xml:lang="en-US" id="id_9807917_1765361_2_1">Third Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_ThirdTrancheMember" xlink:to="sage_ThirdTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_9807917_1643125_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_9807917_1643125_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandElevenStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_TwoThousandElevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_1855330_3_1">Two Thousand Eleven Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_TwoThousandElevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_1855330_1_1">Two Thousand Eleven Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_TwoThousandElevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_1855330_2_1">2011 Stock Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandElevenStockOptionPlanMember" xlink:to="sage_TwoThousandElevenStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_9807917_1738299_3_1">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_9807917_1738299_1_1">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_9807917_1738299_2_1">2014 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_2000438_3_1">Two Thousand Fourteen Stock Option Plan And Two Thousand Eleven Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_2000438_1_1">Two Thousand Fourteen Stock Option Plan And Two Thousand Eleven Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_2000438_2_1">2014 Stock Option Plan and 2011 Stock Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" xlink:to="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_1734414_3_1">Two Thousand Fourteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_1734414_1_1">Two Thousand Fourteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember_lbl" xml:lang="en-US" id="id_9807917_1734414_2_1">2014 Stock Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_TwoThousandFourteenStockOptionPlanMember" xlink:to="sage_TwoThousandFourteenStockOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_9807917_1634968_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_9807917_1634968_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UndrawnAmount" xlink:label="sage_UndrawnAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_UndrawnAmount_lbl" xml:lang="en-US" id="id_9807917_1703034_3_1">Undrawn amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_UndrawnAmount_lbl" xml:lang="en-US" id="id_9807917_1703034_1_1">Undrawn Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_UndrawnAmount_lbl" xml:lang="en-US" id="id_9807917_1703034_2_1">Redeemable convertible preferred stock, Undrawn amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_UndrawnAmount" xlink:to="sage_UndrawnAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UniversityOfCaliforniaLicenseAgreementMember" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1815931_3_1">University Of California License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1815931_1_1">University Of California License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1815931_2_1">University of California License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_UniversityOfCaliforniaLicenseAgreementMember" xlink:to="sage_UniversityOfCaliforniaLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_9807917_1645975_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_9807917_1645975_4_1">Unrecognized tax benefits-as of the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_9807917_1645975_5_1">Unrecognized tax benefits-as of the beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_9807917_1645975_2_1">Unrecognized tax benefit related to start-up costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_9807917_1648356_1_1">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_9807917_1648356_14_1">Gross decreases-tax positions of prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_9807917_1647736_1_1">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_9807917_1647736_2_1">Gross increases-current period tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UpfrontNonrefundablePayment" xlink:label="sage_UpfrontNonrefundablePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_UpfrontNonrefundablePayment_lbl" xml:lang="en-US" id="id_9807917_1873424_3_1">Upfront nonrefundable payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_UpfrontNonrefundablePayment_lbl" xml:lang="en-US" id="id_9807917_1873424_1_1">Upfront Nonrefundable Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_UpfrontNonrefundablePayment_lbl" xml:lang="en-US" id="id_9807917_1873424_2_1">Upfront non-refundable payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_UpfrontNonrefundablePayment" xlink:to="sage_UpfrontNonrefundablePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_UpFrontPayment_lbl" xml:lang="en-US" id="id_9807917_1845486_3_1">Up Front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_UpFrontPayment_lbl" xml:lang="en-US" id="id_9807917_1845486_1_1">Up Front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_UpFrontPayment_lbl" xml:lang="en-US" id="id_9807917_1845486_2_1">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_UpFrontPayment" xlink:to="sage_UpFrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_9807917_1642359_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_9807917_1642359_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_9807917_1645753_1_1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_9807917_1645753_2_1">Change in amount of deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_9807917_1636161_1_1">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_9807917_1636161_2_1">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_9807917_1637752_1_1">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_9807917_1637752_2_1">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_WashingtonUniversityLicenseAgreementMember" xlink:label="sage_WashingtonUniversityLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sage_WashingtonUniversityLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1930456_3_1">Washington University License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sage_WashingtonUniversityLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1930456_1_1">Washington University License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sage_WashingtonUniversityLicenseAgreementMember_lbl" xml:lang="en-US" id="id_9807917_1930456_2_1">Washington University License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sage_WashingtonUniversityLicenseAgreementMember" xlink:to="sage_WashingtonUniversityLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1639712_1_1">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_9807917_1639712_6_1">Weighted average common stock outstanding-diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_9807917_1643551_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_9807917_1643551_2_1">Weighted average number of common shares used in net loss per share attributable to common stockholders-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="id_9807917_1632953_1_1">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="id_9807917_1632953_2_1">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9807917_1641406_1_1">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_9807917_1641406_2_1">Weighted average shares of common stock outstanding-basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>sage-20151231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 7 -->
<!-- Creation date: 2016-02-29T16:27:37Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DocumentandEntityInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfIncome" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNatureOfTheBusinessAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureRedeemableConvertiblePreferredStockAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#DisclosureSubsequentEventAdditionalInformation" roleURI="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsPreferredStockTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCommonStockTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="sage-20151231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DocumentAndEntityInformationAbstract" xlink:label="sage_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome" xlink:title="124000 - Statement - Statement of Income (Including Gross Margin)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:title="148600 - Statement - Statement of Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" xlink:label="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" xlink:label="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_2" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicensingOrConsultantFeesPaidInCommonStock" xlink:label="sage_LicensingOrConsultantFeesPaidInCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PublicOfferingCostsIncludedInCurrentLiabilities" xlink:label="sage_PublicOfferingCostsIncludedInCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sage_LicensingOrConsultantFeesPaidInCommonStock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="sage_PublicOfferingCostsIncludedInCurrentLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_NatureOfBusinessLineItems" xlink:label="sage_NatureOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_NatureOfBusinessTable" xlink:label="sage_NatureOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_NatureOfBusinessTable" xlink:to="sage_NatureOfBusinessLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sage_NatureOfBusinessTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_StockholdersEquityReverseStockSplitEffectiveDate" xlink:label="sage_StockholdersEquityReverseStockSplitEffectiveDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sage_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sage_SummaryOfSignificantAccountingPoliciesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_SummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sage_StockholdersEquityReverseStockSplitEffectiveDate" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sage_SummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ComputerHardwareAndSoftwareMember" xlink:label="sage_ComputerHardwareAndSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sage_ComputerHardwareAndSoftwareMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AccruedDevelopmentExpensesCurrent" xlink:label="sage_AccruedDevelopmentExpensesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sage_AccruedDevelopmentExpensesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AreaOfLeasedProperty" xlink:label="sage_AreaOfLeasedProperty"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AreaOfOfficeSpace" xlink:label="sage_AreaOfOfficeSpace"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_OperatingLeaseExpirationPeriod" xlink:label="sage_OperatingLeaseExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_OperatingLeaseOneMember" xlink:label="sage_OperatingLeaseOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:label="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SubleaseAgreementMember" xlink:label="sage_SubleaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AreaOfOfficeSpace" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_OperatingLeaseExpirationPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AreaOfLeasedProperty" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sage_OperatingLeaseOneMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sage_SubleaseAgreementMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CydexLicenseAgreementMember" xlink:label="sage_CydexLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstAndSecondClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstAndSecondClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstAndSecondRegulatoryMilestonesMember" xlink:label="sage_FirstAndSecondRegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" xlink:label="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdAndFourthRegulatoryMilestonesMember" xlink:label="sage_ThirdAndFourthRegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondClinicalDevelopmentMilestonesMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstAndSecondRegulatoryMilestonesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthClinicalDevelopmentMilestonesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ThirdAndFourthRegulatoryMilestonesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_CydexLicenseAgreementMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IssueOfCommonStockObligation" xlink:label="sage_IssueOfCommonStockObligation"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UpfrontNonrefundablePayment" xlink:label="sage_UpfrontNonrefundablePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_WashingtonUniversityLicenseAgreementMember" xlink:label="sage_WashingtonUniversityLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_UpfrontNonrefundablePayment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseMaintenanceCostAnnual" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_IssueOfCommonStockObligation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_WashingtonUniversityLicenseAgreementMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" xlink:label="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentMilestonesMember" xlink:label="sage_ClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseAgreementMaximumTerm" xlink:label="sage_LicenseAgreementMaximumTerm"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_LicenseMaintenanceCostAnnual" xlink:label="sage_LicenseMaintenanceCostAnnual"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePaymentsExpensedDuringPeriod" xlink:label="sage_MilestonePaymentsExpensedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" xlink:label="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_RegulatoryMilestonesMember" xlink:label="sage_RegulatoryMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SalesMilestonesMember" xlink:label="sage_SalesMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ScenarioOneMember" xlink:label="sage_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ScenarioTwoMember" xlink:label="sage_ScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UniversityOfCaliforniaLicenseAgreementMember" xlink:label="sage_UniversityOfCaliforniaLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UpFrontPayment" xlink:label="sage_UpFrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentMilestonesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_RegulatoryMilestonesMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_SalesMilestonesMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseAgreementMaximumTerm" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePaymentsExpensedDuringPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_UpFrontPayment" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_LicenseMaintenanceCostAnnual" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_UniversityOfCaliforniaLicenseAgreementMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioOneMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="sage_ScenarioTwoMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:label="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesLineItems" xlink:label="sage_CommitmentsAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommitmentsAndContingenciesTable" xlink:label="sage_CommitmentsAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ConsultingAgreementMember" xlink:label="sage_ConsultingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstClinicalDevelopmentMilestonesMember" xlink:label="sage_FirstClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MaximumMilestonePayments" xlink:label="sage_MaximumMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MaximumMilestoneShareBasedPayments" xlink:label="sage_MaximumMilestoneShareBasedPayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestoneBasedShareCompensation" xlink:label="sage_MilestoneBasedShareCompensation"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestonePayments" xlink:label="sage_MilestonePayments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_MilestoneStockCompensation" xlink:label="sage_MilestoneStockCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" xlink:label="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SecondAndThirdClinicalDevelopmentMilestonesMember" xlink:label="sage_SecondAndThirdClinicalDevelopmentMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_ClinicalDevelopmentAndRegulatoryMilestoneMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_FirstClinicalDevelopmentMilestonesMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sage_SecondAndThirdClinicalDevelopmentMilestonesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sage_CommitmentsAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MaximumMilestonePayments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MaximumMilestoneShareBasedPayments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestonePayments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestoneStockCompensation" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesLineItems" xlink:to="sage_MilestoneBasedShareCompensation" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_CommitmentsAndContingenciesTable" xlink:to="sage_CommitmentsAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sage_ConsultingAgreementMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FirstTrancheMember" xlink:label="sage_FirstTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SecondTrancheMember" xlink:label="sage_SecondTrancheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdTrancheMember" xlink:label="sage_ThirdTrancheMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_UndrawnAmount" xlink:label="sage_UndrawnAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="sage_SecondTrancheMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="sage_ThirdTrancheMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="sage_FirstTrancheMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ShareholdersEquityClassAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="sage_UndrawnAmount" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DividendsCommonStock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" xlink:label="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" xlink:label="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PerformanceBasedShareBasedCompensationExpense" xlink:label="sage_PerformanceBasedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PerformanceMilestoneMember" xlink:label="sage_PerformanceMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" xlink:label="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SharesRepurchasePricePerShare" xlink:label="sage_SharesRepurchasePricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandElevenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:label="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TwoThousandFourteenStockOptionPlanMember" xlink:label="sage_TwoThousandFourteenStockOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandElevenStockOptionPlanMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenStockOptionPlanMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sage_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_PerformanceBasedShareBasedCompensationExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_PercentageOfPerformanceBasedGrantsThatWereAchieved" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sage_SharesRepurchasePricePerShare" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sage_PerformanceMilestoneMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_EmployeeStockPurchasePlanMember" xlink:label="sage_EmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sage_EmployeeStockPurchasePlanMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsShareBasedCompensation" xlink:label="sage_DeferredTaxAssetsShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:label="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxLiabilitiesShareBasedCompensation" xlink:label="sage_DeferredTaxLiabilitiesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" xlink:label="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IncomeTaxDisclosureLineItems" xlink:label="sage_IncomeTaxDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_IncomeTaxDisclosureTable" xlink:label="sage_IncomeTaxDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_TaxCreditsExpirationStartYear" xlink:label="sage_TaxCreditsExpirationStartYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sage_IncomeTaxDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_TaxCreditsExpirationStartYear" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_DeferredTaxAssetsShareBasedCompensation" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="sage_DeferredTaxLiabilitiesShareBasedCompensation" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_IncomeTaxDisclosureTable" xlink:to="sage_IncomeTaxDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="sage_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sage_EffectiveIncomeTaxRateReconciliationPermanentItems" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="sage_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsChangeInAccountingMethod" xlink:label="sage_DeferredTaxAssetsChangeInAccountingMethod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_DeferredTaxAssetsStockOptions" xlink:label="sage_DeferredTaxAssetsStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sage_DeferredTaxAssetsCapitalizedStartUpCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sage_DeferredTaxAssetsChangeInAccountingMethod" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sage_DeferredTaxAssetsStockOptions" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:label="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ThirdRockVenturesLimitedLiabilityCompanyMember" xlink:label="sage_ThirdRockVenturesLimitedLiabilityCompanyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sage_ThirdRockVenturesLimitedLiabilityCompanyMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_BusinessRisksAndUncertaintiesPolicyTextBlock" xlink:label="sage_BusinessRisksAndUncertaintiesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_InitialPublicOfferingPolicyPolicyTextBlock" xlink:label="sage_InitialPublicOfferingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_PatentCostsPolicyTextBlock" xlink:label="sage_PatentCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:label="sage_ResearchContractCostsAndAccrualsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_ResearchContractCostsAndAccrualsPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_PatentCostsPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_BusinessRisksAndUncertaintiesPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sage_InitialPublicOfferingPolicyPolicyTextBlock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_BalanceSheetComponentsTextBlock" xlink:label="sage_BalanceSheetComponentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sage_BalanceSheetComponentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock">
    <loc xlink:type="locator" xlink:href="sage-20151231.xsd#sage_CommonStockTextBlock" xlink:label="sage_CommonStockTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="sage_CommonStockTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g111598001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ * $9 P$1  (1 0,1 ?_$ 'T   (# 0$! 0
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M["IC(@KWFTH,N>T3 #,="F8TQJ]<#XCSRY\L\=A<;7!M[-G558:-LD%W<?\
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M+2<I...$0B$@ON1%<D&/$(4 *Y%5'G [Q,;;;;:NM>H*+ZBP\A"QO/[,;?\
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MF53VI@^(P-CV;?R!VXD=^D3^-#0K?K9+\TO,6;Y6+@M%K.XA1+(@!$00A,3
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g111598037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598037.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 2P"< P$1  (1 0,1 ?_$ ((  0 " P$! 0
M       &!P,$!0(!" $! 0$                   $"$   !0,"! ,% P<-
M         0(#!!$%!A('(3$B$T%A%%&!,E((D8(C<:%B,U,5%\'1<I*BLD-C
M@[.5%E<1 0$!                   !$?_:  P# 0 "$0,1 #\ _5(
M     B\_<K"+=DL?&9=S;1>9*B0B,1*5I6OX$.+21I0I=>DE& RYYFEOQ&PK
MN<EM4B0M:6($%OB[(D.<&VD%YGS/P(!!U0]]&;:]E,N[Q2DL(.4>(MQTFRIA
M):E,&_\ 'W=)'0RKU +-L5WB7FRP;M#.L6>PW(9KSTN))1$?F5:& W@
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M9$1U-ERG]0Q12_TW()Z=D$O30FHMHB(X^#42I_G,!>(  4
M       8+@QWX$EBBC[K2T40>E74DRZ3(RH8"FOI<AJ:L&02%DHU*N/INZI6
MJI1T$1)X\>G7S%HNP0                        59]/C;+=AR)MM1'IO\
M^J>/ JIT\_(6BTQ                        !3^R,PV<SW$LKAF2FKLN4
MA!GP(G''$J.GW4BZ+@$                       #Y *CPWTO\?<NT>E[_
C *%O7Z7U&KXVOU^O\'N<M6G^<$6X"@              _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g111598g32j29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g32j29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[21$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %4< 5H  QLE1QP"   "   < E  "')R,38Y-3DQ' (% #1-:6-R;W-O
M9G0@5V]R9" M(#$P+4L@+2 R,#$U($9E8B Q.2!D<F%F="!F;W(@04,N9&]C
M!#A"24T$)0      $%V4J\6H?9)]4!-D&4U2W[ X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 5_\*          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              &8   "$0
M   !                          $              A$   &8
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   &8     %)G
M:'1L;VYG   "$0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !F     !29VAT;&]N9P   A$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     <X0DE-
M! P     &<     !    H    'L   '@  #FH   &:0 &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( 'L H ,!(@ "$0$#$0'_W0 $
M  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _ +[C[G:_G'\J3@YL;@6R)&Z1(\?<FL$E
MX\2X?>2M"[J_KD&S':Z&D-W.F"0UL_S?T?;_ ,9_PRUB9"J%]]:>5C&!XN.?
M 17#Z3/B_>^5H0Z=L.W>$&?\U-N'8\\:K0/6''=^KM!=H3N[2'AI_1[O9M]G
MN4;.H4VX]['T!EMK=K"QK('N+F[G0QWZ%A].OTVH<4^L/Q7''A_1S7H3K"4?
M\%HB3Q)[:2?R)&1J9 .H)D:?-7/VD6W,MII;4YE)I@&9,[Z[C[&^^FUM=C/^
M+4W]7<]PW8[-K7%U;9!V:;/T3GUOVN9^9^9O_P &E<_W?Q4(8=;R_P#,E]K0
MGN9 /!,Z_!.9 #C(:9 <9@D?2AWT?:KQZHU]3F.H8-K7"AH$M:YQ:-WN_FVU
M5^I[6_3_ +"3>JD-:W[.QS6AH],DFJ&"STO3I?O]+W6[[/TEGJ^G_P )8AQ3
M_<_%7MX?\]TWX).?N'[W'.J?4\2>>)[?2_S5?;U5K7@_9*BUI):W32?4;H[T
MS^98QGO_ -"HMZFYK\=[:6M^S->T,!AI]1C:G\-]C?9N_P )_P 8CQ3_ '/^
M<K@P_P">ZC]"7?U?]TTM08UGF-9B)_ZE. ]WT0XZ;M 3I^]I^:KSNKDO-HQV
M"TZ!P=PW8*MOT-WMV_O?0_1I.ZO=ZEMM5;*K;  +/I.;#Q=NX;6_W#_1I<4_
MW?\ G*X,.OZZ]>D);?X3G[A^]^*<F#!,$<@Z%7?VDV(.-7H9'T1 VBL;?T1_
M2L_,L_\  ;/YQ/9U-MA>YV,P/LWES]P)]Q<?;NJ=^]LL_P!)_P $EQ2_<_YP
M1P8J_GO^9-I DS$F!)B3 'YQ_DI@72=':23H= /I3_55IW47NLR7N8?UG:2&
M6.80YK75?3K:UUE+O4=^A_\ !$5_6[GN>Y]()L:YK@'D [OH&R&>[TV>S<ST
MK/9_.?SB;(S_ '?Q70AAZY3N?T);7H?^Z:8D $R >"9 /]4_G*32#(YC4C^]
M'IZE:RNBI[&V4T,#&L,:N$_I=SFV?FN?5LV_S5EG_&(U74G;15Z3-FGZ,$ 1
M^AD;=A_.QO4]_P#I/\(LKG<A%V>%V?A^"$J(]7T0,G<V28/$\%-0]_JUL8)E
MP 'S"T#G;=H]"MP;):)! ESG_N;??O\ TNUO^D_F57H8&EC8TD28Y$^/TES>
M>0XP1/CL]C'A>GP 1@?0!IH__]#MS]4,,DG[1=J9_,[_ /6TW_-##_[DW?\
M0_\ 2:T<KJV'B7&K(N;6X!KC+3$.=Z;!NGZ7_?/TB;%ZQA9=HIIO:;2'.#"U
MS3#'-K/TC^\]NS]]2?>,O[Q_!K_<.6_S<?Q<_P#YH8?_ ')N_P"A_P"DTO\
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MOI;OY2NG Z;CXUP])XK(8^R'DNBD>W;/\E4V?L .#VXN0027 2XMD[6Z>_\
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MR=H@MYG;'T49N/7ZFT6.+F0XC3OQ^9_)5A))3__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    D   "PAVD !     $   "\    Z  .I6H  "<0  ZE:@  )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(P(# Y.C(V.C0Y
M ')R,38Y-3DQ       #H $  P    '__P  H ( !     $   (1H , !
M  $   &8          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!2$U- "H
M   (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"'
M:0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,38Z,#(Z,C @,#DZ,C8Z-#D <G(Q-CDU.3$
M      .@ 0 #     ?__  "@ @ $     0   A&@ P $     0   9@
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              /      0
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M 0$! ?_  !$( 9@"$0,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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MF5^4V=&SP!M'H$!Q-W7G2\Q-4+@&VFL',=XY9B_+G?:8V1)PLU7*_7) S/\
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M:;QQ\[X2BCN5U4.?#FY):WG_ (7I() N1J;N$1M $?2( %UEV.5>K5.D[IE
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M]136'C-EK=*I9TBE6L.2-)0*B4%5PG2N >2^8=_1CQ]6*31ZM,J.!\./\2-
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M"SE8',4EL)UNH0QL(AMJ9<N-,:C'<AH5(N^P3&4GDKC$;L0OOW8'8;$J-7:
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M!MUEBFG5*J5JBRP^$Z@%IK:M).JJ$[-6JV.D =@!(OG<V[8^1*YN75_#N&L
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M<N7EMD-ABP3!,AR)(F;K"N.5*" 7K$]G&$$)]Z$#410%"<8<>LV"G'8(>A!
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M2!)&D[S(U)J]0U\<!I7'%'$ VJE " *KDNT-A@UEK_#=2JF,L=)U5TU;53"
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M%2,58;D?H]TG#[BN4A%=1NTLJRNDK=RDU$4@2T*%54TWS?=YRTRYMHD!7;$
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M8ME?+/\ ]*NK4'!F&:;@S"DK>%[I.*JANJ8A%MXTA,2U7*2[D)*)@;NGNB]
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M\TV[<)F@3Y9CTD-N%-44,TTR!QS_  O$)F((0SPK(\7D[L8RRA,FCO)PFND
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M"/B?_,#_ -H/]@TCMD?YQ7_D'_W1Q3_YUW_M?X5P/[)\)_\ NCLD_LI\"_\
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MVRVS0T'PV -[][;R<OFV1RRAX-]WZQ#]8@&S_P"P_7TUJFL+OGL()/?ME?\
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M\( (!;M'9X>".W;T=%6QQ6*8#G4F9.=\Q?EV@9VO?*]K[=L7.3@K%1%AAVL
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MVQ"XV=3%[0V8QF?Q1BFT->DD@BLH:T;ZP/K>:8<A=&=>6"I"N3&&<7M(4$"
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MS7 5MLLD[ADF1!))J1(+DB8(;) G*.1I':79$CSK'K1J8G/KL^LG[/!G>_\
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M\CG;MY35L5\\T'YLO_6R&_8>YKK'33/U=AN4Y\8HOY'.W;RFK8KYYH/S9?\
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ME*3A7;$3?KUY-I[T:_8][H6ZSY646[8ZDF,"3=;Z+2NV'OT+3RA)(DJLJ7V
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M.7SQ+&7<U#H2ARJV/63(6:WY2TH':7%J7'>&[,=$(R1N<@YR#K+I_*>692[
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M.>@(OG"3'N=I7E=?],0[W7KQYD_O=#.RM.":GW55OR+#GH"'"3'N=I7E=?\
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M>IFK5PDK-)=L[%;4'?$MFU1F)>N 6M@FRQ/[9@-Y24;R I4R4F4$30L+25:
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ME+ EZ"-M=\"*-;HB9E6YH3FO<C/L/29O.?EF465Y UW,[XXU,5<C<52V-O\
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MJN[N8^G^4^Y7:G('C&$3#)$Z>5.$>0H7 XJ^3&5O MFH3%#RY"U1R-(7-[<
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MH6T]Y85!Q.?S-"X4>\I"[ *!*< @N"A$Y2&Q29J4F6XF64D:("Y7:+TR"D%
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MVYI9HD::@+MY':F)6C7LK5:4 \2>WL:YN;W%L2. *4K4[)KE20$JH1VQ?P^
M^#O_ %WVY7B8^3S@C$,ABY$/=X(R+(XDDKY,4;?>4=:"*3R9P>G62.Z!62:4
MM1K7Q;)'GE("% [XE=EB/_)%0)0F(L.2)BWP>(LSND?6>.MK4ZH8JW05"H0)
MK$UB"(-:O?$$?1)4XE)$C2B/$=V(((VIMNT1'94=>OFXO'$Q&UF%\5.$W,R2
MN@4:5S@Y+NRE]4-Y!ZA1_)9T?!<I(,'=SW+D(X^.<J*$W*W>\').]\EANPS"
M(XVZ:<%L[.8QM6-(ZWMU[U'Y);:G*.L4)W>* ?WLJ4*^PX5R--'DZA4F96U
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MR)Q;I?B*%R!@=+VN."J=;W=(M'BXJ;MM*GMUNZ=,?MWDINN>VIM3=A*YFLD
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MG*!0G&D^=%B2PY:NBF/W_'TFC[6VJ#[S#6VZ]XQ9$EKM>F- 7'=%=JG:"U2
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M<\WDQ=F\YXC??,UDD< 1O571IVX4IB%T=D:M6[*IG4]O.FB:M,T@%N9K??W
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M3G.$+FQ#O'=6[QC6&(XXG@..(4^*Y5@9!$G5JG"]K/BSDK5 N>4BM_2 U-8
MDW-.K!U^GQ]>2(MG_7O<8\?T;<K12D<T%9S:,:YP@)\<91C\J>\4O3*V]^./
M5<MDTBA,_<Y$^.TGD9F'"HCF&.GH#K%!+=G: .DIG *K6>5OZ),U(U=(BU@;
M?9GLSV<??'AMQ20K1!J,<WC3<X2]<D-3XZ@4/C9*3'4EQS"[,4O<5S._3&^0
M-:F3X7R2L:U[OCI?$69\YF!@5KL[1%?$ 5I( [--S2Z]>OQ;(D@WVY9<F7'?
M/:;Y9?9>.#-^YZ9)?H?.4;)%H.DE.18;K\9YDYJG,GA2=?E;-+3DC343(#]U
M.,5IV!*WJ7!()UNR$NJVY0EV*5:L*9^>W7O1-OMSXQ]'7OQ@,MZ&,_SJ&3.,
M1G&L CL6E,URE,(O R)!"D%F.GAXP'@Z!8E6-RY7!I4@:FF"OD+FS<8./R8M
M++1MCPL#^U1Y6[):1!N1LS/?&5QRCKX,X[!M/V%\@0C!>7X7-DZ&^5SK(>=9
M6@LY2*=-X(R ZN;@S'KEENT@%YV_^C]G\T=HCX1 '7K_ %^J)_K&OOW%<\>V
MV'6KD$4:)9#>YZQ_ <&F2DXAR48ZU )&Y4UV3!@OL2'JF]2S J$4LO:/Y43)
M04EMP[5?2B .4\7T\O4>$VBE8QW/:>*H_"6*4PU&?&D+_D]]?H'*I;BY\CB)
MS>M-[OCEB>F>,XUPYB6'-!KG/CFQP4@""0.KK>TI9N^.R1_6.R2Q#/P;;Y\O
M)LX^4'C-Q>T9*/Z&<L19+'[5N/(5D" H$NGU_P DX*=I2E21K+\Z8,"S/'N1
MY"_'+FMT9G.1M>2'6(SR]?)$"A)*U4>Y74*^7VMIIUZG+KQ9PMX^7DY._?QW
MOR[(V3TNZ2I9C7)Z&>YB2Q>:R**:>L+X[ADT-/O?W6-RB/.^:;YL@CKF\I@?
M4J1%%YO&HH1);]T<Y(TI%0+;4VU6DIU^BV77CB>/Q#/+B/Q\GQ<7'V/TA"D(
M4A"D(4A"D(4A"D(4A"D(4A&D?= M0$NTN:2LI9U@K3&'^3P<V VMS3-$;BOC
M*NR49)B$0< <4C*[L+H;<E;7Y:L3"F=TH[\6EN,!20!B6_-MS?#3'&.,Z/AV
MHN'39H_34=_4S6V0Y!:TEX_EI0IRWGRTWFMT!6E)S256L<QA&Z+B1]A#!]5Q
M!39+6>[83:7O27<MU,;F6ZJS)A/44-)\B>HH;.%J3H3#982572%!7YN//!&K
MCV&M,'D/DS[7:]4>UJP/SWBSRZC>@X\O>V4QKS-AGR&K^F8>>"-7'L-:8/(?
M)GVNT]K5@CGO%GEU&]!P]LIC7F;#/D-7],P\\$:N/89TP>0^3/M=I[6K _/>
M+/+J-Z#A[93&O,^&?(:OZ9AYX(U<>PUI@\A\F?:[3VM6".>\6>74;T'#VRF-
M>9L,^0U?TS#SP1JX]AK3!Y#Y,^UVGM:L#\]XL\NHWH.'ME,:\S89\AJ_IF'G
M@C5Q[#.F#R'R9]KM/:U8(Y[Q9Y=1O0</;*8UYGPSY#5_3,//!&KCV&=,'D/D
MS[7:>UJP1SWBSRZC>@X>V4QKS/AGR&K^F8>>"-7'L,Z8/(?)GVNT]K5@?GO%
MGEU&]!P]LIC7F?#/D-7],P\\$:N/89TP>0^3/M=I[6K _/>+/+J-Z#A[93&O
M,^&?(:OZ9AYX(U<>PSI@\A\F?:[3VM6".?,6>74?T'#VRF->9\,^0U?TS#SP
M1JX]AG3!Y#Y,^UVGM:L#\]XL\NHWH.'ME,:\SX9\AJ_IF'G@C5Q[#6F#R'R9
M]KM/:U8(Y\Q9Y=1_0</;*8UYFPSY#5_3,//!&KCV&M,'D/DS[7:>UJP/SWBS
MRZC>@X>V4QKS-AGR&K^F8>>"-7'L-:8/(?)GVNT]K5@CGO%GEU&]!P]LIC7F
M;#/D-7],P\\$:N/8:TP>0^3/M=I[6K _/>+/+J-Z#A[93&O,V&?(:OZ9AYX)
MU<^PUI@\A\F?:[3VM6".>\6>74;T'#VR>->9L,^0U?TS#SP1JX]AK3!Y#Y,^
MUVGM:L$<]XL\NHWH.'ME,:\S89\AJ_IF'G@C5Q[#6F#R'R9]KM/:U8(Y[Q9Y
M=1O0</;*8UYFPSY#5_3,//!&KCV&=,'D/DS[7:>UJP/SWBSRZC>@X>V4QKS/
MAGR&K^F8>>"-7'L,Z8/(?)GVNT]K5@?GO%GEU&]!P]LIC7F?#/D-7],P\\$:
MN/89TP>0^3/M=I[6K _/>+/+J-Z#A[93&O,^&?(:OZ9C](NAO59"-9^ (UEA
MC1-3?)RMD>R1$TI-A@Q2=($Y%[LB+ ^]0;<TKB3B7F/'J#>&H9UZ0%7 7 K3
M)_+&Z%@M[@/$KNC.%+G,C[JI+M7_ 'NG*4H22H@)!<2R"W=: "1/0I2+H4@G
MT_N?8V9X\PXVK$@)D/D$-:LS!'N)^$I,RPNHI;S4J2Y;!=UB0L(F6FH6D;I<
MG-_K%'[F)^16$W/*?C,9S#DYO]8H_<Q/R*7/*?C,(<G-_K%'[F)^12YY3\9A
M#DYO]8H_<Q/R*7/*?C,(<G-_K%'[F)^12YY3\9A#DYO]8H_<Q/R*7/*?C,(<
MG-_K%'[F)^12YY3\9A#DYO\ 6*/W,3\BESRGXS"')S?ZQ1^YB?D4N>4_&81R
MP +0"VT MMM  MM      V   '0  '0 !T %1"/-(0I"%(0I"%(0I"%(0I"%
M(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%
M(0I".K3NSO\ Q;NH?_W^(_\ YZXWK;FX5_M2PS_Y:W_^/U6-2;N?^R_$?_U:
M%_\ D5)C\+C,66<YMA!@-]UAKHWE& M4F(T=UAJLDNZUR5E\6:G0#X%:@L0V
M)AN'8'I_0B:>TF$:=]Y)[5(*\DG]E)_:6#^P./(\<?/E.2"F\NY>@WEDZ7[6
M>D0KM1D=\!4-'MLK)L>[++V$7+,I;.FEL=D^!H:FS"QK+V2>8EQVTQN,XL(8
MY6^SEVTT9MA#=&S\GXQ@,#8W%]<V=%$E#$IB[##Y8JD1KC<D2+-$4;$$NBEP
MIHX9XC=)H+D*<TZL5*8\>UG7&K=@UQ1AU\MRJD5>IU!P)+=S.?*<:U.?- TE
M209@WC6: NM!OK3-WAYM,KDA4MN\I-/0T84G473AZZPKB!I+;RZQ0:93Y"I[
MELV8I;AK+:.B[GK*):XS*X]C>?SM?J%T\H8'+)+,L6S6)XGAUL%;FF-MFHC'
M4T@Z&UGCT!E:0YM6R9+IKE25]@B->G5K)3DEC>'%IM<G_=40U3*=5:=348;Q
M).J#9JRJ[!Y6*A,J<QT[7ABHLJ@M+AS4FJDN-67BEDML^4%(EM*//E2W(EM-
M)0H7\JFOGZJ[A^2R<.7=!JM,I%,D4N6V9R\5L7+.5-;MZ;4 MN7$O"]02X9#
M1F3'5<ESU-]!X A5A0N 3)(]M,CE4?R6^YM<]/.5RG6%(=+T-@.I5J6,,OPL
M8VNP8_12*=73-J4=]$J:(/-)3"87*E\5C\@N%*J9$# +9;'M49+D36[)U2&^
M'I.(J0J54>RU\]PNZEN&M<+AJ:A,;4Z73YTL-63A_3F-0J#-#MVWO^OFNM8N
MS*COI<R4MTSJKC$$ZAU"6XI_8K26N(VDUO/HP;. RD.:C.?4^;K50DLZB^8,
M7JVC)P!:0W:!MH5FZ'N;UE%8HR:DR]$9TE98K?CK%.<,,/$7F^4 5KW@A*U6
MMD6;8R0V,SD[IE+0VN0)=\7JE*M$C5@K9MEFQ*$^;RZ2C@B=1G[$N'2:E5:'
M79;QA2A*DR%JFIFN9CS3G2Y*TSEM](2Y8M,F73.*E:^K3)PJK3166M79N@W;
MJIU.K])GLW[]3A<V4$JDRI3<I0J;*6F6X$L3)Y*Y,DIF2$HEVIJF+ROB\W%P
M9_T\M9LL:)Y+W4Y6_P"%W?&F'FUO=FUH)9L*0]Y84,-/R5',>'HE#X-Q+\Z1
MM*L,M:6!7)XHO?'64VC":Z-6)=7[&<435LYU/921JM>D56M+FRI[DN*\^DN)
MSY-,=U03-X3I-9#M24+FNTR'4N1)I]VQ3(K%'FTA6)L,,Y#J6\?$ZU0YU*H#
M26]E-DMZ*SF29#0UEI2E2=\(0YFM4S)J&K)<QHYFS:EG4,[>L3ZI==,E9!:4
M&-\/SK,4Z40FR,1U2POLAYU.;3%\3%(M;E@(HTDETNCJ]X9&VY D615D=6RW
M=1V*DM,I@BJX/W/VC@N9]4K=.H-.X2UMU*GR9*J,BJUEZ9LJ8FSN<QI[I,AU
M-$Q2'\UM-45 *"ZA+N;3L88^=-]6D4[#]1KCXL-5;394R9+K4VF4EE+:SM))
M:-WK]FN<T9&0E;!#EFE*3H%/5:N7*'%<J<5AEAJE8X+')<<6061:8K6G&JE)
MA:9*4403;<>=LL3DD GM\%MH  5MQ*$I2$)R2E(0D$DD)2D)&:B2;"]S<DWS
M-[QJS9HW)("U*6<@2I:[D=J +'8DDW']U-HXM=D<84A"D(4A"D(4A"D(4A"D
M(4A"D(4A"D([M^X22+.#;JV5L..$!Z_%S[$EYF=$R\U60SM+0V6K.]1\+,LL
MO362I')3[6YF3C:)BMM=I%Q=I*2U6XH] _I$-Z!-P2'%44B76&SR6K#QEA!G
MKGS3+UV2.-3-;,+7/L=%,Z4U425[VE>^/T?)U<DXR1)H\J::6Y:3$XCESA,#
M=+63OVJS";D(J4AZN6F5OB53)B)KM"0)9FJD_M)KPK'NB%(0I"%(0I"%(0I"
M%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"
M%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1HEW1W!<_P!2NC?+F%\7)&M;.)D;
MCZYD2.[D6T-YH1[)\,E+F![D<4:2EOM:&5=Q WV;!4!P?O=MH69[N78BIF%,
M=42O59<Z6P8IJH<*D2RX4"YI+UJBR!HD^Z)Z!M&5\K#+ =TZ@5'$^"*S0Z3+
ME3J@]-+,B7.FI;!>K55FY7^L6"E-I$A2A<$&P3<:0C\N'F&/= /%+&_PB,OT
M.O7_ +/^YMSA4NC'<>0_8%W1N:6/2;'SQ]![AOW06X "Z+X[N"T!"T!R.T"
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MHU?NRLWM1W.:ZUI[%[4'3A5)#=LR:N9[MPE5?IDTS WD2YSCM&BM(WEJ)
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M92D7K'4M6?@"9H%AB]PV N<%2UMA#:L6GJ@#\."H]5;T!]X&S;5-3*WN64%
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M ,ND(=Y<7ZG2_O\ RZ0AWEQ?J=+^_P#+I"'>7%^ITO[_ ,ND(=Y<7ZG2_O\
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M)Y!AN'NB9Q>IT_K"524ZXDQVR=N9D_/$H%0$DIY4I;FUS=$:?8D5/"5(\7)
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M36@A8#9%@TA"D(4A"D(4A"D(4A"D(4A"D(ZWNZP-#N_Z"\XM#"T.3X[*S,7
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M]TM+<2>''KD--$AU9K9][E3?)0;'14D *!3E&>3L2;JC@J_R:\9N7EE/7K'
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M9A>-I/DITCT'C:MKP_$)8DF!^-XG&8>QQZ/,K?*EQ:FV2N8I%2Q8*RZ\-W5
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M[19VY'8U!=8T(TVZ)>EUZ_3UVP!;KMVW-_BXH]E?<_FI(8$E@V8IQC[*C-J
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ME21]"UMBV5J6GOO.@:Q QVW6Q).\I$K2[77+42H;0N1J77KUY.2%A]7A/?\
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MVV&Y_P!V#GYB/_3$/:\8QYA:_.]GZ&AYH+&O&,GX/7;M53VV&Y_W8.?F(_\
M3$/:\8QYA:_.]GZ&AYH+&O&,GX/7;M53VV&Y_P!V#GYB/_3$/:\8QYA:_.]G
MZ&AYH-&O&,GX/7;M53VV&Y_W8.?F(_\ 3$/:\8QYA:_.]GZ&C-1C7 QRM\:X
MZVREL3KG=18B1[_!71&D.5WCZ'),5#(OP6\&W7$)^@?#MN#;LVWK#7Z2."<4
MUVE4"GXS0W?51T&K9+W!KUJT+E1&K-2Y-:(N[*@T;W NZ4$G:F+77=P_%&'Z
M2^K#K#:W#:F-R[=ZGB9DY=!O8J40UX'!.K 740JRK*L2 3&Q/.%/^M8]Y-*>
MT5>@]3Q-SVQZ$5Z:C3FM43F=WTN/1T.<*?\ 6L>\FE/:*FIXFY[8]"*]-0UJ
MB<SN^EQZ.ASA3_K6/>32GM%34\3<]L>A%>FH:U1.9W?2X]'0YPI_UK'O)I3V
MBIJ>)N>V/0BO34-:HG,[OI<>CH<X4_ZUCWDTI[14U/$W/;'H17IJ&M43F=WT
MN/1T.<*?]:Q[R:4]HJ:GB;GMCT(KTU#6J)S.[Z7'HZ'.%/\ K6/>32GM%34\
M3<]L>A%>FH:U1.9W?2X]'0YPI_UK'O)I3VBIJ>)N>V/0BO34-:HG,[OI<>CH
M<X4_ZUCWDTI[14U/$W/;'H17IJ&M43F=WTN/1T.<*?\ 6L>\FE/:*FIXFY[8
M]"*]-0UJB<SN^EQZ.ASA3_K6/>32GM%34\3<]L>A%>FH:U1.9W?2X]'0YPI_
MUK'O)I3VBIJ>)N>V/0BO34-:HG,[OI<>CH<X4_ZUCWDTI[14U/$W/;'H17IJ
M&M43F=WTN/1T.<*?]:Q[R:4]HJ:GB;GMCT(KTU#6J)S.[Z7'HZ'.%/\ K6/>
M32GM%34\3<]L>A%>FH:U1.9W?2X]'0YPI_UK'O)I3VBIJ>)N>V/0BO34-:HG
M,[OI<>CH<X4_ZUCWDTI[14U/$W/;'H17IJ&M43F=WTN/1T.<*?\ 6L>\FE/:
M*FIXFY[8]"*]-0UJB<SN^EQZ.ASA3_K6/>32GM%34\3<]L>A%>FH:U1.9W?2
MX]'0YPI_UK'O)I3VBIJ>)N>V/0BO34-:HG,[OI<>CH<X4_ZUCWDTI[14U/$W
M/;'H17IJ&M43F=WTN/1T.<*?]:Q[R:4]HJ:GB;GMCT(KTU#6J)S.[Z7'HZ'.
M%/\ K6/>32GM%34\3<]L>A%>FH:U1.9W?2X]'0YPI_UK'O)I3VBIJ>)N>V/0
MBO34-:HG,[OI<>CH<X4_ZUCWDTI[14U/$W/;'H17IJ&M43F=WTN/1T.<*?\
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M8[[/18 /32)C!HM(>'&Y4P+$R*06GQE3%E+7PGLTPNR^'93?<PLW&["OP_\
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MJ%NR5]M/4[/:*R'=2*2VI#&:S:K=$.'E6>DNR"X4YJCYW4W*E%(0G_/N9B4
M)MO&AM-S%D(LYR!.\R%Z71N&OBA\G1N24Z=V1OHHXY,AO5J+'9A);I*W''VE
MBLV\ER$]Z:U.Z)16)%0;1NS1INJ5.14*Q4W-"P]49]1Q2<8,6CN364M:#B-4
MQXKA2EH:59JI=E.\V=6<5*F*#9H9[5RI!5&,3MSZG3&5+8-JOB"G2:;0!AJ8
M6;EB9]4HB0A!:5)3JDN@"=#)W3=0=HTE:NY3>\4RI5J%JI2J47<:I6*##SS
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M4A#G:#J ??0/JZD(<[0=0#[Z!]74A$<D65HSR===*V)BL:..LM$9 Z(+6_>
M':2&UP;P(WC8 !LZ;@$!V!TC:&-8GJ.%*33-;QI4,-TRCETA =8E>,&M-#KM
MM7 75-%MK-OV1M!)(.9$72D2*W/>"50)%5</@DBU(EO%.=$V)%FHU@).5^UM
ML[T0;G=P-U)B;WXA_P! K7?9M^CKW7;C73&"?SL95P?NH? -T+R'$GX<.=W
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MASM!U /OH'U=2$.=H.H!]] ^KJ0ASM!U /OH'U=2$.=H.H!]] ^KJ0ASM!U
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M0L2<L!N=/HY.O@XK>&XB;]>OU;8JB2:Z<(M25(I8S95)4KCCW(N0B74F%3M
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M3N8)-FUX/Z9[>/Q^<Q%NO%MN,N]],3]VT>1UY=9)>HG<I").K[E2:L4,!&Q
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MDR:G^Q;(F ;5N2\4S".- /\ )2VYFCD7?HPI7MR>1((L2N%P>I4Q/V[*4R8
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**0A2$*0A2$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g111598g35y17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g35y17.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1MN4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %4< 5H  QLE1QP"   "   < E  "')R,38S-C8U' (% #1-:6-R;W-O
M9G0@5V]R9" M(#$P+4L@+2 R,#$U($9E8B Q.2!D<F%F="!F;W(@04,N9&]C
M #A"24T$)0      $.H<B5UCDQ/6<^^9ZB4=D*\X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 97X,0         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              'T   "UP
M   !                          $              M<   'T
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   'T     %)G
M:'1L;VYG   "UP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !]     !29VAT;&]N9P   M<    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M*2DFUO@$MK? )H=^]^"4._>_!)2^UO@$MK? )H=^]^"4._>_!)2^UO@$MK?
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  :/%X  "<0 !H\7@  )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$V.C R.C(P(#$P.C(R.C(Y ')R,38S-C8U
M   #H $  P    '__P  H ( !     $   +7H , !     $   'T
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,38Z,#(Z,C @,3 Z,C(Z,CD <G(Q-C,V-C4       .@ 0 #
M ?__  "@ @ $     0   M>@ P $     0   ?0         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M\AZ9]E:]X.P]1A-AY#T">0],^RM>\'8>HPFP\AZ!/(>F?96O>#L/4838>0]
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MU<^(8_[W3_)O,(I91_V,JO\ +T/^00PH'@/R'[*4<1?2'X^CS_AA2F\/3A$
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M7N;7#RZ %[NKB(7,!)ZDC<D[JY],Y*;+Z?P^2L%KK-NA7ELN8P1M-CAQG+6
MD-!F:_8 ]!T5U9HEO4PB81,(F$3")A$PB81,(F$3"*JM7/B&/^]T_P F\PBE
ME'_8RJ_R]#_D$,*!X#\A^RIBW[0C>@62Q0-QILU%E8562MM8=M)6#E5+8T86
MVNTAM'D9-G@'@Y*=L5LKS:!2DE>;ND)!11ZZC7#%XT1*5 G^U^RC9+4:MN=.
M;"K<M%XA_:=7JZQFH-P6K4UI"PEC:ST3)G5;H6=::@YL'<-%-D6*SAQ"V!@Z
M69.&+<T@19ALG2+UHW>-U"K-G2*3ENL01$JJ"R954E2CU;RG(8#!U!U"'5OW
MX1?2 @/F'?\ \\(M<(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M"+:<=Q1'T?\ C_7_ #P?#]OS^Y/KZ\5Y^-_T@^E5AUITYTBHA'%B-:[G9*;9
M9IZ<\4G7GD41-&'<,$%$523+.>DS*-VS@B[<@(H'.4#J*%(6RG=F&;JX'*YO
M).;5^"HU;]2LP-G-J.8ET[9'M<TUWUXN+G,<QY+GMWV <16[>TK#6<]C<+CV
MNLFW=LTK<\CC!\*^$!L+XV.#A/'8EY-:_E& &.(!) /H( @/FRM59"K[5J;2
MK>ENI%A6'A2@J'<)E0V_=N)%UZ1?&'?_ /A0$-WG'?U!FRPU<V\QB:H\;.2H
MP#\YK448^\?>[?[O#Q"UN8G%;$92R?"OC;TYW\HJTLA__JJ V"X-> V3-&&S
MH-R[^ D; ;]42[T['8IF<:CN'_['((?K?+Y_,.=)VCV6VM;Y^1AW;'9AK#\Z
ME6&L\'I_^9&[_;QYSL\KFMHW!,<"'25Y;!!__569K#?_ -M[=O';K]^ZS!SB
M5VJ81,(F$3"+J)Z(:ST),0KTO$UEXJ0BW.[_ (N;R#19HMN'T\FL;=Z!SU@E
M=7L066?XZ\T4[/O^>)X>WH>GB%XV(6V()Z[_ /!8AEA?M_\ &5A8[]#]Z\>=
M@G:GE49G23926BV2P04'J2RL4PJ+LC]E*PE@F'T*P9E!7FQFY8U%;G@*IG5,
M=TW%)5(K=0BUY]I6C(3!F]:-GD9\19Q+ZM=O%T<L-BK6CL2R$[.#C*0(N.S0
MUI!!Y#:DNSG6$PFPNCS#&[N(,HRU,XN[V*6"S8D@B9M_3+6QM<)-]R200>G7
MV=RAU>:V\9?Z ?\ X^<!#^("&1N/]?N]?\_!%H!RB.X!Z_X"'^H>CKR=^NR?
M7U]?<M^$3")A$PB81,(H3J+J+3]**?,7V^S"<%5H(K0TG)J(N'((<_D&D6S(
M5NT27<K*.'[YJV2312.<QU0ZMP&$,_&8R]F;T&-QL#K-RR7B&%I:TN[N)\SS
MR>6L:&QQO<27  !8&3R=+#T9\CD9Q7IUPPS3.:YP;WDC(F?*P.<2Z1[&@ $D
MD*11<U%S<9'S,0];R,5*LFTC'/VBA5FSUB\2(NU=-U2")5$5T5"*)G*(@8IR
MB'GS$FBDKS203L=%-#(Z*6-XXOCD8XL>QS3U#FN:00?O"RXI8YXHYH7MEBFC
M;+%(P\F/C>T.8]I'BUS2"#Y+LP'> "'F'KSS7HJKU<^(8_[W3_)O,(I91_V,
MJO\ +T/^00PH'@/R'[*B)79P"POM5W-EO$E,_"B=F;GYH5@WL510KLFVF*'&
M5N7Y=9DA"TB6;%EX^+/#&1DY=9[*38OWC]\HN4J*R&R%&R4YJ-:W&H%D1M>M
M,#(5#5^681D*W0M52>1,#7F45$L%$ER59W P4&9A#2C99\=)2<GW[QN]=.VA
MHXBS 9-D6;1NS;I%0;-44VS=$G41)!$A4TDR@/F*0A0*4!Z]P!OZ]^$7$I%1
MBRAE5HY@JJ<=YU%&;<ZAQ])CF3$QA_>(CA-@?$;K9T-#]E1O<6OJL*-AY#T"
M=#0_94;W%KZK";#R'H$Z&A^RHWN+7U6$V'D/0)T-#]E1O<6OJL)L/(>@3H:'
M[*C>XM?5838>0] G0T/V5&]Q:^JPFP\AZ!.AH?LJ-[BU]5A-AY#T"=#0_94;
MW%KZK";#R'H$Z&A^RHWN+7U6$V'D/0)T-#]E1O<6OJL)L/(>@3H:'[*C>XM?
M5838>0] G0T/V5&]Q:^JPFP\AZ!.AH?LJ-[BU]5A-AY#T"=#0_94;W%KZK";
M#R'H$Z&A^RHWN+7U6$V'D/0)T-#]E1O<6OJL)L/(>@3H:'[*C>XM?5838>0]
M G0T/V5&]Q:^JPFP\AZ!.AH?LJ-[BU]5A-AY#T"=#0_94;W%KZK";#R'H$Z&
MA^RHWN+7U6$V'D/0*%ZDMHN)T[OLJG',$5(RF6B03639MB'2490CYR10ARI@
M)#)F2 Q3 ("40 0$!#?F?BH^^RF-A(Y"6_3B+?N<)+$;2#^!WV(^\=%@95_<
MXS(RCY3%0MR!PV!!97D<"#]Q!&X/W%>,3?9HJ3S]'E3]9*M66K'5RJMS:N.+
M*S2'I2<Z$M<F=RC**J%64<LV58 RS9F@9N@FY8I. (95185;]DU9<9VI7M/W
M;<DF"O\ _H0IO=O#6%BE &NA8WB&/DN.#72'D[A*6G9H;M1<>E:CNS.EGJ55
MC,Y2 S;KD>XFG->Y.X]ZX\G.;%4!+6=&<HP0"YSB<Z[WM<T"F#LO+(5ZN.H[
M:&&-DGSUXJS9)5.L/(R.66E%#BV,F=5E)3#9NN1V=!(J;.0*90JB9C)5IC-
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M9E-"Z(TK7VV1K=9A',:!$RY7:C)I&LE'4BK7+2Z8/$3+QO2QFJ\6]BV*?1H
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M=N[=SB222L&CBL=C6R,Q]&M3;+/+9>((FQ@V)@ULLNP V+VL:T\=AQ:UH :
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MJ":N?$,?][I_DWF$4LH_[&57^7H?\@AA0/ ?D/V4IPI3")A$PB;P#SCNPBT
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M.4Q5/J[J[-7*=7'BPVI5J,OL:VC&:;K(R,[9[3K0BD<U[I7,9NQG&)FSFQL
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MKE9\0&3?A$R;<>"R_:AV?822:'(:OP45FO)+#/4BO0V[<,T(<7PRUJKI9HI
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MNR-N'>BL'\=MQQWVV)&RYDZUU>:?V>=5ZA-'O!**9S>1-82CPD$)LEG/I_B
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MR9LDVRT3%PGZ'47TW/&(K)G3GGD>R7=%$PJ/2QD9,LH])XZ,83O'*38BKM0
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M)J@8A2@'4V\-B,A)4EOXO'W9* E%)]NG7L.IB>-L,XK&6-YA$L36QR=WQYL
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M#&QQ1,W)/%C&AHW)/3J257.0OW,K>MY+(V)+=^_8FMW+4I!EL6;#W2S32$
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M\8@)N$.(0 2@)MW6(%$3"4-_F 3#N\V\<(JLU<^(8_[W3_)O,(I91_V,JO\
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M.FF7S)+P69]@PFX_'T/LG33+YDEX+,^P83<?CZ'V6TTXP* F,61  WB(C#3
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MQT1Y%98Q4RJ[S81<,9J#1)A&3<1EMKCQ"$G'-:EE499@)(VPM')VKF&=F%8
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MP24M3[2P/>($4:\BG9X]VO%V!TRD!,@3]U8$/I3>8.O;.TU4XB);VC1:B/\
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I*#\KI0AD56X%0*W<)"?C<$2((\HLF'"!A-U[]VX!$(W_ +_7X[(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g111598g42i94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g42i94.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2C>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &4< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C$V
M.34Y,1P"!0 T36EC<F]S;V9T(%=O<F0@+2 Q,"U+("T@,C Q-2!&96(@,3D@
M9')A9G0@9F]R($%#+F1O8P X0DE-!"4      !!4KS=_,@3*J\(?*?'"@8EK
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0%?_"@         *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #P     $  0/      0 !.$))300F       .
M         #^    X0DE-! T       0   !X.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         !.$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       !F0   A$          0                         !
M      (1   !F0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !F0    !29VAT;&]N9P   A$    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   9D
M4F=H=&QO;F<   (1     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    ).$))300,     !Y*     0   *    !\   !X   Z(
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M?YOT$99LT:N7S#B_14.0Y4_Y/;3YI?\ ?.%_S.K_ .Y;_P#,:F_YFL_[F/\
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M>]SJFY#<AFKOT/KOJ#76UU^G^@9;_+];UE<Z[T&OJC*Z]SL:VDN<Q[6@M/J
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MRO;Z?H?2&W;L^E.D;?SMRL-]'U7[=OJP-\1NC79O_._>V)J'_]DX0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M%    )P!.P "    "0   +"':0 $     0   +P   #H  ZE:@  )Q  #J5J
M   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#(Z,C @
M,#@Z-3DZ,38 <G(Q-CDU.3$       .@ 0 #     ?__  "@ @ $     0
M A&@ P $     0   9D         !@$#  ,    !  8   $:  4    !   !
M-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   )    L(=I  0    !    O    .@   /      0   \     !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,CHR," P.#HU.3HQ-@!R
M<C$V.34Y,0       Z !  ,    !__\  * "  0    !   "$: #  0    !
M   !F0         & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M-$.2X34V4W.R)D148W1U@I.BL[32"455E*/"TQAD@\/$-V5FA(6&I,7B_]H
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MVQULKA[E\T^<L4>DQEIB3"E2Z=#"DE,0E)!+*2"%=X$&X/0!0(.UK\JK-_\
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M#2N6-]&S,RP@IMY$5\Q"3DHTC7[R,A5%3J(H(2\@BV.U8*.%DS()^96:"*O
M% 3\\V'9T!N3%B/364298!9;'=5)O8 QT:DV&KP 5?H>NVT8H55D0JE46*+4
M9%/I"FT5&H-09:XU,U( 0FHR0GLK"G' I"G'TMG5\H#ILA4KUEXC^&F&&F&)
MM 5JQVIZ>,J\%-V623;K/3QT!&/9E^#9(A2J.1:QZ"[D&R F2,J;RXE*)^H0
M$3=6L25-AP4=IG2FH<92.RA;ZBE(=ZE0)O\ *FVQN%&Q2%6OC?4:BUBMN]EH
M]#F5^:A#\WL-,AS9,@Q6U)2XYIBQG"6FE.('>"]&H%;8(0#ZUZK6>W/31U3K
MT_9Y C=5TJQ@(B1F'I&R9BIJN5&L:S6.1HF*B76[(FFGRZ;"@414(*?B94H=
M,;0[4)T2(% &.'BA(?/Y([ZS=1((TJ.^D@CKCU2<OUC,4MV/E^B5.MOM)4X_
M#I=/G37FXP4=3S@A\XLA"5M*4MM0MS$6 Z*D[ELY9N5FCI!PU=-U3-7#1PDJ
MFX;.$C@FJW61.!'"+D![^"HB93@0$5..=92'4N-\T%.C3JN%6!!!((N3=-KB
MY(%QMO;&O?A/1GG8LAI;,AA8;+3Z!&D<W5H6VN,L%>M"TD<I)<4 4W4;G'35
MS&OPTPQ/ZW4K9<'+AE4JS8;2];(>;<-:["R,VZ;MO$*F+@[6/05.5']8@ER8
M>D%E.?4_(X,RH1*>TT]4YT: Q)08R%.Z19W3?6%6OJ!).L;D)Z["\EH>7ZYF
M!]R/E^@U2MOLM)D26:;3'YSK45*Q'#NEF-( +BA=8U)(7<I42=0CY_'F0:JW
M%U:*-;JVT*=-,[NP5N9AVY5%NH4DQ7?-&B/BF$."(%,50.P*GY#C5N/5Z9,<
M99AU.G3)$B^AJ#)1+Z=39!24VZ@]T6W%@<9-4R1FNC-JEUG*V8*5%24!;E2H
M]2I#7/=* EA2Y[#*&E75T05-)NI*E]TE-(ZV6(CAIAAIAAIAAIACS)UG5*DF
M"BBAC^&*:9055 _V^D"%$IC#Q\(^&F/(" ?+5;A+275);^0'??>?$6.YYDW4
M4J^>X'4'IC+0V''^6AM2DN+(0TTU(><> V2EI/+YR25)-U(*+^*;7./35,8F
M&F&&F&*@K%,N5W=KQU-JUFMCYLF+A=G68*2GWJ"0E$>I=K#M7:Y""0!,18>$
M^W)4Q'GJPIM2IU+#"ZI)CP$RM(27Y0BL)'=)(=EE3@O=/M%]]NDEHF5Z[F9Z
M0SERA5>NOL:G.52*;/J2VF[D)==9A177"P=*P$K2%JT$A8) 5+):&G*[(+Q%
MAB).!E6W .(V:8/(N10Y(!N73)\V17;&]2<JI)I"IQW^0Y$>1%FL\^,_'GQ^
MI=@RDD; _E-+.QN#8[^'6UL*H4JH4><N!5J54:14&E%Z1&JD-R.ZTT3NER$\
MA*FDVNG5?EI6.Z4@*48+5W&GPTPQU*0YS&Z 4."9!.H4@ <Y2\ICUF(43B4H
M 9(W4)DTNM06XB F$->"Z@+2USF6EJW;+UOQCVLE6Q\=O#KTL<9O9K\PH05Z
M$+4MR.'GT( 5;FZ-+FAKU D/!()*DZ@H*2.VO>,+#3##3##3##3#'F0#G4!)
M,%%%!-T"DF4%50. @<"@4HE,8?ZGZH@\@/ A]:[):0ZL-'DBZWWG^RQEW\57
M)2JP/0WM8D$D"V8AL+D<M#9*7'"$--M/ON/!/1#(Y8>"BI*@5(T7\4VN<3IO
M6[$ZA'UF;P<XM6XQTFTDI]"+>+PK!TL*7ALGTF5N#1BNJ5R7PBK+&,/C-C!R
M(ICK"<FQ&I#4%R4RF0ZP'8C&M0D/QS_M?_&&X&Y)5ZP_.QM6Z)5WJ7-K;5"G
MNTN*ZS%E55J%*-/B2%AKELNN]F[,TXXEY%B7;J4ZG4%V0K$IUF8CV&F&/,P*
M%("O"HI\G(50 (*1E$2HE5("ABD(?PS'-]DY@_7("OP8.0HDA2RVA+9)U%;)
MD*,B,)!46BZ.85BUTZ;W"=PBXL,;!Q+3:$J6DLI42EMYR,YH=<: 2I)7RDQU
M)3K:4X62" X@N):45$U'6ZG:[@Z78U*LV"T/6R'FW#2O0LC-ND&WB%3%PHUC
MT%3@C\:"7//3XJG(]S\CA3*A$I[33]2G1H#$A!C)6[I&EW3?6%:;A8)W7ZUA
MUVMC:43+]<S ^N-E^@U2MOM-)D2&:;37YSK<1"Q&#VAF/(MS% ZQ=!#ERE14
MH*Q,9W'>0:JV,]M%&N-;9@=,AG5@K4Q$(%.OW33,L_9-4.LWH1$HE5*(AXA_
MA'5IBKTR:ZRQ$J=.F/R2H(;@R$2N\/ !"DE-]_S00#MX8R*KDG-E&9<E5G*V
M8*3!26TNOU*CU*E-!QS0E+;CM08:Y>Z@-+9Y6HA2G-2211^L_2O\[ZSB);^0
M^D_RQXG4*'8.>?D(!Z?X?ZM>3O<C8; ?1BB!K)L-ATOX;6-O+YL0_B&YXZA#
MZ  B ?ZM6G$BQND'VV'\=_\ AC8,-[!7AY>?O_?Y>6.@*%*/// !\_O^X.0$
M1[?[CK$<5O8 D_5X=? #IN?'&:AM-M1TCW]/':WB3OM8],3V/@9^1B9.=CX.
M9DX2"\J$W,,HM^[C(4'(^ W]ZR+5N=DR%TOV0%TJT 0[AQTCK4R9$5IYAN1)
M98>E7+46X2_(V)^02%)VZ6TW/UXD$"B5.;!F5.+2YDNGTKLPJ528C2UQH"5D
M@=I?2516><?45)2!N"0!=)@RG$0Y >.1[B//(?> @///?[A^>L"2L6ZWML!?
M8>\&_A]7CCU%;(22!ZW6_4CKX'?Y]QX>V.1%4X!T@8Q2 "AA( &,1/X"@8>!
M,1/E4R(")U$N5%!:H 81,&HU4'RVI37,;!?'<M:R=]PDD63??H/[0.)?3(R7
M@D%"70T70MQGGZ5!381'L]8%/-D]R[Z]S=OH;JBT@[E'L(\_O'CY_>'(??\
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M%5#>4'&.:5NIKKV7"1G&Y-\CV,H;&-M*4QOBZ?$>092\"/IP4>GY  <ASQK
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MO%B001F13;Q#IJY:(3"[&67=*OQ1PLG38+$'-CV384Z'6V8ZISN5ZV"8$)"
MOE]@;96Q)U.ASE[N-D$1KV2EM2=GQ?HE?J=<X04WC#-R_F#)4Z>BAQN*.2'Q
M'K%2[<&6T/5IZ6B=34=E++=0^2B3&G&FY[D>0IY;Z46J+LZJM5N^ZM/)$O;&
MF.]O]>][P#^)D8B/F;&]LQ22./(QT\?P$C'N#R44"S.5,PBV@C+J)%2.P*4
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MME@PG*<#=\O*DK5M>5>S$\Y^<+-7N^4:0SP,(SHLIIXL+5K$N32L0#2877,
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MA-$B8;^M</\ ,-6,Z(Y5:/.ITZ6 S+JM'7*S!36P;):A/QTE:@D7" IQ(MX
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M1H[TNL5!V.]*TNE;+S"$-+6AF-%IC:%7?0RY;1QOJPG)W[$N<;'A2Y2.::'
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M29)/G2HHQI'\JZ>23KRJ9DV9%GCT[UT4I3JJ=! XA]44$@I39(%C8; 7N";
M 7^KQM;;&/$<7/J$J:X@1P]/5*:#5YJ6FUGO-MF25E"2+#UN\ -141?$ F8
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M<(?;-/6B6H5+R9&V3([7+ %)<T1>GBD&1*^,6R:5E)@+E1A).48]N7K03>K
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M94>F_4D^'S>6_P!6^.[9=9-V+^(-]KWO:USX^7^9Q-V[8QCE*8H"4P"3N)A
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MF1TV>NF_6+..410^$<&L<.Z?4JI)JL2KUVCU&;I3+=H<Z/":D!(!^6#NC60
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M?C>FUU![6)[MU19#:;#O%:0,1]4W@76OM<I1$O2<8WRL99NK_(<_4KC R,C
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MKDJ1/DR ]*57&'Z6J/(E.(N\]*4[$?1SX]2Y6IOTWKY@KEBQ'A7%+>]8_O\
M=*E)VJ<MDEB9DFVQK!M9%=4*S6ZPLDS;1ZC*&BET(ENDS%-WY&)2.]-UO5BF
MKPUR_/B9@KU>73ZO2H$XPXL%%<67JL^4*;5(?E)ZN+<*M3BUI*5*>"E75'!#
MX1?$"C53(.0<CHS%E7->8Z/)JM5KDC(K2&,IT]IY3J:72*0\VV8Z(\6(\(;2
M0H+,>".TI"I9 UMZ['CXKPTPPTPPTPQXK_8#_P H/\!TQ=8_I%?W!_VL0"AN
M?7D>.X_?VTMC)0D#I;<[6Z"Y)^N]\>)_3^__ &Z8O(\?F_CB&((\CW'N'?[_
M ,=8SQ_>/W8RE;)-MNG[\0J@%\4  O!N@H"4..>X\]N/7UXY^8AJPX3I!N=U
M'??[^>V&W,_*W18C\FVH?-?K] OX8[E2\0YP !#D"!R'80#T'@?J "'R'CZ<
M:ULA6D:B1L>A_N@CZ3M;:^-HR@*<*+6!2G<#IWMS:QZ 6O;8'RQ'%3 _K\A
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MXDNW<![=_J #^( /R#7I+BD@)2ZE('0)! %NE@-A;#2=07K3K L%_C6H )"
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MB6(OX;4W^2Z?&C,WZ15W];U#[1A^#7AU^@.2OV5H7V##]'[ O[$L1?PVIO\
M)=/C1F;](J[^MZA]HP_!KPZ_0')7[*T+[!A^C]@7]B6(OX;4W^2Z?&C,WZ15
MW];U#[1A^#7AU^@.2OV5H7V##]'[ O[$L1?PVIO\ET^-&9OTBKOZWJ'VC#\&
MO#K] <E?LK0OL&'Z/V!?V)8B_AM3?Y+I\:,S?I%7?UO4/M&'X->'7Z Y*_96
MA?8,/T?L"_L2Q%_#:F_R73XT9F_2*N_K>H?:,/P:\.OT!R5^RM"^P8?H_8%_
M8EB+^&U-_DNGQHS-^D5=_6]0^T8?@UX=?H#DK]E:%]@P_1^P+^Q+$7\-J;_)
M=/C1F;](J[^MZA]HP_!KPZ_0')7[*T+[!A^C]@7]B6(OX;4W^2Z?&C,WZ15W
M];U#[1A^#7AU^@.2OV5H7V##]'[ O[$L1?PVIO\ )=/C1F;](J[^MZA]HP_!
MKPZ_0')7[*T+[!A^C]@7]B6(OX;4W^2Z?&C,WZ15W];U#[1A^#7AU^@.2OV5
MH7V##]'[ O[$L1?PVIO\ET^-&9OTBKOZWJ'VC#\&O#K] <E?LK0OL&'Z/V!?
MV)8B_AM3?Y+I\:,S?I%7?UO4/M&'X->'7Z Y*_96A?8,/T?L"_L2Q%_#:F_R
M73XT9F_2*N_K>H?:,/P:\.OT!R5^RM"^P8?H_8%_8EB+^&U-_DNGQHS-^D5=
M_6]0^T8?@UX=?H#DK]E:%]@P_1^P+^Q+$7\-J;_)=/C1F;](J[^MZA]HP_!K
MPZ_0')7[*T+[!A^C]@7]B6(OX;4W^2Z?&C,WZ15W];U#[1A^#7AU^@.2OV5H
M7V##]'[ O[$L1?PVIO\ )=/C1F;](J[^MZA]HP_!KPZ_0')7[*T+[!A^C]@7
M]B6(OX;4W^2Z?&C,WZ15W];U#[1A^#7AU^@.2OV5H7V##]'[ O[$L1?PVIO\
MET^-&9OTBKOZWJ'VC#\&O#K] <E?LK0OL&'Z/V!?V)8B_AM3?Y+I\:,S?I%7
M?UO4/M&'X->'7Z Y*_96A?8,/T?L"_L2Q%_#:F_R73XT9F_2*N_K>H?:,/P:
M\.OT!R5^RM"^P8?H_8%_8EB+^&U-_DNGQHS-^D5=_6]0^T8?@UX=?H#DK]E:
M%]@P_1^P+^Q+$7\-J;_)=/C1F;](J[^MZA]HP_!KPZ_0')7[*T+[!A^C]@7]
MB6(OX;4W^2Z?&C,WZ15W];U#[1A^#7AU^@.2OV5H7V##]'[ O[$L1?PVIO\
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M)DU7][*]$/[X.**S5FI?KYGS$O\ O5JHJ_?(./4,)8:* E#$V-@*;[10H]:
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MR.= CY1V!Q.)!\/.;:0BZ%*[UA>Y!/ON0;'KU)\.F^-6^\HB_AX'W^!!.^X
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M&8[/BU@LTM$IE;PH:YL:=C6W93L#YW 7AHZ?VVGT88:IE?1TQ,8SER#W+]
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M#*$UBUJ;)HF3\Z9A@(0Y4J302(&N7&A!$NH28\02$R)9;:0ZPPI];"]E-O\
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M&2N^P5R[X$1 >G[P[#_O]W_7R(=-2DJ)O8C]WWZ#Q/CB#.O6ZG?P%^GE]_\
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M4]8I90;[6<>*46/6]L:YJ[/E,4@ 9-,G4F4B2?PE003+P1),H< 0A *'!2@
M% .D  -=@53FXK"6$)19.Z0D)L@6Z)L $GS'^8^3T5YZIS9$Z4X%.S'W'GB#
M?^E)6=[GNW)M8]+#&,&YO?P. [K4\84VJ.+Y;IN-&P69&-D&B4C5*VDJ5!)5
MHP>MW;5U,/ (_<M6LH1HBLDS-XKCA0PM]W0LG(JD*149TA,*,%]FC*4"LOR
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M(B!B@4P#V'D#%*4!*/J4  >2AQK#*2.EO=X6\_9]P?#&S;>O[?8?O].)TB9
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M1Z0X#OZ&]1$"J%'[8EXX-P(<,,=AX >GD>.0'D>.PB(%+QSQP/7W+U ?K'N
MB;3#$*Z<M6#=P_?N$6C%F@JY=NW"I$&K9LU(995=RJH;P$$6Z8**+K'42(7P
MQ,(=(!IABTF!<_8@W0XM@,V8&N\;DC%5JDK;%UNYPJ#]&)GG%%N=@Q_8W$4:
M3:,5G<8UM57F&3651;C'2Z# DE$K/XQZS<K,,7C^'I$>>0'X@[@(AV'GOQQT
M@4W(=8<#U"*GVATPQQUF^8B'?@P#ZAR8.PB'(%$0]!'H#J'E,_AZ88Y$P@/
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MT;D[DBPW\/ ?-8'RZ'R&*;>.PX-R/80'GG^MSW'GZ\CWX[?+GT#G.:CI.DJ
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MS[R8\AQT$""^!.2D*<4PE"216AE.GU'GXPZ@$>?C*'5Z=0AR3@HB4O6 "F8
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MK[:=^_J/@1X^P>WV>T:T;A1\4^%_9;?:^RO#J??:W8%/F!@Y$2@'?D1'J.8
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MBFDW;-6Q"IHHI))E*1)%),I")I$ ")IE*!2@ =)>76'EY_7U^GQQ].C8!(V
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MO/--@7)*UI%L>4-.+2XI"%J#8N\0"0V#:Q)MW?I'0^[%2B<H]7KR' ]AY-R
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MM\<,J<3.'M#H[>6Y].SJS5FYM7G!]*:.&X[4]@)CVEJ>J2G&Y+2&$SHR'(*
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MOV7%]VQ]T616[2FX\M\BWE\*8EQ1?+(G4&-OH[Z21JM?P?><5UN#+89R4@)
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MY\SUO\_G[\4]OCN?IM?Z;"_N'ECD4$1*4HHI"4HE,4HIDZ2F(("0Q0XX 2"
M"40[E$ XXU3_ (_6+'Z1L?9A<[[]=C[1Y'SQT%HU,<5#-FYCF$HB<44Q.(E,
M!RB)A+R(E,4IBB(]C% 0[@ Z>SPL1;V'J/<?$>/CBMR.A(Z^/F+'Z1L?9MCL
M#=N''""(<'%0.$B!PH8>HR@<%[',81,)@^(1[B/.JW/F?+KX>6*7.QN;A.D;
M]$[=WW;#;IL, ;-RJ&5*W1*J<.#* DF"A@'CD#' O4(#P'81'T#Z:I?ZKV_]
M+<_2=SY^.!)(L3<;;'IM>VWLN;>5S@1NW3^P@B3L8/@2(7L8>HP=BAV,;XC!
MZ"/<>^JDD]23X;[]18_2-O=A>YN=R;$GQVZ?1X>6.I&C5,HD3;-TR")3"0B*
M92B)1Y*(E*4 Y*/<H\<@/<.^A))N22>ER23:UK?02/=BMR=R3?K?WFY^DDGW
MF^/0$40$Q@23 QP*!Q!,H"8"!P4#" <F H"(% >0 .P<!KS8%.D[IM;3X6M:
MUO=A<V N;#H/ 7M>WE>P^@8]-5Q3#3##3##3##3##3##3##3##3##3#''27U
MZ0YXX] ]/I^&F&.=,,-,,-,,-,,-,,-,,-,,-,,-,,0JZQD43J 5104TU513
M3 #K'*3D2D('/ F,'8H!ZCV =>%G2A1WV%]NIMO8>TX])&I24W N0+GH+^>,
M?=ON=RYV@;%-DI-OHX0-@7@?*VMN9%1\)$$7/CMU 11*59OX@(230R8FCG7Z
M@5%"F -<[X;\0V^(M*GU1O+E?RV*?4WZ:J-7H_9W7UMA*BZS^<E!44/ "S"T
ME&I>]NB<2.'B^'=1IE/7F&D9A-1IJ*ASJ2Z'$1[K4VI#EEJ^3<4G7$?N!*:[
MZ&T#8Y =8E*)C'$.D.XB(\=0\_%V$W;@.>#'Z0$/J(\=%)MO=(3^<H_Q-A\Y
M..<;[V2KO'9(NH^P"W\/^&(@INH.PFY .PCQ_6Y^+L($,'T#CY#\QU4$'[C^
M%\5QC'[[W*AN.+#A7*T.W3W3UGL?F6@S8.?<'C )2C)^]AEQLW+06PQ/NH(
M2N@7\^'B:Y2)_%7\*1@&DT7\%GHL*%5[0V*J9_9"LHT=J[5SNUV3R^Q".(O?
MY_-L3U'L/"S\&';?2U6_"9VS3Z,T/F &^WZ;&\3LO8O10YX=[>9YJ9Y7*,/;
M&14A P<NHP5E8>+DE8MV1_&J/V#5V>/?)F*<CQD9=)06KHAR%,5=$2*E,4H@
M8! -=.?A0Y3C#LF+'D.Q70]&<>9;=7'>%K.LJ6E2FG!I39:"E0TBQV&.<Q9\
MZ$B2W#F2HC<QE4>6B,^ZRB5'6%!;$A+:DAYI84H*;<"D*"E @W.)MK)QB8HA
M?'E$>7%G?W-2K:UVCF9X^/M*D/'J6)FT,FND+=O*G;>?03!)RY3!,BP 4CEP
M3[*IP-HW<M9?>KC.97J)2G<P1F.S1ZTY3XJZJQ'TNIY+-04T93;6E]X<M#J4
MV=<V[ZK[EO,=?9HCV7&JQ4VJ%)>$A^C-SY2*6\^%MN!UV ET17'.8TTO6ILJ
MU--JO= .)?D._P!:Q?4)N]W&1.PKD$FW6D7*#59ZO_2G;>/:-V[9(#*K+/7[
MY!LB "FF55=/Q1(D"A@L9KS/1LG4&I9DK\A<6DTIE+\QQ#2I*E)<4([:$L("
ME%;SJVV61W1S=!<(;N1=RSEJKYNK<#+U"8;D5.HN.!EMQQ+" EEE<IY2WEE*
M4M,,,N/NG=6A*M 6LV/GCC(58RK382^4YV:0KL^DZ,P64:+L7 ^0?NHM\V<M
M'1$U$5FDBS<ME@-UE,9!7PO$(IR:N6LS4G-]!IF8Z#)7+I=797(A.N-J8<*$
M/*CN:FEBZ%-.)4V]N02D*;*TE)Q7,V6JMD^O5#+U;8;CU.G=FYS;3J7F],B*
MQ,CNI=02"V_'D(>:%PH(6 L)<2I.+EZD6-!AIAAIAC7AO2]H9C[9C9J)3[#!
M,[59KQ2<C9 90:N1:71)1S#8Z>4Z/6A*LRN#M!Q><@6I]<V;*DT&M@ZL%F7C
M)D(]F8S/3[^7^9]F!V^_S??W8JUQ[13:(QB[W+2V4)2(;8X0:K68'F,LL'.N
MJM=HW&+J/I"C.DNV>6GT/DJ4CL>V-OB1W>CUZ[/V]:EE&,LJBBJP^_\ #Y_F
MQ*)KVEVT&O.W+::O%^8%2+CI-NN.!,_NO>LIE.OSELJE?@X]CC%U-S%B+6*[
M,3-BB(^-<.:8UCY!.V(PTA$R[%@PQ<.P;Y=K-7;+NIG*Z"!&CN79ND6E2OTN
M^;.H6]4O&;M-S'Q-6?/D0<WC(50@(43-2)V5S,D7K2DFQ8R3MHPQ)QW_ &U-
M%O27SK),RPC;_%V:6@924Q3F*+B&I*BM=6U@B[E+R5!:1>.;4R=8VO[%"F7]
MW6+1)/ZA8&L3"OG<:NV388H&6]IQM2)$^=J]HNEHE'$-D:4CX<V(<T5<$EL;
M0M:EI9I:'MDQPQ_(\'R]]QO$0*DTT26L#[)-#-!,YEO:(A5PPO\ ??V_3T^X
MQE!A?<#BO<#%3<WBBQOK+$5^6"&?2:]3N5;CWZRC<';>3J[RWUV!;7*J2*!A
M6A+Q3U)ZF6%(C@8.<?@V4\%AB]FF&&F&)!/>^"PLO^3Q&)YX(R0/"EDS+)QA
MI8C9<6!9 [<2N"L1?%0\X9N8JI43FZ $>D0-ADNM]I+@CJ<2F0ILV=3'O\H6
MK[!S3N@_G$$],5%K[^P_6/X8QKVIN=TKNGV8VZ9E7V%F);5PJI8<T$#HU8,Q
MC_CD0K:[B&\()1202BS@H64/'))^\DQ<@ FWN96\O(DQ!EM3RV!&3VDNI=*!
M(UK1W.TE#P5R@A3AOI"KAO8VQDRNRA8[.24[_G6\QU'6P(M:QV.QQECTE_LE
M_<'S#@?WAV_#6A"4B]@!?K8 7V W^8 >X#&+C'FG;I=O>0,E6_#],RU3)W)%
M#?*QEJI[64(G+,Y%JY,PD&C4CDK5&96BWQ%6$P,(XDPAWR2C"3(T>@5$=K,R
M]78$"+5)=*G,TV<V'(TM3:"TI"^\'%Z#K:#K:N:V7 GFM=]D$=;Q8="=>DE(
MZJ&Y3M<:@+E'38*L=QX$8R(UJ\6<-,,-,,-,,-,,-,,-,,-,,-,,=1*4>.2E
M'CTY !X[@/;^\H#^( /R#3"WAX8[:88:88:88:88:88:88:88:88:88:88:8
M8:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88U=;\_
M:,PVTT(^C4.NFRAF2717?/(E)O./*MC6%*@V4;3^2%ZXT=OF9Y4'K<U:K!G4
M&ZGFB$E)*3D2U9E<.N:\0>)M"R!'91,?ARJS,!%.HRJG!I\B2-*@'G.U*+@9
M2L"X99<=>5=+"+7Y?7^$'"63Q3K+L9ZLL98H$#2JJ5Z;&?E--$V(C1$(T-O2
M5[$\Z1&CQFCS'WRXIEB1A-ME]M#:K)D"L5?<=5\<LZ5>)=C"1F3<6EL$+&U1
M]+.$F<2[L\/9[1<4WU9=OUR(2ED9V"+3K#;H?O8]ZR4=N8N!Y%XZM9BK35 K
M]&-%GRWFV(3S;ZE,<YQ02U%DLO!"VW5DI >2YH+I4@MI;&K'>^+7P/9>3<HO
M9VR1FGXWTJG1%SJI"=AL-2C3PD+-0IDV')>C36FT76XQRD*Y5G&GWU I,GW"
M^VNM,%<9%K@>LXR3QY%2BT3%7+)Y+--+WXJ:XHISD)$5^VTA"OQ,H":BE;;N
MI&QS$S'.&,JX90CI=Q"ML'-7'X0JY*HN5*":XBFO+CRZ@Z^L17W6E:'1%1':
M<4N.A84%37G4MG3=M!1\L,SAO\#.5F'*T'-&?,U*RD*O'9DTRF1XL=<EMJ8D
M/1%3US)#:!)DMJ3HIK;(?9OH=>2\%QF=A7L__:#4O>S"6Z(5B&M(S!C0L6XN
M=)0>K+LWD+-&=)1%TKWFT6DK[GD7$<Z;/(Q^U!_!/D4F*KR2CI&*FY;KF1LZ
M0\YTHU!F,Y D,J*9L$N-2DH<.K2XQ);[DELI%BM"0IMS4A2-8L?F_B[PKJ7"
MG,@HLFJ0:[ EM<^D5>$AQGM##)2V\U*A.W?@RVG%@.1E..-N,J96AY:7"$YB
MYCH4[DRCNJM VU]37SAXQ=#)M2.CBY;M5>L\<[(S>QKDK-\F804%!ZCT&(0Q
MRB@55L:_G?+U0S50'J32J[*RY*?D17D5&*IY+Z&FC=UG2TY%>"7+V4D.[@=Z
MZ;@Q?)&8X65:ZBKSZ)'KD9,64R(CW*3RW7A9N0RIYF8QSF@.[SF5^N1W20H5
M70*Z_J5*K-7EK#(6B0@H6/BWMCDCF%_-.6B2:*[YR91PZ5ZUQ+UF!=TZ7 #@
M"[ITMRH;<4*GR*31Z939-1D5:1"B1F'JI**U29SK>SCSZG5N.+<<M=2EK6H@
MW4M2KG&IS!4F*O6JK58E+C4:/49LJ2Q28:4)BT]ETE3;$=+:&VVVVP;(#;;:
M!;N(0BP%==!.>>@O/UZ0Y^ST_3^S\/\ Y/;TUN<:?_/';3##3#'   =@   >
MX\!QSSZ_OTPQ*)NOP=EB7T%8(B-FH:31%M(14HQ:R$>];B8#"BZ9NTEFSA(3
M% PIJI')R #QR&L.?3H%5AOTZIPHM0I\IM34F#-CM2HDAI8LMM^.\E;3K:AZ
MR%H4E7B#C+@SYU,EL3Z;,E0)T98<CS(;[L:4PL @+9?94AUM0!("D*!L2,<0
M5>@JS$,(&NP\;"0D6EX,=$Q3%M'1S%'Q#J^$U9-$D6S=/Q5#J>&DD0H*&,?I
MZA$=(-/@TR''I]-AQ:? BMI:C0X3#46+':024-LL,I0TTA))(2A(2"3MN<)]
M0G566_4*G,E5"=)4%R9DV0[*E/K"4H"WI#ZENNJ"4(2%+43I2D7LD6G.LS&)
MAIAAIABTZ>):67+TMF=5JX>7:7QW!8S\9VY\=A&52#L,[:"(1<>*72S>R\K/
M&6F'/=601A8=,YNB.+RP]OW^_P!SX8U^9LV3[*<,XSR/>LLW7)5"QU(NVL&_
MGG&2+P_AL>U[(>6"6=_0*U ()S$>CC^[9.M#)[8JU+P<W!N52PCB3!)C3JX>
M$8H?;X[?3MB3J["MA^28*P8::W&^(59G::IBV6QHIE:WQ4'+S&%,+5.C)U*-
MA+(NDE:U8S&XU925L,![QDH291?/8JPP-C_*CQWW_A]_\L5Z_NVQ7F.]H&$Z
MI=\NY;REE>H72Z97S;B[,1%X1VA2*=6H3$Z+O\RE-B(&:NUU6.R96"N6"\3T
MJ6PI(77(C2:L"$=#LHA.$BV&+3Y3]FKLYO->E)N%RX\K,K!5:U8F"V2.3&UD
MK5=DY#'^2*C?7<K'JS4<FWO*E4R;D";DQ0F(1Q%V)X:XJ,$GB;]9XQ2WWW(W
MZ[7 .,A83V<6VUL[@YUJZR)-+IRB=FEY67R1.V,<A/#Y$Q+DYD]N;B36>#.H
MI2&$\80S?PED4G--K,;!._&9E14(PMO?[^?\,9);?\!4S;=06N,\?RMZD*C&
MF:-H%A>+Q8KH:L0,1#1=>K]2JGOY\])7ZI 0D.T:1T'&%:H"LD\DGR3V:DY2
M2<L5Q?C3##3#$/R'/3SV]>D>D3=0<%]>>!+Z%XZ1-U_/G7G4>FDW^K_>Z?QP
MQ[](#Z@'KSZ!Z^G/X\  ?W:KI3>]A>X5>PZ@6!]X&U_+#'.JX8UTV/V9&UF9
MSG';A(: G*/?B75GD&QC4)I1"*M]C;6-M:B.I!A))R@0H.YQF5_)#3EJXI*.
M%%'#Y154PJ#,F.(68F:*JB//M2X)AF!%[2US'HT=Q@QM+2F5(YP;85H;[7VD
M(0 $Z4C?,3->#*F2$+3<J[R18[$#5<;];^95Y[#&5.8-PV%L M(%_F?)M6QN
MSLTK[F@7-HD2QZ<D_+X0K^'R!A29,R+H*2,JZ!&)B".6YY1ZV!4@FCM,H]6K
M2WVJ33YDY<9H//B,PIS0E1(2+$^LJRM"!=2K'2#I4,8Z&7'/43J[VG:UKGH+
M]-_ =?JQ>9,X*%(JF8%$U"%,F8AA,13D@*$4(?G@2'+SW#D#=A'GD=:_%O'O
MIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAA
MIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAC''==E67PS@#)
M%_@%"(V-A'QL'6':J!';>,L]TGXJEUN8=M#\D>,8>;L3"2?-#E$'+1HJB(<*
M=X;Q S.<F9*S3FH-I=<H-%G5!AI6Z77F&%*80H7 LM[2C>U^GLQ(\GT'XS9G
MH&7RM2$U:I183KB3WFVG7 EY8)_,:U+N+6M?8B^/G>CZ!*24(O-^.Z?N9!T_
MD)"1D'"CV4E9%VNJ[D9>7?KF5<R4Q+/W*\C*R#E55R^>.%G+E5190YQ_#2M9
MJJ>9:]-J]:GO5&IU"<W(J$^2M:OEYBS=MOF$E,>.DA*&TC0T@)2A(388_3RG
MS*-EI,/+]/C,Q(D%J-&0TRTAEE)4!<I;2E" 5&ZE63<J-U>&,&JGM^A,QWFX
M&E$4R0,Q,231.L+J.25QTDP6=0[Z=DHQN=).96M9F R!V3U52%&+"/=&CO?:
M\O(27?X%>JU/BT:DPIC*)L>"RX]5UMI7-CKD-]M8@19"P7([--0^6 XBTP.I
M?0%IB-QHS,[D5F-&RR[/J ER:'55/EBAQG%,0Y;3BBA^3-Y9 DHJ:+.*CNWB
M%KDJ[$):Y3[LRKN$8&BYQK[)V!WT5)F5JK5%\[<R+2M2"A'"[%] "_466CFD
MZNV:UZ0BDO%;&7/ %BTV+%*22?:W,.8*G4LNU.GF4RW/@/(FREPVFV7*@RR]
MR'X\[E(1SWHS2UU&-)5NAM,Q4K6M45Q%VJUU]BAQJW 7(<IZ&H\,QISCCRZ*
MY)?6A#\1YTJ4TS,4ZW3I#"#I"/1YCB*EN0F1G3+,I3;=.5W.6-5?=]OI"HOP
M3:*"U)98--5%S8J-.< "+NNVEJQ*Q>)*D54:O@83[ I)J#A7;6+\#.+>8,C\
M0Z))9GNO4F;*;@U2'K7RYE.<<2R^MQHDH2XGF%Z.I?>;5I*  "3QG,=-9XNT
M2HY6K##+TDQU/T2<XTEY^D531\A,CNJ"G6N8[\A)0T078FIM>RB$_3_"2T?8
M86)L$6<%8Z;BF$LP6%/H,JPE&R3MHL<@A\(B@L4QR#VY]>. X_;C'YC>WQZW
M_C?$Y I0#@"@ ?0 #CZ?X=M.O[\,<Z88:88AA4X 3"?@ #D2B;I$H"')0,;U
M[@ G[@4P%_SA@ .]+[7.WB?9]_' WZ)%SX#S\_HQI W2^VCQMB?(LWB7"$%7
M,LV6K2ZU=M-JF;ZU@*='6=LKY=Y6:ZVC&LQ)W:5BGJ#B,L)DEZZPBY(AV+&1
MF7K65:L>09ZXNTW)L@P(](JE:J+*%*F!EEQF# 0 "KM$HMK#CJ+74&VRVE)2
MHR.]HQ].<'_@R5[BC"CUFH9EH>3Z-,6$4[M;J)];JZ3L'X-):?CAJ*LW;;=E
M26WG5#6Q%<:(?Q)L2>U86W'&/@^T0K7;QE2\KLHC'>0F-N>2M G)P'C996L2
M4J>%BIO'T[:&J:T/6EB)S[1=^[!LUG&]B6@(J6B\+BFCB;2JIEG+<M[)N;IK
M(]%.S7G'D.*2ZV](:8EQF4/QWE1D/LI4EI+C22IYK6X$H$ISM\&>K\#Y<+.E
M=,3B%D"%)+587 IZHD^G"4RN/ ESJ+,E2&'XC<Q^,XNU06V\MM34E,=DE9MM
M/>V1EL;P;"H4ZM166TZLD\;2V:+E:7L5&6TK5\[42?UN#:1!9&1JQ(\S1G'W
M:Q3<7*6 C9274K94W;==QI$\<V\IL0LKR&9.>Z]3OQ*J5B%-1&@R)B9+B%1X
M,A<:7(J7):08QE%D*>=;4\MRZL2JB_!"JW$9R9G%<R%PSRY5TQJA1Z._!54)
ML:"Y%;6[)J$9,V%#I';%A4]JGLSY(IS#_9'TL<D)3F1L9]JMB?>-;'.)WK!A
MC_,:,:^FHFO,+BQN-;N<5%!XDN>N3Z#.,>-IV-;E4DY*J2D01PA$^,\B).PM
M8J:7A^O9)XBT_.2'$*IT^B5%A!<7 GI=)=;&Q7&>Y++<D)"D%24H2X+_ -%8
M%6/G[BUP-K_"IQJ4Y5J+FC+\IY<>-6J+*:7R)*;A$6JPDO./0I#FDD:7)4=1
M%C)YIY.-L6NBXXCAIACC@/H'IQZ!Z?3\/N]-,,8\[A<!1.XF!J%*MDF1*@QU
MP4G[U5EHH7R=]A$:9<H6.K2KH9%FG%I,;3-U^W@]5:2Q%C58D9Y,GO()1DP/
MW^_W\\:XH7V1RC.W8*N-DS\XO-AQ/ MR3MAL%)GVUHG;[ Y:NF::OD2JO:_E
M*(A*G*+V^SQ#6_,K-6<D-;I7*35H-HK744WRSMA;IY^\]?/K_GU.^*XQQ[,9
M>&98_;97S##9"&@-8"/8!7,7*TUJ@SQ[MVD,#8J<1:,YD*_N64U29&Y91RD$
MM)O9Q5]>+V1^DE#J03)99MMM]_X??W8I8^?U?1?<]/?OXG%!TCV1Z<#6V$-9
M<J8_GCQ$7$MXJ+A=O[6LX\4G,>8*O6%\/WRQ45SD>?3LE\@G>1K5D*^S\K."
M>\6HE9+'LZ2TK,4"3"Q'CU]GT?0-M_YWVV8UHD7B['&/L902BZD)CRE5:BPZ
MCDXG<*Q=3@H^ 8*.#G%83'4:QZ0JB(B)E3!SR(@;3%<5YIAAIABC+O>Z;C>L
M3%TR!:X"EU" :^>F[-9YEI!0D8U(<I/%>R<BNBT;=2@D23(=<IEE52) 4ZJA
M$S^FFGGW$,QVGI#R]FF([:WGG#Y)0D*4KWCZ<6GWF(S2I$E]F,P@?*OOO)89
M;]ZUJ"$@^!)&^PQ\TKWV@.U^9]JOC;*56W%[DIVFVN0A<6IU5K2C0F%$9FQP
MA<:0Y'+FT7F$LAJ*-H?H6V10'$IS-[2F2S)3;F- "Z[R<CYNC\,Z@Q+R93XO
M8VG:F[4I;P:K*83,CMSRQ";B%?/;CI+)2[-85V%)1R2\,<_9XRY&?K,++,*4
MN=*J3JXC53C1>;3Q))2XPTB:L!+BG5GE"1%#S5BE!4-05C-V!]NSLX?Y4M&.
MK!'9;J->@[1+5J.RX^J+6>H,S[J?K18S'@56;F[A'Q,FLU,^BG:U5,E[F7:R
M,P6$566:MHBKA!G=5&B5R-!;F,2XD><W!BO!=1,:0D/(4(J@%NJT&W+CJ>78
M[(VL->CC/P_].R,O2:NJGS&)3\),N>WRJ=)D1UEE9CRTDHY>L=9"(XON;;G&
MWZGW>J9!K$+=*+:("XU&QLTI" L]8F&<Y!3#!9,3$=QLK&JK,GZ(BF< 406$
M@"10IQ Z9@'F3B'675L/M/,/-D!UE]M;+S=_SD*"5)(\0>GF.N.H,NM2&T/L
M/,OLN"[3D=U+S+HZ72ZA2DK3U(*2?Y5ATE_LE[_<'^_S']^F+N,;]PNU# &Z
M9A58S.^/&=]:4F3<RU<*ZD9R*68.'Y6Q)%NHX@Y"-<NXJ6(Q9)RT4]67B9 C
M)L#MHMY<G1N*+F.N9<7*=HM0=@JFL)9D%"(RP4HYA0X!(:<"7FRM10ZG2M&H
ME*@<76GEM7T>)!WN>\+Z3:XW%S;W^[&1B""#9%-NW131013(BDBD0I$TTDR]
M)$R$* %*0I>Q2@' !Z!K3XM8P-VZ99WI7'<+G^FYXP?6,?X0J4C()8=O,2[4
M/)69!&Q.6,,194]DF$["2<JR25D=NT(>N# /##&.FJB[@K.,EU>I^4XM#HLF
MB5F1.K$AEM55AN).B.M3(4[I_%4<KE2M48)YL@N( <3:VI>6ZTREAI:57<6>
M^-859) -](TZ+$VOM<[>!QGQJ(XQ,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,-,,-,,4)?+PSH,$%@D6+Y^T(_:LED(X[4'10<G.45T2/'+5%8$3IB(IJ+H
M=:?(%YXX&H!/0$^X7_=]_P!^*$I'K&WW]X^K?%F,H0]%W58;O.-H.U,47=BC
M&;AFHH@L$I7+'"R3&QU&9EJT[.RDE6;"S0L8].S."",NS:*(M)!--4KDL:S=
MEF%G#+%>RQ4M0@UZG3*4XZA-UM<^.6TO)*A_2QW2'D$]Y*DI(*38XW67*Y+R
MY7*37X(':J3-BSFTJ_+*%!Q;*K?DNL7;6%;%"BE0*=L:3(E:QXTF9/#^48%Q
M4KI#*F5,S<'.NQ=M7)CMVDU!R1D$$I^J21DQ]V6%BD5 #I/8B5:Q=EC9R C/
MQ)XJ<)LW\,<P.TNO0'%I+^N#5&TNJIM7C)4$<^"\04(/J\V&M7,8D'0XA3:H
MY=_0.GUZC\0Z>C-66I27%<M/I&BR%)-0I\H E(>;"BM(!U<EY"=,C8MK3IVQ
M=QI&EI\_,QQP*1S!6">KSA,P!XH(-'ZSB!64'[/5*5IU!30<<D*G)D3_ ,ZF
MH 9<NO.MRH\L!0;J--@OM+OL7)3;:)[:3>^EBK1YT W(WCK6+)6DGJ<:>Y6<
MH082@0[36D05-@DA/8QR&[[6 =CH;7;Q#FK8+Q(2-5+CG&D0[0@J&4MC&PO5
M"<"+.-I;M.TK.SAP $;+24;#0::H_$5_-,$P$ <)\9RYY:H=>K#R[!$%R(DJ
M/]-*JK*:0TDN;E2@Q)ER@+G4S#420&P!L<UR6:=D*/3'3>149M.0VGS[ Y%J
M#SZDG<MZ8R6%*MI"Y#5Q<7.5 X[NV[O)@83QFF\2K46JV:Y/R(DB;W-0JXX*
M3SZZCPY/+K6E\R.="GULAUW\J^\*070;5UG-S#"??!KX&UW/]?BYBG1'HV6Z
M?.0Y-J;R>4W(Y)MZ/@H6"EYUT("%%*2AADAQ]7-"4O\ &\Q9[I'"#*LFJ3)#
M+N=:U&<>RO1F=+JVG'5<I-3FH!M$IT5-W+DM/3I 4PP"L..1OI8BXQG"1L=#
MQJ)6L?$L6<;'MBF'H0:,6I6C1ND8X")O#02(0!,(\%*4O< U^P>/SCQ-=,,-
M,,-,,:#O:Y;DK8WN%-VHU.9D:Y!3]697G*SN+<JM'UFA)Z8F(*MT@7C=4BR$
M"J>MS[^UQP&*2;35K\>]55@_?\9*?.'P@.(%3RU!IU HS[T.;5$*F3)C#JHT
MAB AX,-LQI""%-/272Y=U!UH$=(NE+MS]J_!&X/T3-Z\Q<0,STYBLTW*[R*?
M1Z5+2W(@3:R[%6_*=J41U*FI3%/B/Q5M1GDJ8>>E!:DZV$XPK=1>((C%;J-L
ML#!FA6$ [<2Z;J/1=I(QC9F=5T9P0$3"H!6R CX8%,42@'PB'.O@R+F>$Y46
M8D*8X[,D2XK3<A*W"^9$Q0T+"TJ"PZ5%&X(-R!<6L/I.J3:[Z6FSU2EI@M@Z
MDG5V8QP%!31B[MEG1<%)04E-]NH&#E VM(Y32DF,LXEB0ZRB[R.K*\](1:57
MC5U#N(Z&-,5URPEI=_'(B5NHLYE3M$3-D2,"$51,Y=;WXYU%%54_EIR%3W8"
MDK-8[.A4N:\S?7-8:FMO1(J7%#FI;90W)45J<<</- ;GM>JO9\LQZ9G-R5/A
MRF.RO46"ZIIDQRG0J/,=0XF3,:TV0OGR'8FFR>2I".>KR#"D?5<JUYG9EW4]
M75I1A!,XR:=#)H5:P2;U%K#RS555/S\LG(/U&L(=:8-(RL(H^1=QTI&1!9A%
MQ@)K=3JE/F4J(IJE5904Z)T)@QQ6(+3!>=CK#1#4126OQO\ %@Q$E %F1'<E
MJCN(S:I7I::1#JC4J5/H\<)99BS$HD2:>\NZ&I:7'2IR>\I8;9US>W2HY=[0
MTXW'5,0O/*0PE'U\L%>*TLI6[I3GQ9FH6Z"5%A9:O+@R6;A+0TB@(N&JRC9P
M[8N_L-WS%^[AY(JS!RLBI$X%8SOPVF,YGI&8YL>7%?0MZ-UC3(Z;?BCH2O0\
MRJP2IAQM39N-@=\<CK%7@9U0]E[-4!JL4N:O1V>6RDH;5N!(AOZ2[#F(O=#S
M*T.@@6-B0?H#V8YVEMPF!JO=K$+=.[1+^5I%\*Q 4VBUIK#LC5Q*H-2"=-BA
M9XE2'M2,:(G&&1G@C/-.A:F<C^M'#O-R,]Y*R_FM#8955X8==91?2U(:?5%E
M(&UM(?9<*+B_+(T[$G'YP\2,GN9!SK7LK*6IYJFOLJB/+(*GZ?.BL5" XHW-
MW3$ELH>M_MD. VL<9<:G&(/B0S-C@ZTR/(V&9C81@0X$%W*O&[)#Q# /2F51
MRJF550W B5%'A81  !+D>-,,8\V+<]5V76WJT-+6EUP8A';CJKD,*Q![H^.]
M;N)@QP_Y,6]?7;\\\.0 0U4(7?2IM87^8@%T]?)/\K^=L5*5:BD;V_I% MD,
MC?=U6M*$[#H5=?JQ;O6\F58JN$']]JU/.0.?==;9(2D\4#<"5)X@])9'BAP,
M(B"K2.AA 1$P?=(*9E3,%7L[3Z34I,<[<[D)CQKV/_?+P#-QL2 \3_& 9CXH
M</LIK+=<SC0XKXZP6WC+JHOTO2(!F5(7Z7,8 ;=3C'>0W=@HN95*RYID2@(B
M+N-DYUBU%0/06[5>R0YDB_$(\$C2^H_WRYKA3F=;7,<=I$%?_1S)+ZAX^#$*
M3;I;<[6\-\<LE_"DX:L/%N'!SA5&^ADP*,WR1MU JM0I\@].J8MMQYB]S*!O
M/<)O6[5ID-R8YU! (')+5P9)<X!P8"S4ATO?,"/9%-*SB4./U31T&M+5.'^9
MJ4V7GX(DM_\ 34MSM['@;@,GG;>0C$"XN!?:79;X]<+\T/LPV<S,T6>LJO"S
M%'>HBB;VMVF6E=/<WN4M1J@\\KP41;&PW'><:Q>12C'/-;M2O/3!OW)%4I$X
M@(@->E!(W0EA/T"<K51-G)E(598S#RR1%QA12L*<3RG0ID]Y*T+;/3\H;6]M
M]@;7M?'8][#4+"X%P6][CJA04M#@V&Z2?$^(.+[Z88:88^._VN.>\L9VW;6W
M#]0E8YWB+;ZA"PD>H:1]X4\,C24&C)VR<5A63A-.>OL$M*'I0*3"QHV@EBW3
M9D19_8K>PU]:\!LH--41_,RZ;>JS%/,0)U0;4&8\9@E(,!A/?677+A^0.7W"
MVVRM]*76W?BGX2'$I$',-.R<JH)7!;0W)GTZG.M\QR2XJ[2:U(D:V8;&P5'C
M(2Y+D-IE/6BMI8F-:(&[>>@\\XF;/9F4DIM;*58;&</7+5-J=?SPOFBR$:Q1
M8QC!1L]CXX@GC6*0J)F5)U& W ]4S/"JM/R]77JA6GZNQ*RYF"%)BNQ(T9M*
M4T&IRBMI++;:BXOD*:UKNZ0NZ[]XXCV0)]&J<ZA*I]+C13&J]*=8<AU'M%WU
M5&&D<U*#R@$) ;[EFPA :00G2DTOCX]VL]M7;U^T2L.JT<(-FY4E4G#$$$F#
M<SH[F*D4'$0^77?G=*E>24>NX3*J@ER!$>D-_EF*7*7&?2_(;6EME*5,<Q#3
M"6XC<8(,4\R&ZE"QK Y)0B_74D'$*S=$HD5=6J%2IT"<\_6*SSURI?9Y,@]H
MGJ0MFI,AF0Q9KE( #H)D("P0DE./HM]C3G+*>&MTB.WN^2<8QQ7FVM3\C$II
MNE(^LKY>@4F,O&+P<*^77)7[;8Z\A.-Y=I'+&C+B:/9NC*QTA"04,_X-\(#*
M["J3$S0U3%IJ,68J+/GT]@<J93WM0954TE 4F:T\VAB.[J<YJ7'><XV5Q6AU
MOX,6?NW5FNY+752IAB&W48E)J#Q<=BR4:.:ND/-#0] D,.*D28:D0UTY:&@8
M[J5..)^NK7RAC[1Q0]]O=4QG2K5D6]S;*M4NC5V9M5KG9$ZA64+7X%@M)RS]
MP"2:BBB;1BW46*FB@HY5'PV[=-1=8I#U:9=D/-1V&EOR)#K3##* 5*<>=4$(
M;2/$E1'LWVL>OI*2HV3>_LZ[?/\ 3O[\?&1O=]M]NBS_ "L[4=KDU.8!QFDL
MLTCBU1NW7S396 ID\*1MUW$5V.+W;U(49*-@:S(0TI'E\=JYM=C\8@(_3&4N
M#U(ALMRLU+<J$\MAQRFL/AF%%7I"^0I;:N9,D %(4I+[<2ZE!*'FT"4K<,T]
MIL%<A5P.A2;H.UQI1;4Y8['2/$@]!?6D3VF&^$-N==P:QW)9Y+8/S^V*TGN1
M,DVY#)ZC4D%6(:-H:MZ4FD[,>O,K<K8YU[!.IA6')+NF[EYX+6.;=.X^(.5U
M9ODN"CQ?13= B$04-,&/VQRI2F'WTLI26S(0B*M *04 'G:M-CBYV..F05'0
M6_6LE(*2FPW%K@]";DV3JOJ"4W&U39![=7<3A68K]"WBR;W,V.W:S9@XLLE%
ML6.::DQZO#/,Q,C#$2A\N1T2C_2)J$='>WIPW\1^WLKMZDUKDK'LX<':<ZRY
M,RBMV+(2E3GHJ2]VAB4E*5J#$20XH/1I1"%*':'9#*N[JY"+NFS(@MJ2%Q"2
M2"2%VLFP/KB]T=/R@+G;>X4?LBJUI@+I6J_<*M,,Y^LVR%B['7)V+<$<QLQ!
M33%"4B92/<$,)'+1_'N$';9<@ FLW4!4H 4>@/FY2%MN.-.H<:>;<+3S:]BV
MZULM!&UC<$&P]^-2H$&Q^_U ]?/IBIM5QYPTPPTPPTPPTPPTPPTPPTPPTPPT
MPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPT
MPPTPPTPQB=O$@Y2PX;=LH64?1,BE8H)\@^CW*S5TF#0[H5"^*B<BHIJ$^%0@
M&X,4W!@'TU+,E+AIKC9GQ8\R,(TI2F9++3[2K %*BVZE22I(/=-B1X>6.5\8
MHU7DY+DHHE3J%'J J$%;<ZFRI$.2EM"RI;?.BN-/!IRVEU 7I6DE*@0<:HFV
M1<CTQ5JG9XM6?+'J];>QP(^Z+,R/R!C.4O+@U05<]0%-XK4813J* B8P@&IQ
M4LCT2J)[3E^8Y3'A<]AEJ+D<%6ZB'R2MHJL=1<,PJ-_,G'%\M\;LYY:Y$3/M
M(1FN&PHERMT9 @5L=W1J>@I"*;/.CNW911R +7(Q0>[3/"%^Q+7Y)_8V4W)T
M&[5YW'C86(LKW&,;*JK3GD<TD04:R,A#NW<]$R3])Z,VBY=P<8Y5<'58MCH_
M(_PG^&4R5PKK_I:E*4JFR(,V#46],J-%+=4CL/*$[2L-J4RZM!(2"I"E))*"
MH'[^^"+Q:R;FKB[E>GT',D5;]>[?29E$D)=IM54IVD2I37-IDD?C*4RFTI2Y
M"+\5)2-+R38XPBEK:U4O[!\B\*B:S5%<C\B@B!#/:H^9IH/S% 1X=.VMK;,W
M#@W*JK:'9-SF,BU1*3\H)>4G7*&6F6POT75FD1S^6M-1CAUYL*M<H0]3U/A(
MV#TN4X 5R'"K]1*=1TTZJU%DMN);>8;=;:"0&TN09*VI+B0+)UN-S(J%+ U+
M0TR"?DTVD=$NBE7GLL6T4^91K'-JO$N/$*J+5$8MO9'*K40$IFX2KB>8)2/A
M=/G @H[S'B"S;^'E5#*\B32\N4M3:C&>7(G22TE.AQQJ3Z/9YH2 'D1XL)YQ
MHN7+8G2DITAYP':3\OLYEK,-I:KQ:9(C0%(7JY8;0S"J$AQ"5!2$J?3+8#N@
M66(4<J!Y3>GZE-EM#C,>[6,$Q+6*0C923QE3;?<CIMTT'$I=[I ,+%<)=^H4
MH*.'CZPR3]4QW)E'":/EVQU.AL0 _8;*M%BY>RU0:'$CLQF*92840-L-(::2
MM$9M+Y"4I2 IUX*<<-KN+)6O4K<_D;G:N/YBS?F6MO.N.FH5JIR6>8XI?+BF
M6\8<=&HG2S%BAIAAI-D,LH2TVE*$A(RN$H#Z@ ^OJ ?,.!_>'8?N[:D>(OCG
M3##3##3#&B7VKFT;(MULU=W/XLAI*WNZO46E/R%4(5JL^GDX&ORTW/P-KKT2
MU(9W. Q7L4^QLT4P*\F3-/<KN*8JD8/T]?.W'CAC4<[4YFKT4"74Z7$E1'X
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M4UI6I#"&BA*23HVZ_P!"&2N*W#?B;5G&\FYGB5V2SEWTJ_#CLR69L6-4Y[:
MF9'DL(6Q(+K;+*VM:G&GN25I0A<0.](ZL7.YS5HAZA7K#(IR\BP9*R[.(E/<
M+!R>LP362</;#Y12$13A60-I!TDH[*Z.82)((NG;]HU5DW"KA/F3/,[+#3=(
ME,4-V:IJ37"VI%)B4R//6],6J6^G0X-*UI2VEX.R%E36M31..<\8?A!</N"^
M6>(<BJ5ZF*SC38BIE"R=&J#+F9*Q4*A0F8U'2FGA+LF+!<<;;5(F)2(345*'
M%K"TIQN9KV?I2HM&D8PAL@59BP;D;-V]9F5$6J#5 G@$3 8^5A51*0  "E\K
MP4...-?I:OA[4"+4^KTF5X%*R^T-MP!HAR!8'W;V-MAC\4HOP@LN.W]+95S3
M$7TYC+=-FM_E:CSW)%+D]23;L]CJ.^+K1&\N11$"*7V_Q?03DWO!C+3)B#R
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M;;)J"'B,O=SI-$P _<@>2O4EU&6J9!9V-2<7.D+2D$O(:*X,-K<$I##Z)[Y
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M,W(@("//8!'C_J_U!R''RT)/32!;V;_,;GV;[>_S @^TVVO;3X=!M[@,=^.
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M-_9C8M42.C\A'L[J?;_9]I^K$[1K;-(..DIO]7_^(_[\:Q52W5=2?]X]?9Y
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ML%R4I8!I:=FU"Q[3<:5B"IU-@V,'7ZO$,X2&9(%$2M8QBGX;=$%UCK+J=(%
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MOUWW\^N/C"M4URCU>I4QVX5"FR(XOU+;;BDM+OXAQL)6#[<5_K-QK,-,,<<
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MZL64[%2<@XV36C78/XY9VR3449O 352\PW443.9!;PEE2 JF8JG0J<@"!3F
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M+YNBI<=9CV=-FD5[4ZV5JE#O"*.R&D9R;:]2:PD8,Q%9^X2!04T42++-%52
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M7ZGAL(.+D)9TJ)Q(!&[!HL\6$QO0 (1(W?G@ X ?GSZ90I]YEA )6\\AA/\
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M:<RT;.N'JG?Z#>XK(<$]0=1BUFA6\BQ9/I6#?+04P)6$NDA*LNB98.4B).T
M\5'I<$%TV7*Z4CU9IDNDU*3!FPWJ>^E0>[,\YS5(;?0EUNS@[JDZ'$D:>Z/
M#<# G0WX4AQE] ;<%R$ #2 +@:1MM8>SW[8R&UK<8>&F&&F&&F&&F&&F&&F&
M-;OM"*LTS51JCMM;9=JN++/F"PM4(ME8 47>VQO .XY]*0D8FBY:F%P=R[AR
M%5(JH7I$S8K-TD^,F3GO$&&U6J=$RPFM,TJ;67TM1D+3K,YE@I6ZUI&DAM0(
M*AT4#N"=L=WX#5)[*%?G\2',H5/-%+R9%7(E/02VVBDN5%B;%8FRG'$/!(1H
M?TI2$BZ=1>06VL9V4FGPU I]4H]=: U@J? 0U;A6I?1O&04<WC&"(]@ 3>50
M1 QP .50$0]2B,U@0H]/AQH$9M#;,1IMIM"$)2E*4"UDI2 $IMM8;6VM:PQQ
MJL5697:O5*U4%EV?5ZA.J4MPE1*Y$UY3[JE*)NHE;BE'5<DD[]2:VUFXUN&F
M&&F&&F&-&N^[VJ$MC>Z3FWK:LE!SV4X%X>*R+E*=;GG*7C*2.D4R]8A(1)RW
M+<,BM".$%'S1P[2K=*6$J,\2PR?C5I/CO$SBU3<AM+@QVTU',#R MN&'CR83
M:]DRIJDDE -OD8HNIQ5RM(2#?Z6X&?!PK_%H/5^IR%Y;R+"4MIZL*9YDRJ2$
M;KB45ARR75(!L[.='8XZK)"9:TJCXTIT;8<_S!+7&^SJ^5\A7>Y6";O-RGC7
M&['>R-AM<@[D9>77C*E(Q,'$E<OG:Z*"<=$1[=FW(FT;I%:M"%#X\F9OSGG"
MI2)[,9N9(?MVJ-3\N0)CJ=124*YCT&;(*=3=P [9)2]HL"<?;5N'G">F4S+,
M*?48%+A<UB,)>:*I3U.N*+BI,E18J<%AR5(#NI]YAE#CIY',-TIQ)T\$9,VV
M7VEY:Q7,2-I=8YML!="8ZR--R4W!V52J336;)&$M\CY^UUIV^.P30!VH[FX]
ML1005A#?:+A4',D2'5J7-JM,@J]&3(-28JE/BLPDH>B3DRFD28C/*@S8[G+2
M%H#,5\H4X>U:R+R6;4G\T99S!EVG5R8Y'S!0:G2'X-;G2*B%L5:GJB*6Q49:
MWJG$FHYK@8D.OS( )49,%P$$66>98ELOC^5D^H=O,,F;*I2,,XBXJ 7JPU-D
MU@T:HO#P3=O$QZD.T9-DDS1B)X^03$DBBY>I2!GKS KPJ)J@7476Y97'C)B/
ML-);BN06HZ(\!V(RPB,A,=EEM"&VN6A:%MD/(YB"E/=LD*R^,O)50&)4.)VZ
MIR:A%J$F4_4F*P[+>DUCTE*ER)<Q<D27W'5+=D+"V7&'HRC$7$*;?X[W@VW:
MAEM#.&WYM+9 ND=5+EC^;@*5!V"YQKR-NL&NQCD[&-8BI=DFE5;DSJMZ61>#
MYDK:K.VS=$IGX<]GX29BEY-GR'*PMFF4V?$D-+:JDV'2B\ZVDNQELIGRHI)Y
M^EM*D@:RX$I.Y!^5OA199R]Q)H,.-19'I#,U%JL+E.4B+)KBXT65/1#JL9]R
MBPI:&V6HG-E-175L. PK[\P$S*FVBM/H5.)@[.2>DVGBO+.L^<+!9G,^_=+/
MI>3LS20*2:0E).5<.9%^M)MD%UG+E9=9$RJ@F-Q3,#=;GUJ?7JY&D&14ICSZ
M)-TO-N)=&MI4=]HJC+TH U%IUU.PZ#;'TOPX8RM"R]3*'E>7"?AT"%%IR8S"
M[2(S3,=M*3*B*Y4J,XO4+B6PAQ2KW)(.(VO73,N1(V9HF-+K-T[$2T@LC8YD
MKYT\C+7+(K, D$*Q4U'80+L&KJ(C4'%PL#&5CQDHMDC'0TPFT3?L;\FJLY3I
MAA561/EO3TB0<K1Y\F+3FFWRPXW)K'+6D*??,:+(1 9Y;VB/'7)D1W&VT#45
M>7"KE;;J=#IU#9D4K5&:SM+I4*?55*1VE+D3+CDAA2D,L=LEI=J3ZU0RY(D-
M,0Y:'WEJO',[&K/!04%-VJ<R81*U,Q<0\L?(/!W1!B86=!5>$@'C>/B5%(FQ
M04F5I(0T>3RLHU5\F*2Z::>@K&=*UE]FDSIV6:!!@5-I#L$)A4^0)"3"I]42
MG4EZ7,84JF56F3$HD.)DJ8G,2$DME1Q#X^:Z#5YU0@LYPS'-F4E[DU"U0J<)
M++G/J-/*V>6S$I4C1-H\YDN1([S ?C2&E -Z4XN9L?N^1O9[;HFV6YVQ2]ZV
M\7"M.J%F^+3@B/+W#0J2OO:J75NUKJ#5C<#T:<(;Q$6\4UL;6LS5L;LB6&0=
MH-1[CP*XYY::JQH=51Z%]*%2$NLO*-),M"[(>4U*4J33M5P"I3BXY!!(9L ?
MF_X1_"S,&>J+"K>7Y+>8ZAEIB8X&%PH\?,$FEDE;\)E4)+3%36E8UQX_8XLC
M8Z%2"HZ?LYJ-OKE[K%?NE,L,;::C:8MA.URQP;Q&2AYN&E&R;J/DH]^W443=
M,73=5-=)5)0QA*H03'(7J+K[H2H.)2M"TE) =2XVH.MNH(.Z%)*@018]TV\1
ML<?F^I"VUE#J5I<2LH6VXV6G&W!L4.-J *2#U"@+$$$=;5AJYCSAIAAIABF;
M3!MK%7I6&<$!1-^P<MQ$2D^$RB(@4W AR ]_EW[!SR/<++[0>:6W8'6DHWWV
M5;4#?J".H.Q\<9$.08TAA\$I*% @@D$=TC8BQ%DDCPV)'0G&NC8#AZP;:)3-
MF&K-=J(O$V"^O<E8MQ\PGT7%Y@JL\ C"<D96OKE2<-H4JQ:\Q:JLTG+-!TDN
MJNJBO)%;$YUD6D/97DURAR)]/<:>J:ZG2(34@B<U3WP"YS6-BAE%V0E*!HU!
MXJMK&.^<<,XP>),#)&;X='KK50IE!9ROFBO2J8MJASZG'6[+IZ($Y*E-/RBA
MRHO.J>$9\I'*$<)B$G9[KI>/GO#3##3##3##3##3##3##3##3##3##3##3##
M3##3##3##3##3##3#&B/VR<7:\\O\%;.,<76FU"Z9,/:;B![G84(-FZ)#HM(
M&)8QO!%GDC-2"$C9B13)H@LNHHT5$4 ("CEMU+AL['HR:OFF;#G2HL%$6)^)
M,I=*.:I<AUU6K9*6N4QJ)MLY;QWDV7E-Q5.U%YE;K<>VR4DC>Q-QX]+7WVN.
MIVVG[6\+Q6W_  AC_%D2U*U:U.MQ,*5(.CGICF:#9'K.4I>M0R27B*+&^(RJ
MIS\]1C:@-=J:ZO59E1<U*5*D+<[Q)-U*.^_GU&YVM<GKC1SI3DR2\^Z222=R
M;FPL-R;W\/=TMM<Y&ZU>,7#3##3##3#$&Y=(LVR[QTLFV;-DE7#APX5!-N@@
M@F=1=1=0X@5-- H**'4$ *":8<F[!PPQ^>![0[>X]WR[D;5F&SSIXW N+Y6;
MJ&W^M/'!RQK&I-7H-%KP,=R'F+=D]TS3FU"F;FE4HM6O5A,A5(?E?ZSX9918
MRQ0FZQ/9:]-5)GGJD+194*G.$F-':U)*D..H6E4A:%?+%2$( 20@[Z+&[.UJ
M6!J6+%1N-%S8)*K7%Q;<^) ZJTXQ)BW&0;&4SRJ1[J@0B[1VT2L<XW<!8I2/
MD6J\<_(PK1%F1X]H_CW+AN92P.4CO&JZJ#JN*(K'*/1#(0\E(4!RRIM8+R"E
MP*0L.(4&'$W94DA#C;CXYS#S92[#  7C(U$"[8-[V*%I*1IN0H$W  4#<'8@
ME05MB"NL;D:NPLO=ZUEO*:MSK\6O( ^?6IR@K*1K%PSF)*+ 8EK'@Q4=A%)N
MF ,"L2HS;:.<. ,@U1*GCNLMB-I2RS("$I6IA<>,MJ4&DJ2IM;(CAI+CK2W&
M0ZTTE=W".\@K0KR'%)TC2A9)M<>N2>Z =2[*WO8[=0HW((-O*O=Y"<QKNA?6
M&?FIR>NM%Q$4926?O)1]+C&9\QH],61?O%57*_EXYJ1-+QU51'PB$+V(7B&9
MGCL_&WAR8[2 T)-;0E"$(2V$+AA:DA(  0KJ4@ *5=6YQ:DB\BGD;7*2#T)W
M'E[/+8DWM?#!S&=GQG))S:[Q#PL"^:5RO1M;N5DJP X;+PUR?OSK5^6C7!D4
M+$6'<-V7B>62F8$TH5(7@)KEFDAEJ:_)+[:RVEUI#2%7:6 F$VV\HK86G6E8
M>=B*:<[C2&UM)!#SB1<< *TE*@DGUKW*1^0?$760@IWN4Z.HU;77E(S(M<CA
M&MVZ9LT&U8IL34ZYR3MV@$4V=+R#:+A; VY>,&J#URY=H-IAE8$$G3A9QX;1
M50ZAKZ4IYGR08"U+*_E4[\PM);U"2E)=2I8 +S[J9;CB4I;;TH%QZ2LD[W)(
M0.8-@ @]U*B0HV!.K8J-[!&GJ9)CW-4Y5;Y6,I8;L<GB[/6*9AO8X$KLA$9F
M,=MBG3>(.VI50:V>GS34SB.GVS=P_CY&-57CWP$.J=J.NK5'IF:Z;*H=2;4C
M6"IOF(0F7#6%:6I;*27&U(N0D.MEZ([JT:E%/<JXR'@IMP"]B0Y9(.RK#8:K
M+-^MP#<=^XV_13V*;K(+>GM9Q9N$A6R<0_MD2NPNE;(X\4:GD&LR#B NE>,(
MF,L+9G/L'AXM9<"J/8)Q&2!@$')#&^*:O2I5$J<RES$E$B$\IAP7N"4FZ% ^
M.M)"KCJ#XXCKC9:64*L2+;CI][W'S8S"UK\6\-,,-,,-,,0SANW=(KH+D342
M<)G05(H4AR'(H4Q#IG(8!*<#D,)#D, @8GPB'&@[IU#95P=0V-QT-QO<>'E@
M"001U2;CV&][CR-][XT]>S>VXY1V=9,W-X2L(P9<)3^29G(& $TI]%U8"TZ3
M<BW= YB!(95FQC4#5N.,J@NN5>77>J*-FQ5VYG'1L\UVGYHA4"J-<X51FGM0
M:R2P0RJ4C^CL]:RG'%=H< L+-H0 I0%A*,P3HU4:I\]KG&5V8-U%SDE+//%K
M%!L$ZNN_4DW\<;CM<YQ%\-,,-,,-,,-,,-,,-,,:JY["64<D^TJQYF"<K+A'
M#F&L:6 T!..G\4JU<WV;0DXP&J48#HLB59)C)MY%!T1HHR!:!!51V=4&C<.8
M2J%4ZIQ(I=9>CZJ+1:0\J.^2P6T5&0746+*E<T.*9D-O!PHUI4TVJX"0G'T=
M3LZY:R[\'G,F4X512G.&<LQ4M-1IXBR4O-T* &)0>5+Y1BK/:X;T5YI$HE2)
M>A23I.G:ET$YYZ"\\\\](<\\@//IZ\@ \_4 ^FNGV\?''SCX6\#U'A]&.VF&
M&F&&F&-?/M)-STOM;VP66S5!V9KE3(,HRQ7B98R95"Q]QM+9XJXLPHKF,BHE
M1JC&6>\^7<$,D^=UU&)6_P##R@,5SGF1G*66:K7I!!,*&LQT;$/3G;,Q6;'8
ME4A;:BD[EM#MC;KT+A5D.7Q+S]ES)L8*2BJSD">\BX,6E14JE5.5J&Z5-PVW
MBV;V+JFFP=13CY5\,5=HBX9E,9P\*BL95PY?.57\A(R"ZPNGDM+2#H5'4A*2
MKYRXD)5^Y45<OWSAP\=**K+J'-^9]:J4FIU"15*B^7I,^8J0\\H\UX KNYWB
M5K39*@E()N$I2FYMM^U]4@T[*.6X.6Z#'13Z72J>W"@QV4A(:C,(T 60E*2Y
M9 *E@ K65*&Y-MP&';M)4B*<DC2LQ;.B-5%4'C<%$BKM2KIM'!.%41!RFD\?
MI^& <%3<' H\-DBZR*-FJ?E[MB89C*3+T62^ H?)A0;ZVW3S70!^0'%@6!Q\
M<9ZH,:NU!#DI;X=;YH0ME:@H<PM\P7\E%IGO"Q46T*4=[XHJY.V3ADX%T9$R
M14%#G.J=(J1$T?UAS" ]/0F@D0RBBJAN"AR(CSSK0HE)<Y25%+CCR@M*4[]Y
M-B%V'12>B3L03L0,;JAI<C.(6V5,H:LI2UD@DFXNI1.Y)/4^PBXN1I6_-C7<
MS9(M.5URND<761*':5ZG(*+(Q>24X-201;Y"M39/H%Y%2[!\W8P5?\3RDQ7&
ML8[GT9(GNJ.B=W6LUNY:@L9=IW)-;A/SERZ@I0<?HG:UH<728#MUMM26>2XJ
M=):4GLTQ3K-/#)Y[AZO0($G,H?JT^1+9RU5(D%***AQ;#=?;AIDJC5JLJ00J
M5'FQ'DLQX 0&I$./"<JJ'BU%:@[-=MV#*A;8^X-K!&-8F-C(!A'U5)HF=@RK
MSY\XY"SRC)G)PI%ZC6V;)<LV@@J99-62BQ:I"/5QKLAT.!FAW,#U??>>?,$B
M+(???*XLU]:M%9GJ,Z*IVE0&VU&<+NODO0] (4H'3\1LY2\GIR[&RYR&&Q,D
M+FPX[,=#4N!&3M1J6D0)2(]:J!<2FD]QME269P=/=3C!G*^$Z[D"/7C;&S>P
M\ZFW<H1=MA'*\+:X SA,4A6BIQD*#Q!%3[*S<PBQD"_"[15+P!8UES-M4RU)
M0Y'<2]$4I*Y%+F-B1"EA+B57=BNZD+=N@:%$)6V-D*2"J_3)],IF88ZEZGHL
MCEK1%K%)D*A5>,'&RE1BSHRD2DZ@JSL93BFEI 0MM8MB?;:6X@5WC"881L;:
M\=-(ED*$5'^0AINJK@JTK=I@6ACG(R9O4HUY'/H<BWBQ<S'23$GC,C1KE[;S
MK3WZQ)CUJEOOOTZO///7DO\ -?@5!"D.5"#,7<!UQ@OM/,.J0.TPWH[@',#I
M3$5UR5"C/4">TS%J-$89"4Q&^13YE,<#B:?4H3+:4MMM.I8<:?B(VAS&'V[!
M@LR5[6[E/+7Z'J,(6*09QE4A*Y'-EU@7=2+A_%46FU&34,LY>N&R#%PI3DG;
M1M&-8U(P+F5?%5?F\0,;.M0F9K@T6G(A0X$.ATZBLQG'$S7Y[\N)D_+E"G%2
MS451H\60G+J7FH\80$EM9>F(<D=\\2HL!K+,^L3S+<=G5JH5"4\VTO1&;9FY
M@K];AL-LH2A[GM(K*V'WYBW5:$<N(I#82D6-M-'3!NL0Z("4Q!*(&3((= ^H
M=P'X?D(?9'CD>?4.2RH<RC/A7R@0FRQ8JL@^8M;YK>K[#CH%'KX4ZE86;I.Q
M*E7!5ZQ\+*5U-K%?L( .4OLH,U2.,<JVG:%9)$RU%N4=-9-P>@Y$ZI:W9&"Y
M'.3Z)'B/P)1$RR>H7Z C4^$FCMI?ETTBH+I%#]0?@L<47,Y99>RW4Y',JF7P
M.RN/**G9%-65!"05$J4N,6W.8I5R0X@D]4X^/_A2<.X](J\'B#1H_+IN:)+L
M6K,,(2EF%7(Z26WBEM(2ANI1 E2 GU9$=]2C=X8^A'7UCCY+PTPPTPQQP'T#
MOZ]ONX_P[?AVTPMC4+D3'.1:Q[3S!N7:I69V>J-EIEJH^1I&-;+*1\/!>1DE
M(IS,NC&(BV;H3<JS?"0X*"JE!II\")2<<GJ],GQ.)V6JU CON1)5.FTVJ+&K
M0RVCF*0M82;;+E-D7 LI/0[6^GLLYDR]4/@Y9]R;6*M!B56!6:1F/+,=]2FG
M'YKDA*)S4)*.ZM:HM+?:7J .N6G43KWV]ZZQCYAPTPPTPPTPPTPPTPPTPPTP
MPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQ\XN9\(9CS][9''.5I"D3OYB,.5T*_
M4+J*:9X%[/5UL_;6".2 BYEVS^*N<]+"54Z:8+GB%ED#"1$QC]EI=9I5'X83
M:4F8SZ8K$LNOPPFTAN.O2XVL=W24JBLMMW*C93@!!U#$QBRH\3+$M"5VF2$K
MTI2O2HJ)  L#?U?'IL+6WQ]&*#<J22*8\&!)/HY$/4?A'^\.0'U^? ^OIQKV
M^V_SXAW6]][]?;[\1.F&&F&&F&&F&,5-ZN4<<X;VK9YO&5+4I4:<AC2UP3J6
M:]:LL:4M,0]K4!$UEJD<JS^U2\W+,(RO1R( JZEGC- ITTQ,JED0XDJ;*8B0
MVB_(?>2AMNU[W_AMY$>%CBJ05'2 5&VP N;]!MU-_'S]^/@6V6;23VFPXZLN
M9>F0$96OLF<,4PHP-4B7+QLU=G8D/RD64.W.<LA/+)F?J]9TVJI61CD-]?5*
MHR6(7-D<LU!F D(CH*EQH;R&+A##944O/H6+=J5=S3=I!0V DRE*+H*UDDDD
M\K\DC:PTJN" -MRH=0+ A(WLV/:)MI8,BEBW\8\3EFC9Q%MGUO=A8#-W[W<^
MY+7*R,>9M!#D5O%XVQ[ ,"W$S"H/YE1=P[4'\HXSPX+'S/F!;GRB5IY*E!TI
MAIY&M"<OI+[Y<*GO1_,GSGG.R!R4AH)2BQC.A5D./**=3-[[#U@?4CVT@JMJ
M&M5R24G<WOJ&-0VXVET"NNJ2A00D!C+3BBO3DVE,3,?-OT['+*2S.=357C&+
M!JQ24.R2.C%@T!6/26124=O%$Q=N^HY?ESGQ+5-+>N/4WV6BTRXP@L-<I;-D
MN+6I9 607-=ED*(2D'0@L!"BI*=/=2H]X*LOO;W%CML?"YWM8XUC8>;(KX!S
MZX63(HZ0Q=@IPW64*4YT3N<[XJ25424$!.FHJDJHFH8H@8Z:BB9Q,4Y@U':^
M5)S-PFL2D.+G*<L2-:E4F,5%=CWBI2BHE5[E2B=SCP[;M%.VZ%&VQ  /MM_(
M>\#&0^S^+@G["BM;'X#>"E\HS:%C4<N3,4 AQR9*0CU=V]\5N=LD6$:@*KD'
M#8S1 A02$A"!Q*Y+KR(=27'"N>AVL\@)0%J4XW,EEK2D ZE%24I"2E5]K]!;
MVJRU)2NP2''4$GP .H >[42-NZ2>FXQ] \3@39!),T1C%Z:]3L+5F[C&[W(L
MN=W'.9&P[K72E6<2A;M',(:1C(VJXAJC6W6"*E:ZNL6JSTE&H,KT^E7?+'*S
MFYMSY7M2.0I:7%(@,!+B6V,MI$I+9B+<=;6Y)JDI46.ZW( ,AAM97!;;15)6
M#W4*4FQL;FPW8O;O7"1=8%[@D'3WB2=66_79O0T$<?R>.X>OUZU,J:TE;5.X
MUM[JQ0J=O>RKV1;C#2#NTVZ38R437G<'!3B2[UI$OY5C+MV\*:+*:1F)KEVL
M+J:9:*F]*4$RUHIC[["8=1B--H0.8A2(T9!2[(0ZZA)0X'(ZT-RE.I6J.B^V
M@*YJ5#1L3<7L$]#HW)3JN ? BPM^4-WO_!HLB0K? .>,!V2S&6S16,RR>39B
ML*MC,VJM#M]=JM=K]LK1%7"AG+)[*5601LA$2![JG5T452E;/XQTZX#Q9AU%
MC-KTN<PTEN?%97%?CI2&9B8MF5/*TC2A])TA2%=\=TWMOB/SD+0_WA:Z0+VL
M-A;;P^;R/L./IOUS7&'AIAAIAAIACCI+] ]>?0/7Z_C]^F&-%^\6EWK%_M3]
MF6XJDUFT2U<R'0K7AO*#ZM0DM(L(IE /UI",?VI['M5FD0S</+E E3?2:J:*
MZ5:.4I3@S("?4\M2H<_AYFFA2Y#++\*;&JU/3(<0%.+? 0\W&#AUKTHB/IT(
M2>7SP18*WEU/>;?RS4X;CR4/L2F'F4E5M32B"I %^]J4+*2+BRB2!^5O+1."
MJ*9P$0ZRD.//K\O4.>P&X$/O[CZ\ZY9B(X]M,,-,,-,,-,,-,,>#DXIHJJ!]
MHB9S '/KQP/R[_=S\N?OTZ8JD D ]+[^[[],:@MA\M9+MO*]H!=IQ]+G8,K%
MCBJ0K9ZNY]W?T%K8(UXXCD%#&; *+>J0X'60$PB1P!3"(=(#R3)#DN;G/B%.
MDAY#+,R!"8;>2L( CHE-K>:!NE2BF/&NM(!4E2+FP3CZDXRLT^C\&^!-&@IA
M\^3"K]3F%A$14M"WWHDMEF4\T.>KOUF:4ID$W+)(Z&VWPYN@H&,;CCL(B8>G
MCN/7SU\  ]^YS>@>@?+K=CX"Y^_E_+'RR3XW2$VN2KZ?9][^&.HG$!+R)_B
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M ";OW>ZB^P%KF]L$\6&RJGMBD(*ZX/\ 0=JK&/,W(O53RK4^]M(Y?:RI\I9
MN0,=?TN&PDF70U4A6=+,5.\#^5#(SINJHY,W#\E$"LBELB8E*4Z(G5C_ !W)
MS11!)()+%'S\4W?DQVQ!,W_4?DSO_P"4[_(?/>VQZ=:'BW&"9CII7R-&VKH]
M),%UH\Y2+4L);_TEW4]VYC:UD,) =!MS^E@(#!-W%4;)/KJ4BM((2W1ZC5PF
M9T* ELS@C(0A. *JB M$9<JKPI6*;D'?"P/BFOY2TT$1#:9\F;I%O]C<CG>
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M\RXN3UN1O<>.WC;?;^/42+64/I\>@\>O6Y\-_#$1;8@KABH $X$"\EX'J !
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MQ*395[6WWZV38=3O<>WPVQPZ;!UN*LC?W7]G7ZC;S\,4C<[(04U"@J @'("
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M#,J,+&O%EW96R2:!S&$RA44BE^0=0CU=7X^@<\ '&MU3J:@?*+(2A'>6M9V
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M*T\C(S4>KY;GHENQW94N+ -*E-@J-,F&2!SKW AOHU<U)//3$4E)/[E\+O\
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M\<-R;J(-S>YQ@P(G;Q3:2K0:-FD4"LR65I)J4-&8',T*CP6I.NZ$Q!EQH:P
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M&<:5DB;E7/3.:93C&3LM9RCYDDT*EU-LR4ORI78<J5@R&Q&G0YS[*%2I*E.
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MHE7=O'<Q)';Q3)H1$%'3UZW13.4PK&U;B1I#C$> VV7I 45!#8&K5'S(4.*
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M;Y_47-9QZR#%JW;M4TD&[9LBV2;HD(FBW;H,2"BW22* $222(@!4TB%*1,"
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MVMZ1(;13ULOTNGO3%*R@'&([JHO(EIX?U5^6MM+=DH5#I<.1%;:2 TE"V4;
M%.,&(.(G(6 F6R[UB[?JFMZJ14&AVI_\HY/AVRJJ1BN%1!-S*J.W+9,!*5N
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M<,(C*3N&5'-U8F.% Z(*^<UJTV*N6W<]Q.F;8\:(?E%AAB<3';VIKMNL<CZ
M*[Q29SIDHZAR_P#*F3G8]DH4Q^H04*17D3%*8+<ZYC5)=R.R"M(']A):I,,
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MU.*X;V9,MQ:9,]SR@4"*4BX1[+$;E\R6>:86L&,30Y8OK!8S@MTDT8T7'(I
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MI/RK[:4(9*EZC9M)!(";?2M9I].IM8[+2H42)&A4^'35KB,,,"4XPHK6\]R
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MR(W"&O)YK3LRE,OU!;4EJNM3:@:GEQI" EBFTY9BZW6HS6E$*SS#(05A;80
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MVCO[<?-#KSSZM;SKCR@-(4ZM3B@G\VZR3;V7MBXO03^P7Z?9#Y  !\OH !^
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M7I,R=M,1;I()$13(4J:90*0@% "E /0"E ."@'R  X#\>^NGI 2+) 2!?9(
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MK4662C/&G4:IT&&9UZFU^'KL%'H%19QD,P:1[-N0@@)2(-FB2+=(I1#L":9
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M96H6=2!BVD7$MI6%7>M5RQZ,>R;LBQ'O,U<2'I5+6^P=/0:!G]J'2V*%7J#
MKE(C!:8[;C+3$J.'5EQPLNI0$A14=6O2'3ZO- )Q)*=F!MF*F!/@QYD-*;(7
MRF@ZG?R4E2;_ -L#6!W;D"QF&:-T&_7:7"X@8OMM3S=O -<;0Y,NY(ID['UJ
MWO<B-W3MI+K151A(>3.1JLP:M)L$&U0!LY7D3,DGC!-$2CXI5!RCF1ZIN#,
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M:J:HS,9M'*;CM,*E%EMAMOY-#*$!M".XE(3L+XIUF!2<>;3B(\' D*0%?+I
M<J9>1(0B@)=?07J-TEYZ2@8>D ZAUO>4W>_+1?1R[Z$WY=[\N]O4OOI]6_AB
M'*>>6-*G75)NHZ5.+(NKUC8DBZORO/QQ.P22*  5-,H '  !"@ !V[  !V#L
M'8.W8/IKWY^WK[??BUXW\=]_'>U]_;87]PQVZ2_V2_N#3#_/YSU/SXYX /0
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M]Q^_5<+>/CCCI*'H4OT] ]/3C]W;2P'06PM]73#I+W^$O<0,/8.X@(" C]1
M0 0'U 0#C3#^'3V8[:88Z]!>..DO'TX#C_#5+#R'A]73Z/##[_3U^G';5<,-
M,,-,,-,,-,,-,,-,,>?_ "O_ /#_ /\ +3#'IIAAIAAIAAIAAIAAIAAIAAIA
MAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIA
MAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIA
@AIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g111598g63h32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g63h32.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[29$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &4< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C$V
M.34Y,1P"!0 T36EC<F]S;V9T(%=O<F0@+2 Q,"U+("T@,C Q-2!&96(@,3D@
M9')A9G0@9F]R($%#+F1O8R0X0DE-!"4      !!4KS=_,@3*J\(?*?'"@8EK
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /
M<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R
M;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R
M:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,
M8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O
M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0&7JT.         *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #P     $  0/      0 !.$))300F       .
M         #^    X0DE-! T       0   !X.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         !.$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       "R0   V<          0                         !
M      -G   "R0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "R0    !29VAT;&]N9P   V<    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   LD
M4F=H=&QO;F<   -G     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    (.$))300,     !NP     0   *    "#   !X   ]:
M !N4 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "#
M * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%
M!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%
M!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'
M!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#1?=:'./J/
MT)X<[L?ZRNGIN;#R,D%M=8L+@ZTMB'D_I(V>WTOYW^:6?9 +YU$NT^96N_!Z
MH^VO;E.M:-H]1WLASB^LLK:\_I+&M=;ZGJ^E;^9<M.9JM1'S>:P1,S*XSR57
MR':^+^LUGX.6QCWNR1MK8U^X.L(=NW^UCO:U_P#-.][?8H58N7;CVY#;O;2X
ML(WN(+AM^C:TNI]_J?HO?^E5AM'5[G-K;>+?5:T0YW (>YGJ"RO]&]S=[]WT
M_P!)_.(8IS:KJW.R?3%S;;Q;2=Y@,]>Q_I_H?YYE=6S_ -1H G]Z-[KS"-@C
M'DX?EW_2D>&/JX_T>*#!V#U5NZ6O]@)=%LF&\N_G/\W]]19B]2LK;:S>ZMS2
M]I]7D#P:7_3_ .#5NS"ZNXG;>;MXV$$[26/?Z8_1P[8SV?I-^ST?YM1KQ>J$
M,K.4&5-9+ '%WLV_H=K=C/;<UGZ+<_\ XSTT./3>'_.2</JK@SZ[:X]_[WRM
M6ZG+I:\V6QZ=7K. L+H'J?9?3W-<6>IZJ+;T_J5;2X.=9M$O#'N):)+&[F[O
MIOVO]C%.RCJM5S'67M]:X_9F>\.)XL=4?T>W;ZC_ ,[_  R+^S^J'<W(R=DE
MK7B=XC<STW2W;^=?O1,MO5%0Q69#V\NFF\8\/]XREP^IK?8\LT>M7?O.T/-6
MZQKP";*R/TNQKGL?1=^C_D)C@]5#@S:_<2X "T&2R=X_G/Y+V_V$2G$SR+FB
M_::-LM!W;FEEF4US'.V;OYW_ -F/41*,;K#LIU#;W-L8Q]F]IW@ESRQU?T6_
MSF6Q^[\RO^?2,JOU0[Z]NBAC!X;QY03Z?08UQ1/J^= <#J<^TE[28#Q;#2?Z
MSWM_._1_\8F=@]2;K+MH +G&W;M!;ZFZS?8-C&_Z1R*W'ZN^MKFW @ %K=^H
M<6MO]/6OZ;:V,L_T?_741M/6*[=WK,M@[2'/):0"^K<[VU?H_P!%>[Z7T*+/
M[8XCW@H8HG]#.+_NN<]^16]U;WO#V.+7#>[0M.UP^DH^K=_I'_Y[O_)*Y=TS
M,_6+\AS&N:UUSH.XN<9M?7#?H._U_2IF]+?<VMV/:U_J-:X^H/2C<+':&;M^
MUN/<Y_T$_CA5V/V,)PYKH"7@"?77]UJ^M;_I'_Y[O_))O6M_TC_\]W_DE;'2
M,OTP][JZ]PW-#B=0-Q?[FM.W8QOJ?\+_ ()1?T;.K)W>F #MW;]-/IQ[=SO2
M_/0,X=PD8<^YC) ++/\ 2/\ \YW]ZF'O_?=']8_WI9&+;BN8RTM+G-+B&R8A
MSZN2!_HU%@)U[>*RN>RD T76^'X+D!()ZWV%X&]T<1N*:F^P6UM#G$%[1$GN
MX*6PL@[3/;Q1,:MK7UZ>_</=WU(^BN;RY9&=DDZ]WJL,(1A\HV?_T.G=]5.J
M$D[Z())^D_N?^*4S]6NN$R<ADP&SZMOT1JUGT/HM75I@0X2#(/!"G^]9/#[&
MC_HOEQMQC_">6_YN=>_[E-F /YZW@?1'T/S5$?5GK;2PMOK::Y],BVP%L\^G
M^C_1_P!A=8F!!X[)?>LG]7[%?Z,P=Y_X[RG_ #9ZW!'VBN"9(]6WF=^[Z'TM
M_O\ ZZ7_ #9ZW)=]HKW.!#G>K9)#CN>''T_=O=])=8F!!U&J7WK)X?8K_1G+
M]Y_XSRCOJQUIQ!=?4XMU:766&"(U;-?M^BU(?5KK@XR*QVTMM_\ (?R5UB27
MWK)X?8K_ $9R_P#7_P 9Y+_FOUG7]-5KS^DLUT]/_1_Z/]'_ ,7^C3GZL]:)
MEU]9)@DFVPF6_P WKZ?^#_P?[BZL$$2#(\0E(,^7*7WK)X?8K_1G+_U_\9YA
M_0/K ]KFNR:B'AH<-[QHP$,;I5[6^[^W^>AGZL=:.AOJ(&X@&RSE_P#.?X/_
M  O^$_TBZQ)(<S,;"/V)/PW =S,^<S_>>3_YL];@M^T5EK@&N!ML@M'T6.&S
MW,;^ZDWZL=:;&V^INV"V++!!$[=L5^W;N>NL32#PE]ZR>'V(_P!&<O\ U_\
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M\Q]/\WU^=X^C_KL]5:5>W]KV_P UN]$?1W>K$C^<_P %L_Z:^8TD#]4CZ/\
M_]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
M 'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H !K!
M)   )Q  &L$D   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,38Z,#(Z,C @,#DZ-#8Z-3( <G(Q-CDU.3$       .@ 0 #     ?__  "@
M @ $     0   V>@ P $     0   LD         !@$#  ,    !  8   $:
M  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !
M1@("  0    !              !(     0   $@    !.$))30/]       (
M          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,CHR," P
M.3HT-CHU,@!R<C$V.34Y,0       Z !  ,    !__\  * "  0    !   #
M9Z #  0    !   "R0         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MEX#QW?)J4Z.TB!GU,V/\%JA?0U,G;5M=5G&TW7F.G/5=\Z^3)F?]J#FW,!1
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MGS+Q'TZS-?E29#JS&8%KA,.L1V4,J:#SZ6@I:DK4I86H!?,])[,M+:\T[?\
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M=4GA%*6U&J^7?2]+E##63 QHU%3$.+7&-$H;W5K 6>3<0[B)\\*/O<Z(QJA
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M)O9S&N&XWX&T=,FVN(TPTE/"#JXCL=4ETKWWG5J2AI3RBM##0PFKRV[;BI/
M60[+D1Q!*WR1L],L-3>IR<\XCW)EK ]B7J\RXDC1\NN\<IFBQZZ2J('<F7,H
M=T0R?"EAJS23.I[3$M#4E%J9B7&)/0IJ*'D!$1EYE+#;"78Z$)(>WAA0 W2
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MA-R<B1$=0=T9/N%JO-MOVJ)UW%W:CM)4B(Q!8A=E<0ZVXU"9*V>*76T*<4'
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M?17/5-UNKU3=;GCJ\#UN?1QX\_-J&1C.1CRYY>FH[JL[NZK>\F#GT=:"0X<
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M7&^PEJE=N9=0UQ91:4AEYQIU;Z9$A#IB7:(PLN.*UMUCIZ_KQ-5R];+<]I-
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MUS&-SM8PL@=%)G&(+"07"<?&L4&L<R!P*20N1:M43N3)D,L8PID *=GT_9K
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M9-N]1QW3HKL?.EMO5EA:C68WRA4J*'E\]8'T=%,^V6,1)+RETD"BARD)UCF
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MV7&[LOY0XA:$OW29(B*65MH"E/15M.^+G="@E>ZH;HP6IULS+BK'FX#+V/\
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M+5$9ARE"*6G'2#G)S6Y^](A0;-5D7$X7(CBTI0C!-A),GB:;MD8AU*NW*?3
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M+<_D;=UT/T3M[VSVQ_@/?'B?)N8+)0SV#& 7?(*#&AV+M(6,M$]+L6E:98)
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MG"WN2LL2Q>UN]5AT@^EHIDT,^?.8+M@GH>:C(Z5 MS@44-12E/579VPGF5)
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M$4=7X-3(RU86FK:O%R<=2ZI',*:I,S=0C<<6.$R-D%XS<P&1<?W_ !\ZFI&
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M*JJG$RBJJ@]=10QCG$3"(CJW4D^7G^W_ %K: , #R<JJ_NSJ/\YX#_S=C_\
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MHAUU*O-U-*4TI32E-*4TI32E-*4TI32E-*4TI7S-?Q9YP_V*W_\ N]+5L?\
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M>.=/V,I8&'9J2;.\2\W']81*1PA%":O+,!. &$@/XMFLBD?JG3*L=!8P"!>
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MDB+(6\@ H0EOV1WTYR8USBMRK>OT</\ $D]_UIE?]VSU]6/L-?N0N_SLO/\
MPUMKY^?9,_=';_F];/[Z=6PG7K"O/5-*4TI32E-*4TI6"^4?X<3'_<?B/I5-
MSN_#_A4?Z53JQ["D25G(^OK&_:KZNV==?C@3%X&)C"'ZIN[K%"45,3GQ$O/R
M<@JL.0_;&3W^?]@*M_'CMW,/Y22>$,DK"L8ZFJE$@ !I*(5<JRQR'[P,F=5P
MU,0X#^R)B0_'AI4%>QQUZ\_)UY\OPX]!KR;@<'47<GAN_P"#LEQPRM(R+!JP
M<ZT3<.&;DJ8K(NV;U@^9J(NX^4BY!LTDXN0:*I.6,BS:NT%"*HE,"I <$Y.?
M\?/^Q[ZU<171&[;JU+%:O,]YN>[BI:?A+K5LM6G/,I/;@V$54JU;J>C$UB:L
M)GCWW&(P-QMC%]&IPCN/.:157='.YCHM:/54)'X/*#\'D_;K3,/1+8\RQ<X)
MV3(.96:L9(X:EU;6RR!Y\7-8L$0UQAJU,6I];&5F?3]M8$M[IXVD)T7[D9AT
M,P0Z#MBGRJ.?^W?^W?\ !5[9!Z,C%B4_3\FRF2<K.W5/NF,+E(Q\E=B! 6J_
MUF@IX-#(5EAD(EK'RETDJ ]082,@DBV354C4W+-FR<NY-1\IG]CR'IYBKT)T
M6V'HMO@I.F7G+^/W6$\357!Y92B9&E*G+W_&--FT[!7ZO>Y.#0:/95HQE#/G
M!744K!28$F)AL1^FRD7*!E0W@._T?HSYZV8L%V2B/D[-VV=>0B#-<&ZZ:PH+
MHE*4Z*W9F,*:Q?\ I)GX4+_T@ ?%5-0[\YR>7H\W3N\Y\E>_2I:CZ_HFD$(*
M%35=-SRM@:@*[)=1JY21CVSF144371,50@D\G >0'@0Y*8IBB8HJJ)R,'!Q^
MW=SSYN@_"<U<M==KOJ_".W1NLY=P\<Y<J" %$SE=FDHN(E*  !A5,<1 H '?
MR =X!I0CGD]<YQCN!SG/D[LGX.@Y0SE#O6=B'@,I ?W79M=&T!^_R?Y-S],:
MO/FW7_-K3_*L_P!BX5B]EV??U7%&3;/%3,77)2NX_N,Y&V"<16<PL'(15>D7
MS*8EV[=!TNM&1KE!)X_22:N5#M452D06,()FZ7*6IN-(<2M+:D,NK2XL90A2
M4*(4H8.4I(!/(\AT/2O/EL91)N,".ZVX\V_,C,N--*"774./(0IMM2E(2'%I
M)2@E:0%$94.M?GRQUNXW14RGVJBHYWLT]DU'(^SA9]%YLB\/97?UVJYCRO!8
MYN[JF98V_7-[1K139V6E(]I'HS+&$M</$I3'D+1M*2;>6A](CW*XLM.,=L>6
M^)%J.[-3'D+2S,E(9<+4B$[P7&E%2 E*PA83OJ1NE:2GLUQT[I^3(CS#9V&+
M>N!JD)<L[ETMS3LFT6QZ=%1)MU[CHEQY3:&5K6ME3L=YSA!:EMH6V[,$[TDN
MXB]JY.K= BL:UZ+D*LK=\+90:P=A<M)"M0.ZJK8$F>WB9BT(3MB;2,=.*J%L
M;VI8V0933":CX2/GT&99EM<*OT]WM+3"8Z$</BQ).XLIX2+@W#*BA2RI8X:_
MWTM1QQ$KW>(<J&,3HBRPT07YKD]YQ+O9KK;N,RAUN0]IR5>6]UUJ,IF-PG6<
M"-VBX*4TMI3ICDEI<TV[I"<U5QE,1\1CS&5IO##<SNGP'%0 S#VIM[$VP/@V
MYY(JTLG(3E@.VB'5ELT!#1TJXD'0QJ43*E1:>3O5V;L;UV]RT!0;:CK=1<;G
M#2G?#7$3#AR)#&]O*.Z75M(22KDD*&[A1!.+CZ.M;RV5NS9K,55DT[=GGTM(
MDEA5XO4.WOH*66B7$L1Y#SC00-]3C1)RA*FTWA0-X62<N[/MXMNFR-*!FK!M
M%R2"D5&4?(.-K13)9#%CRUU5[/4_(Y9@C&2,Z*>1AG]>MUVKLY#IQLNF^8KN
MUXAK59N;\JU71US[3*B-/@I#,B.XTL1N*A2VI&^0LJ.\%-N.MK3NJ24YW1:S
MM-P+=J7349E2IEKNLRW'B*EPYS$IM5P$=]#,F"6]Y!3]K=0]&BR&G2XV6U;H
M<7@+MGW([S<>U"*O]YM5FM4MDF;VZ8WJC;<%N(V_96QX5UFK(=9KLK<TZK@*
M.KV0Z4M -9--RF6XNU4D6DB:+>(*R9#G+@[?/NK#/'D.NK5(7;F&A.E0I,8]
MJD-M+>X4-+3K?#2L'+IP$J*22K!K<]0633,N48,2+'CMPF[Y-DJLUDO%MG;M
MIM\E]N*9%Y4_#DAY;123&0#EL+'B$"KYSGOVST^CY^*9RS&C76@CEVB62<QI
M)/C4N?L6*-YFTC%JEHK4;/$DG23.=J&39Z,5;R#U\[AG#J;CB/')A!P2XF7F
M8I#B4E#+["IC+JF%*X"W(]VMK!<;;4#A*VI"DA*BH-DK0,D$U86C25H#[#BD
M+F0YG@J8PU-0CM3+-QTMJ:X<!YQE+04IJ5 86"AM"'@AIS R4F5;)TG6=VM/
MW"9%A\'UV-I./9ZV5G'\Y<DY2+A@EZ/GZAX5D4+A.M;6+R84FV=LDK(=*%K%
M>3HGFEJRDG%D++MU]7"[_,X4^0W$0EIA3B8[CP6@;S4YB&H/.I>2IS?2\I0"
M4(#  R5ES>JP9T+:#*L<)VZO.2IK,9^='BJ;6^&Y=EF79!BQU1MQL,*C-,)+
MDA]4PNK4VE@-*%>*V;V=TCK<([P<J_Q=#*8K3W))Y'F*-$V)Q6,B-:AMSQYE
MVFGK+^7FG$Q5[%74L@.(V3;G>R;)&<CF<LX;KM%TH=E*Y=KB9JHF_&3V9-P#
MZVD/*;?2W BR65-%Y7$:=:[04A6\K"T@E)0H)$6=+V 65-U2FX+%Q\"*@-3'
M66WHBG[S<+7+3(2VT&I;+RH(=;6&V3V=PH3A22M4DX<WP9GM=8B'3&.Q0$%1
ML,XR?W0<F6N;C\F7R_WK;C-YO8O,?"B)8^T-4CQC.&=USR LQ.E2MDZTFHMO
M7E$'%S%NTQUMLI3'4AJ)&4\9"W#)>>>MZYB%LX20Z.26E)W%*6$NN!:0V0;*
MYZ6M<9YY"EW#C2KI<!%,%AI<"+"AWU%I6W,4K"XRO&6Z'>(6VB8K!9<6^".F
MP](5GAQBZAVO'.**M<[+9\+[6,I62,K<=.7*5K8YN9Y??W7S!CF.N,#9\AC7
MDL=PB<!4Z[+I68Z,X]DECRB#,K4TKEZF=F9>88:=<<BVR0M+>^XMOMB)2GPA
MA#X6_P ,LI"6V\.[JRLC=!!FCZ/M(N4R+/GR(L>/==16YEV0XU&9?-H7;$0^
M-.<B.1H/',YWC2'D*C!;*6T[JEYK8MMES"GGS!&-<ME<0#AS<:^1W*&JZ%I:
M024ZS=.8N>:1[.ZPM>M;)-E+L7C51E.1#=\S624;&5>D2(^<YZW2A-A1Y0X>
M76P5\,.)0' 2E:0EY*'!A0P0I((/+GC)TJ_VTV>[SK=NN!,9\I;XRXKCJF5I
M0ZRM:X;TB,HJ:<2K>:=4E0(.$GQ1.LU_%GG#_8K?_P"[TM5#_IK2/\[;-_;=
MJU/^IVU3^B[5G]U%K2CKTC7SY/4_"?TU%5GPS0[G;G%QM$8>:>/,;V#%3V*?
M'27@'U1L\O%S4LW>1IT!%9VH\AV?8NO*"]@D"A2IBH8BJ>&F6&VSYQGS&>T.
M*M,NS+8=W51G(4UYI]]+C122M:EL-A*RH;B2K"2<$;;:=<:BL5D;L=IE)@L,
MZIMVL6)C'$;N$>]6J'+@PG&9*%IW&$,S'BXSN'B.;I*MT%"K-JNVFDTN?AK!
M7+-DR-4C6%682D:VO,BWB+D-*B1@*P]NC1JD@K//(V$(TBU>T<HM)9E'L$)I
MI(D;% <="TC;[=)CR8DN[-%IJ"V^TFX+0S/-N;+$-<]#:&R^II@-M'"D)>0T
MVE]#NYE6P7C:K?+] GVZZ6C2LMJ5+O,F'*>L$9V;9$Z@EHN%V8L:Y"GVK<W(
MG!Z6A26G9$:1*E.07X?%P+77PCMYCDYRH2]B:@:>Q*QP5+PLI=(UL_4IQ5Y!
MVS1*W*9F^;SBBDRNHF_2 IS@*!DD0,0AALUZ?TNRF3 ?G-CM%E9TZ_'?N#"'
M3 077$H2G+3J9"NT+\?//*!N'OR#&O=I$CP?>(EG=4FW:R?U_#N,2P3'HR;X
MMIB,\X70'F5V]"8* I@@I.XZE:\*KQ!M Q+ Q*ZI;3D2(?EM=@N;B]'O9V5J
M2D;A5H.F6YLI956I#EB;1$U^))(L#AU$GK9LO$*1IT&A4)!H6R165'MMT8<$
MZ5<%7'PCPIB')\.- G(,KAC[1-9B1PZV4C<6A)8+9"<7!VU:TN$QI'@C3,Q@
MVFW6%G3PT\EZTJB6.ZSKY9%BV=H5O3K7,GSNSNI5O.L/+;EB2''^+77NV/%=
MB>VZ8C;!=&<A/7UE>?.=<NBB#VI9$@(4E1D9VMR1$'+Z-G)&(1/#V9"0<2"3
MD@KHK,T%!-Q<+T?9I:IK[4J<AR5<&YRG(TX<6%=(;(A.R8KR4+<;DK:08\U#
MZWD. D*;"N8LX^UK5]K8LL"1:K&ZQ;-.OV$,76P_:+OIBYSA>HUON,5WL[4R
M#'ENB;:W(K<532DMN)<<2":\<KM=IU<Q_E"OXMCF<7)7G#K'$;-C99>1-5V,
M3"1UB8Q#ITNV:/IHCE$UGDY"2D 4=O9!UU%#'15,=P$KVCX$2VW>/:&FVGKA
M86[&VW+>=,)MF.U);8<44H=D)<3VMUUQT*6XX[A7BJ\83Q-K-\N>I=)7/5LI
MZ3"T_K9_6;SMLAQ5W9^;.DVR1,CLH><BP2PHVN+&B,%#+49@K&'$GA5==5PC
M0F^!8[;D]>EG*_#4F*JL^K&R)F<LJY6;D?*V %VCA1[%2<E+@M86+L5.U*[.
M5TFHKU!.-W#T];4Z::TJXZ),=FWM1)*F72V^7%#B&5OH4I;+SL@*EM.DD[Y#
M@WN_%7?7NHW-HLK:='C=@N4J_2[O;4RXR'X;;*'%1V[<IMYK@RHL>#N6V0SP
MPE;*5-J#85XMLPFT3&D,T>]O8,G66PR5HK=I?7FXWV3L]U=.*JU?QT3$*S4J
MFN P"<3+S,4K&>2]51G*N^JJFX*U<-;6/H>TL)652[Q+E.S(<QVXS[D],GJ5
M";6RPQQG@4F,EAZ0R6BW@MO+ *%!"D96X[:=5376DL6[2=JM4:TW2SQM/V73
ML2TV-EB\R&94^6B##4C=N*Y,.!)1)#AP]$05(4VIU#MOL-C^(HWR4[6=R:#F
M+9T^.@'B]Q!TYK,?0+*>U4YC ^4Q:J+)K!22SI)LD=%?MFCM<KP7+KLG2=JU
ML\LC(;X<F\!3+<)F,I4\.&(U;99FP$1M]@I;3&=6ZE/BG>;<6'-]2MX9*5M]
MUI,XZ7[?I4MS)%ZEW%ENR!EJZR=16GP/>Y%R2W*2I]Z?&0RXZM"VMUYE'!#+
M04VNZ8W:=CN&EIJ7A[+E&(5E/=ZHP;1-]E(IM4W>2K!%VJVO:B:-*T>0KB1L
M$0UD3=5XX1,)EV2Z*T:N=EJ\:T5:V'I#[,N\,K>\(EI+-R>8;A+NLIF9-7"#
M(;7'4[)9#W[XL%1+:TK94I!Q$K;%J2=$@PYMJTE,:B*TYVAR9IN'+=N[6EK?
M*M5F9O0DJ=8GMQ+=+7'0> TO>0W(0IJ2A+PDG$F'JAA>"E8*H^=%RSUA?VF<
MDIIXB[DI6;D4&;19VX,T9Q[%$J;./9MD&S%@S;)D0 P(BL=553+V2Q0;!'?8
M@AY1E2G)DI^0X''GY#H"5.*W$-MIPE*0$MMH1XH.[O%2CJFLM:7K7-QA7&]=
MD0;;;6;5;XD%EQF)#@LJ><2RTEYZ1(65/R'GU.R)+SF\K<WN&$I1)Z_[RI_H
M&_%K+K]@K_=5^@UJK?[XW_OI_M"L^[1_"*=_IJ5_XY;7Y*-MOW9=K7])NOO^
M;+O7[2=BWW'-DW]&>@_^5K54/99K^-[CCJT4K+2L,2AW.-7K$ZC.2R,&T>MY
M),_5;(R:KIH9L_**1G#%5LNF[070*Y;&!5 #$U+2D_4-IO\ ;;QI=$Q5ZM,A
M$^&J'$7.<:4PI.5JCI:>#C)W@V^E:%-J;7PW!NNFMVOL2S7&TS;9?E1Q;+BR
MY#DHDOB,VXAU.-Q#Q<:*7NBVU(6'$*0%IP1D8U1FQ3#S:!\T&OF:IVS$ME-R
M!#Y.L.59.S90@7E';2<?36\%8YE!\FVK42TF)Y!G%*1KB/4"8D14*HL<AT.C
M2-L^K')?:A9=(0[<NV7BRRM.P--1;=IR<U>'([]V=FV^,MA3EQE/1(BWI0?;
M>WHC*00 M"]-8V9Z>1$$?PIJ*3,1.MUV8O,N_/3;S%7:T/,V]$>9)2XAN$RA
MZ2AN.6ELD2'^2BI.[$D-T;E#C,GV,'%MN X<G,:UJKFIJ.09L+)<7,?E2\9+
MN,?D0QXXJ5BJ,K*W&)(5P$@:PJ%(\8.Y!!K*/QF-HE?9!7N3IR I%LM?JMA:
MBG7+PNNQP^P6E#^F;1IVU/V%*)&_!ND:+:YA*.!V'FT\VPIR.QV3 1MCUJ9O
M,O?G7#U/2;+$@^#Q=I)FW!QN]W.]7)N[*6T!-@/O7!OQN,9>$+;<=2V\]Q\A
MI;9SBF9A\E59Q-9+;4G)JJ[F0H3&\/F]'KCZ0N"%\G)*I5?L1B8V2L%I0\YR
M3]^A*NF_;O&<,I%,GKINKH,3:WJ6)+T_<T0]/.7C3J$,Q[V[98[EXGL,6I5E
MA1[G<BH2GV(5O68[+3"XR'-UIZ8)3[+;B=N?V?61^->()DWE%NO*E..VQNYN
MIMT-UVX(NDAVWQ-TLLNRIJ.*ZXZE]2 MUMCA-.N(5?&5<;X4FW].L>07-=J4
MI7,BU7(L3/'D8"K/YNST?MEH9M+2CY(CF:CVQ%Q%>/,N!^R(D!%4BE#6%TOJ
M'6,1B[6^Q-S[K&N%@N=@E0N#.N3,.W7=*425Q([*E(AR%E&&WPC&2H%"\FLG
M>[1IR0[;Y=T7%@/1+M"NS,GC18+DF;;0M49,A]U(5(91OG>:*][&[@I YQD&
MT#$$TTC9FG7G)M<(A9LB6NHV/&^1C1*U=B\M*,7&0*;3IB-:K#&T&PRT6QG2
M1#-8ZL/.-$I*NR42N0I@V4[6-50W'XEUL^GK@I5OL-LN<#4%@[2B>_I@.HLE
MVNL:0ZCCWR#%D/052W$!,N$\['GLRD*K"^M_8)"69,"Y7J&$3KM<+?+L]W5'
M5$9OQ:7=;?;Y#*"6;7+D,MRNSMK*H\IM+T5YA6:JU?VTX*2N#>R0\[*2=C+F
MN7W"I(^[)G+K+WM*E-,/2RZI3)KOW<.RC(HD>_07<+.D;"FN9[)"X%1N%M-V
MA:T7:G($JWQH\!6D(FA2L6EV*E%F5>%:HBM)YH:9E.RI!<96EM#2H"FTM,\/
M=<JO$T=I@7!,R/)?>F#44C5:4^$4/%5T%M;T^^2A06\Y&;9:#:TJ42B2%%QX
M+)2;,8='Y@9BA8V:[_)DPQGJ.&/&C&:N[AZVJ-;97MADJMHTO]IIKP#RFW2.
M;S=8?(KJ.&[H!&1-)]FW[#)O[=M:O.07D,Z?BO0[UX>=?B69MERYW!ZS/Z?N
M#EV'&4W.;NEHD.P[@PM"&W6S]H[,2LJL&ME>EVTS&U+N[[,NVFTH:DW%QU$"
M&FZM7J*BW^*E45<"XM)D0W4*WTK)+Q>PG=K[O:#A0SN"1G+;D"8DC4>^8CD3
MV;(R\K*7^$R$\<7.<CK$O)D6>O)1C**K6J$+7CPOF(Z**[%JE%LV[="V:VK:
MQ2S,7"MECAQO#%EU1'%ML"(L2R2[(TBTPY$!N*6V6HKT=";;,5.$LS=]33[A
MDNK<7<+T!IPKB)ES[I)>-NN=A>[;>%R'[K&NCJ[E+9DE[+RGFI!5,BB+V;LI
M""AL-,H2BO5;:5C.F6BMY"8.[E9,CU>V6^^EN%SM*DO,VRV6S'Y\9JKW!_YN
M 7,?&T\&T+"L8MG'-(A!HW51:+J@N#C&W3:EJ"\6V=8)#-JM]@N%LM=C-JM%
MM3%B6RUVN^)U A%I8[20V^_<PJ3+>DNONRE..(6\A!1P[J#H.S6Z9#NK3MQF
M7:%<+A=1/N$XOOSYMPM:K,I4]W@D*:9MP:CQFH[;+; :2H(6K>WZ9M%VX*[>
M:QD92:2K*5SRSE:WY.LS6G+RCRL0*,X_5- U" ?S3*,DWL178T0(@NZBHTQW
M;U^)&A$A3$U?:IM!1KRX:?1#5<E6C3&F[7IZWN79$5JX37(C($ZZS68;LB.S
M*GO[I6AN3("6V6@72K.*.@=(*TG"NYDB&+C?;Y<+U-1;UON0HPE.GLL"*Y);
M:><8AL^*A:V625N.X;"=VLM=<LK?*WK]'#_$D]_UIE?]VSU]6/L-?N0N_P [
M+S_PUMKY^?9,_=';_F];/[Z=6PG7K"O/5-*4TI32E-*4TI6"^4!YN\P/_P#9
M_L ^E4W.[]OVZ?HJ/A$ \1X_#\_A]/A^'NTJ3!_;YJLM#JNKV_5 #",16V3(
MYN!ZA5I206>JEZW <B*#!JH(!WCU@TJIGEUZ]!T/>,<O/@9Z=:N\B"28F%-,
MJ8G,8ZG4*4O74,  90XE !,H8"@!C"(B(  #R !PJ0J/X0?)T]/S9\]=VE2]
M3\-?D]WR4:SLNELAK_7<&Y9O]TE,F[8#UR24QW<E8U"I0$8YB[%:</;F:-9&
M\9B*%K""\@ZR9BK)-<=Q5S>QR\@T="680[%^W[<ZK#H/)C]-8P2]UW?8*PR:
MHXEN6\BMY)INX+=C<I9 (;<;<6]EG&NXVF+0$",>T@4JW+PL]BITXNYK-:IV
M=QW(IRMP,SK\U=I*1\A5'EW_ )_T\_1Y:RDRK4-PF0+M4LR9(ONZ]:MQ?2]9
MHJ47#1LWF&3K-'PBSHV26^*YJ!Q_7T'#1*CC:G\1!)VY./-%*PTT>&=236OK
M.UDG[?XTZ#]N=9L]$]F#<M+0VY*B9WF\O7VP5R6QV6I92R8;(T.QM-EN!;8Q
MGXF#QUE>AU:U4&4K)X9A*6J'J\];\4@@^C!HQH1=M/(R"A'F[_\ #RCX!U^8
M5N:C8MM5+5$L6)!*SFJ^JQ4-P'+B5@U#O"O%U.>LH[>MGKTSE8W)CG13$>0#
MN5*<%)ST\V,\\'X/^GGJKURTJSDQ/QQVB2#>,.B=@NFL=0[QH=W)1RBZQ3)D
M*D;RV*= 1,@J "0D$5!-U@*J! QD<OGZ>?\ [\P>9S\2)O*[S7FI1,(1<1,2
MZY0 >H4[T6T4R$X\<<JD&3ZH#SW(&X\?BJ#D.?3&#W>?',^C'7.?A]M6=D5A
M!(L8A#13Z7BUN?B@D6(D73,AC=WQ2^2HI*E'NZR1RF\#:4.=[(/+'4].G3_'
M'X<>6!K:XD'S5[)/S 'G*<@WK!L4G5!E&*0]A(R0.80 ZBJB*?EJYCE*8B[I
M1N4!32(8>C: _?Y/\FY_:C5Y]V[_ .;VK^6:_L7"H[<MF[QNNS>((NFCI%5L
MZ:N4B+MW+=<ADET%T%2F26162,9-5)0IB*$,8ARB41#742 000"",$'F"#U!
M'>#7FY*E(4%))2I)"DJ!P4D'((/<0>8(Y@\Q6.=7V=[5:54;-0:CMZQ%7*9<
MWL1(VRMP]&@6,587T ];24$[EFR#,A7B\/(-&SZ,.J)A8NT2.&W9J@)QL&K5
M;66G&6H,5MIU2%NMI90$N*;.\A2P!XQ0>:2<[IYC%9R3J?4,R5'FRKU<I$N*
MAQN-(=EO+<8;>2I#R&E%7B)=0M2' G&^A12K*>5$MG6U5NM:W#?;WB1NO>65
M@CKBJWI$$@>RQ]JDXR:L3&9,DT(+YG+S$-%RCQLMUD3R+%!X4A7!14$+5;07
M"(,4%X+2Z0R@;Z7%!3@5RYA:DA1'>H!77G4#J;4)$9)O5R4(:F%Q0J6\1'7%
M0XW'6UE1W%--NN(24X.XM23E/*O0KM$VNN+,[N;C;_B5Q:W[5PR?3[BCP*\H
M]:.ZJ[H[UN[=*LCG<(OJ@_>5U\183@]BG"K1UVR9N-1\%V[B%WL,7BJ!"E\%
M&\0II3!!.,D%E2FR#U0<'E0:EU (R(@O-R3%;4E:&$RW@VA:)*9B%)2% )4B
M4A,A!'-#J0M.#5U5#;[@^@46Q8QI.*:)5L?6]*50M-/@ZY&Q\%8D9QAYJETY
MEB@@1*1)(1O[0<@Z!4%&?[7']B^+JJU!AL,KCLQF&F' H.-(;2E"PL;J@I(&
M% IY'/=RZ5;2KS=ITQFX3+C,DS8Q;,>4\^XMY@LKXC1:6HDME#GCIW<87XWL
MN=8O6GHR-FTG&1$;2L%XOQ<5K?<;W"P+TJ@UIDK<8?'EVA;L-#L)!9E3>5:S
M/(1LSFFY^L/DW)D2]J4HACG-/VI24H9AQXPXT=UPLL-@NI8>0]P5] 6W"@!8
M.<#F 3RK8(^O=3MNJ=EW>X7 ]DGQF!*F/J$5R=">A]K8(42B0PE]2VE#'C
MG=)SD*&UC;>6"A:P3"&,R5ZN0KNNP4,G48@D?%0;^UUV]/HQFV(V*FDU>W*I
M5BSNTP#]L3D%%R*PG<M$E"W_ (/@[B&^R1^&V@MH1PT[J4*=0^I(&.A>0AT^
M5:4J/,9K!^J"]\=V3X5GF0^ZEYYXR72XXZB/(BH<4HJR5(C2I+"3_!:?<0,)
M614<YOV/X'S+4<LP*-.K5"L>;'%35R)?ZM5H(EILJ=4N-=N*+>8<+M>I)I2+
MRN-&\@#OK^4)G,LKVKA-(Y;:9:(<IJ4A++;"YI:,E]IIOBN!IYM[QR<;V\IM
M(5DY/?GJ+^U:KN]MDVUY<N1+8M(D=AAOR7N!'5(BO1=YH GAJ:0^I3>Z!ND;
MHPDD&_$-I6V-K#U^OM<#8L:PM5FYZRUR.;4V%0;0T_:&GD%CEV!4FI!1?3;
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M:L6??9T-Q4*7J"X!VUWSPNB<U)=BLR6;Y':M MRW6N$XZJ.)25B(X]]H1O2
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MP/@/X!_%I41U'PC]-8_91_?WG]*0']UV;71M ?O\G^3<_3&KS_MU_P VM/\
M*L_W=PJ(==2KS=32E-*4TI32E-*4TI32E-*4TI32E-*5\S7\6></]BM__N]+
M5L?]-:1_G;9O[;M7Y_U.VJ?T7:L_NHM:4=>D:^?)ZGX3^FFE0II2FE*:4II2
MFE*:4II2FE*:4II2NI?]Y4_T#?BU*OV"O]U7Z#4[?[XW_OI_M"L^[1_"*=_I
MJ5_XY;7Y*-MOW9=K7])NOO\ FR[U^TG8M]QS9-_1GH/_ )6M54'7,*Z932E-
M*4TI32E-*4TI32E-*4TI32E-*5O7Z.'^))[_ *TRO^[9Z^K'V&OW(7?YV7G_
M (:VU\_/LF?NCM_S>MG]].K83KUA7GJFE*:4II2FE*:4K!?*/\.)C_N/Q'TJ
MFYW?A_PJ/]*ITTI32E-*4TI32E-*4TI32E-*4TI7 ^ _@'\6E1'4?"/TUC]E
M']_>?TI ?W79M=&T!^_R?Y-S],:O/^W7_-K3_*L_W=PJ(==2KS=32E-*4TI3
M2E-*4TI32E-*4TI32E-*5\S7\6></]BM_P#[O2U;'_36D?YVV;^V[5^?]3MJ
MG]%VK/[J+6E'7I&OGR>I^$_III4*:4II2FE*:4II2FE*:4II2FE*:4KJ7_>5
M/] WXM2K]@K_ '5?H-3M_OC?^^G^T*S[M'\(IW^FI7_CEM?DHVV_=EVM?TFZ
M^_YLN]?M)V+?<<V3?T9Z#_Y6M54'7,*Z932E-*4TI32E-*4TI32E-*4TI32E
M-*5O7Z.'^))[_K3*_P"[9Z^K'V&OW(7?YV7G_AK;7S\^R9^Z.W_-ZV?WTZMA
M.O6%>>J:4II2FE*:4II2L%\H_P .)C_N/Q'TJFYW?A_PJ/\ 2J=-*4TI32E-
M*4TI32E-*4TI32E-*5P/@/X!_%I41U'PC]-8_91_?WG]*0']UV;71M ?O\G^
M3<_3&KS_ +=?\VM/\JS_ '=PJ(==2KS=32E-*4TI32E-*4TI32E-*4TI32E-
M*5\S7\6></\ 8K?_ .[TM6Q_TUI'^=MF_MNU?G_4[:I_1=JS^ZBUI1UZ1KY\
MGJ?A/Z::5"FE*:4II2FE*:4II2FE*:4II2FE*ZE_WE3_ $#?BU*OV"O]U7Z#
M4[?[XW_OI_M"L^[1_"*=_IJ5_P".6U^2C;;]V7:U_2;K[_FR[U^TG8M]QS9-
M_1GH/_E:U50=<PKIE-*4TI32E-*4TI32E-*4TI32E-*4TI6]?HX?XDGO^M,K
M_NV>OJQ]AK]R%W^=EY_X:VU\_/LF?NCM_P WK9_?3JV$Z]85YZII2FE*:4II
M2FE*Q'O-,EI2U2KLD58C$,H4A%&<0R=MU2D W"B2QYQL<Q3 8!$#H)B4>0 !
M#XQE2G.<CX.@\V.\>?O-6G[W<Q_FFV?5YC^D6E,J\GYA^O3WNYC_ #3;/J\Q
M_2+2F5>3\P_7I[W<Q_FFV?5YC^D6E,J\GYA^O3WNYC_--L^KS'](M*95Y/S#
M]>GO=S'^:;9]7F/Z1:4RKR?F'Z]/>[F/\TVSZO,?TBTIE7D_,/UZ>]W,?YIM
MGU>8_I%I3*O)^8?KT][N8_S3;/J\Q_2+2F5>3\P_7I[W<Q_FFV?5YC^D6E,J
M\GYA^O3WNYC_ #3;/J\Q_2+2F5>3\P_7I[W<Q_FFV?5YC^D6E,J\GYA^O3WN
MYC_--L]'?7V'R]W\X]*<_P!A\RJ@V]XEMDQ,KQ[2I9%714-&2)I-O6JX9@7R
M)M*-!:$%S?&;E1P<T@54P"V(D1-/N4.)Q NSZ<O[5C<=6Y&<D<1*T@(<2C=*
MBT<X6E8(PV<@!/4'-<WV@Z$DZS:A(CSV()BK0I1>9<=W]U$I.!PW$@'+X(R<
M>*>O*K.^#Y<?YM9%^JE6_6/K;O7$B_Q:_P#E6?U*Y?ZPUT]T,/\ J;_T]/@^
M7'^;61?JI5OUCZ>N)%_BU_\ *L_J4]8:Z>Z&'_4W_IZ?!\N/\VLB_52K?K'T
M]<2+_%K_ .59_4IZPUT]T,/^IO\ T]/@^7'^;61?JI5OUCZ>N)%_BU_\JS^I
M3UAKI[H8?]3?^GI\'RX_S:R+]5*M^L?3UQ(O\6O_ )5G]2GK#73W0P_ZF_\
M3T^#Y<?YM9%^JE6_6/IZXD7^+7_RK/ZE/6&NGNAA_P!3?^GI\'RX_P VLB_5
M2K?K'T]<2+_%K_Y5G]2GK#73W0P_ZF_]/3X/EQ_FUD7ZJ5;]8^GKB1?XM?\
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M1^[ZR?$\_P"LT_=6V7W'W7XRA_0T^!#?_P"17KZEUS]96G[AO4?N^LGQ//\
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MA5B@6.8V=8]>DSVVR$G@%M#[@IQPN]DL:;GHS;C-$RR5YAA@VI3696E6M@K
MUE[>%GCM9G /DV#MZ51!2LLMT^[O..0^B';;Z,#7R<VNY,][^GY918UAOA3-
M,<X"2F$*I*4MQ,72F9 IMDISQU-%GXFTU=C#SCY*+@EDG[!F]F(=TI6'%XZ8
M_<UM7J<_ VG#E<W&HTG<GFC;E"Y?R#FRG8MO&25\&U1'*F0[?=X&F8#I.'J
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M:G*KV"MMSV*"81DJQF(V%ZC\I&9S(N@!/04K'W*'39[T\.0C.&M.&=MLW<[
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MI32E>=1HV6426502450,<R"ITR&41,H  <4E!*)TQ.  !A(8HF#N'G2E=X@
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M) '<F0QBD I3" J5\$BXY-,$2,FI$BE5("14$BI@1?@5R 0" 4"K"4IE2@
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M=+&72Z6+'M-FU<;(60)][&6BX5E]"11H-.8>E=.8PK]DR"0;]:D%V\OJC\!
M6GJLLX:Y(#B@7,X24H(4=X)21G"B1BJF)O!2]QG-U12 CM!+I"E%"5!L+)*5
M+24\LJ!QE('.HMDW72@PDX2L3+K?G$656:L5;2KTFKN%83BEBJ%3;7ZV0*<2
M[.D_/-5>BO&ETL465N+Z%J;IO8I)!M#K)O#5$^#E)"@F*4D A0W%9"E%"2 %
M$X4H%*3C!4"GJ#BFI<Y)(4J4DC((*G00I*=]23G'-*?&//DG"CXIS57AXGI7
M[#+Q=?@([I"9N=FZ9&Y&AX6)9[D9*6E<>3#DK*)OL;',R+/'U+E'ABM(ZT-D
M58-ZY,"#9\JJ($&!-M )/80D++9*EM@)<',H40H[JO(#S//D,'$P-P4=U(FE
M12%@ /D[A. H  Y2>Y0RGH-[/(23E_#_ $L^$,6%S?>+1NT)B/W99!I+C(43
M?LS2-:B7^.+BSQ_+R5F>@]1&F0DQ<7@0%2>7).ON+/(-G246S5[(!/2;?M;J
MRVE,7B;K:]P\/>(=25IQXV"0D!2L$A((R>8S.XBXMHXJS)#>^XC?WWL9;6$'
M/+(RH[HWL<P0<&L/;!N1WB5.<EJS:<\;E*U8X%^YBYROV#*&48:;AI-FH9%Y
M'2L3(SK=_'/VBQ3).6;Q!%P@J4R:J9#E$H7:6(B@%)884DC((0""/*""01YP
M2#5N9$D$@O/I()!!<<!!!P003R(/(U1_A9;IOOE,^^V/(OZ1ZCV:-[79_$%.
MT2/O[WY5?ZU/A9;IOOE,^^V/(OZ1Z=FC>UV?Q!3M$C[^]^57^M3X66Z;[Y3/
MOMCR+^D>G9HWM=G\04[1(^_O?E5_K4^%ENF^^4S[[8\B_I'IV:-[79_$%.T2
M/O[WY5?ZU/A9;IOOE,^^V/(OZ1Z=FC>UV?Q!3M$C[^]^57^M3X66Z;[Y3/OM
MCR+^D>G9HWM=G\04[1(^_O?E5_K4^%ENF^^4S[[8\B_I'IV:-[79_$%.T2/O
M[WY5?ZU/A9;IOOE,^^V/(OZ1Z=FC>UV?Q!3M$C[^]^57^M3X66Z;[Y3/OMCR
M+^D>G9HWM=G\04[1(^_O?E5_K4^%ENF^^4S[[8\B_I'IV:-[79_$%.T2/O[W
MY5?ZU/A9;IOOE,^^V/(OZ1Z=FC>UV?Q!3M$C[^]^57^M3X66Z;[Y3/OMCR+^
MD>G9HWM=G\04[1(^_O?E5_K4^%ENF^^4S[[8\B_I'IV:-[79_$%.T2/O[WY5
M?ZU/A9;IOOE,^^V/(OZ1Z=FC>UV?Q!3M$C[^]^57^M3X66Z;[Y3/OMCR+^D>
MG9HWM=G\04[1(^_O?E5_K4^%ENF^^4S[[8\B_I'IV:-[79_$%.T2/O[WY5?Z
MU/A9;IOOE,^^V/(OZ1Z=FC>UV?Q!3M$C[^]^57^M3X66Z;[Y3/OMCR+^D>G9
MHWM=G\04[1(^_O?E5_K4^%ENF^^4S[[8\B_I'IV:-[79_$%.T2/O[WY5?ZU1
M[>LK9/R>:-/DG(]]R$I#%=EAU+S<+!;#Q17XMA?EC33T@_%B5Z9FT%V#44@<
MBU;"L!Q02ZDZ&VV\\-#:-X@JW$!&\1G!4!R)&>1JFIQQ>.(XM>.F^M2\#R#>
M)P/-W=U;$^B<Z4#)O1F;A8Z\1BT]9\'V]=O%YPQ*Q?II-+9!%(N@TGHEN\$6
M+6Z54[DTC!2'+11X0KJ >/F\7*.3IV-RM[=P8W" E](5PG.\'K@CO! P1WX!
M[L5=P)SD!_B))4TK >;SR4D=X_\ N3U23G&2,<Z_J4;=]Q.']U.(Z=G#!5SC
M+WCB[1B<A#S4<H(*(*  $>1$RP5 CV&GXESUV4Q"R2+>1C7J2K=R@0Q>_GK[
M#L9U3+R"A:3@@CD?.D]"#U!'(C\.-]8D,R6TNLK"T*&01U'?A0ZI4.\'F#4W
M:I56II2FE*:4II2FE*_F _Y2G_\ Q9LT?ZCX@_\ V#%:WZP?Z-;_ )1[^V:T
M:^?Z1=_W&O[M-:%=9JL132E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E;(NCFZ0%+8-:,@V17%*N4_=R\PD[(T2NY:2,6.'LUU#+XE%P-
M2M8O!GRU48 AP1:>:CO0E1+(@V\W+V,Z'VQ"4<0-[O$YE!7^^-*;'+(]CO;V
M#D'=QWU=Q)795E>YQ,[G+>W<;CJ'.NZKKN;OFSGNK+")Z9"$D]O]$P'E+!F5
MK,SH5TO63V%XQ]NJGL47J3OL]F7*^5*JG*6B.QG/3Z5)@V>6IBNST'!RL)99
MYQ&1L["76G&[>,-;&UJXZGFWVT;Z$-E*X_%0$AIIM9""ZD%:BUO!2MX#.-P\
ML7";B.$EIQIT[BE+"VY!;65%QUU()X:L(3Q2DA.ZHX!"T]*O3&73MSV.YW(,
MJ&#95XUL5 VJUZC-6^3JJ_=T6U[6L1V?&$3)>6Y%PEDE%Q3;D\MTO;9B JS"
MCWF,D#^3Q&4D#/YQY+2.V9*P@)?P4N25*^UJPI$AQ*RD[CJ#O)" $J45IPH@
MH5@8G:NA;4LEHD%N.E("TG<5&0M"?WQI8W%A9*TIW%9&4K&5$UV-Z=:LL(+#
M<$WVMV*$0H-1DZO=#UC,]!(C;"3N)Z9C&>3AHVZ;9[S$E@)5:CQUD4K>8&.<
MF<>O(2$5"+Q<:PJB=:&SD\4]J!+BDJ22RO*-UUQQ&=Q]&2C?'-K@@D))2H@[
MT$W, ,Y8P6T%"RA:/&RVAM6Z%LK"0=SHX'L!1"2GD$Q#DGIEC7)CF1G5, O,
M;#E:9H<BU4@<R2SM2N-Z/NXM.Z7L3NG=.+)R[F;5L2-9>N?.$<W;RK16T,V"
M3)=K58^=NU%):*WDN<)*D#?:SD&(&-XC..2QO >3!)*@<R+N.\' EHM[ZD*
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M.)Z2C4FA'EDF8N2JL%7HF2.U9QDFS9$F73-O',?+%VBK1BW4*BJN^574JKY
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M2 I64*+C>%*RI'!4HJ;"".?LBH<A*WI6U-!"6TR$(;:+3;:7MUM*5M(8D**
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&=4JO:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g111598g74x61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g74x61.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1FF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-CDU.3$< @4
M-$UI8W)O<V]F="!7;W)D("T@,3 M2R M(#(P,34@1F5B(#$Y(&1R869T(&9O
M<B!!0RYD;V, .$))300E       07SZV<GTF,#-MG-:*:R41]SA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!DUU0         "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    '@X0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              %-   #?@         !
M          $              WX   %-                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %-     %)G:'1L;VYG   #?@    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !30    !29VAT;&]N9P   WX    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     DX0DE-! P     #P,    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M!T'ZQ8O767/QJK*A06M=ZNT3N!/MV/?X+57%_P"+7^8S_P#C*_\ J7+M%#,
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M3COU[TRX/:X?U5<-]/WG&ZK]7?VGD-R+<DUN8STX8P1$ET^]SOWE3_YE5?\
M<Q_^8U:G4/M?J-]'[7](1]F^S[8VF=_VS\W_ *>_Z" ?M>QN_P#:,_I./LV[
MZ(C=Z?M_XC^7_.+/R_<N.7N5QWZOF=;#_I#VX^W?MUZ?DV6Z5]7?V9DNR*\D
MV.<PUP]@B"6OGV.;^XM=@L$[R'>$ C_OSEGX/K_;;/4^V1M_P_I>C/L_FO1_
M2;__ %*M)6,'M<'ZJN"^G?ZM7F?>]S]?_.4-ZVZ?*I4[L/)LO-K<B&[F/KJ<
MP.:W:'-?PYC_ -)OW_25Q)2L#PU?^+^AN;Z(SWFRIK+I](1JYT?X3_@EL?67
MZOV=7HK?DY6P8NYS13223NVCZ)M?^[^:M+K'VK[*?LOK^I#_ .C[-\;'?1^T
M?HO4_P!%O_PBSA^U_2=_3X],SO\ LWJ;]/3]+TO9_7]3_P!*)YX[%W?1K1^Z
M^W/AX?;_ ,IV_P );ZL]!?TK&?9B98M9E[+/TM)!$#C:VYO[R(UW63GG!_:3
M?4:-Y_4CMC1T>K]HV_1<HW?M/[1[?VEZ7J>[9]EVQ[_H[OTWI?\ J-0;^UO1
M=N_:6_VSN^R[^,G^:]+]7^EZ/J^I_P "@;LWOXLL/;X(\'R?H\-NEU/ R,W"
M..^YC1])[FU$D[7;V[&^MY;51Z#TVVBM^3CY(=ZOL<+:'-(+"[\WUFN_.43^
MT_M.//[2V^FS='V;9&X^O]H_X7^;^A_@OZ-_AU-O[5^U-W?M#T]YG^B^G,V;
M=VW]-Z6W9_Z,_P (JTO8]^/%7OUZ-^+A]7_H3<C[_L2X;]B_7M7%Z?\ "_<:
M3.B-_;!J&4[UV.^T$''=LG<+H]3U=NWW+J&!X8!80Y_YQ:-H)\FES_\ JEAX
M7V[[5C3]NCTZ_5]?;MG:WU/4V>SU]W\]L_0?SGH+>2Y?V/5[-;^NKW_PE<S[
M_I]Z]O1=;?X+_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(
M P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z  9<-H  "<0 !EPV@  )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$V.C R.C(P(# Y.C$W.C S ')R,38Y-3DQ       #H $
M P    '__P  H ( !     $   -^H , !     $   %-          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!2$U- "H    (  @!$@ #     0     !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
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M;XS,CP;(ZYU^22R1T,M:ZW;0^T^J-(AON5TB2AB;&?2;4B*Z:7FE&1&GJD)
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MLMQU3;J9#?!)"O!,;[<.TS=I27,'0[9MHM7!8^IPH!9]VM#Q(-@*=N2[)/\
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M[EUP<OR\QQ]Q&7W+'_3E=*0_(745O1E972(]FV]*0W%8M\AKLE2PB KB,K1
MG5S;48UKWU15$V^MQ:>(N]?T14Z5LQT6MCT'0=.M^M<;C+<DO5./V6-J><GI
M2V\E<Z!9.N2"0@D(DIXC"6TJW$V-V/8P5X,-& E"!T-YQZ?/+(#$SY3)<N4F
M9FRICKAXE.\I&9=4I Z!$0TB*RM:'GI:LH6B/\JR>!D$UN;78Y7XVM2Y,B:4
M&;9S#FS9;YOO/K78OR. RVHS3%C,)2EE"E$MQ]1DI.?XQ66-#"5"GY%89"A"
M(T>&<V)6Q.9PXC!,-,I37QF.,ZM)$J3(>-2GEDDT-LD2DJO3!ZE9T#)\TS0
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M;XU$^DLCZHXZ3W:]VV*^&G_-P=,[LV]T/@EG[Z,\O.J YY!P < ' !P < '
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M&T145>LEENO22PF=,>D.S"TI2LY>PVEO#3:&TX1G*OUU"(M2UUZOKZ>R9?P
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M_GOL15,*9[KV'J'H?5(M/6+U]>R OWR@!P < ' !P < ' !P < ' !P < '
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M+P)^UHR5YL%CVO<--U*-7H+=#]?'PJK0!!E[P1DA@):BU,R6(RZ\1*5SU*7
M*_Z8_2>&]UW8!K6T:SJ0>U31^M#MF)1-@P*S5 8B_:4Z0KTF'3B%PPA_9MH3
M=>J:(.17DMTB:R $IAP46&SN!8EN ,K3WX1]4?SU:?S%L/*EZQ_J_B0"1G*
M' !P < ' !P C0 _;9MWY25?F+1N5/UB_5_$P&**Z^CAV];--=16CQNX!M3@
M;LW'=-J ]BC[=N:4;HJ;9O>=N=,6MZ]8M8>GU0]&C37:G.LE3(C)!J/((32K
M$M,^3!<H L.+]'>Q"VGO0)7NHKIKKVV+74K\=B:UK<"&LM3)^S#G3L8N=A)T
M8D8)$QPE=1UU=-:C;?+$3S,*F;.;=7(6E\H,+ %F[1T86;5]2"V"O]=>J"=\
MO73Q2=?:&CKVC71B+CL6B;(U&5UE=J6>V3>5E)="II.NMM7$=3+3/AW6O6'
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M>BRXSCL>0TKLSW7&G%HSV9[,\_(^P[O !P < ' !P < ' !P < ' !P < '
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M]18"4]7HB@[/<\A'_$9>WOPCZH_GJT_F+8>5+UC_ %?Q(!(SE #@ X . #@
MX 1H ?MLV[\I*OS%HW*GZQ?J_B8"K^4 8B=D=!_4T2F72NZBWY4=>4FVVCJC
MM,JQR1ME(WLBYU2MEVR(\D+0M(",5U5(M9V;1[U *>NR$"N4"JRAX42+*22
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M@UBK/L.I%G>FEQ[#.909;:B$;7*9_FY7OE_]ZH=HL>+_ / 49'^9ZPC(_>3
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M"S0;IZ*#H0T4IY0L=$A3MAOQHT$:J0^J!$9:1'AJ?>S';;RXOO-"[)>/R .
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MJ9(&CWI>(:6,R5P8GCY<Q':PEKZ:$7[ %;\H < ' !P < ' !P < ' !P <
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M[*))@3HKA1.')ARV5QY+#F[&2K<>9<6VK=4E6ZH]#(^J)(\E(1>' !P < '
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M . #@ X . #@ X . #@ X . #@ X . #@!&OI0_!58/^\1U@?_=MN[@!)3@
MX . #@ X . #@ X . #@!8.\=3ND-=6VUT6U7B%$ME&U45W1;@<6--)S@.OA
M1$>)]:SV1\>2IN64($H\8$'QA18TO#JA\-]#?>R 4$/ZW-$$"H$%B=;H9HG8
MX]2L(LA23\67K*P$KRSK0 /VHE47**/[*KV^W7:K*)N>3/OX=GCI#P=A\BV
M2&NUZ"T&( FFVYSC-DN=2HH_$!AI]:35T-10(AR2EV1'PW!1-EM*FOH4ZZS'
MPMQN.^O&&\@%9\ ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !
MP < ' !P < ' !P < ,0'5WFZQNMW1\L:S7#-;<3H:(JM70=L,B6?F2-QV2
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ME/M.2D,Q4/)BLA0O9_7_  (74X%0X . #@ X . #@ X . #@ X . #@ X .
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MM_RSPW/_ .8/;$^N_P#TO.H3^M*V?67'0"D_-4#YLU_*']+FU#V_Y9X;G_\
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M!+]T,JOR8;/_ ",QS$,X_$+OOF-],QL7R6NNS"^!+KZN@;T/(6'34. #@ X
M. #@ X . #@ X . $2NNOWINY?YD#?G97^0QRANLUG/O"!]M5HF7D^=>/!_?
M\[[&LAJZ<Y'#K6' #.9Z)+]HVXOZ65K\CSN=!>1A^3V;_#-5]1D#G]RR_P H
M<)^!K3Z\P,NG-TQI@-4[J^]\[O#Y03G]JGG'C;9UV<_[Y;#Z9#L!L5ZT^ ][
M<#Z!B.'(N$H"1'23[YG1WRD5K^_-\DW8QUU]G_?35?6$B,]LW6IS_O7M?JZA
MM<<[%CCV' !P < ' ##GU>S"">O;I[B.V.Z Q;L'3[3"ZZ:H:XN77]R$)4L:
MH<>WYK(I6FK+/$UP49)/:XV@JWPD, JG"D&!D^OE #*#L+5@'8SX&>1)V0$:
MJK%P163]6*I$F ,RZ4XQ2"!<=)7%EM(*CQ1N5*"R76'6X)5J+-4R_AGPE@%B
M-==%VO\ 71NHG&;QLRU.4X>]%B#K7(U^Z)+DE ;[5HMHL<2OZ]KRC-IB5K9M
MU#/EGWDYL3)C,^X,V,S$ADV "L-,=*6H]"W&[7C7L(S$-W\15!%@P0*8FQ'<
M508R,02::3%CNK+'E1VB=AG37YBIA;,B;#1 5/((E@%"2>J+IPTQL?<M*V+M
M:E42Q(O@4MD"5E*A2DPR>I=8NLS? 9CJ1W)CJ)#G?[>\XYAQ:ONLYSG]$A2B
MU(C,A0O9_7_ A(N7M?7$'7&-O2[@&CZSR%BV/%S<?5@)D'-RSB*3\QX>5>5?
MS(9PVOP^W.7$_<X[>4T,ST(NKV!44'K;JFZ>=PV/-1UCMNH76RX'RBN0P2<Y
M(FX'0EL-RIGAK8;QX+"Y+"7%=[MQEU'N9[>5-*D]4R,B ?C8W57TZZBLKE.V
M7MZG4RSM0XA!P(:G.QYR(4Y*UPY*FT,.8\*0E"\MY[WNX3GW,<$A2BU(C,@%
M?XVOKE6M_MOIN ;.LO4:K-[-,/J]2>H4XSE17S'A]_RF,8SG*_#[?<_R>4T/
M733JZZ:=WUM %OM==5O3GMNS,TW6NWZ=<K1(B2Y[(0+.=?G.0X#>'9DA+:V&
M\9;CMYPMS/>[<)SV]F>5-"DEJ9&1 .?975)T]:=L2*EL_;50I5D6/C%D!CDY
MR/-4-F./M19F&T,.8\%]R-(0VKO>ZII>.SW."2I7K$9@*Z@[7UP2UQG;L"X!
MI6M,!IEAS<VGU*"8"#U/HFDO,>'A7EHRXTA+J_#[4Y:7[GN<IH9'H9=7L +<
MZ^ZL^F[:UHATK7.XJ9;[409F2(0(//=?GR68$9R9,<:;4PWA28\9IQYS[K'8
MA"L^[V<J:%)+4R,B >CLWJ>T!IH['K&TMK5*D'Y8]HM&%'9KD>6\-?>?CLS$
M(0PYC++CT9]M*N]C.5-+QV>YP25*]8C,!6@?;.MS^NU[:#7$*1ULV*)'%W*-
M(4L*D0'S)24GYD9;PK$>#F'*P^KP^U.6%^YGL]VFAZZ:=7UM %MJ'U==-.T+
M0/I6O]S4JV6LMB2H:"$3W7I\S$.,[,E99;5'1A7@16'7U_=8[&VU9]WLY4T*
M(M329$ ]C9_4SH/2YJ'7-J;4J=&.$!J"\(8>FN1Y4D8Y(D1&YK:$,N8RPN3$
MDLX5G.,Y6RO'9[G!)4KUB,P%95W:^N+9K]S:M;N 8QKIH:7+N6^&^I89 P#F
M7@Q-R_EM*L,#LP9>)*NYVHS'<[,9[/=IH>NFG5];3V=0%L:-U?\ 3+LNT"Z5
M0MT4FTVLTN0@4"%$'7I\]<6*_-D)CMJCHPK+,2,^^OM5CL;:7G][E30I):F1
MD0#'CZ8K8M>#435E,1:F!MP<MSEF4$8F/QB2ZWD,;%X**2SW>]!R31Y3O97_
M -.GL[ON=O->>49C>59-BE)$Q.NL;*:QD+<B2U6F9.HBE6V#9N+,G&_ZOBN-
M)]<_5*3U!M#R5,HP_%,UR";F=G5U4"1B[D6*];$DV')AVU6Z33>\VX7%-EIY
M?K$>XE75&!1JU%GV,R6K"46QC"U9=23F]SL;[>_GM\;[R>S/;\&<9Q^]S02S
MK,OIKDL>M&K>%=FY%:*M?D/)DFY-)M41&X3IEO/I=;-LM[JDM/K:CI=56N#W
ME">3U#M'88^EJ8^JUCQHZHA-5ZG4S7#6;)'NQU,.DYZGJ;BM-1UF;O,D.H98
MLY%QU><X0A)2;WE9QC.<XQCQ?@QG/\F.9';[/MJE!72;>YH<DKZV&E"Y4R0X
MXEEA*W$-(4XHI"C(E..(074/JJ(8O2[2MCF1VD2EH\BQ.SM9ZUMPX,5IE;\A
M:&EO+2VDXZ2,TM-K6?5+J),<DJX$82DHE60DPI:<J3A9.;C*DXSV9SC]FS^_
M[G+;CF*[0<O9DR,:KKVY8ANH9E.PGG5I9=<0:T-K-3R=%*01J(BUZ@NN4Y?L
MRPF1%BY79XW12)S*Y$1F>PPVM]EM?#6XV1,*U2E9[IGU.J/W&LY-UC+T4\2S
M'[SJ\K:(S$M]_*U./*SV.X^Z4M2EN*[.U2U*5G.<YSGENN*W+Z&V*BN6[>ON
M#YOI DR'DR#YV23C>I)U1?UQ+3N=7JZEZPNE+:81DE,>14;M':4A<YULHL:.
MN-_8C4F5ZLV2/^H-"B7U.INF.NS=Y;[B&6;00<=<SW4(24F]Y6?O]F/V7_LY
MDMKL[VK4E?*M;:@R2!706^-+EON.)98:WDIWW#*09DG>4DM2(_7&*5&TW8U?
MV<.FILDQ.QM+!W@0H49ME3\EXTJ43;23C$1JW4J/34NH1CFE7 C"RA,JR$V,
MN8SE&'"<W'>PG.,9SC]FS][.<=O\O+3C>,9_E[<MW&:^]N6X*VFY:X3SJR86
M^E:F4N;SR=#<2VLTZ:]1)B\Y3EFS7"7(;.66..4+M@AYR$B>PPVJ2W'4VEY;
M9$PK4FU.MDK730UD)W>C6M,B7U:Z\DRCLR2,8&7QZ4N1/E/1D-Q:0=><6ZAQ
MQ2<X92GQ,YRG/=[N%8]W&.3%L/JLHQW;314V3,6=?-Z&W,A<&>ZX:^"[2SU,
MNFV;BTFE1I,TGV4^P9"".43;XADVP'([W$I%19P.BU!&18UC+1(XS60UB7VD
MNI:0LE))9)61>PK3JD8V JOUG]*]UL@>GU3>5$.V>P$6! 4+ (NN3B1.4YX4
M>%&;5&3A;[SF>XA.58QE7N=O.B!H41:FD].R.7 KS:G4!I?2*P[>V=C5NAN6
M!,Q85)^4N-DDB!EA,Q4;N-.]_$?,EC#G;V=F74??[>4))J]8M0%=4RZ578=8
M#W2DG(%EJI^.N6&.#',O0",9M]Z*MZ,XI*,J0F0P\UG.4X^[;5CL]S@R,CT/
MUP%3\H < &?O9_\ ]_\ XX 8B>G.OZKN?4 FTUF];C!;7LJ+KL"TU_7C.O\
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MAL_\C,<Q#./Q"[[YC?3,;%\EKKLPO@2Z^KH&]#R%ATU#@ X . #@ X . #@
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M_P"S@!U(8 $/>Q)@!1,&1A*D8?ACH<9["5X[%)PZRRA>$JQ[BL85V9Q]_&>
M'V:"!D7O,$ PJ?(PA+>'YHZ)*>\-.<Y2CQ7V5K[B<J5E*>]W<95G.,>[G@!V
MDCX"(?JY$*(@?X:F?(IC,IA^$O.<K:\MA&&/#5E2LJ1W.ZK.<]N,]N> '3B5
M\# ?3)@A!$*2C"L(D1!L.,^G"\92O"7664.)PI.<I5C"L85C.<9[<< /W-!A
M23N'R(<7/?2C#:7IH^)*=2WC.<X1AQ]EQ>$8RK.<)QGLQG.<]GNYX =EL? 9
MA^KVH41J!EM;68+<9E$/+3G>\1ORR489\-SO*[Z.YW5=Y7>QGMSP Z46O (+
MZ),(&'AR6^]X<B*,A1WT=Y.4J[CK3"'$]Y.<I5W58[4YSC/N9X <DT(%)NI>
M(B!9!Y",-H=FP(DMU+>,J5AM+C[3BDHPI2E83C.$]JE9[.W.> '99'P(\3,!
MB%$8@Y0XWF$S&9;B9;=[WBMYC(0EGN.]]7B)[G=7WE=[&>W/: =*+7:_"?1*
MA@@\22UVY:D11D*.^WE2<I5E#K3"'$=Y*E)SW58[4YSC/N9SP Q)^F-BQ5:?
MU7*5&85)^V4ZQYA3+>7_  /8N;<\'Q<I\3PN_P#=^'WNYW_NNSM]WFK?*OD/
MQ\*QY4=]YA2LI;2:F7%M*-/0FS/=,T*29EJ1'H?4U(C]@;C\BR-'D[0<H1)8
M9D(3ASJDI?:0ZDE=&Z<MXDN)41*T,RU(M=#,O9&O3A*<)[N$IPGW<=W&,83[
MOW_<^][O[_P\T 6^^X[QG'G7'M4GQ5N+6[JC3=/B*,U:IT+=/7J:%IIH.FC;
M##37 :9:;9T47!;;0AK1>IJ+AI(D:*,S-1::'J>NNICYAMM.>W#:,9Q][.$I
MQG'_ (XQS[.3YSR%-NS9;K:M"4VY)>6A6AD9;R5+-)Z&1&6I>N1&/@U75[*T
MNLP(;3B>JEQJ*PVM.I:'NK0@E%J1F74/UCT'U2$*_P I"5=GWN\G&>SY\<_#
M,N5')28\F0P2CU43+SC1*,NH1J)"DD9D74U,?M^'#E&E4F+&D&@C))OL-/&D
MCZIDDW$J,B,^J9%IJ&$I3CL2E.,9_>QC&,>[]_W,>YS\./O.N<5UYUUWJ?UK
MCBUN>I_N^K49J]3IU.KU/8'T:889;X+++33);W]4TVAMOU1F:O4((D^J,S-7
M4ZIF>H^8:;QG&<-HQG'WLX0G&<?R9QCGV<L)[J%-NS9;C:BT4AR2\M"B["DJ
M6:3+N&0\[=;7,K2XU A-.(/5#C<5A"TGZVJ5I;)23T]DC(?5(0K_ "D)5V?>
M[R<9[/GQS\,RI48E%'DR&"7H:B9><:)1EKH:B0I.NFIZ:ZZ:F/J_#B2C2<F+
M'D&C4D&^PT\:"5IJ23<2K=UT+73370M?6$]?1GH1_AB:T1W$]Q0^\84GNX[N
M<9I1W&<93V=F<9Q[F>W'NX]S/)TY.3SS^U^@<?=<><YC>EONN*<7H5+.T+>6
M9GH7L%KH0URY5;#$?89DK<=EIALK'&S)MEM#2-3R*MU/=024ZG[)Z:G[(VBF
M*U7(SS<B, "1Y#*\.,OL"H+3S3B<]J5MNML)6A:<^[A2585C/WL\Z6#DH.W.
M$"2F6\DA@\CEGO8:S.A1I>6L+[._AO,AISN=[NI[W=[.]V8[>WLQP [,:-&A
ML-QHD=B+&9QW6H\9IMAAI.<Y5E+;324MHQE6<Y[$IQCMSG/W\YX <_ !P 9^
M]G_\??\ _#@!AMZ+Z] &]3(ZRQNI38.T6[WJS<1:!7;,:V(3;L*Z]L/7M1.6
M<]6C.SK56-=DQSXH8='@7J13"B9>R+,/$1!$(:4JH@'IZ>GB&7NP!H]C FZ]
M+D38D4Z()!I,H;(S$(QHY.&]">?@2\)7F+-9;?4Y%D80O++Z4.82K*>S(!8H
MGTPZ_(Q-;@FBMT%TC6X?78*-KF >871[,.U&8'6+62;$))#2,B-+J%@%PBS)
M*GSZF1L.8\83<Y=EKT$>'B %/]3E;KJF=1V10 *JQ-]1W3\R@]D5!R:0SG8P
M6/EI!3+'GDMYCK6QE&'\)\%:FNSN*RG(!CI^R"/>#,?+EKG\EW#F9X)^/#]Y
M2/I,C6GE6]:Q/?-4?N+ :0/)E'-4. &9_P! E^Z&57Y,-G_D9CF(9Q^(7??,
M;Z9C8ODM==F%\"77U= WH>0L.FH< ' !P < ' !P < ' !P < (E==?O3=R_
MS(&_.RO\ACE#=9K.?>$#[:K1,O)\Z\>#^_YWV-9#5TYR.'6L. &<ST27[1MQ
M?TLK7Y'G<Z"\C#\GLW^&:KZC('/[EE_E#A/P-:?7F!ETYNF-,!JG=7WOG=X?
M*"<_M4\X\;;.NSG_ 'RV'TR'8#8KUI\![VX'T#$<.1<)0$B.DGWS.COE(K7]
M^;Y)NQCKK[/^^FJ^L)$9[9NM3G_>O:_5U#:XYV+''L. #@ X . &-?J9L5=&
M]5^B!I/I,A;7+R7:#ZEVV^%MDR6#F2=CXCL)BS@E+-U-#>K4)F[ PY?[&#9#
MD2(Z=7\P5R"IN& 9&BA0<$&$31B=%&"!$&64*$IS[<:$/'0([DN=.F2'5):C
MQ8D9IU^0^XI+;33:W%JPE.<\ +!3>K?IM&P0Y(AN&GP8)\2=-"Y,N5)CMO0*
MTHTV9R_XL5*H,R,_6ST1D7/3%)D)PB? '0Y<R.XQ@ N_3[Y3=@#UEJ390]I%
MMH$.*(A)C4^%X9^N!;>%<1)8RIEQ!.KV,$=AK;6I+PTM!DISW'T9R >'1OVS
M[D^4@7_NAU5P*%ZY_K_@0N1P*AP < ' !P Z3Y(=&DL0Y,^%'F2>[Y:*_*8:
MDR.\K*$^ PXXEUWO+QE"?#2KM5C*<>[CLX =W@ X . #@ X . #@ X 8@O3%
M_@8U7\I[OYJ&^:J\K7\B,=[ZF_LBT&YO(EZX>4]YCWVY3#7DYH".F8< ' !P
M < ' ">OHS_?C:S_ -0N_P"91WD[\FWKN4'O*^^Q9PUOY6/6/R;X0QK_ +AK
M1M1\Z8CD>' !P < ' "S'400N(C2.RBNOHAR?=!M9ESZ["K8DF>.2B$-QF0A
MD>%"'JT:*NN-MN)7 #F8Q:2SEUH:U/FJ8'R@'Z:#'+Z-E=D/D(FQ[U0+K3-D
M[$UTY8MC.GJYURUV%-LT\J.FS&I$?J#J G5?G6I,F2N)'"GR1Z*RN2@,A8O)
M5;8!F!X . $4^JABQ.,:)?&E0L2OQ^I'2/LE&3@$X@9+9=V%7T!<@SK%E&0J
M]B!,PZ^4Q/KMG];QEMQ(F0CK2IKH!CI^R"/>#,?+EKG\EW#F9X)^/#]Y2/I,
MC6GE6]:Q/?-4?N+ :0/)E'-4. &9_P! E^Z&57Y,-G_D9CF(9Q^(7??,;Z9C
M8ODM==F%\"77U= WH>0L.FH< ' !P < ' !P < ' !P < (E==?O3=R_S(&_
M.RO\ACE#=9K.?>$#[:K1,O)\Z\>#^_YWV-9#5TYR.'6L. &<ST27[1MQ?TLK
M7Y'G<Z"\C#\GLW^&:KZC('/[EE_E#A/P-:?7F!ETYNF-,!JG=7WOG=X?*"<_
MM4\X\;;.NSG_ 'RV'TR'8#8KUI\![VX'T#$<.1<)0$B.DGWS.COE(K7]^;Y)
MNQCKK[/^^FJ^L)$9[9NM3G_>O:_5U#:XYV+''L. #@ X . &#;K#VJHGUQ:Y
MH^O+;K!YP7>.D6J[EJ!:Z0DW0NS]N&TWJO)B5F3?J<3KZJ!(BB+)!)A893V5
MSK@+@E(A<2(D#T@&9G8=23?J!>:(L@X(1=:?9JDLJU$BD'1B;&%FAU$&X$U*
MH<UR%B9F2B)+2J+)4UAE].6EKQP Q]C/1V.K8%@;GM,+<:-.='SMB5:1K^X,
M3;&2K%OV7>:4[5+J1W:>N-2;&V+8\B?82=A+[$O!Z0+8DB;M4Y683XL O/TH
M=(S_ $KS+K#%;7L=LH=B%TB+6==38Q2!5Z"3 B'6;:4K@R7:SP82U<[!*F&\
M"JP%JT(7&=8&3\621"CF$@%^-;PD#SVXXJ)$V2G&SHKWC3Y;\Z3G,K56L)2D
M9D2%K=RRRI[+,9K*NY'C(9CM82TTA. H7L_K_@0NKP*AP < ' !P B5N.HU0
MMU+])AXK6*\3.#2.VDCC) *-FE8&(5 E3H>(1&3&<F1<1)JUS(V&'F\,2EJD
M-=QU65Y ):\ ' !P < ' !P < ' #$%Z8O\  QJOY3W?S4-\U5Y6OY$8[WU-
M_9%H-S>1+UP\I[S'OMRF&O)S0$=,PX . #@ X . $]?1G^_&UG_J%W_,H[R=
M^3;UW*#WE??8LX:W\K'K'Y-\(8U_W#6C:CYTQ'(\. #@ X . %E>HK7=FVQI
M/8>O*8;AURU68*B*",D'R$6!"(1B$(BSF;)%-O$8\5_,/,5]^&R^^TT\IQ##
M_=\)8!$WI\U1N45N6N7[86P-.3JS/SU0W2M!M>[%M5NG6=K>6P==V^.F#&-U
M>MCYE=UG$"X"LFX#L]+V+##RB"%;D^"\%-/X^,]?$)>]0%LNE&TEM2VZX&0S
M.P05'L$VCBB$L)!@S[<F \W78TR59#5<!-1G"[D3#V"AT3%<;[S2YS&5X7@*
MC'$WUF;?19YM?AD)C<G25@T."V_6MAT6G0+I=SV].H]_2Q&KC7]?7&PTP-]K
MRN0VK&.,5(W:(QXM9 L,J[&3 (07P>G_ -?()0=2FUZO(L.J]9MB]E)L;/4E
MH'ODG],;AC:^5X=X EU>%MJ316M52.V)G#3?@7-SQ2G:$:[YI*H& "#/V01[
MP9CY<M<_DNX<S/!/QX?O*1])D:T\JWK6)[YJC]Q8#2!Y,HYJAP S/^@2_=#*
MK\F&S_R,QS$,X_$+OOF-],QL7R6NNS"^!+KZN@;T/(6'341WZANJ_I\Z4A-<
M.=0.QX.N15N(S1-=ES@MG,I)D!\9N9,C-MU@(;?84Q&>;=4N4TPTK"L)0M2\
M93BX0*N?:*<1 CG(4TE*G");2-U*C,B/5U:"/4R,NH9F,1RW.\3P5B')RNX;
MJ&)[SC$1QR--DD\ZRA+CB"*%&DJ3NH4E6JR2D]=",SZ@BM[<5Z-G_2@ ?07;
M'ZA<N?X)9#^;5_[\3_G&#],)L=]NL7P7?>:@]N*]&S_I0 /H+MC]0N/P2R'\
MVK_WXG_.'3";'?;K%\%WWFH23Z=NLSIGZL7[9&Z>]IC]D/T9D*_:VX(&W!<B
M&K$LHV&6[FSU\(F1YY84FE&(69*FO*JR_AK#C.7+=85%C5DT<^,J.3YK)K5Q
MI>^;>[O_ .$XO33?3_>TUUZFNAZ9CB.T3#,[5/1B=XU<*K$QE3B;BSXW-TRS
M?*.9G-B1B7Q3C/$7#-9IW#WMW5.LGN6T9J' !P < ' !P B5UU^]-W+_ #(&
M_.RO\ACE#=9K.?>$#[:K1,O)\Z\>#^_YWV-9#5TYR.'6L. &<ST27[1MQ?TL
MK7Y'G<Z"\C#\GLW^&:KZC('/[EE_E#A/P-:?7F!ETYNF-,!JG=7WOG=X?*"<
M_M4\X\;;.NSG_?+8?3(=@-BO6GP'O;@?0,1PY%PE 2(Z2??,Z.^4BM?WYODF
M[&.NOL_[Z:KZPD1GMFZU.?\ >O:_5U#:XYV+''L. #@ X . &(3K#,6BE=9>
MC"U&V"[7BM_*]/E$.TI^GH?%703G;]CPMI=])782) E8U:*W6:.$LUD@4-9%
M+A179LAZ''A@&2O=^QG-/:7V]MMH'*L[NK=7W_8S=:@N):FV%RD50M9D X;J
M_N&Y190S$".XO[E#LA"E>YC/ #'$5ZW.H[U4J-5=?4VPW^L^K*O;-?S*G.&V
M8[>;M:MJU6O+JL</NBU5B+%H;5 'V:SUR%>+VU>X!"4'%W_7Q-MUZ  24Z-^
MKUCJ?%V.(; 8I6P*L,I!<[3$QB#[ \?::J,F8GP;,XIX):19.P-'2%<)@9#D
M9^F3:I,E]PE-FLL $A]=3&9Y_<<EA$IMO.S8;6$S8,X;([\;5.KXSF<Q",>+
M*2TIQE:H[RF<,RX^6I<5QZ*^R\X%"]G]?\"%TN!4. #@ X . $:]I^^"Z6?Y
MRW'_ +MG^ $E. #@ X . #@ X . #@!B"],7^!C5?RGN_FH;YJKRM?R(QWOJ
M;^R+0;F\B7KAY3WF/?;E,->3F@(Z9AP < ' !P < )Z^C/\ ?C:S_P!0N_YE
M'>3OR;>NY0>\K[[%G#6_E8]8_)OA#&O^X:T;4?.F(Y'AP < ' !P \PR&%6$
M02 G1T(P&,09(TH*(QVI< C F,K8E0ID5Y*FI$:0RM;3S+B5(<;4I*L9QG/
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M2TF((A4.*33*DXFM/X?=[P!50BIU:OSBA,#6J^$)&VA#!H@(##ALXNP @8%
M62DN'&9?(-!!B4CA#<MQU V G$.'AF/C#? "EZ-^V?<GRD"_]T.JN!0O7/\
M7_ A<C@5#@ X . #@!&O:?O@NEG^<MQ_[MG^ $E. #@ X . #@ X . #@!B"
M],7^!C5?RGN_FH;YJKRM?R(QWOJ;^R+0;F\B7KAY3WF/?;E,->3F@(Z9AP <
M ' !P < )Z^C/]^-K/\ U"[_ )E'>3OR;>NY0>\K[[%G#6_E8]8_)OA#&O\
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MC6(KDT@M+D>(IB.^]YK*93[3DI#,5#R8K(4+V?U_P(74X%1\S][/\F?_ "X
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MO(\-W+#BBN5M9=;^X<\/*>^C[E7:GW..A57^;8'S./\ \8?A3DWMCO>KZ_\
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M9_05W\X#7-6<W_*NZ]])_<-#J=L4ZU>%?!)_6Y(G=S%1*0< ' !P Q!>F+_
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MW/=SVX_>X =O@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@!25]I878]
M)ME L:RS=?NE>+5@XH";*ULSZI-PGAY!(T^#EP3 B6Y%D.H:(#)D6;&4KQ&'
MVW,85@ \?66MZWJ"H#*-6)U@>KXOPH@:/9[&2L4@;#9C,Q8087)+/O.Q!,&+
M%;:'"8N6XD-I*DQF4)SG' "XF<XQ[N<XQCW,=N?<^_GLQ\^?<Q_V\ /O !P
MI*V4BM7;-9]D<)<W-1M@B\ ,(F2XF8EC XDI&SEXB/,^:;CXFO\ ?B2?%B/>
M)CQF5]U'8 49KG1NOM5F[#8JM&.++V6&/#OR[#:;#:%"JZ((FBXFIUO!\B0Q
M7ZN,(V$S+@@Q6(\)E<S*<-Y:CQ4, %X. 'SMQV]G;CM[.WL_?[/A[/@X ?>
M$<KWTI:/V5:C-LNM8FF7[+%E,V, Y9;%&IMA(3*05UJJQ&*?$)L5^?:V:"9G
M5.)9'H.2\81Y)EF4EP8,=B %>ZJU+2=-A"-<IB##F3!E^SV$M9[*<N%LL)J7
M#@B$EK!9;*0)G2S\<.%$@1RYLQQN"%"C1,-+4,>PRV 7.[Z._AKOI\3*<KPW
MWL=_*,9PG*\([>]W<*SA.5=G9C.<8[>W.. 'ZX <+4B.^IU++[+RF'%,O):=
M0XIEU.,94T[A"LY;<3A2<J0OL5C&<=N/=QP IBZTBM[!"L5^U0G" J/8*I:&
MH[<N7"4DU2;.(N%<E9?A/,/*1"/@QLQR.IS,>6AA466V]%>>:6 4?6-'T&I7
MTML@9'.R;.39L,:(LU:+ =%UB';RX^P6Z#3 I4A*&5.%:3@D45.Q0D:(Q.F#
M(*E(2W&;;P 7=X .W&?O9[>SW,_R_!P \DK$"G1ID"8:@$A<X=*&GA<S++\9
M\63B.QY<0C'7G./*3(3KS;J'DX0ZPM>,]J,YX 1#E]&?3%)#LH)>R.6W,>E1
M9EDG;@O+ARRUYX$(J\W7YZT.6G!*Q:]? UX*+F4@A-E 7FQ49Z1"7,P[)< )
ME17(KK#2H3D=R+W$I85%4VMCPTIQA&&LM9RWW,)[,)PC[G">S&/<[. '8X .
M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@!9JS0-MD
M=OT%\,S7X&HZT-*E[)/Q<S$>SVBS%8T\!%KDFF,510==; #YF+4P9EV^2^0/
M-11R:Z-Q :./ $%+'I7TF$'8 X[KKJ(UK%J+FS35G.!+>V8L[R]>V>^V6R$-
M;#8Q&NK'0FPP2+4@U;M:$.&0HTR9!BF(<"O,.6< J4#1O2;/IJQBT[<U-#GQ
MR+J+%3JW)KRJW(&PK*1)0I4JQ%NGJ78"3INIO1*J7'!F*AD69CQ+0,+/1FB(
M$J 57J.F=>0>Q4F9NN^U&\@@12KYL$>NV,(+>.PI53+ ;%,D!PFE]?-*GB+1
M856>4F19IM=.@ZL#A@Z57;*A\F1 +<7?1_6I+NMFNE,M?L4$M7G=YX14X_4?
MMR[-DZ\?J#06AO0P]D!@:T*+$"<:0<BZ^DH>U[JHJ4AL56414'EV$Z >WM#1
M_51DT6L>O;]:9XOS&W3U/C3-W;'$F:Q(M-)#Q*""(4:+#9JE]'P;8T\G,*W&
MD-4,;#<,!I)HR:*IR#T_^_9%0;FTMU/W3;1ZP40RNK4IRQ4-T;Y/JBW37\%Q
MXFF7. 1/SJ$(JKE:JKM>N)FK$44&L$,5O:0^O3GMEE"3Q 6,KX!T^F#1'5EK
MO8-3/;?V0FP5"!K<[7SU?=W=MK9ZW;A-.1YR3;2;N.&P2N2"F'B<8@1BM3Z?
M!(.4D#WJ_#CY6%"U]GJC(QP*AP < ' !P < ' !P < ' !P < (G]6 NSR(.
MBK)6J=9KNWK[J(HEWL@BH0HQ(\S61X2WC)Y&&.DS8/GL1))>#XS$=Y4CPG%N
MH:6EM?8%#]C]?\#&-WJ?C]<^U.H"A3M>TSJ K^BQ>[=.V"UUV.^"A,E=;!(E
M N;YMI]BV@9(-Z!;HY409UZS5[3:7Y84^2+["9 F*W1V@KXO7]/XBLM>T[TB
M)] ^%L;9^U8[D@Y/=O\ # :_J&NH8NPP-4[Q>>32KS+V[LTG:*(4V6O4R!?J
M:F:Z$(BC02V8G<-WP+  .8OL3K)UQJDGL*\*VDG?%?-4>=&IIB;JX3HS;"+"
M]6*T!U)4L-/.'4;'+1K$9G/QP41"7KK72S1:2X.53TO@%VNH#7/4F OVD;)1
M2NUKU,K?3\5U_L>UTP@#@R2TO&V>GLK?RT2ODY$8%%V#;M:!=H/T>:D>M,4U
M':'PY8Z=D6IT*>Q\GIZW\/D%.[:I_5I8=!=/%B@Q]GR=OT?:&Z3C$864K\6X
MPJT:U9U$5G0T[9<&+-C5<T6%/G-2LW5A7K&)'-OSITZ/)2S/DH"HI:TA/2 T
M_8]X<!6O:]RI]?H4F90:D+JM-FKOT!S1KZR0TSN@_LJ**HVRU[X>*RQ,C[0=
M\E0!\6H#!;$JG3C# 0*=7]G5_;_\>ABS6J]=^D *;6FG[T0WR-AG;%KJC"K6
MRL#641M)"]WPK1>4D*\2O.QYM?)$*79RD 8<(ER5]4%@2TMR@1H="'P0J/2M
M=1])Z&D:KA@]C[?Q5BU,N"]N'WJ=1]J6X3>QMIV@+U6D%5Q&Q-)># >K&:'*
MLSD*U)%$B$2ND;:/GQ)U\E.@%=R]7];L[=W1W;KO8-PVVG M\[SL6\!XV?4J
MZ %@QY2?4-"DFJ> ,2EQ*_*"V<B6+A8E@M7=$*D.G9Q60#$OM@%U-@5G>5FZ
M@]MB*59;=79DG:0^<:GTHB#%6)&A(_1L;3J6'B>8AOS8]:5U6,6]]E ?'^,6
M9)6*2=6%EF(SH4[/IU/3464$Z]](<_U!ZW$&;/MG[4!"GZI<V+>\2]8LV2,<
M,TP$1W "AFXHQ!H((=O(^3_[+KT6./#.R7TU?R42.,S"?L_^_P#X%1<;J(F]
M>[723I$7K45LQ_J(>U$<?NEFK7L.(3X.W0M.&(K(VU5E!JEC"+UJ/NDLJ.8N
M0O7]=E0Y4RR5>X(E!0B ",-8Z<^L?3QS9%GUI!V?5"VUK2Y8;V;98B;#RY7Y
M'5MU&V6YRX%3B[%HDJ3=#>O;?IPA#DP+6'LKU(;L44,4]>!XH;(!/K1%;ZRX
M6J^H,G?+M:;/N-56&!M#O7P!3J+7WR+&B:/)BG"%"KEIV&&!E)>W7[(S9<%+
MI:D(E1IC<>2D,IEC@.KU=/B_6(\30O7^:&W8G52^_@(2OT'<]AT^&M<W5S=^
M-;%&5CII=UX&V#W&Y, I!F[!9Z@DA!,V;'"D*]*<9+.-!<51$< I8G&])#*K
ML02'L.WP@V(??:L>QY&O*_:+Q8CLJD610F0(T:_N*GKIP4);/4K=ADBNH&Y:
MQL1?V/21=9KM/]G$%(4ZNO<]/C]/EDS3*AU%4'IFMP%.-I$=BHZGCQ^ZSH<@
M1BZV+4MGWHS9[<1U.W/.V$:+;FZQ+24B0L,VZ0"O-F ];GY/Q!4UP*BUV@NG
MK<".GCK9<WK3=EGMB[]OCQ3,:-8:$QM2VZZAZGUI7:M"BD2'G:&FSBAP\J'(
M5D^C-*)60>7"RHN:V56]) +).]/FS$F==SYFAX;VNZY<MG28<M?2O1#! JNQ
M:SU,'38K-TXHOZ:/3"TZQ5NP#T6>F-5R(7\D\4D4^"X7R8,@]/3Y1D5Z46I3
M%ZZ@F @AP#K6-.T[#"ATUV)41P[8L35 9G9\,55X#T@?76H;::9#+@QTA^&)
;M,:P#U.N$(Y!:@H7L^G5$V.!4. #@ X ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g111598g83r49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g83r49.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2324&AO=&]S:&]P(#,N,  X0DE-! 0
M     %4< 5H  QLE1QP"   "   < E  "')R,38S-C8U' (% #1-:6-R;W-O
M9G0@5V]R9" M(#$P+4L@+2 R,#$U($9E8B Q.2!D<F%F="!F;W(@04,N9&]C
M #A"24T$)0      $.H<B5UCDQ/6<^^9ZB4=D*\X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 5_\*          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              &1   "#P
M   !                          $              @\   &1
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   &1     %)G
M:'1L;VYG   "#P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !D0    !29VAT;&]N9P   @\    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M?T7MJ_[<>J]'4'5!XMJ;D/LL=8][X)._T_4;[FO^EZ?TO^$329UK'\4^WAL
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MM8.39E8S;K:78[W%P-3YW""6B=S6?2^DDI__T_54DEFY?7\''>:P77O;H16
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M%C,^@[_D[Z0^AQ\_Y:TO^UP_F_YH_P#&_2'_ (#_ -_24__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ #J5J   G$  .I6H
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,CHR," Q
M,#HP-3HP-@!R<C$V,S8V-0       Z !  ,    !__\  * "  0    !   "
M#Z #  0    !   !D0         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  D   "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(P(#$P.C U.C V ')R
M,38S-C8U       #H $  P    '__P  H ( !     $   (/H , !     $
M  &1          8! P #     0 &   !&@ %     0   38!&P %     0
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MM'>*MDGUR:MU44"9%4>V)MNH_L'K.+?2M:2MG_,$JAY5D8D9UJS4VPJ-% <
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MSW1\3'?C[C\*/AQ9D89@.:9)V^F,<8OD^-U9?,(H)RECL\**^QZ#IU(Q"/2
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MMKR6K>7,V9=E>R0@YRP'1:'E:5M&?5'8DO<@QX=-=5,3%9+E!Q\%&<]Q+G-
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M.W&AIO>P"Y>&<I0(;VALYR.<F@!E"'<DRJJREI FW2!NF1 8<;!E42:JWA>
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MB=^7F[^OK7K&[;=W\PBM\*D)[=I HY!\%YM?08;C'.64L2T0R+']G'9[@,+
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M1 ?<.*7INF;8H-)42M;OJV+M;7*%'-:5LI2M>D]K68F+AX;_  H:YVZ1UBY
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MZD]>>TRQS7YJXJ<U^;]K^0?^U36.U?\ ^*3+/^Y^(/3P68RLBI?_ ,*N9O\
M?'#_ .?RXKSY;_\ 5;DG_(.8?]7BGXOY=3[FO^BV9_\ =^L_\A+6O^3_ .EN
M6/\ >.B?^HQ5K9V_XF<9LV&$<>CWZ(PL4EIM^&>.O$Z*A,.9'%&Z+RMGBJU8
MO56M1[E=%%STU%ZNNF==-Q=K+L[R9BYZ]C[,RU@R1%E2:O,DQ)))\!Q46=%F
M-;CV!'#DAT8VN0!<"S;+:#:5G5F0O9#Q,S8V!Q<:-2(,:9%;8X_"S(4J)(X>
MY XC #S(8"YH<6[A< XE<J/[A=SVW6-C(KF# +R3Q6'BV8=.71B]2VU*/B6U
MC9J\>OA5A\*K2UDBAS5_9'G-;N;G?#FZ_GEI^T?:GLXIT:E9QV<OGTFB0X<,
M5JDO)8*?$:,/?DX\;I.*=V,UI!D"FWL3C^.=>&I[-MD^TRJ2JODG:-A4JK5N
M9)FNHU7 <75&672L?"C1Y1IM1%Y#RWWOTDT%UL"[&A7[PWE:#YE@K"9P.^^P
M0JJLQ<#5VZ;1\%*(536=C2+5O>LDBYMZA!>M$E'#=P@X1<V7=U2E-;$9*S90
M<Y4&/6:"08KG.CR(I:UF-"E-(./%QV@Z/:7 DC1S7!P)OIKCG;*-=R17I%"S
M UO%M8R3@R<'$XB/,B8@(P)<?$-BYCMUS;D-<TM>T@6-YGUEZQ):LT/_ ,5-
MU_\ *6W_ *L:E#_^%G_YQ_\ ]*UW'_Q$'_=T_P#(,4]=H-_<B9>X_8PG_P"X
ML2U8=GW],*3_ /Y?_(3%F6VO_1EF?_\ *.7^W*6J<8B[1W%N-L/XXAI;'^3'
MA"'PB-QUV09CP=@AZ\%"4F*JK%RY/IJ=$LHE6QO<JWLNNLKSX'Q::R^L;-ZK
M4:M49^'4*4&RI<N4&@RQ8%Y<[_5.N_EL+7ZE&F6=NN7J#EB@4N51LQ8V-3:/
M!AOD##A<.YT2&P:O,R_)O9H?1>2-G<4GN2,]Y7W>R6(K8\B^1HVB#A@)Q7Y4
M7'+TC?3G/1%NJLRJ.BS%S4DNV;MBCLQ5P*Y:H=[5LSC+I]/R_2,H1I(J4NF2
MC*F3Q\%KKS!PMB2Z[3*ON7O@;A:Z]U?-EM.K%>SEF7:;4*2:'3Z]#$*DPR?&
MEQG\#NS2!J[>C4R*_B3XLDR2Z.-T$#D=F=^M[E/_ )PN/^>;UR;3OA97_P!C
MM^AB^-@/P<]_[Q-^F8H[R1.H'G+?8!"3:8Q,%B?;@T>.5:2H^'###\\07;*/
MFC>\L[:HO%T#M K9RA\;NMXN7MI3Y5KMTZ#-H&1,?%@09DJL9G#67BPW23&I
M?6[>8"6DQB3< @<6/Q@5::Y6*+F_;%#B5FJTJ+EG(;'8CF569!BQY=?OJUK9
M;@'.$KA@UH()%+E : WY.SN8QG#VY[+>W,%*0,BQQ.""TUQ23 &A1@.F0L94
M)+A$'@MTZ0ZZD?\ %%N:.%^IYB2%U+?EE*TX\XQ)-8RQ1\QX\65@5"GC@*PR
M3$=&/C&PD^,&W'$W)T%N+%^0OR[+ZM RMM$S1D.%/B3Z%67&M9;EPYD25&\.
MYO$8D-ICDZB$X1KW(O2AUXX6;;I?[NS9W_\ K7?]9*ZX,J_T%SCW_P!5*N&T
M3_3)LO\ ,?\ GEM.U%JV)31$T18A,87$<C121P2?1<!-H3+PI*-RR(2L.PD,
M9DH PV69%@1X$3:NAQ8,2:++,7X]\@X;.6UUS=PA=2MW"W?OY@B@'&VQS9CA
MXA4KB7:=MQQH3N)A3%Q""88QY%'UQ>/*NE0!.YT#CK!:K\$J\=KB'/B]2-N<
MKU:U0N7KHBBR,;6=CT'W(&<KCH7BA]F2PK XI&1U(;!RCK!Y],!,C[5K +1,
M:\[QD8R$(+')'([W!5M205L:/$Z6U<TH0)^S3OWT4Y"]H^U@)\*E ^V_!8JF
M=$7;?-708KA+7X6T""SER\;Y)HB$LK-472KUZHNA([7_ (ZKA>^ZG*RU:$7L
MB^&]KD*D^,X?"<881BTOP=%)$^Q''(U$(8).XEA<[<7AY2Y@8T8/0?06.3)T
MW5&%W - <RD"K1R@YZJK5Q2TBX^1MI6W+*4G/9 E>&L:N<KGHD[A/PPWP.).
M,K"P2[%Z/;)")P1"OC;3RU$F]O&V5<W(,UE^[:AQ7NU(N=MTVQ82VJ0!CCK"
M6/8E!Q:;,&G(R<>BT9CAJ?' P5B!K-)XZC @,C))D6:CK%2YQVRM5?O%+KJ6
MVV5[M"+KICL_VIY"3/MY]MIP1-&\JG+?)TH1E&)X0>LD&1VHM$&UGAM,F >)
ME)FU#-VXQO)7ERYBP>@@Q3=50I;2I%/*H,*Y"+QM<0.7CRXVX*N#58-[Q"P>
MYKT5PM0;=95FH/594Z7I? Z:YK\FX[ON(NB?8[@A**"((^A42>0F/J1!<'$W
M8 8YC85> F!$@@ZXL'>V4&CU8<:CH Q%EFZ-E010.*(#>E<#FUU"+&0V!\)Q
MW*<AS@!Q#C4+FB7BDPDMRR*@\<89&D@5&C2B H[-&@M*1EQZ-6 _N,GA-=!/
MI&U:\],A71%$$,V1;;(?DC,.75\80Z8Y+S;()<1ET[F<-AAN7)QN=!00*18R
M'2&D>:F:8S?,PEM[J*%GQ%)VJ_+6NKW5CKNT(NSBFQ[9G!@CN+PK:EMUB4<?
M&H=(WT?CN&<>A0KJ0X\/$I/ #3D<.CK=DN6A4B.FCD5?W)7.@1DJ4(#7#=\\
M<.+B+)7VU+; 5D&,I44V[X3(2?"R*".()$]Q?"G)O%C=!Y<0;)8]++!E'T20
M;$.7B=H)5A;8\K5U;Q==6ZI%W1W;O@231]Q$Y'A3%9Z,.H[-8>YCQ: 14@$<
MQ3),C&2S(T;6&.Q*K!0#.)0""R*8B5$*CY*>$C"9E!RZ9MG%I!IR7&A.VG;K
MC7(4BRSCK!&(H-E&7L;1<KR/$,=1*.S>2#[*M;K!IN5"A+(R79TJP976-R#U
M=O6YJTNK3[ C31%S#^WC DLRK&LYR7"N+)#FB%M/+XCEDU 8L4R/&&-*.D[6
M0":/!2LC#-[.O?6V(CB;=&VCAS2E:477Y(N8VP/A1DG&D6F(\:-4(:+B$?B:
M2$*CJ%L8!X^,V2.!B0%B8ZGE0N'2--$W&![&K=L#*\$QU&SKXVB+&26UC;(9
MFTZR65V^86)9#R9%2D%R1.7^,X<\EL[A!T98%,Q*9R%P&5*2.-F EM@PF#,O
M' ]X*ON:.F]S?FE2+UR?:CMAFSN*$9CMVPE*G\!E<CGD&>2'%\++NH?-I=*%
M9M*I?'%B05=4%))+,UG$J,FQW@/RL@ON.$7+@C6KBA%W83;M@&-Y2.YOCV$\
M5 \R2>M:R3*XB Q4?D4_<JS2'W>=3-H)1/DZJL$TF=]79->MS>O@7<H6TX(O
M9.MO.!<I%9 <R3A;%<_+RZ ?!1*2TT@47DI*38RM/72:S'AMX7$O5RL(]HZ5
MD-D:>++AK"U:D[6%KNO44(NDD.VW%KS;Y(]LL(CXS#>*SD+-00<"Q7&H: %Q
M,*;1<6O$XY$G\;,P.C:Y1VO>[$EXJ5C1>CATU.A28YVZ;."*NF'.S%V@8LPB
MXP!),30#.,*?Y(?9=*-LO8DPLZ$.<AO  >*(R$5CJ"XT@N((:H-BD<#Q]BUQ
M_CR*-$FC2KRYK<4)DR3\BN.!Q3C*,R\OD".8]A<?G4@C,<AAV8AXP$&R<Q$H
MA<]]DXP5D#-DB5(1Z-5)/:1\,N\O'"NJ<4&MV]KAQ31%PIUA?$&36DR&9&Q;
MCR>,,DQ8'!,@L9C#@$B9SJ$1<H?-1V(2] L.>HR"-@#,IDA<,&*6N1PTI("[
MIJV;N"CNYR10T/V%;'QF.SF(QNS_ &SL,5RF0#I5)<;-,'8X0@IZ3AD+VXF1
M&8HC&K A$R-;7*MQY5TT7=-;+ZV-U^+Z\D4Q3'"6',CXW^!J?8IQY-<1^7AQ
M5,8RR'1\]C_RJ/\ 3U!CK8B3'.@-S(+TK'RYO:QHW:4;-K6U;>GIP1>1&%,.
M@&F,1H/%>/@X_"E'=,.LQ<.C[!IBNA "0B3VF.T6@Y.R&7.HV4)1QU6.4'^(
M$).QMW(]TNA4BC$;LGV>"9/+IJ,VK;>1\SGK@TZG$J8X:Q^TD4O7D+RC\\M)
M328%,@=5-O>7910FLXH2>4ZAS2^M*5H1>YYLRVBD'>17Q#;!M_>OLP)R%+*[
MMWB* +KY(ME1:.2"3)3MRI'U%98C(C<2BA@O0]5]0D2CH-\_\=Z,'W-R+HZ[
M#=D=8Z,A]=H&VGV3"$G1@1&KL(8X\A'&"",(;O23$56.U9-WSUMC3'C=ZY11
MZE:V PZQ3O6QH-TQ%F$\VG;7\J)LT,F[=,(Y!0'3-YD5@C-,70J2HLY^_;,6
M#Z<-+3(9VFVE;M@(%M79]*GG"C1@S;7N:T:6<$5B+;:64I;;2VVRVWBE*>E*
M4I_HI2E/W_P<>I%^M$31$T18&(!QG'3 \^M<)#V+\J\-DG;U5-)-"YVKRFV3
M4IQ2C=O^L-F_K\]MOOI2XB@$M-MOK:7J3QIC\.:G3>VM&\R3B81(RI?8ETR?
MZO/4DBZ7*?V&EU?7IKN_[N:4[O2E3X;H_I&6(%B>"XQW#=MS'W[<]/@VM?0Z
M!6@Y?H9J7370M*-7M;I8PH725N5N*W>*MV'4#0:#5=!'Q\BS=.D)(8:]+&Q:
MR'B6VU4Z5-HU6\=,(S54I2CURX7_ -TW7S\4K\DI1JUUTE=^_>]U/.9162R^
M.Y(-Q(:&1V>.&=+ 9,HC>HG96BEBCE)LKPK:Q?.F_CMVS]PW=)M5;>_1K2_N
MN$,3SG$S--RU58V4)T:G5_'BEL*5*#G,:XWN0X7;'QR/@X[L"0UA+;LN YF5
M9(E96A9GI4G.4&54<OX$D&=%AN:'. ^ 7@V,B.UVZ<>.W&CNQ6C3$M=KZ3M-
MU.ZJ+,+HQ.]J<JD\O;V=';(8VD4K'R"_'A)OET@H.0B%.:\N%[6!ILUKWKJ4
M\LMI3B#(^UG:U2<$TO,.R.KU&L1P6.J5*XMU*DG\H<:?"J4<W WR(LIS>5^%
M=H)ZQMD.R"LXXJV7]L5(I%&D%V(*95G0VU.,W4F.PU"?3)@.NXTR*;C/'.\H
M7)DC95AJ<XT"9$F>1V+4'*LLRBR1K19G5&B0!DW5+.D45+&Z[I)JLL]/DNZ.
M15<6-&23*BEUCGJ&[?)]B.2JWE>)F:LYCC1J95,W5<5!U)BZB$S#,M['6#G;
MA<Z?C6CC>$>/AX(%B+-Q3;IGBA9IF98H669,FI4O)U(=2A6)7PZE(+849SPX
MVWVC ID8NDEN&9$G$D$-\#N%W0]H-!IG/(1C<?#8N:D[P=D1,B\;A!BY19J/
MH")I7.G*;9-2Y%&U96Q&MUU*4I2ZVM:\?%U;?9%9?KF8*'E?"H-,F5/'B9D;
M,EX<.)Q+F11!F-+B "0+D"X -S8'76Z^QNS#0\O9AS/)KU8AT? D9;=%C.FR
MVQF29+I\1P8"XMN0 YPY@#4V"O%*#2T:CATZW%$#BX800(M@HA"]V4*+LFRJ
MS<>Q;I67JJKO%$Z-V]MGO4K[Z4M])XJDQ].IM0GX<634,6)%DRV0X@WY4IV&
MPN;'CMU)?C.%FVOND7UY+7^EP\.HU.!3\29%I^%,F18KYLQ^Y%B-D/:QTJ2[
M\7 C@E[_ "-/6M;&WW9Z#R:"E>4=S40+N9Y.IB;,IBWY.2QY<..N<J^-:HP'
MD&"Z521)5TJU;KT^*)2$U0[M/2NLVSS8U"S53ZKFG:C2ITFOUVKS9;8DB;5J
M6^'%+SO!T>++BN:9,ETES0;#A!$(',G:7:3MMGY2J-(RGLHKD3 RWER@P8+I
MD:)2JFV;++ XD29462UPCQFQ6N=@6O+XL$=0YNX?9! @&-W\GP)%"HG(\6)C
M#PQ,<;DA<@5;-'?RYHQ;$2S^ZA!O8I:89U;(7.[W(RUI96O4][5=I&P:@4W+
M6-5]GE*F0\T4J7!J$019]6FRI;8K_P"'C16RY<JTEHM+P? M\.'Q;#>WEP[-
M=O\ F*I9IP*1M%K4.7EBKQ)L"4Z5 I4.+%?*P[1Y$IT:'':8SB#"D>'?X!N#
M+..X?P=C;M$O*<A;;C!$Q&3 6:2+%LA8E(L^'.&)1*3>0D1CIHW&JV=11!\4
M2JL+I7^R&CEM?7U4K;J9L*95<Q[,Y&/-I4NGUVI94GQI5(EQ71I3*JZGR8KV
M",0"&R)8+HS>1P'8=CSM"Q@TG+.U&%%A5:%/H5,S;2I42K1I;)$,TKCXLO Q
M'26'=)CQ"&RS?Q<=F.#:RCK8K%I)"\ "0,M"%8X91D<H75&&&3A@_2;KD/%0
M6N;.4DE?!6I;=Q6M*=[B[XU/7C&-@5(JM$V=18%9@2:;-;5:R]T67%,20UCI
MCBUQPSU.L2TV\@T:LG]D!6:57MH\^H4:?%J<!],I#&RX<ILJ.YS(EG@/;=N\
MTG=<V_BFX(!"P?=7A[)U^1,?;C<(LVYB>8\;7#"T;OK950T#LO)K6> G>JUJ
M\MZ8P88DA]%^L<LWEEPNVUXA;2^R[6<FYK]L>7MI60\)DVO9>88<NDN(!FP@
M)I#F:W<',ERHDJ.S^'QHTGWM:0T W[8_G;*GM9S-LOS]CNA9;S,\2X=6%RVG
M5,\'?>=N8XP'>$A0)4:06^ P9$7WU? ?=L537/>Z;-D6*XLB&V6600E+F"X(
MY)Y%>61&-!Q!'IBO0+FP,>8C+E6BKE*KE9\2<VMJUN:-:N_ YQ*N[0-K.=J7
M*RE2-EU9R]*J<=T.;6)G%"*V));N2G17U&#3(\>S7/:"Z3+<6M=X%I.ZY9?0
MMG>R+(M6C9NK&U2D9BC4:2R=!I%*,-\G$F1"7Q!)%.GU.5):)+<-Q#(L5N]8
MX[C'+U/_ ,"^8,4;98WC;!,D$MLA1Y9L7)$WJ"5Z9YVX?N#I]@(7?)*,&=7A
M):C-HN895:N1"'ECJC'J;G;:0QDG..4-EU-RUD"I0\',M,#9DN3+:PMJ<ITA
MTRJ8,1\@</@<5+>6Q^(P-UT4<-CF.Y[I+8X]O63,X;5JCFC:#3)F-EFJ;\.+
M%BD[U.C-BMIU,DRV1W-D8W"Q6B3)$3'WVRW&3'$C=$5\1W[K=T+44O%CFT:4
M/YS>VO85,#T3RL14>*)]RU\JV0"$V2C:MWJNV0F'3UYK2KQOK#W;6]JV%%-*
MF;':MCUPDQ.+C&=T3J .*=:%*C%O:WILL)L3)T6:#8]LEQ)@J\#;32,"@-<)
M8AR3!Z>& ' ^ %YT61OVL0XT4/(.D9QM::ME6$9-A3$SD9,K;&LFE4D=2LD,
M17371#).!XX6R'**-JJ-+W%J(WJ7%S;Y-2YU:WI2^C3G6;[$,C53(N3L:)6B
M!5JK4WU:5'8Z[8F]$AQ<"*38MWFB(#C'"T)<6BPN%@>W;/E(S[G+!F4(.=2:
M/264B++>UP=4',F3)4B4W?\ X<1RZ61@#'.^ TXQ +["Z&IH4++6TG )K3M'
MELAUBIRD'KC&@ZDNJ*=>15(^SE&]6WF?@]'5QX]+6_2^/]M3W:D0U&!^#@0!
M*A\<*KO\+O7E;G%7WK7ONV)^BXY*#!1:Q^'9U:Z-E]#^UT1.D^$/"\2(8\3B
MNVQ+;<[^+SM>9=\$<D$OVPY+C45#%9%("=(C1B("M%'Q-W5I.(V^==.V;V*K
MKVHM&SA9>VEM>ZWMNISQ;SJR9)F1:?F>G2YF.V+'PQ,&)B/(:T$P);1J3S<X
M@7Y&X',A97M;I\ZJ;/<P0:7$E5"?(; $:)#9X:3B.;5H+B6-Z]UH<Z_4&N=U
M:^_'N' TXVDX]Q)DN.K-K7^*XJ%.C"+.]L8#E&H1G6Q:RCA&U9D7#/[$G+>M
M4N\T<MN.*TI=2OQ4*WB0LVU"KTJ00UE7E2XCP?%Q&<6YVHO9S,<&_9XVG4N2
MBY6BU?9M0LM9@@.:)&6Z=$FQ9+0),60(.&#<6O@RHF..O5KV $6!!@79TEFO
M"LJE&VK),8DQR#AGA!SC#)[8,_6C5P^^EQ"\.N5305:L6;]!6I%DW<K5J-->
M<!NL<T<"N+]G)U#K<2-F6FRH<:?+N:K2-\&2QP>&%^Y>SBTD,.EY&!:1H2X'
M#-E@S9E*H5+9_F"G5251X4B4[+N8VQ)+J:_ MQ(C8DJSFX(QV.+\-KB.'EB3
M$ONF*#@>V<9E;">+=V,C4QO,ZRUW-WY3'X%2.%+W4A>NJOV@=ZT8T;47>!DW
MCELX).F].Y095>^OI;3O7+-&-2J[4\I115H9CMA##FRW2@YL7><W?#B;V<&@
M[H/(D:&UE9-GD7,F4J#M,J#J#5#49%5?*HL$PY6_,)XEL3<PW N=@#$<QT@L
M^#@-OH5S=M_9_P"-3N+0TIW!Q(R:RC+GQ&2&K2,CDP1^)1*.K[F U^V$EQ_+
MZJ2=Q4E1ZVJ\J2)NVSJM>FXIQ9CV@5+ JLB+EZ<S HT7WM!W(D.S\,6LX?P;
M^9\4 'D ;Z+GR)L3H$O+F!4,\4J7*S!5,>94)@E3)T65#XLFT=XB2\ #'=;B
M9#C;'$F3B!VK;+HMR.RX5B(5",N;4X4;;3['\X!%GP0>3DLH=FQM5[%$%4F)
M1\5<*)CR:3&UVV8TMM="79.KBMU$:5USY;SKBUC'J%(S5.P#3ZK$<SBSAQ(H
M:]HO\)N$QHWVZW)U(:&:GQ>IG[9-&RS%HV9]FU*F1ZY0JM$DO@QI4^IF5$WS
M9IBS)4@.X?'W+M;J(KY).EDW7*98)YGVRYT@N%IW*_9B)M)&1C204JDX&E%R
M"#U2.&%&XYZN+((46N;.;;VMOQK*T[M;*4NNIE,TK"H^9J'/K$&+QDKA&RC*
M;NE@:!Q487 Q&$-/C7/BD#K7QM)]LN/FW9[F^C92K%4%-I0G2HC8DJ\?'?)8
M_HV21$<8TH;SP=ZWP'7  "SJF]3=16M*?4/SRG-:4YJ[E'IS\_\ :1\VN Y*
MRO8_]MH1\EH?^/5S_"MM#_\ Y15KUS_^CK9(#>NB@44^>LE!3UZ,9.W8Q:MW
MB,G+A!-1PS4[R:=]*M55>GN[R-M?BTYMI7GB,<5K68F(QI#@'$!UP=[6W,:=
MFH[;VULI^C8C\:/'QL7!.!BXV Q[HYU."2T.<PD:$M/BDVYB_7ID.OE=A4%[
M3LG(@^PS<H1BKHRQD2$!X#.0,A>14S1ZJ9$(HV#),.OM( G+B]?IT"Z-:+#K
MKZN*UMMI71%J(S9M;WF2+%CV$8VVMYA'XGE.5<TR+'.*I9G41-<HX%9O,28;
MBT)6,K6[VH!BX:%F&81V:,CWR-.3[G#.,Q1ONQ[&-2^2I$UB94MU=EK=_P!_
ME"EO$.TG=['IL%EZT G45RS-J[/IEE'-!W(T)D(MS(X7LGFV*LAL94S;90,G
M#TBB.;5AA*2T81ER%D;8F,+ I/)+&Y"H5;O\ZK]'[_V**-MNP[>=?!7$(S2E
MN33&23*6U93- .:9?A YK.%XAD)<KG3),+EN-\^SF7GX_)HYXS"82&57XTR1
MDL*Y%-#..EW0VC=H5+6])OW]"[N1["MP0YM.DD<7;@B)E[@G(^'H=.,:YDQN
M[FX?'4'W^3_(>,<9.U\F9ECB$B9S/;*3@P8<%*$F+(W"QIS'$WR+BTN_0)4*
MOV<O3;6]O/IU?-MT[/6(9J@.U7'T,SO&+HA.(\^E;%L'=DR+\XE$[Y*4=QAS
M)&#S,NX<?&#2XMPA5>%QC-D]A45:U9B8B_$@FHV+A"*[VB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+BK-
MT722J+A--9!:WN*(K6543434].XJBISZ<UK2E/3BO/-*<5IHBPSX,L?^-U/L
M>"[_ '_%[OEK?I^_[N.E\+P>.?\ X'N]>?FTMU]:+,6K9LS0L;M$$6[=&WN(
MMT$D[$[$[:>J:=B=>/=2G/TUX]-$7,T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$7YOLL4MK9?;;?9=Z76WVTNMK3Z*VUI
M6E?W::(OUHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBP>:3^"X\8-"V0)K$8*)=/K!S0
MK,I&'BPUV24:K.4F+=\<>,D%W]R#1VO1JBO<YZ1LYO[M;;*UT18O&\]8-F9Q
ME&H9F7$\ND9/J/+X_&,C1$\:>]&V6?.:L1 TN[>O*,V+-P^<T;M[NF:-G3N[
MBRVM=$4P:(FB+JR)$>'8/2Q9ZS&BAS1V_)DW[I-BQ',62:CEX^?/'%Z3=FQ9
MH)KN7+ERO;8SLMNNNNMMMT18PCDG':]L1JA.X6M2>T6K [DY.$4]MJ-TTG+F
MZ(UL?U]ING151<.O):O.Y;6EUWI=2M"+.]$31$T1-$31$T1-$6,!);%I*X.,
MXW)(_(7,:*K@)$U"&AQ9Q'S;>M:.1!M-BY65%%D*^K@:1HV>65]:V\Z(L@L4
MM4LMO3NMNLNM[Z=]GV2U2V^G-%$ZTK6OOKZT]:<5]_%:5T1>_1$T1-$31$T1
M-$7HO4M3LNO4OMMLMM[]]]_V.U.EGO4OK6M/?6E.*>E*TIQSQ2M=$7OT1-$6
M,@Y7%I.L<;QJ21^0KQLJY R-$&;&EU@!UG6M'04VFP=+J#"[.O=JY'/^F>MJ
MUXNLISQ0BR;1$T11CDN32*&0DY)HK"'V1) *2:+#H<-(H#"!BY5XV;*> ^<(
MNDD.F0<K/KJ],XOO3:W6)4\:O%.]2XL:;.C19DYE,P)#G#$FXF&['9'&X77+
M&EI<-X!OP@-=[4-6/YJJU3H= J=4HE DYJJ<3 :Z+0(LO#A2:BYV.UA8R3BL
MQF8>ZUQQBXX1)#2W=WG:X3G;-8_!.WK(F<Y2%?UK L?$97[(L[K7ILN?3&^(
M$@PI-EX]2$BD<B<L8D&:,K7-Q(N3:MFM+[G-NNCB-:U^*S#?X4-<=TC\8#D0
M.=GVO8W-BKW&Q'XN!@XN-@F/B8L=KL>.=TNP'N:'.P7.:2QQP77!<T[I<"1<
M+3_MHWR;O6.,X?@*416Z5[P+MQ ?'1)YN<#G\2WO\;Y6P=ES/P/*+@%%A9)[
M2.Q^88JREAZ'BF#7]7A>+T*D2 IV3J9;%R<QV><'3SA=[ M]&Y+(LWI+Y6/B
ML=Q<?B?9>/Q<#B1TKY[%IWN&W29(Q/DVZV2J"&5\DBI6L*.-5QY1)O<1 @X@
MA8U'.2LFHX?7IS]/E^KSJJE^);Y,O9%Q3C[),MC>*HL*RQ.MDTXQ8&QAF-V9
MGS/$^XS/8&$5"Y;C3T$**BBP(<H@SDSX6U<PZ4&E);"&=6M\9=OR+L\OV711
M1"NU6S&5Q1$YA,H#@,%*<UX.PQF?!S**RC->4T4Z9(G(G'96&3.#8KQ/-LF%
M)HB6(+%HA'8:#<-3UX66QLY((TC!STTJ5+COVWY>?]P)*C0/VK6XEZ&";@S.
M.86CC.";9-_4GRAAL22.,R\HRGM=W!8FQ%'# J1$8Z^(0\:NYDH[KVQ%N3]D
M14@G%Y9I(WH&-NM%7OW^;N=-GFQS<UE[<1#<AKYNPN[Q%.L=RQJ%N9IM2PYC
M+1!B-C9$,,C@,E[I^//$KGZXIT,)KD6K]%J-DHPK>S/4'C"+)8;G'..4Z3V
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MV$9@K6(.UYB;E$;%PXHW*%76UQKYK_5?T*%RG:C[A\[[? DOQI#<9XI6"Q7
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MN<+80Q=!]M^\CM"7.?T<@%LZP:</H7A,9M?8$7\\+QV!$"0(Z:>3UL*J=@3
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M9')3A?-V8",O$-)!*"PI/#4VV]PM"+"<>1&,R.5S4Y,7V?6= K2,H.3E28!
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M< K06[>#*-7=Y%L)T1-$31$T1-$31$T1-$31$T1-$5;MV^6I7@G;1FS,4''
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M'#0:-(J31_LSA V)@<>']V>ZF;X\Q^)EC7#,)-*[>8^+PT?D<5D\,$S>,O\
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MRQH(TR7ED['Q[MG$H@\>QF6]QVO>\?>70R5'+A5H, 3)MR+#=M.[*99ODV\
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M8T7>WH=(AET6B1OZO"TUKMUSP.4F29$HFV]CNY#?S)^SC*&2(W@:!28V#)L
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M'H]6)Y(#TC(4?*\;7(%;X26:O&=9 6ZNEUI ;^H'UW^Q8=VHG]RB6_RYA_\
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M:/FD1[R0($+1C5P2=TH)9M*\]7<ZXRW+N)/D4>-,J.-Q,B4!-L6PFN$26+Q
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ME::UZVD5BGUG.N89U%CQ8U!BR^B*-AP]&]!TM@IU,?I8[TB)%PY$L@6XG$>
M==9GR139M(RM2(E4QW2*JZ*9E8<22XU2IN-3J;3O<FQY4Q^#AV NQHL+*+-8
M(LI6PKLWBZC+.I@===PB:Q^;0NMY]R[(L"()JTKZ?[PDY^;CU]*TXUM[[#"H
MNC;4)\ '^!J.4ZLPMZMZ--HTECC;R,D#RD"^MK:Y^R?A-Q]G]/E#0T_,4)P/
M:V1#FQ[>2SG-T)Z[ZFRWK:]2UH&HW(97Q4*>NAA7)&/AI!DM>U?,"$QCS-\V
M<-JUL4:NFKDBFLBNC=7XS=S96ZE;JU^;G1%QJ9EPU3GC*^+J<TK2O$WBOK2O
MOI7]5_6E?GT1/AEPW]]C%WO[W]N\5]]/=7_=?W_A]^B+S\,V'/OL8O\ =Q_;
MQ%O=2E:4I_NO[N*UI^*M?IKHB\?#+AKCCX5\7<4KSQ[;Q7CGZ?\ =?W_ (=$
M4%/-\FVX)F5+"TCG(^+G"[-B]B$L+.P=,;SE9VERY$QV<#"Q$2W."W%Z#=R%
ME-8\]<.W;.@FTK1ZVNJ5-X7MYOG&GS+U;WL.3/.^"'L"@*(US(',BCY9.TD_
ML'M:M!SF]1S?<YOM5I2M:*4]]*4[O%*5^+6NLKR76(-"K0GU $X#8LM@ !==
MSP-V]A?R$]5]5&>UK*E7SED_'HM%X45 S(4I@EO\ PB*7.M?E?7KT/(ZDK3-
M]:YW8?<F%_QT:_T?4R?A-RM_:R_D]OV+5;W/FT;^PIORN5YIV76[&E>:"H92
MOTTFK:E?W^GT_";E;^UE_)[?L0>Q\VC#48--![15W!/K7>['[E0S^.K;]!I^
M$W*W]K+^3V_8J^Y]VC_V-.Z__J[NOGZ[F_:O/UKO=EZ?J7#?3W?[=FWI^+[!
MZ:?A-RM_:R_D]OV)[G[:1I_!4[3E_'#M.K3LT3ZUWNRYY\KAO/T^VS;G]_P.
M=/PFY6_M9?R>W[$]S[M'O?P5.OV],.OZUX^M=;L?N5#/7W_[=6WK_P#X-/PF
MY6_M9?R>W[$]S[M'_L:=KJ?XW<GUKK=A[_*89S[_ .W5K_1]/PFY6_M9?R>W
M[%3W/FT;GX&FW.I_C<ZKQ]:YW7_<B%_QT:_T?0[3<K?VLOY/'V)[GS:-_8TW
MY7<MXFT3&DIPSMTQWC>:),4I3&J2:PHB/=V/FB=2LSD!QG:FY3MY6MHQ)-J7
M7VTYI\:O-:VTU"&:JG&K-?J%2BCWO*,7=#KM(W(4:/8AP!T=AVUMHMNMF67:
MAE7(]!H%6W./IK)PE>!<,5@,BJ39;=UX-B!@R6W[#IU*T&L?6>+ Y]CB!91C
MCF(9(A<:G48?=VYT#E0=D;'**T[W<6M:$$5DD72'/>;.D*T=M+O5K6RM*7:(
MJ@4VNYBP?;U>T7-3T3'6W%4< 9Z<&\CXENL2YHB,B4L4=K9.QFW]]:6BR\CC
M_>K3F,>F@Z_V=[=];*ENSU$G[3Z]5U[_ '?L!# CCK=1CR1[6I5(V+V.#9A)
M%TI9@4^1)MUV32X'F@"FD#8=1XEKFHR;LX24:I5MLNMN=5]+36Z;B5>B5>E8
M9&$ZI4N="#B00QTN(^.#STW=^UAV:"Y"[U+F<!4:=4,07X.7$EN:#J1@2VNW
M1>P)<0.9 .\+D#55NIV8T[OYNMR;$KK:_/Y07^?\%%?3GGFOO_>UYV>X>S;?
M^F>7@.L<#4#YO4MT?=59<_-6L#G;WW#//RD>C0+S];$GOWS(E^:3'Z75?</Y
MN_/3+_ZG4/L5/=4Y<_-2K_K<+[J?6Q)[]\R)?FDQ^ET]P_F[\],O_J=0^Q/=
M4Y=_-6K_ *W"^ZGUL2>_?,B7YI,?I=/</YN_/3+_ .IU#[$]U3ES\U*O^MPO
MNI];$GOWS(E^:3'Z73W#^;OSTR_^IU#[$]U3ES\U*O\ K<+[J?6Q)[]\R)?F
MDQ^ET]P_F[\],O\ ZG4/L3W5.7/S4J_ZW"^ZGUL2>_?,B7YI,?I=/</YN_/3
M+_ZG4/L3W5.7/S4J_P"MPONI];$GOWS(E^:3'Z73W#^;OSTR_P#J=0^Q/=4Y
M<_-2K_K<+[JN#M*VPG-N2D\4-2D7)*S!.,VMJ#6+MKTE0-TAN4\7J:UJK<XH
M:1[M:<]WIJUK2E>[2NR?L>MA]6V-^VT5.NP:RW,70G#\%%E1S%%+Z7#O"&27
M$EXJ30-W^KZX2VR[5Z=M-&7!3Z1+IG0CJL7F7(P,3B.DA2]T-\'JT,Z/=<7U
MWP1UVNUK950>FB)HB:(FB)HB:(FB)HB:(FB+6CVELL<#,80J(-K[K*2N6.'[
MSN5XHLRC#&M:ME?FJG<^,#7-.*>]MZU^G2SV:]??"R-EK+N$2TU[,+YD@CD^
M-0X@/"N'8Z55(LOJ_FEOQK'9_P!BS2,.5FVN5G%%^B:.V-'O;Q9-4E$;[=-7
M"+"EMO?0./4#;3W&85,9LNY:PZ)R>7.622:SUO&0)0\X:HJ*]Q*]RB,:NUD4
M:J<TIXW'/=K2ONK2GG50\LYFS)BXV%ES+U>S%BQ_&D,I%%FU1\0.-@^4(4*8
MYK2=07V#M;'5;JU2OT&@X>!BUFL4JBX4FXC&K3H=,:]P%RUIEN9O.#;<AI:_
M(+K$0II<G4&W$$G!I-5PUO#HCW2A--PSHKU[=4>DCUG4,?"7JY;50I<UXN]/
M3G72PJ74L:H&FLA3)53WID1T,19QE-E8.\9&&8[6&6<3 W7<6S<NS=)<+ V[
M3JC 9#XY\Z&(1:")9F,,5WAR!&<)1)8&XX<S=?O:[R]! 8_$O%1Y1@\&/T/#
M\=@0;WLGJ/B)VJI>*U<HHJH>,BIU'%?F]:<\4NKP384NGX^/%G1Y,61&^%'E
MPL2-( Y^/%Q 'M\MQ;ES7+%EQYV )$63%DX !W9$5PD1W6/C;KV.<UVX0&D"
MYUU*ZO737*FB)HB^ES;%*UIK@/%DA=755>*Q5H)>N+^+E7#Z/+.(Z[<J^[[.
MNX$]4O\ 3??=6OOK2GMAL0KKLR[)LA5G'>,>0[+L.%*Q-"7RJ5_%,EQ_[QQ8
M!<X<]Z_6O+C:M1\/+^T3-M+PKB.RK8DN.- !AU)K*GAM%@/%8V9N-Y"P5A-2
MPH^31$T1-$31%I)[3)BI9ER"%*V_8GV.TV"5WN[U["2R!2^ROS4KP2;U_=YK
M77F1[-N,YFT#*\X\L?*#8S>8(X2L5E[O)J);?1VW6]GL5Y#7Y,S#%'^KYD=)
MM_\ =4B"SYA$/7>]O3K5UI<MG$T1-$5QY%MKCPS& 28BI;(WY$D.AI"IWV82
M>8L7>2IRR:/0?M0")EGT<(16I']5'$U&B&[NK*]LTMZIVT9ZV-K>Q6C0LBTG
M,E.S!5)4^5$RU+=5S2!(R+*D5]T02J;[8*;+JF/0I5 XLMJGMDB4H/X8\*T2
M),:,Z%:;M4J<G-D^BRZ-2X\:)+K$,0^E^&S>V/2FRG1JCT54XD6-5(M6X7>B
MMH,J6[#XK?<=V/(<L?<;4<AK2Z:Q&,D8O*7\)<7,G]HXRBDN\>HBU";AJD/N
M^4,NG\*K>KLUT3'J^\TJ]JYM>-6UFD; LZ8F8,S9=H\R@UV5EF88\KA9S1,E
M2!%,J4SAB'RHP:UCFB34S#A^$ONR>(;+;&N.#MBRNRBT*LU/ J]+CUYHD13+
M@N<&8!F-B-<<=AW91.\'G A\3(#/X3A]W<Q#C,FP#)([&QDD1.1LRT>8R%91
M)H#WZE70<$9D*,=8)*IWI<.UEEWC6O>0IQ3@M;2M>BHX>6:N[):W2*1 K3*I
M2:E@2,D0L]36Q)9,JE4VK5QE)C;X>V\MQER(]_!V /% M;PI=)N])VD4FI5.
M33,2!5:;C,S9-RE#?+B!K)E3BP'5.1ND/(#0(\B^\+%O!D'WR WE.MLN3V#:
M4O2*<<&LXB\3&D7Y*2C!P]4I6+,9GY>U(.ETF";B@,F/NIYBX8LJNG5K%LZJ
M[YMM[./L1SS%PJ[)DX5'CQZ'(,*5*F5:%%BNF]#QZX8T25CO9&#FTJ7$(=*Q
M(^!Q<H1H\ETD!JX</:ME.0^DX,9U5DX];C.F18T.DS),IL0UF30^),>,UTHM
M,R)*N(S,>0& 2"S<O>NM*UI[JUI\WI6M/3Z-0V"1R-O,I(7C1$T17Y[.MDLY
MW"J.;:77)C8+)'B]U?[RQ5T&8<<U]_V9VWYI[ZTK7T^>FUWL.(KL;:^[%:#:
M'E2L27=@#\2%$'K=)TY6L5K[[)B3AX&S886EY68*1'9VDMPITDD7UT;'=?R$
M>G?/KU:7GRJ['=INUJ5FR<DDVVW TDD1Q^Y*FI =Q# 2IHL3>JU5=/BA(D <
MO7SYPM6]=RX<.>JK7BM:UNYT33L'J"Z_ZBS9U_@H[;O\Q^-/ZLZ(GU%FSK_!
M1VW?YC\:?U9T1/J+-G7^"CMN_P Q^-/ZLZ(GU%FSK_!1VW?YC\:?U9T15[-=
ME_M3DF8FF39!CB#TC8!L.LB&(HICF P&!L"2:=*D3$JK#0 H_D!RZ<HT<-1\
MJ+NH^TLK<S\I=VW=ZCOZU2W?ZO,K![DL]1C:9B"F0W\3=&H^() 8TTCT>48B
MZM$7_P A9),DED^D28L4$:4HW0I\6VVEJ=M*>ZH!<;#ZOK(55KG^O98J^\K/
MOS]'_P!'INO_ *H_2_8B?7LL5?>5GWY^C_Z/3=?_ %1^E^Q$^O98J^\K/OS]
M'_T>FZ_^J/TOV(GU[+%7WE9]^?H_^CTW7_U1^E^Q$^O98J^\K/OS]'_T>FZ_
M^J/TOV(GU[+%7WE9]^?H_P#H]-U_]4?I?L1/KV6*OO*S[\_1_P#1Z;K_ .J/
MTOV(GU[+%7WE9]^?H_\ H]-U_P#5'Z7[$6T';MF@7N'P[#LQ!0I"/#)E:=JU
M#DUFKI^SH#DAJ-J6K.6]/!5JJN&77I7]BY]:^FA%B1V(IQU1%'^0LGX\Q+&W
M4OR;-XO!(VT]%C4I,L@S&JWAU53:(*/%D:OGZU*UZ8:VI>\>7?$:MKKN+:D5
M0KMU>7,T\L]H>"2D@!.;>XAGC/29C%6'_#4M[Z).-1QPUMRID8?=2E:<AP,=
M%=[C]7^*UIIWYA4OW.G?T\_-JNO?;0_;!J\F^\3*\MW&+ 47$AMQJS3^#S X
MA88GYBA8/Q;'GZ5LJ=L:(W(-B61Y#*[W=M*77M6E;JTIT*E.PJ53:A4L4'P%
M-B2IK[ ;W@XL=V.^UR!?=8=+M%_6>U"B8L^9&@8!!QI<B/%9O7:W?D/:QM]W
M>\7?(OS( O;0WX_URG _[5LL_F&&?U[UJ;[MC95\0[0?D>@?YH6Q?N6MH/QO
MD_\ 7ZW_ )>7GZY7@O\ :SEK\PP[^ONGNV-E7Q#M!^1Z!_FA/<M;0?C?)_Z_
M6_\ +R?7*\%_M9RU^88=_7W3W;&RKXAV@_(] _S0GN6MH/QOD_\ 7ZW_ )>3
MZY7@O]K.6OS##OZ^Z>[8V5?$.T'Y'H'^:$]RUM!^-\G_ *_6_P#+R?7*\%_M
M9RU^88=_7W3W;&RKXAV@_(] _P T)[EK:#\;Y/\ U^M_Y>3ZY7@O]K.6OS##
MOZ^Z>[8V5?$.T'Y'H'^:$]RUM!^-\G_K];_R\GURO!?[6<M?F&'?U]T]VQLJ
M^(=H/R/0/\T)[EK:#\;Y/_7ZW_EY/KE>"_VLY:_,,._K[I[MC95\0[0?D>@?
MYH3W+6T'XWR?^OUO_+RG[!.Y:";A[I4G"1,M&^R7DMQ&LG'B6'C5.U*]%8QJ
M,.F?'HG4.ZH[N7HU[MES:VE+JW774EW95MJRIMAZ>&6H&8(/M>%*=-Z:BT^-
MO"JF<(HC=&U>J;VZ:;(;(#_ ;MV ;P+B(UVA;+<Q;-.B>GIE'D],F:(G1,J7
M)L:=P?$<0)4&'NDF9AANZ'@G>Y;JLMJ9%&J:(FB)HB:(FB)HB:(FB)HB:(M4
MW:>C'2L?Q$8MI;TC S,!JMU..:+EF@)RV^;W7(AW=*5Y_%SZ\:%^SEA8V+2M
MG=0_U>-4LQP7&W_S:A%HLG OK_5IDD#3SD=>V_L496&RI9T@G^6DPJ+);>P\
M6'*GL<!YC+PK^87T*UPXUR0-@D8R0-=!61Y],!T99"VQ<7:3C]MX>0I$W*A1
M.]ZT6X\%*G1]/U/+NZM+J<5]--<FYTA95H>=H&+2H]2D9DB4B/$AS(PDTT.I
MM9$R9TDT2X;Q[T8>&L9>[( <X8=BMG\T98DY@JV6)6#.QZ;'HLNKR)3H<KA*
MDYLJ Z(SA3PSVD;SO?(<6#P!\4FXO-$.SUC..QV+-W<9*5*"F+9HL-&1:,(L
M1!:SVD\TEPF25+IGBI"4MR[8<3$D6[)BS9TK7K7G1"&K:2\O[5,DTBBT'"Q*
M!+X^F0XD8Q(M%I#<"EU-@K)F5^G5TSA4ZK*KHJD2+*I4F'&CQ8PN),H1*9$;
M@=:V=YKJ51J^-A5>*(TN9Q(E2JQ5W8\N&>B!%H4JEB$ZG18U,,3$E1ID9\B1
M*E.L(T;B)3CS#&XK'KEJ==#HP1O+JWNW3(<4B\4<,3!FB<4]GY.=D"I!<T*>
MPY<&Z\M!C6Y5D6:\4H[:4?F&SCM3ML&4)$>L2XU)E=($SN#B3*+EN7&JU4M1
M6TO,%3JQF"J0Y%$Z-E<+2X\67&F ZR8QE5-KNO"V99GPL:G8,FK11 ;N"5)A
MU>L-QX4/^.C5*73*4(G!RX]<Z28)$J5)BR(KR?>^/PL4C'LC9FPZ?&HBXQC<
M@FRL,CD56K^P8!4OB8468<C6WF@)1X^\Q<S*5'"12E/_ &0%C33JJTY;,[/G
M+:3LZK$' @T7)<IL?I:&QT*3P5,/M?I4&?+C0N*IKI$CB<7,V8:G*DZV?"I%
M#B\59IB1KGEC(N=:=),NJYGC'&X.608CIE3;TK-FPFRG<+4Q'CMC,H-'ID:+
MH )LVJNM:SY,A1W,F$%ZF%D;2D9*O@)<RH_(0>)NTX\;0QH(BK5A$TU9$NG(
MW]#PYR<&^94C57E7WKT;SEY3+J1M&V98W'OP6U:B5&12)LLRY65\MS12ZJW)
M=&R_$CT$.K$GIZ2*G$=4HIE"@B4<8WX64>*=C=2R1G_#$'#Q3#J<6/-APQ#B
M5NLL-3ANS/,JSI55+8%Z5&Z,EMILKA34RTQQ<R(H$85%R;(PDOGLED<>'7"1
M!-^FJQ:7LF Y:M;6Z*3A^X8#/D#!P562<$G;0=RU:NGE>[SZ5KKYG>M4W,&:
M:S6:- ;3:=4I&]&B<-%B$M9#PVODR(T.\6-)J4L.J<J/%/!1)<A[&W:%,V4J
M7/HV7:12ZI(XJHQ8_OMPE2I@:7%Y9%$F5>1*C1&O;%CR97CXC8X.A.F_#9:-
M<"=LF*FCNE++UAYTE;;=3FO3EY<=,->?HNZ%ZASSSQ6O%>:TK6GJ[[&>'BT_
M8?D+!QOQXM:FMOK_  53S)5ZE%/E][2V:CMTT7G?MRE8<S:KF_%P^J7!BW%M
M'0J/ AOM;M?'/EO?L5K-3RHH31$T1-$31%JT[3.'WOHAC:=(65KY%("\:>]R
MVE:U0DC!!^V44KSS1%!8"LWXI[NOIS^'1CV;N77R,NY-S3A#2E5:?1)):?Q:
MW$9)CDCGNM?2<5IYZR +&X*VP]BK6V8%;S1E[$-C4:;#JL8WT#J7*?%QP+?C
M.;5&8FOY/KH"M-6O-Y;L)HB:(K#O=Q4I=1,A&6L4QT'?FH^*C$@FX6-*CYD>
M""E65]C8DX3)>2=YSY<-H]=-PC5VZM:4I:ZIQ?6Z8Y&V*MXV7I]%P:!DFESJ
ME3(E&JV8J/27Q<RU.FTKA'MC29399IEGF)$,C'B4Z))F<&WWV'6)CC V94AE
M8CU3%K&8I<>FU.55Z5EV;56R:'3*A+XH&1&:8C:D6MXF6Z/&=47QVEQ&[NFP
MS=OO#G;8N\.6PO'-7[V5.YQ=6]G,J(V2<J 2C1@G<W3F:22]"HI.B*[8E5TT
M8W<O([04]I6ZF2X?LC,T1ZA(JC<LY+,B3F"?F-QX;,A8*_,HW0-6E,#<SVQ#
M4Z80'-D\7%BDF52^C)8NK%C;$<NXT3 @FNYJX>-2</+XM*HWC4N).=4X<4N=
M1+L;$EG>:Z)X-TFP;5.+9=8*RW!R- 4."OHG"#C)GCFW%9&TJC):7GXFV/(R
M,,W)>62@=X)"/%$*JCGH;RF[NO+Z%O-*T:5:8M$VP5C IT:FR\OY7J47!R4,
MA2N,;6 ZIT-E8%6I;:F(F88FY)I<MIQ(DFEBF$AP%3XRT5K,@Q]FM+Q)LF?@
MUC,%.Q\;-/MOB&(^CEM,K>)"-+EOB&5291?'JD5S1)CS'2QXOO00_P"$W\K:
M;N,B#Y'*I<U"0MH=EKID]7=,T)4Q38*,8VSCJ36P>SE;5@;$]&Q;NO(YHVD0
MBA:O66#+;J\4R")[(/.4*LY@S%%H] CU6N2H<QTV'TY%9$=@4>#06-;&BYCP
M(U6B&+&B2NB\R,KU-XP&68MG."M&/L;RW)I5'HN-4:]CP**'X;&XAHTETEDF
MKOJCG.E8](QY4*8#)?'Z3H;Z9/,,;IE'F:KUIWN:_LOQ>GS_ .OU_<_'J #K
MJI=N0;=A/;KU=^X7HT7RFB+;-V8\04J]R;/UD[[4DT \.&*5LIX:MZRBA@PE
MWZU]>FJU!UKZ?\*I3XO%.-_O809;=X?.>;\0'=;&@Y;AD=9Q,0U.I@GL8^-3
M'#3G))OVZ@>RLKC/ Y2RYAG4NF5N6WK :T0H1(T^$75"X_[H/7<[>M>A2TV3
M1$T1-$31$T1-$6L#M<_[D M_E[!O_K7NOIG\HS^]_P#M*+Y5M=Y==7+VCX B
MF:7,Z<SH@U#@![0##HZ1?S&.PQ"S)4^(K,XTXJ\DQ(<B:M"C!$BD+F)!:.Y#
M(?*ND:-'7-.>L]_?RZ>?YR=+: +L=^SGY[>E3KB_8Y''<32=SXC*+Y>39Q(E
M<V]F7X^&QE(X1GPUP#2E+:0_[:9*BO#:('!U&$=K'G=.D:.I#\JJT^7/-[=?
M,^3GW\_5<:"+]^1\_P"[K6"J;&;!0^2GI7D<V$B\<:DRM"K7&=2#@\$$8DCN
M4G+^/-GTY!LBB]:2.D?;4H9Z3JVO5NRS3JJ-&GUX;R=0ZAU=1MK;G?[$^CS=
M?/T\PN['[%P0><Q,++)U.#@8YE@=$>M@^*UG@>L2NF4)C3A_*):K)U6./Y*\
M1FHYRV%$0L@%-:5[M"SMT[%-2OP,0]GIUZNS3J\G5YU2_E[^OF>J_7JNDFNS
MJ--DRA<#.WH,'$HPR/RUO*8I469%LS@.5NH41?L74S=HHOI1*XRA!B8UL0Z6
M/%RHAUU3SK*M*?6^WMMY@?3Z^JYY:%/3U<M/7WT]2A_=+MK^ILDD?C])I697
M%V16U\XNBK^*59%X\3\G)HC;5B1=$T#6<<U&'6Q%JZ>?*NJ$B=?37;QUY@:_
MO-M;#GRTUOUCY[Z&PMH>K73EZ?*=-!5G787 OIIV6;IL'8+V2X"$3^:M?; L
MC/TX_C6+M'LQR?)'#C*L\JV;A<?1EN4DSKJ>[W+'5P^T52^G+MVUIZZZ+_A.
M\_5]/7Z^M<]QR[]_F4_^V>]7/W-,=0<1M"QT\I7PISF%FPGF=2#1:WO).P>(
MA#^Z&0QUS2YK=9/Y.8>M?MZ /=KY5==+6].OT+.L=;*,.Q21-<ASKVDS[EMM
MQ>EE#.ABZ>'1J_BU7[L4$/$DH9!T$7'JR;P^/"*M;:TMZESW>]HEE<:E*4IQ
M2G%*>ZE/2FB+"L@_V@S;_)B1_P#13S6-YP_HGFC_ '=K'_ITI7O+7](Z#_MF
MF?\ .X*^537@VO6U>:>^GXZ:(LJBT2D<T)7"(N*5+$$V:[]1!"]*RB;-FE11
MPZ45<K(HIMT4O7WUKSZ4IS7C5\H>7ZWF:<Z%0H#JE.9&FRW,8YHO'P+F5*)D
MEK0&Z-OIJ0="K;5ZU3:%%$VJ2!&CNDMB;Y!(XB0?%:  27$ZV&NMAIS]2\:.
M-I#2*N&/=.5()C>@ZAK?6KUQ5.B:5'*:M65?%\6GK:O6E:^E/3FNN/%HE4P:
MP:'BX&[5^($4QC,C7$G'L-QTH/,<WWK7\)8:=9L?O#J=/Q:;TSA2+T_AC*$H
M"2+Q@#XUBSB/%W;VW1SN=5Q2X4J!>T'EV2P][>Q&D;4%N*WWL3(UJ8&.?H\%
MZ->-W+?W\T<\>E==>I4^92Y C3H[H\@QX4K=< '</5(4*ITZ1S/B28DJ)('*
MS<0<ES0YT.HX7%0L=LB.)$R(7,^#Q,288DD&]_&C2H[\!]OQFGRVZ/5O7931
M$T1;;^RW_7<Y?XF,_P#GS[7H)[!;X>U'^[DO_CS<M/?98_ R%_>S/]&7EMQU
MZ"+3E-$31$T1-$31$T1-$31$T1-$55]W6*U\MX1E 48A<ZDH*Y&6QMNG9XE[
MDF 35N48)ITYJLX*"5R8YI97UZIVVNK3BVE=0;[(;(>+M"V75VEP\'B*O3-S
M,5&: 3O3*6'^$C88ZY4RER)\2*"![XQVNWF@74I[&<WX>3,^TFH2L48%-G[U
M&JSW7 9#G%H$@D&X9%EX<:2]W5@X3KCJ/SCUYYKS[_G_ !Z\:5Z:IHB:(FB)
MHBS> PLUD::1J#1Y*JQ>3%6XQM\2M]C>Q2EG5/W/A^M&S!EU!)WQ2M*,VU:U
MXXI2N2Y4RU4<Y9BI&6*/&WJA7)D.'#!!+6[UW2Y+CU1HT8/ER;D%L5CW:VWE
M9\Q5V%EFAU:OU-P; I<1TLV(!=NBS(S;_P#SY4DB+@;MPYSP%]0,7CK")QR.
MQ<39W!<:!BP0].^M*WV,@[!NP9^+7GG]8;^M:U^VK[Z\Z]S*%1H>7Z)1Z% !
M;"HM+I]'A@VOPE-B,AX%^?C##PVW[3?F%Y.U6I2:Q5*C5I9#I-3FS)\D@Z''
MER727D<M-YYY]7G64:NZZ*:(FB)HB:(H9S=C1KEO%LQ@3BY--<V)4J-=7VTI
M:S.,5DGX5W=6G/*211DRN=?-5IW[>>[6G,?;4,DQ]H>1,R92Q"UF-4X0,*0[
ME&JT1S)=,QW$ V:V9@1QC@6+HQ>VX:5EV0LTXN2\W4/,>$'.93Y0XM@YX].E
M,=&G88M>[G1<3$W.KPFZ>H+YFR@P@&)$ Q5FHP)BWKH:19.+*)K,GK)55LZ:
MJI_%K19!9'P*\^M*>OS^OB/4(<RESIT"=ANC5"FR)L.7&?>^!)CN?#F17#QO
M&8\.8;&W82+%>JD.5&GQHTZ)CMDQY,9DN'*8;MD1Y#6O:YG7N%KFN;R!-KE6
MQV6L*$<D3).UB\(/$,3RYR*2&A <B,6$TG0.K94,(D_ZAOS*'_ V9.E&5_/A
MNJTMNNU/OL:8@EYQS+@-CR),B)D',TZ&R)1Z-7*H)3,6CB*ZD4NM@TZ54P-[
MA\.7>,]WB8EF.)4-[=<?ALK4$\1&CX#LZ442S+FSJ7%,5V'.WA+F4O\ C&-%
M)MQ&)%]]-YL)(UF64XG=3*0Y$-3" 9+F$@BT<Q??$8H0!0O&4E,#Y#+3XTK>
MJ'QLT)BGC=#PB+EN[M_5;AE7JZ49LZ5I)%;R%CYAJF;:AF'*>=,R5:@4G)1R
MYEZ31<LY"KM5AU7,U:B5)[J5D^%,IDR* )6(R;82_>]Y?O6,W<P:DYPPJ)3\
MLT^BYERK0Z=5:MFGIBK1:A6LU4R)+IE%@RXK1+S2^+*PW.O$;N \':1XH,DD
MNR%#$4"C,8G((<<L?@/(MPH-F>)VCR" =D#R'A,?843O3200J0%($B"#IXW6
MIU=S7Y+5I3GB]86SS*=$H&;:=#JPD4P4?;'1XE7F"%*;2HE)SELSAMJ0+0T<
M3$$J5Q,IMKM:"TQ#<&W8F<\PU.K9?GR(/"S^-V9S70(G%Q3-DS,LY^E&(6DE
M_#RG1HSX\=U]W>U#CJN@-[9<3#YV"CS43,%$G+'+GABG!6P<M+6$)B*Q>,20
M40=M_&12*OK/ \\0'5AYBM.!%?D3UK6SU+8AD"+FFD4? AYB=&QXVT%HBRYO
M#NKD7*^7#5*'7*5)D0A+#)DL%KZI#B] U*W\5^+&EL-S@;5\WX^7:A59$VCD
MX$K);C+9",AE#DUVL"'5:7+C1O%)B12XB(Z5T]%O:9K)C8BX@;#6/!S>9LT<
M?%5)E? ,,2]2*OBC]_)L7O9!-DF$N2HDDR3>I>5"DADL)^=M>L$AW=&1CY%U
ME*]:F[-<H0\/,T;!RG+.9/:ELRS'[7)<N5)KV0I%6S.(N8 0R&)312Z8(>8)
M0JL7B(=+DB/4_>XEE<DW/68Y6)0L;%S)#%#&8LZ4;IB/$B1:3FK I5&,NDEK
MC+(/&2S*I,7A)!CRI482(E\?="Q7)6%(LS9Y".C(S*)<XI*<XWF9@TDX<6+Q
MN^A4O=C8X*/HOD&PU5<\RM;DW+5RNU,2"TM5K$FG7-.-63.^S&@0XN;:G HE
M?S#C#,&TTU;,4*L08\7)TG*^9Y<6B1*JW';&AN=4H@9*?$ES8M3JG20AY?BF
M1$:#=\JY^J^/C9:ITFJ4FC8 I&0##HSZ3-F2LT8%<HK9-3E4QT4OE#HR5>*U
MV'AOA4LPR^JOX?$%^W?[98(,,E5B(>64B;K)^&P<0(,"36U20Q.;1=\5+N0S
M\NLT%DO%*I(-FY.B]6S:O5M&GRRR[7?E[#\K0:E/?+@YB% D9WV:T?+<N+-A
MMZ4H>:*/)F5652Y53;%B2]Z4W#:R4=&6QXK1Q#26]./M4S'*@PF19M(=5X^4
MLYS:S#EPW6IM<R_68T2(R;&B;TN*3%<XF+8DN,>408YU@+<;C,)C621UL!9J
MBQQV.4)>7$'<@L+I+(OWC%54E')7&HW)(O:MX/R9F2H7;/:4\V9F*LWG2M8B
MVQY'I>2*U2<"EX+HN!4J29S(TJ=6.E&$3)D>\RA5ZC4.O9?WC#(B1IC:FV4T
M-J,>IXD60UD21MF.:YN:J;5\6H8[94FFU0P^*BL@&(YCH<60!%J=*J]2I=5W
M=\7D1'171S[VDQ>)P"]]>$45EUK&S>R]5=:^Q!))*RM]]]ZE?#33LL3_ %WQ
M?=S3BG=IS]'$086$_'Q&X>&#(QY#@&M:+N<XG0 'F2;7T!'DZY,Q,3#P\,XN
M*0  7/<XV:UHL7.<X@;N[;N.7TE;9<5TP[AJ)1)=.RPZHVO.R;CNTK=(#/A.
M"#>M;*4HMY8C:V#T<4K6MU&%M]*UYK37M/L0R%^#C9QE_+F,W=JCL!]5K(.A
M%4J9$B3AD=?!L.!3@ZVK8;3UKR[VJ9O]NV=ZO6L(W@!XA4G_ &;"+F1W6N;&
M27/EVZN)MI96*U+BCM-$31$T1-$31$T1:P.US_N0"W^7L&_^M>Z^F?RC/[W_
M .THOE6UWEUUSTR)!%"C-%^\0:4>)DZ-D7"J:%"#=%9)J_HEXO@T?H(K.:MG
M/S5_?UQ^7GU<^L^:Q[!;0VTULJ=G+MUMKS/FZK^4BRVMP_#=D23@3L/N&D 6
M;RV"Q.6-09@YC6;+DU\LXJ(366U#8_7,')=$'P6KWQJRR5Q0/U5>2L>+>;.Q
M;K77<^^@\QU[#?YSKY/*NR>KZ-+:W/<#KO=0"7VL9T%QF-%Y;EJ,QZ#/8*1-
M/"LCD&3V8>"A!SB!1Z^.R '6#*'+7#U[DN'#!OLR%/QYVU*5=5+^4-'3S7UX
M06YG3J^SL%E2_P"SG^WK^:Y[5WT1VE92(L8H9G&7@8*+3L3*IG2C*72(F5%J
MQG&LZGD-EQ]C015F\ EF\#K^KL<<R,J*%.6E735J[="VE'A!Y>V_E^?4?NL4
M&O/D>5M;<R+:#EH=?WX-(=L.9KFAHF5R7$3EYD&0,QE&Z3SAV]S#&XO (]FD
MN3BG6QA&ES8)#I %D-6V0',)>]6\Z42S=GVG2Z^O"^7GSN//Y/+Y=?(OG<;S
MM<^GRGT:6!]"J$3,EC*C=<R5)%EFS-NQ:J$G;I^J@/;4ITK)LLZ66JBW1_X,
MV_\ WXY/VZWY&Y]-A>Q(-A<D:ZKAZOV>:UNKR@&YU75ZY%5?6!V74 @PO:3B
MB?#8;&&4YDS&:-)#,68$:WE!MH.R?-FPYF2.)M/,GC)D@D@@W;.7'3-;;*]R
MG/>YZ6)\-W[^KM78'?[5LHU\(FB)HBPK(/\ :#-O\F)'_P!%/-8WG#^B>:/]
MW:Q_Z=*5[RU_2.@_[9IG_.X*^537@VO6U>:>^GX]$4I8PGUF.R<A+4'HDG)6
M&R..L4GC 84'I/336B39P0%G&9 858(UMMZMFZ;.K7EE:VW<V75MKG>1\WC)
MLVL36Q\.3C5*@5>DQA*AP:I%;(J$;A8LJ72JG$ETR7$!),J-(CR]XW%N=\5S
M;EOVRQ:="..Z-@Q:]2:M*X:5-ARC'@2-YPBRZ;*BRH<HW!;(P<=CF6'7NVL-
MC7=!'8;$6H,G$B+DHI- TP*W!E1@J.KO TZC<HM<BHJQ2'@P2U189S'N S!K
M2O4VTK6K/NM&DO9*VYTC+N7(U*GT"7(G#-%'S),-,=#IU"=*IF;*17>+I5"C
MPXU.I<K$IE/QZ=NTV+%T<UKKQCX&-'&:=D]2KE;QJC$J\3!BF@S:-$9,;+E5
M-L63EZJTHLE5609-2J;6S*A'J)XN2\7:[421Q$GAUW&P]R&4:/8M(O,V$8-!
M BS4@*Z.J\AP9%,1$7)-%1&B]$4'$6H8:4:KUI7KJ]ZVE6U>KXOPTY>D4U\>
M30:L*A&H-9I%(,&9$;&=(KFS++>0)3ZG>"UQ;$=075+ X<@#B TCWH-[D.R^
MN8<YN-@U:DB/*JD*9-WXDPR1T=M"K.=HK(I#BP%[*J(L@8^\+Q^?C:>^7;JD
M)7#\K1MX(.KN)W*)$2%N'A-F[11!%KA204473=-WEU+H>@.56!^6_%;.7GR6
MHFO5.'?)F';SA5_+^?Z))I]5XC->8*Q,BNF2HDI@IE2,0TREU(286.]KLL,B
M.Z-$4L+9,BT9T6TLR>.C;(<:CU?)M2P9T(-R[2J1$EL;$EM<:C%9+;4I<3AC
M&!%;,D"HF5H6Q]Z1Q?B-P*5UUK.IQ31%MO[+?]=SE_B8S_Y\^UZ">P6^'M1_
MNY+_ ./-RT]]EC\#(7][,_T9>6W'7H(M.4T1-$31$T1-$31$T1-$31$T1-$6
MF?>?L^)BRQ;+N+1*A$(257(S&+#T:WNP;Z_E1^?%-$[?LP9>EM71)NW^,(<4
MJ\I2T/WJ"/.'V2OL=)T&H3]H&0X1DT:4YTW,F7X+"9-)D7!E5*F1VW)I&.7&
M3,B,N*7B'$E-'1F\(&[&P[;5$EPX.3LWS1'GQ6,BT:L2G>+4XP\6/2Y<@V+9
MC2=V,]VDP6PR>*!$S5OK15;8)HB:(NX&"R)PDS#AV#PF6).$V@X:P;JO'KUP
MI6E$FK5JCXJZRZU:\_%XKQ6OI2[CBX4^GSJG.CP:7!D5.9*F"%$B1(3I,F3)
M)T9%B,!Q'N//=##8<S;5=>7-BT^-CSITB-$A107S)<MXC1X[; %[GOW6-:#N
MC4\^6EPMY.SK:G\"XV^<SA)!;)9YE1O8RLN370B E>M+[QJ2B=*HKF'O-*E'
MB7-EO%&#>M$[GKQ[ZD^QNV!G9Q!]M6:<&-B9VJ<8,PX[1OMR[3<0?S1I^":I
M*%NDY3 6-#1#CN=:5)EZ [;ML'MZDB@4%SF97ITDO.)JUU;EMT$MX=_",AX
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MS[C.-Z#Z($KC<G&O<*)@-JIPW2G2W$M/_P!5XJ_OL+GQK">"(?#8MDXZ&&D
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M*S_L7CZUONP^Y4)_CJU_H^GX3,K_ -M,^3V?=3W/>T7^RIGRL_[%9':%L-W
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M10M3L$-DM"QTW>_R6X+2+"61,)$S#\=@ Q+$V62('DO&!&:A,A&<#$LC1&5
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M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M0.=,$9R
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M9-W@;V]B,W,0V.)=NZ'6W-TDL/(\6+B9D(>#&:UUW8L40YD(W#R!@1)G&0K
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6$T1-$31$T1-$31$T1-$31$T1-$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g111598g84s67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g84s67.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1I04&AO=&]S:&]P(#,N,  X0DE-! 0
M     %<< 5H  QLE1QP"   "   < E  "')R,3DU-C<V' (% #9-:6-R;W-O
M9G0@5V]R9" M(%-A9V4@1F]R;2 Q,"U+(%\R,#$U+C(N,C0@1')A9G1?+F1O
M8W@ .$))300E       09AQ@Z@B4>K?T<7#%X4PQ\3A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M \     !  $#P     $  3A"24T$)@      #@             _@   .$))
M300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              .(   ):
M      $                          0             "6@   .(
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .(
M4F=H=&QO;F<   ):    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   #B     %)G:'1L;VYG   "6@
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M^V=T-W_0]F_]]+5+BX^.UUF)Z.[<;,66M'+!A/TW&-C/3W)8>+6VG$>6@O\
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M ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "
M0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !
M&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@
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M          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP,CHR-R Q
M,#HQ-3HP-@!R<C$Y-38W-@       Z !  ,    !__\  * "  0    !   "
M6J #  0    !    X@         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M             \     !   #P     '_X49;:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&
M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*
M(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ
M+R(*(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @('AM;&YS.G-T4F5F
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52
M968C(@H@(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!H;W1O<VAO<"\Q+C O(@H@("!X;7 Z0W)E871E1&%T93TB,C Q-2TP,BTR
M-U0P.3HU,#HT,BLP-3HS,"(*(" @>&UP.D-R96%T;W)4;V]L/2)04V-R:7!T
M-2YD;&P@5F5R<VEO;B U+C(N,B(*(" @>&UP.DUO9&EF>41A=&4](C(P,34M
M,#(M,C=4,3 Z,34Z,#8K,#4Z,S B"B @('AM<#I-971A9&%T841A=&4](C(P
M,34M,#(M,C=4,3 Z,34Z,#8K,#4Z,S B"B @('!D9CI0<F]D=6-E<CTB06-R
M;V)A="!$:7-T:6QL97(@,3 N,2XY("A7:6YD;W=S*2(*(" @9&,Z9F]R;6%T
M/2)I;6%G92]E<'-F(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C P
M,4$P.35#,T)"144T,3%"-S Y.3 R,T8T1$(Q-T8P(@H@("!X;7!-33I);G-T
M86YC94E$/2)X;7 N:6ED.C R,4$P.35#,T)"144T,3%"-S Y.3 R,T8T1$(Q
M-T8P(@H@("!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z1D4Q
M.3 Y-4,S0D)%130Q,4(W,#DY,#(S1C1$0C$W1C B"B @('!H;W1O<VAO<#I#
M;VQO<DUO9&4](C0B/@H@(" \9&,Z=&ET;&4^"B @(" \<F1F.D%L=#X*(" @
M(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D
M("T@4V%G92!&;W)M(#$P+4L@7S(P,34N,BXR-"!$<F%F=%\N9&]C>#PO<F1F
M.FQI/@H@(" @/"]R9&8Z06QT/@H@(" \+V1C.G1I=&QE/@H@(" \9&,Z8W)E
M871O<CX*(" @(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D^<G(Q.34V-S8\+W)D
M9CIL:3X*(" @(#PO<F1F.E-E<3X*(" @/"]D8SIC<F5A=&]R/@H@(" \>&UP
M34TZ2&ES=&]R>3X*(" @(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D*(" @(" @
M<W1%=G0Z86-T:6]N/2)D97)I=F5D(@H@(" @("!S=$5V=#IP87)A;65T97)S
M/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&%P<&QI8V%T:6]N+W!D9B(O/@H@(" @(#QR9&8Z;&D*(" @(" @
M<W1%=G0Z86-T:6]N/2)S879E9"(*(" @(" @<W1%=G0Z:6YS=&%N8V5)1#TB
M>&UP+FEI9#I&13$Y,#DU0S-"0D5%-#$Q0C<P.3DP,C-&-$1",3=&,"(*(" @
M(" @<W1%=G0Z=VAE;CTB,C Q-2TP,BTR-U0Q,#HQ-#HT."LP-3HS,"(*(" @
M(" @<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B+SX*(" @(" \<F1F
M.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T.FEN
M<W1A;F-E240](GAM<"YI:60Z1D8Q.3 Y-4,S0D)%130Q,4(W,#DY,#(S1C1$
M0C$W1C B"B @(" @('-T179T.G=H96X](C(P,34M,#(M,C=4,3 Z,30Z-3DK
M,#4Z,S B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC:&%N9V5D/2(O(B\^
M"B @(" @/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(*
M(" @(" @<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A<'!L:6-A=&EO;B]P9&8@
M=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"(O/@H@(" @(#QR
M9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)D97)I=F5D(@H@(" @("!S=$5V
M=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]P9&8@
M=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"(O/@H@(" @(#QR
M9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)S879E9"(*(" @(" @<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#HP,#%!,#DU0S-"0D5%-#$Q0C<P.3DP,C-&
M-$1",3=&,"(*(" @(" @<W1%=G0Z=VAE;CTB,C Q-2TP,BTR-U0Q,#HQ-#HU
M.2LP-3HS,"(*(" @(" @<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B
M+SX*(" @(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @
M(" @('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z,#$Q03 Y-4,S0D)%130Q
M,4(W,#DY,#(S1C1$0C$W1C B"B @(" @('-T179T.G=H96X](C(P,34M,#(M
M,C=4,3 Z,34Z,#8K,#4Z,S B"B @(" @('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC
M:&%N9V5D/2(O(B\^"B @(" @/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX]
M(F-O;G9E<G1E9"(*(" @(" @<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8B+SX*
M(" @(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB9&5R:79E9"(*(" @
M(" @<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F(B\^"B @(" @
M/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@(" @("!S=$5V
M=#II;G-T86YC94E$/2)X;7 N:6ED.C R,4$P.35#,T)"144T,3%"-S Y.3 R
M,T8T1$(Q-T8P(@H@(" @("!S=$5V=#IW:&5N/2(R,#$U+3 R+3(W5#$P.C$U
M.C V*S U.C,P(@H@(" @("!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*2(*(" @(" @<W1%=G0Z8VAA;F=E9#TB
M+R(O/@H@(" @/"]R9&8Z4V5Q/@H@(" \+WAM<$U-.DAI<W1O<GD^"B @(#QX
M;7!-33I$97)I=F5D1G)O;0H@(" @<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#HP,3%!,#DU0S-"0D5%-#$Q0C<P.3DP,C-&-$1",3=&,"(*(" @('-T4F5F
M.F1O8W5M96YT240](GAM<"YD:60Z,# Q03 Y-4,S0D)%130Q,4(W,#DY,#(S
M1C1$0C$W1C B"B @("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](GAM<"YD
M:60Z1D4Q.3 Y-4,S0D)%130Q,4(W,#DY,#(S1C1$0C$W1C B+SX*(" \+W)D
M9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MYKG G[NZ_P#BNP_SCT?"OI!\XK_,87]A!]COH;\RH_3=I?OD+\US@3]W=?\
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M"_-<X$_=W7_Q78?YQZ/A7T@^<5_F,+^P@^QWT-^94?INTOWR%^:YP)^[NO\
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MYP)^[NO_ (KL/\X]'PKZ0?.*_P QA?V$'V.^AOS*C]-VE^^0OS7.!/W=U_\
M%=A_G'H^%?2#YQ7^8PO["#['?0WYE1^F[2_?(7YKG G[NZ_^*[#_ #CT?"OI
M!\XK_,87]A!]COH;\RH_3=I?OD+\US@3]W=?_%=A_G'H^%?2#YQ7^8PO["#[
M'?0WYE1^F[2_?(7YKG G[NZ_^*[#_./1\*^D'SBO\QA?V$'V.^AOS*C]-VE^
M^0OS7.!/W=U_\5V'^<>CX5](/G%?YC"_L(/L=]#?F5'Z;M+]\A?FN<"?N[K_
M .*[#_./1\*^D'SBO\QA?V$'V.^AOS*C]-VE^^0OS7.!/W=U_P#%=A_G'H^%
M?2#YQ7^8PO["#['?0WYE1^F[2_?(7YKG G[NZ_\ BNP_SCT?"OI!\XK_ #&%
M_80?8[Z&_,J/TW:7[Y"_-<X$_=W7_P 5V'^<>CX5](/G%?YC"_L(/L=]#?F5
M'Z;M+]\A?FN<"?N[K_XKL/\ ./1\*^D'SBO\QA?V$'V.^AOS*C]-VE^^0OS7
M.!/W=U_\5V'^<>CX5](/G%?YC"_L(/L=]#?F5'Z;M+]\A?FN<"?N[K_XKL/\
MX]'PKZ0?.*_S&%_80?8[Z&_,J/TW:7[Y"_-<X$_=W7_Q78?YQZ/A7T@^<5_F
M,+^P@^QWT-^94?INTOWR%^:YP)^[NO\ XKL/\X]'PKZ0?.*_S&%_80?8[Z&_
M,J/TW:7[Y$%M'3+P6GK=^VKQ^B%E6FLV%RPM-A[A&"F8@B1][?./>$XXECWQ
MG'X?LS^SUR-O],>DN&V'MC$2-J3)4Z1LS'SI4Q,G"A4N9*PLU:%@]1=*D@BA
M#@.#'2V-[FW0F=M?9DF=L*7,E3L?A)4V6<9M(A<N9/EH6D_;@+*22"Q!8T,'
MG'::ZW'^C+!'*(5].UD H^4D^T0J5(8X]Y"2)+VC'&.Z<LSE^V6<YSG/KPO1
MW:VT=H]']A;0QN,7B,9C]C;,QF+GK"0N?BL5@I$^?.6$H2D*F35K6K* EU%@
M!2/HFU]C[,V9M;:FS<#A)>'P.S]HXW!8/#I,Q29&%PF)FR,/)2J8M:RF5)EH
M0"M:ED)=2E%R9_BW_$2B_P#B?^V+#U3W/OP0V3V[0_ZICHWZ9_A+M+_V?ZAA
M8L#U[./+PO1!"]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$$
M+T00O1!"]$$+&??]G]_;\/1!"]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$
M$+T00O1!"]$$0&U_XK;)_P P7'^SF?7&Z1_@]MW\C;4_49\=38?]=;'_ "IL
M_P#6Y,0G&'_JZTC_ *+TO_8 ^N3[G_X$=$_R!LO]4EQT.F/X5=(ORQC_ -8F
M0=>O7QYN%Z((7H@A>B"%Z((7H@A>B"%Z((7H@A>B"%Z((6,^_P"S^_\ R_Y/
M^3T00O1!"]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$$+T00
MO1!"]$$+T00-[AG&=3V;V_\ [!;_ /8&/7$Z2_@YM[\C;3_4IT=;8/\ 7FQ_
MRI@/UJ5 ?H7^(VE_]$]<_P!CI^O,=$/P3Z+_ /EW8G_3<-'=Z2_A'T@_+>U?
MU^?$IQ;_ (B47_Q/_;%AZ?\ <^_!#9/;M#_JF.A3IG^$NTO_ &?ZAA8L#U[.
M/+PO1!"]$$+T00O1!"]$$#VU[9K6BZS?;EN-W7:WJNKU3MYL%];LP4K*BIKP
M39=>=9)G$!A7 .9)Y]\RS[8C&,I2C')!&-N#?J.=+/41OM;QWQK?<BFM]D5<
ML-'M]IX3Y?TC3^0:RO5RZY9:;N&VZ54:_9JC5Q\@.&'D6'@_KJ]=L.<$]$#Q
MKC4.1-$W\VVKZ1M^O;8;0MOM- W45!:J6D]6W>D DU<:I>X4*7[=?U@+) K]
M8SXVE8MA\PX9GC'H@@R]$$!59R/H-UN>R\=5.X:[9;YIU?56NU:>E;)L;%K]
M9>^?[,_;5(BR<25L_C,82,<4('R&>!YSG'H@@T]\?W_O_?\ Y?;T00LY]O;_
M $_A_?\ O_I_9C.<$$+.?;_3^/M^'^7_ /[^'^CW_'\/?.""/.[:OJF=(.I[
M_P @<9GN^7MBVKBW:6]*WH6B=.'/^_5-%M"(%V6Z<VP:?QQ<T9V0@:7+GXCY
MQR&6$QSG&6,^B"-ZZSL5;MNO4FT4_P [[5L%4C<UV+.KLJ6QPE8+P96^;46Z
MJ5I6M>*<?.C8*+.+$[A, &2.8X((KCG#G#4N =.3W?<:O<KBJ>VK5M0"KHVJ
MV6WW$;/;KE6CKFC5E9')@5*K3<#6MB3,0()Q*<F<XAVY((%])ZD-5WGJ.YTZ
M::^EO%-KX%U;B?;-CO7,(XH;=7EQ'8GZ=:H\3)'?-6 U\D;#+:X(9(R.*^9X
MAF4B"-%_AC\,?V?V8_;_ '_M]$$+W_\ #_K_ ,GH@@(WCDOCWC,% SR%NFLZ
M6OM6S5&F:T;9KA*G'>[9?G^-2:Y53=,&+MQ:L?J$$ 9FPR7.("A*6<8R00,;
M3S7JFH\L<<<.657N#.S\H5NS6E!956K6-CJ2"^JA >P'LFS C]OH66(L0C6
M<EB3TXSB/V[??)!%O^B".,9]_P!G_=_?_N_^GN00O?\ O^S_ ._MZ((Y_;^.
M/1!"]$$+T00O1!"]$$+T00O1!$!M?^*VR?\ ,%Q_LYGUQND?X/;=_(VU/U&?
M'4V'_76Q_P J;/\ UN3$'QCG']'6D_C[>VKTOO[_ +/_ $ ']OKD^Y_^!'1/
M\@;+_5)<=#IC^%72+\L8_P#6)D9:XQ^H?TP<O<O X5TF_P!^;VFUM=DI=3O;
M'A[E2GXWWNPU!>T;V*&D\G66HKZ-?JHJTMHTK8@O(5MZHK)S76[=4@3$]?'F
MXUAK?(.C[C;;C0ZIME!L5UQ[=AUK>:NGLU7WM2V!BM4N 4VP++DF2KLBU3Z5
MB-1J(S33: >,,C)'.2"##W_#W_\ O^'_ -_1! 8IR+H;^\W'&26WZ\WR)K]#
M6;1>:2"U3)L]5KERR=.JO'Z:)<NK5=@TL==5TH8@*4<H1G[^WN009>_[/]/H
M@A>^/V9_#_E_\?[^_MG_ "9]$$<^_P#X^B"//'<OJC=(>D\C<A\5.7G+>P;E
MQ5L<]1WU70NG3GOD&LU_9!J@=+4L7^F<=75(9H:[ B9PL^:$HR[H3G'VED@C
M=NI;15;MJVN;C1XL<4VU4=5L51BXJ+77[;%;<H@L4L65#>)U]U3/_&8%\NJM
MD$K.O/WJO*+LB(*)! OR_P I:]PKQENO*VU(;):Z]HM&S?6U;I]"WL^SNJ+2
MA"8*6@1_K=HZ21(X&N+,<9CW$G. H2G@@BI?SJ]+ES[PUT_"H-IQL'-O"^T<
MX:Y<-I@KD:O7-79UU=BIO4'##MD;T_Y2)YPG\2<5I@: U,1H8CD@C46/;^SV
M_;G]G^7\<Y_Z_P!OO_;_ )?1!"QG&?\ Y^WH@@4WG>],XRU2YWOD+:*/2]-U
MU<;=[L^R6*U325"QF0)!/86+A!+*C*VRNM"921Q(QQ#QG,IQQD@@!Y1YYTKB
M8_$0+U';;R/-7)>L<6:@WI6L6&UH*WFVKMM55SLKM;B:]!J,!)RD[LC<_A*X
M*"4NX<Y3@01=7O\ W_\ K^/^3_K]$$<>_P#?_P"7[/\ Y^WH@A=V,8]__P"/
M[?;^WV]$$<^B"%Z((S[U(=4/#/2;HJ/(O-^PVNO:S:;/2:;53H]0VW=[:SV;
M8V/B4U0A0Z72WURRT^Q[!#@:.89)* ^_O)",B" ;@'KKZ8NI?:[SC_BS?;2?
M(NM5@+N[X[WOC[D;BK>%*5F?8"X!K7)NJ:G96U5+.8=]C2AL4@9(.#!PDGB'
MH@C7?H@CCWQ_?^S_ $Y_T8_;_P#S[>B"%G/M_?\ O_?]GX^V/1!&?>J?J'UC
MI1X$Y"Z@-RIKK8-;X\4I&;*FU[*7WA[%]M%)JBD4OGG64QD;UZL<^3'AVJA/
M*$2$C <B"+JUZY6V*@H]@3&8*E[45MRJ(\8X.->S3 \$9L0E,>#0&>,28'.<
M>_$NR4HX]_1!$Q[^W]_[_P#U_#T00O?&/V_A_?\ O_H]$$9WZD.H_4>F75-/
MVW<::^ND-RY2X_XJKP:\-$C2USR+L*NNUEBU%]Q(>*U-IN!G<C)-C 8Y\ 2S
M[<9((N7<,?\ FGLW_,%Q_P#5 ^?7$Z2_@YM[\C;3_4IT=;8/]>;'_*F _6I4
M!^A?XC:7_P!$]<_V.GZ\QT0_!/HO_P"7=B?]-PT=WI+^$?2#\M[5_7Y\2G%O
M^(E%_P#$_P#;%AZ?]S[\$-D]NT/^J8Z%.F?X2[2_]G^H86+ ]>SCR\+T00O1
M!"]$$+T00O1!%'=2?!M'U*\#<K<#;)9O4U+RIIMKJ+UO6XQEZLB^..0/KCE,
M<324;$ \@2G"+$(2!(D(DS+!!'EMQ!S?U-](.^< =#'6=JFH[CJ/*P&^'NG+
MJTX4>*@1ZXIM<;^TT'(NAW*:C>H;=#7DYFC<T)WJ7)58R$2REALP2"*Y^EUP
M*#0-_P#J"\EV74!R_&NXPZU>I33+%3:-O49TZS7JM6TIMKDK=4&D8+V.U)@/
M-MNV.42N0H \P<#%+W/X_P /1!&<_P XRSTSDKI(Y-X!YQZ^N7]:Y1ZEM#XS
MW#E#F[0[&IZ:.6].Y!M+"GLB:JS:5="H!L9NQ_4B:_2 3: KF86""'[S((T;
MP!TSFG]77J\N?Z<^<88U&AX:Y)E68W&'V[8Q;';;+9XTC8P?"][#2J;V^!3U
M.)CRLA[@R<F,]WH@BV^(^;N4[7I&^JAMUGOU^YL_$_+'6U4\>73#L9OZ;6:3
M0WA]03IRYAC*H: JX25L,XGXI#CG'=[?B010W*N]=3EUTZ_3RY4V"TZEMBZ:
M+'@&GO>IO8NEXH'><!;S<:?2&UW=-D0C->[MM!0(5ZPV'.LY-9KFB=LJ;4(@
M1=(CV]J?2(]ENE+;=&WCI\XOV7C?E:]YNTJQUZ,Z+D[:"Q+LNS*8;9[2[#CX
M-88=Q7__ (6Z%JO4=$5/M;#ACRRR1,>-'1PUUR!ZB/J0PZ9J+I1L^/\ /77M
MLMJ9YTVSEZBW$5SG3-'BY#7T] TO8J1BLC484FL6R>5:E929&4,58C+,@C0'
M4KCG;E;ZEG#?3-KO4!N_"G&^U]%^U<B\FH\<%6B_>6&O<MU5:0&L6EFO,NO6
M+TF5J\FQB5+90UL5B@ 2S#V&5R",0[5U6=25%T%\EU37+FP/\@=/GU(-&Z95
M.6$6\"V/=>/0<KZ+V1O'8"P)Q@]!LL]<M&1BC)\2<BG_ %Y32R0</;0QI7=N
M9;3IXZPOK+\W4E=&VN>,^D_I-VFH0)"11GM$M.Y.^!DHX_B4 FB#.87X8($4
MH9]L9S[$1Q[1ZA&?.(=\ZOLDZ8^5^.:;ZCF^<F;AN7'EGSIGES0M=3Z:]KT/
M>C!SO+NO*(;6Y/5:35TK:=OI;5>GA@B%6F%\A)G-.1W\/4_#N.L#Z,?,?7],
M:=UWC3G#JSZT?J'Z';]7'-/%O$_#6^<24NB:3Q<_74KM9<[;P9J]V2UE?M*M
MLQJ$+*35E#71 BG86CA67CDA'X\B)'U^N/-7F:ZY.ZL.B_H6W#E[E_?R<A:!
M]06HZ8=@VG4K45/5;V36^8V=9K>6HK06F*>X)U::>:VZ%@<!V4+$\E92/+&"
M"/7O<+'D/@OK@^GAT\4_+O(^UZ+<\>]0)MS+N=["WM]\<J1JVE,_M;F%@XL6
MJB;Y%J\F("\"@0"]I=G=D@BLNC'1^=^M;0 ]9MUU;\T<=[)MO-&W6VD\::FS
M3RXOTWCC2N0+*BK^.+W2GD<QNB6M)5F3V%]UZ-EDCD7%CB/',9$$:1Z7N3]^
MVCGKZI=!L>VV]O3<5\V:E3<=UKK6"+ZA3M]/.F;"RC2C[8_%5/>.N6<\>\O=
MM@A/?'O[8((\P>.^5.L;E3Z;/0+RU*]ZB^2M!<V/?[+K!MN &ZMSJ1MM07S?
MJ:,]JXWS(M6E14[&$3&WI4QA6Q*9=?"V,]N<Q((]O.A[=N-M_P"GG5]AXHYD
MWGG+326-\JGN/)?GQOJ32EB4+VI[2%VMJ+-:UUAF)*PZ]JE"P%D7:P0OZ!)$
M'M[>W;5XUU^WT00O1!"]$$+T00O1!"]$$0&U_P"*VR?\P7'^SF?7&Z1_@]MW
M\C;4_49\=38?]=;'_*FS_P!;DP.<<A&SQKIRQ<9\;&HU02>TI0SV%K1#GVSC
MG$HR[,Y_2CF.8_MQ+W]O7)Z ?@1T3_(&S/U27'0Z8?A7TA_+&/\ UB9'D;Q;
MR[U"] ?(73[T:]1^CZGN_3AO^WJ<!=*W4CQW=&_*?68058J>*M%YGTZUJZ[(
M-F)1BK:$NVZR8Z#3^9MSRW KV4_7QYN*W^GOTX#T#JE^H#N]AU$\X,H\-]09
M*IY?9MT YKVW LN =78+L_(JI$!PN[2A'<>:N:E-<:\:>L[QSPMGO((S+L/4
MG9:1O'2YS#T]<]]>G,E/NW5?Q;QONO)O+.B.5O2IRUH^_P"U-ZQLM1KCKE52
M5JK0LS\FGNZU583+%,Q@.,Y",V"#V]O7W1IG3NF$]S]9+J 9QSQSM6XI>".(
M>3\@K=S@N*TA8;W:9QHME'*,O/HR6%\X3J(]LA1,;'GEW^WH@B[^C;F;E+<=
M.^JNYMN\WUVUQ/U4<_ZKQTQ8N1)/3-<H.)]3MZ6HII=D?BHUUDXPZJ/VGXS'
MG/WSF6,9((R%9<D=56W]$_TS>8+F\ZD]PX)M>*+G8.L#9>FXZCG/9[MZAJ9<
M?[8ZK(J]O::36.CV)[;L:UWV@_$I.2K6)+@D0>QCVPZ/MSX^Y!Z=.-]IXMY=
MV7G/1WZUL=)R5N4Y3VRY@E9NHM)[)@M?4M"NZ-Q=BDLUGD%;!=JO(%X?R8$S
MD@CQUZ5&NN$'5I]4*'2U1=*=KJ>>LMB6U&Y^VOEZ@V,5SC1M?P.&OK<=Z9LU
M8Q69KLCE,UBTJY\[O'$/@Q F2('TGUF+[ZQ++G??OJ'='731J?/6Y\(Z7RAP
M-S?LG*...2+2:MSZ4QJ3N5J)JT!.54XQ(K""E_\ &(\E7,'R)>#!<3$1,99Y
M0YDY_P"FSCSZMO3G7\Y;]O(.G3AS0>6>#^4MHM1O\G:4+DBHK'+'5G]@"J&+
MWVRQ*R:G89%-L580&2D(0Q9^B"-)PVE\G7_]/_=KPS=S:$^FAS!M5PS/,2/6
MK\L<4VSYI2SVQ(V\QY29E^&)&+G/Z.,X]$2U'YM;Z?HCS;T#J+ZS>H3IR1ZN
M.+*SZAEYU-[CL%AO?'5-I^A:]9='/V2MWQNN!QC\/.QB<N]4EK-<U66FPFJ
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M$S68K%QX'&$F<]A$>VOJ^GZHO3AWD#DZ/U0><>%-GY!NMFT[3.C/@S8%*AK
MU*@VYN;,_5['N"U0'$@I6%[X>]N B$$+!, CG,1QSZ(F,>CY&ZQN3.E3K,;X
MCV'DC>-JT?ZA^_ZB\GHMA58Y75Z>=9=T1K:=3XB+<R7K8;$M3MV7V)(IQG)E
MAD*9HN%!VGL>?L*0<:_PI;VXQZB="FZ:#NW3Y36/'NV\R[34UVR;71VH>H,+
MRO,FI;+7VY\7FF[TE9CA8)V%(V7.$Q'DR(E0Q7LU[CE4=%DA!'UK/5ZWLG-S
M?"LNE#K$UX*NQ76O_P!,6S<1TM;PBS&F(R.-ZKN@MZ;?+KUO\;R4MAG7H$<$
MPM,BJ_ESB)!&,_K2%V-;AGIE9T^NJK?; =;_ $REUFKOK)FGH[&^'R C.I1N
M+9.OM6ZRK:?B +SZM98L*+$*<*+1!P#,@BJ^F^PY+Y7^J]R!MW5;KNK<*\Z\
M!]/&=>XUXKX[;9W'5.2N,=_M!,W'(ZG)5@.FL=H)76E;BI#KA-/HG:*4BS8'
MW3+B1!&$-"ZB^KWJ:X%M.J[CY+ZB#G4+N&S;5MO#]/QGQ]KKW253TM!NMC54
M/&;*!=J@WL%(6IJ3U.T[ ]62MX7+#D\0/A/$V1HAZLQ[6<1M/K$Y#YBU;F^A
MY"ZH]AZJ^".DRWX2T)N@WOIL_P (:WPMS&^,S&_$Y[#3"L]A51K#-IJ5-G*G
MN-=S!-K+@A!\I_1[?3$Q<.][5OW5EUJ:]TI:KU ;UH'!7&W3/IG-^P;=Q;;)
M4NY\Y6G())(ZJ\/;%E#06U=6N!*[?A2P7^:^ZC(98*3F*1!&$NJ+>>4M>Z1/
MJR=(W(G(^P\R4W3M8=/5KQUR1N!5V]PGJ7)O(N@78M0VFR476%:6FLNJ-0&[
M,,#RKFDX'[YQD21!&[:GGW:NEWK*U>FY6W:R-T\=171"IR#QHI=-9Q2:=RQT
MWZZM<\AZ[2D)& DH['QS:%VJQSB3,IEJD88&+]+)"",.W'4GU4"X<Z)]7V;9
M^HAR\^H%RQS]S9M,N$**MV7F34^$-+J$-GT_B7C="UL:=*E(_1W5(6]L1M1;
MJD*^V?6'/)_C%![/I[=_*(J'X< *Q<&F]0_5?TS\:=?VYFTSJF;X)XQZ?TN5
M^ =AZP-:K:W?*'DI;[E5;7I WJ^ZM2;30$DQ5[15G:8P6OPDRFQ'M-&1R %]
M&[7'MY_72HNISISY?TCI\Z+N9MPZMN5>6[+D#J)Z5+KE;4-S:J[O1]AO=IWF
MBNZZRT@ E4F-,EK3;(E%@(395>J0F7<!)DF'!D3'Z7-P_P 4]G_Y@M_]GG_O
M_;_W>N)TE_!S;WY&VG^I3HZVP?Z\V/\ E3 ?K4J [0O\1M+_ .B>N?['3]>8
MZ(?@GT7_ /+NQ/\ IN&CN])?PCZ0?EO:OZ_/B4XM_P 1*+_XG_MBP]/^Y]^"
M&R>W:'_5,="G3/\ "7:7_L_U#"Q8'KV<>7A>B"%Z((7H@A>B"%Z((K7E_C1+
MF'C;;>-K#8]LU%;:ZWX&=FT:Y+K^V41AG"TM945N&,YIO+,+B)"4AE%/&)",
M(@B3A(@C#_&'TXJS7>7M!YHYLZD^?^J+9N'W+.PX@K^8+K7)T&@6=HG]O-?)
MUFKZ[10L]A^WR(I&ULYL8&.<I+@#/,I9((+]9Z!-0U+FKGKDNDY:Y94X\ZDV
M-KN^5NGJ%K2QXKO-NWG6%=3VG;AXQ2QV9.TM:Y7SE@O?17&\21Q#C"(@C((H
M34_I):S2)\&:SL75/U)[OQSTS[]HV\\'\<W=QI0=9U3\@'?DT5%8#K]/5:V-
M!=:,*@#-FQ.P0K!X$BRN>9&)$$:2V/HAIWNK5;JYT[F?ESC7:+2HU+7N2M&U
M*RH<:-RI1:2ZV]15FTIVE'860 1FZP!W--85Y6UI8%*<,XS/)!%"<@_2>X\W
MG<.<&Z_GWJ!T'B7J-M[7:.7N!M(V:FJ^/MIVZZ0BG979"%HF;]4%HP,=G;TX
M+3%7:NQF-X!4CL*%(+Q:^Q]"5S'1.'M#XEZKNH3A"OXAXIHN'83TI_3FU=QU
MBD6RH"RV6GOM5L:B.U>"4\#O:A6NF#NC'"^0B$*)!&F>G/@#0^F'AW3>%..(
MVDM6TU1D*SMX[FQN[5Y]L]A:7%N[V"BS8V;[)VV9C$(6)D[ B&.,88((Q6?Z
M9Q:CDKF?D;BKK*ZK.%,<Z<CV/*>YZCQW=\=+ZQ^5EH@A6,MHBNN/[>QA#*58
MF",6+!B6("CCOSZ((SOU$=&G(O,7U'>GYM+D/GG2*GC?H;VRIK>IG1VUD+]#
MDQ/E:I@LK?V<ZHNK6MEL>O.V[-IKMA4S1> <K@4URK+%"01J8_TP>"C]+M)T
MMBV/?E:!+ES6N<MDWD5A4L;WO')5#NR.^.7VS/V%2ZB?.P72 PV 5T%\+5G8
ME6R2B ,AD$7OCH]XM:Y=ZF.6[XMULANJGCOCOC'D?4+8J$M6#K?'5/LE(CBF
M&LB"T U;)[,WFS*W9-QB994B$$\Q)Y"#CS_E%"<1?3VV7AJSTVHUSK3ZI6^&
MN/7*XFH<+6%]I\M>1IJK(XUNGO[$+4Q[;::HB$4%%:X]S _Q1P RXS'N[B",
MB4/0?R-RWUM_45Y+5YBZC.F#.V<A<,5.M;AQC8)5--R9HD>#=6K]C %/8Z:X
MIK"=9<HE2#?5X!6-2[@P(LYC(@<D0/I/I):-G;1],S@6WZ2.-^D35[7=^/M7
MXBV;7=_X\WW6K50G(-'R3KFP,[8'?2V=J@^C8WECLKKMO:_,0(JR=F<!@",8
M8B(F#ZGZ+*.'(O35RWNO+G*?)/)'37K'(&MU6T;<UK16]Z_I$-Y+6RW2-=KZ
M,2-UPL"4IX4WVE8"8 "8"S*&92((HZD^E_KVH;S?.\?=374EQ[PIM/)3?+%]
MTXZCME-5\<,[/9;&OM5ND@_"BSMU/K5O;A\K]'6WJXI!))1<@%/U/HB&HW9$
MURU]-'4N2>:N2N7=>Y]Y]X@K^=*ZHK.>>.N,-GJJ35N4EZ2IA0JEL6CT[5_1
MN,TL(U=B]K]I7MG1A& C )C!,D3#C7?ITCXPX-X<X0X%ZGN?^%$>%E=KKJ78
M-5?TUMK9JO;;B%NTCM]-;:LWK]E]J+'(Z1I6M0<1Q+,LF-F9<$((TWTN=-&D
M=*?%@N+])L]CV(3&Q;'N6R[9M[P;':-NW';;,UQL>QWC*JJ*F7;*P.0TA)IJ
MJACVC""$,>WH@C1GH@A>B"%Z((7H@A>B"%Z((@-K_P 5MD_Y@N/]G,^N-TC_
M  >V[^1MJ?J,^.IL/^NMC_E39_ZW)@5T6M7N.)]9J6I'@M9Z2C7L35.15J '
M:B"QI+-!E RY\#++(CBG$H2=I!RC.,<XY/N?_@1T3_(&R_U27'0Z8_A5TB_+
M&/\ UB9&$.-_IHTNM\H\8<D<L]2G4)U&)\%V\[OA'1>6MAH7=4X_MA(9JJ>Z
MR*GH:RQV6]H:_M!5VM^\Z89ACL"Q*_##7KU\>;BP5N@G6JSJ-Y5YVI.8N7*3
M6><XMM<P\#I6=%GBO?KYG0I\<COK,)Z0NQ+-+T6$SC"A=K+YLZU!F4,P&0!"
M",\4'TA=,K*?B+2+GJ@ZE-HXHZ?N2=+Y)X6XLM+S3AZMI[^C;,+9*BL=RKJ0
MK#9TQ_URF&:[;9<2JWV,HG7LL0?B01I_DGHFJMTZGM>ZJ=1YHY<XAWE?5J31
M][I] L*"&N<GZ;KMWG8*RAVA:ZHK9H (.Y\)C4[2!S)3*'OB4F#1((I+D'Z6
M6A[AR;S/N.N\^<_\6Z%U&69=BYRX7X\VBHIM&W[9SU0:=R].R2D9V*J/:I@"
M.Y!5VRXK&(%PYP->$Q$((,Y_3[;UGBK@[BGA3JIZA>#ZOA'CK^B]-S3;'3G(
M;EK&&!G"?:Z>[U5^EG?H8P:%;<U*-6PM%B491,.$!Q((TYTR=.>A=*7#&J<(
M<;DN6M9U<MX_FSV)V-A>W=YM%[8;-LM];M#"N$EA=W]M86;6%UUU1F9E!< 1
M1@.)!&/+'Z9^4N6>;>6.+.L+JFX09Y\WXG).]:KQO=<>+:T7:"5JE5)I05WH
M%S8QCA1,4(1/8'S#&<QC+$?;&"",P]5G1KR7RYU[]!U>EOG/531\6]-?--+9
M=3^I,K*;=5;Z@KIX*"WVB\#49UAB[V\J;C%G5-U$:NX(=R(J\4(CP(@C5U']
M,3BX'!G4OQ+N7)_*_(NZ=7"8E.;>>-JLJ%KD^]&BBG6TP*Z<:..N55?KZ"04
MZFN'2$5&'V\\&"1C/!!&@:WI#T&LYEX,YJ%>[2:_X%X'O>G[6:DQJF5';ZI?
M_DU\NTOAXK(NFO(8UA.(2(N)H>QV?(C/W'XR!Z-WQF"B^F/GCMBXUOA+J^ZG
M^$.$[F_NMCAPEH-_J ]7UUO872V-O7:=<6^J6>S:S1.O,MM9K$+3$59GS% B
MD(1AZ(AO;V^GZ V;.:>CCD[F_P"JWM/(-%NG.' U/1]*VIUFG\[\7E$F#.R?
M?WU;K57#75;::Y?P:JS][=98)F.O*(752K'A$OHB8V[K/TX^%J'I4Y>Z5K&_
MWW:JSGHVQ7'+?*%]=+GY-W'<MC; ^?<G;<*0:\5M7N)H$JP K85RHD0+?#F#
MR#F1 #>U.Z(Q?Z>--:Z5TV:GR9U \W<K.]+_ %#Z5U#Z)M6X.ZA*[>MN/ZU^
MJUS2[G-?JRB<]/ D[+!AI+)7)2P\F+4>)SC(B8@>0_IIT.Q<O\E<K\5=1_4)
MT[CYQ>4M>;]+XCV&BK];Y"ME4L5N;N6;BAM;'7KQY".$[&SHG%#'!&.8>%@<
M#1((GN:OIVZUR9R?HG,W'_.W./ ').I<3I<&7^U\7[#4XL^0N+*]T%DG0[<;
M9J>\^59*OART'8E_#;>4DLG.;Q+X$01&\>?3;U?A;A#8>&>$NH+J XS/><WW
MW.PN1:O9:2SW539]DJ4JFTIGVK>@<1V/66@I1,PE?J/N,,FD8C_D&"0B !O;
MNC5O3IP4/@'1;#6&M^W#E3:-DVJZWC=^2-\)5RVG<-HN\*+$?L!TE?55*H4*
MBMJ**L400 )>KJ4A3\IHE.0@B^_;'M[?V?WQZ((S=U*],6F=3]+QM1[G=[)1
MK<8\Q\=\U4Q=:-6A.]L7&UZOL%16V6;*OL83IW6EX"L1K06<F#,HK-KSSB>"
M"(_D+I2T?D#J1X6ZHY7VTZUR/PO3;9K"<=>8K 5.YZIMZXXOZWN 7*UQINM6
M= O9HY0:09 X''N>0)E#,@C*M5],B.@6NS5O _5QU+\!\0[;M5_N;_#''EUI
MWY*TMQL[A+*]#I]C?:I;;!JU38O&,P2N0L?"MDN1H?$'&$<$$'_4/T%674%8
M[@@WU7=1NC<7<EZT'4.2^(M8O-69U':-?E5SI;5-=B^UJUNZ#\I:TA5-BG4V
M(<6 #'S&(#ED7T01\<O_ $[./]WON)M[XAY.Y0Z9^4>&>-4N'=0W[B:RK,OM
M\6UZM>FEIFS5NSU=Y5W]:FO6KY3*TM%\!H0)!OVQVY((B\?3'X=9Z:^<.GF[
MWKE#8['J/OJC:N9N:KRWJ+'E7<MDI+W7;M"Q8>9IB4*PEL:S75:E>M2004K,
M$&N 9Y>;!!!=UD_3TX?ZU^(>,.(>1=AWC6$>)MAJKS6=ITA^JK]JFJGJMEIM
MSKCKMC4V2Q-?VZ@LB*;(D%0,G, 5R,H?#''H@@PZBNBSC?J!TGBC6H[%NG%&
MT<"V];>\*<F\8V:U-NG'5E74\*"4:D[J3]8W6V=(.%=;55D@TB\$2\YBP9=<
M@R"(KC[HU8K=(Y:T7G;J#YFZH:;F+4Q:5L2/*S^N@IZ>BP.X$V+6*74Z&B3J
MVK.%M'-@^7#;99UZ$HE'@.<3((RLC]'_ $IE#B[7MZZI>I[D73N"=TT_<.$]
M.V3:M:^PZ%'2[E&UK*N:BFL _*4<UD\T,G]@R\^I3FE"M*D]CYOH@CUAW#_%
M/9O^8+?_ + QZXG27\'-O?D;:?ZE.CK;!_KS8_Y4P'ZU*@.T+_$;2_\ HGKG
M^QT_7F.B'X)]%_\ R[L3_IN&CN])?PCZ0?EO:OZ_/B4XM_Q$HO\ XG_MBP]/
M^Y]^"&R>W:'_ %3'0ITS_"7:7_L_U#"Q8'KV<>7A>B"%Z((7H@A>B"%Z((7H
M@A>V/\GH@A>W_CZ((7H@A?W_ ._T00O1!"_;Z((7H@A>B"./;&/[/[^_O_\
M?/H@CGV]$$+T00O;]O\ I_;Z((X]L>_O_;Z((Y]$$+T00O;\??\ M_9Z((7H
M@A>B"%Z((7H@A>B"%Z((7H@A>B"%Z((@-K_Q6V3_ )@N/]G,^N-TC_![;OY&
MVI^HSXZFP_ZZV/\ E39_ZW)B$XP_]76D?]%Z7_L ?7)]S_\  CHG^0-E_JDN
M.ATQ_"KI%^6,?^L3(.<XQG]OKU\>;CGVQ_?_ $?L]$$+T00O1!"]$$+V_M]$
M$+T00O1!''MC^_\ H_9Z((6,8QZ((Y]$$+T00O;'_=_U>B"%Z((X]L?W_O\
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M#'!,PD(TI5[G?1I&*E2S)VID6Q+;>VX0:JHDC:&FZ'>]#6)/NB]+TSD(5CL
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M1M$K2LY#[^[<(&X5$$>^+>,FE;59B\7D^Z-TMFRUDXW YPID'WCV*6&0FO\
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M@+,Y#Q*$M$X'9:4K2=D;'6M393[W88*E@>,H!$M*%$ME986 /%2"7BWPFZ1
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MRB,H<>]V"(N;CJ6[2*FQ- ZXZ2](CBE).W=JE/42R$G'XC=5UDP*4$F8&S
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MNGL.Z[ES'NJFA+[^ZW5EL["#"UL^FRG4.T4 J"4PV>RPDDT+5<R9X1B%( 4
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M.TL*:DPPN>D17@$PQKHH,W(Z5080C3KJZC4#3BKQP;D?/!*,W.* (F(FI#$
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M39PM(IQT(N[M=XT3P5M6\K_4'ZT"?@E;[-R7K=G3P1*LS12V3CV2]ON-&&3
M(LX^3J<+=Y0C$3S]E&%(#$8X)37GA'@6%L0F4I)N[+;(L$THIB[:O>,,2$G!
MR235,M>8.1N+I?3EZFBO.*.7,<*=?')-($S>3O=0 UWJ+P^)BY'NFF<?!:MK
M (/9#$:MNO,TDD81BJLVDX3E/'R<DWERQ,PB#2F"F[SEDA*)A"=/&!KR32XC
M7!2PK!R2E\HV;,R$D'=1AYC"@9P"Y-BUJU<V-#OFN_49O-EUMQ&B=I*G6TJ:
MNK%U6JF5A*MI+QRU+-\!4\1K%4JZ.'XPB&E*Y/XY +.C)%7#%!V9*"G4DE9)
M)9FF*%&I7.372ICI[:*58G$)OO2B568"1+[M7(YGA UU.AMZ[KTW:UK]4_)[
M<$=;X1W#[:"Z2:5M%=3UBJV]Q*%O@15&V[ZVOP?/-YHS)FO9FNP4(RR.S(8X
M1#G.EYR,U&&8E(4UV"0:5J1:D<Q! PR');XQ(86*E$.=:@&M+MP:T>O38[+3
M>I_Z>/+>QO/56LTW&V_[^K65M>H6.LQV5_3ZA32UR5:6?E5PCMU$7[2PD9G+
MUI9NX;$B1.NKZ81(5(QDL!*EJ7+1F<[V5*SGTJ "6<,*:/%9 !E8A"2"I2DI
M>^8 S%E1?D[EC4:O%T=3&Q[AQ=QYHO4-R)L"N-5EN7#E'1WV5&BK5='07^Q&
MM,Y;:LF45K:QNW3W%DY"J@*Q6RM7*-+X0RJYC(2F;,7)0"Y3-)W@^9N56  %
M" X!-WC&6D3%&6$FJ5LS@N["[FP&M]'N?TNG6^B?2TYMH-V NS5V_'UVS.^D
M?YEO\XNIZ_*!Y,R#)5?("A?,N:)3!4?<G ;$_$<LJE87M"44 @]8D-HQ47<'
MAZA %YL2@@-\8  1;>( U]JZP.?2 L*;DOH[WK7J1:'Y!Z'R#S"U;6N5I*L<
MCW+]W>;!K+;HIR\Y*:NI7:L\ FA$)+%7*^82(F;MMM))1B4$@%2T2LHJR!E2
ME7'5V(9@6&D7QJ2F=6Y0@@#R6 #<*,:7J[U @<^C5R==7^G<EZIOFOWA@Z=:
M%NM:OJQ..5A:GK6LTG#= KE-N.%".:=I>J4OQGXPL#E4=\DPS(V3SQM&6E*T
MKEJJL K<LTQ0"U&E<JE$TN.3"*XF2E"U3$$GK2%K=J+4E+E/)3 D:*'"!?B3
MD2I_/6ZHN =?=M%+'==CY;UK!IL7+1MAW5'<ZI[3*"TO6/N#?9BI6LBO[ V4
M[: 6W;,YSLPE+.DQ!&%D3"Q"1*4S!P@I:8KM)TXAA=XF8@]3+6:AD6=P"[UL
M]!3C%4=<K"'&OU#Z#F#2-6JZMGBWC;B7:-IIZ J%?70:6Y;T17[E-62H0GBG
MMF4=>(]\67?!\#A19  WJ^%)7@3+6K[I,F)"E %1)0O5M020"7+, 2T:RB?!
MR%'=F3>K"B 6*DE# O5W<TJU') .JOK$6%5MW2'Q!N6P/2Q5[OU9\95^,)@*
M2-,LKQWRXBE50RO,##ZU9N,6'2=TQKN,#DSX>PF<3PV<,N(FI2!N899%" 29
MDHD\0Z2&!L1&>$<39C#^Q50M8E!UU(]9[KRBWN&R?3]WS>[BY6EL2'36J582
MUV=.%C25>FK);5*WIJ9A&#3_ -O49J*AC8*YTM82*GC9D$S43Y;HQJ$I=NOI
M2H=1*2"02Q)8A)>ITI&8^^69OC" W-1+,=+"G;<11GT0+BQL^%>;]!M%DAT&
MK;Z\)*S;LCFD,EA1:W>(V5@%B(\Q9M'[RW=.T)KN'!$ .P<<BG/3:H2)LM64
MAT!_.00#JS >IR#%L6H*FV4"PK0)L^[1R$N$D\0SL(Q91[/L7_E<^3Z6ZO8?
ME/0WFQ5U?C%<^QJ?S"O+/[D92$89(LRO5W=)LCQY0(=G%?5UDS06QC V5)'O
M:@@#*H DFYT06UJE20^COPC=:?M-"J:$G6VZ_(E! I<]\:5^M#M&N<1;!TFJ
MUZX+.^VVOYJJ,"7CGYFPW)P\5XP\^S"!RY,-HJC8B,9F2!"+^TLREW^LMFH5
M,&(4VZ#*4?Q:+![BQO4MRBF$0I:9AH E4M1K9LX#\0=16I%*UV=R/J&CB^GC
MRMN]%R!N4*'=>G]EY^L9>6>'#8I:;A=9%D T,,J85!\>GS29D%1,"JDXA#D$
M<Y6EJ6K&2D%*71.&\&^626/9O9G=S2YC!#]>D4)$P 58>,=-0[UI76,?_1/V
M'3N8M=WJROGE8W&B&T\.M51"+Q7#26C6W;9:Q-3M)QBI\ZRV$3 LS9:P9&%:
MZED9E2Y48VF%22A(!(45D\R,J Q%79)?C4:A]L8G(I/%0+FSLR?_ *@4-;&T
M6-]6:&N7V[=*8M8)5N[A;]0CE$R_51!8/!HG^/JA%HEA)6<_9!,AL2(1B6,+
MSQ'/=#.??..S<P&,*@H)2G-6E=U1^DGCYH4P#Y]IDDTFI(?B,+A13C4,;6+V
MCT=Z8JC2]BZ<]5T\6CI<2_=M8$L#6:-Z-?:JK5Z -41V&LD*('*VW55UY+$Q
M0'@],RB!8V90&.1%L05">HE9F@%P3S/6$&SBN;O+&!?CDYLS%W-B=6Y.3W09
M5<=*%Q@3(^9[Y+6D[\!J_D;.V^)U@--15I#_ ";EF65&T9"3;;;"Z,U7W^3!
M%9*1BKG,%76$F4G,262$L-[7*#Q+/W$7;"7G*IVYE/6J 8-UJ2B6TPMJ[H#A
M]T5!C3W[(_C^/MC_ .?X?Z??_O\ 6<:Q!,PQC8:>7;CWRA=?I?AW?\959SCW
MQ_ISG\/V?VX]5/C)[%'OW!ZH5F??>&_\'%>O#W\_IB=SCWQ[?W_O_?\ #]N+
M0U$'L,<0H;6,<8CC"+&(QQ^$<?H9_#&,8_M_;_E]_P!GX>_JDSQ%=AA3'_>>
M)_\ "5$O$8\$D;$1X+,<12+B.,3D,623'"6?;NE$<C$E&&<YQ'))R_;+/J\-
MQ]^W^3M]L^^<_P!F,^_[?V>_]N??.?;\?[<_A[Y((ZY"%.0YR&.4AYSD4Y0C
M*0_?VCGLSG&<QS+VQC.<?V8Q[X]_1!#)RGJK*0YOUJ+LQ8]AS:5 P2$?)$V(
MPF:$NV."P&7VCGV\D8RQ^EC&<CM9Q>B:-P/\/7$@M:\1-Q4UF3U[.:Y++)GZ
M]4K$E5\F(L"#6 KR)V=T@CP4F(#SGLA@DXQCC&??U53DI<FBPU=&U[/H$+8D
MN9%W\(EAWY+]' <^Z)$VO4+)('8IZPY1YAXRF26F2'CC. ^R<A9S'MB0D8^V
M<?HDGC]DLXS8O;V:_'^1AC@Y/L3;0QU*:Y3(G?:"F+SV1?(>98Y-VQR&(LJK
MQ+WX62E^M/E(&(+Y:;>;R/+#C))CD]@H :GS\^Q^<'M6(:CUVC*'#\ZM3+<7
M[^'EP/&(RQ.]9E+)0QSX2SQE<.1F*.9!8''QSCC.<9JA\M[*4>\+.G.%<)]Q
M/'K\4_;X5.AYC2=0PRTW^3=/EEPS)V322%*3!'4R(.>3,HRQD;*99KG#[>(D
M)R[H9EGW]7S&@<L/0--14&H[(;?4^FKZ:OZ=(AE]0UL&T,G^UB8)BGK<A^<9
MJRPKXK%Z01(PL#M#KP!D.$@K)P7 *>,2$&$\YSZH[K(=V2D#B*J_AQ]3JBN-
M7_PLIGK_ &LX/ZOH9HF&-(U1J$QGIE9P*7R]DO-XX%\TVLR"+)/&#!&)R*:
M8P&>7M$\21QB.+A1&IAI_:GU>U.$(>D:O"(/D5*U@PN.(A/V<<OV4<1Q"$<X
M?9S-J&8X&+LR(D.R4(RAVR_2]%;Z]H'LPT[H.?=I_.U(0],H!G$Q(+IV!EC/
M)GKBXLRG",9H#19/9/-F-5"(Q-L53,F:T;^(.Q5PU#R>HS$!B0+<AKXO"E^/
MG$1WGAW<(<'U376)8E*J6!/#$FLD1R6O+,\@Y#DI"U\UB%GD<O;'DE+MS&!(
MXP2$)QERW\.[^%XGU<_;VI U/C[7F'!+S?LV*I2$IFUUN_N;.,GIA")-N1["
MT:>4&-"+(?MP9C2:R4;>1X,OWD,Q9Z&U0!IJ +VYM:KQ&AL=#[>PLXCZQQAK
M."0\.' )8QB9*\;&<B.S.,\./&:)$EC)ZQ*-%EYK#D3F;KEG.^+17"M&97XK
M=FC&@O2M.3B#N]O;U=KQK/']6.WI\L6>P-]\VP@8S=/J6JZ(Z^12I9OT#+7[
M"[5EDUF:![*<!GF("L%E%  C51+H##5WM5/"HKV0M.)\(PG]Z=I7[D3>]XGW
M-,U_ V#69V250(2;*LV\QE48XPB6S(\0I99:5?D+Y=B%K,@&8F\V:,SO-D)8
MDWU'#E[?0S "&=7[ZL6U>W>28C;C2M>#16LADMSE2IK ,BGV.^;.8D$22B2Q
M,:QF5UV$<+2BT[,KF/C)S\O<L&4:J4K(MODJJPX/;Z& %;:KXP_:F*N?M>>_
M?*4_GCL3TNL4<<33V&R3P<8S+5R5AB-BLE+!5K')WF9.6+X[)R1&6;!F7SON
MDS-_.^X2^1"Y-"6<V!L W8&!\W9>&=7J'.G ]H-7#@\K7C[KM?UF-@ZKKMM]
MMR'M'8TU"TN$(Q"%\2*Y!P@4E?$)!XQ"5?)$@<CROY.S&(1"3K;2E6 U-''.
MFIK$.[_5_(=MX85FDTXK>V'BTV"+T2UG8[+8[+[JRJJ@M(H/D98P6*$V3".T
MHK$"F32!#(X!E@,J)4<RF %BS#07%R/9Q:%Y)?$8I@Q"Y51<_$I.A^@023U"
MC86.#);(Y9$QB5B6\M7K,!0]L\#$XXZR4 8&C$TZR.<5TRYS,B6<RE[RY.KZ
M4MYM(9))^OLX$^>(6_U>LPK ]HXY9/3O:)K-PZU$#M=@%FKA>->5."8ZQ5:4
M<RB-6 H$+(YF\G.=@I*J)IXK!2=-,P\[UJ;49FA7$DI1*-#]L88%TB@,Z6DF
MH8&H(-P:@NQ#AG3:AX@FQVCF-J$GWI[)!Z7W6*LC"(*!P*E65L*7!Q")]L;7
M+62/'Y'C^=G+7JY4;-1G -JGSAG%:MQAFWKK?3C?^+\7^5=)% I".[7L5CL!
M1B8F_*S&BP,4 X6P-5&K$D)6GDP(+)*V,)(LO+Q.W%A@K9& *;0![@ %^UZD
MV!5ZG8C\+Z\6^BM7NXI6(>HURIS7FU^GOYU=L&]V=XV/F!N;<XV+1Q=R;8;D
MSK1%_C- "#!/ZO7 FDLK 2@UU\507!.7REN.!S*U'L=:PMA/N<UO]JQ9YC[:
MFB_;KK<N:Q88:_4%@B7S:_%R < Y6'M=DD-?(HXAD TP6P *0%V^.*P0A$",
M<"&(<(8AC8*4/('F5]!:.@+#L$>0/6"GCBKCZTW+6;E:56Y]1W7=IV"VE8RK
MYB2J.:U=GOJ:84Q &X #=)=5Q5<8AGQA9*Z1R;1IQZ*2)N-Q*5 DI1BTI</4
MKF(20_ %)&C,11C%,,I2UXC,"5";M$ '>/WSB @[W#=RGY*0U&CS]JH[YI'T
MVX;>?9E-KK-8ZA.%M28MKUADEU52T[EK4<4E@M8E+XB#UZ_P@]A,ZV"FDP5A
MELXQ^*.OQ:\;ERJ0529JR **"Y:RKL*D[GK!AI@K$43E"Y:R6 .ZJ4O-QW@G
M,Q%VXP$;?'E!'Z4%1.\3^9KNP\A\-?.V*R?>#LQGT.5^(TRJ-I-$/\FKKGJB
M%>M/)\$DQC)\AC!?'<#JSM3=(!3*Q# 58%!((-@[@O4Z7($8**3M60Q%,/CL
MH <$-*+D@W%";/?2FCGN+JW@KHKVIRJ1KR7U38].FIL3!-X18O[!U+:MNLY'
M\8ET1JAI]ZU@==G"^3DA7%&NS-86<PIUAGXIE'=4)RA=@T@IM<;R%&^L:H69
MLXYK$32YLR496IS![;:0?[6I9<??3.Y;OUY^=O:Z*LV78<WOR;$XQ6NVU5D<
M#43RG79Q:7>TN>XV(C,6E$Y@+1YHB@O1.]CY8-DDI200"<J<K@D_)36];@5B
MH(7BD@&Q2'U8,S<0U#8 ]PBC.'WJ@OTI.KQ>K<UH%3R@/ENJLK0*A:C,N1[J
MM4@L"8^PE=! ]2F$0VV"C,[9,KJBP6<A88VF$C'X?,%9D=4:,=Q+N'OXQ!['
MX1JHJ3C);V2I#:[KN>[M&FC1<6I=./(7$O0%U*:QLMM5/.;KQ]36#VR6"&8N
MW5+<:9JD]NKJ(2N(KPJ*N]=27KVDR04&[97>##9864\&*IR9F,D$ @(60 "&
M&^<IX#,'=F- 8IUHF8B6I(*0"I@.U1!J&K8G5GO%@5.LJ4?0;NEQJ81H5B72
M]RRE8ZPA6C&.8:J\VW3U+LI%,B\UQ8TH%0O2\$XO?DJB=R8/AKX)DI3X^4A8
MS$S$G-PS&4IAQ8EZV"N,)$OM/#TS*ZJ:0LJ+ =;A*9>9+O<$$5*BXYT$;5*U
MUWF;?*>L%]C#6B1*^")'&!VRE/M^L@U7%>D64#2#82MCY>" CJ@5V:]=;!#R
M'/3%@)5*0:FC72"%*"BH\R*U9S#,\$9 HEV!>]%,?,S&NFH:!/Z7G*M?_04.
MK30J;AW5NG&IK=A=#\QN]0VW9.1.?5M;H,IA 3XTB:Y7:I-DD\K^*F;7;8+G
M.9>33'RR9SN0%3U )< 94IDN:#Y177RB-6,7Q26F*47&99:S,$H!+7U(;B(@
M?HZJ;#L^G:IM.+V_0L!\60I-5K5&[%.IREQZPD@R"X5B40[&MM+5N$8(D@56
M$IFM QRPRH6!M-DK6A@PFE2K$NLJ(RG0L/,P:A><8R5J2,U5%1?\<$M0W:A)
M[+O#+Z:C8;OEY(V*.[O7-:O^4YBH+?*XZRN MR;RDU/>M90;B*4[$F+2%+$Y
M)=\F F!#"Q1D)B<=1)<@9NKJ+ET2MU1%W"23SKQ@Q-&<@TEDMXRB42P4JX,2
MX9N-Z1*]$O"0[+J5Y#Y!H##UMGD??.M+9+N;=;B.P7#NN]33;6HH6.'.UG7B
M:U8I5EE%A+$75F@& 2$2SBP*,7-^(0@BJ$85(JX#X?>8B[@D,^4W(H(G$3"9
M82'W4R0D@D,#+K<T+$O=V%2#%(=!'$&Q;AU^;)R?46OP:G8=ZZJKFS?\"[=@
M@?6^77%1GK8'(9'+7F-I ,-E3/#*$[544,P:,3UKBYB1@A+54Y,. -"3+"JB
MS>.6>[<*Z8A:>H$LT+23Q-9;CS',SZLYTBR.%*=^CZS=^W6PJC66]DZLN:A:
M=6+V;-)KNVL+\7$I'/EMP\QL9J6K'+ZE= <R,PS:+D^0@-L)<YI?"B6%,GP5
M&>EGF.S!KI2 _)/%XPGDG#% 8@R$YB6S E1(-G:E^8-8S"GJ5VQ]5A;F*K7D
M93=.H,NEU>N[".=>TN_3<?TFQL(D0=A.-/>W;BU#4H7$ASBNT8*A)#S.!,-8
M=21L_J7+HP,U9*1NDE"T N+@/4 GE#.SU?T;+E:IV;F<5<'#K059@*I9Z&M;
M&T:]OJZI?ZV-AV"0"US]1R[H&C UNS/ <)H[/I]1:N@?$L=V.(X1T@1%RD[B
M9KRM3QF,2$Q/FX4ML^4BZ5(G+#-XPF*3PU*P#]#T;VT5#&X@"H*4*H[;LF4E
MNS>(I6W"DOSAI=AR%U==7ESJE:>U/QU3]/=3K3==!@LQLWO"%D2KA$,!=S#!
M;Q=7XXI0&.8E)]PYYCC&=I2@C#X<*5289I(-CEG!]&+));@XX@QS<P1*PV@7
MUA/"BR!K9G+GESBQ>?M!C9]4?2KH&S?=&4<]-A0Q1M%1 -6NW_)O&&O6U0HM
M@.)@&A]I#8)JY.1U%UDD\->#*XA9RIGVOB)B:?'!AR2B8Q2!J0[O0AC2,TK:
M5,4+JF(L&9DS"/._%RS!XJ;ZG'Y.,?3?Z<N/Z86Q'63>T04%35MF(S=54:3?
M2PVQ8-+RK&2LA0,ZK.;I3NFA(XO(01?'K@:8V<M1#$K))9WSII9P+ !AIVQI
M(6)<]<Q9"0'=1<,5*"$T L5%(IQ87>-B]6T=>HOI:[/HNNJB76MNG?33N,!"
MIXDZ%P^GU=M?6)XD6B6Q*%^4X,Y[V'6NXDI3C&?LMAG5CTJ)=IRVYD.0PH!5
M]-+:'.2?MI)(=6<E@P>Y2&T(/\G#12O1WP2]P!T0[C0\9.O68:C6=WOV[*HO
MMAIY[/M0N/:>$[D,JAY,I*VMW9FT^51VQ)U_VQ=@<Z^48G\VF(G==BDJ6 EU
M) W4D)29BM"[$I 9JB+39G73\Y'C$ BS *9J$!R #5W,49]'_56=WU75]AFT
MX6SJ-$VC>+.L1:80J;:]O;RKSK";BWR<B<36"B9,ZY83":!3S+*,CXS#7:1
M6M( (*P-ZI 93GTN SV9XTQC"8H6=8 >[)!<M2[NP%J.T370Y5:I<]6W-NW[
M?;5:-[J74)RP3$[!):LM[&-5NK%#,V29C ,BT5N!&JM#Y)W*5L6IXD,1<RS&
M+*AAI82*&3*>K@%27R\6-Z4[K9SG$J4 ^7JY;@6% 1Y[CM(?2(OJ]8T5WKDY
M%)M%#8ACR7PCHVAV&MW2,96:R6P;]Q@R]9!4)AM/+1DZB9DP$D2 GT!3C@!<
M3C*)(5X&C*QRX@+<&^4FCZ,2]Q3MC&<5>!R\NF-P:Q:XQ4H:;USYK@L\6_\
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MN X,%0]=;OPI2M1V4IR,225/L]ZG]H^V?:T*R1@V<+![8Q#9L%F6<AJZ5C#
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M<:L7:5TV9-$&(0HRFS(?JV.GL)B$(!2R$E2F-52D $/8Y5,-;=HOBICE02D
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MC*:2%?8VNH7$%Q2)YFY:W:Y#X\G9B1F<DC"*F,S87"H<U9S,"@_'>22]?%%
M(:6GXDJH&E2A458DI5Z5#L)%[PY^IYR3IUYUJ<#4%)?U[MUIG'N[)6R '!8(
M9YUBX3M=;(+&1.R,O69&:R&+RC^':J=G;DL\SC!2R,-.*TG*M:"*69LBA=@]
M7I7LBLE#R9A*7 6@]BDL4JKS:U3V"GIAU"VE/I?T[=OL#JD@K4\$QQ6I(Y#
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M\+EQ!0M*EA9B*DE\5:@58DCF#@?6,I2E3IDPJWER9JBWDM+*7I?=420*YJV
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M?/(U[;6C*A90C8,O;5J%&=.:RJP<45)V#F1\.)40HKQ4M2DG>F&K72^0 /\
MBI4H4\I52!%4UGC,]5W:BD'=U8&QJY=]"(^=-;L]O^GEA<#@X5]'P+U+J7V
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M9?2OY&I]>Y ZH']FMH4Q]OZC>IJZR%Z0\KV%IJEUQQ1V8P1!,D\G&PXF999
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MQ?!I7X))!_L=FE)"2G+]Q*27!.<<"DL='B9>V>ET[ZQ/&5S:NH6=+"KW?;+
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ML;Z(\,V=0ZQ&L^S(_+80^386@PV-7$A6U30257;89L@KM-UT&E$V3BJ$EG)
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M?.)2 ,+!6\+BM1:A&KW%.5(CV/\ #VY]D;5;FVI"X''4=B>J:QZTP.[K/M3
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MD202WC%(.E2 2*7'%GBX.&.5V:_H4^HKR/OZB>-GTO=>1=)5*_6KC<9K2UE
MS6K%-^MD4-K9/C4)GW OVU2*[((LUQ"YSFRQX5@T)=EI0JA# @ES<5#6XFY$
M"Y7QTA*2PF)1I8NH/;UZ5=C2OM=Y?<ON%OJ/YVBC0!JZG)=R326E6RG<N#[)
MQIID57W*<E?X?M= ;C&AQC/S?"\?9[ %E!/%0J6SNJ7EFX+*HA1E[[C=2!,7
M0J-B<YRZAG#@T%( 7A<I<Y0%7N)AU+ EE'46'$"(7I%V9ZHZ'N<:K8K@TZ=7
M1.8LZX2[8358U.TSQ;1VNQ2N!A9F6*>V[D\:>O?)P5IFVKK6!@"KPU3+U,4
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M$9]AMNLB7&R?$\KB&68I0*T4WL'QD)*1/1PJ]&K2SZ\%6#LW*T%> M1R:$D
MOH//IK GQRQNV#;+:6-"OW.W8),"-8^UL[6 K IUM@M@R%>,!I 76*6EMQK'
M6BPQC[RQ)80V8W<RLI!%&9V%!;S$:\H7E,<3BZTS26N2PDI_Y>=%,U:6BQEK
MC9RMDRUJ14JR"V"0S]WJVK1@Y(GSX?BA/A$$U\KX@2.;$XCXL%"B8Q(#@8!
M:BGO6O9RX^B[PS30/VL.-JGMO7MH0C:B6]FS0VH]-?)!>XJ()Q):UM<>4LV:
M>9@V-1GVD!,;\%7$/M9[O/:LRX40F(+H-ALV9G4AW!(HH%@SN[\JM5A"V).Y
M+L/MC#7>OQZ7%BVC<ZND5@B^Z\@*Q,P]J%=9"Q@4Q5M#>K&?%F)L D,;=]"@
M09).,LV&9%^WC4$*:@BV)S0D&622&+<U#7N?CW5O#%_X]_#6UV'?;ZC9[$PQ
MFT)Q^>,D&'$4@M6FO9O<K$ FS.Q5(&R9JAJ/9Q-'*N;0;<64XY/*"ILS",'.
M]2[L>3AFJ7]#M /0*ZN_*]_0WF@J?\J%:YQO.IT#JZ^T;+8+T]8POFYD4FSV
M?B,&=E*MI(V4Q&BRZ[.S#$9(,X#\R981]52ULS54')--YBXN0]!V0MA?N<SA
MX5BJJ)< 8F:^A&7@+LPTK9X;S88A%B6EV,I8'#$I!MJ"892Q'&,R%,U@N60L
MY_$<B@ 24/;,PCEG,(LA(8;YL/)_A#X-!0V'#ZX\Q>L&PJ]GT'>]@9V>NXD+
MJO4Q75%-:U5NFX;>;G6^7K2YSJETY2/4[%#*^S1S(?YKWS% 'F+!AM0Q$;3$
M8O$"LQUXLG-0("EJ#AP7RYLHHQRV:"7E$V>$$S_C<6Y(+@F=-"TAP_Q3E >A
M"078",/]3.LU+WTZ*UW3MF;9V'DVQZ;N!.(^2VG7%0WUW7[WQF;7=]85 1E@
M4=BLDMWL+:S[FFH5OL1,;,B!$WIAR4XUUI9*$SILR4X&5!0H*EC3==*186L*
MQK*<3R2!E0)RRFM-Q98  .U#H:@4N*;W#:[^S^E7Q!S-?U-Q0/'WS@VKC6X9
M8!4IT>K<R\2FI]@K(L$C\=-Z%8<<[" CM%9:5A_Q"Y"1LE 3M-4L;Q,G$ERS
MN99=)\X;0'E&2D@;4EH"@HJDXTT%"6DN[OO D,06"<_%C8.[ZCL:729LO)6O
M)B2T6\%Q DW8A$MXMGE4\QZ@L@59]0T[ $I$:0O4[ \V,V*D6<K.Q^4Q*(E2
M?"$H)(6GK3J<N>6HF]VMZ""!&J"\W+8@3'N0D92XR]S7L.Z(_1:K:$_I;<I\
MF:AI]8:UW&C!J82F"(5YL.7N4YY09'9L/_.(KJUQ>V*T5[3 &GE6RDPT[&JJ
MEC2H@X^7+4HLDYBQHG<2Y  89DIK05#-O&+EO"T JW4J"@>#(L+ .P%*7I9O
MF-$8GTQ>I3>-L72-\C7^9-5N "AAZU;WG:[2O3-9V%B"0A/5-?8I*UM(G)=Y
ME";\GIN"^VX,Q /V_)0GR52R/)  !*0!4N0Y-1XHI4Q4$C%2V8 *ED"H =(&
MESJ7!>K 1:7#?3 GL?11R9:V0H:[RZ'BO<ZRVV&TK'95)&=P:I;$.%%6SX:^
M".CU4)0MB-@Q8;FW(681 (C=9L]L2C+O2\X(3F#D)H1H&S*] X14S09PRU3F
M#48[K@78742U+#@\#?"W U7K'1_SEL"FPK[&H?@V[UNZJGAP81KK?;]!U7DS
M&QBR\(AU[%:HY,T6JD@K .8"UTW;(^&@3#69-4<;(#!.\I:2+[DP2FLQ?(LN
M2^]H17";-4=H8=+ #JYRCH_53L-+35Z,0LN"7S,&:#CZ;M6O:]*K'(*A\[28
M]IMT=YIU(@1D*MIM/H0!NK59MVKPR=2:5/D0_ X1E5"7A ZQ/,@F.)&("31L
MI2:EB5DT:VI9P*GMC7%#+.4&(  R@U8/F+%Q5U%@:/>D5-]*36[.SZ;^6MB5
MLT !L]-M+?8-GL%8V6UCL*V-E9-B3 41DPI"JFEJY LUS%R'\98)(# #:;14
MT^4&+YD@$>+85-CXSNU!2H$:8L@S@DB@:UB"S4<5)#FH+F]!'?\ 1>97YFX%
MEH;@F8&TN_U'DGQ_;4"4P;;2ZK&I:3$CS&3GBR\[2@OW(A35/G[=VC+-8Q"-
M&TAU4XJ#',DI%2"<XSJ-JLHE(>G&D6Q@R3BIW<,*[U";AB*BW#,'BJ>AFIO.
M5^J_>Z,#%YK]DOO?.]WJ>]ZZR%)NOU"[Y N-E*)_+'G[W:C\IWZF-:"48.EO
M('P,R2[V?6F**9>&0JBG3*24$74E 00*\ [D!F[H)X"94NQ>5+!!&N3*6((I
MK4/3A8HZ#M(N.3.>>KGCFM0O:21NIIC?+;;JV*U0'2ZS3NH;=+NVU^D9*$SD
MKZTP)BOPH1PI:BN.9G/R2%%&5<6L2Y.&5ND=1U:4TWLTI(%U"P+@ZL&#@1,\
M@(DJ(2_5-E(9WEH#D$URT:^G!HB^@7CUG:NNGJ4H;#5VV-.ON0>5M>NK 03%
M.K2:1O\ 1G#*XNQ=J&0W5EH%&FJN,*SZQ+VW,J7)@Y(O;&* PV'WMX(EJ N%
M%4M0+"A=.<ZL6 8!X)Y D24YJY$4HQ#*) )!(8DBIT'&)W@#A_>]C^I=SJKJ
MMZH_J-?R?R9L.YNG>76G34B>@-<5$+5UO9)E^R;I]LKM=79'B&57$E'F(LB&
M\R'.?,0G9\HD',9:$IU<DF8'MNYTDD-5RU&BF(4@8(?*$E@PN:KWK4=^+^:,
M]5''.ZN_4]HD]0)6&*UU17&N7P]KG\X=@WQ[P=K^VT^S65I@#S3Y10M+>S55
M<%+LNE$3X6F6<O&WAEH& )4X; 3"DI( ^,S@@)L-$T%4N':-MGJ'@$LK8$[-
M*DY4L!GDS$D 4 8L*6%(L[DSCG7I_4)U#B';K6VO;W;.0M"^U;B6##6'505V
ML&V&D:D+MA78JB;36#"13&,B.ZDY-;$:YDLDL&M1V;G0,N5,T90?%/63,JP:
ML24J=[\8Z.U\QQ>*4&RA$L%(T49$H)4S,26+4M&9NOOBEJF^H;O^@:\C>;61
M;B;1J(TVBJVA[2I;T$]BC=7F(HJR):UQJAE/RX&:4LM*2P:4,'[W<(O[30LE
M*3UBCJP.>H<7"G%V9BP&J6'4V%2IP&4L@VRD+L'XN]-!K&T.NCANYK^H+HAH
MM5 J$;7 FTEO^/\ *2A$+'9K3.DZ>5ZY?\8G)YM9.52[;)^_X^==E-&&&''?
M*MA9HZC$E9J)PRS 6*0D*6 '/$*.CYM (7DS$B5/*@YS)W]0#F4X:[,=6+BP
MM/=7^F<M\>_3^X 09N9!U/7M?U)Q37HHUXFUCH<<[)L-RK>1('Y4UQMN&J%F
M%S 9#&K19*G*1&#%C#*EKQDTY74I2MYW%5@4%G9Z$]YU))"L0O\ ') +@FJT
MAZ.U^-J %HNC6]^:W+Z;74MSI1(+DV7G&JY+VC6_GE*[F1F>/M*J*U1,85C*
MYQ6U.OE02E+()1,I*499@T?NQ* G&R):JIE*0@LP;XQ1)/&I>@MPH(S4 G$2
MT*-):@DTMOE1[:J->^EA3GTIN+ 6/2MR9MQ&G*:UU.OON*D\5]A\5C8U-<XH
MU?9]GK8K&7PJ&OVNTW5DLFIP9=6D%8RY@GAC,==HS#U\M( (5\80?))FJ2FM
MRR4 $4!>]8OBR>M <;S+>Y&^I(&M@+&EVHT6M](7<*L6K;7QM9ZLS=>:GT#4
M+W>ZU$T$ #IN*])I*+7[R(VYG0\]3$7C?&.2Y;)B6,LKS85%//:*3F"\VJUI
M!)+YUJ65,16I46)=FC/$A692CE"2I9EI!).4K42IF#$JS!G(  :,,=/^G[#O
M_P!3KD[;>-*NE7QH75QM:.=K>BVJM84FP[=L^]7"RD\*9A9)66I:NXI"4)0)
M+(JXB1R*-P-AJ>M,O H2LG?PZ' N%)2A-C2BE5H:@\H:F*RX9 )?/+2L ,PR
ML@7:H-N L(+?J5*:3R+U^]/&J5: _P!?<<-6]VE3KLQS5TUQR9K"#FP%)($:
MT%A+.X#FH-M<,LL-P(<1R%Q#-<$I4O!SEJ+/G2DDNYZL@AKFQM09;",Y*^JP
MTZ8LLG,$"^\J: E*:5WE$ FK7W16-I];W"TZOBKI+XJM]CM;'D57E+?-8GL;
M$IDK&(<@\:\E:M]S,M9SL)P&W=W5!=#6Q%I=HU5<C.P)J0&8K86:#,GS ED9
M4*9)8GJYDM09V38*#G10+1C)76:IF:6#<Z3)>468T!![=;Q>G/?#R'!72UNM
M3K+&-?NJ&A7Q8-49;%1*SHV%&6+0DZ9>P$!HY)@_)A>R8B6"$6BM^"6/>'K*
M3,,V>DJ&8+4*,+TL2_)3 ZL_')*L\Q+ZE(.MFYBI[[QF[Z2VK1X^Z;^1.<-O
ML*OR[?<O4 O?$VED:F@UY8U"JO>IXPRJ)BR7 %I6<EQ#L6I PV=@5;#UKM!?
M63^I .X$F[$E12I1 )X%G%P#2+8B=UF(FRDIRIPZD)-*K*D)65-3*W696>K.
MXS-&3N >F=#E'ZBVX-.V?QKVCV+FSD-1Q9CMJZC:W5>"2*N5L !DRZOX6=A.
M95HLTW&Y*^?O"VYB;4Z>J7@DA- 1*00:YDO/IPN$UI30D PS-F*&&2G1:9:2
M#0D SCYPP#EZ=D$7UD:35;?DC@K;TY"1QIH;G5+@81+K,*;U4HV6T# S%45C
M&;MC4,V8H@:#DXQJ^0/N$BY?6> 4L2YB0^\N6:7R*6 JI#-XI#-<O"Z%J2@)
M02Z\1APH@?V:I@0KF!9R6NW QN_F/2+KBWHLT;61W*,K.MUO6:XZ%6H&O3OS
M,<;"C:VMG ,\F1_P!.%(-1D9(LMTBEEWB^9\8:DM258I:B"RE*-2^7?+-H'/
M,4)@209Q4U"LJ.K',"0!:K^JE8Z/I_4FK.\++6VTZ:J78]:?T;@^EN+BI[_R
MWN=6X[T#;M=VA=0'9(2)K+?]K@Z#Y$L-0J(ARS*8!2]6QA5UQ91985-R@L)8
M4I2%(?LEH(X%1<:P3O'=)<**UAG)3F44D$G7=%;,T"_U"^/:O=^9^F%3:]?!
M7!%M_*!MQ?KA&'7'RKPWBW%8JE7D$UD!2UKD[3Q.8B:0"968QY).!@8&842\
M7D54F7E)=V.3A2M4TH_*,<$2E>T5.Y$Z64L6/WOA07//,0PU:[UV5P6S/2NE
M'A2RWFJA7J?T0\=0I=FU2C,[:Z_.='4$7*W%@)3I!O&9XNB'F)!>M^YLU;N8
MP6@UC&8,T^8$7$Q1(46S!RP#'2@N7B\P#K)@31EK8&CD*5J">YK\.-N4.H:*
M_I-RI6\EW"5 U=  I=I[#3>6N9-KZ:(4T[1=>:_M.#7O)4A&ALLCSG,RCGV9
MP!4%5EATN&*7S4%2-6L.0A="AFG H*,LU0!_UC(EG/:K Y2SOEO!<KQSQ?@N
M:T5J8[HY0%:?)V)AIBS<P@5>!6_D,3@1H4R3=_JXX8@Y/,YP]I>/T%2C6C"@
M9(IV4Y=W9&E^WTOIZ>^.DO'7'A]@UYE-W(E\H6ADUD+O($X _P "X4&L(!8]
MHXR5$04H>TI2![8E*,,QQ0J4% &NZJIJ0^4^GGV4U76H^%8=( 8RL032S&0S
M%W%SQ<7B?7TW2*X%^<%TXJ%MUIC938O#1$=CX/ZR#/<7QC\5<*&<P!B']7#/
M)/>!&?);,2*@%K4>G&C-I]=F8J>Z["EM>&GFCOOJ*D2H+@1M@- \D7<BG]R6
M1DNNR($B""LOX%\0)  )D+(4C$[<%D24LYSG-9.15-"S.XM:M6'.]85QKC"3
MR$TZI6AX>WI-8[PZ[1C*5K.YVA4"E\<ER7:^8Y..4X0$-Z,8V,8Q.3RX6&W@
M668]WCS*<NZ^]P ;D2*<18\W X<8:]%?-QI?SF'8*M4(9J_EQ8_%FW,\0"LE
M8G@G-N:ZJ@VYQ+8!&-C! 39$>!63XF.4^V.!##6X;2VMZV%^\0-75BS#ZK7A
MW"I7\LQ9W&RR*62^!0=@D+((18E[#B88L-SD#.,KSD8TYS]I1)[RCGV.35[W
M]<'*.HU(QC.4TMR:"0O:-PCDUW+64F1EP,*3<YC+78.&1"#& 7>,@ALI9!+)
M\GCL [ *4Y>F"]O;E[5B"NZ5-%9,SF[7.%@681OM,7"\)#8&#(WB28P.$UB3
M@(7<J*0@JYE.2P0R-+,X54IW;J!%.+^D>?0\(7Q(#X=ZGPF7W%EOI?M/&M6@
MCE5(P0=8_*FSP@RF^1LT;($A>-H!!-N )@>?BRC.>#@RKXX*GAB((PQ*4)6U
MLW+3^1A@U]O;NX0L5L2+*$'N=G)(A?&B7#-82!C]_LF/#N5)%=F @B1Q@QBY
M=SB4&_D1Q'&(L["_;H.]J:W'K"U"79^ZX9C6Q@5I:^K(FP![=G_ A=648 %=
MX0,K+%JY!83CHS8899E(;!)S(6.3^:6#PGF$)1$4% +KN-,QKW>K2%L)]Q)_
MW^*[/OJ<P_E$_;*+KP43O]S95C$I9(Q\JR)#+RC%1/+Q)Q)EUM)XRK@6\^+W
M:6!D@LQDWYPLQH;5U[2S6;VXM48TJUW%K!Z>=F?SPURB;\H'Y%W5W&&J6L*M
M/OI5X@C]P;)#P9 H'RB+G(<9[Y$[QSS",L88EF5?*MY(KWDL6^OC"HKC5FP\
M&EUHWW6;3CY^--8D9T[62R8=W9_"40S\RX#K)#(24_ZWF36<S* ,&))Q5BO(
M)58PDM)@PW6(3M#08#CS]?\ #M/9'.*$+*WR[#9GK$"Q&)(M8: HNF&4<CQW
M_#Q!5DHA3.OEEB$YR"<D)XSGMS@>U/._\# _(?2W,Z^KE':PC\D<@$W)\;0
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M\(6=!4:]L>L7JKZTEXL KF-<LKV/S4US'#9/T3*H?-B,,[8AA*E3B,P.'EI
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M34@BVH(O8,0;Q<"O*VC\X=(O4BM5$>F '#G*.J&N6%W*_+UNYJQS[:NP%F)
MA.E:598KE7PNN86#P74[ YS&G5JE8F25:S992.#'=MQ33C;L.:0I$Y+MXR3Q
MH[O?R@U+\55(%8_2WV)HFL:>QM5F[;[%'BM;5[RFPT"=;BB7J^-ZVJND/-*
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M/>_T&+<?HI]-/KLT=R-+OI*]8-EO 5;#[2*!RUU!5SE&XF!3Y+&)/#,(R*[
MVL+ABJ I8-1D<T<C'#U!*0] *VS/0FEF8F]3K:#VXZ7LU].RL.85F\)D533V
M.I=K\+ER]96]<8URN\,"< +JKJ,K),I.&RZZ8KC$&Z^/QU!_<XG^0B;AJR@:
M "C-K6IH12A!!N&8SJX>[Z<K4[=/X=4D.2LG&;\H=3E&(X>52.NV(5I%A(D)
M3QB5TRWV,"-@TAX>C(#"2XXE*%ECQSNTH38NX<4J+<>SO#&(KW]M/5Q]7..I
M*OY,5C9'L-JU5TL5L8JEHZTVA6_(SWD+*QG&Y,\+&)8"FNP!HH\!RRX9 QBK
MJJ0Z:44*ERX/.E$]]Z]K1-&'K]8LVOF;G#*S3Y +:U&1[!K")OC-C4%'7W[$
M67HJEFPVW.=T@>0"AR( UU\0RO+R'D4_O $*NG,@L;D^,&.ZWR=2?HYPI.?P
MC"5\N=I5NH/<Y=[,S1(N0Y&_ <+'69)G* ,WZVL96LE5V,PBTZ'%M;OU8"5H
MXFFJ0H+<;YB@\M4 (#18D%/!3LXL1WD#V$-<&]8;TT[36D15S2[]"FOXFW6H
M(H2AL2R(/5"0>Q8X5)G$898V!M(57.,(C,J-6+,AY+@3J[DY/^H64Y57!8FX
M(9K,PXTJ(7QC>"XH_P#=YU#QZM7#A]'=$F^WN5(!^S,_KUNA7*3:;5((U8_!
M<>(LV#>'(284QE18; ZZL*C"+D\K_.NTX>5G%@Q:]:4(()(+,Z0SEJDLU&)A
MAJ]M'JWFH[F@U>E(%]4MM\VFC(7\HJVN; JBDRY]I69,4ZE8KEZ^K*B<EY*
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MN/!@:#E1XBZ).W26FK5[>-IW.U72-XY<S4;8%&+]BTF %<O)51>V*L=#)(P
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M\V%DN@U9G')4\21#@:Z8(6J_DO>R6I1F9M1<7 (9R[5>-V)KY@7X/5N%Z4<
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MO:[W$PSE\.?^$'=?UJ*SDGY$9 -Q)B+'=,-9*T^%2RBKJ("2" '"@& UH2_
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M;O[(*^ST[JOKPAAE/:TDF@4M=J*LRS))<97;3"HR'B:9F2^*KSDG:S(7:I"
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M;(3LEXXRD"4)ED0T1VIJ3Q--;<>Z&;ZL>)<^WG\\15P#80Q0RMK^M Q!^DB
M\;$PY"-]V1\RT\!ILR@ O=(BY!^3WP*>&!@S.$9U585/C)N/QAP/9],+8OQ)
M7+%87A_KT<?HKSB5&#9AAL!!UW4EQM&[I!)8M#&Y(L"8>,UA:D-B>#G_ $P9
MG#)2K&QEF #Q(/U:G$^8?7#78_/Z8Z$J[8:M>22&OZ4%-AF&6P*OV*L)IX01
M3C+(8T1(,L@7!BOAYB#$9%-+.)+XEE1:2QN5$\P&]=-&[XBGMQ_A;ZK1":A>
MV[Z-P.NIZ=H53M6R4;J +.42K-AM63%!F94A)=BH&EL&&,D_<DS#AC]7C,Z
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M.7)!4:L$BK".>(J-74>NK>>3ZQ[*^NZQS%RQJUO25N2H*I5E;J7+FP,#:Q"
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MP0EDGLULLCM96PZRTFT"CKE4=$9.ND!(2AYF7+J@ A)"N.8UY,-2J-DT7+8
M'.S&X#L02W :$MWP1\><>7BW3/R-C?\ 6GJ:]U/I W'8*]X8!*4UT#>-#M+M
M00<Q6S)JTU@<#4UNYAJ+1)L269B1=B4V:J7]MR\JG2J<7!N,LQ"0!VYLQ#:
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M/NE0<.!VS?<P_:H>2O)C%4^LHO&<;,4^X*5("2AW74$$&E:$$"MJ-8ZT:7(
MXU.A#&G=J--'%(+E=;T"QH,K:U2LV.K"&*BQKM*2!\)T"6U[6VLS $,'DUK^
MXNC%%<4E\P^V*KL28(ODIHP5+S&HS>,:U*E)2+6W4@UXO2*VU/ D'4DZC0-[
M7 8SJVNT!K&TU30]NJ;FTEI@**.Q)61JM&ZH,6QZ<0[1VSL&D:^VF6NJV5U$
MDP)Y&1ID&#M-']0I14$)4H$!;$IHHA=[ /EJ>#GS93RL]3E('QZ IO*!<D<*
MLE[%B-!$[L8*+6B =K=/AHU\MLNOR.V^&-BUNE?*Q^:U0:SC#K31]AN<JQ++
M(ER.8(-CYA/$<I\REZIS9@00!8)-=ZKLD5+:!N+1L!V><=U_5VB##.P\:VS-
M^[<\<;2/%HB*PMK+:]'M)IE3BG7D/)C-P(Z58&IQ6HS."<%5@-J%=#"9,,,S
M@YP0<S97;*JK!1%>T$U(L:UB*@,'#:BAX ]HM AJE<:JCLF*?C:TV.P9LX,M
M3L;.H@>#M5L^R.$D]8#S"?W%IAY=DZ\887;2;-&?L 1%25!2H)=5 5@;I4!4
MO0D@@LP)MI6HPPK=4 "*3<0[O0#$S:'C8@<Z6:'.GR*-78D#\5;7*V?K'*2W
M5DY U8M("@TT::-TRPK D,TAELELJL<Q ;.ZF&/N')B7(=OC *A0H7JSEF9W
M?QNWE##6'("P LUG+#5X"=TC5*[K1T0]2VBH-LM)]Y<5%8,/@$CI.14:YHB/
M[X&:+&WUD(X!D<)NK+_)P5##AL0@'?)(.4)#V4742^9G<9*FM%$U)A< >%S*
M)!&'D@D"M9DWRKGQ31J5-V:X!;C?98KR XUN+C:5*:LU[:@&)5)S7S:&]P,L
M$- P35I6%V&V/MS,L"4L!F?6-( 1+A0*G,D)<Y"0YJ&/?:IOR8F&"U2'-!1F
M/)^X<G/?%=#E6EH-R1'Q%M&V+E'.KO2#G7%+*[H;*W=FN%0CD4^[6C.5T:EI
M:!+"?BBK&,AU  PN 73\8$U</6B@ ;7S%R7.G.#*2:FQ<.371@:O4E["E'B;
MU^&A4ND9IYZCN?)]:=&MN=KV';-?<N;%[[;%1JM#9?>\F?:LJ=+,BT]<F,JE
M7A#"ZQD\F6R:JBLJ)=,LNP2@E(8CR<KLFSEW?BT#N2?H[AZ/,T-=EY Y&I(Z
M"EQ_J;E9K,:D]WL;-[7?,A7ZO)RG73G/ )K,AM Y9LV9(+B,;"01X*#!#!(*
M0A)"BHNIV%:YFXFI']XT+UB0Q>[LP U8DW M=P&!N8@UJ^QV\!;G8A\@#W"P
MMES29K!Y32)2Y6'5'UNG2PU$MEIXKE)Y@JMV ,4V=EA9,DC\V!/02!E"<F5J
M!B2Y<YSH%%TN1HFP+Q!9Z!WT9GJ_'N=[4T>#I)4-5<*VFL<-WREFVR"SE%GX
MZJS2BU4=55MMHSK :FX#&14IUDHSG( JH,B9$,>%HJ0QF)%#Q+5&[0!A1V!J
M7IK!Z!Q%6=W[ZDD:\&:/L5KINO;#5S3X[N 6K#%O!RMJZXMJP%V[KP;(]73A
MF4$1'+DQ-@M P-@8GG3-EG)^Y/(^923U8"AEWJ&U 0 Q>II3A>%9P/A&%8EL
MTX,3PE$CG8 EZ@1*:+LM11K-27XHWW5(3E4*P3_)^3BR=;5U%544JU>%&<YK
M(JQ[TH)B"22I1/-GG!.<#^KD%1<K234T-\Q))5Q/$UAHN'K4WNQ?EP.F@!&D
M0>W7%<35+]%7C/9A(0J-N8T[<ZM!+:(+L-XL7:VPIC89;L:Y2T<+(U;".%JE
M.MDJ'SHUF0P!50W5$J%4U%02&\HV)"0'-7-:ZX8H X7$@T2</-!8 D)*% GD
MPJ?4T<W&YHI,\;9>TAEJ]N-QBC7A3"&0=BL5M4O+->[%$$(U?AFC3IVZUFSW
M_:\8$J$@V(^K@%6=ET <N]!2@*CF[@]-6C<!QQ;1NP.Y>OT.><"-AU(OU%K>
MK5_%.[(ZJC?!JMGW6R0;RCJ]\V&.;,C%6B-F[;K12FF!%VI0.D^X0L@,9A(.
M6+=3N@E8SE.Z!4J#M2PJYO8'+32<NZ[A[E.MV'*W$T';$/2:EJCEC=W-XIC9
M^,JZU'9+[$0U@Q.I?EK"\K6U:F]&9[W6[)IC88G8A)Y.;%JM,RTX)(.U<.05
MA)"9E S)9F'-@13@"QA>5EZW%,&.:5GL[]6AFM9+.UZ\8,:.'#5- %C^0&PZ
MO6(5T:1&WFG;5J5W5XUYE%*V;"FP%<K4U"WM-6%?Q*[7998D (<62YY"L]LX
M4HLZ4M13T8$OE!JQ2Q ' 1N:W()(KV6]-6\]8<8VC3;94,U=-V(E&EMZDZ#8
M& LVBUY;8C%9EU5^$'2YKSP=R$=V^[.!;D\H]\60%D+-:5,#F#G*"DAF25)H
M0=*'= 9M*!U<4X1*93'PG#N 15)Q$L-?@3F#<(D5F-8UM:[Q=:!L=;2[#+7R
M5ROV7%]9H,Z]2)5<R@K%_FE4KZ-H*!JO(1,2-=VKKXE<%<-*=P[@)4' 4X=@
M74[.11ZZ6";PRWJ\]0+: :'FQK#>%YK[VCV-?FKWG&IXM&[%+9,(60+!-]B_
ML+Y2R7RRDKB-,@$BSJX<+Y76Q'-"0+#,<*2#F"JY7RY2&!#90"]W)# \P]JQ
M;@]+<+6>ES=^<1.O50ZS74:M&@VC7JN@?V?,=S48<48#K6P[(^>P^$JL:;N-
MB?GD99QBC)BJ9EV EV9F254U*K$E2F2 ]4J4'>S<@:ZC2%\.I*D+4 S8C$"C
MFJ9\T*)J:J-::Z"';%;(ISE:XTY.LF2&(1BQP>L!A\\YRD5W <+&P'#1,R/@
M6#%P/R=GD)[=V6TJ3E2Y2^4.P7=H?2$L-[0:'A QU(USMCKVPU_,2@+_ (TN
M.=J:DJ-?T=1J&T-V]SS@G7Z=)MD[D<D5"XP"=Z!2.&60X/%#M+D4/59C#%XD
MR72L3,65%9INJF%;:7"LM*4:L+2BDS)QDA03X1CO&JHE,^>)IUHI064N"0"G
M@8I?JAH^4,=/6G4_))M2N*%OE;IAI6*JFK+*G?P@WRSI:&P?)*ZXS@;"]&5C
MXB^(8Q*R'VFG@4HXP2%(ZU:D9D_%3U$J4X)$I1%&I6^K/2-99&<W'Q<PO0VE
M+8"@:U1S[HM?JVXZQ8]-^N\5C98-@UYT\:0!X/QXMSF/G_@FF"Z'Y(YK#9Q.
M$& R*.0QF]I2C[8]8R%?;06?]7BEESQE*) .CV[">R%DD^'8<BI\&QQ:VF')
M]31W=7>NT-ETENZZBD-#7Z_9.)4$JZ"RG@$GKG*VH!76^+X/A^"?V^(Y#^/@
M/BEF.18Q^CZMAB1B 7JK.:DW4@F]"?.!4PQ+++>]%"M35+<CJWG:'_4E1UMC
MT?;UKU@##]6Y3JU+P&H"_KJ4MK21*)F(H#%F)5\8A*.!QAB&,0A"(\8ABLDD
M3T$$AE./,].7\8)9^,16QI2['7S]L/\ E?7:LW21RSK-/@>$):WM=9%9E<8U
M08@_,!D<!AB8B)B@.2XL9AB) XQB0\8S[8KAB>LE$WS TOR/J[KPKL[[C(/
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M\JE38DFOL6X4C,OTV2B=Z+^E";3C1GU=&O\ *X_?)\?#%L%Y7QPQ.4LD755
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MZC&.(QQ3V.,8Q^&(XBD;&,1CC'MC&/;'X?\ AZJOQ%?W5>HPMC/O/%?\-/\
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MQ;52O_L>S6L*X3[G,;_:L9WGPJ=4^UH-PYE@0L=O_NX?VX__ $X]; I_%_\
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M!*,U?5YBK+UDL **.K*V'E%%";D .2P;GG%;3,OJLZQ+S%603DA.92#+*R
M"HHW5$N2 '- 06.Z_;9LJ.6%/>(2/>3.#K?A[I2CC\,FQG/O+.,?AC/M[^^?
MP_'TN<-.*D')0$OO(U21\J$)LB:9^%(31)FOO)H\H@:C7@(F_L=I_FO^O7_W
MWJW@\[Y'^)/^:&>JF?)]*?KB*O:"W)27(X*=TYU5A"$?.MCNE)0V(X]\FQC'
MOG.,>^<XQC^W/MZJK#SLJMSR3Y2>']Z%\7(F*PN)2$U5AYP%4W,M0&L2>*2T
MEG/LK^S\/^/7_'W_ /WO]'JW@\[Y'^)/^:&.JF?)]*?KCG-):8Q[_%_UZ_\
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$=L?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g111598g86y30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111598g86y30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Z64&AO=&]S:&]P(#,N,  X0DE-! 0
M     %4< 5H  QLE1QP"   "   < E  "')R,38S-C8U' (% #1-:6-R;W-O
M9G0@5V]R9" M(#$P+4L@+2 R,#$U($9E8B Q.2!D<F%F="!F;W(@04,N9&]C
M #A"24T$)0      $.H<B5UCDQ/6<^^9ZB4=D*\X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 5-CUP         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              %;   "#P
M   !                          $              @\   %;
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   %;     %)G
M:'1L;VYG   "#P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !6P    !29VAT;&]N9P   @\    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M-S1H 8VB8,M+OZJ8]0O< #?(;QJWLEZ^P1^I[S^R/_?+MQ<AQ>!69J<6V D
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MJ+CWB.27?]4Y6*?LE%8JIVLK;,-' D[BL\=+T!&??#^XO^D8B6^Q'HZ?95N
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MOI?S?T_40U[):WVCZN[Y]''W. /\V[0>[GV>QRN8.1A!MC\&NMH+HL+&EON
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M ":M)*=C:OV-_P"^/\T_^32^QO\ WQ_FG_R:M))*:OV-_P"^/\T_^32^QO\
MWQ_FG_R:M))*:OV-_P#I!_FG_P FE]C?^^/\T_\ DU:224U?L;_WQ_FG_P F
ME]C?^^/\T_\ DU:224__V3A"24T$(0      50    $!    #P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ #+EL   G$  ,N6P  "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-CHP,CHR," Q,#HT,3HR,@!R<C$V,S8V-0
M Z !  ,    !__\  * "  0    !   "#Z #  0    !   !6P         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$V.C R.C(P(#$P.C0Q.C(R ')R,38S-C8U       #H $  P    '_
M_P  H ( !     $   (/H , !     $   %;          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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MP2AB8V1T=7:"AK/A-T=F<X2BI?%ELH.TQ/_$ !X! 0 !!0$! 0$
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M4TN'$V@:@(:!H/\ APYO^.-+G*L 5!2K@<^WB MJ^[PWC?*=0M+1LW?;<)R
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M.Z&S.*J2K-EAT2N9>N3\4W.<$RN)*&DF*!E# (E("KIJDF)S 4PE+O:B!3"
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M3GKYCD1>WX>&(2M*5:B4@9DI-TJMJ-AQ]!$YNN&\8^O$0U'@/ 0#>#AIQYM
MTZ\6,P.Y*;VS\5M7'S^N,C+&ZM*U_P  =8U\=MG'%R!8#"42CJ EXAH(<?SA
MKU\0X?#C"3'<Y'_3I>,Y*I*U&U[$6U&Y.O++9MV<\5R2NNNNH ' 1T$??$0X
M<W#34/\ AC5*BNQMSGFRSOKVYY:K1NM): ).H9;";'*^KC_TVQ<4#".HB&@
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MMU<M<@^ZPW4I:9<:7)K0C2=*FTS+8>9: R5I)X>S-:UMG=[*C4Y&3DHDDQ)
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M<T5*!<0$DWUMA9N;[0/%G'(T'(J0<Q$3!&R#TT1(LI C-V "T<&9K$<%06*
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MMD;A)$7 !VC81J\0U9?ZQX. EU'FUTU$1T#WM!UTYN AK_@.-/F_XE&_$#Y
M?!J/A\,;A)I%QGW8!/, 2+9YC.]^/6+10.'K-(IA5/J<O,"11%0>/, CH&Z
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M;)!(!2K;L&8P=PX<O'"KIVNJX=.%#KN'"RAEE%UU?\JHJHH83F.80*(''4=
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MZ /=6()20;6XB 1^,2]0ZPZ>D/S?\,+^'R'U17HD$'9EG^/@\<4IBB8=2Z"
M!QT,4?\ OQ2M0T=N?_95Q^"+IO;F#JU$'\+\<0'4I1-T% 1Z-!$"!P'CU] <
M?S8MM9M;7S&X&D>;B/-%1"@HJ(-K<6O(9?=%,EJ8AE#"4H!J&FNHCQTX  <>
MCW@X\./"V<R7J-N<>/R?G'JQKTL@.ZOD0=N5K7OJ&KUQ/(4H" G'G/J !QYP
M'0=>;7>T#CTXQDTK)12#_ =AS(_&XU<=K1E97+2TLDJ-T[=8(&8O;/C\HS,5
MB9>?7B(AJ'O!H.G1U\><>;&L3Q!18:]5@E6R^>8'A\=\HV>G(4HI '^;2-R
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MOD@?^G*Y]98=F/!_RC_HJO?0[3_=D^2D/3![F'J?^UKY('_IRN?66'9CP?\
M*/\ HJO?0[3_ '9/DI#TP>YAZG_M:^2!_P"G*Y]98=F/!_RC_HJO?0[3_=D^
M2D/3![F'J?\ M:^2!_Z<KGUEAV8\'_*/^BJ]]#M/]V3Y*0],'N8>I_[6OD@?
M^G*Y]98=F/!_RC_HJO?0[3_=D^2D/3![F'J?^UKY('_IRN?66'9CP?\ */\
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M '9/DI#TP>YAZG_M:^2!_P"G*Y]98=F/!_RC_HJO?0[3_=D^2D/3![F'J?\
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MD^2D/2Q[F)#G8&VN"%#3)V2./2!)JM#H \-?92Y0Y]>G73!6Z_A'(]5OD_\
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MJN&^ET(.&PSI$]"A['EDU!,)=!Y,1QAG?V7-TYU14):G#4,YPG(#4?W!N/\
MYM60M:-A8W;\%D)"U5!*/_A6RH$:S<S-['8+W_")K798VKTSJ<ODG+')OZ)B
M26KA="\-!$!G!WMWF 1 . !J'3C$3'[)VZJY93;-*!SN#-D&^PBTN1;9;9X+
MWR)W;]SY &@[4P3K"I1K6.*TU;P[=47@VR5M([@ZY-SZQ]_>'>G:XD4VH<0
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MRJ:9_P#04.1 Q"B(& -X1$HZ:80CY^Y?=D+CK0_I(W3(S,;*^H9H.I:)RXS
ML#F&D*M:9R+0D'18L7+(Y'<8=TVB)-1NN[:B&\U$@)*".\1 &\=-PNTAE:>
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M$S.2+5)9*&@G$0#@[R&7=+MMQQ) 1#>43:+'31WP3,8IR& $(ZJ !   >(@
M!PU /,(B/G$?APA$<(0PA'/.TWG]&[-N61\Q9&KREQY2R56IQ]>A739E(R,O
M<K!'5F)00=/"F;(;\A*-RG46W4R$$QCG*4!'"$<Q1/9&:<:)M1KIEC<,OK33
MK9E969^K6"2@W*C-GFS<H*G0DZ66BG#N..Q9.9UJ\>I*"DJFW(H G*("8$1?
M+\>A V9QV*USRRE<U%S>D[]7.]6/?(QKV5(] 4FTFJNDU38J([A70NE%5@*"
M)4#J& #*$ 4TU# B00=43)#/C)R*KL-;9#,6L-J[855$(64,_ Z,@JB@LY7*
MBFD4[@ ;((*J.3*(D(V*!>7,F)TP,A?ITZ7RBZ3.;V6%>6K[>:O-;CU;5R8U
M\JTBB(29%CHII*H'3$Y"H**.$$B+K&31,JJ1(%-\P%PA%IS9S+7RWKS"9B:;
M8LP).:FF$!#P%6*V.X<NGS=VZ[<=O'1^UF$6T:LUEE7NXXT4,@D5 XJZ@@<N
M?P1:<@,\83/NE/[7$PTK7'<':)FFV2!F#(+.HJQ09&:CUL5VU,+=ZAVN_9JI
MNDB(@8RITQ1(9(PBA&\L(0PA'DWX(_\ /^.$(^:>8G9&XK+S,3,^J+Y)7R;J
M.3]HB*I>LQ(B8KPQ,4^F(.O3J*G<=\LTE'!$6=CC@5[5Y<-1,(&$V\F1"^OF
MCH"A;7>4=UO%VH9Y=I7)2K6J J\;W;>)H*6=S8Z)4;XQ<1R/)D%L@HRN#9L0
M':WW5TW= F;4HID1%[_=GQWVQN1'.'*]:X+9?)7BO&N;7E"+U\KTO;::J#9!
MVNAO"':YG"+=RBHJW*L9=,#[ITP.4Q2HF/-<SFRKMLC,Q5;OM;EY"O%74F&S
M603WF2+5=9JX<&.IR:2K9%PW62.Y0.J@!DS?=--!%"+A4,QZ-F(W>.Z-:X>R
MHQZH-W@QCL%.UUA*10@*%$I3E*HFH11)84U$5DSD.D)RF PH1SZZVLX>,SNA
M<G9F@7"(;VBU2-,K%W>%9!$SE@B6@N9#D(PJIY!.'*H4[5*7$_(*JE'5)-,-
MX$(ZZ(.FZ&N\(AKJ(AO:#Q#70I0X<P<-=.?"$3,(0PA'G?+IKO!I\.$(]81%
MQQCRPPA<<8\HAA"XXQY1#"%QQCRB&$+CC'E$,(7'&/*(80N.,>40PA<<8\HA
MA"XXQY1#"%QQCRB&$+CC'E$,(7'&/*(80N.,>40PA<<8\HAA"XXQY1#"%QQC
MRB&$+CC'E$,(7'&/*(80N.,>40PA<<8\HAA"XXQY1#"%QQCRB&$+CC'E$,(7
M'&/*(80N.,>41C-S@E+34K-64G(,CV&OS4(5Z*9E@9GEHUS'E<B@51$5P0%Q
MRHI<J3E )N[P:Z@A<<8\HCYZ(;$&9\UEEE-DO?,VZ,_R[RBLRMOB35++2=K]
MPEYA*/MS&+2E9N9S$L\1W.0&W/5WZ$?7(]T\.U9$0>LTNVDW*(N.,>7ITO>-
M93O8O)60ALMBPF;T57;?0*Y+5Q:WDH*<^I/QK_,BSY@,HM_6[7.3U0&(CU[,
MY)R8P!Y=1\3MGNP5IR,>BZ?UUP[DBQ4#Y/\ 3[L[QOY+8VFT+[<[DZL.6MS+
M?/!DO*IYA9:/Y*3A'V7L$G"*#3Y&K7.GEKD;)*)&EVL6W:JM(R2=OSE(LU=E
M:HH73>]QSY_URY^.,9/L$.U7[E%S>J^K&N<_W6?"EG[R5_"R+MTB1+O6[^N^
M+M(T&U0$(UJD>MB(1#9BR5Y0[3ME5"X.T>/\-GY^2+E7-@U*$S0>6%SF&Y>9
M705CS&N^5.7"$*#9Q0KAFN@S<6Z0/. ^.C)L6M@1?3-7CDXE@,*:6D&ZSF03
M.W!NB;CC'E_K&EJ+V+=:EUVTPBF:C&6=SF5EGRQ93BM6E4WY$;))O'QY&<3[
M[#L)L"D<%47(9DU74D5'SQ)R@5T"*:(N,^Z'E&KP:B=FK5:)&=VQY/R=KV;<
MILMX*>BX!'*2,RESYOT% 1\-1Y;+B&:HM0;@LV="^0N:LB66DF:3E)\D1&0;
M Y<NCB<00ND97'BMTZ7YX^NT>Q;QK1JP9H)-6;)J@S:MD"%30;MVR94FZ""9
M0 $TD42$2(0NA0 H:!KJ(HG2'&/+%=A"XXQY1$#:Z#N\^@Z?#T=?^&$+CC'E
M$?.W*OL<.2%0NEJS)OT,CF/?IG.&TYKPDNZE+M&PL*I,6AS9()@XI87!U399
MU7S*MT0D'L$8'J[<'"S8!.)0#+*(NF][C/P<0C'+!V.QO-Y86FD)WYA'3UBS
MV<9S+6=I4R$!^U->4KBSJ5A:$E"/IADP*BFT06"5: 5RFB](BGR8("A=/&/$
M;?A$:EV/IQ3&N7:T==JQ)R-#S)MF8*\'9:=*S>7$^ZMU?GJ\Z4=U):WIO&\J
MQ2GE9%B]93S9DA)M6S@(PR9!0,B=(<8Z<?%E]\6B[]CKE;H9XJE>Z134GE#H
M=.+"4^A3;6N1RE+SHRTS8.YBV,O>IF0;M'[?+]:$28GEE09K2I'Y5E"-!:+H
MBZ>-/-L_,^39%W8]CQ09+-I,ET@ L*.U#$[0I["G22DF%(F+[: ])"0"8!Z4
M7*;HZ82 KBT( F 8HY3&**)N+ZQKOD;??Q^7P:HMM%['C,4-W#2A+[1KNXCZ
MEFI374%F/EN_L--,PS+G:[/*R4;!L;C"O8^<9FKB,8O(%F%!<QKY^B@DS55(
MNFA<<8^Z*+-CL==BS6M;>Q2&9=1C6D0XRJ=U6*C\OI5@2K.,N;$$XY*V?1]V
M:RE@9RK85HR/971]9VD$DX=+LT!?&;.FJ()%[Z0U6.?D\F><==;,N0#[9_@\
MPXAY:4+2I>LT[#F.5PWB5(@D>G.Q%<C.Y1TEG\D=PHV/!&6!X*I 4(Z%,$""
MGO'1-QQCRQTUA"XXQY1#"%QQCRB))B")C#IKKP#B/#0 W>!1+IQWM3?A::<1
M  #"%QQCRB/GTS['7DI-9Q9M9QYK1(9BSE_S A[G7FAIB\5^,K3*&IU2KC>&
MDX2'N+:M6LP25=>2X/)>#4WB22;-1%1-DD8S[X73QC9M\//S\5XL%S['PSM#
M[.>6:6VNQ,OFCG10,T8:3)22+OZC#TBE5FJ%J2#LLNW<+(.EH%P^0<-5(]LS
M*^%$K%0P*K+-EO\ 3R1%QQCRWC'5^QWV"3SRB<Z9W-&NR3^.S.M%V4;-Z(\@
M5G5:GTD6S.G+IUVU1, JI%LVZ;<]D4@#3TDH*KR1?.72@K A<#:-I.WIGG;R
M1C-2[&1.U*.S+K$1G<2&I&8%'GZ<TK<+0HE-S4B2KIRX9*5^YS+F<S!39-5'
M"CAU'2%LD"O'KAXJ15LV619MD+IMK&WI:^?YQT9LF['/\6:7M,VM:H^S/[/
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M %7[\Z_Z)AOX##A>G][-'](KGQB//>O,^4*T\^G]"IO/KI[E>O#@"K]^=?\
M1,-_ 8<+T_O9H_I%<^,1'O6FM-?"#:M.?^A4WJU]RO5AP!5^_.O^B8;^ PX7
MI_>S1_2*Y\8B'>O,^4*T\^G]"IO/S:?YJX< 5?OSK_HF&_@,.%Z?WLT?TBN?
M&(=Z\SP'PA6GCS?R*F_97#@"K]^=?]$PW\!APO3^]FC^D5SXQ :Q,ASYA6GH
M_P!2IO2.@?[J]>' %7[\Z_Z)AOX##A>G][-'](KGQB(]Z\UY0K5P_P#,J;T:
M:_[J^^'GPX J_?G7_1,-_ 8<+T_O9H_I%<^,0[UYGRA6GY%3?>__  K[X8<
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MWII*:MC7-6_UK?2C(.*181D&[8I,(Q).OQ<0T<E8"LJF1ZHV,\=D,)G*ZIP
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M80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80B
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MF("Y0USB8=ZU=0.28Y 1\:,M(JQY,O32#F5,U5[8<K+N7PNWKG[X++'=@4X
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MGT_SWMG/U?UOAUJR/SS$GVLQ%\3AUPSGS2B?4%%_0Q$:%$!Q[J6S3_VWMG0
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MCUFUA_O+G'EB.ONMDV$M0">+K>HM_P#_ $8#_"8-MT--:AEF&NFGWTS/XZ@
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M;ON0RS]*9G_;G#L"8/Y3QE]L<1_$H=?5;^;4#[/4;]##US!MN^Y#+/TIF?\
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M$G-C?9HL3"BP<GDU21J>7+F?=5>C-H5FSHS9:SP\C S(/:@V23@I-%Q'RKP
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M7'$\.37S9C+7^].40]=5.?('8?TC0^N<1V*6^5CYM/JAPY-?-F/.F'KJMSY
M[#^D:'USAV*F^5CYM/JAPY-?-F/.F'KJMSY [#^D:'USAV*F^5CYM/JAPY-?
M-F/.F'KJMSY [#^D:'USAV*F^5CYM/JAPY-?-F/.F'KJMSY [#^D:'USAV*F
M^5CYM/JAPY-?-F/.F'KJMSY [#^D:'USAV*F^5CYM/JAPY-?-F/.F'KJMSY
M[#^D:'USAV*F^5CYM/JAPY-?-F/.F'KJMSY [#^D:'USAV*F^5CYM/JAPY-?
M-F/.F'KJMSY [#^D:'USAV*F^5CYM/JAPY-?-F/.F'KJMSY [#^D:'USAV*F
M^5CYM/JAPY-?-F/.F'KJMSY [#^D:'USAV*F^5CYM/JAPY-?-F/.F'KJMSY
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MTO?%G0<(=9NZVX.Z2%!>CH9 K .2@D'B%'4[EE*ZDF5++@594J^+G15W6D4
M A)()%AW1%R;).T*!LH]F(I%R/>!R-S9L,ZE5K;6(]W87;%ZI%MKDR:L)5Y'
M*&D!,D^53:-O9:?A(I&-H"91QY.5G"C[99X3I[3)6F8*1,I[IV7_ (,K'CL
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M\-3#KH ??/G'0= YQT'$]BEX6O4T9Y#]T<SQ#CAP\_\ -&_/'V(>NN,HN/\
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MMV:C&6I\_P!7(6%H#3K:KZ&D%:2+7TDD$$@$D$$ C;:XO]/$H:*.0!%@U'H
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MVRF(.0Z/].:]_#U=[,?R-UW]*)GYN':R4'OAJOT)?V(=LIB#D.C_ $YKW\;
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M2=D:(KYVOTUYY9:_N\,0-6N_/&WL3$PPA#"$,(0PA#"$,(0PA#"$,(0PA#G
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M"&$(80AA"&$(80AA"&$(80AA"&$(80AA"+U ?UBE_P!E7_Y1\(1L[-0ICDC
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MC<B2=&7.1,BPO;7<7ME'JU^V'1]*Z<#U%LI%]/AF5L$DA*BJU/O8 D@#,JL
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MF"(OMV9[#_3G\>6<?62D6$ENIU1MB21D4K16H&P$2,51(4R3$8UD$TS)G$5
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M2OKL3MU6MF8\X1XPPA#"$,(0PA#"$1 1 =0Y]#>RXZD]B/LRZ=)>?3I#4,2
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M*I\8Z<2$=4:VP?NSR!G;UE Q35V[-*<@,F9PN@T355&1[5; ^,H83/.U6_;
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MNDG2&I) "@"0#8D'2J3N4[M]$FFYND4+$-)FF[I;G*>9B2F&TJ%EA#TFIEY
M7E<:>@2!=)L+7NU[&G9+[V,N:[T7/ZXGGU8A>=-:9JU6 )M: +(E@5I<)9\\
M[I.(0LU,DB%G@+=S22LD1D"!'[H%:)?$F!)52%,OT1L2VDJ50W)2:0TM])2X
M6CO6DT>Y2201<Z%\P(OJCN:;N=:5,"K4[%]00\)54R*C,3\V*BY*KFC)JG=\
M=4N95(]4S/4Q>4M# F5[T$[XX%4T)L3]DDK3FO/:YEUGM /:B@[0JCN%E+-%
M.ZP@]=*.W3>!<L7K<\0B[=++NG*$<=NDHNH=50ACJ"885B3!+B'4/3E+=2^
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M;:03+OJNE<^MO+1<::*VI?22-$3#JAW0R_0^5,0$  I@#>$>.N@"(EX\.&G
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MMOI97*+F)=M+C3CB$-L3J"6'])!E7%MK23QUCH<<(CR/ =3#S>R+KQ$HZ"
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M-:+0(T2!4S69FT3-)OD I#B&1E23)I0M9RQ"O]V9*?;@VE9V7[0BD"O)YT4
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M7_VF>]/ .GIUPZUVN6L4_7\Y[<.&U<E4+ZJE_5#P*5773NC;-1Y@[YGNH_\
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M>D:BL*A50.WY<. #H( "R>@:\-0UX]&F+*98?>*=YFNI]ERUOHOQVNG4.?\
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MDV9H-.)FDJ;WP%1%VY=Q)MMS%K1CX]D>D@YZ^_#X460<_ /]I=>,#VZ=+R'
M-?N=0T)'/P?WA&5[5Z;&?#5+\LYX/F?' >R/20<]??AS<Z++IUT_VETZ#I\
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M $)'XA#M7ISEJE_^,_1Q$.R./C .L%)@&\4QC%;L.!=0 ^GWTU$H$WATYSB
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M9'MPZME.36O.GV(=_%R\;M_D _2\.#JCRHKS(]N'5LIR:UYT^Q#OXN7C=O\
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MZ4\S(S68<#)HM$'#MK#/2D AXYA?5TMS\VK5JA<>+7T^^/HF(B;V0AP$3=0
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MJK1F*<JENJ?FUJ#C$LTJ9F^JI5I(&C-+7+O.+TM*4: &ES6.^!3 /-H&G/\
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M_I(=<^&N^&A_6TA^HB:6DW734*C: $H!P& E= T$"ZZ&:@ ")Q -. <=X=
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M?.0Q/2"<QE*3>S7_ -)LVP_CXY->3>]<VO\ 7,1S=?\ 1.;#MW\(=YU>XO\
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MA*"L:0S;=2A2@AU![E;=[I.L"/FZMT:?P_5)VD5-@R\Y)/*:=;L0FZ38+;)
MTVUCND+%PH'(VC*0RVK(\Q7@_ Y)^YQG(Q41\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*
M"?N<(0\&M:_%>_*"?N<(0\&M:_%>_*"?N<(1 <MJUH/L7H>_VP3A[_\ D<(1
M/9Y?03%<CE 77*D Y0$ZI3ET.42C['DPZ!Z\-M]O39JATUV_",YPA'SSVX-K
M^Q;,[K+YC2VE*DI!Z]D+KF&UN+Q5LJUR?J+)[*7%S600E(TZEL=MF"D?72*%
MD$0DG+8RD6^3*9NHB";??LXAQ[(NF:>W76,L[)8(E++VT6^N4VGU._VVY03^
M*+%Q-/M#Z)8J2:*#@2.7Z\>G+$="R2%(':2*I0=M3" X1,:XC-N:YRN93BL2
M%/B*54&.T$7*0+!()N+,M-1*-3M-A>*F3;R]=)6Y!5.#3<)R1R6)JT137:'B
MG9G*;QJA<?ET\'](H,UNR#A4<Z*E7Z,-.NF3,[EQ?IJ=OS(LFNM5KC#.82!I
MW;:Q9%!JI RMVL$'5I-F#)%TDM-M7J<HBDT6170Z=!&NZKV0_-,<T\H(VY0F
M7K;+"WY"RV:5ZF(V*G6DO"3+.#LLI'A&O7%G?L0A7SZ%910,W,:X>"O))G)(
M!P(*(OF!EF/O^_\ .UMMXH*3MJ;6V9E7JL768S(Z S.M^U19\E6*\_5+I(51
MI38;*6V9H1\@YC6>8+"35L+E" :-CNTY=&/Y-PKNQ13"0Y'X0N<LA<[,[<>P
MC9]_-&P+'ML9ST+)G-YC>83*AOM)Y=9DUC*N !D\F&F5-HG+@U6FHN25;2LN
MA,Q+1"OQ=@<O62MC=&(M'D,5Z4JQ"80OG;BM]]XVO;-KFQ!L(R^T]3BU#OSB
M(2,(];23>1F:>PLJ5TBJA8RKLXJ78RR\8B9TXD&"3>7[9.W.T$RRV]JHZ=-4
M3X.GX?C'-N2'9);2XC,V+%FZZRWS)J%+@\NE(2W9(U2\TUDI>;K(6%HIES)L
M<PIF:7<3#)I%-9=618N46K*/55,JU<J+MBF0\GBO^9/0QTK#[?-4LU8K;BJ9
M;W.P9@62U6^IH9?-EF39<CRAP]<L%E>(SKU)!L\C$(NXUL6CE-D4SQ^^69BB
MW[547,B 0?\ 3F!_.)%U[(9EY1KO!T2;HEZ0D5(.G3ER2409]NTGOY7D&T+&
MKQ[-5Z,K((GC55Y))NZ:I,V3N/<$<.%'*[5FB;_Z[!X8DDV_(Q21E$PRDM[>
MMH9BW+*"'N#F2B0BI?,>K)*N&\81H4!>-HR7;)B=.54+OM5DG#8[%?<*NHB+
M].G-G&/4';]F+#E]09V4R1L+^\VZG3V9$K5:O-1ZK2 R]C+),0;*<5D)$K<R
M[EX:&D$6[%)$3.5HQRL<[))9% B%^;IT^_RQO/+;:OB\WLT5*%E[1)R8@&E/
MH%Z?WUW),F$8T@,QZM$VV!,$;VNX=K2(,)=$KID54J22I#;KK=, %1/3\(X4
M9[=^T5-;4UPR=CU\K8VH5W.R;RX8(JY*9JV"7<0T7,+,473R[QN9#.KMI%9%
M,%5ESP2;1LH<2';%!,0PB <SEX->P[3JV9?Z1TJW[(A2&T@]7M67=TJ]*;V3
M.6J-+PX7BI"/DYC).;FHBRIM(]!1)YVNY&'4.U75%(P.%#-A1.1(KI5"_09Q
M=YK;KCZAE\-XO.3E\ISF5F*M"TF&DWL,X3MJMS9QC^'7)),SJ=H-FB$NT[OB
M=BN>+,1VDW"2%N4543&%-^R25J89.'U2R9S"M"<'E_.9AW!LU=14>O6(FJRR
ML39T%R2($[HK,EVKON<JU,4DP*:.G:1' '31!-OSYOZ:^ES$,L-OUW:+])PM
M@HKASE[,9XL,HZ%F# ID9M4SVAR+.GEGF,A+/7+]U).5V*+YZS)&(L3+G.2/
M=<F!#H7V=..WD\7X1B%Y[)BS(K9:O2:.O$W&,F*%W$=6W=F("9KE@S7J%#GE
M%!@7C)!&30C+ [=,$6$[+M&SI)(SM=<J9FBZ)BT+=D%S+1>/(MC1X"<1;P6T
MA/N[@C%OHIO -\EX62>,"'J"MKD5[ !'+=!:372MD&:60(JT:(0QW)73=#Q#
M[_+MS^Z-V4;;U@;-FG2LH%J=,/)NP-JX65LJ9XZKQZ;RPQ+V10>PT!.R;E:3
MBDE68(/"L["[?M2+%.V;R:VXU6@:OZ6^Z%\P./\ I^9L(^B.)A#"$2C?AA_V
M#8@ZCX#^$1M'@/XB/S&;06OAJS)Z@L[\>OCOAS!U^_\ #C\/-UO_ -)F-3_]
MO3?X-Q^K&YW_ ,QL+G_[)EAY4<?3;%/E'6JC99B::VMP<AFT$LXK[)23[BL9
M6>[?CTT&+Z7&(G2M431YY%T4#-4 46;)E!VE^ I1N>T:@5F?J2*Z\EM;%(??
MHLN[.&G2M0K FI-#4G-3HI]1$NTJ074'DJ+#8+TNT"\C2LJ<:56L4N2D7Z2T
M'=\J3352=1*B>F)2G%B9+LRQ)&<D-_6B93*M']\NR'5D-*(!3MN/R*8R.:,!
M!O:U8H2M&JKFTV)!"QPT^+AHT=.&@.ZY/-8YHS%JY77C$2-7[$7K53MTR@J$
M.B4O19+<KDI['-)IDS1ZS2:.N@N5ZL2[%5IM6$U*,N.,F9HU99EI:5WMYY<F
MR69J1+S*D3&^:9WH'3)G= FI;"E4GV*K2JA5A5FJ53%+ID_3 AYUI#Q;J<B\
M^^[OS;*)EPKEW=Y=0ED)T5::C:)?*&!HLQF<_M;2:D8:G*U$(*&CY)K'/)$;
MZUD7\.9[)J1DDW!G&MXQPU?':L2G7? <Q5&Q0,F./J&YY2L+U+&#^(&:G4*=
M058>-+ITK,2LA,S@Q0S4)REA^?<DI]E$O(L2KK$ZMN50)J:S1U,$%)O)+&T_
M7Y/"4K179.6GJZBL&I3DS)NS+$HG#[K$M.%F53.2B]\FW9EMZ60X^K08MII6
MI25G*H;).#E9*NO9&GSM:8R]6L$D5E(7"OR4/)2$0,6Z:KLIZ*8G6BT183#8
MLC'2,6LZ07 %RNA(Z*T:YRF[F,A/SM)F)S#52H\K5,/UB?0U.8FI,Y39N;IA
MIZV79:J2,BX])IZCG99,Y3YR24\PZDNMS*T/AAC%U#'E1E9.IRTI6*;5IF3K
M%-E'7I:CU*3G965G$S33R'Z?./:$TL3,DX99^5FDLK;NT6])A3S^J[GEZNI(
M1<74JZS[><-G3M=*(MJ%D!1!,X!O'.K%096QD]#E$H;^]N[VO,&.?8DPBX],
MR$E0Z5*F><9>??13:TBK@M(4!IJ*Y2G)82C-105.+4%!1R(!VZA8F0):=FZS
M4GNIVG)=MMR;H[E.(<6V"0 )J;WQ)4192@DVR.>JHK\#1RT*US]JJDLW<5W6
MO,7+:Q))*RUN5WCD3*T/".$D6T:B+<[\I7:BIBKIF3,GRFZ6\H=+PUUJ8@JN
M(:'--NTG?*1)SDK5&4&?Q$L*4&3+KI[P;9DT;TY- .K4H/)"%BYCQJD_7SB.
MBT^D5B1>;J2DU1]ARF.:,E2&\E.E]N?;4X]-+WQ#&DRELZ"D+20WI&C4I%*=
M9?T:>A'MDD)Z9NCVLV(7+5DS:HJHPT#(BSAF:2CQ98C5245;E?N'0"]*F5?M
M!F!A1"V7A;#DQA+"U5I,S5I^L5/$TW1JXAV5EY-EI;-.I<ZEBF2S;\VMQ+'5
MRFA.NOH$WH!X2DII;R/=.(*ZSB3$%.J#%*EY"1H4M4Z>&7)EUUS?)VHL)>G7
MEI;0DNHEFW5,--*#&GO0FGM$+.99YY2U6BPA)*OI.D5V]VGZN8I+(SLK=:+B
MTTS,GL@JVA88T9,N#G.5TQ*#IF7= 4%A$P@&Q[J6Y]0,+4M,]24O-K:Q-5:%
MHBK2]80[(2++3DM-SCC%/I_4E3?<<6)F6 ?:2 DMNE2BE.%P!C"LU^=,O5'&
M76W:!3JLE?!#](<3-SJU;]+R[;]1J/5,DT@)WM]2FGE+*M-"1E'+>ABE, \W
M 0]_C\'P]..$ 9'FMJU>2Q^\CQQU@@6Y]O-LX]7B\FJ)>$4PPA#"$3PUT)J/
M1PTT$2Z!H&O#00,' 2Z[P:CQ#GQ4+@Z)%DJSN->L9\6>72T5:A;8H"^>N_E(
ML<]5LA;/7]"-AG:%LM2O$'E)*<M+4ZV/5&C,B93+.H&46356;NVP%WA,R773
M(B_25U*B@H=X50A6QDE/K_\ 99W7ZY0,54S $Z'JCAO$4Z9:50$.+?I516EQ
MUN8:T,NIG7$!,V'$A*&U*?WP!HM.?-^[_N;4FLX>G\8R>A)UNC2Z7GEJ*$-5
M"40I*767M*UGD-*4Y+J38K6@,%)4X'$_<EOS&'>W@$>&@::<_#B #^?IZ@Q^
MHP%K\Y)Z=/%'P+>X!YNG0148F$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(
M0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(1S#F
MAL@Y!YTW9S?,UZ.C>ID]="KM$YMXZ4CXB*,JFJIW*9ME&H-'*ZJ955W7**JB
M(G - ,.$(Q]'8HR21K%@IZC2SNXJT9=0V5DJ=W.BL[4J$ HR4C&I'0M"G%TB
M9BV$[I4JBJQ2&*J8V\;5"+R&R+D_WR$LQF4XJLG?4\S#1*DB@O"JW).#EJ^>
M34:KL#.EDW47-2+5PP4?&8G!P)BH)'*0P(156?9(R&M+BP*/J'&L&=ER^GLM
M9.&K[5G 0AJ_8I:#GGKEO'1+5JDUFTYFN0\BUETP%VU>-$ER&%0"F*AKC7TG
ML";.TK76U8<P=A-&M:+6LN&XDL#I)VC5:U88^R,69'*:9%.47=QI&LBN83&=
M1[ARW.  J8<(6B\/-B;)AS'-F,?WXUQ1CF2MFM'R==L0L)1C<%Z<ZH*[AHY5
M9.]QDI67[EB9N=-3055%0-J( "$6]78(V<))C%QUFK$U=&T?:Y"\OT[=8Y*:
M/9K8^BNX))JR**G3/(+QD0LZ9Q3=(S5DQ*\<*)MA55$Y41;U].EHS**V1,E*
M]E7<\E(*$D(O+.\V-"S2E70DUE&C&01=0#\$891P5=PR8*.:U&JJ,1661$P+
MB3<Y8Y3(F*28V-<BYD+2B: D(R/MZ-.4F(:(D"M(,\W15')JY:V<0+51FTL;
M9%VJT?/$D@;3#/D6\PQ?%:-120L.+ITZ7BY.=E3+)9"MJ$<6B/L55E+-+0EP
MB9",CIYJZM\9$P]C)R3*%;U[M>5CH*'1.B6 3!N>/1<LS-G8JKJH6_/[\^GW
MQ;R[(.4"5D2MB3>R%F%8>M0LXY<2J$LM9FM07DEX%:9>3<?)2:;UHK+O@7<P
M\A$JO$A;(NS.$FC8B*(L/7S^&,"R]V'J;7%)U6[V28O"#[.:[YSPL& #"5V&
ML%O4Y-%<&2:SY^\>Q<< ,4U#RJ42J?E'985!RX64.B;6Z#F'X#\8RYGL9Y2Q
M;&#80[BXQ18*KRU(8NF,\V1>&HTQ+2$XXJ"ZIXE5-:);R4O)JLESI=W6Q7JQ
M"S(@)=Q#ITZ7C9^6^0^6^4\U*SM&AG$,YFJY3*JNS[=6<,6D'0J]'5BM,VR;
M@552&:P\6S05466<*N%$SJ+*&.8QA0C7C/9&R_BKC8KI"6S-"!=VRX2=XFX:
M*MZ;>ONY^9=F?2BYHX\2J8B#ARHH<S<KC=#>$ '3AA#5$)#8TR+EH-E6Y2!E
M)&#CK5FG<4F*\RX*1>8S@E).9O!':J"22YFCQ]+O19)(J)'9)G3(FJ82 ;"$
M2WFQQE3*1$=%S;V\6 8*1J,G6)"<L:<BXK#FCMXUG6QAX]:.[A&29MHA@1T2
M6B909KDCJSII)9RZ461%N//\O!TO&!NMABJ/;_-6%2XV-K4+!E/(Y6S=7BP9
M1DI,-IR5&1G'LE.-VPLRHRR2KEH9I$P42NQ,X%U'OVRB212M43&Q8[8[R/AF
M3:.C(.48Q[#,VNYNLV2,NX%!E;JL_0E(8Z9SD.X&/:N&R6K051.HF7=Y<IM#
M A8#5X=OYQ@;3L?>STU9P4:G'VT\76&<?'5V.5G6_:\-'Q=JB;HU8(G2BT73
MI(L]!QSA5>1<O'ZY4C(J/# J<XH1DBFQ/D<*#E!NTL\>#QOF<P?N&LRD*CN+
MS>8NHZ\Q2W;+!P1-K(H/% ;F;)I/&1P(9L\()1U0BX.-C7)9Y/56?=QTL\6J
M$C49:&9O'<>Y3;2E%=HOZR[0E%8HUCC>Y[YN@[790TS&1TJ*(-95H\9*+-CH
M1UB :  =0:80B.$(DG$-\./,0VN(.H^ Q&T> _E'YH,_H>84SGS%52B9)1,]
MF?F(JFQ='3,01TU*8J0E, ZZZ@(AIS\,?B5NKTRI.;I.-'44^=<:579HI6B5
M?4A0(1FE0;((YQ?PB/U.W/9V33@?#*%3DJE0I,N%-J?:"@0FY!!5<$;0;> Q
M@M>>6RM=TD6U?4?,IACW.DX^2A'3IJ[:@JDX*0ITTVSQJJ15$ABN&3MLN4N\
MF"G)J*E-K-%F,040SG4M*4_+S\HY*3LI/TMZ9EIAA3K;Y0JR&YAE>DRA27I5
M]A]-M%+R6UN(5GJG+T>J]2.+J8E'Y"8$S*S,K.LMN-NZ*VKK2LN-/-E#J@6G
M6U(*M!9&DE)C+5\P\SE(0]>81[N#A08-XUHUAXB3;JL6";MV^49MGZJJ\@9)
M\]6%Q(=M.7"J@M614UDD4=P^Q/8QQSP8:)*2;].I9E&9"7EZ?3IN7<DY%#TQ
M.O2\M-/*F9Q,O,34RER9+TR\ZXIA@)6VTUH*PK.&<*HGN$GIEFH3AFGYEQZ=
MG)=Q+[RV664OO2Z4MRX5+-MEJ62VTVE*77RI+A7=/@F8&: H(M7K%W+M2P2-
M<>MI6%=.PEHAK(/Y-BG)*F*1PJNP=RL@#-ZW6;OD4%^0*Y!( (%+>+\=AA$L
M_+/SK"*2S1GV9^F3$V*C36)N:G99N>6Y9U2Y5^>FA*33#K$VTTX60YO82D5K
MPUA0K6ZP\W*.JGU51E<E/,RYE9MV7EI28<E$ K;2V^U)RA=EG4N,.+:WPM:=
MU&<TS"S!8-F47'UQNT@&*4RFC7D8"5&,UL(,23"JRZCD\RHH[",8I*&5EE"D
M*U(#=-$@@!JY?&.,9.78ITM16Y2D2Z:L6Z4U2IXR@<K/4B*D]OKCBZDI4TW3
MY1*@JH%#89&\H;TE&/%W"^&YEUV;F:H^]4'URKBZFJHRHG!P<N8,DA#:&DR*
M6V5S4RXE(D[J+YTE&UHP]XO/J*)*Q%4/65T06*9>":65%9P10J6J:YWTF^'D
MP$#" (\D<P'T4$VZ&-:?<JRUI<IU >HI0'4A^C2];8=F=,(!2^J;J$ZK1 1E
MO>CK[LKN"C.LL2*4.(G:P*LTX4J0U4G*4MIM8O924,2LM=6RZRH9=R!>(+/;
MFYK*%45CY(8EI.2%A*F:*=BNK*R31BR=NEW!TQ.N51M'MDR%'\ R9U!WCJ&U
MJ=?Q-,41J@O2DVFG,U6<KA2F0FNJ79^<EY27>=?<*%J<"FI-E"$D]RI"U7[H
MD&I:B-U=^LAV71..4Z5IA<$ZQO(DY1Q]]IIEA*M%JSTPZI7\R5!.0 $5,=+7
MF)C(N(9,9-!K$6)>SL#EB5N71EG+5DQ.ORIT%"F(+:.:Z)&3$N^!QU]EH'K*
MU#%,A)RDC*2D\S+2-776I1U%.=$TU./2LG+*<#A01HK9E&;(6EQ*<Q;:?*:D
M*!/3LY/S#\LMR=I3=*>5U8D-F1;<>?#0;2Z@I(>F7E!8.G903;N1:Y62TWFR
MQKN+<0!6+.1G'EFDTHN#D4.Z4^^ I74@Z,Y,\.0RHIE$6[0[5BF4H<BT2$3"
M-Y6J]BBN2<S3W:.9.3G*O-5N;1)TR;9,[59PWFIYTO+F5-ETVLRPMJ6;2 &F
M$9WM:71Z!2IAJ;;J"YEZ7D6:;*KFY^7<$M(,*4MF7:2V&AHMZ2@''=]?5?\
M>.JC #04Z(#]YI7\$-/O<\XZF 1_ZGCH.NFG1C4>"ZI=2A39_N[ _P!CF-:?
M_P /F\4;&9Z1S/5DH2O5_:&;Y6_[9L+;+Q)[@3OB66]'//W.'!54Y-G_ $.8
M]W$=727SR5](:]N'<"=\2RWHYY^YPX*JG)L_Z',>[AU=)?/)7TAKVX=P)WQ+
M+>CGG[G#@JJ<FS_H<Q[N'5TE\\E?2&O;B>6!G1  "&E-1 I2AW.><YM */\
MD1'\,0)H ?A#U>Q'T32*H4E)IM0*UE.]IZCF#MUE(;NL'(!(MF1<D B)$_(
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M_M*'^(>_3\(0\*E@]I0_Q#WZ?A"'A4L \S*'^(>_3\(0\*=@]I0_Q#WHY_\
M7\(0\*=@]I0_5_D'OP^W^K"$/"G8/:4/U?Y![]/PA#PJ3_M*'^(>^_\ ^?\
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2$(80AA"&$(80AA"&$(80C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6809607824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 16, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAGE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sage Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001597553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,022,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 903,465,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6809505744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 186,753<span></span>
</td>
<td class="nump">$ 127,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">188,491<span></span>
</td>
<td class="nump">128,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">189,016<span></span>
</td>
<td class="nump">129,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,159<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">10,148<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesCurrent', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,307<span></span>
</td>
<td class="nump">7,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 15,321<span></span>
</td>
<td class="nump">$ 7,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2015 and 2014; no shares issued or outstanding at December 31, 2015 and 2014</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 120,000,000 shares authorized at December 31, 2015 and 2014; 28,823,549 and 25,621,791 shares issued and outstanding at December 31, 2015 and 2014, respectively</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">335,032<span></span>
</td>
<td class="nump">188,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(161,340)<span></span>
</td>
<td class="num">(66,845)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">173,695<span></span>
</td>
<td class="nump">121,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 189,016<span></span>
</td>
<td class="nump">$ 129,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797086976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,823,549<span></span>
</td>
<td class="nump">25,621,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,823,549<span></span>
</td>
<td class="nump">25,621,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807614576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 69,357<span></span>
</td>
<td class="nump">$ 24,100<span></span>
</td>
<td class="nump">$ 14,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,293<span></span>
</td>
<td class="nump">9,710<span></span>
</td>
<td class="nump">3,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">94,650<span></span>
</td>
<td class="nump">33,810<span></span>
</td>
<td class="nump">18,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(94,650)<span></span>
</td>
<td class="num">(33,810)<span></span>
</td>
<td class="num">(18,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(94,495)<span></span>
</td>
<td class="num">(33,811)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (94,495)<span></span>
</td>
<td class="num">$ (36,105)<span></span>
</td>
<td class="num">$ (18,288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (3.40)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (12.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares used in net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="nump">27,778,288<span></span>
</td>
<td class="nump">21,574,347<span></span>
</td>
<td class="nump">1,492,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6812479024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Initial Public Offering [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Initial Public Offering [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Initial Public Offering [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Series A, B and C Redeemable Convertible Preferred Stock[Member]</div></th>
<th class="th">
<div>Series A, B and C Redeemable Convertible Preferred Stock[Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series A, B and C Redeemable Convertible Preferred Stock[Member] </div>
<div>Series B Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series A, B and C Redeemable Convertible Preferred Stock[Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
<td class="num">$ (13,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,394)<span></span>
</td>
<td class="nump">$ 14,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,395,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Amount</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during period, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock, Amount</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in payment of licensing and consultant fees, Amount</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in payment of licensing and consultant fees, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="num">(31,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,675)<span></span>
</td>
<td class="nump">$ 37,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Amount</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during period, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,970<span></span>
</td>
<td class="nump">$ 37,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,999,999<span></span>
</td>
<td class="nump">8,973,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock, Amount</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="num">(2,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,359)<span></span>
</td>
<td class="nump">$ 2,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in payment of licensing and consultant fees, Amount</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in payment of licensing and consultant fees, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends', window );">Conversion of redeemable convertible preferred stock to common stock, Amount</a></td>
<td class="nump">92,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (92,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock', window );">Conversion of redeemable convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,007,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,723,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">121,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,621,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Amount</a></td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued during period, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,628,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock, Amount</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in payment of licensing and consultant fees, Amount</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in payment of licensing and consultant fees, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">15,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(94,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 173,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (161,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,823,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Redeemable Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Conversion Of Redeemable Convertible Preferred Stock Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_StockIssuedDuringPeriodValueConversionOfRedeemableConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sage_SeriesASeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797649392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Preferred Stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Preferred Stock, issuance costs</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Preferred Stock, issuance costs</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6809864912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (94,495)<span></span>
</td>
<td class="num">$ (33,811)<span></span>
</td>
<td class="num">$ (18,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">15,240<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_LicensingOrConsultantFeesPaidInCommonStock', window );">Non-cash licensing and consulting fees</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(681)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred offering costs</a></td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="nump">4,353<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(70,681)<span></span>
</td>
<td class="num">(27,042)<span></span>
</td>
<td class="num">(17,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock option exercise and employee stock purchase plan issuances</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of commissions and underwriting discounts</a></td>
<td class="nump">129,720<span></span>
</td>
<td class="nump">96,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(584)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">129,866<span></span>
</td>
<td class="nump">146,870<span></span>
</td>
<td class="nump">22,783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">58,987<span></span>
</td>
<td class="nump">119,700<span></span>
</td>
<td class="nump">5,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">127,766<span></span>
</td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">2,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">186,753<span></span>
</td>
<td class="nump">127,766<span></span>
</td>
<td class="nump">8,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_PublicOfferingCostsIncludedInCurrentLiabilities', window );">Public offering costs included in accounts payable or accrued expenses</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LicensingOrConsultantFeesPaidInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing or Consultant Fees Paid in Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LicensingOrConsultantFeesPaidInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PublicOfferingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public offering costs included in current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PublicOfferingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800002800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>1.</b></td>
 <td valign="top" align="left"><b>Nature of the Business</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Sage Therapeutics, Inc. (&#x201C;Sage&#x201D; or the
 &#x201C;Company&#x201D;) is a clinical-stage biopharmaceutical
 company committed to developing and commercializing novel medicines
 to treat life-altering central nervous system (&#x201C;CNS&#x201D;)
 disorders, where there are inadequate or no approved existing
 therapies. The Company is targeting CNS indications where patient
 populations are easily identified, clinical endpoints are
 well-defined, and development pathways are feasible.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company was incorporated under the laws of the state of
 Delaware on April&#xA0;16, 2010 and commenced operations on
 January&#xA0;19, 2011 as Sterogen Biopharma, Inc. On
 September&#xA0;13, 2011, the Company changed its name to Sage
 Therapeutics, Inc. under its Second Amended and Restated
 Certificate of Incorporation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company is subject to risks and uncertainties common to
 companies in the biotech industry, including, but not limited to,
 the risks associated with developing product candidates at each
 stage of non-clinical and clinical development; the challenges
 associated with gaining regulatory approval of such product
 candidates; the risks associated with commercializing
 pharmaceutical products, if we are able to obtain regulatory
 approval; the potential for development by third parties of new
 technological innovations that may compete with the Company&#x2019;s
 products; the dependence on key personnel; the challenges of
 protecting proprietary technology; the need to comply with
 government regulations; the high costs of drug development; and the
 uncertainty of being able to secure additional capital when needed
 to fund operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company has incurred losses and negative cash flows from
 operations since its inception. As of December&#xA0;31, 2015, the
 Company had an accumulated deficit of $161.3 million. From its
 inception through December&#xA0;31, 2015, the Company has raised
 aggregate net proceeds of $90.6 million from the issuance of Series
 A, Series B and Series C redeemable convertible preferred stock. In
 July 2014, the Company raised net proceeds of $94.0 million from
 the sale of common stock in its initial public offering,
 (&#x201C;IPO&#x201D;). In April 2015, the Company raised net proceeds
 of $129.1 million from the sale of common stock in a follow-on
 underwritten public offering. In January 2016, the Company raised
 net proceeds of $140.4 million from the sale of common stock in a
 follow-on underwritten public offering. Based on its current
 operating plans, the Company believes its cash and cash equivalents
 balance of $186.8 million as of December&#xA0;31, 2015, in addition
 to the funds raised from the public offering of common stock in
 January 2016, will be sufficient to fund its anticipated level of
 operations into the beginning of 2018.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790996160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left"><b>Summary of Significant Accounting
 Policies</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following is a summary of significant accounting policies
 followed in the preparation of these financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The accompanying consolidated financial statements include those of
 the Company and its subsidiaries after elimination of all
 intercompany accounts and transactions. The accompanying
 consolidated financial statements have been prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&#x201C;GAAP&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and the
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all highly liquid investments with an
 original maturity of three months or less at the date of purchase
 to be cash equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 A deposit of $39 thousand was restricted from withdrawal as of
 December&#xA0;31, 2015 and 2014. The restriction is related to
 securing the Company&#x2019;s facility lease and expires in 2022 in
 accordance with the operating lease agreement. This balance is
 included in restricted cash on the accompanying balance sheets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are recorded at cost and depreciated over
 their estimated useful lives using the straight-line method. Upon
 retirement or sale, the cost of assets disposed of and the related
 accumulated depreciation are removed from the accounts and any
 resulting gain or loss is credited or charged to income. Repairs
 and maintenance costs are expensed as incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Long-lived assets consist of property and equipment. Long-lived
 assets to be held and used are tested for recoverability whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. Factors
 that the Company considers in deciding when to perform an
 impairment review include significant underperformance of the
 business in relation to expectations, significant negative industry
 or economic trends, and significant changes or planned changes in
 the use of the assets. If an impairment review is performed to
 evaluate a long-lived asset for recoverability, the Company
 compares forecasts of undiscounted cash flows expected to result
 from the use and eventual disposition of the long-lived asset to
 its carrying value. An impairment loss would be recognized when
 estimated undiscounted future cash flows expected to result from
 the use of an asset are less than its carrying amount. The
 impairment loss would be based on the excess of the carrying value
 of the impaired asset over its fair value, determined based on
 discounted cash flows. To date, the Company has not recorded any
 impairment losses on long-lived assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenses are comprised of costs incurred
 in performing research and development activities, including
 salaries and benefits, overhead costs, depreciation, contract
 services and other related costs. Research and development costs
 are expensed to operations as the related obligation is
 incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research Contract Costs and Accruals</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company has entered into various research and development
 contracts with research institutions and other companies both
 inside and outside of the United States. These agreements are
 generally cancelable, and related payments are recorded as research
 and development expenses as incurred. The Company records accruals
 for estimated ongoing research costs. When evaluating the adequacy
 of the accrued liabilities, the Company analyzes progress of the
 studies, including the phase or completion of events, invoices
 received and contracted costs. Significant judgments and estimates
 may be made in determining the accrued balances at the end of any
 reporting period. Actual results could differ from the
 Company&#x2019;s estimates. The Company&#x2019;s historical accrual
 estimates have not been materially different from the actual
 costs.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Patent Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company expenses patent costs as incurred and classifies such
 costs as general and administrative expenses in the accompanying
 statements of operations and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company recognizes compensation expense for all stock-based
 awards made to employees and nonemployee directors, including
 grants of stock options and restricted stock, based on estimated
 fair value on date of grant, over the requisite service period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For stock options and restricted stock issued to nonemployee
 consultants, the Company recognizes the fair value of such
 instruments as an expense over the period in which the related
 services are received. The fair value of the awards and measurement
 of related stock-based compensation is subject to periodic
 adjustments as the underlying equity instruments vest. For awards
 that vest upon achievement of a performance condition, the Company
 recognizes compensation expense when achievement of the performance
 condition is deemed probable over the implicit service period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of each option grant is estimated using the
 Black-Scholes option-pricing model. Through July 2014, the Company
 was a private company and lacks sufficient Company-specific
 historical and implied volatility information. Therefore, the
 Company estimates expected volatility based on the historical
 volatility of publicly traded peer companies and expects to
 continue to do so until such time as it has adequate historical
 data regarding the volatility of its traded stock price. The
 expected term of the Company&#x2019;s options has been determined
 utilizing the &#x201C;simplified&#x201D; method for awards that
 qualify as &#x201C;plain-vanilla&#x201D; options, while the expected
 term of its options granted to consultants and nonemployees has
 been determined based on the contractual term of the options. The
 risk-free interest rate is determined by reference to the U.S.
 Treasury yield curve in effect at the time of grant of the award
 for time periods approximately equal to the expected term of the
 award. Expected dividend yield is based on the fact that the
 Company never paid cash dividends and does not expect to pay any
 cash dividends in the foreseeable future.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company also applies a forfeiture rate in order to calculate
 stock-based compensation expense. To the extent actual forfeitures
 differ from the estimates, the difference will be recorded as a
 cumulative adjustment in the period the estimates are revised. The
 Company recognizes compensation expense for only the portion of
 awards that are expected to vest. Expected forfeitures are based on
 the Company&#x2019;s historical experience and management&#x2019;s
 expectations of future forfeitures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basic and Diluted Net Loss Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Upon the closing of the Company&#x2019;s IPO in July 2014, all of
 the Company&#x2019;s outstanding shares of redeemable convertible
 preferred stock were converted into shares of common stock. Prior
 to this conversion, the Company followed the two-class method when
 computing net loss per share as the Company had issued shares that
 meet the definition of participating securities. The two-class
 method determines net loss per share for each class of common and
 participating securities according to dividends declared or
 accumulated and participation rights in undistributed earnings. The
 two-class method requires income available to common stockholders
 for the period to be allocated between common and participating
 securities based upon their respective rights to receive dividends
 as if all income for the period had been distributed. The
 Company&#x2019;s redeemable convertible preferred shares
 contractually entitled the holders of such shares to participate in
 dividends, but did not contractually require the holders of such
 shares to participate in losses of the Company. Accordingly, the
 two-class method did not apply for periods in which the Company
 reported a net loss or a net loss attributable to common
 stockholders resulting from dividends or accretion related to its
 redeemable convertible preferred shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Basic net loss per share attributable to common stockholders is
 computed by dividing the net loss attributable to common
 stockholders by the weighted average number of common shares
 outstanding for the period. Diluted net loss per share attributable
 to common stockholders is computed by dividing the diluted net loss
 attributable to common stockholders by the weighted average number
 of common shares outstanding for the period, including potential
 dilutive common shares assuming the dilutive effect of outstanding
 stock options and unvested restricted common shares, as determined
 using the treasury stock method. For periods in which the Company
 has reported net losses, diluted net loss per common share
 attributable to common stockholders is the same as basic net loss
 per common share attributable to common stockholders, since
 dilutive common shares are not assumed to have been issued if their
 effect is antidilutive.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company reported a net loss attributable to common stockholders
 for the years ended December&#xA0;31, 2015, 2014 and 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Risks and Uncertainties</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The product candidates developed by the Company require approvals
 from the U.S. Food and Drug Administration or foreign regulatory
 agencies prior to commercial sales. There can be no assurance that
 the Company&#x2019;s current and future product candidates will
 receive the necessary approvals. If the Company fails to
 successfully complete clinical development and generate results
 sufficient to file for regulatory approval or is denied approval or
 approval is delayed, it may have a material adverse impact on the
 Company&#x2019;s business and its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company is subject to risks common to companies in the
 development stage including, but not limited to, dependency on the
 clinical success of its product candidates, ability to obtain
 regulatory approval of its product candidates, the commercial
 success of its product, if approved, the need for substantial
 additional financing to achieve its goals, uncertainty of broad
 adoption of its approved products, if any, by physicians and
 consumers, significant competition and untested manufacturing
 capabilities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Concentration of Credit Risk and of Significant
 Suppliers</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist primarily of cash and cash
 equivalents. The Company has all cash and cash equivalents balances
 at two accredited financial institutions, in amounts that exceed
 federally insured limits. The Company does not believe that it is
 subject to unusual credit risk beyond the normal credit risk
 associated with commercial banking relationships.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company is dependent on third-party manufacturers to supply
 products for research and development activities in its programs.
 In particular, the Company relies and expects to continue to rely
 on a small number of manufacturers to supply it with its
 requirements for the active pharmaceutical ingredients and
 formulated drugs related to these programs. These programs could be
 adversely affected by a significant interruption in the supply of
 active pharmaceutical ingredients and formulated drugs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company accounts for income taxes under the asset and liability
 method. Under this method, deferred tax assets and liabilities are
 recognized for the estimated future tax consequences attributable
 to differences between financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases.
 Deferred tax assets and liabilities are measured using enacted
 rates in effect for the year in which these temporary differences
 are expected to be recovered or settled. Valuation allowances are
 provided if based on the weight of available evidence, it is more
 likely than not that some or all of the deferred tax assets will
 not be realized. During November 2015, the FASB issued ASU 2015-17,
 Balance Sheet Classification of Deferred Taxes, which simplifies
 the presentation of deferred income taxes. The Company early
 adopted ASU 2015-17 effective December&#xA0;31, 2015 on a
 prospective basis.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Fair value is the price that would be received to sell an asset or
 paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. Financial assets and
 liabilities carried at fair value are to be classified and
 disclosed in one of the following three categories:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 </p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="6%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="4%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="88%"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Level 1</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 &#xA0;&#xA0;&#xA0;&#xA0;&#x2014;</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Quoted market prices in active markets for
 identical assets or liabilities. At December&#xA0;31, 2015 and
 2014, the Company&#x2019;s Level 1 assets consisted of money market
 funds totaling $186.8 million and $127.8 million,
 respectively.</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Level 2</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 &#xA0;&#xA0;&#xA0;&#xA0;&#x2014;</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Observable inputs other than Level 1 prices,
 such as quoted prices for similar assets or liabilities; quoted
 prices in markets that are not active; or other inputs that are
 observable or can be corroborated by observable market data for
 substantially the full term of the assets or liabilities. At
 December 31, 2015 and 2014, the Company had no Level 2 assets or
 liabilities.</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Level&#xA0;3</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 &#xA0;&#xA0;&#xA0;&#xA0;&#x2014;</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities. At December 31, 2015 and 2014,
 the Company had no Level 3 assets or liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company&#x2019;s financial instruments generally consist of cash
 equivalents, accounts payable and accrued expenses. The carrying
 amounts for the applicable financial instruments reported in the
 balance sheets approximate their fair values at December&#xA0;31,
 2015 and 2014, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Deferred Offering Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company capitalizes certain legal, accounting and other
 third-party fees that are directly associated with in-process
 equity financings as other assets until such financings are
 consummated. After consummation of the IPO in July 2014, $2.3
 million of these costs were recorded in stockholders&#x2019; equity
 as a reduction of additional paid-in capital generated as a result
 of the IPO. After consummation of the follow-on public offering of
 common stock in April 2015, $0.5 million of these costs were
 recorded in stockholders&#x2019; equity as a reduction of additional
 paid-in capital generated as a result of the offering. As of
 December&#xA0;31, 2015, the Company had recorded deferred offering
 costs of $0.2 million which are shown as a non-current asset. They
 are for the follow-on public offering that was consummated in
 January 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Segment Data</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company manages its operations as a single segment for the
 purposes of assessing performance and making operating decisions.
 The Company&#x2019;s singular focus is on advancing medicines to
 treat central nervous system disorders, where there are inadequate
 or no approved existing therapies. All tangible assets are held
 within the United States.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Comprehensive Loss</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive loss includes net loss as well as other changes in
 stockholders&#x2019; equity (deficit) that result from transactions
 and economic events other than those with stockholders. For the
 years ended December&#xA0;31, 2015, 2014 and 2013, there was no
 difference between net loss and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Public Offerings</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On July&#xA0;23, 2014, the Company completed the sale of 5,750,000
 shares of its common stock in its IPO (the &#x201C;IPO&#x201D;), at a
 price to the public of $18.00 per share, resulting in net proceeds
 to the Company of $94.0 million after deducting underwriting
 discounts and commissions and offering costs paid by the Company.
 The shares began trading on Nasdaq Global Market on July&#xA0;18,
 2014.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 In connection with preparing for the IPO, the Company&#x2019;s board
 of directors and stockholders approved a 1-for-3.15 reverse stock
 split of the Company&#x2019;s common stock effective July&#xA0;2,
 2014. All share and per share amounts in the financial statements
 contained herein and notes thereto have been retroactively
 adjusted, where necessary, to give effect to this reverse stock
 split. In connection with the closing of the IPO, all of the
 Company&#x2019;s outstanding redeemable convertible preferred stock
 automatically converted into shares of common stock as of
 July&#xA0;23, 2014, resulting in the issuance by the Company of an
 additional 18,007,575 shares of common stock. The significant
 increase in common stock outstanding in July 2014 will impact the
 year-over-year comparability of the Company&#x2019;s net loss per
 share calculations over the next year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 On April&#xA0;20, 2015, the Company completed the sale of 2,628,571
 shares of common stock in an underwritten public offering of its
 common stock at a price to the public of $52.50 per share,
 resulting in net proceeds to the Company of $129.1 million after
 deducting underwriting discounts and commissions and offering costs
 paid by the Company. A description of the sale of shares of common
 stock held in January 2016 is included in Note 13.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Recently Issued Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In May 2014, the FASB issued guidance that outlines a single
 comprehensive model for entities to use in accounting for revenue
 arising from contracts with customers and supersedes most current
 revenue recognition guidance, including industry specific guidance.
 The guidance is based on the principle that an entity should
 recognize revenue to depict the transfer of goods or services to
 customers in an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The guidance also requires additional disclosure about
 the nature, amount, timing and uncertainty of revenue and cash
 flows arising from customer contracts, including significant
 judgments and changes in judgments and assets recognized from costs
 incurred to fulfill a contract. Entities have the option of using
 either a full retrospective or a modified retrospective approach
 for the adoption of the new standard. The guidance becomes
 effective for the Company in the year ending December&#xA0;31,
 2018, and the Company could early adopt the standard for the year
 ending December&#xA0;31, 2017. The Company is currently assessing
 the method of adoption and the impact that this new accounting
 guidance will have on its consolidated financial statements and
 footnote disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In August 2014, the FASB issued ASU 2014-15, Presentation of
 Financial Statements&#x2014;Going Concern (Subtopic 205-40). The new
 guidance addresses management&#x2019;s responsibility to evaluate
 whether there is substantial doubt about an entity&#x2019;s ability
 to continue as a going concern and to provide related footnote
 disclosures. Management&#x2019;s evaluation should be based on
 relevant conditions and events that are known and reasonably
 knowable at the date that the financial statements are issued. The
 standard will be effective for the first interim period within
 annual reporting periods beginning after December&#xA0;15, 2016.
 Early adoption is permitted. The Company is evaluating the effect
 that this guidance will have on its consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In November 2015, the FASB issued ASU 2015-17, Balance Sheet
 Classification of Deferred Taxes, which simplifies the
 classification of deferred tax assets and liabilities. The new
 standard requires that all deferred tax assets and liabilities,
 along with any related valuation allowance, be classified as
 noncurrent on the balance sheet. The standard is effective for
 interim and annual periods beginning after December&#xA0;15, 2016
 and allows for early adoption using a full retrospective method or
 a prospective method. The Company has elected to early adopt the
 provisions of this new standard using a prospective method. As a
 result, all deferred taxes as of December&#xA0;31, 2015 are
 classified as noncurrent on a net basis in the Company&#x2019;s
 consolidated balance sheet, while prior periods remain as
 previously reported.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In February 2016, the Financial Accounting Standards Board (FASB)
 issued ASU&#xA0;2016-02&#x2014;<i>Leases</i> (ASC&#xA0;842), which
 sets out the principles for the recognition, measurement,
 presentation and disclosure of leases for both parties to a
 contract (i.e. lessees and lessors). The new standard requires
 lessees to apply a dual approach, classifying leases as either
 finance or operating leases based on the principle of whether or
 not the lease is effectively a financed purchase by the lessee.
 This classification will determine whether lease expense is
 recognized based on an effective interest method or on a straight
 line basis over the term of the lease, respectively. A lessee is
 also required to record a right-of-use asset and a lease liability
 for all leases with a term of greater than 12&#xA0;months
 regardless of their classification. Leases with a term of
 12&#xA0;months or less will be accounted for similar to existing
 guidance for operating leases today. ASC&#xA0;842 supersedes the
 previous leases standard, ASC&#xA0;840 <i>Leases.</i> The standard
 is effective on January&#xA0;1, 2019, with early adoption
 permitted. The Company is in the process of evaluating the impact
 of this new guidance.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800018816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_BalanceSheetComponentsTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left"><b>Balance Sheet Components</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Property and Equipment, net</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Property and equipment, net consists of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Useful&#xA0;Life<br />
 (Years)</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer hardware and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">400</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture and equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">147</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(146</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Property and equipment, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">286</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">163</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Depreciation expense for the years ended December&#xA0;31, 2015,
 2014 and 2013 was $0.1 million, $0.1 million and $47 thousand,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Accrued Expenses</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Accrued expenses consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,466</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,788</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Employee related expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,718</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Professional services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,148</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" /></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_BalanceSheetComponentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_BalanceSheetComponentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790996160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>4.</b></td>
 <td valign="top" align="left"><b>Commitments and
 Contingencies</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Operating Leases</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company rents its 22,067 square foot office space under an
 operating lease that was expires in 2022. In March 2013, the
 Company signed a sublease agreement to sublet 1,900 square feet.
 Rental income from this sublease was $4 thousand per month. In
 September, 2015, this sublease was terminated.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Rent expense, net of sublease income, for the years ended
 December&#xA0;31, 2015, 2014, and 2013, was $0.4 million, $0.3
 million, and $0.3 million, respectively.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Future minimum lease payments under non-cancelable operating leases
 are as follows at December&#xA0;31, 2015:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="15%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 95.55pt">
 <b>Years Ending December&#xA0;31,</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,088</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,132</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,154</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,398</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,926</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>License Agreements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>CyDex License Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In September 2015, the Company and CyDex Pharmaceuticals, Inc.
 (&#x201C;CyDex&#x201D;) amended and restated their existing
 commercial license agreement. Under the terms of the commercial
 license agreement as amended and restated, CyDex has granted to the
 Company an exclusive license to CyDex&#x2019;s Captisol drug
 formulation technology and related intellectual property for the
 manufacture of pharmaceutical products incorporating the
 Company&#x2019;s compounds known as SAGE-547 and SAGE-689, and the
 development and commercialization of the resulting products in the
 treatment, prevention or diagnosis of any disease or symptom in
 humans or animals other than (i)&#xA0;the ocular treatment of any
 disease or condition with a formulation, including a hormone;
 (ii)&#xA0;topical ocular treatment of inflammatory conditions;
 (iii)&#xA0;treatment and prophylaxis of fungal infections in
 humans; and (iv)&#xA0;any ocular treatment for retinal
 degeneration.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 As consideration for the inclusion of SAGE-689 in the license
 granted by CyDex, the Company paid to CyDex $0.1 million, which was
 recorded as research and development expense in 2015 in connection
 with execution of the amended and restated license agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company is obligated to make milestone payments under the
 amended and restated license agreement with CyDex based on the
 achievement of clinical development and regulatory milestones in
 the amount of $0.8 million in clinical milestones and $3.8 million
 in regulatory milestones for each of the first two fields with
 respect to SAGE-547; $1.3 million in clinical milestones and $8.5
 million in regulatory milestones for each of the third and fourth
 fields with respect to SAGE-547; and $0.8 million in clinical
 milestones and $1.8 million in regulatory milestones for one field
 with respect to SAGE-689.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 For the year ended December&#xA0;31, 2015, the Company recorded
 research and development expense and made payments of cash of $0.8
 million related to clinical development milestones that were met
 for this agreement. For the years ended December&#xA0;31, 2014 and
 2013, the Company did not record any expense or make any milestone
 or royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Washington University License Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In November 2013, the Company entered into a license agreement with
 Washington University whereby the Company was granted exclusive,
 worldwide rights to develop and commercialize a novel set of
 neuroactive steroids developed by Washington University. In
 exchange for development and commercialization rights, the Company
 paid an upfront, non-refundable payment of $50 thousand and is
 required to pay an annual license maintenance fee of $15 thousand
 on each subsequent anniversary date, until the first Phase 2
 clinical trial for a licensed product is initiated. The Company is
 obligated to make milestone payments to Washington University based
 on achievement of clinical development and regulatory milestones of
 up to $0.7 million and $0.5 million, respectively. Additionally,
 the Company fulfilled its obligation to issue to Washington
 University 47,619 shares of common stock on December&#xA0;13, 2013.
 The fair value of these shares totaling $0.1 million was recorded
 as research and development expense in 2013.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company is obligated to pay royalties to Washington University
 at rates in the low single digits on net sales of licensed products
 covered under patent rights and royalties at rates in the low
 single digits on net sales of licensed products not covered under
 patent rights. Additionally, the Company has the right to
 sublicense and is required to make payments at varying percentages
 of sublicensing revenue received, initially in the mid-teens and
 descending to the mid-single digits over time.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 For the year ended December&#xA0;31, 2014, the Company did not
 record any expense or make any milestone or royalty payments. In
 September 2015, a regulatory milestone was met for one of the
 programs. Accordingly, the Company recorded research and
 development expenses and made a cash payment of $50 thousand in
 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>University of California License Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In October 2013, the Company entered into a non-exclusive license
 agreement with The Regents of the University of California whereby
 the Company was granted a non-exclusive license to certain clinical
 data and clinical material for use in the development and
 commercialization of biopharmaceutical products in the licensed
 field, including status epilepticus and post-partum depression. In
 May 2014, the license agreement was amended to add the treatment of
 essential tremor to the licensed field of use, materials and
 milestone fee provisions of the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company will be required to pay to The Regents of the
 University of California clinical development milestones of up to
 $0.1 million and pay royalties of less than 1% on net sales for a
 period of fifteen years following the sale of the first commercial
 product.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The license will terminate on the earlier to occur of (i)&#xA0;27
 years after the effective date or (ii)&#xA0;15 years after the
 last-derived product is first commercially sold.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 For the years ended December 31, 2014 and 2013, the Company did not
 record any expense or make any milestone or royalty payments.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 During 2015, three clinical development milestones were met.
 Accordingly, the Company recorded research and development expenses
 and made cash payments totaling $0.1 million. In June 2015, the
 Company entered into an exclusive license agreement with The
 Regents of the University of California whereby the Company was
 granted an exclusive license to certain patent rights related to
 the use of allopregnanolone to treat various diseases. In exchange
 for such license, the Company paid an upfront payment of $50
 thousand and will make annual maintenance fees of $15 thousand
 until the calendar year following the first sale, if any, of a
 licensed product. The Company is obligated to make milestone
 payments following the achievement of specified regulatory and
 sales milestones of up to $0.7 million and $2.0 million in the
 aggregate, respectively. Following the first sale, if any, of a
 licensed product, the Company is obligated to pay royalties at a
 low single digit percentage of net sales, if any, of licensed
 products, subject to specified minimum annual royalty amounts.
 Unless terminated by operation of law or by acts of the parties
 under the terms of the agreement, the license agreement will
 terminate when the last-to-expire patents or last-to-be abandoned
 patent applications expire, whichever is later.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Consulting Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In January 2014, the Company entered into a consulting agreement
 with a nonemployee advisor whereby the Company is obligated to make
 cash payments of up to $2.0 million and to issue up to 126,984
 shares of common stock upon attainment of certain clinical
 development and regulatory milestones.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In January and March 2014, the first clinical development
 milestones for each of two programs included in the consulting
 agreement were met. Accordingly, the Company recorded research and
 development expense for the year ended December&#xA0;31, 2014 of
 $0.2 million, comprised of $50 thousand in cash and $0.1 million
 related to the issuance of 15,872 shares of the Company&#x2019;s
 common stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 During the year ended December&#xA0;31, 2015, the second and third
 clinical development milestones for one of the programs included in
 the consulting agreement was met. Accordingly, the Company recorded
 research and development expense for the year ended
 December&#xA0;31, 2015 of $1.7 million, comprised of $0.5 million
 in cash and $1.2 million related to the issuance of 23,809 shares
 of the Company&#x2019;s common stock, related to the achievement of
 these milestones.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6796324304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>5.</b></td>
 <td valign="top" align="left"><b>Redeemable Convertible Preferred
 Stock</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company has newly authorized preferred stock amounting to
 5,000,000 shares as of December&#xA0;31, 2015 and 2014. The newly
 authorized preferred stock was classified under stockholders&#x2019;
 equity (deficit) as of December&#xA0;31, 2015 and 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 As of December&#xA0;31, 2014 and 2013, the Company&#x2019;s
 Certificate of Incorporation, as amended and restated, authorized
 the Company to issue no shares and 37,750,000, respectively, shares
 of $0.0001 par value preferred stock. In July 2014, all issued and
 outstanding redeemable convertible preferred stock was converted to
 common stock, see Note 2.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company had issued Series A, Series B and Series C redeemable
 convertible preferred stock (collectively, the &#x201C;Redeemable
 Preferred Stock&#x201D;). The Redeemable Preferred Stock was
 classified outside of stockholders&#x2019; equity (deficit) as of
 December&#xA0;31, 2013 because the shares contained redemption
 features that are not solely within the control of the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On March&#xA0;18, 2013, the Company issued an additional 5,000,000
 shares in the second funding of the second tranche of Series A
 Preferred Stock at $1.00 per share, resulting in net proceeds of
 $5.0 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On July&#xA0;1, 2013, the Company issued an additional 5,000,000
 shares in the third funding of the second tranche of Series A
 Preferred Stock at $1.00 per share, resulting in net proceeds of
 $5.0 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On September&#xA0;12, 2013, the Company issued an additional
 12,500,000 shares in the third tranche of Series A Preferred Stock
 at $1.00 per share, resulting in net proceeds of $12.5 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On October&#xA0;18, 2013, the Company issued 250,000 shares of
 Series A Preferred Stock at $1.00 per share, resulting in net
 proceeds of $0.3 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On October&#xA0;15, 2013, the Company entered into a Stock Purchase
 Agreement whereby the Company would issue up to $20.0 million of
 Series B redeemable convertible preferred stock (&#x201C;Series B
 Preferred Stock&#x201D;) at $1.50 per share. The initial purchase
 and sale in the amount of $10.0 million could have occurred once
 certain development milestones had been successfully achieved. The
 second tranche of $10.0 million could be issued after the initial
 closing and at the discretion of the Board of Directors. In
 November 2013, the Company met the development milestones to issue
 the first tranche of the Series B Preferred Stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On January&#xA0;7, 2014, the Company issued 6,666,666 shares of
 Series B Preferred Stock at $1.50 per share, resulting in net
 proceeds of $10.0 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On February&#xA0;12, 2014, the Company issued 3,333,333 shares of
 Series B Preferred Stock at $1.50 in a second closing, resulting in
 net proceeds of $5.0 million. At that time, the Company decided not
 to draw on the remaining $5.0 million of the second tranche of the
 Series B Preferred Stock.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company incurred issuance costs of $30 thousand in 2014 with
 the issuance of the Series B Preferred Stock which were recorded as
 a reduction of the proceeds received.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On March&#xA0;11, 2014, the Company entered into a Stock Purchase
 Agreement whereby the Company issued 8,973,905 shares of Series C
 redeemable convertible preferred stock (&#x201C;Series C Preferred
 Stock&#x201D;) at $4.2345 per share for net proceeds of $38.0
 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company incurred issuance costs of $0.1 million in 2014 with
 the issuance of the Series C Preferred Stock which were recorded as
 a reduction of the proceeds received.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6796891600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>6.</b></td>
 <td valign="top" align="left"><b>Common Stock</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 As of December&#xA0;31, 2015 and 2014, the Company has authorized
 120,000,000 shares of common stock with a par value of $0.0001 per
 share.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Each share of common stock entitles the holder to one vote on all
 matters submitted to a vote of the Company&#x2019;s stockholders.
 Common stockholders are entitled to receive dividends, as may be
 declared by the Board of Directors, if any. As of December&#xA0;31,
 2015 and 2014, no dividends have been declared.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800087760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left"><b>Stock-Based Compensation</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <b><i>2014 Stock Option Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On July&#xA0;2, 2014, the Company&#x2019;s stockholders approved the
 2014 Stock Option and Incentive Plan (the &#x201C;2014 Stock Option
 Plan&#x201D;), which became effective upon the completion of the
 IPO. The 2014 Stock Option Plan provides for the grant of
 restricted stock awards, incentive stock options and non-statutory
 stock options. The 2014 Stock Option Plan replaced the
 Company&#x2019;s 2011 Stock Option and Grant Plan (the &#x201C;2011
 Stock Option Plan&#x201D;). The Company will no longer grant stock
 options or other awards under the 2011 Stock Option Plan. Any
 options or awards outstanding under the 2011 Stock Option Plan
 remained outstanding and effective. As of December&#xA0;31, 2015,
 the total number of shares reserved under all equity plans is
 3,862,172, and the Company had 859,363 shares available for future
 issuance under such plans.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The 2014 Stock Option Plan provides for an annual increase, to be
 added on the first day of each fiscal year, by up to 4% of the
 Company&#x2019;s issued and outstanding shares of common stock on
 the immediately preceding December&#xA0;31.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Terms of restricted stock awards and stock option agreements,
 including vesting requirements, are determined by the Board of
 Directors or the Compensation Committee of the Board of Directors,
 subject to the provisions of the applicable stock option plan.
 Options and restricted stock awards granted by the Company
 generally vest based on the grantee&#x2019;s continued service with
 the Company during a specified period following grant. Awards
 granted to employees generally vest ratably over four years, with a
 25% cliff vesting at the one year anniversary for new employee
 awards. During 2013, the Company also granted a pool of option
 awards which vest ratably over one year. All awards are exercisable
 from the date of grant for a period of ten years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During 2015, the Company granted 497,100 options to employees to
 purchase shares of common stock that contain performance-based
 vesting criteria, primarily related to achievement of certain
 clinical and regulatory development milestones related to the
 Company&#x2019;s product candidates. Recognition of stock-based
 compensation expense associated with these performance-based stock
 options commences when the performance condition is considered
 probable of achievement, using management&#x2019;s best estimates.
 During the quarter ended June&#xA0;30, 2015, the achievement of one
 milestone was considered probable and that milestone was achieved
 during the quarter ended September&#xA0;30, 2015. The related
 expense was recognized over the estimated service period. This
 milestone represents 35% of the performance-based grants that were
 made during 2015. The achievement of the remaining milestones was
 deemed to be not probable as of December&#xA0;31, 2015 and
 therefore no expense has been recognized related to these awards.
 During the year ended December&#xA0;31, 2015, the Company
 recognized stock-based compensation expense of $4.8 million related
 to stock options with performance-based vesting criteria.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Stock-based compensation expense recognized during the years ended
 December&#xA0;31, 2015, 2014, and 2013 was as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Stock-based compensation expense:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,924</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,093</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">38</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,316</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">23</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">61</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For stock option awards, the fair value of the options is estimated
 at the grant date using the Black-Scholes option-pricing model,
 taking into account the terms and conditions upon which options are
 granted. The fair value of the options is amortized on a
 straight-line basis for awards to employees and on a graded basis
 for awards to non-employees over the requisite service period of
 the awards for awards to employees and graded vesting is used for
 non-employees. The weighted average grant date fair value per share
 relating to outstanding stock options granted under the
 Company&#x2019;s stock option plans during the years ended
 December&#xA0;31, 2015, 2014 and 2013 was $34.08, $14.33 and $0.38,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of each option granted to employees and nonemployee
 directors during the years ended December&#xA0;31, 2015, 2014 and
 2013 under the Company&#x2019;s stock option plans has been
 calculated on the date of grant using the following weighted
 average assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90.54</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">98.86</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">99.89</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.59</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.95</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.66</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.03&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.38&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.04&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Expected dividend yield:</i> The Company has not paid and does
 not anticipate paying any dividends in the foreseeable future.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Risk-free interest rate:</i> The Company determined the
 risk-free interest rate by using a weighted average equivalent to
 the expected term based on the U.S. Treasury yield curve in effect
 as of the date of grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Expected volatility:</i> As the Company has only been a public
 company since July 2014, there is not sufficient historical
 volatility for the expected term of the options. Therefore, the
 Company used an average historical share price volatility based on
 an analysis of reported data for a peer group of comparable
 companies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 <i>Expected term (in years):</i> Expected term represents the
 period that the Company&#x2019;s stock option grants are expected to
 be outstanding. As the Company has only been a public company since
 July 2014, there is not sufficient historical term data to
 calculate the expected term of the options. Therefore, the Company
 elected to utilize the &#x201C;simplified&#x201D; method to estimate
 the expected term of option grants issued to employees. Under this
 approach, the weighted average expected life is presumed to be the
 average of the vesting term and the contractual term of the
 option.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Forfeitures are estimated at the time of grant and revised, if
 necessary, in subsequent periods if actual forfeitures differ from
 estimates. The Company estimates forfeitures based on historical
 termination behavior. For the years ended December&#xA0;31, 2015,
 2014, and 2013, a forfeiture rate of 10% was applied.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For options granted to nonemployees, the expected life of the
 option used is ten years, which is the contractual term of each
 such option. All other assumptions used to calculate the grant date
 fair value are generally consistent with the assumptions used for
 options granted to employees.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The table below summarizes activity related to stock options:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="47%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br />
 Average&#xA0;Exercise<br />
 Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining&#xA0;Life&#xA0;(in</b><br />
 <b>years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,996,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.98</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">59,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,516,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.64</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(417,475</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.44</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(92,638</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26.93</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,002,809</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26.67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,479</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested or expected to vest as of December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,421,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">82,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable as of December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">723,895</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14.47</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.27</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">31,729</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2015, the Company had unrecognized
 stock-based compensation expense related to its unvested
 service-based stock option awards of $31.5 million, which is
 expected to be recognized over the remaining weighted average
 vesting period of 3.01 years. The total fair value of shares vested
 for the years ended December&#xA0;31, 2015, 2014 and 2013 was $9.2
 million, $1.0 million, and $9 thousand, respectively. In addition,
 the Company has 358,976 shares of outstanding unvested stock
 options that vest upon the achievement of certain performance
 criteria. Total unrecognized compensation related to those awards
 was $7.8 million at December&#xA0;31, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The intrinsic value of stock options exercised during the years
 ended December&#xA0;31, 2015 and 2014 was $28.4 million and $2.4
 million, respectively, and the intrinsic value of stock options
 exercised during the year ended December&#xA0;31, 2013 was
 zero.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Stock Awards</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 During the year ended December&#xA0;31, 2013, the Company granted
 restricted stock awards to certain officers, employees, directors,
 and consultants of the Company. During the years ended
 December&#xA0;31, 2015, 2014 and 2013, the Company recorded $0.3
 million, $0.2 million and $11 thousand, respectively, of
 stock-based compensation expense related to its restricted stock.
 The table below summarizes activity relating to restricted
 stock:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December 31, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170,832</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Issued</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(128,051</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Repurchased</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December 31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2015, the Company had unrecognized
 stock-based compensation expense related to its unvested restricted
 stock awards of $34 thousand, which is expected to be recognized
 over the remaining weighted average vesting period of 0.56
 years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During the years ended December&#xA0;31, 2015 and 2014, no shares
 of restricted stock were issued. During the year ended
 December&#xA0;31, 2013, current and former employees of the Company
 purchased a total of 130,158 shares of restricted stock, resulting
 in proceeds of $50 thousand.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Unvested shares are subject to repurchase by the Company, at the
 issuance price, upon the employee&#x2019;s termination at the
 Company&#x2019;s sole discretion. In the year ended
 December&#xA0;31, 2014, the Company repurchased 6,778 shares of
 restricted common stock issued to employees at their $0.04 original
 purchase price per share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>2014 Employee Stock Purchase Plan</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On July&#xA0;2, 2014, the Company&#x2019;s stockholders approved the
 2014 Employee Stock Purchase Plan. A total of 282,000 shares of
 common stock were initially authorized for issuance under this
 plan. The 2014 Employee Stock Purchase Plan became effective upon
 the completion of the IPO. As of December&#xA0;31, 2015, 3,852
 shares have been issued under this plan. Included in accrued
 liabilities at December&#xA0;31, 2015 is $64 thousand of stock
 compensation expense related to an enrollment period for which the
 related shares had not been issued as of December&#xA0;31,
 2015.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797868208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>8.</b></td>
 <td valign="top" align="left"><b>Net Loss Per Share</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic and diluted net income (loss) per share attributable to
 common stockholders was calculated as follows for the years ended
 December&#xA0;31, 2015, 2014 and 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic net loss per share attributable to common stockholders:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Numerator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Net loss attributable to common stockholders
 (in&#xA0;thousands)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(94,495</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(36,105</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(18,288</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Denominator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Weighted average shares of common stock outstanding&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,778,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,574,347</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,492,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Dilutive effect of shares of common stock equivalents resulting
 from common stock options and preferred common stock (as
 converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Weighted average common stock outstanding&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,778,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,574,347</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,492,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders&#x2014;basic
 and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.67</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(12.26</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following common stock equivalents outstanding as of
 December&#xA0;31, 2015 and 2014, were excluded from the computation
 of diluted net loss per share attributable to common stockholders
 for the periods presented because including them would have been
 anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,643,833</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,621,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170,067</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Employee Stock Purchase Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,689,921</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,791,973</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800041520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>9.</b></td>
 <td valign="top" align="left"><b>Income Taxes</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 There is no provision for income taxes because the Company has
 historically incurred operating losses and maintains a full
 valuation allowance against its net deferred tax assets. The
 reported amount of income tax expense for the years differs from
 the amount that would result from applying domestic federal
 statutory tax rates to pretax losses primarily because of changes
 in valuation allowance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A reconciliation of U.S. statutory rate to the Company&#x2019;s
 effective tax rate is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tax due at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State taxes, net of federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Foreign rate differential</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Federal and state credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(46.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(40.5</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Significant components of the Company&#x2019;s net deferred tax
 asset at December&#xA0;31, 2015 and 2014 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">(in thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net operating losses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,172</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Capitalized start-up costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,335</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accounting method change</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,347</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,020</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tax credit carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,433</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,062</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">494</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Depreciation and amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">716</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">332</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,097</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">623</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Others</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total net deferred tax asset before valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">69,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,303</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(69,069</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,303</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2015, the Company had federal and state net
 operating loss carryforwards of $131.5&#xA0;million and $130.7
 million, respectively, which begin to expire in 2031. As of
 December&#xA0;31, 2015, the Company had federal and state research
 and development tax credits carryforwards of $1.6 million and $0.7
 million, respectively, which begin to expire in 2031 and 2027,
 respectively. As of December&#xA0;31, 2015, the Company had federal
 orphan drug tax credit carry forwards of $16.4 million, which begin
 to expire in 2034. At December 31, 2015, the Company has excess
 equity based compensation tax deductions related to net operating
 losses for federal and state purposes of $18.9&#xA0;million and
 $18.9 million respectively. The Company has excess equity based
 compensation related to credits for federal and state purposes of
 $1.3 million and $0.2 million, respectively. These excess tax
 benefits have not been included in the net deferred tax assets
 before valuation allowance since these benefits would be credited
 directly to additional paid in capital if subsequently recognized
 through a reduction in taxes payable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2015, net deferred tax assets increased
 approximately $40.8&#xA0;million primarily due to the operating
 loss and tax credits incurred during the year. This increase in net
 deferred tax assets was offset by a corresponding increase in the
 valuation allowance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Management of the Company has evaluated the positive and negative
 evidence bearing upon the realizability of its deferred tax assets,
 which are comprised principally of net operating loss carryforwards
 and capitalized start-up costs. Under the applicable accounting
 standards, management has considered the Company&#x2019;s history of
 losses and concluded that it is more likely than not that the
 Company will not recognize the benefits of federal and state
 deferred tax assets. Accordingly, a full valuation allowance of
 $69.1 million and $28.3 million has been established at
 December&#xA0;31, 2015 and 2014, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Pursuant to Section&#xA0;382 of the Internal Revenue Code, certain
 substantial changes in the Company&#x2019;s ownership may result in
 a limitation on the amount of net operating loss carryforwards and
 tax carryforwards that may be used in future years. Utilization of
 the net operating loss (&#x201C;NOL&#x201D;) and tax credit
 carryforwards may be subject to a substantial annual limitation
 under Section&#xA0;382 of the Internal Revenue Code of 1986 due to
 ownership change limitations that have occurred previously or that
 could occur in the future. These ownership changes may limit the
 amount of NOL and tax credit carryforwards that can be utilized
 annually to offset future taxable income and tax, respectively. The
 Company has not completed a study to assess whether an ownership
 change has occurred, or whether there have been multiple ownership
 changes since its formation, due to significant complexity and
 related costs associated with such a study. There could also be
 additional ownership changes in the future which may result in
 additional limitations on the utilization of NOL carryforwards and
 credits. Further, until a study is completed and any limitation is
 known, no amounts are being presented as an uncertain tax
 position.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company applies the authoritative guidance on accounting for
 and disclosure of uncertainty in tax positions, which requires the
 Company to determine whether a tax position of the Company is more
 likely than not to be sustained upon examination, including
 resolution of any related appeals of litigation processes, based on
 the technical merits of the position. For tax positions meeting the
 more likely than not threshold, the tax amount recognized in the
 financial statements is reduced by the largest benefit that has a
 greater than fifty percent likelihood of being realized upon the
 ultimate settlement with the relevant taxing authority.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following is a rollforward of the Company&#x2019;s unrecognized
 tax benefits:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="90%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Unrecognized tax benefits&#x2014;as of the beginning of the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gross increases&#x2014;current period tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gross decreases&#x2014;tax positions of prior periods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,880</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Unrecognized tax benefits&#x2014;as of the end of the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 During 2014, the Company filed an application for change in
 accounting method with the IRS to capitalize start-up costs that
 were historically deducted and included as part of the NOL
 carryforward through December&#xA0;31, 2013. As a result, the
 Company&#x2019;s unrecognized tax benefits, which historically
 related to start-up costs, are zero at December&#xA0;31, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company will recognize interest and penalties related to
 uncertain tax positions in income tax expense when in a taxable
 income position. As of December&#xA0;31, 2015 and 2014, the Company
 had no accrued interest or penalties related to uncertain tax
 positions and no amounts have been recognized in the
 Company&#x2019;s statement of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company files tax returns as prescribed by the tax laws of the
 jurisdictions in which it operates. In the normal course of
 business, the Company is subject to examination by federal and
 state jurisdictions, where applicable. There are currently no
 pending tax examinations, and the Company&#x2019;s tax returns are
 open under statute from 2012 to the present. The tax attributes
 prior to 2012 may still be adjusted upon examination. The
 Company&#x2019;s policy is to record interest and penalties related
 to income taxes as part of the tax provision.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 During November 2015, the FASB issued ASU 2015-17, Balance Sheet
 Classification of Deferred Taxes, which simplifies the presentation
 of deferred income taxes. This ASU requires that deferred tax
 assets and liabilities be classified as non-current in a statement
 of financial position. The standard is effective for public
 companies for fiscal years beginning after December&#xA0;31, 2016,
 including interim periods within that reporting period. Early
 adoption is permitted for any interim and annual financial
 statements that have not yet been issued. The Company early adopted
 ASU 2015-17 effective December&#xA0;31, 2015 on a prospective
 basis. Adoption of this ASU resulted in a reclassification of the
 current deferred tax liability to a non-current deferred tax
 liability, which is netted with the long-term deferred tax asset in
 its consolidated balance sheet as of December&#xA0;31, 2015. No
 prior periods were retrospectively adjusted.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790996160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>10.</b></td>
 <td align="left" valign="top"><b>Employee Benefit Plan</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The Company maintains a 401(k) profit sharing plan (the
 &#x201C;Plan&#x201D;) for its employees. Each participant in the Plan
 may elect to contribute a portion of his or her annual compensation
 to the Plan subject to annual limits established by the Internal
 Revenue Service. Effective November&#xA0;1, 2014, the Company
 instituted an employer match of 50% of eligible contributions up to
 6% of employee contributions. For the years ended December&#xA0;31,
 2015 and 2014, the Company contributed $0.2 million and $15
 thousand, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6782012352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>11.</b></td>
 <td align="left" valign="top"><b>Related Party
 Transactions</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Since inception, the Company has received consulting and management
 services from Third Rock Ventures LLC, which through its
 affiliates, owned 16.4% of the Company&#x2019;s common stock at
 December&#xA0;31, 2015. The Company recorded expenses of $21
 thousand, $0.2 million, and $0.6 million for these services for the
 years ended December&#xA0;31, 2015, 2014, and 2013,
 respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6799996928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>12.</b></td>
 <td valign="top" align="left"><b>Selected Quarterly Financial Data
 (Unaudited)</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table contains quarterly financial information for
 2015 and 2014. The Company believes that the following information
 reflects all normal recurring adjustments necessary for a fair
 statement of the information for the periods presented. The
 operating results for any quarter are not necessarily indicative of
 results for any future period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>First</b><br />
 <b>Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Second<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Third<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fourth<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="18" align="center"><b>(in thousands,
 except per share amounts)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,059</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">94,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Loss from operations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16,897</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(25,059</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(24,082</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,612</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,650</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss and comprehensive loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16,871</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(25,027</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(24,035</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,562</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,495</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss attributable to common stockholders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16,871</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(25,027</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(24,035</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,562</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,495</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders&#x2014;basic
 and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.66</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.90</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.84</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.99</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>First<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Second<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Third<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fourth<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="18" align="center"><b>(in thousands,
 except per share amounts)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,790</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Loss from operations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,790</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,188</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,471</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,361</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,810</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss and comprehensive loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,790</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,192</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,468</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,361</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,811</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss attributable to common stockholders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,116</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,769</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,859</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,361</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(36,105</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders&#x2014;basic
 and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.70</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.50</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.48</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.67</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791448592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>13.</b></td>
 <td valign="top" align="left"><b>Subsequent Event</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On January&#xA0;12, 2016, the Company completed the sale of
 3,157,894 shares of its common stock at a price to the public of
 $47.50 per share, resulting in net proceeds to the Company of
 $140.4 million after deducting underwriting discounts and
 commissions and estimated offering expenses payable by the
 Company.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6812561408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The accompanying consolidated financial statements include those of
 the Company and its subsidiaries after elimination of all
 intercompany accounts and transactions. The accompanying
 consolidated financial statements have been prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&#x201C;GAAP&#x201D;).</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and the
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenues and expenses during the reporting period. Actual results
 could differ from those estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company considers all highly liquid investments with an
 original maturity of three months or less at the date of purchase
 to be cash equivalents.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 A deposit of $39 thousand was restricted from withdrawal as of
 December&#xA0;31, 2015 and 2014. The restriction is related to
 securing the Company&#x2019;s facility lease and expires in 2022 in
 accordance with the operating lease agreement. This balance is
 included in restricted cash on the accompanying balance sheets.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Property and equipment are recorded at cost and depreciated over
 their estimated useful lives using the straight-line method. Upon
 retirement or sale, the cost of assets disposed of and the related
 accumulated depreciation are removed from the accounts and any
 resulting gain or loss is credited or charged to income. Repairs
 and maintenance costs are expensed as incurred.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Long-lived assets consist of property and equipment. Long-lived
 assets to be held and used are tested for recoverability whenever
 events or changes in business circumstances indicate that the
 carrying amount of the assets may not be fully recoverable. Factors
 that the Company considers in deciding when to perform an
 impairment review include significant underperformance of the
 business in relation to expectations, significant negative industry
 or economic trends, and significant changes or planned changes in
 the use of the assets. If an impairment review is performed to
 evaluate a long-lived asset for recoverability, the Company
 compares forecasts of undiscounted cash flows expected to result
 from the use and eventual disposition of the long-lived asset to
 its carrying value. An impairment loss would be recognized when
 estimated undiscounted future cash flows expected to result from
 the use of an asset are less than its carrying amount. The
 impairment loss would be based on the excess of the carrying value
 of the impaired asset over its fair value, determined based on
 discounted cash flows. To date, the Company has not recorded any
 impairment losses on long-lived assets.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development expenses are comprised of costs incurred
 in performing research and development activities, including
 salaries and benefits, overhead costs, depreciation, contract
 services and other related costs. Research and development costs
 are expensed to operations as the related obligation is
 incurred.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchContractCostsAndAccrualsPolicyTextBlock', window );">Research Contract Costs and Accruals</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research Contract Costs and Accruals</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company has entered into various research and development
 contracts with research institutions and other companies both
 inside and outside of the United States. These agreements are
 generally cancelable, and related payments are recorded as research
 and development expenses as incurred. The Company records accruals
 for estimated ongoing research costs. When evaluating the adequacy
 of the accrued liabilities, the Company analyzes progress of the
 studies, including the phase or completion of events, invoices
 received and contracted costs. Significant judgments and estimates
 may be made in determining the accrued balances at the end of any
 reporting period. Actual results could differ from the
 Company&#x2019;s estimates. The Company&#x2019;s historical accrual
 estimates have not been materially different from the actual
 costs.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Patent Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company expenses patent costs as incurred and classifies such
 costs as general and administrative expenses in the accompanying
 statements of operations and comprehensive loss.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company recognizes compensation expense for all stock-based
 awards made to employees and nonemployee directors, including
 grants of stock options and restricted stock, based on estimated
 fair value on date of grant, over the requisite service period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For stock options and restricted stock issued to nonemployee
 consultants, the Company recognizes the fair value of such
 instruments as an expense over the period in which the related
 services are received. The fair value of the awards and measurement
 of related stock-based compensation is subject to periodic
 adjustments as the underlying equity instruments vest. For awards
 that vest upon achievement of a performance condition, the Company
 recognizes compensation expense when achievement of the performance
 condition is deemed probable over the implicit service period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of each option grant is estimated using the
 Black-Scholes option-pricing model. Through July 2014, the Company
 was a private company and lacks sufficient Company-specific
 historical and implied volatility information. Therefore, the
 Company estimates expected volatility based on the historical
 volatility of publicly traded peer companies and expects to
 continue to do so until such time as it has adequate historical
 data regarding the volatility of its traded stock price. The
 expected term of the Company&#x2019;s options has been determined
 utilizing the &#x201C;simplified&#x201D; method for awards that
 qualify as &#x201C;plain-vanilla&#x201D; options, while the expected
 term of its options granted to consultants and nonemployees has
 been determined based on the contractual term of the options. The
 risk-free interest rate is determined by reference to the U.S.
 Treasury yield curve in effect at the time of grant of the award
 for time periods approximately equal to the expected term of the
 award. Expected dividend yield is based on the fact that the
 Company never paid cash dividends and does not expect to pay any
 cash dividends in the foreseeable future.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company also applies a forfeiture rate in order to calculate
 stock-based compensation expense. To the extent actual forfeitures
 differ from the estimates, the difference will be recorded as a
 cumulative adjustment in the period the estimates are revised. The
 Company recognizes compensation expense for only the portion of
 awards that are expected to vest. Expected forfeitures are based on
 the Company&#x2019;s historical experience and management&#x2019;s
 expectations of future forfeitures.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basic and Diluted Net Loss Per Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Upon the closing of the Company&#x2019;s IPO in July 2014, all of
 the Company&#x2019;s outstanding shares of redeemable convertible
 preferred stock were converted into shares of common stock. Prior
 to this conversion, the Company followed the two-class method when
 computing net loss per share as the Company had issued shares that
 meet the definition of participating securities. The two-class
 method determines net loss per share for each class of common and
 participating securities according to dividends declared or
 accumulated and participation rights in undistributed earnings. The
 two-class method requires income available to common stockholders
 for the period to be allocated between common and participating
 securities based upon their respective rights to receive dividends
 as if all income for the period had been distributed. The
 Company&#x2019;s redeemable convertible preferred shares
 contractually entitled the holders of such shares to participate in
 dividends, but did not contractually require the holders of such
 shares to participate in losses of the Company. Accordingly, the
 two-class method did not apply for periods in which the Company
 reported a net loss or a net loss attributable to common
 stockholders resulting from dividends or accretion related to its
 redeemable convertible preferred shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Basic net loss per share attributable to common stockholders is
 computed by dividing the net loss attributable to common
 stockholders by the weighted average number of common shares
 outstanding for the period. Diluted net loss per share attributable
 to common stockholders is computed by dividing the diluted net loss
 attributable to common stockholders by the weighted average number
 of common shares outstanding for the period, including potential
 dilutive common shares assuming the dilutive effect of outstanding
 stock options and unvested restricted common shares, as determined
 using the treasury stock method. For periods in which the Company
 has reported net losses, diluted net loss per common share
 attributable to common stockholders is the same as basic net loss
 per common share attributable to common stockholders, since
 dilutive common shares are not assumed to have been issued if their
 effect is antidilutive.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company reported a net loss attributable to common stockholders
 for the years ended December&#xA0;31, 2015, 2014 and 2013.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_BusinessRisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Risks and Uncertainties</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The product candidates developed by the Company require approvals
 from the U.S. Food and Drug Administration or foreign regulatory
 agencies prior to commercial sales. There can be no assurance that
 the Company&#x2019;s current and future product candidates will
 receive the necessary approvals. If the Company fails to
 successfully complete clinical development and generate results
 sufficient to file for regulatory approval or is denied approval or
 approval is delayed, it may have a material adverse impact on the
 Company&#x2019;s business and its financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company is subject to risks common to companies in the
 development stage including, but not limited to, dependency on the
 clinical success of its product candidates, ability to obtain
 regulatory approval of its product candidates, the commercial
 success of its product, if approved, the need for substantial
 additional financing to achieve its goals, uncertainty of broad
 adoption of its approved products, if any, by physicians and
 consumers, significant competition and untested manufacturing
 capabilities.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and of Significant Suppliers</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Concentration of Credit Risk and of Significant
 Suppliers</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Financial instruments that potentially expose the Company to
 concentrations of credit risk consist primarily of cash and cash
 equivalents. The Company has all cash and cash equivalents balances
 at two accredited financial institutions, in amounts that exceed
 federally insured limits. The Company does not believe that it is
 subject to unusual credit risk beyond the normal credit risk
 associated with commercial banking relationships.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The Company is dependent on third-party manufacturers to supply
 products for research and development activities in its programs.
 In particular, the Company relies and expects to continue to rely
 on a small number of manufacturers to supply it with its
 requirements for the active pharmaceutical ingredients and
 formulated drugs related to these programs. These programs could be
 adversely affected by a significant interruption in the supply of
 active pharmaceutical ingredients and formulated drugs.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company accounts for income taxes under the asset and liability
 method. Under this method, deferred tax assets and liabilities are
 recognized for the estimated future tax consequences attributable
 to differences between financial statement carrying amounts of
 existing assets and liabilities and their respective tax bases.
 Deferred tax assets and liabilities are measured using enacted
 rates in effect for the year in which these temporary differences
 are expected to be recovered or settled. Valuation allowances are
 provided if based on the weight of available evidence, it is more
 likely than not that some or all of the deferred tax assets will
 not be realized. During November 2015, the FASB issued ASU 2015-17,
 Balance Sheet Classification of Deferred Taxes, which simplifies
 the presentation of deferred income taxes. The Company early
 adopted ASU 2015-17 effective December&#xA0;31, 2015 on a
 prospective basis.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Fair value is the price that would be received to sell an asset or
 paid to transfer a liability in an orderly transaction between
 market participants at the measurement date. Financial assets and
 liabilities carried at fair value are to be classified and
 disclosed in one of the following three categories:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="6%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="4%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="88%"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Level 1</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 &#xA0;&#xA0;&#xA0;&#xA0;&#x2014;</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Quoted market prices in active markets for
 identical assets or liabilities. At December&#xA0;31, 2015 and
 2014, the Company&#x2019;s Level 1 assets consisted of money market
 funds totaling $186.8 million and $127.8 million,
 respectively.</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Level 2</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 &#xA0;&#xA0;&#xA0;&#xA0;&#x2014;</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Observable inputs other than Level 1 prices,
 such as quoted prices for similar assets or liabilities; quoted
 prices in markets that are not active; or other inputs that are
 observable or can be corroborated by observable market data for
 substantially the full term of the assets or liabilities. At
 December 31, 2015 and 2014, the Company had no Level 2 assets or
 liabilities.</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="8"></td>
 <td height="8" colspan="2"></td>
 <td height="8" colspan="2"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Level&#xA0;3</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 &#xA0;&#xA0;&#xA0;&#xA0;&#x2014;</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities. At December 31, 2015 and 2014,
 the Company had no Level 3 assets or liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The Company&#x2019;s financial instruments generally consist of cash
 equivalents, accounts payable and accrued expenses. The carrying
 amounts for the applicable financial instruments reported in the
 balance sheets approximate their fair values at December&#xA0;31,
 2015 and 2014, respectively.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Deferred Offering Costs</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company capitalizes certain legal, accounting and other
 third-party fees that are directly associated with in-process
 equity financings as other assets until such financings are
 consummated. After consummation of the IPO in July 2014, $2.3
 million of these costs were recorded in stockholders&#x2019; equity
 as a reduction of additional paid-in capital generated as a result
 of the IPO. After consummation of the follow-on public offering of
 common stock in April 2015, $0.5 million of these costs were
 recorded in stockholders&#x2019; equity as a reduction of additional
 paid-in capital generated as a result of the offering. As of
 December&#xA0;31, 2015, the Company had recorded deferred offering
 costs of $0.2 million which are shown as a non-current asset. They
 are for the follow-on public offering that was consummated in
 January 2016.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Data</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Segment Data</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company manages its operations as a single segment for the
 purposes of assessing performance and making operating decisions.
 The Company&#x2019;s singular focus is on advancing medicines to
 treat central nervous system disorders, where there are inadequate
 or no approved existing therapies. All tangible assets are held
 within the United States.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Comprehensive Loss</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Comprehensive loss includes net loss as well as other changes in
 stockholders&#x2019; equity (deficit) that result from transactions
 and economic events other than those with stockholders. For the
 years ended December&#xA0;31, 2015, 2014 and 2013, there was no
 difference between net loss and comprehensive loss.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_InitialPublicOfferingPolicyPolicyTextBlock', window );">Public Offerings</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Public Offerings</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On July&#xA0;23, 2014, the Company completed the sale of 5,750,000
 shares of its common stock in its IPO (the &#x201C;IPO&#x201D;), at a
 price to the public of $18.00 per share, resulting in net proceeds
 to the Company of $94.0 million after deducting underwriting
 discounts and commissions and offering costs paid by the Company.
 The shares began trading on Nasdaq Global Market on July&#xA0;18,
 2014.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In connection with preparing for the IPO, the Company&#x2019;s board
 of directors and stockholders approved a 1-for-3.15 reverse stock
 split of the Company&#x2019;s common stock effective July&#xA0;2,
 2014. All share and per share amounts in the financial statements
 contained herein and notes thereto have been retroactively
 adjusted, where necessary, to give effect to this reverse stock
 split. In connection with the closing of the IPO, all of the
 Company&#x2019;s outstanding redeemable convertible preferred stock
 automatically converted into shares of common stock as of
 July&#xA0;23, 2014, resulting in the issuance by the Company of an
 additional 18,007,575 shares of common stock. The significant
 increase in common stock outstanding in July 2014 will impact the
 year-over-year comparability of the Company&#x2019;s net loss per
 share calculations over the next year.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On April&#xA0;20, 2015, the Company completed the sale of 2,628,571
 shares of common stock in an underwritten public offering of its
 common stock at a price to the public of $52.50 per share,
 resulting in net proceeds to the Company of $129.1 million after
 deducting underwriting discounts and commissions and offering costs
 paid by the Company. A description of the sale of shares of common
 stock held in January 2016 is included in Note 13.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Recently Issued Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In May 2014, the FASB issued guidance that outlines a single
 comprehensive model for entities to use in accounting for revenue
 arising from contracts with customers and supersedes most current
 revenue recognition guidance, including industry specific guidance.
 The guidance is based on the principle that an entity should
 recognize revenue to depict the transfer of goods or services to
 customers in an amount that reflects the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services. The guidance also requires additional disclosure about
 the nature, amount, timing and uncertainty of revenue and cash
 flows arising from customer contracts, including significant
 judgments and changes in judgments and assets recognized from costs
 incurred to fulfill a contract. Entities have the option of using
 either a full retrospective or a modified retrospective approach
 for the adoption of the new standard. The guidance becomes
 effective for the Company in the year ending December&#xA0;31,
 2018, and the Company could early adopt the standard for the year
 ending December&#xA0;31, 2017. The Company is currently assessing
 the method of adoption and the impact that this new accounting
 guidance will have on its consolidated financial statements and
 footnote disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In August 2014, the FASB issued ASU 2014-15, Presentation of
 Financial Statements&#x2014;Going Concern (Subtopic 205-40). The new
 guidance addresses management&#x2019;s responsibility to evaluate
 whether there is substantial doubt about an entity&#x2019;s ability
 to continue as a going concern and to provide related footnote
 disclosures. Management&#x2019;s evaluation should be based on
 relevant conditions and events that are known and reasonably
 knowable at the date that the financial statements are issued. The
 standard will be effective for the first interim period within
 annual reporting periods beginning after December&#xA0;15, 2016.
 Early adoption is permitted. The Company is evaluating the effect
 that this guidance will have on its consolidated financial
 statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In November 2015, the FASB issued ASU 2015-17, Balance Sheet
 Classification of Deferred Taxes, which simplifies the
 classification of deferred tax assets and liabilities. The new
 standard requires that all deferred tax assets and liabilities,
 along with any related valuation allowance, be classified as
 noncurrent on the balance sheet. The standard is effective for
 interim and annual periods beginning after December&#xA0;15, 2016
 and allows for early adoption using a full retrospective method or
 a prospective method. The Company has elected to early adopt the
 provisions of this new standard using a prospective method. As a
 result, all deferred taxes as of December&#xA0;31, 2015 are
 classified as noncurrent on a net basis in the Company&#x2019;s
 consolidated balance sheet, while prior periods remain as
 previously reported.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In February 2016, the Financial Accounting Standards Board (FASB)
 issued ASU&#xA0;2016-02&#x2014;<i>Leases</i>&#xA0;(ASC&#xA0;842), which sets out
 the principles for the recognition, measurement, presentation and
 disclosure of leases for both parties to a contract (i.e. lessees
 and lessors). The new standard requires lessees to apply a dual
 approach, classifying leases as either finance or operating leases
 based on the principle of whether or not the lease is effectively a
 financed purchase by the lessee. This classification will determine
 whether lease expense is recognized based on an effective interest
 method or on a straight line basis over the term of the lease,
 respectively. A lessee is also required to record a right-of-use
 asset and a lease liability for all leases with a term of greater
 than 12&#xA0;months regardless of their classification. Leases with
 a term of 12&#xA0;months or less will be accounted for similar to
 existing guidance for operating leases today. ASC&#xA0;842
 supersedes the previous leases standard, ASC&#xA0;840&#xA0;<i>Leases.&#xA0;</i>The standard is effective
 on January&#xA0;1, 2019, with early adoption permitted. The Company
 is in the process of evaluating the impact of this new
 guidance.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_BusinessRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Risks And Uncertainties Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_BusinessRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_InitialPublicOfferingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering Policy Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_InitialPublicOfferingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent Costs Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchContractCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Contract Costs and Accruals Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchContractCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6750159056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Property and equipment, net consists of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Useful&#xA0;Life<br />
 (Years)</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Computer hardware and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">400</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Furniture and equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">147</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Less: Accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(261</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(146</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Property and equipment, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">286</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">163</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" />

 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Accrued expenses consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,466</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,788</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Employee related expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,718</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Professional services</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">46</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,148</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6753815984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments, Under Non-Cancelable Operating Leases</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Future minimum lease payments under non-cancelable operating leases
 are as follows at December&#xA0;31, 2015:</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="15%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 95.55pt">
 <b>Years Ending December&#xA0;31,</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,088</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,132</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,154</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,398</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,926</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" />

 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794932400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Stock-based compensation expense recognized during the years ended
 December&#xA0;31, 2015, 2014, and 2013 was as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>Stock-based compensation expense:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,924</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,093</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">38</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,316</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">23</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">61</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The fair value of each option granted to employees and nonemployee
 directors during the years ended December&#xA0;31, 2015, 2014, and
 2013 under the Company&#x2019;s stock option plans has been
 calculated on the date of grant using the following weighted
 average assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.00</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90.54</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">98.86</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">99.89</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Risk free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.59</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.95</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.66</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected term</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.03&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.38&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.04&#xA0;years</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Relating to Stock Options</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The table below summarizes activity related to stock options:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="47%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br />
 Average&#xA0;Exercise<br />
 Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average<br />
 Remaining&#xA0;Life&#xA0;(in</b><br />
 <b>years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate<br />
 Intrinsic&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December&#xA0;31, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,996,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.01</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.98</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">59,362</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,516,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.64</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(417,475</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.44</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(92,638</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26.93</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,002,809</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">26.67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,479</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested or expected to vest as of December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,421,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24.89</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">82,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable as of December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">723,895</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14.47</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.27</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">31,729</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Activity Relating to Restricted Stock</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The table below summarizes activity relating to restricted
 stock:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December 31, 2014</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170,832</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Issued</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(128,051</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Repurchased</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Outstanding as of December 31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6754955872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic and diluted net income (loss) per share attributable to
 common stockholders was calculated as follows for the years ended
 December&#xA0;31, 2015, 2014 and 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic net loss per share attributable to common stockholders:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Numerator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em">
 Net loss attributable to common stockholders
 (in&#xA0;thousands)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(94,495</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(36,105</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(18,288</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Denominator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Weighted average shares of common stock outstanding&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,778,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,574,347</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,492,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Dilutive effect of shares of common stock equivalents resulting
 from common stock options and preferred common stock (as
 converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Weighted average common stock outstanding&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,778,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,574,347</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,492,288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders&#x2014;basic
 and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.67</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(12.26</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Common Stock Equivalents Outstanding</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following common stock equivalents outstanding as of
 December&#xA0;31, 2015 and 2014, were excluded from the computation
 of diluted net loss per share attributable to common stockholders
 for the periods presented because including them would have been
 anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="80%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,643,833</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,621,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,781</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170,067</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Employee Stock Purchase Plan</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,689,921</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,791,973</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756468656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of U.S. Statutory Rate to Company's Effective Tax Rate</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 A reconciliation of U.S. statutory rate to the Company&#x2019;s
 effective tax rate is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tax due at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State taxes, net of federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Permanent items</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Foreign rate differential</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Federal and state credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.5</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(46.0</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(40.5</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Significant Components of Company's Net Deferred Tax Asset</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Significant components of the Company&#x2019;s net deferred tax
 asset at December&#xA0;31, 2015 and 2014 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">(in thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net operating losses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,172</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,907</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Capitalized start-up costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,335</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accounting method change</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,347</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,020</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tax credit carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,433</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,062</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">494</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Depreciation and amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">716</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">332</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,097</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">623</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Others</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total net deferred tax asset before valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">69,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,303</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(69,069</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,303</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Rollforward of Company's Unrecognized Tax Benefits</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following is a rollforward of the Company&#x2019;s unrecognized
 tax benefits:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Unrecognized tax benefits&#x2014;as of the beginning of the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gross increases&#x2014;current period tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Gross decreases&#x2014;tax positions of prior periods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,880</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Unrecognized tax benefits&#x2014;as of the end of the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=51663037&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6584108032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table contains quarterly financial information for
 2015 and 2014. The Company believes that the following information
 reflects all normal recurring adjustments necessary for a fair
 statement of the information for the periods presented. The
 operating results for any quarter are not necessarily indicative of
 results for any future period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>First</b><br />
 <b>Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Second<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Third<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fourth<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="18" align="center"><b>(in thousands,
 except per share amounts)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,897</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,059</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">24,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,612</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">94,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Loss from operations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16,897</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(25,059</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(24,082</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,612</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,650</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss and comprehensive loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16,871</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(25,027</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(24,035</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,562</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,495</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss attributable to common stockholders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(16,871</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(25,027</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(24,035</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,562</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,495</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders&#x2014;basic
 and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.66</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.90</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.84</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.99</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.40</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>First<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Second<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Third<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Fourth<br />
 Quarter</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="18" align="center"><b>(in thousands,
 except per share amounts)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,790</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Loss from operations</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,790</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,188</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,471</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,361</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,810</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss and comprehensive loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,790</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,192</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,468</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,361</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,811</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss attributable to common stockholders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,116</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,769</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,859</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,361</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(36,105</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss per share attributable to common stockholders&#x2014;basic
 and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(3.70</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.57</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.50</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.48</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.67</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797340400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Apr. 20, 2015</div></th>
<th class="th"><div>Jul. 23, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (161,340)<span></span>
</td>
<td class="num">$ (66,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,753<span></span>
</td>
<td class="nump">127,766<span></span>
</td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 2,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten initial public offering of common stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,720<span></span>
</td>
<td class="nump">$ 96,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten initial public offering of common stock, net proceeds</a></td>
<td class="nump">$ 140,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_NatureOfBusinessLineItems', window );"><strong>Nature Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Convertible preferred stock proceeds raised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_NatureOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Business [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_NatureOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6810441792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 02, 2014</div></th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">584,000<span></span>
</td>
<td class="nump">2,285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="nump">2,628,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="nump">$ 52.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of common stock, net of commissions and underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with preparing for the IPO, the Company's board of directors and  stockholders approved a 1-for-3.15 reverse stock split of the Company's common  stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_StockholdersEquityReverseStockSplitEffectiveDate', window );">Reverse stock split effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issuance of additional shares of common stock upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,007,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten initial public offering of common stock, net proceeds</a></td>
<td class="nump">$ 129,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,720,000<span></span>
</td>
<td class="nump">96,255,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,800,000<span></span>
</td>
<td class="nump">127,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of common stock, net of commissions and underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_StockholdersEquityReverseStockSplitEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Reverse Stock Split Effective Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_StockholdersEquityReverseStockSplitEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807666224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sage_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sage_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sage_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787414912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6796782896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AccruedDevelopmentExpensesCurrent', window );">Development costs</a></td>
<td class="nump">$ 6,466<span></span>
</td>
<td class="nump">$ 2,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related expenses</a></td>
<td class="nump">2,718<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 10,148<span></span>
</td>
<td class="nump">$ 4,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AccruedDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Expenses Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AccruedDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797116272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense, net of sublease income | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sage_OperatingLeaseOneMember', window );">Operating Lease One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AreaOfOfficeSpace', window );">Office space rented under operating lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_OperatingLeaseExpirationPeriod', window );">Operating lease end year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sage_SubleaseAgreementMember', window );">Sublease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AreaOfLeasedProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Lease income per month | $</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AreaOfLeasedProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AreaOfLeasedProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_OperatingLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_OperatingLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sage_OperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sage_OperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sage_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sage_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6796917264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments, Under Non-Cancelable Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">$ 978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2019</a></td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2020</a></td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total Operating leases, future minimum payments</a></td>
<td class="nump">$ 6,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6809942272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 69,357,000<span></span>
</td>
<td class="nump">$ 24,100,000<span></span>
</td>
<td class="nump">$ 14,357,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | First and Second Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | First and Second Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Third and Fourth Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Third and Fourth Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Clinical Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember', window );">CyDex License Agreement [Member] | Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payments based on achievement of certain development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_CydexLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_FirstAndSecondRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ThirdAndFourthRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6811033728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Washington University License Agreement - Additional Information (Detail) - Washington University License Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_UpfrontNonrefundablePayment', window );">Upfront non-refundable payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_LicenseMaintenanceCostAnnual', window );">Annual license maintenance fee</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_IssueOfCommonStockObligation', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_WashingtonUniversityLicenseAgreementMember', window );">Clinical Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_WashingtonUniversityLicenseAgreementMember', window );">Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payments based on achievement of certain development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IssueOfCommonStockObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue of common stock obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IssueOfCommonStockObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LicenseMaintenanceCostAnnual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance cost annual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LicenseMaintenanceCostAnnual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_UpfrontNonrefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront nonrefundable payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_UpfrontNonrefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_WashingtonUniversityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_WashingtonUniversityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807695024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - University of California License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestonePaymentsExpensedDuringPeriod', window );">Milestone or royalty payments, expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember', window );">University of California License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_UpFrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_LicenseMaintenanceCostAnnual', window );">Annual license maintenance fee</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember', window );">University of California License Agreement [Member] | After The Effective Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_LicenseAgreementMaximumTerm', window );">Licenses Expiration period, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember', window );">University of California License Agreement [Member] | After The First Sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_LicenseAgreementMaximumTerm', window );">Licenses Expiration period, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember', window );">University of California License Agreement [Member] | Clinical Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember', window );">University of California License Agreement [Member] | Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember', window );">University of California License Agreement [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment', window );">Expected milestone payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payments based on achievement of certain development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_AdditionalPaymentsBasedOnAchievementOfCertainDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LicenseAgreementMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement maximum term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LicenseAgreementMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_LicenseMaintenanceCostAnnual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance cost annual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_LicenseMaintenanceCostAnnual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePaymentsExpensedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone or royalty payments, expenses recognized during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePaymentsExpensedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Net Sales Required for Royalty Entitlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PercentageOfNetSalesRequiredForRoyaltyEntitlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_UniversityOfCaliforniaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=sage_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=sage_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=sage_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=sage_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807670096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Consulting Agreement - Additional Information (Detail) - Consulting Agreement [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_ConsultingAgreementMember', window );">Clinical Development and Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MaximumMilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MaximumMilestoneShareBasedPayments', window );">Shares of common stock for attaining milestones</a></td>
<td class="nump">126,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_ConsultingAgreementMember', window );">First Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestoneStockCompensation', window );">Payments for stock issued upon reaching a milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestoneBasedShareCompensation', window );">Milestone based share compensation, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_ConsultingAgreementMember', window );">Second and Third Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment', window );">Research and development expense related to milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestoneStockCompensation', window );">Payments for stock issued upon reaching a milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_MilestoneBasedShareCompensation', window );">Milestone based share compensation, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MaximumMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MaximumMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MaximumMilestoneShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone share based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MaximumMilestoneShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestoneBasedShareCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone based share compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestoneBasedShareCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_MilestoneStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone stock compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_MilestoneStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense related to milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ResearchAndDevelopmentExpenseRelatedToMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sage_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_ClinicalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_FirstClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_FirstClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sage_SecondAndThirdClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sage_SecondAndThirdClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6810169248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2014</div></th>
<th class="th"><div>Feb. 12, 2014</div></th>
<th class="th"><div>Jan. 07, 2014</div></th>
<th class="th"><div>Oct. 18, 2013</div></th>
<th class="th"><div>Sep. 12, 2013</div></th>
<th class="th"><div>Jul. 01, 2013</div></th>
<th class="th"><div>Mar. 18, 2013</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2013</div></th>
<th class="th"><div>Oct. 15, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Redeemable convertible preferred Stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Third Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="nump">6,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Redeemable convertible preferred Stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_UndrawnAmount', window );">Redeemable convertible preferred stock, Undrawn amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="nump">$ 4.2345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">8,973,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from the issuance of preferred stock, net proceeds</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Redeemable convertible preferred Stock, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_UndrawnAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undrawn amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_UndrawnAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityClassAxis=sage_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityClassAxis=sage_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityClassAxis=sage_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityClassAxis=sage_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityClassAxis=sage_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityClassAxis=sage_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756823792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights</a></td>
<td class="text">Each share of common stock entitles the holder to one vote on all matters  submitted to a vote of the Company's stockholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6812374496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation granted under plan vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod', window );">Share based compensation, vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.08<span></span>
</td>
<td class="nump">$ 14.33<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate', window );">Share option, forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,240<span></span>
</td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,516,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares outstanding unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued, Shares-Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from restricted shares sold to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SharesRepurchasePricePerShare', window );">Stock repurchased, purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share based compensation, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember', window );">2014 Stock Option Plan and 2011 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of shares reserved under equity plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,862,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandElevenStockOptionPlanMember', window );">2011 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_PercentageOfPerformanceBasedGrantsThatWereAchieved', window );">Percentage of performance based grants that were achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Stock Option Plan [Member] | Performance Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod', window );">Options with performance-based criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_PerformanceBasedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember', window );">2014 Stock Option Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption', window );">Percentage of increase to stock option on issued and outstanding shares of Common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options with performance-based criteria</a></td>
<td class="nump">282,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares outstanding reserved for issuance increase percentage on stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_CommonStockSharesOutstandingReservedForIssuanceIncreasePercentageOnStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PercentageOfPerformanceBasedGrantsThatWereAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of performance based grants that were achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PercentageOfPerformanceBasedGrantsThatWereAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_PerformanceBasedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance based share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_PerformanceBasedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Estimated Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted during the period for which vesting is contingent upon company corporate goals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedShareOptionGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_SharesRepurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Repurchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_SharesRepurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanAndTwoThousandElevenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandElevenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandElevenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandFourteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sage_PerformanceMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sage_PerformanceMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sage_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sage_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6632442000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 15,240<span></span>
</td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">5,924<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Stock-based compensation expense</a></td>
<td class="nump">$ 9,316<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787140864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.54%<span></span>
</td>
<td class="nump">98.86%<span></span>
</td>
<td class="nump">99.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.59%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 11 days<span></span>
</td>
<td class="text">6 years 4 months 17 days<span></span>
</td>
<td class="text">6 years 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6798231408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Relating to Stock Options (Detail) - Options to Purchase Common Stock [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, Stock options</a></td>
<td class="nump">1,996,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Stock options</a></td>
<td class="nump">1,516,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Stock options</a></td>
<td class="num">(417,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, Stock options</a></td>
<td class="num">(92,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, Outstanding Shares-Stock options</a></td>
<td class="nump">3,002,809<span></span>
</td>
<td class="nump">1,996,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest, Stock options</a></td>
<td class="nump">2,421,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Stock options</a></td>
<td class="nump">723,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">45.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">26.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, Outstanding Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">26.67<span></span>
</td>
<td class="nump">$ 7.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest, Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">24.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price-Stock options</a></td>
<td class="nump">$ 14.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Life-Stock options</a></td>
<td class="text">8 years 8 months 1 day<span></span>
</td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest, Weighted Average Remaining Life-Stock options</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Life-Stock options</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value-Stock options</a></td>
<td class="nump">$ 96,479<span></span>
</td>
<td class="nump">$ 59,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest, Aggregate Intrinsic Value-Stock options</a></td>
<td class="nump">82,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value-Stock options</a></td>
<td class="nump">$ 31,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6813170528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Relating to Restricted Stock (Detail) - Restricted Stock [Member] - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Shares at beginning balance-Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued, Shares-Restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares-Restricted stock</a></td>
<td class="num">(128,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Shares-Restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased, Shares-Restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Shares at ending balance-Restricted stock</a></td>
<td class="nump">42,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6812491552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (28,562)<span></span>
</td>
<td class="num">$ (24,035)<span></span>
</td>
<td class="num">$ (25,027)<span></span>
</td>
<td class="num">$ (16,871)<span></span>
</td>
<td class="num">$ (12,361)<span></span>
</td>
<td class="num">$ (9,859)<span></span>
</td>
<td class="num">$ (7,769)<span></span>
</td>
<td class="num">$ (6,116)<span></span>
</td>
<td class="num">$ (94,495)<span></span>
</td>
<td class="num">$ (36,105)<span></span>
</td>
<td class="num">$ (18,288)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding-basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,778,288<span></span>
</td>
<td class="nump">21,574,347<span></span>
</td>
<td class="nump">1,492,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Dilutive effect of shares of common stock equivalents resulting from common stock options and preferred common stock (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common stock outstanding-diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,778,288<span></span>
</td>
<td class="nump">21,574,347<span></span>
</td>
<td class="nump">1,492,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (4.57)<span></span>
</td>
<td class="num">$ (3.70)<span></span>
</td>
<td class="num">$ (3.40)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (12.26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6796911584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Common Stock Equivalents Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">2,689,921<span></span>
</td>
<td class="nump">1,791,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">2,643,833<span></span>
</td>
<td class="nump">1,621,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sage_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">42,781<span></span>
</td>
<td class="nump">170,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents</a></td>
<td class="nump">3,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sage_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sage_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797619552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal operating loss carryforwards</a></td>
<td class="nump">131,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State operating loss carryforwards</a></td>
<td class="nump">$ 130,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear', window );">Federal and state net operating loss carryforwards expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal orphan drug tax credit carry forwards</a></td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_TaxCreditsExpirationStartYear', window );">Tax credit carry forwards expiration period</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in amount of deferred tax assets</a></td>
<td class="nump">$ 40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 69,069,000<span></span>
</td>
<td class="nump">$ 28,303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax position description</a></td>
<td class="text">For tax positions  meeting the more likely than not threshold, the tax amount recognized in the  financial statements is reduced by the largest benefit that has a greater than  fifty percent likelihood of being realized upon the ultimate settlement with the  relevant taxing authority.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit related to start-up costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,880,000<span></span>
</td>
<td class="nump">$ 1,477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits carryforwards</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development tax credits carryforwards expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsShareBasedCompensation', window );">Excess equity based compensation, tax deductions</a></td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxLiabilitiesShareBasedCompensation', window );">Excess equity based compensation, tax credits</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits carryforwards</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development tax credits carryforwards expiration year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsShareBasedCompensation', window );">Excess equity based compensation, tax deductions</a></td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxLiabilitiesShareBasedCompensation', window );">Excess equity based compensation, tax credits</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DeferredTaxAssetsShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DeferredTaxAssetsShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DeferredTaxLiabilitiesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DeferredTaxLiabilitiesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal and state net operating loss carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_FederalAndStateNetOperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_TaxCreditsExpirationStartYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The year in which tax credits will begin to expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_TaxCreditsExpirationStartYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797578560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of U.S. Statutory Rate to Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax due at statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal and state credits</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(43.10%)<span></span>
</td>
<td class="num">(46.00%)<span></span>
</td>
<td class="num">(40.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6796940816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Significant Components of Company's Net Deferred Tax Asset (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 44,172<span></span>
</td>
<td class="nump">$ 21,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">2,335<span></span>
</td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsChangeInAccountingMethod', window );">Accounting method change</a></td>
<td class="num">(1,347)<span></span>
</td>
<td class="num">(2,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">17,013<span></span>
</td>
<td class="nump">4,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_DeferredTaxAssetsStockOptions', window );">Stock options</a></td>
<td class="nump">5,097<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total net deferred tax asset before valuation allowance</a></td>
<td class="nump">69,069<span></span>
</td>
<td class="nump">28,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(69,069)<span></span>
</td>
<td class="num">(28,303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized start-up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DeferredTaxAssetsChangeInAccountingMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets change in accounting method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DeferredTaxAssetsChangeInAccountingMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_DeferredTaxAssetsStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_DeferredTaxAssetsStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776256240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Rollforward of Company's Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits-as of the beginning of the year</a></td>
<td class="nump">$ 2,880<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases-current period tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases-tax positions of prior periods</a></td>
<td class="num">$ (2,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits-as of the end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776111552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sage_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sage_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795356464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - Third Rock Ventures LLC [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership held with related party transactions</a></td>
<td class="nump">16.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payment for consulting and management services</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sage_ThirdRockVenturesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sage_ThirdRockVenturesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6797777664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 28,612<span></span>
</td>
<td class="nump">$ 24,082<span></span>
</td>
<td class="nump">$ 25,059<span></span>
</td>
<td class="nump">$ 16,897<span></span>
</td>
<td class="nump">$ 12,361<span></span>
</td>
<td class="nump">$ 9,471<span></span>
</td>
<td class="nump">$ 6,188<span></span>
</td>
<td class="nump">$ 5,790<span></span>
</td>
<td class="nump">$ 94,650<span></span>
</td>
<td class="nump">$ 33,810<span></span>
</td>
<td class="nump">$ 18,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,612)<span></span>
</td>
<td class="num">(24,082)<span></span>
</td>
<td class="num">(25,059)<span></span>
</td>
<td class="num">(16,897)<span></span>
</td>
<td class="num">(12,361)<span></span>
</td>
<td class="num">(9,471)<span></span>
</td>
<td class="num">(6,188)<span></span>
</td>
<td class="num">(5,790)<span></span>
</td>
<td class="num">(94,650)<span></span>
</td>
<td class="num">(33,810)<span></span>
</td>
<td class="num">(18,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(28,562)<span></span>
</td>
<td class="num">(24,035)<span></span>
</td>
<td class="num">(25,027)<span></span>
</td>
<td class="num">(16,871)<span></span>
</td>
<td class="num">(12,361)<span></span>
</td>
<td class="num">(9,468)<span></span>
</td>
<td class="num">(6,192)<span></span>
</td>
<td class="num">(5,790)<span></span>
</td>
<td class="num">(94,495)<span></span>
</td>
<td class="num">(33,811)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (28,562)<span></span>
</td>
<td class="num">$ (24,035)<span></span>
</td>
<td class="num">$ (25,027)<span></span>
</td>
<td class="num">$ (16,871)<span></span>
</td>
<td class="num">$ (12,361)<span></span>
</td>
<td class="num">$ (9,859)<span></span>
</td>
<td class="num">$ (7,769)<span></span>
</td>
<td class="num">$ (6,116)<span></span>
</td>
<td class="num">$ (94,495)<span></span>
</td>
<td class="num">$ (36,105)<span></span>
</td>
<td class="num">$ (18,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders-basic and diluted</a></td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (4.57)<span></span>
</td>
<td class="num">$ (3.70)<span></span>
</td>
<td class="num">$ (3.40)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (12.26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6799233008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Apr. 20, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,628,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of commissions and underwriting discounts and estimated offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,100<span></span>
</td>
<td class="nump">$ 129,720<span></span>
</td>
<td class="nump">$ 96,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">3,157,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 47.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of commissions and underwriting discounts and estimated offering expenses</a></td>
<td class="nump">$ 140,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MXJGKOR?+NI:ORV[<ZMKOX]=Q4@G'A/7PZ*T#CPK"Q5XW)C#AYMD&T3%"@MB
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M7DY<V=KZ[ICZ$7U[5?4G4$L#!!0    ( '.)74B97)PC$ 8  )PG   3
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M2 :0;"<(VYMQ .4 RG\#FGOZ%P;IF%FR'VMA 50 J-@)=+KB&)\20.6NH F
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M'$492M9P_MW4].SP%2)ARU:I4[KV0W\SO-NK;\C/GR\^_P]02P,$%     @
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MI"9[H4)@^;B1#:EK%4DJ_QF"/C05T1S?HW_KRY7I[S G&UK_K@[B++,-?>]
MCOA:BS?:?2=##;$*N*<U[W^]_94+VMPIOM?@#_VLVO[9Z7\B--#<!#@0X$B
MT9<$-!#02 !?$Z*!$%F$0)?2OX@M%K@L&.T\?L&J/<!"PID*(B-[O(_&]/N5
MKX++U5L9%L%-A1D0L$>L3008$8&,[12 _I0.#3IT"6Q,!'(AMB8B>IX"NJ>
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M2*D@,I?P1>[A6=ZZQDE-CD(-4SEF^AZB)X)>[M>J\6Y7_@-02P,$%     @
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M'YPG2@61\>!&_BU*>4?>!C4Y"=6-99\-M\8P$+2;+L';39S_!U!+ P04
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M #4$J$L 0#0 AP"\!"!& _00H"\!2D4#S!!@+@%&1P/L$&#?*=EH@!L"W"7
M^FB 'P+\^QSR:$ ^!.3O&4PTH-OS?N>RU*V#RV8G[S:<MQL4"YGWA74JRV71
M%#=7Q^IM4K\4W<4*'SO\L1NG'7Q2GP8\]N7>5F;=_OKKQJNK^:]NH '21RP(
M!"7(+8%H";(D$"-!/A&(E2 K G$2Y#.!> FR)I!<@FQ"2)Y)D"\$ A+D*X&(
MJWM'(.^K.V\W3]Y!==Y!W>^@"@=@:^_Z'>PAAQ-D!H@R;)T&VX0PT+G+$D@C
M(XTA:58-MB\8#--@;I1#"?>%X$QV>B4PTHR1#AE9*=-"AYFDI5G)B'$2AI$P
M(0DGI?AB@A2J71.5D,:R-#9,X\75MT$:!*<3LCB6Q859<G'O')V,2=P[SS+Y
M(!-DF;AY/DPE0E8CD'$>.>.1$QX@+FP>EHBS-JC^\420L4R=QUQ2.7$+%P-F
MN)Z=..4H9J@X@G$I;(&S!;(P2J8+01JK9;HCF @7+I>@"!=14Y80:IQV%O*4
M5%SD $DJ<4H+"/7+BC6S&L-$N'!Y TVXB)*[ $T<P"LO\EG'<!%.7.W $$ZR
MZ$(H>#,$@R)N17"M7\C$V6#6&:GD-P2'SF5)^\]E%BR9GW@%+B%46K"M"LI%
ML"' EE.J6 +792#"/++JH3)K62[',!$J7+@A5&[9\&XAE.4<PWXC@'TB,-&=
M/_.1;"[!OM*1]$C".P)#Y_.D%>"6 :%GC'@QA)[AG78IEJ&X9:C0,F0__J1"
MJ3>LQ +@5P+,^Y<$O"- GSO,LR3VW$(4M1#9XQ60G1.K=@P3X?);QTTM1/9Y
M1=ID])#YE%S<0U3H(2-&KT)[F"G%^_;SS DL1]$#UA0%:,2+9$-@)&5D<MR4
M%#4EN2]0I*E6<A\S"HJPX7:DJ!W)G8$B-F.\2^F_%7<&19U![@Q4*/C*@+@\
MJW%4A ^W!.4(GY$R"_4^5]ZB5!E+ AOAS$<2]7I#8#.:,3(Y;C**WAZ(.K54
M1/1]ECG#>X/!APER9JQ3K:8EE3_7?D7O%^2>3(7B/\-62.2>+(:+W)=SE\#0
M)0!DG<6,7&W@^8'.4 H$)UY/*SJ4;Z\G\0)?$]S,6J]3; 2YC2"Q$7DIEPCD
MDK(*7)ZTF-PHD)S-R)T6ACYA9=59C8(B9'X[<B%G+G*OA>0P1>7@Y$XJAHM0
MXOJ/Y-!%;GXP5'8-B=T/<G%'<K0B=S](SE:L\B9M6ES=D:K[R#5$^G[9U<8P
M$2Y<V9$J^TC!.[*=/C-)\^9"BT1H9;]:(!':$3L?!478<'5%HJX@VSF&JHG>
MI+BGYIJIB6:.M#&:::9\IS^.BO#A(J=IKRS/7!.10Y]TBZNYPFG:"LN-C":M
ML $GW\%'8!%&7.8T/72135735EAK^0QZ'<-%./UVMDSZ7'YC,AS2:]+".K2<
MTV"J!">V8"L*09.ADG!K@IN!!4RZC==<7#7IG$$^S]=$7;U7:#2ON7GP].JE
M>"K_+(Y/VT,]^5$U3;4_/;1ZK*JF;,?+/K3C/9?%P^7+KGQLNH^N_7SLG[CV
M7YKJY?P ^?(4^^9_4$L#!!0    ( '.)74C'IX=[YP$  &@%   8    >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&ULC539CILP%/T5BP\8M@1H1) FJ:KVH=)H
M'MIG!RZ+QL;4-F'Z]_5""*"HY 7LR]DNX)L.C'^(&D"B3TI:<71J*;N#ZXJ\
M!HK%"^N@54]*QBF6:LLK5W0<<&%(E+B!YT4NQ4WK9*FIO?$L9;TD30MO'(F>
M4LS_GH"PX>CXSJWPWE2UU 4W2]V)5S046M&P%G$HC\ZK?S@G&F$ OQH8Q&R-
M=/8+8Q]Z\Z,X.IZ.  1RJ16PNEWA#(1H(67\9]2\6VKB?'U3_V:Z5>DO6,"9
MD=]-(6L5UG-0 27NB7QGPW<86]AKP9P18:XH[X5D]$9Q$,6?]MZTYC[8)XDW
MTAX3@I$03 0_^B\A' GAG; SG=IDIJ^O6.(LY6Q HL/Z8_L'!>=:1"DC8=2X
M?5VJ,Z&JU\SWH]2]:J$1$QC,:8&9$*Y2?V@1.$MZ,*.'P2.'\QP2?=FV"&\6
M.]M%N.@BWA;8K01V"X%D&3*V(2VFM9ADVV._\M@O/)[H,EH)1-LA3]$L9.AM
M>\0KCWCN$3PAD*P$DB=")O,WZ:]-W-D?3(%7YF0+E+.^E?;OFJK3\'@-] E8
MU4]JJ-@9<)?)T@Y7\!/SJFD%NC"ISI<Y#"5C$E0X[T5]IUJ-O6E#H)1Z&:LU
MMY/ ;B3K;G-M&J[9/U!+ P04    " !SB5U(4/ 'O&8$  "9%0  &    'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;)5838_C-@S]*T;N75N4;,F#3(")C:(]
M%%CLH3U[$N4#:\>I[9EL_WW]E8Q(,!/-);&51^I1(I\8+2]U\[,]6-L%OZKR
MU#XO#EUW?@K#=G.P5=%^J\_VU/^RJYNJZ/K79A^VY\86V]&H*D.(HB2LBN-I
ML5J.8]^;U;)^Z\KCR7YO@O:MJHKFO[4MZ\OS0BRN S^.^T,W#(2K97BSVQXK
M>VJ/]2EH[.YY\2*><FD&R(CX^V@OK?,<#.1?Z_KG\/+G]GD1#1QL:3?=X*+H
MO]YM9LMR\-3/_._L]&/.P=!]OGK_?0RWI_]:M#:KRW^.V^[0LXT6P=;NBK>R
M^U%?_K!S#/'@<%.7[?@9;-[:KJZN)HN@*GY-W\?3^'V9?C'1;,8;P&P -P.1
M?&H@9P/Y8: ^-5"S@2(&X13*N!!YT16K95-?@O9<#.DAGGIX,SCI/0?MZ*V9
MUK=?BK8??5\)$,OP?7 T8V#$K!'FA@A[[^P4L,#FX)@#-T'F(B0+R5U(DCXF
M(:\DY!2G1''"8P?JZF!Z?5&N@RC&)/44Z80YC9C?4J52%I8AF)1&" Z6(Y@P
M8#S6/B9AQRAL^=A!0L).4-@*$TVFL!.'J(A!11PJ<U$0"^! N0M*/.+5A*Y&
M\?)TM4L7Z.+/;#%(LV1=3*(>DS6$K$%D8Y:L<7D(%I.YF)@-)W<A2C^FFI(\
M2A'5Y+$#$9%@!PW^*'(^V!DSIWQB^*W!*,TO2HY14G@$+03E["J?3'G. I5I
M$GO, W0>5]V4Y.<!MWZ2E"\RA%**3P8$2K1'Y@I)&6,]9>MC/8/FQ%2\>F0(
MI63,AI\C%$B?#*0*+I"$@^$Y(]75T=TD1#C0D>(%#>.$CH4/=2KC NNXQ_DG
MJ) +I.2239^U2!#;E%VCC*#XE<PQRN/H$53,!5)SR6[$6F@ORMJ+LOXJ94,W
M"FFZ].@S1$JC1EHK[ZA!ZC#5_&YF",2?RCG"Q#[='15VB!!?_LP%5XW[!-;
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MTNZZX5'WS\UT<SB]=/7Y>A%ZNXU=_0]02P,$%     @ <XE=2'=D10^@ 0
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M322T+H0W/C;I2J7$X; \D/655N]02P,$%     @ <XE=2%4_IKN? 0  L0,
M !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULC5/;3N,P$/T5RQ^ T[0%
M5*61**L5/" A'N#932:)A>W)VDX#?X\O36@1@GV)9R;GG#GC2S&B>;4=@"-O
M2FJ[I9US_88Q6W6@N+W 'K3_TZ!1W/G4M,SV!G@=24JR/,LNF>)"T[*(M4=3
M%C@X*30\&F('I;AYWX'$<4L7="H\B;9SH<#*@LV\6BC05J F!IHMO5EL=JN
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M"^%G'YMTI5+B<%P?R/9*ZW]02P,$%     @ <XE=2+V[4/&@ 0  L0,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULA5/+;MLP$/P5@A\0RHJ<&(8L
M($Y1M(<"00[MF996$A&2JY*4E?Y]^9 4.PB2B[B[FIF=Y:.<T+S8'L"15R6U
M/=#>N6'/F*U[4-S>X #:_VG1*.Y\:CIF!P.\B20E69YE=TQQH6E5QMJ3J4H<
MG10:G@RQHU+<_#N"Q.E -W0I/(NN=Z' JI*MO$8HT%:@)@;: WW8[(]%0$3
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MA,Z?;#R&%M&!-Y'=;"GI_?M9$PFM"^&]CTVZ4BEQ."P/9'VEU7]02P,$%
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M0OC-QR9=J90X[.<'LKS2\@U02P,$%     @ <XE=2*CJ_!ZB 0  L0,  !D
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MPFL?FW2E4N*PGQ[(_$K+#U!+ P04    " !SB5U(_)]*#J(!  "Q P  &0
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M(UIWLN$8&D0+SD1RM:6D<^]G320TUH?7+M;Q2L7$XK \D/65EO\!4$L#!!0
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M+H1['YMTI5+B<%@>R/I*J[]02P,$%     @ <XE=2%_T>M2D 0  L0,  !D
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M@W)_:M226Y?JAIE> Z\"20J6)LDUD[Q3M,A#[447.0Y6= I>-#&#E%S_.X+
M\4 W="Z\=DUK?8$5.5MX52=!F0X5T5 ?Z-UF?\P\(@#>.AC-*B;>^PGQPR=/
MU8$FW@((**U7X&XYPST(X85<X[^3YE=+3US'L_I#F-:Y/W$#]RC>N\JVSFQ"
M204U'X1]Q?$1IA%V7K!$8<*7E(.Q*&<*)9)_QK5381WCG]MDHOU,2"="^HW
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M'26]?S]+(J%U(=S[V*0KE1*'P_Q EE=:_0=02P,$%     @ <XE=2-C,-]6
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MF1,%%B3W=V6/K088RG-"0CD_N5@!PM#:A5 !T/VZB%<7<=M'@LNT((.,2PA
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M7!)MOW4$O=IA*75H$N+$H408="Y%AZBQAY8C:*#"%*$D=B+3)0LKFD6,[;_
MLAQA2+%5*58Z- &;6JP5:$H@=A,"K L=CI1\.?0>OHK)J/PX?E3ZL2X46%$*
M:E2*%29*U0BU:NE:A8I=Z]B'6!<6K"@+#1U<4#T]].'TZ'* 4Y?TI'+_F--B
MAMB_\;IB@"(&-#(&,H)N!6*!V /1)0442:$.S0O_#2P/3RR@]S^$#G6!\'XZ
MS!![('H70W2K+J.Z0&0/9)R<+!![(/I@ ;(62''8/1"]+.3ALNA-"^HX8"S+
M$I1Y((G=! +TF0#4[@Y-:5T"593+@497 %"_]N;9 ^3VM@P?@73<.69[]CVK
M]WG5>&^\%2>G_IBSX[QEPA^:B&(>Q*G\^E"P7=O=)N*^'LZIPT/+CY=C]_7L
M/_\+4$L#!!0    ( '.)74BW#4TV7@(  "P(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;)5638^;,!#]*XA[%]L02"*"E%!5[:'2:@_MV4F<@!8P
MM9UE^^_K#T*,2PM[B3]X\^;-V)Y)VE'VR@M"A/=>5PW?^840[38(^*D@->9/
MM"6-_'*AK,9"+MDUX"TC^*R-ZBI  ,1!C<O&SU*]]\RRE-Y$53;DF7G\5M>8
M_3Z0BG8['_KWC9?R6@BU$61I,-B=RYHTO*2-Q\AEY^_A-H>1@FC$CY)TW)I[
M2OR1TE>U^';>^4!I(!4Y"46!Y?!&<E)5BDEZ_M63/GPJ0WM^9_^BPY7RCYB3
MG%8_R[,HI%K@>V=RP;=*O-#N*^EC6"G"$ZVX_O5.-RYH?3?QO1J_F[%L]-B9
M+VO0FTT;H-X #08P_J]!V!N$#P.=NL HTW%]Q@)G*:.=QUNL3AMN)9PI$LGL
M<<W&3+ID9%SNOF5H':?!FR+J,4AC#C8&#HA LD^Z0/[8'-DNIASD-B)$\Q["
MNP>SW(>C())Y@NA.$!F":$2P'HM,3!@&TVC,*DJF,+F-"<%F7LC*$;(:"=F,
MG<1&R,IR\@G%< J4CT PBN>EQ(Z4V#Z4R7 /L>7DK\O3"[$Q, [G=22.CL1.
MR0;,$ZR=V['^Z.W8. HV(P5.O@WF,,8LN,,0.%Y4S9F]A#W(I#,"8#+E(Q "
M"\X>0E?,J"YL%AP;1$[:(?IHWF'HJ@@79-X!10O\N,\?+GG_T'[<\!\%8 P"
M;MX"JSC7A%UUT^+>B=X:86KSL#LTQCW2Q?T!S](67\EWS*YEP[TC%;)%Z'I^
MH500J0(\R==?R-8]+"IR$6J:R#DSS<PL!&WOO7GX@Y#] 5!+ P04    " !S
MB5U(&2$! =<!  "X!   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R-
M5-F.FS 4_16+#Q@3($DG(DA95+4/E4;ST#X[<%DT7JAMPO3OZP4(B=#,O&#?
MZW/.7?!UV@OYIFH C=X9Y6H?U%JW.XQ57@,CZDFTP,U)*20CVIBRPJJ50 I'
M8A1'8;C!C#0\R%+G>Y%9*CI-&PXO$JF.,2+_'8&*?A^L@M'QVE2UM@Z<I7CB
M%0T#KAK!D81R'QQ6NW-B$0[PNX%>S?;(YGX1XLT:/XM]$-H4@$*NK0(QRQ5.
M0*D5,H'_#IJWD)8XWX_JWUVU)OL+47 2]$]3Z-HD&P:H@))T5+^*_@<,):RM
M8"ZH<E^4=TH+-E("Q,B[7QONUMZ?? L'VC(A&@C11%AM/B3$ R&^$9(/"<E
M2!X(V)?B&G$FFF2I%#U2+;&W8[4S<&E%C#)23DWZ_II6*..]9M'S.L57*S1@
M(H<YSC&K"8&-^F*(*+BG1_,02P%.<T2\"#G/(9OGSY.(QR1B7V=\5^?F<X%D
M%/#F(;D3V-XGN?65>@SWC0K#)<SI"YCS')-L'W+%LQ_,0%9N4A3*1<>U;_[D
MG8;Q$-D+\N _FB'U,W63R=*65/"+R*KA"EV$-M?/W952" TFM_!I':#:/".3
M0:'4=KLU>^DGRQM:M.,[,3U6V7]02P,$%     @ <XE=2.66O$?[ 0  V 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC93=CIP@',5?Q?@ BQ\H
MSL0QV;5IVHLFF[UHKYD9',VB6&#&[=N7#YU%0SJ]$?YXSN$'"N7$^+MH"9'!
M1T\'<0A;*<<] .+4DAZ+)S:20;UI&.^Q5"6_ #%R@L_&U%.01%$.>MP-856:
ML5=>E>PJ:3>05QZ(:]]C_N>%4#8=PCA<!MZZ2ROU *A*</>=NYX,HF-#P$ES
M")_C?8VTP@A^=F023C_0[$?&WG7Q_7P((XU *#E)G8!5<R,UH50'J8E_SYF?
M4VJCVU_2OYK5*OHC%J1F]%=WEJV"C<+@3!I\I?*-3=_(O(1,!YX8%>89G*Y"
MLGZQA$&//VS;#::=[)LBFFU^0S(;DKLAAO\TI+,AW1B )3/K^H(EKDK.ID",
M6'_L>*_D7(>HY$"8-&ZW2ZU,J-%;E>R*$MQTT*Q)C.9EI?$I:E>1?DJ  O!2
M) N%+9^3%<7N<4"Z!$ ;D+H 4;2&1'895C,830[SW">J75&"BN(Q"MR@P!5*
MO)XEMRAP-4M<^$2U*XH3]!^[DFU0LA5*XD7)G%EV:>8E<349@H]!\@U(O@))
MO2"YNR<[+X<K@?EC#+3!0"L,Z/U+D+OK40P+[V^"5B0%VK  YQ".^$)^8'[I
M!A$<F53GV1R^AC%)5%3TI':W5=?LO:"DD;J+5)_;F\<6DHW+/7J_S*N_4$L#
M!!0    ( '.)74@E-6M75 (  -D'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;)55V6ZC,!3]%<0'%-ML2420FF4T\S!2U8>99X<X 14PM9W0^?OQ
M @0CVJ0O 9NSW1OP35K*WGA.B' ^JK+F:S<7HEEY'L]R4F'^1!M2RR<GRBHL
MY)*=/=XP@H^:5)4> B#R*ES4;IKHO1>6)O0BRJ(F+\SAEZK"[-^&E+1=N]#M
M-UZ+<R[4AI<FWL [%A6I>4%KAY'3VGV&JSU$"J(1?PK2\M&]H\(?*'U3BU_'
MM0M4!E*23"@)+"]7LB5EJ92D\WLG>O-4Q/%]K_Y#EROC'S G6UK^+8XBEVF!
MZQS)"5]*\4K;GZ2K(52"&2VY_G6R"Q>TZBFN4^$/<RUJ?6W-DP7H:/,$U!'0
M0$#!EP2_(_B/$H*.$-P(\$M"V!'""<$SM>O.[;# :<)HZ_ &J_<)KB2<*1&I
M['"MQLP?(GO'Y>XU]4&8>%<EU&&0QFQL3#2'V8XQ<$!X,L%L#.3:%LBRB&<M
M;,QB#K,;8U"TG,/L;9WE_;!^']8W/?/' A#<%PAZ@< (!)8 M%/&IEJ#J34F
M & .LQMC_'G,_C/,IV'#2=C0"HON"T23=D7?;5<\21!; KY=9F3:%8_*1 A$
M\7V;Q<1F8=D$LS:+L0U #W1C.7%96B[A?0$()OU4Q]_W&@KA) 2T/FD8S=6Z
MZ4"F6+A\Y-V!:&ID?6PPGGM%-QVH>]<G+M[H/*L(.^M)PIV,7FIASI%A=YA6
MSWI83?:W:HKI<_(FDR8-/I/?F)V+FCL'*N1IJX_&$Z6"R&S@21:6RSD[+$IR
M$NHV5A6;R6,6@C;](!VF>?H?4$L#!!0    ( '.)74CU^(*H[@$  *(%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(V4RVZC,!B%7\7B 6HP"9>(
M(#4=59W%2%47,VLGF(!J8\9V0N?MQQ=(#4)*-OC"^<]W?AE<#%Q\RH80!;X8
M[>0^:)3J=Q#*4T,8ED^\)YU^4W/!L-)+<8:R%P17MHA1B,(P@0RW75 6=N]=
ME 6_*-IVY%T >6$,BW\'0OFP#Z)@VOAHSXTR&[ LX*VN:AGI9,L[($B]#YZC
MW2$W"BOXW9)!>G-@LA\Y_S2+G]4^"$T$0LE)&0>LARMY(90:(PW^.WI^(TVA
M/Y_<7VVW.OT12_+"Z9^V4HT.&P:@(C6^4/7!AS<RMK UAB=.I7V"TT4JSJ:2
M ##\Y<:VL^/@WF3A6+9>@,8"="M +K@#V9@_L,)E(?@ 9(_-V44[+1?&1#L#
M:=V$ZUX'E7KW6L915L"K,1HUKN3@:U#RK8':?Q6")DCL(,@SB+:;^P;Q9) X
M@]@:="Y!&"7SF*F+Z8OR](&8FP5E,Z>D<XH3'7Q1%&8/8+8+S':.R58QOBB*
M8G0?DRPPR1R3KV*2&>:1HTD7F'2&0>$J)IUATN0^)ILP&X?)9M_I>C.93XGS
M!XXF7U!RG[+L9?S,<H^2Y&C9"_3^OQZ?R2\LSFTGP9$K_2O;_Z[F7!%M%3[I
M4V[TA7E;4%(K,TWU7+@[Q"T4[Z<;\78ME_\!4$L#!!0    ( '.)74B0K)77
MX@(  +L,   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)57VXZ;,!#]
M%<0'%'O,+2N"M)NH:A\JK?:A?683)T$+.,7.9OOWM3%); L2> FV<^;,.98'
M#]F9M1_\0*GPONJJX4O_(,3Q*0CXYD#K@G]C1]K(?W:LK0LAI^T^X,>6%MLN
MJ*X"0"@.ZJ)L_#SKUE[;/&,G494-?6T]?JKKHOWW0BMV7OK8ORR\E?N#4 M!
MG@77N&U9TX:7K/%:NEOZS_AI#8F"=(C?)3US8^PI\>^,?:C)S^W21TH#K>A&
M*(I"/C[IBE:58I*9__:DMYPJT!Q?V+]W=J7\]X+3%:O^E%MQD&J1[VWIKCA5
MXHV=?]#>0Z0(-ZSBW:^W.7'!ZDN([]7%EWZ63?<\ZW]2U(<-!T ? -< '-\-
M('T N06$=P/"/B!T @)MI=N(=2&*/&O9V>/'0AT/_"3AK2*1S![OV%J]OW(K
MN%S]S G@+/A41#T&.LR+B;DA LD^F )\.QR,<!A*L )+Q!!D;4+BQ6,1Y"*"
M:)_$3('18X+P0J"GSZ&ET1&9:*<:T_0B290@A(: *Q,((49H!+@V@3AT&$>U
M1X[VR-).'A/$SN[%<W<O<10D]W8OUKN7F%[M+1G-DSIY4BM/^)A@X3A=S'6*
MD2-!O6P,#=&@UQZDS:83S6+LIK*K-YY  8Y?#+,-$U<%F6*8&(;)9,=N%6*[
M#),)%)'K.)KM.'95Q%,<Q^9Y)E,=NY6#[=)))U"DKN-TMN.%JV(QQ?'"/-31
M1,?@%A#8!33A90_8<0QXKF, 5P5,<-R#YI4QN 4$5@$1-)R*C*<R<"L+-PA9
MCT#&!;M5"%85$CPL.'P@N+\++=SP+3@"&1?L7H!@U;S18HQ3N%<@S+X#P2UE
M2.X=J;Z' .L:'#Q3@='BU;3==[TR]S;LU C=?EU7K_WX,Z@6T5E_D7VZ[JIO
M-'EV+/;T5]'NRX9[[TS(!K3K%G>,"2H5HF]R,P_R2^(ZJ>A.J&$BQZWNK?5$
ML./E4^'ZO9+_!U!+ P04    " !SB5U(XT=! 'T"   ;"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-BYX;6R55EUOFS 4_2N('U P8$@J@M0FF;:'254?
MMF<G<0(J8&8[H?OW\P<AML42FH> S3GWG'NQN<Y[0C]8B3'W/INZ92N_Y+Q[
M#@*V+W&#V!/I<"N>' EM$!=#>@I81S$Z*%)3!U$8ID&#JM8O<C7W1HN<G'E=
MM?B->NS<-(C^?<4UZ5<^\*\3[]6IY'(B*/)@Y!VJ!K>L(JU'\7'EOX#G+8 2
MHA"_*MPSX]Z3YG>$?,C!C\/*#Z4'7.,]ER&0N%SP&M>UC"24_PQ!;YJ2:-Y?
MHW]3Z0K[.\3PFM2_JP,OA=O0]P[XB,XU?R?]=SSDH!SN2<W4O[<_,TZ:*\7W
M&O2IKU6KKKU^L@@'VC0A&@C12!AUI@GQ0(AOA/0N(1D(R8V0W"7 @0 =0J!S
M5Y7;((Z*G)+>8QV2ZPD\"SB5041DCZEH5+\043LF9B]%',=Y<)&!!DRD,*\6
M)DRG,&L3 T9$(!Q,VHA\6R*R;"23$B8FFD)LK"B3D*T)29>/C<97H[&N5VQ*
M@/!Q@.0:(-$!$BM3:)O,=#4TIE48&(K?8QGHR$!+QGEGJ9:!A@R LV121R:U
M9+(IF6UJR"19"F94/7-D,DLFG"K:-C.S">=5;>'H+"R=Q>, 2V=Y++^Z/$#H
M6) ?-V,1P\DW-X!TLMG,9 %PI>S-/^.]@,C)%T1?3CAV7<3W$AYVQ  RML0<
M*7?O@>3Q.EJ#_^\^ [:Q8'/,N#L4V%L43)N!\\S .V8"HR,TF)Y4+V;>GIQ;
MKK_$X^S8[U\BV5&<^;4\!ZA.<PM3Y!TZX9^(GJJ6>3O"1;]2S>5(",?"6_@D
MO)7BI#(.:GSD\C:3A=&]6P\XZ:Y'D?$\5/P#4$L#!!0    ( '.)74B'+S:@
M[0(  )D,   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)U7W7*B,!1^
M%88'*$D@H XR4VV=W8N=Z?1B]YIJ5*9 W"36[MMO0A"33+;">B$A?C_G))QX
MR"^4O?,C(2+X;.J6+\.C$*=%%/'MD30E?Z GTLI?]I0UI9"W[!#Q$R/EKB,U
M=80 2*.FK-JPR+NY%U;D]"SJJB4O+.#GIBG9GQ6IZ649PO Z\5H=CD)-1$4>
M#;Q=U9"65[0-&-DOPT>XV*!403K$SXI<N#$.5/!OE+ZKF^^[90A4#*0F6Z$D
M2GGY(&M2UTI).O_N16^>BFB.K^J;+ET9_EO)R9K6OZJ=.,IH01CLR+X\U^*5
M7KZ1/@>L!+>TYMUWL#US09LK)0R:\E-?J[:[7O0O,]#3_ 34$]! &'S\A+@G
MQ#="^B4AZ0G)C9!\2< ] 8\EI#TA=0B17JQNJ9]*418YHY> GTKU ,*%A#,E
M(I4#WJDQO8-RL;F<_2CB!.31AQ+J,:C#K"P,2'V8M8F! R*2$7C#0*%M@0QZ
MXC4P$<B'>#(1L1?R;$+2N0^RL522$:G$UU1BO:*Q*0#!?8'D*I!H@<2*P$DD
MT[EJ3-MA@ _Q[$?\,PCL!(&M(.+[ JFS#.G49<B<"#(K N>AT)BUC<'W36:.
MR<P22'TKN9H9*XF!_-RWF3LV<],F=FPT934W;" >90.!XZ..4B.?;(0$=/8-
MPJD;!Y$;A5U#,^_6.:#Y")_8];%*#8\)-7&S329GZU8*Q&.RM4!XQ+$"4]?'
MJBB,1DAD;K;9Y&S=@H%6Q2#LJY@--$L&@G$U ]VB@7;5>(^Y-9S_AQ5RZP99
M=1-#KU4/FF@%72NKOO"(DQ4A9QL1FKJ-R"T=%'^UC?V)U(-TPMG8A-V_,V25
M&$Y&2& W83PY8;=Z4'K_N5WU()TP KZ,(Z.]:@@[=)TP#[;TW K=U@RS0[?]
MB%1[YLROX>)9]\PWF2(_E0?RHV2'JN7!&Q6R^>LZM3VE@L@(P8-<B:-\3QAN
M:K(7:IC),=.=L[X1]'1]$1C>1HJ_4$L#!!0    ( '.)74C1-VIHE (  * )
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)5676^;,!3]*X@?4+ !
M0RJ"E!)-V\.DJ@_;LY,X"2K@S':2[M_/7Q!PT:!Y"+9S[CG'%]_XYG?*WOF9
M$.%]-'7+U_Y9B,MS$/#]F328/]$+:>4O1\H:+.24G0)^800?=%!3!S ,4=#@
MJO6+7*^]LB*G5U%7+7EE'K\V#69_7TA-[VL?^-W"6W4Z"[40%'G0QQVJAK2\
MHJW'R''M;\#S%F0*HA&_*G+G@[&GS.\H?5>3'X>U'RH/I"9[H2BP?-Q(2>I:
M,4GE/Y;TH:D"A^.._9O>KK2_PYR4M/Y='<19N@U][T".^%J+-WK_3NP>$D6X
MIS77W][^R@5MNA#?:_"'>5:M?M[-+UEHPZ8#H V ?4"O,QT0V8#H$8#^&Q#;
M@/@1$.O4F*WH1&RQP$7.Z-WC%ZR.!WB6<*9()+/'-1LS^96IX'+U5D1)D@<W
M160Q4&->1I@036'*(0;TB$ ZF+0!_;$$'-F8EAABX!1B.V*!\RZBSH69;J*1
MBW2>(.X((D,0#PE .$^0. Z2D8-LO,O4Y,I@6I.'4'_FA9 CA$9"J[$0,D)H
M( 0@6F7QO$[JZ*1#';3 :.:D-/MJ2E>.@]60( JG4KI=?4KIO X('2'U+S-0
M E,YW5J0D4H6*@%7:521"$SNR8+LZUNZ*>A*C6H*P>E-P:%4DJ4+:@^XQ0=&
MU8>B!11N^8$OUQ]P"Q D\\>E!,,2!.G2W+HU"-#\@2D!<@_,$BFW#$$Z?V)*
M"^H*?JE6YFIE\T>FM"!;<E$6KARE8'"/-82==$/ O3V]ML+<'_UJWW1LH+H'
MG?52-2/Z?GS0%/D%G\A/S$Y5R[T=%?*6U5?BD5)!I+_P2;[BLVR7^DE-CD(-
M4SEFIH$P$T$O73_4-V7%/U!+ P04    " !SB5U(D:,P-PH$  #+%0  &0
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M61$X(@(_1PCZ"-R* .J,^C7K,8<.0UR(9Q/!XS@DS0=13 "*":QBP&"*OIC
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M'PJS:_O;I,]O/ P>']KJ=#G;OAZP+_\'4$L#!!0    ( '.)74BJ7+VA/0(
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M(2CI6>KM0NVYG> VD*SI'Z3A5<S^ U!+ P04    " !SB5U(;Y3>6AP"  #
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MCYLP$(;_"N)>P&-CPRJ)M*&JVD.EU1[:,YLX"5K *78VVW]?\Y&L;3D;U$L
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MW FAN*XOB;1K'/0'PO6@YCO5[S*]WXTC\WB@Q/'R!7#]#%G] U!+ P04
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MFZORQB/-^"#8\7)"FX^)J[]02P,$%     @ <XE=2&DU;"UI @  $@D  !D
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M"C13C--G9-C#.'WL ,\.PM$!MM((;<AD3&/4M(,F#&&"7*K"5"&8@>0Q3+B
M"2V8R X3CS"A&09CIZBP1!$,'Z-$"Y3(0HF=*)$1Y0O$8>)DL50((/ 8)E[
MQ!:,,\P^-L+ !$#LA(FM4F+\F"59L"0&R_)[F5 2$P7$R$EBBL)L1872!4AJ
M;J[,_5)2(T@"G54L3 U>LP>S!4AF52=U@F1&D BX:0M3%*,5M8%@@:+;K\&2
M.5DFT;Q3G2BV9L4G"^$2Q6J0$7"C0#/E#,1.XL*2H12#->\&+8',7AD!=YTF
MT;1;/R&R=&N1ELT76MTW@L[N"\W&"IRM]S^2$20PSK6.7.A/PB]5*[P#D^J(
M',ZS,V.2*D?@236K4OVZW"<U/4L]3-28CX?Y.)&LF_]-[C](^3]02P,$%
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MK;D=#'8C63N.N6G6YO\!4$L#!!0    ( '.)74C,%\Q,QP$  ,T$   9
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MABEFI.9!GKG<N\PS<=&TYO ND;HP1N2_'5#1;H(HZ!,?];G2-H'S# ^\LF;
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M WD20H,Q%SX9=Y5YJX: PDG;[<KLI;^^/M"BZ1^CX47,_P-02P,$%     @
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MRH[HU+@Y$+5W0JW>,QQY*;AKH1[C=YBMC?$QFL/LQA@\A]F/,'.(@XT(/B!
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M.\64=\HH9]=%!_H=G6RUV>]BDOYC6=W>(7D6L#+4ZNL]L6)8N!V/R7S?P4-
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M"<E^I7R..':GG<KRDS.LCT,6;S2?1"<EKA#F]ZE!"V;#Q^?JZ(FPVA(5_#"
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MA0DOUO)L/,5HTANT"3OY3P27UPM^P_*:.H4L_B-:<%]OJ W!(";>;)0-C3<
MM$0 V0-H2PR>+;$?E]/O K=?(=X:8BJ]J6[*1( %9:IY3N<FG0Y>D%]@CY<
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MV2CTP8\NK1')R0-5^;3PZ$=D^B1>G,O$42]2U>KZ-A%8QFJSY^"0# S/R(K
M#GI9@(X&2@AE:KHL4W+F.,SP $$(]<0-:F%[1E9G263CFBH+ENI TT#LJF6
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M9<S+!(@]P7&Z;AJ)/A]D37%;2N/ZH BAQY+">DP%R^D@ %FM6ZQX/ _[DNC
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M7?0WV0B86U9QJ0T'O*5C[XW>G5RJXWO('M=(3[Z%N ZA8>DENB38-4_)*+,
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MV(S1J0Y!>M2  _?DEC*F?UM(F'=IO"4*F6PV 6A[8<L UN5!Q%B%ZZ48O^"
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MIB33&&6D-4HN9XML<3Z7WN;]T&4VO<SF2P-[,LXG<X01GN?+B_.$FQLDF=?
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M!-:9;.W]\D"6W7QP$P]6=@W-.B)$:V4?I#@;$U>04T_0CCX/@^/I<7>^I<<
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M+^& _RYN%3J$0!&B/6HDER$OFG-M$. %W&5B4&H8UV(D/)UX1B<]]@K[:NQ
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M\DK?&CTDP]/8O KW@BC0DPR6V<GJ 6,]B36^=]0#_D?5PO@D"N#<Q_?(9/X
M\Z+M>_/F93K*<XA(!N=QV#X,XM_-0PW\[*ZZY[Z1I&!;C99[W.L6S9&H7([F
M";U!: WMSY5/K"^H-[=MR358YOPT7+> _QU!</M2>7U]?)N_=QYAA*=SX'0/
M@:0D/ 4J1>G+XJ$P"$+')IQJ=AH7I/^FZW:_^_\ 4$L! A0#%     @ <XE=
M2#0^6*'X 0  R"$  !,              ( !     %M#;VYT96YT7U1Y<&5S
M72YX;6Q02P$"% ,4    " !SB5U(2'4%[L4    K @  "P
M@ $I @  7W)E;',O+G)E;'-02P$"% ,4    " !SB5U(??R5]OD!  "2(0
M&@              @ $7 P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !SB5U("]*IM#$#   .#@  $               @ %(!0
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '.)74AOR>RV/@$  &D#   1
M              "  :<(  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M '.)74B97)PC$ 8  )PG   3              "  10*  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ <XE=2+^2OYE3 @  5@L   T
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M2P$"% ,4    " !SB5U(J;I1+"P"  "5!P  &               @ 'N'0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ <XE=2)#S>P4
M P  G0L  !@              ( !4"   'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( '.)74B2?*N+S 4  -$>   8              "
M 88C  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !SB5U(
MQZ>'>^<!  !H!0  &               @ &(*0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ <XE=2%#P![QF!   F14  !@
M     ( !I2L  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M '.)74AW9$4/H $  +$#   8              "  4$P  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !SB5U(#3U%MZ(!  "Q P  &
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M970Q,RYX;6Q02P$"% ,4    " !SB5U(J.K\'J(!  "Q P  &0
M    @ %..P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M '.)74C;,('2H@$  +$#   9              "  2<]  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ <XE=2-&\ ^>B 0  L0,  !D
M             ( ! #\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !SB5U(,=0AK9\!  "Q P  &0              @ '90   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( '.)74C\GTH.H@$
M +$#   9              "  :]"  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ <XE=2'*,'O"B 0  L0,  !D              ( !
MB$0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !SB5U(
M7_1ZU*0!  "Q P  &0              @ %A1@  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( '.)74B 5./GJ0(  %L+   9
M      "  3Q(  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ <XE=2&4%)3BP 0  %@0  !D              ( !'$L  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !SB5U(ZYWN_J(!  "Q P
M&0              @ $#30  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( '.)74AMX<Q4RP$  . $   9              "  =Q.  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ <XE=2%P(EN^Q
M 0  %@0  !D              ( !WE   'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !SB5U(KT#0$KX!  ![!   &0
M@ '&4@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '.)
M74B!-&1[I $  +$#   9              "  ;M4  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ <XE=2-C,-]6  @  + D  !D
M         ( !EE8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !SB5U(?^F68GP#   '$   &0              @ %-60  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '.)74BW#4TV7@(  "P(
M   9              "  0!=  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ <XE=2!DA 0'7 0  N 0  !D              ( !E5\
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !SB5U(Y9:\
M1_L!  #8!0  &0              @ &C80  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( '.)74@E-6M75 (  -D'   9
M  "  =5C  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M<XE=2/7X@JCN 0  H@4  !D              ( !8&8  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !SB5U(D*R5U^("  "[#   &0
M            @ &%:   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( '.)74CC1T$ ?0(  !L)   9              "  9YK  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ <XE=2(<O-J#M @
MF0P  !D              ( !4FX  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !SB5U(T3=J:)0"  "@"0  &0              @ %V
M<0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '.)74B1
MHS W"@0  ,L5   9              "  4%T  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ <XE=2-(NXX0& @  Q 4  !D
M     ( !@G@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '.)74@=BVV_. (   ,'   9              "
M 7^'  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ <XE=
M2++D64\L P  (0T  !D              ( ![HD  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " !SB5U(2Y4^(D$"  !@!P  &0
M        @ %1C0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( '.)74@:'&TO,@,  #(.   9              "  <F/  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ <XE=2&DU;"UI @  $@D
M !D              ( !,I,  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " !SB5U(2WVKZ80"   L"0  &0              @ '2E0
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( '.)74@"USRE
M^P$  '<%   9              "  8V8  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ <XE=2,P7S$S' 0  S00  !D
M ( !OYH  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !S
MB5U(LA":FNH!   =!0  &0              @ &]G   >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( '.)74A50.+=L0,  '40   9
M          "  =Z>  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#
M%     @ <XE=2&510_DM @  $0<  !D              ( !QJ(  'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !SB5U(K7V\@\=R  "F
MNP$ %               @ $JI0  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&
2     $  0 !R$0  (Q@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>160</ContextCount>
  <ElementCount>278</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsPreferredStockTextBlock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommonStockTextBlock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlockTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsBalanceSheetComponentsTextBlock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Nature of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureNatureOfTheBusinessAdditionalInformation</Role>
      <ShortName>Nature of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNet</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformation</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Balance Sheet Components - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedExpenses</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Commitments and Contingencies - Operating Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesOperatingLeasesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Operating Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments, Under Non-Cancelable Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeases</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments, Under Non-Cancelable Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesCyDexLicenseAgreementAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Commitments and Contingencies - Washington University License Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesWashingtonUniversityLicenseAgreementAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Washington University License Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesUniversityOfCaliforniaLicenseAgreementsAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - University of California License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Commitments and Contingencies - Consulting Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesConsultingAgreementAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Consulting Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAdditionalInformation</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureCommonStockAdditionalInformation</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToComputeFairValueOfOptionGranted</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToStockOptions</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Relating to Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStock</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Relating to Restricted Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Net Loss Per Share - Summary of Common Stock Equivalents Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureNetLossPerShareSummaryOfCommonStockEquivalentsOutstanding</Role>
      <ShortName>Net Loss Per Share - Summary of Common Stock Equivalents Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Income Taxes - Summary of Reconciliation of U.S. Statutory Rate to Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfUSStatutoryRateToCompanysEffectiveTaxRate</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of U.S. Statutory Rate to Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Income Taxes - Summary of Significant Components of Company's Net Deferred Tax Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfCompanysNetDeferredTaxAsset</Role>
      <ShortName>Income Taxes - Summary of Significant Components of Company's Net Deferred Tax Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Income Taxes - Summary of Rollforward of Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfRollforwardOfCompanysUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Summary of Rollforward of Company's Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialInformation</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.SageTherapeutics.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sage-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.SageTherapeutics.com/taxonomy/role/DisclosureSubsequentEventAdditionalInformation</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sage-20151231.xml</File>
    <File>sage-20151231.xsd</File>
    <File>sage-20151231_cal.xml</File>
    <File>sage-20151231_def.xml</File>
    <File>sage-20151231_lab.xml</File>
    <File>sage-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001193125-16-485683-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-16-485683-xbrl.zip
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M#$$0="S84"A8:\UP>6*ZDB KEFHZ>FZ=I'5]4X^8PVKZ'0P[\&8?%O>S8%P
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M4P++U:::*M%5M:F.-?4UD-^W,4#1@7#-MGB;Z. -N 8!,7 MWA <RY1,&^3
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MX]6TX.9SRDWR;1M6"3-G#U0"Q\PQN+VP[NX76=X?.'OE06*<RF<.7[XUQ_O
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M$.*Y_R2'^!GC(5GZS??#$B_""3O'JS*MU@%[S85S/*@00XXW)O^S2-(L%WU
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MXQQOY5M2K#^VIRXJ=N 'I H,A@&NW&QU($ 4=A0@K.0I1/R64NB*5>K\?V!
MO?BY=)_.[B,8V?H$4A7!SILS"SG.U\P=WOH)M^'54P@\<,";JR8^.U+)0A&A
M]\2,.BZTC/SU]9@1C==^PEW2A&.P\5C>#7]CQF9>E&[Y<<HL)V,&WILS#H@;
MX.0&2=D#1:<R,]<+F)8XQ<)V=(/RY.O<@<<[<X\*^0G:)/7!]X)5M( -P7,I
M3CKB8//-?%_F&#.E,LJC0?F[UOS7DL;)/3QPXF%Y8@0G09_=]\:/[ @,%1DP
M.(Q"?KD F5 5'TIK[:>L&.P1O#0?C]&V.,Z( )!YRPB)@KO=7*7 D^ UR0(H
MS$>$3%B.Z:<]Q*SI2]0F52>I<&*!95/0%DP3%.5GT3VROS0>''0^HNRER^T6
M<Q[+JH7!(8$7G;FW&7I,Z']#SL-,A=$L>LB=-%#A^;ICNY(GCUF N9^6RF:W
MU>&6//!L,(4+/V:K_D^?H2LE41CZLW7N9TH";D\Q!I'--&@)'Y3R\VJ S]EM
MH9^9(AP5Z%T<%-S\@''VD-&:,PAIR.YX#!X>\W _%OR!LUD5A1Q( IZR$O+G
M%?!3P7]6B@S3 9X1/AQW7F!+L,,HF(B0C8LM>+ATN@C+*FR R_RQ!$+!CD_S
MO4WHX[$ >.]LISR=1:#/\9P8-S8KE0R.%59%9Y%=GVT$;CFC J6X[<@W8_)J
M"*@KUT [V#$UJS@G"KF5N*=@-F-/QUR)?)NT?"="AD4+F-P#+ZU0'7MX H1K
MYP$V) ^HEO%D&40.-_&,AK_HPJU2O'I5.QHDL!MG\CP%G8]!:GB*,<K_YDS&
MP/R#A4ADOO_$A&?,XHPIPR^:%W'&[ #]%@P"FK<%B')6N%K9=+*Q;AD?O14J
MX\M5*.*F9&=;I7+:?)\+VHRIAOGB?A:,X:HI<\50^U;<KG<?[JKA9]P5,Z.]
MA:%;!IB%MO]"1/V6;/)PUPB]O!B89]:>V=9O,;J=X?J V7AR=P!'I&P;$3QC
M@VF$"K?TB!&Q/74^I@,C8L CJ.984R%<5,Q57,$+S&<>!H[* \V#/QG\U\X
M%3REP!%@-&C*K;:DP3NXXI".7%_ESCB670,QQ3I8\6&-J"TL6;EA.=^_P3B
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M-EL+E5W< A#/C=7;.\6T8R>PCOB7PH6[Z>R!E^M+)]_NLNAH9:_[/=_K;IF
M8Z6]ZW?VNRU]K5P\O]LSX.T7$4:D^4GGA>TUZ4C1.L:T?X$J58*%.8D6]S._
M1VW0_*6#5:HOC(^GG/=W=;RJ7<CQZF:R0OW$@[6$!<P18QW/L1\E./99M^TX
M]L('UBK2?%Y=\L%[QJ^,;UX\<;T@_KLW6_A&DBR>YJQ(SH&M ;8!_7LT@\?
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M9W;#.SR%"KT9/.*C_]4/%SZ7MPB'@4^G\!@LN'H??5T[4B<CUM)V5$['@6<
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M6K^(/*$7E>=XY6+[^2Z7Z+!(^R,S4>K-=H!Z<O?^-(I]'-W%%XLI.NQ?&Z-
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M6'^&C&!P_@?]Q7:[=6OH1Y1;?GX54'W@*/*SC H19"[VF:R[^H3;(-E_%BZ
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MD[$]]KJMGML<-4?.Y+ N,#6AMXFW6^9N'?1%-A,<J&DR(Q_*N1>2&D"QXL0
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M+*\3!#T5"0)T9 0,ROT:X.=@K=Y'J3"JN;PQ1J$!O/XDNBCT0PAG2Q@9G(>
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MO@1I#EN+FP<[ #1'8"33-,QA-WW8/MHZDU:*U&%0!2PMD]U%8 S:DFZC)[<
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MV>/ZT&@IB@N2_LJ);FB0_!F96!(6C% U7]0B%2\F+AQDN8X5XVJ160#I^AB
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M@=ZP0SE1HYT2GNG!GN, JRB3+,P9W5*W3Z/F609^ 5T?/,%9ZM_ R?GBGNX
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MR65(?\0,;T4<1S+ S2? KF4_,RF3\_!%#W!J4WDHK.H\(-P6ZPPT]:/@3UQ
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MVH:$WU*T[AO+@$XG\MK;>B H$QYVR_=ZXPF6V?H^EME\\@NT0]FA=7$)*TA
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MT"([3G_0Z0SLL3MNVJW>X,P>]$9GMM,:>=UA?PQK'WY_T/AN\V&P\?7Y672
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MU7]FHV\9=TN'E1,9=,20'_PSDK[6",QPC/NV.<D9@5]541BL(J3*#4GCA %
M^2(/N#\&EZAV)&"1ABEP.S.;N!# YB.J[D[1%66=TUN\W0*2BV/  8>E"[JX
M.;)PM^)"Y>>K:CB (GX7AU+X\M(_Z;PWBR]?54X19-LF2[>EOBUIZEO_T07Y
M!&]D\/@0JM0LF#5Q^J?R3@]4ML'LD9[C<:WG.J"7>[JC69[K:HS;NF7 35U.
MU&%#1KC(B'KQU4HDO 7)F^(ZYD/LJDHB(%Q>$"39@;IVIU2)4NK]EN24>.#!
M.DPE.$B5]SY(Y\DTL&9PL5866&NTWB5N'@-CF8?-:4;L[N]=(KZ'%;A BWT*
MD_]%J?\#=$*,JV[4?+6Y&GUP)]P>X&EBFK7C4JW7,XG6LP=FSZ;,&.@MJV<G
MV2-5[0*#6NU=@('"!0K:YU$XDFHT,[7!\HH#]+HLR9 %BC*SFBO4/VX^WUQY
M4:3L4C^>?;LJIP*A.8O1" =@G^!.WW!1'<4R" ->PC"4QC*,XKSY%1[ZQU@/
MK&>429"+\2E:K6F$%=!FL8Q$8,&TG_[R0C0*W8.IJLB7U<A;07-62BW?'U-K
M_"P6-*?WYNK-0OS@:NR'$UP,HEV?#7'\>*;"+VII>S6<  ?07I7]%WP5Y1FE
M06XLY1W&8+=#' $\&(>30#HM<UX5+X*L#!$H\-5&Y6^1F_E?<L#$?\+H5IA*
MBR\-I%]81O!L5# KBY^HZG7K#/373 G(U\>M@%4!N2WC(?M,15;1;P[EUNI_
MLB!>+.=H%A50HI:YO&%.?1DJH.Q;J:G:-7 AE2[&)+P/U5XM5G!\P*I1T^'3
MG(4%\)E<Y'LJSV4/_.$L.(7;PU]1:TA)7('Z^EMD[>:R63,7QZ5KU/9M%N>]
MSL0\*R<)3,(06ZJN+T7RQGFZN=R8'MZ%P!]YTV\1S(EK,-VYLI.!D*]QY(]^
MRLKY96XLCB["R]F[%'O)UZAG'NZ>$A!^?SHOM0.F&>B!8:48H<0+O&-5D!$$
M<0;&!B.X6-1L-D:O+E;;/D/_H7#.-[IWVQBX<BBC%#['\RSITR<5'I8_?,;0
M<%$NMK]7J&+)-NK,-(D^X-J $+"-KDDU!U;>&L6?+>JZC%M?.*;08Y!4(Z9&
M6!Z4V/*=#Q&YD?_G3L +_Y<Z[:%._!R,'0X3IN4ZKD8,FX*_,' UVV94LQS!
MP%<"QXCVU(F"C_3/?8,S:X@I\6EUB6 L(@'3:*+R#.$BD%BXYQO0G*TJ><Q4
MR6,[X]/VQ)0=1[5^E#5%D<W1M)ZJ=8SHQ,*@'/&P:AUEGF8;EJGI1.\Y?5L?
M6 [MD@N/EUQXH/)Y2S5J"X'J$@T/FX23U5R3!K8HN':-.R!=/DX5EBXP,%A@
MH/1KPB3-(X+SOL1;]N*MBX^L]M2'P^2%=&H[ZT@L]NMH;.[0T=@Z7D?C(S[:
M;&4SY1>$NT*[FW:VM(VC'T5+VXKM;?](@O&LE'+P-AP'\L?XZE7V8K]B5#/Y
M:T5/9,6[M)AC%5M1M[7_=%N%^.AP=GVL6]''^F0EMLS5O9_<V+NN5&+EI<JO
MX71^[[SZ_[:J_0!RL9VS67/#VQ?=W"V:W^*Z>H8I]7=^//J1Y^4FT3C%/YZ'
M4EO>@?#DNIW_LAN=@I +H92ULY'[]B;AN//<F\53F5NX&*8XN0FNGYK8[]U3
M59Q4.^^#D$RZ!K+;/^/0X[KFUPO/;'[Q>8E</+X;WLWIF@SWY=DQ3NSCV['3
M=UW?!DGR&Q[?F-W/U#F"4:F&4_,>[ 5.WE^907<5Y;^>UJ3]E8J=%YPODMHY
MG9V[U#F=;>3B\9W.N@PK?]&POI"YTEG5&B.:5LT1S=902HTND'/2$EY1,W/0
MS*-H]G42-&@.=G]H:ZWJF?'QG+)Q:RF>LE C.COH7E1YJMBA_B=56:EH47_U
MPT^PHF=1G>1ZX2\Y[A=A7N4;Z9M;VI\63O76+LS*[5_E[5TDL^9)""?+MEJJ
MVF:\"DI-?# ;NDN&[I*A#Y$,;1I[)D/KVR=#&\?+2*[]T6>5&M?EUYXG)%V.
M;)<CN\]JK,L[;<>F7JFAFZK*M-,2]P@Q+>-:&)<2OV/7IF752^ME;&'GS>Z+
M2GA!>?UX2OF7(!*T9I%H']'TFIDGE\IQ&G;@8QR- UD-%\OG9/W/3VY6V/SB
M\I)U4YS:C&BC_,M6G44)SM,U"S6KQ_91O'N6T/EM;5;<:3JKI)&.B^>1>M/B
MY1<EUU2<G+.]ZXG&:\.J.4/\#%7JF64,='QL)//B:WPUG/A)\K>?G8>'2:"%
M&/\<WF$Q1&T:_)B$T^!G54E%7KY4/O/E,G^E@H ?_11^DM73ZZH;S?HV$;IM
M:3IV,!=]1K2>PSS-,1DU+:_/==IXBPKR4MEHQ1/5ED(RMZVUHO.*NL7N_8-Z
M<]4ZK]2,0;4F0'$*QUA:-YG)/@[%N*PMA!SF+_2+G]\[ZS@%RR#U5%75=5YI
M&%,&(E7*/&]B@2/CX Z+N\.=L)73QL*OZ^6Q++0+_6WDX#=9MYPW4U?5EWX[
M;P71QB+XS/[Y-37T>1'\+6DJ<>-=. F2%*;XQ[QUQX[T?J$&9_!ZC]0TN4X,
M_%O8AH4%IXE!]0K\T)_S@_5<P0:&YKC$T(0C>IK=MX7F](CK&LSFE-M?*+P1
M5H/5LT;PJ^E:1;.L!BOKPI:KQC;  =7/:5-7^.K4\Y]?,VX555XW$+B*%;)>
M<,-<J$,.&/:'6"D(SRA<T8#)F8Y*^U99#M@G%=*_C99EZD19!+:2FF46[4:]
M8M\LT;[Y_L/+]S@$HRR3BYT8(P:<"YU2;4!T9 P\U1KH5//T/B$.I<PVA/(@
M:,:42C35K4.1WD(P*#I!QFZ"8=BL[UE]5^M3&[M:.U2S+,_5'#)P>[S7[P]Z
M/248 LD'16I55:3'FS;'X@Y9XLX^4T=9;O#+X1OX^&'\/D@_8X.,3ZHS!_:+
M^Q0]^9/T::"ZOA^&>Q;501MLU3#/M9V^;7NF)BP+O)&![6JV3@9:SR(>!Y_<
M-EU>Z%]R0_)^-5M35^^L4I0?1&[, 3'[@NJ:J[.>)D0/F#%@ PT>8-.>Z+N]
MP=PSH6V?4$=A#%EBS-YS2;6""IR\;]T[_S&\G]W?!O'] 5DD"'P '<1LG='G
M;9VX:?;8@&@$](HF>F*@V39EFCD0PAIXA'K<*<C_R,P_%]I8K7SW8U$(?S!N
M[T8ARR3_(]6WH["&66]SE.:Y<)N$"=W::7T&VHZY_8$+AJ('M+M$UWJ]OJGQ
M/A?]/K/[.NLOVE*]Y3/_>,PAB\PYA!/J3&"MCP-7MP,Y@#<JN"T>X5_;%KLQ
MR31ZNLZ$I0WZ7-<$URW-=H4#_V=X@P%GINNZA=V &6@L>*35"#P24P1CU*B/
M*2Q3FKK-Q-Y,R4]&?YSXTQ1$KNB+H"I/8[WIO3BB$QTY0F'A];S=3W^@.[9A
M:H08X$P)<*LLDQ'-ZAD#1OJZZ%F#0@0^HO[<XJV/0*;-=4&LW<C,0?W(]R%3
M O]U<_>?KRN[_V2-?S[A3E4R]UCW88Q!#8IJ0K<65O/+CO:JH$^U[D>%J\WT
M.=]J8<,2IS&(\B9)9L&H+WMSJ79)__(GL^!]\$/^LI?)-@GGR#DA*-U-E_2X
M8X$\:KKG@"[IF>!_"L,& 20F)0ZA/=/[@@U$]2^XDN,6!HS@0KJ@4RK168DU
MDN/)P7F#;AK./_R;&;JY=7"Q,I^4N09'\#4SF*6;=".7ED@^H@25N"0H.#CU
M2A3_8AQ4HAQ8%X_"R0RW4CX'0[@*@_>#1Q78]^+H7A5WEM/\PWC@Q]CR&>>N
M1,"YCV;[N8@VL:0:8\*PMA8PPS88M2FL_(@);!OT#<TV+:+9&(_T#+#Y@[DB
MXYR8)8M^",);RDL.5]3#R]R6,I!YB_-+8*<-D]RB];"39QZ88*9%:V&F7/?,
M&S@'8);G39OW:ZHH6<28 0LZR@5;T3X06"=T;Z Q8O0U87N>YL#Z7].YP3R#
M"L/!G<:,!8RPO.'DRZ];HLN) __#^ ,VP0T^/_C#O?RI15+F:/]WG&["NCJA
M.'5@D)E1^HR -5%;^#S&D]#3H5I[_!W<K32YO?/3?P> M^JPNA^08-^!>K1H
M8JNP[4"WA$,L!WQ)9N)V,M<L2S<T SZ1?H]3JR]I9P@RN>'ZBK!M-?(.T5=T
M^4ERU ?9=58]],TA)D6)E^@=,%/7<4,!%(&QM1Z!E:CKVL+4^A8\7)BX;C6$
MJU'7(8PX.BYK"]D2-GH$^_8KK<RD16E]?DT=@8"*S*T>3*XJP(K!"SLS6Q&]
MA2>?G_22@S[.,*LJ"7"ENI?3FG/.8K:]M1A:7A]X[=@:L76N@?$?:([M@#ES
MF&<:+C5L/BBF.;=T5M&#7T_JBN7W+L*LY#99%-R_QU%R %Y:N@XRLOV4]AR7
MPH)*&S@>F N']M'9-]'WMUS+I2#:I>7WTMK[L#PHS>!^, XP%>O6?W22) #]
MZS^Z\'>8NGX</X&@XZV2/(8Z-\O8)&T/7@KX9,G%$]%7['68/=)S/*[U7 ?D
MKJ<[FN6YKL:XK5L&/,3E1/'*D#Y$;EGWHJ9-7.&&>![WJL05Z:OKR!5.#\>5
M>0 MNY><N7LG94J2+:IB#4)_'M$DQ!E03^B:-T!_6KBXB6Y8&C=Z!O5ZNN5X
M5M>P^7@-F_7#-&S^%(R"X%[BY4;3[T&<AOBYD#:XGQ2XEQYV3B7CZJBI5<[,
M!7-[A=G:3U?^++V+XO#_8!WQD',;.(5SVI<+2A"FJS2"Z_5K<('PORME[S!!
M-QJ_4%\NKRLG;N2SY?/@/B\\$>O/%>G (S"P(+'JI[MH I^3["%P4QM)PGR/
M].GJUU$ 2ZDP_>L6K[1=LG3;Y*.6DH+.R\R;UPF\EAG7F2R5(4G@+BY.7H##
M3P.\W9OI,(H?(F5/KA$@_UX5)L2[@1AAHO;HNB05<(_2[4'VKD+T(H&Z0O#@
M2FY>F[H4Q^N%&H37V2"X"SS]%W*#F^57#V"5OV,\=%GD;N %K_XY@XF %,)K
M3";J<?+]\":S%%YQBCH5GE-HJ6%)2ZV48O4[?"?GSC"ZOX^FZG=XPR"X>A\!
M?U@GAIOTU"B'XS.XK_!JSG7^J2?E(/O#+8$C^;T>GE_1?,_%!65M+L-NR13]
M])>Y <K,3S&N___^JK1:R7(M#48YP%>9ZS.4I7 DI\4ZI;9&I?WTE_7SDE]]
M#8;^#-;72$HV1= ?\\-I,))\N9<K ;C)./"QD5L"0_WT"ELV3B-91 I8 ?8^
MO<M.4^#E<33)RRUF<'32^EQ:/TROWJ'3/(>%6M?/M>1<J5RA@Y:JHA6%2<43
M*PJX#( D  A&5^.9TCP9#MFW*:SHAG=2CO)9\5Q6KP#@7RBHOZL'-*)X=ZDI
M9Q-ITN$YTR"%R1$-@V"4R=@O^@W)J[UV8*\$&VU%">L#0 V3+NZ0;A_2GX.'
M=$GC4E85;[@%#-87'>8%P%= NPPL.LM;0@NCV8W>(?LBLA^&:;2(ZTLJF^D+
M(,KILPZQ2GC!]0N(D1O> ;8E8/HJP&0M1H BG,*BP<\0R:/+N,#)$X2O?MS!
MP*]/"U?_B&:3S-N\FCW@NN,71N9:<@'X7M6UP*]EUS*_>(-CF0F17A(BY6N&
M4] N8$L>YB3)CMO^)"B.P:KM;ZD(RB\_E,3=^=]!X0RSP[?1="A]97AW<!6O
M1J6RBO=Y,FPB7?"O03#%P[G#($G&LPF&#;+=.?EB:-*>V:M5S_\:%,IRC(W#
MTSE1TE..$IPE\K1O*G\<A<DP#E+%?OE-+_)!>>(Z-8S!B8_B!)=P</7[Z+O4
MUBODXC[([K::PGR%F2T\QV&<I&5*\,L"]R7@N@F[VDORIS,_+CE*YG6VP%ZA
M8(UKPY#_K5*QSSB^8G9L5K%E6>P@6PF9%WR-%S'+O)W5H/%KSN5_6X(&^/BY
MML@F_")\<)=G/DW96;UR4K5Z38%MBZ^&^V\868(U+<[EZ&H4^S] S<E!,6CK
M$!-F%FZWWM].I5X[Q+Q_K$^('AYWE:''1OL.G-0,J]Z48;>@5E'] J<29A%D
M!2]0TCDINJO@5)%A5XS+9+:IN&*#60(')QS>7?T +P<$?XA;/V!3,1SEH^<R
M&Y9-:C'58&00HE$_;?R:BO/05>IQ/Q\T4Z[6M6WR:YOH<^5:!#I_^LL^OJ>[
M8D_MF>\I;A@7^MR^RKY"SY0RMVXPF-%9U;TG?;G'4O5)[]8YZ=7_%@OA;,@!
M>'8^2-X?TU;?9 1\&"]>ZDQ'ZHL BT*E!\TCV"$EK&]YO8'.N3;H6Z8F!@-/
M<YR>KO5<V^,F,VW'HT6RDTV,I9H.NU%\H'RG@=PV>#,%69S) Z"R..SMG3]=
MF06T#Y]5ZMV.J?O,TTV+PG/ZE+F:$()JO0'M:Z;G]GI,IZ[AF47:W2&2H+9D
M3%-P>%$\#L(4BR@=&1'JDOZ \CX>J^4:S")/LQBCFFXSXO5)CPC.ONCRL$Y#
MB#SC35.@X#FUAA%Y7I:N.AX<3P-91*=-@++(FQ59K9^"/"RU(M_S!*1;7Y3N
MC20MLJ!(:%5EZ%?C\!Z=-62C9'ER&Z7^I/P[5E=['Z5_!D#A,/HVQ6P(]4BL
M:**^PG'T<.Q<KFA$A<LLZFB.B4=$+5/7;*]G@@DT.75-UZ0FFQ\@-MXQUI_S
MK%D>-'P4?9T85G<OW)X+WL7 U S&'4T8Q-0LPR0:L3S7)AYUS/QP-I@^ON1<
M['(2?=_$X4P/8[[ (77B3L?4>IY#=-UC,(_[F ?J"<UR=61>WW$X3F8N"BME
M,X-;ATN@7L&' QT2SQ[P89YC].\ #TG#[(!5G?\M^)0'K5Q,R/"'Z<R?8%D3
M=C@@EK/4^T:_SXFMN3V*.<;$ H4I'*VG.R[U/-,V/$,=8&.@ :P_K7>T?X!S
MXKMSXK!0#!Z#>!@FN+:N^ ('4<9[0B$D%/R=>4 H=N#$ENHGV7[>+;U)]H[!
MQSC<ZQ3@.MU44NY?'H+XRW-=]?QDG#T0#N_;3!M0Q]!$7Q]HEFX(C?5=U^P/
MF.DX<TW%C!N;;Z&I#LRR P.VN)0Z*ZQ V0G]QA 'Q*HZM]I\)JHILX[55W5X
M3/DP?VTGHPZ&<0[C>4X*7(#>B$/.B:WXM<712OGCTC-.P9D%#@MJ"E.O>*YR
M)9VGOE)=Z1SU+&H0!YRC'NOW-.'T+<VF@FJF-V!&KT\]UR#SE2K_4[1DH;JO
M6Z;B,%BZZA'//&#E.OQJ>\>Y#7XKEWZK^<XXH-]Z. ;5 5RNUSP_C&6!G@/"
ML$-,HOHL8KBL7@I*U,62P_H[SVR*G,IO .MPFH1#^<@3 0%7#)98A4+-_%FN
MR"YK9G[TX_3I%AZ3^')K416@23Z,2]_MQ5A;5L,EW&*[5<2DE C1<W3-,_M"
M$QYPM^=Z6&7:L0S+&U ^H/-*-(M%M;:@\=@E'IJHUD:*:FVB784>&MS4J<SF
MYYLZVS*9M6IKIS&ONE%!)H?WK5^\7GT/SF'F=I[.E#>*'C"[$;K(I/=!BH>"
M[X.W>T8><AYP3EB-Y1>! ^(+=C41(#&:+82M+UB*!7JJ5Z2L:_+478V2Y-4H
ML56407CE4I05YH\S^L\L2:62NHV<XC#51S_$9E/^0PB.R6JG4[9^2,(T7].I
MYY:687N[>4VSEYLRXF4NE>FNF4/5Y?<36(TXQ 66RFQ"4[-W,+%Q)M.L8U$U
M$5Y+<W6VK76(3HIM,O6D.M_6$EV=;W58S^;XI2._:/6RO1M,Z'+I3_#YPB&V
M-\#JH=M8$1OK15$!@*[M*U@Y;FR9PC$,AVDND(_EQ3VM9[.^9IO"%09Q7<?5
MO\@UK,9OS!(C-E!S$.^A J$;(*]('GCNFF[:I*J+L/"3\]T/)[CC>ANYLF+(
MYU*9",F6%E(,ND SZ%([B2W)6N1)40FVU4C354BO>/4UM WR!J;MHPQ;8:PE
M+'_O6C62?A"-9(B^ZU!N:SV/8#8;9YK3PT@0=[T!,4F?T$&FD<B-81Q#([U(
MZ 8T*Y*'&HD:UE+1^..II 9(YIM)/H).:H!PJ@BWS8:54@.D84^W]935K96H
M4KT&)\WX24QJ)7&CFPUKI<V$'L+&,*F5#"JWE(ZLE)JB&)62:1IV6W124W13
MB;1E-:>2FJ(,5-)ZPAK12/I!-%(E#<PR/\EN>N6VF=!#&!BED> 5EL(:QU-)
M#9#,-Y-\!)W4 .%4$:[;#2NE!DC#7B/K*:M;*S&E>NVF_"2>:26]::VTF=!#
MV!@NM9(M#.OX2JDIBE$IV9;>&C^I*;JI1'IIS5JK2FJ*,E!)ZPEK1"/I!]%(
ME31PKI$L<0R-]"*AAS P2B,Q07CE7?":55(#)//-)!]!)S5 .%6$6ZQAI=0
M:>@GK:>L&3])[4@VX2>)3"L)ZRA^TDN$'L+&"!7E9MQH092[*9+Y9I*/X2G5
M3SA=27@#KE+]I&&4>SUES?A*!]%*E;1PKI5L^RB^TAYP5B1/^DJ6;K0@S-T4
MR7PSR<?PE>HG7/I*ED$;]Y7J)PU]I?64+6JE[.WED[9X>WDQ7!Y,TS!]ROZ"
MO\,1?C,.L1;A\"ZX#_[V\UV:/OSVZM6/'S]NDF!X\RWZ_LI]\S\_O\:$9=TV
M=9W__FI^67[C5PMW_OUAGNPN_TY2/T[[?AJ\QI?2X$T)ML\KOBT&!J"*YL.8
MAEWV\N_R1Y5N_ONKC"$[<4>TD3NB&G=$[=S)5PFMXHZN$;.2[!!;XZ1.V6DC
M=T0U[H@ZN;,0B6\5=T H1#79,>KECF@C=T0U[H@ZN;.0[=(J[H!0T&JRPVO3
MR@L)BJWBCJC&'5$C=S:DH=?-+N1(\ U/CKS^_?%K/!F%OP6/#Q-L,O=.-<X8
MA?!K$D;3O_T\SU$')N UZA AGB>)IGCXQ'D,DY]?ST^EK#R(HN[[^ZN5CWL-
M6&3O4Z>TU^>#;#B0=LIX?@I4\\!\+7ZI0,K3E:<,9&EY?6D8+E0/:"6&:TH,
M)+VG\B\*4-G'_18;QWT"+/\%#\(:;V_#>ZR3_#;TOX:33 S\Z=/%05VNP-%*
MJ.5)P=NGAV!Q>BZ<BU-'8R\5.UE6]Y2P6SH+>FFX+71;:"5NA8ETL0/SA[$Z
MLKN$8=Y(Q9WW45GLV'!QN#)NX9J$&Z*E\U$%TF_]1T>UC,]-9/Y['WY-TG#H
M8J6>^.*,80X@)3H]30#EQ'6FH[?1T)_\<Q:'R2@<7J!MY#8L/QZI!:SG]8=3
M=H(2S_"_]^^#LI/Z([K-.I@-)L'W8%IR;G#X98)HPC+$;JFA?!E$+YK%:1!,
MU]9PN%1 A:!B[L&:)C'UED;QECQ8B?#'(!YC=[/I,'B7M\+=@.2!!:K3"X48
MM5-L.ABKP,B8 3!2+AAO)XQO U#4I3J!2XJ@2..0XSYLU +GAR"QZ".U!2YI
MVXF@ _<88?I;^#WX' S!(T[#(!D\#B>S43#"?H,8^)NELL[7A_&S#+JGU3<H
M"4%GW!>$H=6AQ#J%H0M,/I.$%@<FFY"$RPYS<I-PCE( UH%V6_9;O,7L:P*R
MY<=/G_U)L#+X^N;CATZ:+FZ?N9.@@TE02R6FPVT%;@8UI#>A6[2E?B56@0?W
M8"D4O[KHO(PGP8(27O("%XR@M'58,')=D)9ZAA_C""A/GW %EV(K'%#>#ZI'
MP-+J7WF(0?P/0!10Q6V7S]$XQ8^7"2NX=@9K:Z"^"JSY8&\&[CYF"<% +WR4
M^4(7!RFW!4+*&&VIMZ[V0@LO"[<\I89=7H,%?CR\PU.0P?=@$DG0LV-7%XHI
MM^UV)RALP/3OP32(_0E ZHSNPVD(JVP?U^$7BBHCIH4VE0C=D"C;AH79FTSH
M+45Y]:0LQ=GS=G*W4;;7YD6Q;+V3/+/"__:3._"]TFCZQQ1D($Z S+?A$ 7!
M^18'\G:'6E?AHS^,2^]9>H]/P;?9Q$^C^*G8$[PXFZ$D$=QTF\LU.M$QCQC^
M8+RE;L$A)7$N?Q_&KC\)8?0T].N2Q4)'?H;[^P!FZ4WRKVY_1)T(RE1V9NNL
MI8O^\Q;!"USC+HE@9H]M-,\MC5^<K@B^9)'="?B&0W]2(JDSS2B4G1!6$L(S
ME0'3M$PN+D\QN4^CX+'30RV2P4[F+@IRKI-Y? *&$*.M^SD'%8%HFLPF<GNH
M2:7S.0#$1D" //C:J:"6ULIJ"WO$LP/\)K7TTZS$D,E_C/E8ZI\>;LW)3^YQ
MCRU6+J5R!, O-2_K7/'L2JF<"Y 7E.)V=AAVI50N!^JNE,K)8]?B$PO'+J72
M2MSR4BHF8?3$%B_K2ZMD2Y6M5B7=XNGX GA1 G>V2'*N:A.<D2KI=:KDQ 3P
MH@3NW)#LCL4?Z5A\BX6AU<O")@Y#=XO,[D#TJ1YG/25INJ1H<2=!!Y.@EDI,
MA]L*W+JC>6>+:7<T[ZQ0[8[F7>#1O!9+8I?[?2&YWZV6P85$8&J;W#9:ZL><
M02*P%\9)VHEA2[O!MH4]O$L'/8"X\VIX\F/@V:6#G@N0%Q3@.SL,NW30RX&Z
M2P<]>>RZ=-#3PBU+H1&4\'/+X7*Z'*X3$\"+$KAS0[+;9#M?3+M-MK-"M;S)
MUDY46[:I=J82T&UN7<CF5NMDL%V["FU@#Y7<(7RQU9]-N45;&KO<T.KO\PS6
M-GYC.I97 A"&U0J@0 E_:>_6-$S#:.G*^@SV;E<H6*!F13I+&[9P85A=PDAD
M!2=BP(>NF.51BED:E<I4P3!.:A4!@2+0+G,+9(MJW!'U<H=3NCA!NB510^::
M5O2W:%T"(*VU02C\F;7,$NK,F=G6S"K,[ _^.\-8U/<%;VO-@!KQ0]T&OO F
M_(IA=>$'WA8QNZ/ >WHJ9B5/!8?5A2.GA%K==L ^^I1HU*J@3]6PVG D=JY/
M,6,?5SLZ:-83P15/YMY%DQ&8PVQK#P%>SMO(.A$>?#>Q3=)$[ K:O1A6GW8W
M&>_.W577Y:;&> 5=KH;5C%J[5APM8@[)%"0N-:3#8A!=_FWH)BA,%/&6*D@L
M1?'>OR^O(VY_1+=WT2SQIR,OFL5I$$Q+.5 5:E=47_W@*F=Q/KWS'\/[V7W=
M<XILU(3%L)K%IH5SJ@7,X< <6G8Z#,/@UMDX':HL_45X'6:U$+X:5I<XZ42P
M=D;,&*D4,6,U!DP$X;0KX[>70<&@5@6=J8;5IS-YMN#N=.9IZTQ>:=V?#:M-
M+5!*6K>I+ZH%F8MA]>E,E@5%NB#ECCJ350A'%,-JP)%TFP5;X1=. 2L87=X#
MR+\[-"QZ=PYW;Y"*=DG-@=0=KFTU.MV)V98!TQV#/7'\NK.M[02D.[#: C#@
MDX6>&S?:?<SHUG]T9NE=%(>Y)LM_[\.O21H.W6@V3>/ST%DY*I3H+0WQ;4)%
M.@O.=(2GPB;_G,5A,@J'YZ+"U)8A ZX*WM)9L].6(;;@G0\:3(+OV^XJGA!\
MU 2/SK9/&;Z&^A8<"25A&C*H (X"E?%R7<5^3-;63'K/#^-_^9,9MAE(DB M
M1<>+K7-8,CV]\^/_#5)O-AUM6KON\NCBXS^ ',Q;?GJ+6<N+[U$,>C-]F*6)
M'$'/26RX2?7ZX^+[BLG.6+&SP@K^;6G0XQ!8\?/ 2B<ZGM/0!6FKSQ-'0'?Z
MA!80#Y]AG$H>U5AQ1@Y[Q 3Q/V"=!VL]=%0_1^,4/YX15K!^,%A;'9PJ6!63
M:A9/0PQ4P4 O?)0AJ[/ :64Q +FN:*OM.HMB #+^Z61^]%W])==;)UVBI5KA
M#*6KP<(3[1.SEFX&GX68R6+ILL =IEQ=HA)K:2;/&4K7A2JQKBS3&95E:I5@
M74I;I:,)UEG:PZ.G^39)L^C2"_<63-$\2%UZ8:O1Z=(+6P9,EY[6+D"Z;>?S
MV78^@MATV\XGA%6W[7P"6'7;SB>&5;?MW&:<VA1#J)_FKDSA7B*951^L"Y[G
M#2-/H?O5*72?*J'(ZYYD73_>DP2I"]2U&ITN4-<R8+ICBRT!HTT>;.TTL\Y%
MJM]%8LVCV%G?5J/36=^6 =-U2]YV:Z93QB]+59O<B-II7M.0:IZ09M'V&J36
M-:@Z2(8:5JM/&DE.RUI='4VV+B79L3VRU7#V8S,"UB:%73O-76.>/4,1JM].
MG?#HW<;27O#H-<+3M4/:>;G0GCF<=3FJ;W.XZW*TQ5:PZL]3(QA%?YZN.M,^
M*)$:ITS7\>4\%*MJY%*?O]Z.1BZ+_KKJSU*?_NKZL^REN%3;E?H45]=VY1P4
M%Z]U56? C#7:I;@,V5S#J%-Q=4U2]E)<K.9%"EM<R3Y37&V&J^6*ZVRD!'R/
M/ 2?Q3M *"S[7*1$%B,Y=R%!!ZCFD#)=W*?!1KBZ<7G53O[M)W?A]%L:3><[
M-I=3_.3X<G8I^X%MD;-&=P,;$"^R6%MG>;OY4M18>[:;CZ;(R)9),[-IJ,0L
M3"+!J/GEC\_]0E#N S^9Q<'K[+??X+??7^5?JIOA]>OO] 4>_"5!;R8I;CH*
MOX/DS-\?KWL_NP]BG(_%UU6>KFA;?;V\;3^81O?A=-V-U8NMN^?SBW]_57KW
ME:0OD?K2@U9>_P"_/KL:OZQP;?+?<?KLVED:_X8_K+E>R>#K_P]02P,$%
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M94^?[J7#,Q1X)Z8Y&7+A^5183"-QN/C=0(&/L<WU2@HDD5A'GSY]&JJG6NG
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MX&#4?DD4YDCF" 9Q OW8W<+)N$ Z<,A'T@[AXQPH,(\"#T[.Z]]28-U1Z$V
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M1G 2,)GE1W!C%*0',.*_E7C9FNW(;>YHK(QAKJ\_ -W1 \+T.QX:W/9F(D>
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M<(@A8LUTJ?OZL2%876YC?:7B=ZENO[<8R=Q$*A?,QFO;"22/<X>\RDR>2%.
MB=%+;\0='9O.0EZ)ABN?6R2CJ<OA1"'2C#1I<M1;]RP>;(B2ZTV4W)%019?<
M="#1@[08.<Q,"T^WO(;5!^EY)%7O D.4A7SC/I-]%>17K")BKS%SY]@A]9/
M>$C9$%=DS('.U84.,VY(1N,ZS$"AH;9XA0\LK"W>+:(,A?7 8X)X9@OC$4)#
M',D01]+223J$51Q!=(H=SEUCY?CY3@WS48]RN]0>E_>!^?S;[ S#7O\I\H")
MR74$C/V&<.*3^HT8S1#&()X0J<P:5_\X<.)X,J- "2VXC(8F3($WCH]_<8(4
M7:ZHG#>/ N"-^/JW%!B"PBC$0KK[ >.FRXQ.C7!DP[IS080!HY4)VJZ5OIR#
M2:G)=; YSY(L[&($A\H10M<X'J7)' [#W]%V(13)3F;PB%R$O/@&+I U52<S
MB5.3BV+;\30Z8AHW JN9D61ZA$%;&E4I(0QO$O4PA\&E,@;L'N8P&"MCP.YA
M! /V#2,JS"#H8;2H1%FRD2DL46MOQ"6*%LL(.WB5D?)R58:*%:.FT-$"?,:@
M$ZR(/KB(4E ED@3[+VE"H /%$OBHYHYO/XX%V-8LFV*D[EH&.W8".U!Q@NG>
M\*CP"6H_W>ERJ'![6X"9I(#5U,L:3&AY=24L\AY:I"3JFVX4DABM-!7!\;#S
M'F;' &OB:@-S!C:^/EY)$A')<'T(>5!!DR/HF4]RTHLF1QHT7@%& DU5P\56
MY,K6J6 \-J5+C%G'8!_R$5LCS+(2F2_H))F?V*SDE/>Q/(UZ8M/O"'\[G%UJ
M:9L\);&,/^NT-XYGHU]=7:-DEBRH$^C@41?M#N/1!;4 2UG=LQ(Z(4&8 PRN
MU$"JNO)H<W2E!H3Y=@";@RNUK?1:N;8Y=K(-LCOX:FR.KM2P[C(F2IO#+55(
MP+*A&(^IU,WI0@^Q^3@DW?M:[$M6S2*RH-!&_F:D(+3&,) 4/!JB7(Y.MB84
M:.2Z(*IY=[[SX@< $HK'*<99OME]%+K9!X[]6+*SD1H? 1T\#PROT3_/A^#A
M)=?9"%[O#O8:<K2K;4Q 6=J98V?I)TZ0'38DDA2_T=*]-VD"NV-]X/+BSY3'
MT58)))\VFV^2)G'BA![<_*6IUY/>ABY&P"2E8L7Y2[9+7L4 S3.86./KQ3*(
M5@@] K"^B]A;Y9Y(BC'L),J3\5,$2UC^G5RT]U'R/RB9(C=Z#04NM^[F.RCJ
M966126WL["O2[GS?)&4#893.Q6X1AMSPVYN ?IW&*(*XVD;[^V9Y1#\YA2AK
M_(P=D)>?YD[R*\(H+TO/?)"MQ2BZH*_,I2(!M!A -\P2!;P$K8V$=@9.>.\L
M1"))I8E)&(7!U%N->@*GH?>9F$8B3%YHF,PR750E<K?:T4@E')*.(JI\M/G=
M&'3">Z#<PGH(#?$LB-8)]MU$)OB6W=;,2VYSY*5D>[!OHG)R5>Z%+9<ZR-1!
M072HOO'UA-8W <&#@?XS#OS9[!=8.^%CL=KG,!:.W1J)"OP\#4'K%,9H]-*,
MP(L(@:G_.D_B0IX5$4O[7+WBK.S^O@WAZ$PSPSI) P8Y/\QTJ3@3_&]#YM;<
M^_1FSZMK6/ %,3."HCQ#/K%C3>&CUO.*-T>O]B*H6CZFC9O91LOXO=IS-9>/
MKMUT9S3EH#78]RF1U')AICF47_\\?:;6F^,'1)2#XX*>E1T3K39=KVB77RK7
M'W!;^S':W"O41GH;@OH0QKY+(V-TTU%EZC[2M'I1_XRC6/OQ)IBI_Q3[%1$Y
M$GFC-X1!@* _7L'%OPG7W0LUFZ'HE1R2X[CQB%0/,]U22<-L?:3<+Q21-7=L
MN$"H?78QG5FYG^E?R$ 6JD?[FM7*TX]K>2JB'4)/RGK>R50#S92G,F0#YJ!"
MP<PREB8<WUN;$?2=-/$4+5/LSDD8"/9=7LZU1 <SA1?R\,KJ\\T9H!6G^\,:
M9F 6?EF&=J,9P[Q8"@; (B3%'?4D:;]'3_,HC9W0NP[0&RI'%A&R"1*WY7KJ
MAO(F2G&"4,A=:"F(94?I"OHM6I%*[CH68N?A]X3O+L@8],7E5GJ!G[C<PB"$
MPNN\VJ874):E!2-YP<S(VUIJH'9QS'A"I5S.K!'JV)93+&(?5I!4)3>CG^NN
MAI8="]:<5,/6B8IZ#CIO\PT]+NQ-,I*GAQRJ7^W-AMUYZ>O(VIL4JHYLH\Q=
MH&TJ^U&RPOYVN%^EO'LYELW\@257ZUX2H;Z<P8QXPC)&6Z'QQ2EJZ $TZ;H3
MVJ/Y6-=MWXIQ=$J4TLXP7J'##HI4M-B<)E^/G"9;&DQ.E3_85\M%7Z!013_3
M1]L#+@[3#>U;I,OVH;!,1XS:6:13'VK66$934;1.'ZKBZ"5G)\GC?:BH8QE7
M,O,;^E"6IP-VU)]-TX<:0!TRI/YDDCZ4&;*,H/6,@#Z\@&[3]E8(0NM#;?$.
M2*M81Z /%:R[H9)RK8@^U+ZV3*1I&^3=AX+Y-AV+W)P\\^7+3?%LAX6>^O#.
M0<^(RJG_5%#Z6+2?[G,6"IH>I2+4><9<0=]!+U+C66Z&4D'28]&2-NX=R8*@
M!86.1=G9>53EH@^%L_Y85*6-?UZB:%9!G:/3CB12)0KJ')]"PT\!*JAR;-J)
M+G<@JPSZQ;%I):VSM J2'9MZ(5M O:!0CY6%'1)*66;56JG3(GBTQX+!CD2J
M60CJE8L+,O7X#M1$)DY)QX)$ILYPN3!D1CX9(U"O9TDA*DCU)1R9F; F(8BP
M\\J+VT!.R[3R$9/'=+%P\(J\#+6V/K(;KI7KX1T0;7C]C$)8NP".R)&W ":
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M)W/;&ZO\S7ON_1Z]TY^$U;^;.QO!J\K[3=HGM[D%L(NCZ)EM+8!:J"JRFMH
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MBTC&=26^L8N[86J)Z"4V/60#EQ1!N+>7<0./O+6#>?0P5[W.]KUPG8H%T-Q
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M2UX^IG"?/$8/$#L-?:)/,/T8;J(]O(T2]/MK] @:C;SZ6[A]]_8[,NYC>'?
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M8[YI!ALL=83#:SE9NUV]&!(,4(=%16?EFXK+9XQC2(W9550EU.R#9T$U)XE
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M&@UO<$G)[Y*$N2RBA9G9']8H7>,>^>Z E>%6*V _;X($FTI('%5VYTV^PL(
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MG\$H/U5UNOKFLP[TLY\WP1!-)22B.2_M7(MF+,,TP$^SJ8U0IDW:\<D*L4Z
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M1'OD0#S *": V489P>YC\TK*'@>82%H_P?3:2U[(5=-;N'WW]CL:0W\,LX.
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M#+';*+8[PK8;S\#&=X8KZ@SCC"4)]195R;C/T+ INX?NVDLPL>)_<$&U5R]
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M/+08[H_HI=ZD9_SD[6'MZ"QWRY[ BQJ1TZ^-^'TDSCQ#47Z%?9;T&-TOI]I
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MA-;ES9L'M'T+F4R;_UI+> W_D18*]^']/6C8AZL<7%Y[B%L"XKBF0^W@,P6
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MN*ZO^7WU<7\0\XP-*AK-?Q<]7-TF\>LKG*GV21VJZO<[J#CE4Y!!1;Z:$.U
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M[7*>!3!K\3S/'PZ _PCI<O_G.D=.+4MCC%81F]/2&3%FA_HRVY3559QHWB2
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M!-OX^ Q29/:&FKW!;8"L$:/%@@1"LCI4Z?.2DKZ^:"1Y_^W@DRN>0G(CY']
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ME%YZ;#5O;H9"V6A")=8K?3T"N9G-RE>I"N?5"ZFL-,U2:N^BML@>0%+_MD$
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M%%PZ(L/ PVD>&-@+!(, R79=DH&6*6%D!^RPW*3OE7LI<WM:=K+.@]TF6;J
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MDD7^QQ$\DU(,/RH0;FA0>[-SH3T[S3WL<7"IS4%S#RL<%*J+NL@R(;!]7Y@
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M2UE)+=F(N9K*YF2 U-%@->+9I$AUO2Q$+^B=[Z/GIIF\%_0^[Z/G:"H,98U
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M,VOT!-Q%;2S7=! /K=$A4/I6'IW^^&CQ=#.GZ@(X.FR-#EL# VKT0QK]D%S
M7^"')#!$N>II/;I%&'6+F*$ U@T].F$MO2*28IK!>\,RDPD'XPMQ&7I),ITS
MHH3J_X:&-C3)-QXF/WEAAB[63%)<Q"&LK.3ZMPP6!:-1R(5R=W-V9+H=_(7
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M#^/JF:6.K>OV+NE[O I;TX7@.D#J3_[&Y"/[L#KK(=$1,=$.=M99HAMF?!6
M^XX2RLH< 6"-,)_8@;:G-Q+@M:_-<-69V@!8?*66J[[4QE;81LODJJMT&Z Z
MF&]==:8VL-Y4+!ZN>E?KP->D '75A;K5[A0ZNG3R\8-=_1P[A97$H>9PD:H#
M\.NC?L]Q-##_O9(F3<N<2D];N7\*NA0M<J(>ECGX*::.Q#/\LN ZT?%:VZ#\
M"K_B '9,4B&*0W9C4QLTYZ>8Q"U@IY'-X[>9WIKJ3K0#7'_%:<%SNN\V.4S-
M>]GU9YK6\JF?SH=[>@U EF'\LX#+:JSE8,2:B>^3#*#'WC,.@2247&:$SGT>
M;>+G_^ <]HJ=K513#]G@19CK'OY%1#J/+[7.5OCZYI% DE:KWL:R8';IK7#J
MA?G]2@/)R"NKK'23I; [-F]"N<BF.(ZQY(TUN6":I4GJ10$]Q,I/;SYZ&_D$
MP2*IU)+*.T]7O"1OAK]@1X3='''3>75W%%D>V"N?\?9<39HA$1\[#FI%+%ZN
MPGB-T"-,&O91\Y%Q3Q61"7# ]F;R%,-2KOZ=,G8?IW]'Z0SY\4LD>(3U]SVG
MT,NK:-$2;OFO:+M/AX:TF0BK.)>GAC#(@]_>!O6;9#PBBNMMC-P#U>* 16 S
M/8W9TOB1>'#R/"V\]&=$4%%Y<7?/MAW%%/6U;^E(0BT&,$VS0H9M06LKP82A
M%]U[2Y%H5FMBDT9A\.Y.H\$$9A):GG,ZSY^>/-KE':TDC*5!^Z)4N-N_6Z-.
M>+I66UA*N)L2[*<J 8K-;:T$]OD+%&1TZ36?G=7T#H77937%7/Z0$T30F1O?
M3/BQC @>#>P_ER&>SW^"N:O40-T_\XU_PUK(:FLF:O3S9%JCG["&T;.<@6<1
M [G*L93 1& 9_]91K:S\;KR-X.C,<JL]S=\#DFF42_])+JK>1HU;\^"?MWM>
M7<.$+ZE" IYV<X2I!FH&_S1Z7O&^<51[$1X'F+#&\F5C9/RCVG-['B&F=M.=
MU4#FUF3?9U12*X09N3N"^>\<,UJO'@ZI* ?'!3LK>P9M[W-'A5UQJ5R_P6V-
M$[2]5YA6[S:"YT.48)^9NDWCJ//I8\2T?E'_2.+$^/$F^-+Q(_8SHG(D"B:O
MB(  P?YX!1?_-CSO(&C*J3@J.:3@<:O#KQ]FIJ42R=>.$;F?&".;U;%=!<+7
M9Q^?LROW-VK$<Y*%SZ-#?760IQ]7\U3Z*42!DEZZET\-"#-&9!ZC/N78/=J,
M8&[/)#.TRHB_H*X(!/L\SV>%#G;2K!51""BXRLA6O9436C-X/FQHAJ7"3\+6
M;C1KG)=3T4"PB$EQ1S-)C+[%3XLX2[PHN [1*ZIZMU#8!(F-U'J:IO(FSDB*
M4,2=:"6*54?IB_H=K&AY*A,3T7GX _';A1F+5J5"WRRP)E9;6*10>)G7VUBM
M[=;D4[F7AL&XB.-Z3+T9!\':/)@SI[H.?I,O2BW>\,068_/[HLRE9?)NW&)Y
M[F;U"G4LU6#Z[&: 5><EMP^4FZ%$^D!)I>X2,C?3$^RYD]6J&E6]N5P_V!M<
MUZI8['@.ET>SFP6?C3N<-<D,)Y*RK5<L*QO8^3QNO0)9>PQOH#P?H6P!Y<X[
M> /FYQ',%F":< IR/V&A.=<I3N2Y:OBIZ]D>^@&Z/]\EU]-*#&P^1+X[G3)9
M'$6B+K.3T4L(N>OI"@>V'QKC+%S/>=C#-C ?$>1Z@L4>-X+Y8!K7ZS0/;#+V
MHRD.EQ;2A0DXF/.?ZW6B>I@6S6P%KE<%Z@=A[6P6KM<3&IC8V38@P/6B:T.Z
M!KBQGR=13LKX7NDQ?9;K=?:.;$(X&;G*61I?U0=X0TCC><KY&!_8A[ORU2)1
MR[D9W]N'VRO<J,%R.L;7M_ITJ*;F+=$=']$'.(BT$\"4OE3C$UQ]?E02VY7(
MCJ]NC96O$.16(CL^E'4>ROS SQ+1\=5[>,>)IGHEY^-K5_/0:!,37,+=XMEZ
M@EX16^E/L>!$B>^)/D,[I$UH,JKLI5,N0R1.5'SK"/">OFP_LWH)\8E*&X8@
MYB3_+>%U\\9KB/-N\'P_E0C.QIAR!9FJ.:E*>;WTK5P8; VJQVRY],B:UDO>
MJ.B;&VXT,F,9I[%XCF$<?D01K.$0;H%)L,01IJ2D^!45<R-,@:36UP97MQ'L
M1L3*)5*([^B7Z%'$3]@AZC$@#H0)/<1]+!4-0'#!+&")7*%7%,8K2IC*VE+I
M.184$(T_H+1JPTK$/&9B.:U,+ J70159R<E[HF@)WX;R,][U:#)MU!3E+M>+
M&/<: 2S<^&/VA#&XVKIZ[C#N&VTBJC4-),/7L>PX<4^2)%OF;A5?H<M33#ME
M%9_NZ;P260(TCCH*:SJ*UMMH.YF5V:;;@RJRK_ K#F#Y-90-.MQWCRH1O8BK
M)T26QE/1RS_HS&K\*8;=1\VQZT.OQYTO'SVB,YS\>D,0NH53&RZ?]%!X-G[7
M,9U#_^>PZUE@CF12=H\CUY_O Y^6YC/-==U 3Y/2D^ASN/PPPW]K3?P43G4X
M/.A,X>CE*:[XYB16S-A-&>9WK=6U-J-1VMZ#3^#1U<@BO_UH(AQ-A$=0J[5#
M;%P1MTCGLQZLV%=E.,$'CVH][;.3N_:;7E[<[QPY6CL*U4W\+(M.Z1]#X=>/
M?!_O\#9#U(@(8M1E'+$[.?/"7O1M'2@YQK5<I@_A58WL\TO'B-A865B7CTK2
MT8,4M>9_[\C1Z_5NWO_.B);&=WXY/W:\+,@RJE\?D>WIZS97;0?IC,\=3SH[
M[TE.;$/),:[F/%/3) JV&M^8_JK"_N3EA: 7+T4'N>/;T^,F^KU>=LJ?=Q-;
M"\=W1Z*.\4S79OG0*@&#! YRGW0(D]9=_6T^=5R8\1+J]7&6F"7B*'%N4"[9
M0%J7C*/$6I@7^B P:U!@!6%1-I^J$\"&5*[*57^@L8+]Z (D=P$:XR8'$4"T
MLV'&:*PQ&JOW*3#F>6(R[W2#(J.3$_0JOR=3CZ3C=!@R<;KN_MS35+20!=OY
M-'^?(QTQG6=PDECWX0O1SJ5YG(P^#*S=:E_FE\)U-$Y'KQ:(L32FQ<H=50_.
ML2RFY7-+K!KK5#1S%' /I\,<RVA:F2)-T\E8BM/*+&D;7L9:G@.^E6HR=ILJ
MGJ.,;=$392S]:5GR5IT>-Q/%]S@]AW85':N!VJL&:L8#;*P?:F,&6\7OC>5$
M+4N$_/JN8T'1(4E_7 _[L4:IY<-N+^G R5<E/6!9J][+DQYCKJ&=8E5CNJ$Q
MW9 8!TYULT;VFMN.:89$XP_2U;MU%>Y"[8N"OI)&M*# +81WZYP?&-Z=S[N%
M[7T<O3)INY^H2>WOC^CV^/UC2\P@Y2]_*%H[&78^?U38[KT''4J?U]-KS-G0
M3BJYSM"JJ*?>X)TK"LH2=QR#L)Q3>(Q!6*[&#8U!6&,0UM"TIX<U0.A+]&-P
MUA"G:5=E,$9L#6M^=A]N8YS7T&:H0:UYN)(63DV1PNNJ73#7N/P/J3GK%LWE
MBC>P(6,VQ\1VN#BM 1BR[U%Z%R<)G 0,T?(Q MABGY;/QF%&5R!*\\K%U=:3
M%/![SE+Z^F#%2I=QQ*!<Q"%@:*6HSK5'J%M;2:/8,LQM;J7$S XQ.W.@R,)N
M+QN<P%HA;*MZ8;$LV"6SNV#@>",)+/+I_&&SRW+WB&9.NXYJ XG:QI$LQN:V
M]JE^]7#(V^-LM2GQ(Q_E"#C5FD'UT6QPON,1G,L8TWEQ;.1;J^+MR.%8=Y0!
M<;I'G&1RM8<9,J^B?:LWADU147;;5\6]UCO=]?JO.B!*1137E5S"^[S#<G,_
M44?'FY:/;<-&=3-RQ2""^E=BI_P81P!N6R&A#:I[.][- &$3D'9^2;JN,.YQ
MW?*? IT2?Z4Q3.81Z\@V41Z58Y>J<E^]D"EQ*SC9B/*(4AS0><.OZ!'Y&8"+
M47+]YH<9 '(#2X<J5;,<N.E\3_9;QEG$>P"9&=O&JZ@CY1?KY@%$D30]?O$(
M$=RSH)B%Z\ZJOV<S\5+?36FW(>B@CTI_;JE$>P*W":/ITWE!$?U-??B'PO1*
MS5*-1"EU&2/1]"/1.AXM:N%H1CYBU4^Y_QNRYN4I/3)==Z(U?:'*T=46 EU7
M?*K>V[H1\(ZJ/G7@4KL 75> M%E@4J\4-]48.D8(TW>[ZU=-/[*0P0M'+#V<
M4 C(0.?GSDXTR !T?[F]Y<E[@\48!#@G[S::QV3)/F]#Q7=5  Y439($I<ET
M!=S0/#-437GI$;(&^J@K9 +7#%PG7$-_FY&L)(51I_,1E@5U_[P#:L+N;->'
M,Z(6V/MZL[]KDWI M>L@Y@A^N(1_X[0&*(@W"$[&A>K42$;I9T;$'[U^6V'"
M@/X[_%MIGK0&',3LT<QI^1T8AO$W+^)6#U7I:7J6[K#WC$-VA[7://+^5N:@
M.&(OZ>N;K(6*MN:V1G"^07##>R$<>NSPNT?I_O%X4ZQ@^5;H,)HEQ^7\OI]D
MZ8)))P(;#Z?Q,.@6FAZXS:W27HI=$JN#J(>1/=#P 9X%2]Z^+XJ:--/BME9G
M]_K-6^*(;>\KE/@$KQI.:M5>0^'D <%[@#U5H^ V@M<-G,H3WR<9-UQ#=Q3+
MG-(K$5V@",VQ=#?NM+9!^>9FIW?*5Q ]2 JG&I#V$"?L\99<9H0^QSFL*'>W
MDR*G\A;YO_"&3P+L2XV<LEXV.&D4AX6N)Z(>1L[7[0<J4@C+B< 3;,0=;*#Z
M-2+(CU\B_#L3<HMMR!->>*UM4+[_9-A]55PN:/#G;21<)-K#V%3ZB27-'1=(
MCFSGNN):)M564>*\GERO9J #D?0"<;W2@,)+8VN\Y O<KNXZY9=/X^&T*RJZ
MZCS0"J56*GM7_0GZ1G#'!."JDX$6C)TU>Z[Z'YA9C#);1[=X"4?0,V%K<35(
MLM4R%#ZC70V&U%]RDJ>]JX&-!O8FS[CF:@GN3I I&"5=+8K=ZO325_JX6JO:
MC S29+'O5#S:-<2DEBA7"S:W0HNK37:U;K*Q-26T";I:RK@5>NK6.E?K!RO9
M]L7& ,>=I)414EB!I^N\O$U:,(-#/?)ATQ6NWE\?J2XH2V.RGGEIGDQFY47K
MY'H^1[2,)>U/_V(EF>>&ABTGE!):LAI'&8Y>"O45'!0<BZ#& %8"EAO)JT_1
M)"W4=MMYJC768EQOY*$BLGD6M/=9-?V5H2(%URK"+U&MQ16&CO2PQ5S_>"-#
M#Q43EF1[$OQ/EJ0LEW0'#/:&,I,V0.'+#X@LO0B^R?5(;#'*4&>L9L^IW&D=
M9HX[Y% Q*'68';BN#.*0G^]P_0B,7O.NVM-[Q)1_<+AJ6F_CZ-+FOG&_5$X/
MRU$NC;EJ9.\1U.K%Z'X%FQX U'I-N6I^[Q'?_?>&JY9YHR V*WFZV>J/+.]H
MD_KN$2X0/,>^%Z5441='+.7H?*.TNT?I[C[6T]NI1DA?>BL,:%+C$'.E^+IB
M)7>;7J+*??N)Y=X:D7V?6I%A07U!Z6*O4+MFYT'$:/](XH3W'N0T'@3=L$I5
MJ:9-!T$SW]U4E17!",/@D%Y4RLRPQH.@^X'$@&RZIHG%4GCMT5S,JR4_QD]C
M@)[R?92IX]0.S%J'06#>[+2I"CBG]U XV_RNB&B@KJCDE5GSF17?"Y/"FE_Q
M^-)@O=7P@\#&8DZ040/92<;6NLY&3:/ )98K^(XJ11%J7"%\U"3*MBKOKAV5
MA5+<VMWDK@;KF )6('"/^D%1-$5-[A^U@!())7^.NAJ=8PJF0@?4+2)'1S%Z
MG#")@R-T?$%/2?1@BKIN43<.Z-QG<1@68E>I:>>%1[CSJATS%QV*\E_.AT3[
M%?()\A)$8["SD+[5:'[P![IY'Q#\-Z@&:.@QJC?T@#!A52CW""^B4[JBHCOX
M$=TH\B"R-CJF%<.$J5^<NG]-+;Y1%:4"J^8Y-RJJU&"%RZR;:BK?W=>1,EH#
M$!LWE8X*$*AF9$CE(G!$,Q%$><EDZLX)]!4D$\H$08Q2LJXV$J9:[#BH)7.6
MB.0O7@I[(WJI_1T1'U;0=,[^V X*A7$'A,87[PTOL^4DBC):<+O\(ZT%LUGE
M!?EZ>&B-;,3PSK)P/.]FX9@00FT15%]YL2Z;/'AK^JL)>^7E.KI*)>>= MG7
M;T G3A!<%CYU,"_W>GDD))PWV*!(LQ;0.Q0 FK4@7<\)5RVH1SIU>H>:J]+S
MD4Z>LIQRN#R/ Q X9RBD#XH'> *OGV#R$H\E\AU.D3)J%$S7N97_-GI%N??[
M]%L$0"_PJMAMP#(OGE&YOYV:V"7\PD(K#0UMTUM9+OG62:;SRN\4&)&-," .
M[SA56Y2[#8@7GD2IW&U(O%RLJW\1%%G2&,!NG7DU0M7*R>N,9:;\Q0*38!;[
MO_X$IRJ]J>_P$J>E8\RZL'LUEAII,X)-11?_]"YSAFKBX6J2:=WCM1;8I2X"
MN/I@Z@*?UIWMZJ-%]TIL+A.N=32[6MZA_8W,6Y6G4H:FTQVOL*4;H7<VH=^A
M4+T[V;Q_CRA$/B#RMPP@021<W^#(BWSLA5=>ZGV-O"R@LLS6P6F_G6WEP4[]
M^0LOP?XD"JYH"7MN9459+QO/@WN4YF;5.WZH;KV-=2HGKQX.Z5YCN2"7-(T.
MR,&+.(0]E#!,5?A0&,4&I]NXIR(D@#<G^^VL4BM=0TTM;5 L/$J4_1-U1[%Y
MC;7DN'J!-2Q*UQ]$)E&K;@[7WT$&<-NYDCII+EX1>8Y/#3.5"]+UX#P#F$J%
MO,/%X0U!9L^>$_1;!E^[?J4VUZ'8\1Y([",4)-0W\C9),AHZPZ(@-NN><X7+
M^UG1UM.%EE!ZX+U(#=6;Q<?3R'/;VRD #KCEQ%QE!/9.[J>:$WF/OK$_\21$
MQ<Y6^*JO?9G-CMM\ +2+2[$WMAT U3++(K?Y &@7&M2:F@Z!9OB>P.3):ST0
MRH4.#_SV5G6-DA.F7B5;[91U_8FFA1G_7G7]1:8#DX(PY?YS3';WU-95XUGO
MO+U)<,.)T-G>*N[;CMHA9,DD- R,=F0.R4(Z&=NN3+X1X+3O_-.WLL>:HN(^
M3E'R%&^U/:RT LMG/24O7H1_SW.)QU$2ASC()S "4: D:SIOZ%PIYP947H3T
M"K1A9^G"@^3M9&9L*]8GTS/; T!-G[%YG!A=235KA_').-S[98"G5B6/>IF3
M\ % ]3'TL'D6[9,C.6 $':PH#-20Y6@/U#K;W.'R^:E)#(IHC)M1"M+F%^.F
MU*>?VM:2Z7R'JG7^7]FF5.QL) [A(DO@C98D,YS\2O-T;JM"T]2<8G+U^]N8
MB4LO60!=]'_4/_[5"^D.4)L(M;[#X6J&8,ECZHDHHER+6<4AK6!0":@M7%)9
M:FC%N57L;8LS@A9 WK9*C\[YH=S=#F\1C4+)*PS14R//M4Q_XK+#[V$S3?_E
MPB,OLD-2L9.5,J@[_B!JC,AZV>#DQL.$)AQ%7Y!''UU4R-'9,.K]K1116*Z
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M>(W0(R*OF/K';&:MRLDD9+2P=*8SY,<O$?X=.&%U&!A[ZG8#T]^SBUXS^64
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M$B/9U-SF5G8O%T@UXH>Q"V4S4-MN?(XM;ZF_?*3$4J]*^,?_!U!+ 0(4 Q0
M   ( '.)74@VE^- \/8  ,'G"0 1              "  0    !S86=E+3(P
M,34Q,C,Q+GAM;%!+ 0(4 Q0    ( '.)74C6MU: 3!,  $[5   1
M      "  1_W  !S86=E+3(P,34Q,C,Q+GAS9%!+ 0(4 Q0    ( '.)74B@
M #_3S1$  .;T   5              "  9H* 0!S86=E+3(P,34Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " !SB5U(S']9<I@K  #)( , %0
M@ &:' $ <V%G92TR,#$U,3(S,5]D968N>&UL4$L! A0#%     @ <XE=2'+?
M/A%*=   !ZT& !4              ( !94@! '-A9V4M,C Q-3$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( '.)74CZMB-NN#X  %_T!  5              "
M >*\ 0!S86=E+3(P,34Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  S?L!
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
